P00001606T0076|0 9|Comparison
P00001606T0076|14 34|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|13 19|aspects
P00008171T0000|30 47|hyperbilirubinemia
P00008997A0472|4 6|CSF
P00008997A0472|8 11|HCO3
P00008997A0472|24 31|function
P00008997A0472|34 41|CSF PCO2
P00008997A0472|44 47|data
P00008997A0472|60 63|rats
P00008997A0472|98 105|controls
P00008997A0472|139 143|slope
P00010943A0733|0 9|Flurazepam
P00010943A0733|44 47|drug
P00010943A0733|62 65|dose
P00010943A0733|69 71|use
P00010943A0733|81 88|practice
P00010943A0733|96 97|mg
P00010943A0733|100 104|night
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|18 28|CO2 removal
P00013683A0210|40 53|CO2 production
P00013683A0210|54 57|VCO2
P00013683A0210|68 78|ventilation
P00015731A0090|11 24|administration
P00015731A0090|28 32|mg/kg
P00015731A0090|44 63|anhydrase inhibitors
P00015731A0090|64 76|acetazolamide
P00015731A0090|78 90|methazolamide
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|109 117|sulthiame
P00015731A0090|142 145|rise
P00015731A0090|156 156|p
P00015731A0090|181 188|increase
P00015731A0090|191 191|p
P00015731A0090|197 201|p CO2
P00015731A0090|204 211|decrease
P00015731A0090|214 215|pH
P00015731A0090|226 230|blood
P00022143T0000|13 17|study
P00022143T0000|20 30|etoperidone
P00022143T0000|36 38|rat
P00022143T0000|42 47|rabbit
P00023348A0601|10 15|polyps
P00024600A0522|11 28|HMG dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|86 99|dosage regimen
P00025557A0100|7 17|CO2 content
P00025557A0100|28 28|%
P00025557A0100|32 38|animals
P00025557A0100|59 69|body weight
P00027739T0000|0 30|Serum gamma glutamyltransferase
P00027739T0000|34 42|diagnosis
P00027739T0000|45 57|liver disease
P00027739T0000|59 64|cattle
P00027967A0207|2 9|contrast
P00027967A0207|20 32|HI antibodies
P00027967A0207|56 60|onset
P00027967A0207|63 69|illness
P00027967A0207|80 87|patients
P00027967A0207|97 105|formation
P00027967A0207|124 133|antibodies
P00027967A0207|148 153|levels
P00027967A0207|161 164|days
P00027967A0207|170 174|onset
P00027967A0207|177 183|illness
P00029555A0861|7 15|exception
P00029555A0861|18 28|virus assay
P00029555A0861|31 42|quantitation
P00029555A0861|49 55|methods
P00029555A0861|102 136|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 31|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|10 16|disease
P00030183T0000|18 28|association
P00030183T0000|33 38|HLA-B5
P00030937A0119|0 3|SGPT
P00030937A0119|5 8|SGOT
P00030937A0119|13 47|alkaline phosphatase concentrations
P00030937A0119|72 79|subjects
P00033873T0001|0 28|Gamma glutamyl transpeptidase
P00033873T0001|28 31|GGTP
P00033873T0001|33 40|activity
P00033873T0001|53 57|fluid
P00034935A0545|0 7|Patients
P00034935A0545|12 20|Parkinson
P00034935A0545|23 29|disease
P00034935A0545|51 59|incidence
P00034935A0545|62 70|psychoses
P00034935A0545|77 90|drug treatment
P00034935A0545|96 96|%
P00038408T0000|9 19|stimulation
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|57 65|treatment
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|89 91|FLA
P00039271T0000|12 17|action
P00039271T0000|20 27|diazepam
P00039271T0000|49 59|application
P00039271T0000|65 67|rat
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|33 38|mucoas
P00048373A0377|61 67|absence
P00048373A0377|78 87|epithelium
P00050628A0202|2 4|IgG
P00050628A0202|15 24|gammopathy
P00050628A0202|40 44|serum
P00050628A0202|48 55|patients
P00050628A0202|71 81|proteinuria
P00050628A0202|93 99|patient
P00052597T0000|0 6|Studies
P00052597T0000|9 24|immunoglobulin E
P00052597T0000|28 33|impact
P00052597T0000|37 43|sojourn
P00052597T0000|48 63|Professor Dan H.
P00054900A0226|10 24|reaction stains
P00054900A0226|50 57|esterase
P00055040A0000|3 14|out-patients
P00055040A0000|19 37|pustulosis palmaris
P00055040A0000|70 87|immunofluorescence
P00055040A0000|92 100|technique
P00055040A0000|104 113|deposition
P00055040A0000|116 125|fibrinogen
P00055040A0000|138 157|degradation products
P00055040A0000|158 167|FR-antigen
P00055040A0000|192 195|skin
P00055040A0000|229 236|fraction
P00055040A0000|238 240|HPF
P00055040A0000|243 254|cryoglobulin
P00055040A0000|263 279|plasma fibrinogen
P00055040A0000|284 288|blood
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056837A0000|97 105|carcinoma
P00056901A0308|1 7|mixture
P00056901A0308|15 21|albumin
P00056901A0308|23 23|%
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|68 75|dilution
P00060529A0695|12 24|control group
P00060529A0695|27 42|acquisition-rate
P00060529A0695|75 85|0acteriuria
P00060529A0695|95 95|%
P00060529A0695|98 103|figure
P00060529A0695|116 125|percentage
P00060529A0695|128 132|women
P00060529A0695|145 163|practice population
P00060529A0695|172 175|year
P00060529A0695|215 218|A.B.
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00061478T0000|48 56|nutrition
P00063680T0000|8 16|diagnosis
P00063680T0000|19 31|galactosaemia
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|21 50|fluid alpha fetoprotein levels
P00066874T0000|61 73|contamination
P00066874T0000|83 87|blood
P00066874T0000|89 95|results
P00066874T0000|100 109|experiment
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|16 24|diagnosis
P00072928T0000|27 42|haemochromatosis
P00073344A0367|3 10|subjects
P00073344A0367|14 36|phytomitogen reactivity
P00073344A0367|41 51|lymphocytes
P00073344A0367|68 76|treatment
P00074758T0000|0 7|Patients
P00074758T0000|10 13|risk
P00074758T0000|16 29|hypothyroidism
P00083846T0000|0 6|Albumin
P00083846T0000|16 25|AMP levels
P00083846T0000|37 42|fluids
P00083846T0000|48 52|child
P00084275T0063|0 6|Preface
P00086313A0000|11 17|strains
P00086313A0000|20 31|Legionnaires
P00086313A0000|33 48|disease bacteria
P00086313A0000|88 93|groups
P00086313A0000|99 103|basis
P00086313A0000|106 113|findings
P00086313A0000|143 158|antibody testing
P00088391A0181|10 20|hand factor
P00088391A0181|22 29|activity
P00088391A0181|43 60|coumarin treatment
P00088391A0181|64 69|factor
P00088391A0181|72 78|antigen
P00089778A0000|3 15|concentration
P00089778A0000|18 38|alpha 2-macroglobulin
P00089778A0000|39 57|alpha 1-antitrypsin
P00089778A0000|58 68|plasminogen
P00089778A0000|70 82|C3-complement
P00089778A0000|84 114|fibrinogen degradation products
P00089778A0000|114 116|FDP
P00089778A0000|133 140|activity
P00089778A0000|165 170|humour
P00089778A0000|174 178|serum
P00089778A0000|187 194|patients
P00089778A0000|199 203|Fuchs
P00089778A0000|216 224|dystrophy
P00089778A0000|228 235|patients
P00089778A0000|259 266|cataract
P00089778A0000|298 314|cataract patients
P00092689A0352|6 6|%
P00092689A0352|12 19|patients
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|27 32|volume
P00094639A0313|43 50|patients
P00094639A0313|54 57|dose
P00094639A0313|67 68|mg
P00096241A0087|0 1|T4
P00096241A0087|5 8|FT4I
P00096241A0087|25 31|courses
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|77 82|values
P00096241A0087|116 122|infants
P00096241A0087|130 134|weeks
P00096241A0087|136 138|EGA
P00096241A0087|145 156|term infants
P00096241A0087|157 157|P
P00097989A0106|13 20|analysis
P00097989A0106|23 37|treatment plans
P00097989A0106|42 49|patients
P00100540T0000|0 18|Aspirin intolerance
P00100540T0000|28 41|susceptibility
P00100540T0000|44 67|platelet cyclo-oxygenase
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100791A0425|5 11|results
P00100791A0425|24 41|cynomolgus monkeys
P00100791A0425|87 100|rhesus monkeys
P00100791A0425|126 132|effects
P00100791A0425|135 144|norcocaine
P00101300A0257|2 6|cases
P00101300A0257|29 35|cancers
P00101300A0257|37 38|T1
P00101300A0257|40 41|T2
P00101300A0257|43 44|T3
P00101300A0257|46 47|N0
P00101300A0257|49 50|N1
P00101300A0257|63 70|followup
P00101300A0257|76 80|years
P00101300A0257|90 94|years
P00101300A0257|99 104|months
P00105401A0635|3 8|effect
P00105401A0635|11 13|CBZ
P00105401A0635|17 19|DPH
P00105401A0635|36 47|interference
P00105401A0635|52 74|thyroid hormone binding
P00105401A0635|75 77|TBG
P00105401A0635|122 135|clearance rate
P00105401A0635|137 152|thyroid hormones
P00105401A0635|170 180|maintenance
P00105401A0635|183 202|premedication levels
P00105401A0635|204 206|FT4
P00105401A0635|210 212|FT3
P00105903A0288|10 17|research
P00105903A0288|30 40|possibility
P00105903A0288|45 63|polyethylene glycol
P00105903A0288|67 69|PEG
P00111174A0351|26 35|properties
P00111174A0351|45 51|neurons
P00111174A0351|74 80|neurons
P00111174A0351|93 99|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|115 121|neurons
P00111174A0351|146 152|stimuli
P00111174A0351|157 163|neurons
P00111174A0351|181 187|stimuli
P00112627A0542|0 12|Pentobarbital
P00112627A0542|28 32|mg/kg
P00112627A0542|49 59|combination
P00112627A0542|79 83|doses
P00112627A0542|86 98|normeperidine
P00112627A0542|104 108|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|125 129|mg/kg
P00112627A0542|132 143|alphaprodine
P00112627A0542|147 151|mg/kg
P00112627A0542|157 164|fentanyl
P00112627A0542|169 173|mg/kg
P00113657A0628|0 6|Pb foil
P00113657A0628|11 15|gcm-2
P00113657A0628|39 49|improvement
P00114144A0189|28 32|study
P00114144A0189|56 70|result emphasis
P00114144A0189|85 94|hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|130 133|Type
P00114144A0189|136 159|glycogen storage disease
P00114144A0189|159 166|Andersen
P00114144A0189|169 175|disease
P00114144A0189|220 232|enzyme defect
P00115974A0576|3 8|groups
P00115974A0576|35 38|maze
P00115974A0576|59 62|days
P00115974A0576|65 67|age
P00117748T0000|0 11|Erythromycin
P00117748T0000|15 36|clindamycin resistance
P00117748T0000|38 64|Corynebacterium diphtheriae
P00117748T0000|68 79|skin lesions
P00118044A0000|14 26|displacements
P00118044A0000|29 34|monkey
P00118044A0000|37 41|wrist
P00118044A0000|59 63|peaks
P00118044A0000|66 73|activity
P00118044A0000|75 82|terms M1
P00118044A0000|83 84|M2
P00118044A0000|89 96|M3 peaks
P00118044A0000|115 126|EMG activity
P00118044A0000|140 146|muscles
P00118810T0001|9 15|disease
P00119339A0400|6 11|animal
P00119339A0400|75 89|T. cruzi stocks
P00119339A0400|94 99|strain
P00119339A0400|118 128|myocarditis
P00119339A0400|142 153|degeneration
P00119339A0400|158 164|lesions
P00119339A0400|170 179|oesophagus
P00122718A0500|3 10|majority
P00122718A0500|13 21|MRF units
P00122718A0500|76 79|case
P00122718A0500|86 93|activity
P00122718A0500|120 127|behavior
P00129659T0000|0 10|Variability
P00129659T0000|17 20|Down
P00129659T0000|23 30|syndrome
P00129659T0000|32 41|trisomy-21
P00129659T0000|63 77|sex differences
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|18 24|indices
P00131739T0001|35 45|populations
P00131739T0001|48 57|Uzbekistan
P00133214T0064|4 11|concepts
P00133214T0064|27 34|function
P00133214T0064|40 43|USSR
P00136175A1137|3 13|maintenance
P00136175A1137|44 50|density
P00136175A1137|67 72|amount
P00136175A1137|75 82|exercise
P00136175A1137|95 95|h
P00136175A1137|98 105|exercise
P00136175A1137|111 114|week
P00136175A1137|140 150|enlargement
P00136175A1137|153 155|ECA
P00137671A0896|5 16|observations
P00137671A0896|50 59|VIII-ratio
P00137671A0896|76 84|indicator
P00137671A0896|100 110|coagulation
P00139624A0318|5 9|hours
P00139624A0318|18 31|administration
P00139624A0318|34 43|colchicine
P00139624A0318|48 72|serum ceruloplasmin level
P00139624A0318|95 98|rats
P00139624A0318|112 115|rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|19 30|pregnenolone
P00139827A0000|32 43|progesterone
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|68 70|DHA
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|92 98|estriol
P00139827A0000|103 110|cortisol
P00139827A0000|127 131|total
P00139827A0000|137 138|ml
P00139827A0000|147 152|plasma
P00139827A0000|172 177|course
P00139827A0000|193 200|delivery
P00142718A0156|9 16|patients
P00142718A0156|40 46|changes
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|115 131|chest radiographs
P00146327A0147|3 10|majority
P00146327A0147|13 18|tumors
P00146327A0147|37 44|cavities
P00146327A0147|65 74|incidences
P00146327A0147|93 98|larynx
P00146327A0147|100 106|trachea
P00146327A0147|110 121|stem bronchi
P00149899T0001|0 9|Prediction
P00149899T0001|15 19|times
P00149899T0001|29 39|development
P00150066A0100|11 20|fibrinogen
P00150066A0100|33 43|coagulation
P00150066A0100|52 59|thrombin
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|3 20|Southern technique
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00154430A0906|73 85|transcription
P00154430A0906|92 93|kb
P00154430A0906|107 114|fragment
P00155973A0387|26 31|limits
P00155973A0387|43 48|errors
P00155973A0387|56 56|%
P00155973A0387|79 84|system
P00155973A0387|116 143|carbon dioxide concentration
P00155973A0387|153 155|vol
P00155973A0387|157 157|%
P00155973A0387|172 185|gas flow rates
P00155973A0387|194 198|min-1
P00155973A0387|206 210|range
P00155973A0387|213 230|minute ventilation
P00155973A0387|237 241|min-1
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00159600A0871|56 65|compliance
P00159600A0871|84 86|SHR
P00159600A0871|91 99|ventricle
P00159600A0871|125 129|shift
P00159600A0871|149 153|curve
P00163384A0000|3 9|carcass
P00163384A0000|24 26|owl
P00163384A0000|28 43|Bubo virginianus
P00163384A0000|80 86|Ontario
P00163384A0000|103 110|necropsy
P00167544A0067|8 11|ears
P00167544A0067|25 39|microdissection
P00167544A0067|64 70|regions
P00167544A0067|111 129|electron microscopy
P00167544A0067|157 182|surface specimen technique
P00168176A0000|0 6|Patulin
P00168176A0000|22 41|apple butter samples
P00168176A0000|44 56|ethyl acetate
P00168176A0000|62 68|extract
P00168176A0000|83 99|silica gel column
P00168176A0000|117 123|acetate
P00168176A0000|136 141|eluant
P00168431T0000|0 19|Steroid glucuronides
P00168431T0000|29 33|fluid
P00168431T0000|36 39|term
P00172199A0270|3 8|matrix
P00172199A0270|23 30|clusters
P00172199A0270|50 59|morphology
P00172199A0270|74 83|appearance
P00172199A0270|101 116|cross striations
P00173860A0475|0 9|Riboflavin
P00173860A0475|25 34|percentage
P00173860A0475|54 60|animals
P00173860A0475|80 97|excretion patterns
P00173860A0475|115 123|magnitude
P00173860A0475|129 140|disturbances
P00173860A0475|143 153|elimination
P00173860A0475|179 183|acids
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 30|suture absorption
P00176742T0000|36 39|role
P00176742T0000|50 56|enzymes
P00183063A0300|3 11|incidence
P00183063A0300|14 27|DNCB reactions
P00183063A0300|35 38|cent
P00183063A0300|42 46|Stage
P00183063A0300|53 59|cancers
P00183063A0300|63 70|patinets
P00183063A0300|78 81|cent
P00183063A0300|95 99|Stage
P00183063A0300|103 108|cancer
P00183063A0300|112 119|patients
P00183063A0300|130 133|cent
P00183063A0300|136 143|patients
P00183063A0300|172 176|Stage
P00183063A0300|180 185|cancer
P00188387A0975|0 6|Studies
P00188387A0975|9 20|lipoproteins
P00188387A0975|44 51|children
P00188387A0975|56 63|families
P00188387A0975|75 76|FH
P00188387A0975|92 104|heart disease
P00193088A0196|18 25|subjects
P00193088A0196|31 31|g
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193587T0000|0 14|EEG theta waves
P00193587T0000|29 37|phenomena
P00193587T0000|40 45|review
P00193587T0000|49 56|analysis
P00196255A0000|0 16|REM dream content
P00196255A0000|27 36|categories
P00196255A0000|61 69|influence
P00196255A0000|79 88|hemisphere
P00196255A0000|99 101|ego
P00196255A0000|114 126|verbalization
P00196255A0000|138 147|hemisphere
P00196255A0000|154 158|music
P00196255A0000|167 174|salience
P00196255A0000|176 186|bizarreness
P00198510T0000|0 10|Innervation
P00198510T0000|23 31|diaphragm
P00198510T0000|37 42|locust
P00198510T0000|44 61|Locusta migratoria
P00199012T0000|7 19|ACTH syndrome
P00199012T0000|31 47|thyroid carcinoma
P00201881A0487|9 15|finding
P00201881A0487|26 32|studies
P00201881A0487|45 55|correlation
P00201881A0487|63 69|PI ACTH
P00201881A0487|72 83|MSH contents
P00205074A0000|7 22|hypophosphatemia
P00205074A0000|38 41|type
P00205074A0000|55 61|rickets
P00209664A0836|10 20|correlation
P00209664A0836|28 35|serum LH
P00209664A0836|53 60|bone age
P00209664A0836|66 74|age group
P00209664A0836|95 105|correlation
P00209664A0836|132 149|parallel phenomena
P00210220X0000|9 22|neurochemistry
P00210220X0000|34 38|drugs
P00211881A0602|0 6|Efforts
P00211881A0602|29 34|amount
P00211881A0602|37 40|time
P00211881A0602|52 65|kidney lesions
P00211881A0602|112 115|site
P00211881A0602|118 123|action
P00211881A0602|126 128|PBB
P00216939T0001|0 5|Effect
P00216939T0001|8 15|succimer
P00216939T0001|21 29|intensity
P00216939T0001|45 72|acid dehydrogenase reactions
P00216939T0001|76 80|brain
P00216939T0001|83 86|rats
P00216939T0001|107 114|chloride
P00219533T0001|0 11|Distribution
P00219533T0001|15 26|correlations
P00219533T0001|29 43|serum uric-acid
P00219533T0001|59 69|populations
P00219533T0001|77 79|men
P00219533T0001|88 92|women
P00219565A0172|3 11|incidence
P00219565A0172|14 32|hepatitis B antigen
P00219565A0172|40 50|transfusion
P00219565A0172|65 68|cent
P00219674A0000|0 13|Technetium-99m
P00219674A0000|22 34|pyrophosphate
P00219674A0000|45 55|scintigrams
P00219674A0000|89 96|patients
P00219674A0000|108 112|weeks
P00219674A0000|114 118|range
P00219674A0000|146 155|infarction
P00221136A0984|8 17|phenomenon
P00221136A0984|39 44|humans
P00221725A0523|3 9|decline
P00221725A0523|15 22|activity
P00221725A0523|25 42|cytochrome oxidase
P00221725A0523|43 52|peroxidase
P00221725A0523|61 73|lipid content
P00221725A0523|85 95|neutrophils
P00221725A0523|110 117|decrease
P00221725A0523|133 140|activity
P00222102A0227|0 8|Treatment
P00222102A0227|12 19|patients
P00222102A0227|24 52|pseudohypoparathyroidism type
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|134 141|response
P00222102A0227|146 151|regard
P00222102A0227|157 169|normalisation
P00222102A0227|172 184|serum-calcium
P00222827A0000|0 6|Workers
P00222827A0000|12 22|sensitivity
P00222827A0000|33 44|diisocyanate
P00222827A0000|46 48|TDI
P00222827A0000|59 63|depth
P00222827A0000|68 74|attempt
P00222827A0000|86 95|mechanisms
P00222827A0000|107 121|hyperreactivity
P00224013A0661|5 7|VO2
P00224013A0661|26 31|groups
P00224013A0661|44 50|hypoxia
P00224013A0661|54 61|limb VO2
P00224013A0661|89 93|group
P00224013A0661|95 104|beta-Block
P00224013A0661|117 120|fall
P00224013A0661|131 134|limb
P00224013A0661|145 154|resistance
P00224013A0661|167 173|hypoxia
P00224013A0661|216 226|utilization
P00224013A0661|236 243|delivery
P00224013A0661|254 257|limb
P00224013A0661|260 269|comparison
P00224013A0661|280 283|body
P00224013A0661|294 310|extraction ratios
P00224013A0661|326 333|pressure
P00224013A0661|335 360|beta-Vasodilator receptors
P00224013A0661|383 386|part
P00224013A0661|392 405|vasodilatation
P00224013A0661|422 428|hypoxia
P00225352T0000|21 31|alterations
P00225352T0000|37 46|metabolism
P00225352T0000|50 51|3H
P00225352T0000|53 62|vitamin D3
P00225352T0000|83 91|rat liver
P00227393T0000|0 9|Modulation
P00227393T0000|12 46|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227393T0000|63 99|cytochrome P-450 monooxygenase system
P00227610A1593|11 18|respects
P00227610A1593|31 38|DBP mRNA
P00227610A1593|54 63|messengers
P00227610A1593|66 69|SV40
P00227610A1593|73 87|polyoma viruses
P00231555T0001|0 5|Effect
P00231555T0001|46 62|combination drugs
P00231555T0001|74 77|ACTH
P00231555T0001|81 99|cortisol production
P00232354A0286|0 9|Serum ACTH
P00232354A0286|24 30|insulin
P00232354A0286|34 43|metyrapone
P00232456T0000|0 6|Anatomy
P00232456T0000|12 14|RNA
P00232456T0000|18 30|gene products
P00232456T0000|32 35|MC29
P00232456T0000|39 41|MH2
P00232456T0000|60 72|tumor viruses
P00232456T0000|84 91|leukemia
P00232456T0000|95 103|carcinoma
P00232456T0000|105 112|evidence
P00232456T0000|120 124|class
P00232456T0000|139 143|genes
P00234206T0000|0 7|Bertioga
P00234206T0000|9 19|Guama group
P00234206T0000|23 29|Anhembi
P00234206T0000|31 46|Bunyamwera group
P00234206T0000|54 64|arboviruses
P00234206T0000|75 83|Sao Paulo
P00234206T0000|84 89|Brazil
P00234264A0164|0 37|Gamma glutamyl transpeptidase activity
P00234264A0164|53 57|times
P00234264A0164|77 81|limit
P00234264A0164|84 91|children
P00234264A0164|104 114|aminopyrine
P00234264A0164|121 125|weeks
P00234626T0036|0 2|XXI
P00239014A0000|26 31|method
P00239014A0000|38 50|determination
P00239014A0000|79 82|CPIB
P00239014A0000|84 87|acid
P00239014A0000|90 101|blood plasma
P00239169T0000|0 25|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00239169T0000|60 64|study
P00240016T0033|0 1|V.
P00240518A0000|18 26|procedure
P00240518A0000|33 45|determination
P00240518A0000|51 76|fungicide 5-fluorocytosine
P00240518A0000|78 82|serum
P00242427T0001|4 8|field
P00242427T0001|11 16|stress
P00242427T0001|34 38|nurse
P00254537T0000|5 13|graduates
P00254537T0000|25 29|types
P00254537T0000|32 39|programs
P00254537T0000|49 60|state boards
P00261981A0434|18 36|serum somatomedin A
P00261981A0434|60 63|rats
P00261981A0434|76 82|litters
P00264240A1843|3 11|sequences
P00264240A1843|24 41|X. borealis oocyte
P00264240A1843|50 57|5S genes
P00264240A1843|85 92|residues
P00264240A1843|112 121|T clusters
P00264240A1843|144 149|region
P00264240A1843|152 174|X. laevis oocyte 5S DNA
P00265964A0562|4 12|mechanism
P00265964A0562|34 47|grain boundary
P00267764A0651|4 9|report
P00267764A0651|30 36|reasons
P00267764A0651|40 57|treatment failures
P00267764A0651|73 82|philosophy
P00267764A0651|91 100|management
P00294502T0001|0 8|Diagnosis
P00294502T0001|12 29|treatment planning
P00294502T0001|31 38|Class II
P00294502T0001|39 46|division
P00300314A0132|16 25|infections
P00300314A0132|27 31|fever
P00300314A0132|54 76|degrees F. granulocytes
P00300314A0132|89 90|mm
P00300314A0132|96 110|hospitalization
P00300314A0132|116 125|drug death
P00300314A0132|136 143|patients
P00300314A0132|149 166|calcium leucovorin
P00300314A0132|173 177|mg/m2
P00300314A0132|194 197|days
P00300314A0132|203 214|methotrexate
P00300314A0132|227 242|treatment cycles
P00303189A0247|14 16|way
P00303189A0247|24 28|drugs
P00303189A0247|36 42|patient
P00303189A0247|45 59|serum chemistry
P00303189A0247|79 86|efficacy
P00303189A0247|122 128|process
P00304240A0369|19 23|tests
P00304240A0369|43 50|presence
P00304240A0369|66 72|disease
P00304310A0000|3 11|end-stage
P00304310A0000|26 30|phase
P00304310A0000|54 64|retinopathy
P00304310A0000|76 88|stabilization
P00304310A0000|91 96|vision
P00304310A0000|104 110|periods
P00304310A0000|113 116|time
P00304806A0760|5 9|basis
P00304806A0760|12 38|serum alpha1AT quantitation
P00304806A0760|45 51|infants
P00304806A0760|73 78|groups
P00304806A0760|107 120|concentrations
P00304806A0760|136 138|mg%
P00313766A0666|2 9|patients
P00313766A0666|53 62|depression
P00313766A0666|65 72|function
P00313766A0666|80 80|%
P00313766A0666|83 89|control
P00313766A0666|91 95|range
P00313766A0666|103 103|%
P00313766A0666|105 105|p
P00316723A0558|0 6|Changes
P00316723A0558|9 19|body weight
P00316723A0558|31 38|behavior
P00321261A0104|10 17|response
P00321261A0104|20 35|prostaglandin E2
P00321261A0104|36 39|PGE2
P00321261A0104|44 64|prostaglandin F2alpha
P00321261A0104|105 110|routes
P00321261A0104|139 144|phases
P00321261A0104|159 163|cycle
P00321261A0104|191 195|women
P00330364A0132|1 5|total
P00330364A0132|10 20|BCG strains
P00330364A0132|44 50|strains
P00330364A0132|64 71|cultures
P00330364A0132|74 76|BCG
P00330364A0132|88 92|batch
P00330364A0132|95 101|strains
P00330364A0132|114 122|abscesses
P00330364A0132|125 132|children
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|157 163|strains
P00330364A0132|173 177|cases
P00330364A0132|183 197|BCG-vaccination
P00330364A0132|204 210|strains
P00330364A0132|230 241|laboratories
P00331128A0000|4 9|levels
P00331128A0000|12 27|serum calcitonin
P00331128A0000|38 45|patients
P00331128A0000|62 68|failure
P00331936T0000|0 8|Detection
P00331936T0000|26 35|antibodies
P00331936T0000|44 80|immunoperoxidase antiglobulin technic
P00336354A0543|3 10|response
P00336354A0543|13 20|serum GH
P00336354A0543|22 38|arginine infusion
P00336354A0543|74 85|hypoglycemia
P00336547A0000|3 16|mortality rate
P00336547A0000|36 43|features
P00336547A0000|46 64|Nocardia asteroides
P00336547A0000|67 98|Nocardia brasiliensis infections
P00336547A0000|124 127|mice
P00336547A0000|130 132|ICR
P00336547A0000|136 149|C3H/eB origins
P00336547A0000|195 198|mice
P00336547A0000|213 225|mouse strains
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|243 259|New Zealand Black
P00336547A0000|259 264|BALB/c
P00336547A0000|266 272|CBA/LAC
P00336547A0000|277 282|C3H/eB
P00337102T0058|0 7|Williams
P00337102T0058|10 15|August
P00339289T0049|0 2|Use
P00339289T0049|16 23|isotopes
P00339289T0049|29 37|chemistry
P00339289T0049|40 47|proteins
P00340692T0033|1 8|Emeritus
P00340692T0033|10 40|John Henri Roosegaarde Bisschop
P00342623A0228|9 16|vaccines
P00342623A0228|20 39|whole-virus vaccines
P00342623A0228|49 62|type B antigen
P00342623A0228|87 96|reactivity
P00350465T0000|9 17|diagnosis
P00350465T0000|34 42|disorders
P00352569A0000|7 19|oxygen supply
P00352569A0000|30 45|blood parameters
P00352569A0000|69 73|rates
P00352569A0000|85 89|mg/kg
P00352569A0000|105 113|endotoxin
P00354315T0000|7 17|dysfunction
P00354315T0000|20 27|patients
P00354315T0000|32 52|ataxia telangiectasia
P00358945A0225|10 15|period
P00358945A0225|18 26|treatment
P00358945A0225|70 74|weeks
P00361059T0000|1 5|study
P00361059T0000|22 29|efficacy
P00361059T0000|32 54|diflucortolone valerate
P00361059T0000|57 66|% ointment
P00361059T0000|69 89|clobetasol propionate
P00361059T0000|93 102|% ointment
P00361340A0529|9 17|phenomena
P00361340A0529|29 42|osteodystrophy
P00361340A0529|65 84|vitamin D deficiency
P00361340A0529|92 100|condition
P00361340A0529|102 111|deficiency
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|157 168|significance
P00361340A0529|187 205|hyperparathyroidism
P00361340A0529|213 219|failure
P00369397A0280|5 7|FSH
P00369397A0280|11 19|LH levels
P00369397A0280|43 49|addicts
P00369397A0280|56 71|GnRH stimulation
P00369397A0280|74 80|addicts
P00369397A0280|82 84|FSH
P00369397A0280|88 96|LH values
P00369397A0280|134 141|controls
P00369683T0000|0 9|Adriamycin
P00369683T0000|11 20|comparison
P00369683T0000|30 37|schedule
P00369683T0000|49 56|schedule
P00369683T0000|62 70|treatment
P00369683T0000|73 85|breast cancer
P00377466A0188|9 16|controls
P00377466A0188|30 36|hormone
P00377466A0188|38 39|LH
P00377466A0188|42 69|follicle stimulating hormone
P00377466A0188|69 71|FSH
P00377466A0188|74 82|prolactin
P00377466A0188|84 87|HPRL
P00377466A0188|90 99|oestradiol
P00377466A0188|101 102|E2
P00377466A0188|105 116|progesterone
P00377466A0188|118 118|P
P00377466A0188|123 134|testosterone
P00377466A0188|136 136|T
P00377466A0188|143 151|catabolic
P00377466A0188|155 167|healing phase
P00377466A0188|173 179|disease
P00378492A0475|0 12|Renin studies
P00378492A0475|37 44|patients
P00378492A0475|51 63|control group
P00378492A0475|67 76|recipients
P00378492A0475|87 95|elevation
P00378492A0475|98 118|plasma renin activity
P00378492A0475|122 145|plasma aldosterone level
P00378492A0475|200 214|artery stenosis
P00378735A0000|19 23|trial
P00378735A0000|40 47|patients
P00378735A0000|68 72|fever
P00378735A0000|82 86|blood
P00378735A0000|90 103|marrow culture
P00378735A0000|114 124|amoxycillin
P00378735A0000|128 142|dosage schedule
P00378735A0000|145 145|g
P00378735A0000|171 174|days
P00378735A0000|188 202|chloramphenicol
P00378735A0000|207 212|regard
P00378735A0000|226 245|temperature response
P00378735A0000|250 256|respect
P00378735A0000|259 266|carriers
P00378735A0000|270 282|relapse rates
P00381783T0000|0 31|Bone marrow transplantation-1979
P00383169A0000|6 12|article
P00383169A0000|25 31|actions
P00383169A0000|46 62|dopamine receptor
P00383169A0000|73 78|agents
P00383169A0000|80 90|apomorphine
P00383169A0000|97 107|derivatives
P00383169A0000|109 117|piribedil
P00383169A0000|119 139|rye-ergot derivatives
P00383169A0000|157 161|basis
P00383169A0000|198 207|properties
P00384744T0000|23 34|hypofunction
P00385457A0187|8 17|inhibition
P00385457A0187|20 25|pepsin
P00385457A0187|40 44|juice
P00385457A0187|70 78|influence
P00385457A0187|84 90|healing
P00385457A0187|101 105|ulcer
P00386251A0899|3 21|IDF standard method
P00386251A0899|26 34|detection
P00386251A0899|37 46|penicillin
P00386251A0899|49 52|milk
P00386251A0899|72 80|detection
P00386251A0899|83 103|sulphonamide residues
P00386251A0899|105 108|milk
P00390932T0001|8 15|antigens
P00393598A0198|3 8|course
P00393598A0198|11 25|endotoxin fever
P00393598A0198|47 49|ALS
P00397806T0039|4 17|Algerian cases
P00401521A0138|11 17|percent
P00401521A0138|20 27|patients
P00401521A0138|39 49|ticarcillin
P00401676A0414|18 24|staging
P00401676A0414|35 42|patients
P00401676A0414|71 82|radiotherapy
P00406585T0001|8 17|hematology
P00406585T0001|23 25|age
P00409927A0570|0 7|Neomycin
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00409927A0570|127 135|organisms
P00411465A0142|27 33|section
P00411465A0142|42 45|cent
P00411465A0142|51 60|trabeculae
P00411465A0142|67 73|contact
P00411465A0142|86 93|cavities
P00413854A0958|0 6|Changes
P00413854A0958|9 19|tissue PCO2
P00413854A0958|86 90|blood
P00414575T0000|10 19|evaluation
P00414575T0000|27 33|calculi
P00415543A0320|0 10|Recognition
P00415543A0320|13 21|emphysema
P00415543A0320|33 43|radiographs
P00415543A0320|56 62|quality
P00415543A0320|91 95|films
P00415543A0320|98 102|films
P00415543A0320|107 114|patients
P00415543A0320|133 144|lung disease
P00416758T0001|0 8|Isolation
P00416758T0001|11 30|T. gambiense strains
P00416758T0001|31 35|Zaire
P00416758T0001|44 53|adaptation
P00416758T0001|56 73|laboratory animals
P00417166T0000|15 21|profile
P00417166T0000|24 33|clonazepam
P00417166T0000|36 49|rhesus monkeys
P00417301T0001|11 20|mechanisms
P00417301T0001|30 40|brucellosis
P00417301T0001|43 48|humans
P00418341T0000|10 19|adaptation
P00418341T0000|31 35|parts
P00420460A0291|2 9|patients
P00420460A0291|34 47|drug treatment
P00420460A0291|48 81|log baseline plasma renin activity
P00420460A0291|81 86|change
P00420460A0291|93 106|blood pressure
P00420460A0291|111 112|SQ
P00420460A0291|142 142|r
P00420460A0291|150 150|P
P00423649A0259|5 14|techniques
P00423649A0259|33 38|people
P00423649A0259|46 50|years
P00423649A0259|56 60|claim
P00423649A0259|78 87|innovation
P00423649A0259|94 99|regard
P00425547A0000|2 9|patients
P00425547A0000|21 33|osteomyelitis
P00425547A0000|48 49|os
P00425547A0000|91 100|cephalexin
P00425547A0000|112 116|weeks
P00427715A0000|1 5|total
P00427715A0000|10 17|patients
P00427715A0000|22 28|Hodgkin
P00427715A0000|31 37|disease
P00427715A0000|55 63|diaphragm
P00427715A0000|65 70|Stages
P00427715A0000|82 82|B
P00427715A0000|99 115|radiation therapy
P00427715A0000|125 134|University
P00427715A0000|137 143|Florida
P00429151T0000|0 3|Year
P00429151T0000|24 35|practitioner
P00429151T0000|43 46|unit
P00429151T0000|59 70|Glasgow area
P00429893A0000|22 26|array
P00429893A0000|30 41|round window
P00429893A0000|49 60|implantation
P00429893A0000|79 84|system
P00429893A0000|99 100|mm
P00429893A0000|109 121|scala tympani
P00429893A0000|126 132|minimum
P00429893A0000|135 140|trauma
P00429893A0000|164 174|stimulation
P00429949A0000|17 41|World Health Organization
P00429949A0000|44 59|Expert Committee
P00429949A0000|61 86|Biological Standardization
P00429949A0000|90 100|preparation
P00429949A0000|108 116|prolactin
P00429949A0000|119 126|ampoules
P00429949A0000|161 195|International Reference Preparation
P00429949A0000|195 197|IRP
P00429949A0000|206 214|prolactin
P00429949A0000|218 228|immunoassay
P00430889T0001|15 22|fistulas
P00431832T0001|0 17|Plasma ion changes
P00431832T0001|24 28|blood
P00431832T0001|42 63|beta receptor blockers
P00432615A0541|10 20|differences
P00432615A0541|46 55|literature
P00432615A0541|57 78|heterophile antibodies
P00432615A0541|91 103|gammaglobulin
P00432615A0541|134 145|interference
P00432615A0541|151 165|Sephadex system
P00432615A0541|167 170|RIST
P00435187T0000|14 26|flowers bloom
P00437749A0242|7 26|treatment modalities
P00437749A0242|42 48|context
P00437749A0242|54 63|psychology
P00437749A0242|75 84|physiology
P00437749A0242|104 107|pain
P00439618T0001|0 16|Lethal Tachmalcor
P00439618T0001|23 36|diethylamino-2
P00439618T0001|39 51|hydroxypropyl
P00439618T0001|54 61|ajmaline
P00439618T0001|63 71|poisoning
P00439618T0001|74 82|childhood
P00439716T0001|20 29|evaluation
P00439716T0001|32 50|blood flow velocity
P00439716T0001|67 73|fistula
P00445259T0000|0 27|Serum ferritin concentration
P00445259T0000|29 51|bone marrow iron stores
P00445720A0263|11 27|pressure gradient
P00445720A0263|28 30|SPG
P00445720A0263|46 54|ventricle
P00445720A0263|56 57|LV
P00445720A0263|66 71|atrium
P00445720A0263|73 74|LA
P00445720A0263|91 124|high-fidelity pressure transducers
P00450367T0000|12 16|trail
P00450367T0000|26 37|hysterectomy
P00450367T0000|39 50|hysterectomy
P00450367T0000|62 67|radium
P00450367T0000|79 84|radium
P00450367T0000|89 100|hysterectomy
P00450367T0000|103 107|stage
P00450367T0000|120 128|carcinoma
P00450559A0269|5 9|basis
P00450559A0269|13 19|patient
P00450559A0269|22 27|report
P00450559A0269|43 51|Clinitemp
P00450559A0269|80 87|accuracy
P00450559A0269|94 104|thermometer
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 24|Raynaud
P00450760T0001|27 34|syndrome
P00451192A0248|0 3|Data
P00451192A0248|36 51|computer program
P00451192A0248|81 85|curve
P00451192A0248|100 120|LV region-of-interest
P00453780A0430|15 32|serum IgA response
P00453780A0430|44 61|patient population
P00453780A0430|100 105|tissue
P00453780A0430|119 122|lung
P00453780A0430|136 141|source
P00453780A0430|155 157|IgA
P00454780A0340|0 18|Ultimate strengthes
P00454780A0340|36 53|cast cobalt alloys
P00454780A0340|60 74|titanium alloys
P00454780A0340|81 82|Ta
P00454780A0340|84 84|V
P00454780A0340|101 113|fatigue limit
P00454780A0340|118 126|corrosion
P00456424A0000|3 9|effects
P00456424A0000|26 34|injection
P00456424A0000|36 41|i.c.i.
P00456424A0000|45 53|clonidine
P00456424A0000|56 69|microgram kg-1
P00456424A0000|72 85|blood pressure
P00456424A0000|88 97|heart rate
P00456424A0000|119 125|rabbits
P00456424A0000|141 148|catheter
P00456424A0000|154 167|cisterna magna
P00463973A0000|0 14|Platelet number
P00463973A0000|17 25|life span
P00463973A0000|48 56|trimester
P00463973A0000|59 67|pregnancy
P00463973A0000|72 76|women
P00463973A0000|116 118|age
P00463973A0000|120 122|SGA
P00463973A0000|124 130|infants
P00463973A0000|138 142|women
P00463973A0000|147 153|infants
P00463973A0000|166 178|birth weights
P00464387A1185|6 17|measurements
P00464387A1185|25 33|serum IgE
P00464387A1185|51 55|index
P00464387A1185|58 73|disease activity
P00464387A1185|75 78|ABPA
P00465223A0373|6 13|patients
P00465223A0373|17 35|difference betweent
P00465223A0373|50 55|values
P00465223A0373|58 65|delta PU
P00465223A0373|68 75|delta PM
P00465223A0373|90 91|SD
P00465223A0373|93 96|mmHg
P00465681A0000|1 4|rise
P00465681A0000|7 30|hemoglobin concentration
P00465681A0000|45 52|increase
P00465681A0000|63 66|iron
P00465681A0000|72 82|blood serum
P00465681A0000|89 92|mice
P00465681A0000|106 120|oxygen pressure
P00465681A0000|123 125|atm
P00465681A0000|131 134|hour
P00465681A0000|149 153|state
P00465681A0000|159 161|atm
P00465681A0000|173 177|state
P00465829T0000|0 5|Nernst
P00465829T0000|8 30|Planck analog equations
P00465829T0000|42 55|state membrane
P00465829T0000|63 72|potentials
P00473229T0000|0 6|Effects
P00473229T0000|9 26|methylene chloride
P00473229T0000|27 41|trichloroethane
P00473229T0000|43 59|trichloroethylene
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|83 89|toluene
P00473229T0000|95 105|development
P00473229T0000|108 120|chick embryos
P00473249T0000|0 5|Effect
P00473249T0000|24 37|administration
P00473249T0000|40 53|streptolysin O
P00473249T0000|58 77|electroencephalogram
P00473249T0000|80 86|rabbits
P00474064A0205|6 14|situation
P00474064A0205|18 37|convlusion threshold
P00474064A0205|44 53|substances
P00474064A0205|66 74|pethidine
P00474064A0205|77 88|mg.kg-1 I.V.
P00474064A0205|89 99|piritramide
P00474064A0205|103 110|morphine
P00474064A0205|115 127|phenoperidine
P00474064A0205|130 130|R
P00474064A0205|138 145|fentanyl
P00474064A0205|148 157|sufentanil
P00474064A0205|162 162|R
P00474064A0205|177 180|I.V.
P00476020T0000|3 14|biochemistry
P00476020T0000|25 29|fluid
P00476020T0000|43 48|growth
P00476572A0139|24 29|lesion
P00476572A0139|94 98|cases
P00476572A0139|113 124|radiodensity
P00476572A0139|127 131|cases
P00477794T0000|0 6|Effects
P00477794T0000|26 35|tractotomy
P00477794T0000|41 57|response patterns
P00477794T0000|59 65|neurons
P00477794T0000|81 98|nuclei principalis
P00477794T0000|101 106|oralis
P00478714T0000|0 7|Efficacy
P00478714T0000|33 57|alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|35 45|environment
P00479222A0682|65 73|retention
P00479222A0682|86 95|properties
P00479222A0682|101 115|immersion times
P00479222A0682|137 141|fluid
P00479222A0682|143 146|PECF
P00479222A0682|152 160|degrees C
P00479222A0682|176 180|years
P00479246T0000|28 40|osteomyelitis
P00481612A1121|23 31|receptors
P00481612A1121|58 66|ventricle
P00481612A1121|102 107|action
P00481612A1121|110 117|fentanyl
P00483716A0366|2 5|case
P00483716A0366|41 47|carotid
P00483716A0366|57 70|carotid artery
P00483716A0366|97 107|anastomosis
P00484177A0242|4 13|expression
P00484177A0242|26 45|laminar flow regimen
P00484177A0242|50 59|expiration
P00484177A0242|76 83|CT value
P00484177A0242|90 94|range
P00484177A0242|97 99|VT.
P00485615A0935|5 8|data
P00485615A0935|19 27|existence
P00485615A0935|51 56|crisis
P00485615A0935|68 73|entity
P00485615A0935|89 98|importance
P00485615A0935|116 123|syndrome
P00485615A0935|126 130|order
P00485615A0935|141 150|occurrence
P00485615A0935|158 169|pancreatitis
P00485615A0935|176 186|performance
P00485615A0935|221 227|surgery
P00488534A0308|2 9|addition
P00488534A0308|22 51|Treatment X Strain interaction
P00488534A0308|66 83|defecation numbers
P00488534A0308|113 119|MR rats
P00488534A0308|147 153|MR rats
P00490336A0181|5 23|conduction velocity
P00490336A0181|43 47|m/sec
P00490336A0181|49 55|group C
P00493818A0422|3 10|failures
P00493818A0422|34 52|patient intolerance
P00493818A0422|68 70|fit
P00493818A0422|95 98|days
P00493818A0422|109 114|months
P00493818A0422|120 128|insertion
P00494659A0391|15 25|metabolites
P00494659A0391|33 47|3-carboxyphenyl
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00494659A0391|85 95|glucuronide
P00494659A0391|98 107|toloxatone
P00495097A0663|5 19|characteristics
P00495097A0663|42 49|activity
P00495097A0663|63 77|fiber synthesis
P00495097A0663|83 88|matrix
P00495097A0663|101 106|tissue
P00497494A0112|3 13|ventilation
P00497494A0112|32 36|PACO2
P00499588T0000|0 22|Carbohydrate metabolism
P00499588T0000|28 40|semen profile
P00499588T0000|41 47|glucose
P00499588T0000|49 55|insulin
P00499588T0000|60 72|sperm studies
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|34 37|CIEC
P00503336A0285|45 51|attacks
P00503336A0285|61 65|fever
P00503336A0285|73 78|levels
P00503336A0285|81 100|alkaline phosphatase
P00503336A0285|103 115|transaminases
P00503336A0285|121 125|serum
P00503336A0285|139 146|findings
P00503336A0285|162 170|diagnosis
P00506559A0000|12 30|inhalation toxicity
P00506559A0000|32 39|furfural
P00506559A0000|64 71|hamsters
P00506649T0000|0 6|Changes
P00506649T0000|19 42|serum protein components
P00506649T0000|58 63|stress
P00509703A0581|5 15|differences
P00509703A0581|54 62|textbooks
P00510341T0036|1 5|study
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|10 14|study
P00512215A0000|26 35|dependence
P00512215A0000|38 58|difference tone level
P00512215A0000|58 58|L
P00512215A0000|60 64|f2-f1
P00512215A0000|81 90|parameters
P00512215A0000|104 108|input
P00512215A0000|110 111|f1
P00512215A0000|113 117|f2/f1
P00512215A0000|119 120|f2
P00512215A0000|132 133|f1
P00512215A0000|136 137|L1
P00512215A0000|139 140|L2
P00512215A0000|145 146|L1
P00512215A0000|148 149|L2
P00513284A0000|13 23|preparation
P00513284A0000|26 36|doxycycline
P00513284A0000|38 41|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|54 59|Pfizer
P00513284A0000|76 87|tetracycline
P00513284A0000|112 124|drip infusion
P00513284A0000|128 133|series
P00513284A0000|136 140|study
P00513284A0000|146 161|pediatrics field
P00513284A0000|168 174|results
P00513284A0000|191 194|DOTC
P00513284A0000|199 200|mg
P00513284A0000|220 221|ml
P00513284A0000|224 239|glucose solution
P00513284A0000|246 250|mg/kg
P00513284A1255|14 17|days
P00513284A1255|23 35|DOTC infusion
P00513284A1255|36 51|laboratory tests
P00513284A1255|54 58|liver
P00513284A1255|67 75|functions
P00513284A1255|79 83|blood
P00516545T0001|10 24|characteristics
P00516545T0001|30 49|erythrocyte membrane
P00516545T0001|50 71|peroxidation processes
P00516545T0001|85 92|function
P00516545T0001|95 102|children
P00516545T0001|114 131|glomerulonephritis
P00517890A0468|10 14|route
P00517890A0468|29 32|mode
P00517890A0468|35 46|transmission
P00517890A0468|50 60|hepatitis A
P00517890A0468|71 76|levels
P00517890A0468|79 105|hepatitis A virus excretion
P00517890A0468|117 121|onset
P00517890A0468|124 131|jaundice
P00519173A0126|5 12|patients
P00519173A0126|29 36|evidence
P00519173A0126|39 50|oesophagitis
P00521732T0000|7 15|excretion
P00521732T0000|18 25|oestrone
P00521732T0000|27 44|oestradiol-17 beta
P00521732T0000|47 54|oestriol
P00521732T0000|57 67|pregnancies
P00521732T0000|81 109|steroid sulphatase deficiency
P00524451A0136|22 39|locomotor activity
P00524451A0136|41 44|mice
P00524451A0136|63 67|death
P00524451A0136|72 82|amphetamine
P00524451A0136|90 97|toxicity
P00524451A0136|108 120|hexobarbitone
P00524451A0136|129 132|time
P00524451A0136|143 151|depletion
P00524451A0136|154 167|catecholamines
P00524451A0136|179 184|organs
P00524451A0136|190 192|rat
P00528144T0000|5 8|role
P00528144T0000|11 21|transferrin
P00528144T0000|27 32|uptake
P00528144T0000|35 41|gallium
P00528144T0000|44 54|tumor cells
P00534613A0000|0 10|Irradiation
P00534613A0000|18 32|blood platelets
P00534613A0000|36 39|UV-A
P00534613A0000|59 65|ability
P00534613A0000|68 76|aggregate
P00534613A0000|82 90|challenge
P00534613A0000|95 102|collagen
P00535520A0239|11 20|exceptions
P00535520A0239|24 29|method
P00535520A0239|74 88|cholangiography
P00540707A0255|24 30|results
P00540707A0255|44 50|account
P00540707A0255|58 70|complications
P00540707A0255|91 94|rate
P00540707A0255|99 103|cases
P00540707A0255|108 123|tip displacement
P00540707A0255|126 140|pouch haematoma
P00540707A0255|165 171|Authors
P00540707A0255|190 195|method
P00540707A0255|204 211|approach
P00540707A0255|215 230|PMK implantation
P00540707A0255|249 251|use
P00540707A0255|257 270|vena cephalica
P00541752A1032|7 20|determinations
P00541752A1032|38 44|samples
P00541752A1032|47 52|plasma
P00541752A1032|68 73|adults
P00541752A1032|76 82|October
P00541752A1032|87 92|values
P00541752A1032|121 124|mean
P00541752A1032|128 129|SD
P00541752A1032|131 135|ng/ml
P00550399A0615|15 20|causes
P00550399A0615|23 27|death
P00550399A0615|50 55|groups
P00553858A0000|8 12|Grice
P00553858A0000|15 23|operation
P00553858A0000|45 49|world
P00553858A0000|63 69|account
P00553858A0000|91 100|literature
P00553858A0000|111 122|publications
P00553858A0000|134 142|technique
P00553858A0000|162 166|terms
P00553858A0000|195 204|principles
P00553858A0000|215 223|operation
P00555492A1034|5 11|changes
P00555492A1034|42 51|blood flow
P00555492A1034|74 82|injection
P00555492A1034|85 94|cimetidine
P00555492A1034|106 114|injection
P00555492A1034|122 125|flow
P00555492A1034|152 165|blood pressure
P00555495T0000|0 4|Study
P00555495T0000|7 22|re-establishment
P00555495T0000|25 33|ovulation
P00555495T0000|39 49|termination
P00555495T0000|65 73|treatment
P00555495T0000|88 100|re-appearance
P00555495T0000|103 111|ovulation
P00555495T0000|117 124|abortion
P00555495T0000|137 144|delivery
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00555583T0000|33 35|man
P00555583T0000|38 43|review
P00557559A0170|5 13|compounds
P00557559A0170|21 25|alpha
P00557559A0170|53 79|N-methylnitrone 1,4-dioxide
P00557559A0170|98 102|agent
P00557559A0170|151 159|organisms
P00564032A0724|0 6|Changes
P00564032A0724|14 20|content
P00564032A0724|54 63|mechanisms
P00564032A0724|70 77|pressure
P00564032A0724|92 95|duct
P00564032A0724|101 105|gland
P00564943A0444|0 5|Calves
P00564943A0444|9 16|MCT-milk
P00564943A0444|38 54|blood cholesterol
P00564943A0444|58 63|calves
P00564943A0444|67 67|T
P00564943A0444|71 78|SBO-milk
P00565136T0000|7 15|mortality
P00565136T0000|18 21|mice
P00565136T0000|31 40|inhalation
P00565136T0000|48 52|doses
P00565136T0000|55 58|CH2O
P00565136T0000|60 65|SO2Cl2
P00565136T0000|70 72|Br2
P00565314A0293|0 10|Guinea pigs
P00565314A0293|37 37|g
P00569989A0239|5 24|halothane anesthesia
P00569989A0239|28 48|flow pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|60 63|time
P00569989A0239|75 103|acceleration pneumocardiogram
P00569989A0239|105 110|dPn/dt
P00569989A0239|132 136|apnea
P00569989A0239|154 169|pneumotachograph
P00574222T0000|7 14|kindling
P00574222T0000|16 27|implications
P00574222T0000|31 41|development
P00574222T0000|51 60|prostheses
P00574956A0304|17 26|stereotypy
P00574956A0304|47 50|case
P00574956A0304|78 81|tone
P00574956A0304|115 125|equilibrium
P00574956A0304|163 169|systems
P00574956A0304|195 202|dopamine
P00574956A0304|226 236|development
P00574956A0304|253 265|manifestation
P00575231A0422|0 3|None
P00575231A0422|9 23|cystometrograms
P00575231A0422|41 61|detrusor contractions
P00577440A0298|5 12|duodenum
P00577440A0298|19 22|part
P00577440A0298|40 43|dose
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|10 16|effects
P00578648T0048|34 47|administration
P00580106T0000|0 8|Treatment
P00580106T0000|11 16|Graves
P00580106T0000|18 24|disease
P00580151A0706|61 72|testosterone
P00580151A0706|83 93|se-T levels
P00580151A0706|108 112|range
P00580151A0706|117 127|convenience
P00580151A0706|133 139|patient
P00580151A0706|164 167|cost
P00580151A0706|183 189|effects
P00580151A0706|200 204|doses
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|116 122|lesions
P00583004A0445|142 154|inflammations
P00583004A0445|160 163|skin
P00583522T0001|30 37|problems
P00583522T0001|52 63|inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|9 16|patients
P00587791T0054|34 41|diseases
P00589073A0000|15 45|plasma prolactin concentrations
P00589073A0000|47 53|samples
P00589073A0000|86 90|phase
P00589073A0000|103 109|control
P00589073A0000|111 115|women
P00589073A0000|129 133|group
P00589073A0000|138 145|patients
P00589073A0000|164 170|history
P00589073A0000|173 183|infertility
P00590594T0000|7 25|allotransplantation
P00592887T0000|8 15|reaction
P00592887T0000|18 35|Patent Blue Violet
P00592887T0000|40 51|lymphography
P00593119T0001|0 8|Screening
P00593119T0001|11 25|asthma patients
P00593119T0001|27 39|determination
P00593119T0001|42 44|IgE
P00593119T0001|50 62|comprehension
P00593119T0001|65 72|spectrum
P00593119T0001|90 103|IgE antibodies
P00594466T0001|3 11|induction
P00594466T0001|14 21|seizures
P00594466T0001|25 35|Papio papio
P00594466T0001|45 56|allylglycine
P00594466T0001|66 76|combination
P00594466T0001|99 109|stimulation
P00594617A0192|18 28|correlation
P00594617A0192|47 54|presence
P00594617A0192|69 88|degradation products
P00594617A0192|89 91|FDP
P00594617A0192|99 107|incidence
P00594617A0192|110 120|nephropathy
P00594617A0192|129 141|insufficiency
P00594617A0192|161 168|presence
P00594617A0192|177 184|monomers
P00594617A0192|186 190|Godal
P00594617A0192|193 217|ethanol-gelification test
P00594617A0192|233 237|signs
P00594617A0192|250 256|disease
P00594617A0192|258 262|fever
P00594617A0192|275 277|ESR
P00597715A0256|0 8|One-third
P00597715A0256|14 16|men
P00597715A0256|21 31|azoospermia
P00597715A0256|39 51|sperm density
P00597715A0256|79 91|FSH elevation
P00597715A0256|97 106|experience
P00597715A0256|118 121|work
P00597715A0256|124 129|others
P00597715A0256|152 160|prognosis
P00598012A0174|2 23|girls prolactin levels
P00598012A0174|28 32|stage
P00598012A0174|52 59|menarche
P00598012A0174|63 66|boys
P00598012A0174|76 81|change
P00598012A0174|84 99|prolactin levels
P00599601A0260|37 46|procedures
P00599601A0260|64 75|pinealectomy
P00599601A0260|104 114|alterations
P00599601A0260|132 141|physiology
P00599601A0260|166 168|rat
P00600943T0001|1 5|cases
P00600943T0001|13 31|lymphomononucleosis
P00601401A0181|6 24|hemoglobin solution
P00601401A0181|46 53|affinity
P00601401A0181|57 62|oxygen
P00601401A0181|70 80|Bohr effect
P00601401A0181|96 123|delta log Po2/delta pH ratio
P00602622A0362|9 21|ulcer therapy
P00602622A0362|25 32|atropine
P00602622A0362|36 42|Vikalin
P00602622A0362|44 48|Roter
P00602622A0362|68 68|p
P00602622A0362|82 90|reduction
P00602622A0362|116 123|activity
P00602702A0309|5 11|patient
P00602702A0309|22 29|diarrhea
P00602702A0309|33 53|estriol concentration
P00602702A0309|55 59|serum
P00602702A0309|84 91|function
P00602702A0309|108 128|estriol concentration
P00602702A0309|148 155|diarrhea
P00603783A0647|0 11|Serum levels
P00603783A0647|13 15|IgG
P00603783A0647|19 21|IgM
P00603783A0647|53 60|findings
P00603783A0647|68 87|observers IgA levels
P00606849T0000|20 32|heart disease
P00606849T0000|41 54|thromboxane A2
P00606849T0000|56 62|rabbits
P00614915T0001|0 9|Vitrectomy
P00614915T0001|18 29|traumatology
P00616575A0000|10 20|sensitivity
P00616575A0000|34 49|brain structures
P00616575A0000|54 59|action
P00616575A0000|79 83|field
P00616575A0000|86 100|decimeter waves
P00616575A0000|101 103|EMF
P00616575A0000|106 107|DW
P00616575A0000|117 129|investigation
P00616575A0000|138 150|unit activity
P00617815A0215|12 26|L-R differences
P00618078A0367|1 8|decrease
P00618078A0367|14 30|lysozyme activity
P00618078A0367|54 64|improvement
P00618078A0367|79 88|meningitis
P00619305A0759|18 23|groups
P00619305A0759|47 55|dimension
P00619305A0759|70 79|dimensions
P00619782A0058|4 7|tans
P00619782A0058|26 30|backs
P00619782A0058|33 42|volunteers
P00619782A0058|55 62|exposure
P00619782A0058|73 93|ultraviolet radiation
P00619782A0058|94 97|UV-A
P00619948A0000|4 10|effects
P00619948A0000|19 26|subjects
P00619948A0000|40 43|dose
P00619948A0000|46 52|Motival
P00619948A0000|57 62|tablet
P00619948A0000|74 85|fluphenazine
P00619948A0000|89 90|mg
P00619948A0000|94 106|nortriptyline
P00619948A0000|109 110|mg
P00619948A0000|135 143|variation
P00619948A0000|145 147|CNV
P00619948A0000|150 162|reaction time
P00619948A0000|163 172|heart rate
P00619948A0000|173 186|blood pressure
P00619948A0000|200 205|scales
P00619948A0000|209 217|alertness
P00619948A0000|219 225|anxiety
P00619948A0000|227 233|tension
P00619948A0000|235 244|detachment
P00619948A0000|248 257|depression
P00619948A0000|281 288|diazepam
P00619948A0000|291 292|mg
P00619948A0000|299 300|mg
P00619948A0000|305 311|placebo
P00619948A0000|314 324|propranolol
P00619948A0000|328 329|mg
P00621626T0000|0 13|Stress effects
P00621626T0000|15 37|affiliation preferences
P00621626T0000|42 49|subjects
P00621626T0000|63 66|type
P00621626T0000|82 97|behavior pattern
P00622556A0111|16 23|collagen
P00622556A0111|30 35|tissue
P00622556A0111|64 69|tendon
P00623361A0221|0 6|Smoking
P00623361A0221|28 39|contribution
P00623361A0221|51 61|dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|20 26|lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|13 22|bagassosis
P00627039T0000|25 67|Louisiana paper manufacturing plant workers
P00627129A0944|5 13|responses
P00627129A0944|30 35|others
P00627129A0944|45 52|subjects
P00627129A0944|65 74|conditions
P00627129A0944|115 120|effect
P00627129A0944|123 131|labetalol
P00627129A0944|155 162|blockade
P00627129A0944|174 191|beta-adrenoceptors
P00627202T0000|0 8|Diuretics
P00627202T0000|23 34|pharmacology
P00627202T0000|49 51|use
P00628990A0000|5 12|patients
P00628990A0000|33 37|units
P00628990A0000|63 76|reconstruction
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|157 160|loop
P00628990A0000|170 181|ureterostomy
P00630713T0000|0 9|Evaluation
P00630713T0000|15 43|Du Pont aca ammonia procedure
P00633909A0000|18 25|patients
P00633909A0000|27 32|scores
P00633909A0000|35 40|Rotter
P00633909A0000|43 65|Internal-External Locus
P00633909A0000|67 79|Control Scale
P00633909A0000|98 106|treatment
P00633909A0000|135 142|patients
P00633909A0000|171 177|control
P00635143T0001|0 5|Action
P00635143T0001|8 19|strontium-90
P00635143T0001|23 30|metaphos
P00635143T0001|33 47|Cyprinus carpio
P00635194A0093|0 14|Kodak XV-2 film
P00635194A0093|65 81|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|24 32|diagnosis
P00637637T0000|11 17|factors
P00637637T0000|27 47|plasma renin activity
P00637637T0000|57 68|hypertension
P00639410T0000|0 8|Cortisone
P00639410T0000|16 27|bone changes
P00639410T0000|33 40|response
P00639410T0000|43 63|lipid clearing agents
P00640584A0250|17 25|principle
P00640584A0250|46 54|stability
P00641395A0441|4 16|blood samples
P00641395A0441|18 25|patients
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|67 77|measurement
P00641395A0441|80 82|ZPP
P00641395A0441|89 99|fluorimeter
P00641395A0441|126 131|levels
P00641395A0441|150 166|extraction method
P00644314T0000|7 22|hypersensitivity
P00644314T0000|25 27|man
P00644314T0000|29 35|effects
P00644314T0000|46 60|anticoagulation
P00644539A0783|18 27|inhalation
P00644539A0783|31 32|ml
P00644539A0783|39 44|saline
P00644539A0783|53 56|FEV1
P00644539A0783|66 66|%
P00644539A0783|71 71|%
P00644539A0783|106 112|subject
P00644539A0783|115 123|reactions
P00644539A0783|129 142|test solutions
P00646023T0058|12 18|studies
P00646023T0058|21 35|virus excretion
P00646023T0058|51 62|transmission
P00646193T0000|0 6|Potency
P00646193T0000|9 17|enflurane
P00646193T0000|20 23|dogs
P00646193T0000|25 34|comparison
P00646193T0000|39 47|halothane
P00646193T0000|51 60|isoflurane
P00656008T0000|0 9|Prevention
P00656008T0000|17 33|paraquat toxicity
P00656008T0000|35 38|rats
P00656008T0000|41 60|superoxide dismutase
P00657551T0000|0 10|Measurement
P00657551T0000|13 32|magnesium absorption
P00657551T0000|34 36|man
P00657551T0000|48 51|26Mg
P00657551T0000|55 60|tracer
P00659962T0000|16 35|riboflavin excretion
P00659962T0000|53 66|acid ingestion
P00663166A0000|12 22|angiography
P00663166A0000|37 48|body imaging
P00663166A0000|83 94|particulates
P00663166A0000|128 135|shunting
P00663166A0000|138 145|patients
P00663166A0000|150 173|patent ductus arteriosus
P00663166A0000|173 175|PDA
P00663166A0000|181 202|Eisenmenger physiology
P00664320T0000|7 15|detectors
P00664320T0000|32 38|pathway
P00665053A0276|34 37|type
P00665053A0276|39 43|06a6b
P00665053A0276|45 47|K13
P00665053A0276|49 50|H1
P00665053A0276|67 81|group affection
P00665214A0374|3 8|method
P00665214A0374|45 54|physiology
P00665214A0374|65 69|cycle
P00665336A0908|9 12|time
P00665336A0908|43 57|EEG-information
P00668122A0414|0 7|Analysis
P00668122A0414|10 31|liver biopsy specimens
P00668122A0414|34 41|patients
P00668122A0414|46 54|hepatitis
P00668122A0414|67 75|variation
P00668122A0414|81 97|mean iron content
P00668122A0414|101 124|liver ferritin molecules
P00669800A0579|6 9|mice
P00669800A0579|42 50|infection
P00669800A0579|55 59|males
P00676416A0320|22 26|years
P00676416A0320|42 55|liver biopsies
P00676790T0000|0 17|Angiotensin effect
P00676790T0000|27 32|kidney
P00681550A0000|0 6|Procion
P00681550A0000|51 65|auditory fibers
P00681550A0000|67 74|goldfish
P00681550A0000|91 102|relationship
P00681550A0000|113 125|response type
P00681550A0000|132 137|fibers
P00681550A0000|146 149|site
P00681550A0000|152 162|termination
P00681550A0000|176 181|macula
P00681571T0028|10 17|findings
P00681571T0028|23 31|epidermis
P00681571T0028|54 77|eccrine sweat duct units
P00682762T0001|0 18|Silicosis mortality
P00685922A0451|26 35|strictures
P00685922A0451|66 69|tree
P00685922A0451|71 73|IHB
P00686836A0000|0 6|Pentane
P00686836A0000|10 15|ethane
P00686836A0000|33 50|lipid peroxidation
P00686836A0000|71 88|gas chromatography
P00686836A0000|90 103|breath samples
P00686836A0000|105 108|rats
P00686836A0000|116 120|weeks
P00686836A0000|122 128|vitamin
P00686836A0000|140 143|diet
P00686836A0000|172 191|IU vitamin E acetate
P00686836A0000|192 193|kg
P00693987T0001|0 13|Thromboplastic
P00693987T0001|29 36|activity
P00693987T0001|42 46|blood
P00693987T0001|52 65|administration
P00693987T0001|68 77|intralipid
P00693987T0001|80 82|men
P00693987T0001|87 93|history
P00693987T0001|106 115|infarction
P00693987T0001|122 125|year
P00693987T0001|128 131|life
P00696680A0000|3 9|authors
P00696680A0000|36 43|findings
P00696680A0000|50 54|cases
P00696680A0000|62 66|women
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00696680A0000|120 125|cervix
P00696858A0000|3 8|effect
P00696858A0000|22 37|porcine secretin
P00696858A0000|39 47|endocrine
P00696858A0000|69 77|secretion
P00696858A0000|116 131|porcine pancreas
P00701144T0000|9 16|analysis
P00701144T0000|30 39|lens power
P00701144T0000|56 65|emmetropia
P00701144T0000|67 73|results
P00701144T0000|79 86|implants
P00701462A0722|0 15|Urine antibodies
P00701462A0722|47 51|cases
P00702773A0327|0 10|Althoug RBF
P00702773A0327|34 40|therapy
P00702773A0327|76 81|change
P00702773A0327|84 86|RBF
P00702773A0327|88 90|GFR
P00702773A0327|101 106|output
P00703350A0418|0 12|99mTc phytate
P00703350A0418|13 25|198Au colloid
P00703350A0418|29 33|99mTc
P00703350A0418|42 48|sulfide
P00703932A0000|3 10|patients
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|35 45|association
P00703932A0000|69 73|shunt
P00703932A0000|99 103|modes
P00703932A0000|106 112|therapy
P00704675A0199|3 6|mass
P00704675A0199|9 11|UO2
P00704675A0199|31 37|bronchi
P00704675A0199|46 56|bifurcation
P00704675A0199|84 84|d
P00704675A0199|90 99|inhalation
P00704675A0199|120 123|mass
P00704675A0199|129 135|trachea
P00710217T0001|8 12|cysts
P00710217T0001|18 26|hip joint
P00710372A0302|22 32|dysfunction
P00710372A0302|62 69|function
P00710372A0302|82 94|GH deficiency
P00710372A0302|125 132|features
P00712117A0521|6 13|outbreak
P00712117A0521|16 26|influenza A
P00712117A0521|39 42|base
P00712117A0521|49 56|February
P00712117A0521|71 79|A/Texas/1
P00712117A0521|88 92|virus
P00712117A0521|95 101|variant
P00712117A0521|107 118|A/Victoria/3
P00712117A0521|122 130|prototpye
P00713525A0268|7 15|decreases
P00713525A0268|21 36|disfluency rates
P00713525A0268|38 47|stutterers
P00713525A0268|69 80|presentation
P00713525A0268|91 104|stimulus words
P00713525A0268|108 111|data
P00713525A0268|137 141|model
P00715180T0074|0 5|Effect
P00715180T0074|8 11|time
P00715180T0074|15 18|dose
P00715180T0074|21 31|alterations
P00715180T0074|41 50|inhalation
P00715180T0074|53 81|plutonium-239 dioxide aerosol
P00715180T0074|82 84|rat
P00715753A0241|2 24|biopsies CK-MB fraction
P00715753A0241|40 42|CPK
P00715753A0241|48 48|%
P00715753A0241|53 70|total-CPK activity
P00715753A0241|85 91|muscles
P00715753A0241|104 113|% fraction
P00715753A0241|115 119|CK-MB
P00716366T0001|0 4|Value
P00716366T0001|7 19|determination
P00716366T0001|22 52|alkaline phosphatase isoenzymes
P00716366T0001|66 74|diagnosis
P00716366T0001|88 95|jaundice
P00716366T0001|106 120|liver cirrhosis
P00722298A0619|8 15|analysis
P00722298A0619|18 25|variance
P00722298A0619|49 51|men
P00722298A0619|55 59|women
P00722298A0619|63 73|differences
P00722298A0619|93 98|groups
P00722298A0619|101 116|field dependence
P00722298A0619|123 134|significance
P00722298A0619|136 138|rho
P00722298A0619|157 163|females
P00722298A0619|172 177|famale
P00722298A0619|198 202|field
P00722298A0619|237 242|groups
P00722298A0619|256 260|males
P00722652A0118|11 34|2nd-generation schizonts
P00722652A0118|48 55|diameter
P00722652A0118|68 77|micrometer
P00722652A0118|103 109|surface
P00722652A0118|115 119|cecum
P00725257A0452|13 22|pD2 values
P00725257A0452|32 32|E
P00725257A0452|40 42|DHE
P00725257A0452|52 53|M.
P00725336T0000|0 35|Newcastle disease virus surveillance
P00725336T0000|35 43|Hong Kong
P00725336T0000|61 67|poultry
P00725534A0888|29 37|challenge
P00725534A0888|40 48|M. leprae
P00725534A0888|53 60|antigens
P00725534A0888|66 80|IgA immunocytes
P00725534A0888|95 104|epithelium
P00725534A0888|121 129|tolerance
P00725534A0888|139 152|IgA deficiency
P00725534A0888|173 179|atrophy
P00725534A0888|195 199|villi
P00725534A0888|205 212|patients
P00725534A0888|228 234|leprosy
P00725752T0001|0 8|Treatment
P00725752T0001|11 22|hypertension
P00725752T0001|28 38|combination
P00725752T0001|54 76|beta receptor blockader
P00725752T0001|76 82|obsidan
P00725752T0001|90 100|vasodilator
P00725752T0001|102 109|apressin
P00726581T0122|0 5|Orthop
P00728718T0000|0 14|Thyroid disease
P00728718T0000|17 25|pregnancy
P00729003A1182|0 7|Residues
P00729003A1182|19 29|transcripts
P00729003A1182|32 39|splicing
P00733067A0188|10 15|reflux
P00733067A0188|28 31|loop
P00733067A0188|34 39|number
P00733067A0188|51 55|steps
P00733067A0188|91 97|section
P00733067A0188|110 114|stump
P00733067A0188|132 143|construction
P00733067A0188|149 159|anastomosis
P00733067A0188|182 189|creation
P00733067A0188|207 218|valve system
P00733067A0188|233 243|anastomosis
P00733067A0188|246 264|spiral introflexion
P00733067A0188|269 274|mucosa
P00733067A0188|290 297|stitches
P00733067A0188|332 336|lumen
P00736376A0371|6 10|stage
P00736376A0371|27 35|mortality
P00736376A0371|43 50|ischemia
P00736376A0371|75 81|urgency
P00736376A0371|87 95|operation
P00736376A0371|101 105|skill
P00737422A0832|0 8|Pathogens
P00737422A0832|45 51|bacilli
P00737422A0832|76 81|member
P00737422A0832|84 88|staff
P00737422A0832|96 102|numbers
P00737422A0832|133 139|numbers
P00737422A0832|144 151|patients
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00740409A0000|45 63|cerebellar deposits
P00740409A0000|74 78|Tonge
P00741476A0000|11 15|woman
P00741476A0000|24 42|Ergotamine Tartrate
P00741476A0000|45 51|mg p.d.
P00741476A0000|62 65|days
P00741476A0000|74 81|abortion
P00741476A0000|89 93|birth
P00743335T0001|0 13|Reaction times
P00743335T0001|42 48|stimuli
P00743335T0001|51 59|diabetics
P00745775A0170|12 19|patients
P00745775A0170|45 57|arteriography
P00745775A0170|88 100|complications
P00745775A0170|110 118|injection
P00745775A0170|121 129|Urografin
P00745775A0170|133 134|M.
P00747722A0486|3 6|data
P00747722A0486|27 34|reaction
P00747722A0486|40 51|B1 injection
P00747722A0486|52 56|Phase
P00747722A0486|72 80|injection
P00747722A0486|89 92|drop
P00747722A0486|98 107|parameters
P00747722A0486|120 122|sec
P00748978T0000|0 19|Serum relaxin levels
P00748978T0000|20 35|prostaglandin E2
P00748978T0000|42 50|abortions
P00753237A0000|22 31|phenomenon
P00753237A0000|38 42|level
P00753237A0000|48 51|ends
P00753237A0000|64 67|arcs
P00753237A0000|77 87|body weight
P00753237A0000|90 93|PAIN
P00753237A0000|102 105|role
P00753237A0000|108 116|outsentry
P00753237A0000|118 120|fig
P00753237A0000|130 130|B
P00753237A0000|133 139|Plantar
P00753237A0000|151 160|ulceration
P00753237A0000|162 164|PPU
P00753237A0000|177 187|combination
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|219 219|C
P00753237A0000|225 231|patient
P00753237A0000|243 253|body weight
P00753237A0000|254 263|traumatism
P00753237A0000|265 271|effects
P00753237A0000|295 301|process
P00753237A0000|322 322|D
P00753237A0000|325 340|PNEUMATIC INSOLE
P00753237A0000|371 381|compression
P00753237A0000|387 390|ends
P00753237A0000|403 406|arcs
P00753237A0000|415 423|attrition
P00753237A0000|436 452|blood circulation
P00753237A0000|461 464|cure
P00753237A0000|468 478|prophylaxis
P00753237A0000|481 483|PPU
P00753237A0000|485 487|fig
P00755245A0000|0 5|Effect
P00755245A0000|8 16|indoramin
P00755245A0000|24 28|doses
P00755245A0000|41 54|vasomotor loci
P00755245A0000|70 79|chloralose
P00755245A0000|92 95|cats
P00755245A0000|122 126|sites
P00755671A0485|14 20|heparin
P00755671A0485|40 60|recalcification times
P00755671A0485|66 76|development
P00755671A0485|101 109|hematomas
P00755869A0216|0 22|Contingency contracting
P00755869A0216|29 35|clients
P00755869A0216|44 61|parents/caregivers
P00755869A0216|78 89|consequences
P00755869A0216|98 112|self-monitoring
P00755869A0216|128 133|intake
P00755869A0216|135 145|weight loss
P00755869A0216|149 156|exercise
P00756511T0036|0 8|Dietetics
P00756511T0036|11 19|childhood
P00756511T0036|32 39|diabetes
P00757244A0000|3 9|results
P00757244A0000|25 29|study
P00757244A0000|48 56|membranes
P00757244A0000|62 70|placentas
P00759049A0185|3 13|micromethod
P00759049A0185|18 30|microcuvettes
P00759049A0185|45 53|ferrozine
P00759049A0185|60 88|bathophenanthroline chromogen
P00759049A0185|93 96|ICSH
P00759400T0000|0 17|Platelet serotonin
P00759400T0000|18 21|5-HT
P00759400T0000|26 29|5-HT
P00759400T0000|39 44|factor
P00759400T0000|47 52|plasma
P00759400T0000|65 72|patients
P00762763A0253|10 18|incidence
P00762763A0253|21 24|SIDS
P00762763A0253|44 49|births
P00764737X0000|3 16|vigilance task
P00764737X0000|22 32|measurement
P00764737X0000|46 53|deficits
P00767155T0001|3 10|December
P00767155T0001|16 21|revolt
P00767155T0001|24 29|Moscow
P00767155T0001|47 55|personnel
P00767161A0837|11 19|increases
P00767161A0837|26 47|serum E2 concentration
P00767161A0837|55 59|pg/ml
P00767161A0837|77 81|hours
P00767161A0837|87 100|administration
P00767161A0837|103 105|day
P00767161A0837|113 117|hours
P00767161A0837|120 122|day
P00768220X0000|3 12|motor unit
P00771729X0000|17 22|system
P00771729X0000|29 38|variations
P00771729X0000|41 49|responses
P00771729X0000|52 59|hormones
P00775582T0000|10 19|properties
P00775582T0000|22 30|sumithion
P00779272T0001|11 17|studies
P00779272T0001|20 29|antibodies
P00779272T0001|44 48|virus
P00779272T0001|61 73|mononucleosis
P00780639X0000|16 22|antigen
P00780639X0000|24 26|CEA
P00780639X0000|28 37|procedures
P00780639X0000|49 58|evaluation
P00792847A0000|21 43|antilymphocyte globulin
P00792847A0000|44 46|ALG
P00792847A0000|74 78|agent
P00792847A0000|81 86|humans
P00799988A0554|5 9|basis
P00799988A0554|19 37|assessment patients
P00799988A0554|61 70|preference
P00799988A0554|74 83|imipramine
P00799988A0554|96 102|placebo
P00799988A0554|115 121|therapy
P00803867A0315|0 7|Patients
P00803867A0315|40 45|groups
P00803867A0315|64 69|cancer
P00803867A0315|84 89|cancer
P00803867A0315|105 112|patients
P00803867A0315|129 135|disease
P00803867A0315|147 152|months
P00806295A0193|0 9|Absorption
P00806295A0193|33 36|cent
P00806295A0193|47 56|absorption
P00806295A0193|64 67|cent
P00806295A0193|98 105|subjects
P00807356T0001|30 37|activity
P00807356T0001|40 60|hydroxy-9 ellipticine
P00808266T0000|0 7|Advances
P00808266T0000|13 22|management
P00808266T0000|36 41|cancer
P00808266T0000|44 60|radiation therapy
P00808898A0000|23 26|data
P00808898A0000|32 38|patient
P00808898A0000|71 77|failure
P00808898A0000|79 82|IPRF
P00811852T0001|8 19|satisfaction
P00811852T0001|22 28|nursing
P00811852T0001|32 40|encounter
P00811852T0001|61 68|patients
P00812183T0000|10 24|transfer factor
P00818380A0239|10 15|factor
P00818380A0239|30 43|antibody tests
P00818380A0239|69 77|reactions
P00818380A0239|80 91|gold therapy
P00818380A0239|128 138|populations
P00819176T0001|3 8|effect
P00819176T0001|22 29|pressure
P00819176T0001|35 51|swimming activity
P00819176T0001|71 79|crustacea
P00819176T0001|81 101|Anomalocera patersoni
P00819176T0001|102 122|Pontella mediterranea
P00819176T0001|123 143|Labidocera wollastoni
P00821833A0000|4 9|report
P00821833A0000|20 27|analysis
P00821833A0000|38 47|repertoire
P00821833A0000|50 63|howler monkeys
P00821833A0000|64 80|Alouatta palliata
P00821833A0000|96 106|field study
P00821833A0000|120 125|Panama
P00822611A0467|10 15|number
P00822611A0467|18 25|patients
P00822611A0467|58 64|persons
P00822611A0467|77 89|binephrectomy
P00823087A0608|0 7|Deflunia
P00823087A0608|28 35|patients
P00825571T0031|0 2|III
P00827364A0000|4 13|instrument
P00827364A0000|32 48|freeze-fracturing
P00827364A0000|61 68|material
P00827364A0000|71 75|ultra
P00827364A0000|80 85|vacuum
P00830568A0000|20 28|secretion
P00830568A0000|39 52|emptying rates
P00830568A0000|61 69|test meal
P00830568A0000|70 72|LTM
P00830568A0000|96 102|persons
P00830568A0000|106 113|patients
P00830568A0000|126 136|gastrectomy
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|160 165|STG-BI
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|191 197|STG-BII
P00830568A0000|205 212|patients
P00830568A0000|224 231|vagotomy
P00830568A0000|235 246|pyloroplasty
P00830568A0000|248 250|V&P
P00832096T0000|8 25|calcium metabolism
P00832096T0000|41 51|sarcoidosis
P00833472A0907|16 22|patient
P00833472A0907|35 44|gallstones
P00833472A0907|54 64|institution
P00833472A0907|67 76|colestipol
P00833472A0907|78 87|saturation
P00833472A0907|90 105|gallbladder bile
P00833472A0907|109 119|cholesterol
P00833472A0907|149 152|drug
P00836637A0000|11 20|experiment
P00836637A0000|65 79|music-listening
P00836637A0000|91 100|reinforcer
P00836637A0000|111 132|arithmetic performance
P00836637A0000|134 145|EMR children
P00836637A0000|172 184|reinforcement
P00836637A0000|196 205|preference
P00836637A0000|213 222|reinforcer
P00837262A0000|3 16|responsiveness
P00837262A0000|25 30|cortex
P00837262A0000|32 33|VC
P00837262A0000|46 55|colliculus
P00837262A0000|57 58|SC
P00837262A0000|94 105|conditioning
P00837262A0000|107 108|ON
P00837262A0000|113 115|OFF
P00837262A0000|117 127|stimulation
P00837262A0000|134 139|rabbit
P00837811A0675|1 9|diagnosis
P00837811A0675|12 13|MS
P00837811A0675|44 48|signs
P00837811A0675|56 86|fluid gamma globulin elevations
P00837811A0675|88 100|abnormalities
P00837811A0675|121 127|testing
P00838152A0863|14 34|mean temperature rise
P00838152A0863|47 55|degrees C
P00838152A0863|61 69|degrees C
P00838152A0863|76 84|selection
P00838152A0863|109 121|disappearance
P00838152A0863|134 147|qualifications
P00838152A0863|153 166|triplet groups
P00838152A0863|175 186|predominance
P00838152A0863|203 216|qualifications
P00838152A0863|227 232|groups
P00839378A0649|11 16|Viso V
P00839378A0649|21 29|RDS group
P00839378A0649|39 46|increase
P00839378A0649|54 70|airway resistance
P00839378A0649|84 90|disease
P00839378A0649|98 104|therapy
P00842406A0771|16 20|tests
P00842406A0771|44 47|task
P00842406A0771|50 53|test
P00842406A0771|57 79|visuomotor coordination
P00842406A0771|83 98|recognition task
P00842522T0000|18 27|intubation
P00842522T0000|33 42|management
P00842522T0000|76 84|emphysema
P00843232A0100|3 12|background
P00843232A0100|47 52|factor
P00843232A0100|59 67|character
P00843232A0100|70 75|lesion
P00843232A0100|81 90|epithelium
P00843670T0000|3 7|sense
P00843670T0000|10 13|self
P00846559A0000|6 12|strains
P00846559A0000|15 27|Fusarium poae
P00846559A0000|30 48|F. sporotrichioides
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|67 73|strains
P00846559A0000|81 87|species
P00846559A0000|96 118|F. sporotrichioides var
P00846559A0000|118 127|tricinctum
P00846559A0000|132 137|U.S.A.
P00846559A0000|141 146|France
P00846559A0000|172 179|capacity
P00846559A0000|187 195|T-2 toxin
P00847967T0000|17 20|uses
P00847967T0000|35 44|tomography
P00847967T0000|55 62|medicine
P00851041A0000|10 14|study
P00851041A0000|19 26|patients
P00851041A0000|31 37|Ebstein
P00851041A0000|40 46|anomaly
P00851286A0375|0 5|Deaths
P00851286A0375|15 19|hours
P00851286A0375|25 45|copper concentrations
P00851286A0375|62 64|ppm
P00851286A0375|68 72|signs
P00851286A0375|75 82|distress
P00851286A0375|124 128|hours
P00851286A0375|141 145|death
P00857024A0888|0 9|Recurrence
P00857024A0888|12 25|bladder tumors
P00857024A0888|42 46|cases
P00857024A0888|76 91|properdin levels
P00857024A0888|107 112|median
P00863184T0043|0 9|Adaptation
P00863184T0043|24 40|transport maximum
P00863184T0043|60 63|load
P00863184T0043|69 71|rat
P00863773T0000|0 6|Dangers
P00863773T0000|9 11|use
P00863773T0000|14 32|live-virus vaccines
P00866577A0579|0 8|Treatment
P00866577A0579|13 19|heparin
P00866577A0579|21 42|plasminogen activators
P00866577A0579|61 66|agents
P00866577A0579|96 103|function
P00866577A0579|122 128|patient
P00866577A0579|135 138|term
P00866577A0579|156 162|therapy
P00868301A0043|2 23|diethyl ether solution
P00868301A0043|29 32|peak
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868301A0043|83 96|retention time
P00868301A0043|102 108|minutes
P00868301A0043|117 125|condition
P00868903A0000|0 7|Amikacin
P00868903A0000|20 28|treatment
P00868903A0000|53 62|infections
P00868903A0000|67 74|patients
P00870859A0121|3 6|data
P00870859A0121|48 54|account
P00870859A0121|60 68|direction
P00870859A0121|71 83|recirculation
P00870859A0121|107 112|factor
P00871237A0601|6 13|activity
P00871237A0601|21 27|patient
P00871237A0601|37 42|angina
P00872442T0000|0 9|Estimation
P00872442T0000|12 20|L-alanine
P00872442T0000|23 27|serum
P00872442T0000|30 35|plasma
P00872442T0000|44 69|LKB reaction rate analyser
P00872922A0204|3 7|acids
P00872922A0204|22 31|hydrolysis
P00872922A0204|50 55|esters
P00872922A0204|82 89|activity
P00874942T0000|12 21|amnionitis
P00874942T0000|25 35|prematurity
P00874942T0000|49 54|report
P00875778T0000|0 9|Evaluation
P00875778T0000|18 40|Gravigard IUCD inserter
P00876722T0000|9 18|meningitis
P00876722T0000|30 36|abscess
P00876722T0000|47 52|septum
P00877857A0763|0 12|Serum amylase
P00877857A0763|40 48|CU/100 ml
P00877857A0763|58 66|serum FFA
P00877857A0763|72 80|mEq/liter
P00879329A0176|5 23|control preparation
P00879329A0176|29 34|weight
P00879329A0176|79 86|pressure
P00879329A0176|88 90|Pci
P00879329A0176|101 104|mmHg
P00879329A0176|114 120|colloid
P00879329A0176|128 135|pressure
P00879329A0176|141 146|plasma
P00879329A0176|148 150|IIp
P00879829A0564|0 6|Infants
P00879829A0564|26 30|hours
P00879829A0564|36 38|IVH
P00879829A0564|61 74|birth asphyxia
P00879829A0564|103 109|symptom
P00879829A0564|122 127|apnoea
P00881630A0000|16 22|effects
P00881630A0000|28 39|snake venoms
P00881630A0000|40 46|N. naja
P00881630A0000|49 61|A. piscivorus
P00881630A0000|81 86|Factor
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|106 114|compounds
P00881630A0000|127 133|N. naja
P00881630A0000|138 142|venom
P00881630A0000|162 165|lung
P00881630A0000|169 185|cremaster vessels
P00881630A0000|187 190|rats
P00885562A0281|5 8|GAGs
P00885562A0281|15 24|components
P00885562A0281|27 42|cartilage matrix
P00885562A0281|46 54|depletion
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|94 99|method
P00885562A0281|121 133|GAG synthesis
P00885562A0281|135 141|culture
P00890028A0507|3 15|length scales
P00890028A0507|20 29|turbulence
P00890028A0507|51 65|Reynolds number
P00890028A0507|77 86|macroscale
P00890028A0507|98 99|mm
P00890028A0507|104 120|Taylor microscale
P00890028A0507|131 132|mm
P00890028A0507|140 156|Kolmogoroff scale
P00890028A0507|167 168|mm
P00891370A0000|15 26|arteriograms
P00891370A0000|32 36|limbs
P00891370A0000|52 66|xeroradiography
P00891370A0000|83 91|injection
P00891370A0000|94 108|contrast-medium
P00891370A0000|115 122|arm vein
P00891370A0000|141 148|patients
P00892353A0686|2 12|hypotension
P00892353A0686|23 30|patients
P00892353A0686|35 41|toxemia
P00892353A0686|54 58|fever
P00892353A0686|68 77|degrees C.
P00898500A0246|3 6|sera
P00898500A0246|15 24|secretions
P00898500A0246|30 37|patients
P00898500A0246|56 57|HD
P00898500A0246|60 74|mites skin test
P00898500A0246|109 112|test
P00898500A0246|114 117|RAST
P00898500A0246|143 163|IgE antibody activity
P00898500A0246|164 168|mites
P00903772A0359|0 7|Wherever
P00903772A0359|11 14|site
P00903772A0359|20 43|conditioning stimulation
P00903772A0359|49 61|modifications
P00903772A0359|78 86|ischaemia
P00903772A0359|92 94|leg
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|19 21|DAN
P00909114A0000|35 46|nitrosamines
P00909114A0000|77 85|neoplasms
P00909114A0000|88 91|rats
P00909114A0000|104 112|incidence
P00909114A0000|126 137|tract tumors
P00909114A0000|151 158|hamsters
P00909114A0000|166 167|sc
P00909114A0000|186 190|doses
P00909114A0000|196 203|compound
P00910823A0196|4 7|term
P00910823A0196|26 35|conditions
P00910823A0196|53 63|blood gases
P00910823A0196|64 65|pH
P00910823A0196|67 73|uterine
P00910823A0196|86 96|blood flows
P00911590T0000|12 20|responses
P00911590T0000|23 32|antagonism
P00911590T0000|35 50|bocurarine block
P00911590T0000|54 81|atropine-neostigmine mixture
P00911590T0000|83 90|children
P00913623A0242|3 11|mechanism
P00913623A0242|24 32|molecules
P00913623A0242|43 55|diphosphonate
P00913623A0242|69 72|EHDP
P00913623A0242|88 100|pyrophosphate
P00913623A0242|102 105|pass
P00913623A0242|113 123|capillaries
P00913623A0242|126 129|bone
P00913623A0242|134 150|passive diffusion
P00915090A0536|11 14|days
P00915090A0536|20 28|injection
P00915090A0536|34 36|mCi
P00915090A0536|39 44|Tc-99m
P00915090A0536|58 61|rads
P00915090A0536|67 72|testis
P00915090A0536|77 82|number
P00915090A0536|85 94|sperm hads
P00915090A0536|107 107|%
P00915090A0536|110 116|control
P00916099A0000|0 16|Self-emasculation
P00916099A0000|22 31|end result
P00916099A0000|53 60|disorder
P00916099A0000|92 100|treatment
P00917572T0001|0 10|Possibility
P00917572T0001|27 32|method
P00917572T0001|36 44|detection
P00917572T0001|47 60|hypothyroidism
P00917721A0484|4 11|analysis
P00917721A0484|31 38|evidence
P00917721A0484|52 71|presleep suggestions
P00917721A0484|93 105|dream content
P00918556A0000|3 12|prevalence
P00918556A0000|15 41|hepatitis B surface antigen
P00918556A0000|40 44|HBsAg
P00918556A0000|49 56|anti-HBs
P00918556A0000|97 123|radio-immunoassay technique
P00918556A0000|126 131|series
P00918556A0000|134 141|patients
P00918556A0000|153 166|liver diseases
P00918965A0728|18 25|patients
P00918965A0728|46 52|failure
P00918965A0728|72 82|ventilation
P00918965A0728|90 101|componenents
P00918965A0728|116 120|shunt
P00918965A0728|125 132|parallel
P00918965A0728|171 174|PAO2
P00920381T0000|16 23|glycogen
P00920381T0000|43 51|injection
P00920381T0000|97 100|rats
P00921032T0000|10 19|evaluation
P00921032T0000|22 31|mibolerone
P00921032T0000|43 48|Beagle
P00921911A0159|0 5|Levels
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00921911A0159|67 72|labour
P00921911A0159|85 94|dilatation
P00921911A0159|106 107|cm
P00921911A0159|122 126|onset
P00921911A0159|129 134|labour
P00926272A0000|13 17|cause
P00926272A0000|25 37|deterioration
P00926272A0000|49 52|cord
P00926272A0000|60 66|patient
P00926272A0000|95 100|reflux
P00926604A0504|0 10|Propranolol
P00926604A0504|12 18|Inderal
P00926604A0504|35 38|dose
P00926604A0504|68 76|apparatus
P00926604A0504|82 86|heart
P00926604A0504|98 108|development
P00926604A0504|131 136|effect
P00926604A0504|150 154|doses
P00926604A0504|157 170|strophanthin K
P00926604A0504|199 208|myocardium
P00926751A0000|6 12|studies
P00926751A0000|25 34|rat larynx
P00926751A0000|49 53|organ
P00926751A0000|59 68|evaluation
P00926751A0000|71 79|irritancy
P00926751A0000|89 97|materials
P00927633T0001|8 15|electron
P00927633T0001|27 40|investigations
P00927633T0001|46 54|formation
P00927633T0001|57 64|Reissner
P00927633T0001|67 71|fiber
P00927633T0001|74 86|Rattus rattus
P00928529T0001|0 15|Feeding behavior
P00928529T0001|26 36|body weight
P00928529T0001|39 57|hibernation rhythms
P00928529T0001|67 74|hamsters
P00928529T0001|110 116|bundles
P00929418T0001|0 3|Role
P00929418T0001|9 37|infectious-disease specialist
P00929418T0001|63 71|incidence
P00929418T0001|86 93|diseases
P00930947A0629|13 29|drug interactions
P00930947A0629|42 47|effect
P00930947A0629|50 59|probenecid
P00930947A0629|67 75|secretion
P00930947A0629|78 80|PZA
P00930947A0629|115 120|effect
P00930947A0629|129 133|drugs
P00930947A0629|161 166|effect
P00930947A0629|173 176|drug
P00931089T0001|11 16|arrest
P00931089T0001|22 35|operating room
P00932738A0116|11 24|blood pressure
P00932738A0116|25 26|BP
P00932738A0116|32 35|mmHg
P00932738A0116|37 54|C02 responsiveness
P00932738A0116|91 96|levels
P00932738A0116|99 100|BP
P00932817A0499|0 9|Iodine-123
P00932817A0499|44 46|MEC
P00932817A0499|50 68|pinhole collimators
P00932817A0499|76 79|turn
P00932817A0499|87 96|MTF values
P00932817A0499|124 128|99mTc
P00933251T0000|7 16|meningioma
P00933251T0000|19 24|plaque
P00933251T0000|49 57|ear tumor
P00935526A0000|3 14|difficulties
P00935526A0000|24 37|prostaglandins
P00935526A0000|39 40|PG
P00935526A0000|54 67|chromatography
P00935526A0000|85 88|lack
P00935526A0000|91 101|sensitivity
P00935526A0000|144 145|ng
P00935526A0000|159 168|resolution
P00935526A0000|180 186|columns
P00938594A0149|2 10|cessation
P00938594A0149|13 27|steroid therapy
P00938594A0149|30 36|patient
P00938594A0149|61 74|manifestations
P00938594A0149|89 104|osteoarthropathy
P00938594A0149|106 108|HOA
P00938594A0149|129 147|laboratory features
P00938594A0149|159 167|arthritis
P00938594A0149|169 170|RA
P00941050T0000|3 8|effect
P00941050T0000|11 14|food
P00941050T0000|17 39|procainamide absorption
P00947327A0000|12 17|survey
P00947327A0000|23 31|situation
P00947327A0000|44 53|resistance
P00947327A0000|59 64|region
P00947327A0000|75 81|Bavaria
P00947327A0000|110 117|activity
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|138 140|SMZ
P00947327A0000|142 153|trimethoprim
P00947327A0000|155 157|TMP
P00947327A0000|159 169|combination
P00947327A0000|189 199|antibiotics
P00947327A0000|219 224|agents
P00947327A0000|229 235|results
P00947327A0000|238 242|tests
P00947327A0000|253 263|combination
P00947327A0000|266 267|N1
P00947327A0000|295 307|sulfanilamide
P00947327A0000|310 320|sulfamoxole
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
P00947327A0000|365 374|pyrimidine
P00947327A0000|376 387|trimethoprim
P00947327A0000|392 396|ratio
P00947327A0000|403 404|CN
P00947327A0000|410 414|Nevin
P00947327A0000|416 424|Supristol
P00947327A0000|446 450|tests
P00947327A0000|455 461|TMP/SMZ
P00947834X0000|0 6|RESULTS
P00947834X0000|13 22|IgE levels
P00947834X0000|29 36|tendency
P00951909X0001|12 24|loop syndrome
P00951909X0001|38 43|author
P00951909X0001|46 52|opinion
P00951909X0001|57 65|diagnosis
P00951909X0001|80 92|loop syndrome
P00951909X0001|116 123|patients
P00951909X0001|135 157|Billroth-II gastrectomy
P00952734T0000|0 5|Letter
P00952734T0000|23 28|damage
P00952734T0000|41 45|cause
P00952734T0000|66 76|elastolysis
P00952734T0000|80 89|cutis laxa
P00952734T0000|90 93|PECL
P00954819A1041|5 8|data
P00954819A1041|31 38|recovery
P00954819A1041|59 66|function
P00954819A1041|72 83|intoxication
P00954819A1041|88 92|Soman
P00954819A1041|95 99|Sarin
P00954819A1041|120 125|return
P00954819A1041|128 140|AChE activity
P00956364A0138|0 13|Batch cultures
P00956364A0138|15 32|S. mutans serotype
P00956364A0138|46 51|growth
P00956364A0138|54 61|MSB agar
P00956554A0414|5 11|samples
P00956554A0414|14 18|serum
P00956554A0414|45 65|solid-phase allergens
P00956554A0414|71 80|reactivity
P00956554A0414|95 108|IgE antibodies
P00958550T0001|0 5|Crisis
P00958550T0001|22 30|community
P00958550T0001|38 44|Britain
P00959656A0250|8 12|women
P00959656A0250|15 18|term
P00959656A0250|31 36|levels
P00959656A0250|39 50|antithrombin
P00961711T0000|0 17|Hematology problem
P00961711T0000|22 26|month
P00961711T0000|28 31|band
P00961711T0000|34 36|seg
P00962222A0633|22 31|variations
P00962222A0633|34 46|heme turnover
P00962222A0633|58 64|changes
P00962222A0633|67 93|erythrocyte characteristics
P00962222A0633|102 119|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|30 35|bypass
P00962277T0000|42 60|gelatine derivative
P00962277T0000|63 69|priming
P00964758T0001|14 25|plasmacytoma
P00964758T0001|31 43|parotid gland
P00967223T0059|0 1|I.
P00968181A0264|12 17|calves
P00968181A0264|31 38|immunity
P00968181A0264|57 65|challenge
P00968181A0264|73 76|days
P00968181A0264|90 98|infection
P00970320A0000|3 13|performance
P00970320A0000|33 62|chemical cartridge respirators
P00970320A0000|64 66|SO2
P00970320A0000|90 99|conditions
P00970320A0000|103 116|copper smelter
P00970488A0105|22 29|increase
P00970488A0105|39 49|DA turnover
P00970488A0105|52 60|indicator
P00970488A0105|67 72|degree
P00970488A0105|75 94|DA receptor blocking
P00970488A0105|144 149|effect
P00970488A0105|152 163|neuroleptics
P00970488A0105|170 180|development
P00970488A0105|200 207|symptoms
P00970839A0118|0 12|Rainbow trout
P00970839A0118|39 48|trout farm
P00970839A0118|62 66|water
P00970839A0118|70 76|feeding
P00970839A0118|91 97|pellets
P00970839A0118|105 109|weeks
P00974901A0080|0 10|Stimulation
P00974901A0080|13 31|macrophage function
P00974901A0080|39 64|Bordetella pertussis cells
P00974901A0080|86 91|effect
P00974901A0080|105 118|susceptibility
P00975314T0001|7 17|amenorrhoea
P00975314T0001|56 64|karyotype
P00975314T0001|68 69|xy
P00975314T0001|82 95|gonadoblastoma
P00975540T0000|14 20|methods
P00975540T0000|31 39|chemistry
P00975540T0000|41 51|application
P00975540T0000|54 73|mass fragmentography
P00975540T0000|75 96|high-accuracy analyses
P00980255T0000|0 10|Application
P00980255T0000|16 39|2-deoxy-D-glucose method
P00980255T0000|44 51|coupling
P00980255T0000|62 71|metabolism
P00980255T0000|75 84|blood flow
P00984209A0614|0 19|Serum gastrin levels
P00984209A0614|38 42|group
P00984209A0614|52 90|background serum gastrin concentrations
P00984209A0614|115 126|V&P patients
P00984209A0614|130 141|V&A patients
P00984209A0614|154 158|study
P00985110T0001|8 18|projections
P00985110T0001|31 37|portion
P00985110T0001|43 49|putamen
P00985110T0001|82 88|regions
P00985110T0001|94 96|cat
P00985110T0001|105 110|cortex
P00985276A0000|0 8|Preflight
P00985276A0000|10 17|inflight
P00985276A0000|22 55|postflight exercise response tests
P00985276A0000|71 80|astronauts
P00985276A0000|92 105|Skylab mission
P00985276A0000|106 111|Skylab
P00985276A0000|116 119|part
P00985276A0000|124 133|evaluation
P00985276A0000|149 158|adaptation
P00985276A0000|170 183|weightlessness
P00985279A0493|0 3|Mean
P00985279A0493|15 39|hemoglobin concentrations
P00985279A0493|58 58|h
P00985279A0493|81 86|groups
P00985279A0493|91 99|CO2 group
P00985279A0493|115 122|decrease
P00986800A0325|3 11|Cu values
P00986800A0325|26 31|organs
P00986800A0325|55 70|saturation level
P00986800A0325|73 85|mug Cu/g diet
P00986800A0325|91 99|exception
P00986800A0325|105 110|values
P00986800A0325|114 120|body Cu
P00986800A0325|130 133|dams
P00986800A0325|153 155|day
P00986800A0325|158 165|delivery
P00986925A0002|3 8|effect
P00986925A0002|11 20|calcitonin
P00986925A0002|28 33|amount
P00986925A0002|36 42|calcium
P00986925A0002|55 66|pentagastrin
P00986925A0002|70 77|glucagon
P00986925A0002|80 111|plasma 47Ca radioactivity curves
P00986925A0002|111 118|subjects
P00986925A0002|133 136|47Ca
P00987649T0001|0 4|State
P00987649T0001|10 13|body
P00987649T0001|16 24|disorders
P00987649T0001|47 53|rhythms
P00987649T0001|66 76|hypokinesia
P00988572A0000|0 13|Oxygen tension
P00988572A0000|23 35|lymph vessels
P00988572A0000|36 39|PLO2
P00988572A0000|46 61|rabbit hind limb
P00988572A0000|97 103|chamber
P00988572A0000|121 149|catheter-tip oxygen electrode
P00988572A0000|168 171|data
P00988572A0000|177 182|source
P00988572A0000|185 190|oxygen
P00988572A0000|196 200|lymph
P00989973A0000|3 10|response
P00989973A0000|16 38|plasma fibrinogen level
P00989973A0000|55 63|injection
P00989973A0000|66 75|turpentine
P00989973A0000|95 103|injection
P00989973A0000|106 114|endotoxin
P00989973A0000|134 140|rabbits
P00989973A0000|146 152|rabbits
P00989973A0000|196 203|busulfan
P00992316A0178|21 35|pressure curves
P00992316A0178|49 58|activities
P00992316A0178|100 107|criteria
P00992316A0178|127 135|gravidity
P00993176A0066|5 13|myoglobin
P00993176A0066|35 44|hemoglobin
P00993176A0066|50 62|heme pigments
P00993176A0066|79 85|portion
P00993176A0066|91 97|extract
P00993176A0066|116 125|hemoglobin
P00993176A0066|132 132|%
P00993176A0066|134 136|NH4
P00993176A0066|138 150|2SO4 solution
P00996272A0397|16 22|sources
P00996272A0397|25 29|error
P00996272A0397|39 49|variability
P00996272A0397|62 74|investigation
P00996272A0397|101 112|instructions
P00996364X0000|0 0|E
P00999494A0000|3 10|patients
P00999494A0000|18 26|diagnosis
P00999494A0000|34 38|mania
P00999494A0000|58 62|doses
P00999494A0000|91 107|agent propranolol
P01000378T0000|0 5|Effect
P01000378T0000|8 13|trauma
P01000378T0000|16 30|plasma glucagon
P01000378T0000|33 54|insulin concentrations
P01000378T0000|56 60|sheep
P01003819A0498|7 10|help
P01003819A0498|14 25|nomogram one
P01003819A0498|38 47|refraction
P01003819A0498|53 63|axis length
P01003819A0498|66 82|corneal curvature
P01004298A0744|4 13|up-grading
P01004298A0744|24 28|score
P01004298A0744|34 45|CA component
P01004298A0744|58 58|%
P01004298A0744|73 80|students
P01004298A0744|85 90|scores
P01004298A0744|103 107|level
P01009451A0728|10 17|controls
P01009451A0728|23 24|UB
P01009451A0728|28 35|OCS rats
P01009451A0728|75 83|reduction
P01009451A0728|89 100|nocturnality
P01009451A0728|103 110|drinking
P01009739T0001|0 5|Effect
P01009739T0001|8 19|indomethacin
P01009739T0001|30 40|circulation
P01009739T0001|42 47|effect
P01009739T0001|50 52|ECG
P01009841T0001|4 14|innervation
P01009841T0001|21 26|fibers
P01009841T0001|29 41|trunk muscles
P01009841T0001|43 56|lamprey larvae
P01010638A0161|3 6|feed
P01010638A0161|34 34|%
P01012640T0001|7 21|characteristics
P01012640T0001|24 34|eye changes
P01012640T0001|36 43|patients
P01012640T0001|48 63|pheochromocytoma
P01012640T0001|73 78|Sipple
P01012640T0001|81 88|syndrome
P01012904A0333|13 31|interference effect
P01012904A0333|59 69|populations
P01012904A0333|82 92|Stroop test
P01012904A0333|122 127|sample
P01012904A0333|141 146|format
P01019207A0232|30 39|conditions
P01019207A0232|47 56|dependence
P01019207A0232|73 84|betaI% value
P01019207A0232|87 89|lgC
P01019207A0232|99 103|range
P01019207A0232|113 126|mug ruscogenin
P01021091T0000|3 11|influence
P01021091T0000|24 29|nerves
P01021091T0000|35 42|response
P01021091T0000|45 57|blood vessels
P01021091T0000|62 71|rabbit ear
P01021091T0000|98 108|vasopressin
P01021091T0000|110 120|Octapressin
P01027644T0001|10 13|test
P01030985T0090|0 1|I.
P01035457A0623|5 10|tumour
P01035457A0623|20 35|nipple discharge
P01035457A0623|45 54|importance
P01035457A0623|61 69|diagnosis
P01035457A0623|73 81|treatment
P01036714A0072|0 6|Studies
P01036714A0072|36 42|changes
P01036714A0072|67 73|animals
P01036714A0072|83 92|chrysotile
P01036714A0072|102 109|increase
P01036714A0072|115 118|lung
P01036714A0072|123 137|cell population
P01036714A0072|159 164|levels
P01044338A0240|8 19|measurements
P01044338A0240|22 40|temperature changes
P01044338A0240|43 51|estimates
P01044338A0240|57 63|heating
P01047417T0000|8 34|National Health Dis-service
P01047895T0001|2 10|criticism
P01047895T0001|13 24|patient care
P01047895T0001|57 61|value
P01047895T0001|63 70|Patients
P01047895T0001|72 80|criticism
P01047895T0001|102 113|patient care
P01048020T0000|0 7|Critique
P01048020T0000|22 28|Effects
P01048020T0000|31 42|Test Anxiety
P01048020T0000|45 60|Credit/No Credit
P01048020T0000|62 80|A-F Grade Condition
P01048020T0000|113 130|Course Information
P01048968A0152|5 11|studies
P01048968A0152|28 35|majority
P01048968A0152|44 56|staphylococci
P01048968A0152|72 83|penicillin G
P01048968A0152|84 95|erythromycin
P01048968A0152|108 121|beta-lactamase
P01050144A0297|16 23|decrease
P01050144A0297|29 34|number
P01050144A0297|37 43|strains
P01050144A0297|66 76|antibiotics
P01050144A0297|102 108|strains
P01050144A0297|114 124|83A complex
P01050400T0000|0 10|Improvement
P01050400T0000|13 31|nursing instruction
P01050400T0000|45 48|time
P01050400T0000|51 59|discharge
P01050400T0000|67 70|ward
P01050400T0000|83 89|infants
P01057137A0192|2 11|difference
P01057137A0192|25 37|acceptability
P01057137A0192|69 74|groups
P01064124A0560|7 7|d
P01064124A0560|9 18|subsurface
P01064124A0560|42 47|lesion
P01064124A0560|64 72|specimens
P01067493A0119|16 22|pattern
P01067493A0119|28 32|women
P01067493A0119|51 57|percent
P01067493A0119|78 84|methods
P01071715A0903|16 24|technique
P01071715A0903|36 60|blood pressure recordings
P01075075T0038|0 1|I.
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|69 91|antilymphocyte globulin
P01078982A0227|92 94|ALG
P01078982A0227|96 104|treatment
P01078982A0227|109 126|ALG administration
P01078982A0227|142 147|dosage
P01078982A0227|150 165|cyclophosphamide
P01080374A0709|0 7|Evidence
P01080374A0709|23 27|Leber
P01080374A0709|38 55|aneurysm retinitis
P01080374A0709|69 74|entity
P01080374A0709|86 89|form
P01080374A0709|92 96|Coats
P01080374A0709|98 104|disease
P01081904A0198|22 29|catheter
P01081904A0198|42 49|patients
P01081904A0198|59 80|pull-out arteriography
P01081904A0198|110 117|symptoms
P01082726A0248|3 11|influence
P01082726A0248|21 25|pupil
P01082726A0248|31 38|response
P01082726A0248|44 49|DC-ERG
P01082833A0000|34 38|agent
P01082833A0000|40 45|Y-8004
P01082833A0000|66 75|inhibition
P01082833A0000|83 94|indomethacin
P01082833A0000|96 97|IM
P01082833A0000|114 121|response
P01082833A0000|139 146|erythema
P01082833A0000|149 159|guinea pigs
P01082833A0000|160 176|carrageenin edema
P01082833A0000|208 216|pleuritis
P01082833A0000|238 248|peritonitis
P01082833A0000|251 254|rats
P01083321X0000|2 7|stands
P01083321X0000|17 25|dominance
P01083321X0000|43 45|age
P01083321X0000|47 59|subalpine fir
P01083321X0000|96 100|rates
P01083321X0000|115 126|productivity
P01083321X0000|132 137|stands
P01083321X0000|158 162|years
P01083375T0000|0 18|Alpha-1 antitrypsin
P01083375T0000|27 45|childhood cirrhosis
P01083784T0000|0 24|Lymphocyte subpopulations
P01083784T0000|25 33|serum IgE
P01083784T0000|41 57|eosinophil counts
P01083784T0000|59 66|patients
P01083784T0000|80 85|asthma
P01084413A0271|1 5|range
P01084413A0271|25 36|measurements
P01084413A0271|43 45|EMI
P01087288T0000|1 10|comparison
P01087288T0000|35 43|estimates
P01087288T0000|46 59|radiation dose
P01087288T0000|61 68|patients
P01087288T0000|80 89|iodine-131
P01087288T0000|93 109|thyroid carcinoma
P01088654T0001|0 8|Technique
P01088654T0001|28 35|ceramics
P01088654T0001|45 48|mass
P01090210A0417|0 3|Mean
P01090210A0417|9 21|lung capacity
P01090210A0417|40 47|capacity
P01090210A0417|60 65|volume
P01090210A0417|95 113|mean closing volume
P01090210A0417|116 126|lung volume
P01090210A0417|139 144|volume
P01090210A0417|152 156|phase
P01090210A0417|194 199|cm H20
P01090210A0417|217 231|airway pressure
P01090210A0417|232 242|differences
P01090210A0417|246 251|cm H20
P01092248T0000|7 12|status
P01092248T0000|15 29|zinc deficiency
P01092248T0000|34 45|pathogenesis
P01092248T0000|93 101|disorders
P01093055T0000|0 6|Calcium
P01093055T0000|10 30|phosphorus metabolism
P01093055T0000|39 44|uremia
P01093845A0208|0 13|Modern studies
P01093845A0208|27 37|Delta-9-THC
P01093845A0208|48 58|voluntaries
P01093845A0208|75 84|comparison
P01093845A0208|94 101|identity
P01093845A0208|107 119|modifications
P01093845A0208|128 135|cannabis
P01093845A0208|140 144|sleep
P01093845A0208|148 152|dream
P01093847A0000|13 18|action
P01093847A0000|21 45|tropatepine hydrochloride
P01093847A0000|66 72|effects
P01093847A0000|82 93|neuroleptics
P01093847A0000|126 131|states
P01096741X0000|10 15|growth
P01096741X0000|29 35|animals
P01096741X0000|54 67|chickpea haulm
P01096741X0000|82 96|supplementation
P01097100A0217|3 10|patients
P01097100A0217|30 37|regimens
P01098179A0167|0 6|Results
P01098179A0167|44 55|preparations
P01098179A0167|76 93|dissolution curves
P01098179A0167|105 110|assays
P01098179A0167|126 140|chloramphenicol
P01098179A0167|155 161|release
P01098179A0167|171 178|activity
P01098179A0167|184 189|creams
P01098179A0167|208 216|ointments
P01098592A0567|0 9|IgG levels
P01098592A0567|45 51|samples
P01098592A0567|63 66|days
P01098592A0567|83 87|onset
P01099693T0000|0 5|Letter
P01099693T0000|7 18|Perspectives
P01099693T0000|21 47|bone marrow transplantation
P01101272T0000|0 9|Assessment
P01101272T0000|15 29|carcinogenicity
P01101272T0000|45 53|sweetners
P01101272T0000|57 66|Cyclamates
P01101272T0000|70 84|cyclohexylamine
P01103390A0149|13 21|behaviour
P01103390A0149|38 41|mice
P01103390A0149|53 62|occurrence
P01103390A0149|69 75|animals
P01103390A0149|85 89|phase
P01103390A0149|101 108|increase
P01103390A0149|114 124|parasitemia
P01107226A0808|8 21|amphotericin B
P01107226A0808|37 41|feces
P01107226A0808|47 50|mice
P01107226A0808|83 98|mg/ml dose level
P01113908A0475|15 22|increase
P01113908A0475|30 40|transferrin
P01113908A0475|42 43|hr
P01113908A0475|50 55|tablet
P01113908A0475|59 64|values
P01113908A0475|90 99|experiment
P01116254A0000|20 33|administration
P01116254A0000|48 60|concentration
P01116254A0000|63 81|tracer thallium-201
P01116254A0000|82 93|potassium-43
P01116254A0000|98 108|rubidium-81
P01116254A0000|125 128|mice
P01116254A0000|130 137|thallium
P01116254A0000|161 173|concentration
P01116254A0000|179 188|myocardium
P01116254A0000|194 194|%
P01116254A0000|207 207|%
P01116254A0000|211 219|potassium
P01116254A0000|227 227|%
P01116254A0000|231 238|rubidium
P01116254A0000|243 249|minutes
P01116466A0185|0 18|Thromboplastin time
P01116466A0185|26 44|thromboplastin time
P01116466A0185|45 57|thrombin time
P01116466A0185|72 77|fibrin
P01116466A0185|79 93|clot retraction
P01116466A0185|97 112|clotting factors
P01116466A0185|115 115|V
P01116466A0185|117 120|VIII
P01116466A0185|125 125|X
P01116466A0185|133 146|platelet count
P01118293A0150|3 6|data
P01118293A0150|17 22|notion
P01118293A0150|27 37|suppression
P01118293A0150|40 45|images
P01118293A0150|61 67|rivalry
P01118293A0150|87 90|eyes
P01119586A0337|0 19|Glycogen utilization
P01119586A0337|35 47|tissue levels
P01119586A0337|49 66|creatine phosphate
P01119586A0337|67 69|ATP
P01119586A0337|74 80|lactate
P01119586A0337|101 106|hearts
P01119586A0337|122 125|flow
P01119658A0000|3 9|records
P01119658A0000|53 60|patients
P01119658A0000|73 86|cell carcinoma
P01119658A0000|95 100|cavity
P01119658A0000|102 111|oropharynx
P01119658A0000|125 130|larynx
P01119658A0000|134 144|hypopharynx
P01119658A0000|177 197|lymph node metastases
P01119658A0000|202 203|N1
P01119658A0000|205 207|N2A
P01119658A0000|211 213|N2B
P01119658A0000|230 243|neck treatment
P01119658A0000|262 278|radiation therapy
P01122015A0467|7 9|vol
P01122015A0467|12 12|%
P01122015A0467|30 35|values
P01122015A0467|43 49|mumol/1
P01122015A0467|55 63|mg/100 ml
P01122015A0467|70 76|mumol/1
P01122015A0467|82 90|mg/100 ml
P01123658A0000|3 9|authors
P01123658A0000|21 29|technique
P01123658A0000|47 56|tomography
P01123658A0000|62 66|spine
P01123658A0000|83 93|description
P01123658A0000|104 110|anatomy
P01123658A0000|128 132|spine
P01123658A0000|137 139|L-4
P01123658A0000|145 150|sacrum
P01124944A0830|15 22|attitude
P01124944A0830|28 39|protein diet
P01124944A0830|43 46|g/kg
P01125117A0183|2 5|none
P01125117A0183|13 16|type
P01125117A0183|18 24|attacks
P01125117A0183|30 33|type
P01125117A0183|36 42|attacks
P01125117A0183|74 80|changes
P01125117A0183|112 117|groups
P01128985A0000|27 32|method
P01128985A0000|76 82|periods
P01128985A0000|85 89|apnea
P01128985A0000|101 108|patients
P01130186A0568|21 27|patient
P01130186A0568|47 61|insulin release
P01130186A0568|63 70|response
P01130186A0568|73 83|tolbutamide
P01130531A0224|0 16|Nerve stimulation
P01130531A0224|23 30|cycles/s
P01130531A0224|59 68|reductions
P01130531A0224|71 73|CBF
P01130531A0224|76 83|decrease
P01130531A0224|88 94|percent
P01130531A0224|118 126|frequency
P01131946T0001|0 5|Effect
P01131946T0001|8 16|ingestion
P01131946T0001|19 28|Norbiogest
P01131946T0001|47 52|period
P01131946T0001|65 70|organs
P01138215T0001|0 3|Risk
P01138215T0001|6 14|infection
P01138215T0001|20 28|treatment
P01138215T0001|31 39|fractures
P01138330A0204|6 12|pouches
P01138330A0204|29 37|solutions
P01138330A0204|43 49|% Na C1
P01138330A0204|52 56|N HC1
P01138330A0204|59 67|% glucose
P01138330A0204|70 75|% NaC1
P01138330A0204|81 89|% peptone
P01138330A0204|98 108|% solutions
P01138330A0204|110 131|acetylcholine chloride
P01140184A0342|0 15|Liver microsomes
P01140184A0342|42 42|%
P01140184A0342|48 71|epoxide hydrase activity
P01140184A0342|86 86|%
P01140184A0342|105 112|capacity
P01140184A0342|115 130|liver microsomes
P01140184A0342|137 139|rat
P01141114A0188|14 17|work
P01141114A0188|28 35|increase
P01141114A0188|56 59|mmHg
P01141114A0188|68 70|P50
P01141114A0188|76 79|PH-v
P01141114A0188|83 93|degrees C-v
P01141114A0188|99 104|Pv-CO2
P01141114A0188|131 137|effects
P01141114A0188|155 165|temperature
P01141114A0188|170 170|H
P01145884T0028|34 38|study
P01147436T0000|11 35|Burkitt Lymphoma Registry
P01147436T0000|36 50|progress report
P01147502T0000|0 9|Vitrectomy
P01147502T0000|27 43|instrument system
P01148868A0284|12 25|clearance rate
P01148868A0284|27 38|progesterone
P01148868A0284|51 54|S.E.
P01148868A0284|56 60|1/day
P01150658A0683|4 11|sequence
P01150658A0683|55 61|hormone
P01150658A0683|63 68|Sairam
P01150658A0683|70 71|M.
P01156631A0658|3 34|mean plasma sodium concentration
P01156631A0658|50 51|SD
P01156631A0658|57 62|mEq/kg
P01156631A0658|77 85|treatment
P01156631A0658|117 125|treatment
P01156631A0658|138 139|SD
P01156631A0658|145 150|mEq/kg
P01156631A0658|152 152|P
P01156814T0000|0 8|Editorial
P01156814T0000|18 24|heparin
P01156814T0000|31 40|prevention
P01156814T0000|49 70|thromboembolic disease
P01157191A0536|13 23|dose levels
P01157191A0536|28 43|sodium saccharin
P01157191A0536|46 61|sodium cyclamate
P01157191A0536|77 87|carcinogens
P01157191A0536|110 124|bladder tumours
P01157191A0536|155 161|tumours
P01157191A0536|187 191|weeks
P01157614T0000|0 6|Effects
P01157614T0000|19 26|salience
P01157614T0000|32 54|matrix task performance
P01157614T0000|75 82|children
P01158512T0000|19 31|dehydrogenase
P01158512T0000|33 38|G-6-PD
P01158512T0000|40 49|deficiency
P01158838A0438|49 57|flow rate
P01158838A0438|62 67|ml/min
P01159822A0353|12 20|epithelia
P01159822A0353|39 45|animals
P01159822A0353|71 84|ultrastructure
P01159822A0353|91 103|invaginations
P01159822A0353|105 108|tilt
P01159822A0353|118 121|axes
P01159822A0353|125 132|increase
P01159822A0353|138 143|number
P01159822A0353|147 150|size
P01159822A0353|153 161|lysosomes
P01159822A0353|181 186|bodies
P01159822A0353|200 206|numbers
P01159822A0353|235 242|granules
P01168607A0672|10 23|administration
P01168607A0672|37 44|vitamins
P01168607A0672|86 101|prothrombin time
P01168607A0672|104 117|serum vitamins
P01168607A0672|121 121|E
P01168607A0672|124 132|intervals
P01168908A0000|0 15|Prostaglandins F
P01168908A0000|16 18|PGF
P01168908A0000|41 44|vein
P01168908A0000|53 58|artery
P01168908A0000|70 80|vein plasma
P01168908A0000|99 105|tissues
P01168908A0000|115 119|times
P01168908A0000|142 146|cycle
P01168908A0000|175 200|plasma progesterone levels
P01168956A0552|10 13|date
P01168956A0552|18 21|drug
P01168956A0552|43 53|weight gain
P01168956A0552|64 74|sensitivity
P01168956A0552|80 87|placenta
P01168956A0552|105 107|day
P01168956A0552|121 143|maximum weight decrease
P01168956A0552|148 152|organ
P01168956A0552|155 155|h
P01170143A0247|0 5|Groups
P01170143A0247|26 36|saline mice
P01170143A0247|70 79|conditions
P01170143A0247|99 107|cylinders
P01171020A0711|3 9|effects
P01171020A0711|26 48|nucleus accumbens septi
P01171935A0313|3 12|appearance
P01171935A0313|25 42|movement disorders
P01171935A0313|44 49|humans
P01171935A0313|69 71|use
P01171935A0313|74 81|levodopa
P01171935A0313|84 94|amphetamine
P01171935A0313|101 113|manifestation
P01171935A0313|134 167|dopamine receptor site sensitivity
P01171935A0313|174 181|striatum
P01172734T0035|0 10|Association
P01172734T0035|19 22|W-27
P01172917T0000|0 5|Letter
P01172917T0000|7 29|Lactose tolerance tests
P01172917T0000|31 39|predictor
P01172917T0000|42 55|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01174873T0000|16 20|study
P01174873T0000|30 36|history
P01174873T0000|40 48|prognosis
P01174873T0000|54 58|cases
P01176905A0094|10 18|melatonin
P01176905A0094|20 34|serum melatonin
P01176905A0094|43 50|mid-dark
P01176905A0094|59 67|mid-light
P01178153A0056|0 1|D.
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|3 9|authors
P01185956A0722|33 52|Doppler-cardiography
P01185956A0722|85 91|changes
P01185956A0722|97 109|stroke volume
P01186344A0303|3 12|attainment
P01186344A0303|21 28|maturity
P01186344A0303|31 35|terms
P01186344A0303|53 67|characteristics
P01186344A0303|72 81|production
P01186344A0303|84 94|spermatozoa
P01186344A0303|100 103|male
P01186344A0303|125 131|pattern
P01186344A0303|136 142|release
P01186344A0303|145 147|ova
P01186344A0303|151 160|end-points
P01186344A0303|179 185|process
P01190120A0832|15 27|% lengthening
P01190120A0832|39 57|thromboplastin time
P01190120A0832|73 77|hours
P01190120A0832|80 86|storage
P01190251A0335|0 6|Caution
P01190251A0335|29 31|use
P01190251A0335|39 42|dyes
P01190251A0335|46 56|lymphograms
P01191955A0077|15 18|test
P01191955A0077|36 47|incompetence
P01191955A0077|65 68|cent
P01191955A0077|71 77|varices
P01191955A0077|103 108|reflux
P01191964A0000|5 10|groups
P01191964A0000|13 20|patients
P01191964A0000|44 56|thyroidectomy
P01191964A0000|60 65|Graves
P01191964A0000|68 74|disease
P01191964A0000|93 98|goitre
P01191964A0000|123 128|goitre
P01191964A0000|135 139|years
P01191964A0000|162 176|serum thyroxine
P01191964A0000|177 179|T-4
P01191964A0000|181 185|level
P01191964A0000|216 224|subgroups
P01191964A0000|230 234|basis
P01191964A0000|253 284|serum thyrotrophin concentration
P01193458T0001|7 25|isotope cystography
P01193458T0001|33 49|Tc sulfur colloid
P01193458T0001|51 59|detection
P01193458T0001|63 71|follow-up
P01193458T0001|89 94|reflux
P01193770T0000|0 13|Air ion action
P01193770T0000|14 21|bacteria
P01194673A0652|2 9|evidence
P01194673A0652|36 46|chemography
P01201977T0000|3 16|interpretation
P01201977T0000|29 46|disc sensitivities
P01202616A0466|9 21|retransfusion
P01202616A0466|44 49|lining
P01202616A0466|91 104|lamina propria
P01202616A0466|123 126|loss
P01202616A0466|139 144|detail
P01206772T0000|1 5|study
P01206772T0000|8 18|chromosomes
P01206772T0000|21 31|lymphocytes
P01206772T0000|36 43|patients
P01206772T0000|55 64|hycanthone
P01206896T0001|0 14|Characteristics
P01206896T0001|17 26|anesthesia
P01206896T0001|30 42|resuscitation
P01206896T0001|45 66|emergency lung surgery
P01208811T0001|0 4|Study
P01208811T0001|26 30|state
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 77|citrate solution-blood system
P01209618A0409|0 9|Tobramycin
P01209618A0409|12 13|mg
P01209618A0409|37 42|effect
P01209618A0409|47 55|dibecacin
P01209618A0409|59 60|mg
P01209618A0409|76 94|potentiating effect
P01209618A0409|99 104|action
P01209618A0409|107 120|d-tubocurarine
P01211754A0192|20 24|cases
P01211754A0192|29 37|operation
P01211754A0192|60 70|improvement
P01211754A0192|74 81|patients
P01211754A0192|116 123|deafness
P01215067A0000|21 30|resistance
P01215067A0000|49 53|fluid
P01215067A0000|67 71|means
P01215067A0000|74 86|conductometry
P01215067A0000|91 95|cases
P01215067A0000|98 117|meningitis purulenta
P01215067A0000|120 124|cases
P01215067A0000|127 143|meningitis serosa
P01215067A0000|146 150|cases
P01215067A0000|153 164|encephalitis
P01215067A0000|179 186|subjects
P01217450A0295|2 19|Chemical occlusion
P01217450A0295|52 56|block
P01217450A0295|75 78|dogs
P01224116A0576|18 25|patients
P01224116A0576|35 55|serum immunoglobulins
P01224116A0576|63 65|IgG
P01224116A0576|74 78|Russe
P01224116A0576|80 84|Busey
P01224116A0576|88 94|Barbeau
P01224116A0576|130 135|family
P01225339A0590|17 26|occlusions
P01225339A0590|40 43|time
P01225339A0590|49 58|infarction
P01228258A0000|13 23|preparation
P01228258A0000|25 30|OK-432
P01228258A0000|37 40|type
P01228258A0000|54 58|agent
P01228258A0000|73 80|patients
P01228258A0000|93 98|cancer
P01228258A0000|101 111|combination
P01228258A0000|116 126|Mitomycin-C
P01228258A0000|128 131|5-FU
P01228258A0000|135 154|Cytosine arabinoside
P01228882A0437|11 21|correlation
P01228882A0437|47 60|concentrations
P01228882A0437|63 81|CSF immunoglobulins
P01228882A0437|84 89|degree
P01228882A0437|113 120|response
P01228882A0437|136 144|component
P01228882A0437|164 171|diseases
P01233561T0001|8 16|lactation
P01235347T0001|12 25|cardiotoxicity
P01235347T0001|28 37|adriamycin
P01236224T0001|8 16|pathology
P01237206A0199|0 12|Demonstration
P01237206A0199|18 22|agent
P01237206A0199|54 61|day p.i.
P01237206A0199|80 86|methods
P01237206A0199|88 92|Stamp
P01237206A0199|96 112|auramine staining
P01237206A0199|124 141|antibody technique
P01237206A0199|146 161|Coxiella content
P01237206A0199|176 184|titration
P01237206A0199|198 200|hen
P01237206A0199|203 206|eggs
P01241437A0152|3 10|patients
P01241437A0152|27 32|groups
P01241437A0152|42 47|NLA II
P01241437A0152|60 69|nalorphine
P01241437A0152|71 78|morphine
P01241437A0152|81 87|Micoren
P01241588A1470|3 13|alterations
P01241588A1470|16 19|5-HT
P01241588A1470|23 35|5-HIAA levels
P01241588A1470|44 50|regions
P01241588A1470|56 60|brain
P01241588A1470|69 78|conditions
P01241588A1470|102 105|IDPN
P01241588A1470|108 120|neurotoxicity
P01241588A1470|152 159|neurones
P01241866A0682|5 12|increase
P01241866A0682|15 30|leukocyte-counts
P01241866A0682|44 57|administration
P01241866A0682|60 64|serum
P01241866A0682|77 82|rabbit
P01241866A0682|89 95|phase-2
P01242636A0678|3 9|results
P01242636A0678|55 60|system
P01242636A0678|81 99|beryllium retention
P01243628A0286|6 10|cases
P01243628A0286|17 19|end
P01243628A0286|22 29|exposure
P01243628A0286|37 41|level
P01243628A0286|44 66|blood carboxyhemoglobin
P01243628A0286|67 70|COHb
P01243628A0286|80 80|%
P01244236A1122|3 9|results
P01244236A1122|40 49|blood flow
P01244236A1122|78 87|resistance
P01244236A1122|101 109|gestation
P01244236A1122|120 127|increase
P01244236A1122|138 143|number
P01244236A1122|146 152|vessels
P01244236A1122|165 184|vasomotor reactivity
P01244236A1122|197 204|increase
P01244236A1122|215 220|amount
P01244236A1122|229 234|muscle
P01244236A1122|243 251|thickness
P01244236A1122|254 259|muscle
P01244236A1122|272 278|vessels
P01245162A0262|0 8|Reduction
P01245162A0262|11 16|dosage
P01245162A0262|31 41|taste sense
P01245162A0262|63 66|drug
P01245162A0262|109 127|transaminase levels
P01246210A0648|3 15|calcium ratio
P01246210A0648|16 25|mean ratio
P01246210A0648|49 52|TBCa
P01246210A0648|56 58|men
P01246210A0648|73 73|%
P01246210A0648|79 83|women
P01246210A0648|95 95|%
P01247475A0000|5 13|diagnosis
P01247475A0000|16 29|retinoblastoma
P01247475A0000|48 51|fact
P01247475A0000|65 70|growth
P01247475A0000|82 94|deterioration
P01247475A0000|100 106|outlook
P01248124A0281|5 15|cholesterol
P01248124A0281|37 42|fluids
P01248124A0281|63 68|stages
P01248124A0281|71 79|gestation
P01249198A1097|3 25|serum FT3 concentration
P01249198A1097|53 58|ranges
P01249198A1097|67 75|pregnancy
P01249198A1097|80 91|GTD patients
P01249198A1097|106 120|hyperthyroidism
P01252223A0347|3 9|authors
P01252223A0347|28 31|fear
P01252223A0347|35 43|pugnacity
P01252223A0347|59 76|trait correlations
P01252223A0347|91 98|contrast
P01252223A0347|101 105|Winch
P01252223A0347|108 116|principle
P01252223A0347|119 122|type
P01252223A0347|124 138|complementarity
P01253191T0000|1 4|note
P01253191T0000|10 45|phase-plane technique representation
P01253191T0000|53 69|action potentials
P01256410T0001|1 10|activities
P01256410T0001|16 21|factor
P01256410T0001|24 31|molecule
P01256410T0001|44 49|infant
P01256410T0001|52 55|term
P01259027A0416|3 9|concept
P01259027A0416|23 37|identifiability
P01259027A0416|55 62|analysis
P01259027A0416|79 94|model parameters
P01259027A0416|156 159|data
P01259027A0416|174 182|procedure
P01259027A0416|192 200|extension
P01259027A0416|207 213|concept
P01259027A0416|246 253|approach
P01259027A0416|271 284|design problem
P01261005A0711|29 37|variation
P01261005A0711|41 51|differences
P01261005A0711|54 64|performance
P01261005A0711|78 85|bandpass
P01261005A0711|93 119|bandpass spectrophotometers
P01262596T0000|11 20|compromise
P01264640T0028|1 4|case
P01264640T0028|15 20|Saigon
P01265443A0159|10 16|glucose
P01265443A0159|45 65|Heidenhain pouch dogs
P01265443A0159|81 90|inhibition
P01265443A0159|113 126|acid secretion
P01265443A0159|133 137|pouch
P01265443A0159|148 154|stomach
P01265443A0159|173 178|saline
P01265443A0159|184 189|effect
P01265887T0001|8 28|factor VIII inhibitor
P01265887T0001|43 50|patients
P01267446A0210|0 15|Biohydrogenation
P01267446A0210|26 29|acid
P01267446A0210|46 49|acid
P01272816A0000|3 7|study
P01272816A0000|10 27|calcium metabolism
P01272816A0000|44 51|children
P01272816A0000|69 76|controls
P01272816A0000|86 99|administration
P01272816A0000|102 105|47Ca
P01272816A0000|134 143|absorption
P01275335A0158|10 15|agents
P01275335A0158|35 39|semen
P01275335A0158|47 49|end
P01275335A0158|66 70|phase
P01275541A0405|21 32|CPK activity
P01275541A0405|45 52|newborns
P01275541A0405|87 95|dystrophy
P01275541A0405|120 124|weeks
P01275541A0405|130 137|delivery
P01276105A0313|2 9|contrast
P01276105A0313|14 29|insulin response
P01276105A0313|57 61|value
P01276105A0313|73 75|day
P01276105A0313|81 90|puerperium
P01278251A0000|3 9|authors
P01278251A0000|19 25|results
P01278251A0000|29 34|series
P01278251A0000|50 54|tests
P01278251A0000|73 81|materials
P01278251A0000|83 94|polyethylene
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01278251A0000|163 172|sensitizer
P01278251A0000|203 211|materials
P01279197T0000|10 17|analysis
P01279197T0000|28 42|homology region
P01279197T0000|44 68|Mason-Pfizer monkey virus
P01279197T0000|69 71|use
P01279197T0000|74 95|saturation mutagenesis
P01279352A0297|3 6|site
P01279352A0297|8 10|PAL
P01279352A0297|29 50|bp sequence GGGGAGGAGG
P01279352A0473|7 14|extracts
P01279352A0473|50 59|cell lines
P01279352A0473|60 70|mouse brain
P01279352A0473|74 84|mouse liver
P01279352A0473|91 98|proteins
P01279352A0473|124 127|PROX
P01279352A0473|131 143|PAL sequences
P01279352A0473|157 164|proteins
P01279352A0473|181 196|target sequences
P01279352A1197|16 17|NF
P01279352A1197|19 19|H
P01279352A1197|21 28|promoter
P01279352A1197|46 51|tissue
P01279352A1197|60 65|manner
P01279352A1197|72 82|development
P01279352A1197|93 96|mice
P01279352A1197|110 124|promoter region
P01279352A1197|133 164|beta-galactosidase reporter gene
P01279374A0396|30 34|genes
P01279374A0396|62 72|suppressors
P01279374A0396|106 115|truncation
P01279374A0396|118 123|PET122
P01279696A0862|8 14|studies
P01279696A0862|25 32|Hisanaga
P01279696A0862|34 35|S.
P01279696A0862|37 44|Kusubata
P01279696A0862|46 47|M.
P01279696A0862|49 55|Okumura
P01279696A0862|57 58|E.
P01279696A0862|60 68|Kishimoto
P01279696A0862|70 71|T.
P01280413T0001|0 8|Treatment
P01280413T0001|12 19|staining
P01280413T0001|22 27|smears
P01280413T0001|31 38|sections
P01280413T0001|42 50|detection
P01280413T0001|53 66|microorganisms
P01280807A0575|11 12|Kd
P01280807A0575|18 43|MetRS/CAU operator complex
P01280807A0575|47 61|order magnitude
P01280807A0575|80 105|ThrRS/CGU operator complex
P01281322A0604|18 29|relationship
P01281322A0604|51 70|percent area density
P01281322A0604|77 82|muscle
P01281322A0604|89 102|percent change
P01281322A0604|115 123|flow rate
P01281472T0000|0 5|Rabbit
P01281472T0000|14 30|muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|26 29|gene
P01281771T0000|38 48|cytokeratin
P01281771T0000|57 74|expression pattern
P01282014A0275|0 6|Animals
P01282014A0275|19 23|DSP-4
P01282014A0275|51 64|motor recovery
P01282014A0275|79 90|saline group
P01282638A0934|3 18|prophylactic use
P01282638A0934|23 32|medication
P01282638A0934|36 43|patients
P01282638A0934|68 72|cycle
P01282638A0934|75 86|chemotherapy
P01282638A0934|90 98|agreement
P01282638A0934|106 114|estimates
P01282638A0934|137 153|health care costs
P01282638A0934|168 174|quality
P01282638A0934|177 180|life
P01282638A0934|188 195|patients
P01282638A0934|208 219|continuation
P01282638A0934|234 241|schedule
P01282638A0934|249 260|interruption
P01282638A0934|279 293|life expectancy
P01282638A0934|298 304|patient
P01284032A0213|0 1|AP
P01284032A0213|25 32|infusion
P01284032A0213|47 60|concentrations
P01284032A0213|79 82|acid
P01284032A0213|84 87|GDOC
P01284032A0213|90 93|mmol
P01284032A0213|99 102|mmol
P01284595A0102|3 11|isolation
P01284595A0102|18 21|gene
P01284595A0102|35 48|identification
P01284595A0102|54 65|Y-231 cosmid
P01284595A0102|77 79|CpG
P01284595A0102|84 92|sequences
P01284595A0102|94 104|HTF islands
P01284595A0102|115 120|insert
P01284828T0001|0 27|Tissue plasminogen activator
P01284828T0001|30 38|inhibitor
P01284828T0001|47 56|parameters
P01284828T0001|59 70|fibrinolysis
P01284828T0001|73 77|blood
P01284828T0001|80 87|patients
P01284828T0001|103 113|hypertrophy
P01284828T0001|119 126|prostate
P01285009A0000|0 14|Gene constructs
P01285009A0000|31 44|growth hormone
P01285009A0000|45 47|hGH
P01285009A0000|49 52|gene
P01285009A0000|80 87|sequence
P01285009A0000|90 110|mouse metallothionein
P01285009A0000|111 113|mMT
P01285009A0000|121 136|thymidine kinase
P01285009A0000|137 139|vTK
P01285009A0000|142 160|rat cholecystokinin
P01285009A0000|161 164|rCCK
P01285009A0000|169 186|chicken beta-actin
P01285009A0000|187 189|cBA
P01285009A0000|191 194|gene
P01285009A0000|214 222|cytoplasm
P01285009A0000|235 245|medaka eggs
P01285009A0000|251 259|micropyle
P01285358A0396|0 12|Serum gastrin
P01285358A0396|15 24|AFP levels
P01285358A0396|34 42|evolution
P01285358A0396|65 72|interest
P01285358A0396|84 89|course
P01285358A0396|95 101|disease
P01285554T0000|0 8|Prospects
P01285554T0000|31 37|systems
P01285807A0365|3 6|mean
P01285807A0365|11 12|SD
P01285807A0365|14 17|PaO2
P01285807A0365|42 45|mmHg
P01285807A0365|65 68|mmHg
P01285807A0365|77 84|infusion
P01285807A0365|86 86|P
P01285807A0365|99 103|PaCO2
P01285807A0365|139 142|mmHg
P01285807A0365|144 144|P
P01286732A0572|6 17|hepatomegaly
P01286732A0572|25 33|elevation
P01286732A0572|36 42|enzymes
P01286732A0572|70 79|proportion
P01286732A0572|82 89|patients
P01286732A0572|91 101|involvement
P01286732A0572|104 108|liver
P01286732A0572|123 131|hepatitis
P01286732A0572|134 152|liver cell necrosis
P01286732A0572|172 183|complication
P01286732A0572|186 206|P. falciparum malaria
P01287197A0761|11 15|group
P01287197A0761|27 34|decrease
P01287197A0761|37 52|plasma potassium
P01287197A0761|62 71|salbutamol
P01287197A0761|113 118|mmol/l
P01287197A0761|135 139|group
P01287197A0761|148 156|decrement
P01287197A0761|198 203|mmol/l
P01287197A0761|210 211|iv
P01287197A0761|213 214|po
P01292230A0283|6 10|drugs
P01292230A0283|22 25|rate
P01292230A0283|42 48|filling
P01294345A0591|25 35|improvement
P01294345A0591|44 57|administration
P01294345A0591|60 68|Bromergon
P01294345A0591|82 89|symptoms
P01294345A0591|104 119|overreactiveness
P01294345A0591|128 143|prolactin levels
P01294345A0591|157 163|tension
P01294345A0591|165 169|edema
P01294345A0591|171 181|weight gain
P01294345A0591|184 200|breast tenderness
P01295373A0651|3 11|magnitude
P01295373A0651|22 29|response
P01295373A0651|41 41|%
P01295373A0651|44 44|A
P01295373A0651|46 58|% baseline RL
P01295373A0651|58 61|mean
P01295373A0651|65 66|SE
P01295373A0651|91 91|B
P01295373A0651|100 100|%
P01295373A0651|105 105|C
P01295373A0651|115 115|%
P01295373A0651|118 118|p
P01295500A0366|9 16|patients
P01295500A0366|47 53|Attacks
P01295500A0366|57 57|%
P01295500A0366|89 96|Deficits
P01295500A0366|100 100|%
P01296815A0059|21 24|gene
P01296815A0059|31 34|LD78
P01296815A0059|42 51|LD78 gamma
P01296815A0059|57 73|sequence analysis
P01296815A0059|100 109|pseudogene
P01297332A0983|4 11|analysis
P01297332A0983|26 38|consideration
P01297332A0983|44 47|SCBs
P01297332A0983|84 88|genes
P01297332A0983|100 107|proposal
P01297332A0983|118 135|consensus sequence
P01297332A0983|161 167|element
P01297332T0000|10 17|analysis
P01297332T0000|21 32|DNA sequence
P01297332T0000|49 63|gene expression
P01297332T0000|68 77|cell cycle
P01298173A0153|10 16|history
P01298173A0153|24 30|lesions
P01298173A0153|44 53|efficiency
P01298173A0153|68 77|treatments
P01298173A0153|86 89|part
P01298173A0153|98 109|chemotherapy
P01298173A0153|111 118|survival
P01298173A0153|128 132|death
P01298173A0153|147 156|modalities
P01298173A0153|168 174|measure
P01298398A0461|3 8|method
P01298398A0461|25 37|determination
P01298398A0461|40 57|nadolol racemate A
P01298398A0461|59 64|change
P01298398A0461|73 89|phase composition
P01299489A0788|22 26|study
P01299489A0788|41 48|evidence
P01299489A0788|54 59|effect
P01299489A0788|62 76|supplementation
P01299489A0788|87 97|performance
P01299489A0788|101 108|athletes
P01299489A0788|128 131|RDIs
P01300914A1066|5 11|absence
P01300914A1066|26 33|criteria
P01300914A1066|63 66|view
P01300914A1066|72 82|variability
P01300914A1066|85 91|results
P01300914A1066|104 110|dangers
P01300914A1066|127 132|biopsy
P01300914A1066|171 175|walls
P01300914A1066|180 188|diagnosis
P01300914A1066|191 194|ACRV
P01300914A1066|220 228|existence
P01300914A1066|255 262|criteria
P01300914A1066|275 285|arrhythmias
P01300914A1066|320 321|VT
P01300914A1066|340 346|feature
P01300914A1066|358 363|degree
P01300914A1066|366 376|sensitivity
P01300914A1066|389 399|stimulation
P01300914A1066|401 408|exercise
P01300914A1066|414 422|existence
P01300914A1066|429 438|potentials
P01300914A1066|448 464|amplification ECG
P01300914A1066|480 483|sign
P01300914A1066|510 520|sensitivity
P01300914A1066|532 536|froms
P01300914A1066|611 626|RV abnormalities
P01300914A1066|684 691|vaulting
P01300914A1066|697 702|stasis
P01301171A0979|6 10|cases
P01301171A0979|15 22|enhancer
P01301171A0979|35 57|c-myc bearing sequences
P01301171A0979|58 67|chromosome
P01302765A0999|5 14|components
P01302765A0999|29 30|R2
P01302765A0999|54 56|R2s
P01302765A0999|97 98|ad
P01302765A0999|105 114|components
P01304515A0178|11 17|results
P01304515A0178|34 46|control group
P01304515A0178|55 64|volunteers
P01304809T0001|3 7|years
P01304809T0001|10 18|dentistry
P01304809T0001|24 52|Friedrich Schiller University
P01304809T0001|53 56|Jena
P01309244A0798|3 8|target
P01309244A0798|25 33|positions
P01309244A0798|45 48|acts
P01309244A0798|64 74|orientation
P01309244A0798|87 96|cell types
P01309244A0798|99 105|species
P01309244A0798|115 121|context
P01309244A0798|137 144|promoter
P01309587A0715|11 25|transactivation
P01309587A0715|31 44|BMRF1 promoter
P01309587A0715|49 67|Z/c-myb combination
P01309587A0715|89 95|binding
P01309587A0715|101 109|Z protein
P01309587A0715|118 130|c-myb protein
P01309593A0095|3 19|UCR core sequence
P01309593A0095|19 27|CGCCATTTT
P01309593A0095|52 57|factor
P01309593A0095|77 86|regulation
P01309593A0095|89 110|MuLV promoter activity
P01309593A1092|5 11|studies
P01309593A1092|20 24|UCRBP
P01309593A1092|39 51|target motifs
P01309593A1092|73 81|UCR motif
P01309593A1092|101 117|virus P5 promoter
P01309593A1092|119 126|elements
P01309593A1092|132 151|immunoglobulin light
P01309593A1092|166 170|genes
P01309593A1092|180 187|elements
P01309593A1092|199 211|protein genes
P01309815A0972|12 26|scr1-1 mutation
P01309815A0972|39 56|signal recognition
P01309815A0972|71 76|arrest
P01309815A0972|96 106|maintenance
P01309815A0972|122 127|arrest
P01309815A0972|130 142|AEP synthesis
P01309860A0559|11 19|sequences
P01309860A0559|32 47|integration site
P01309860A0559|62 71|% identity
P01309860A0559|80 88|sequences
P01309860A0559|103 117|mouse L1 family
P01309860A0559|144 152|sequences
P01309894A0807|4 8|Rep78
P01309894A0807|12 16|Rep68
P01309894A0807|31 42|AAV sequence
P01309894A0807|51 54|site
P01309894A0807|56 65|nucleotide
P01309910A0428|0 27|Nucleotide sequence analysis
P01309910A0428|49 55|protein
P01309910A0428|74 86|CREB2 protein
P01310154A0879|5 11|results
P01310154A0879|28 28|N
P01310154A0879|43 51|mutations
P01310154A0879|72 86|transrepression
P01310154A0879|89 99|FBR protein
P01310154A0879|124 132|mutations
P01310154A0879|163 182|protein modification
P01310154A0879|187 201|gene regulation
P01310154A0879|203 213|FBR protein
P01310178A0876|3 30|JS78 mutation changes Gln243
P01310178A0876|30 32|gp0
P01310178A0876|39 49|amber codon
P01310178A0876|66 75|production
P01310178A0876|110 120|polypeptide
P01310178A0876|154 159|domain
P01310178A0876|162 188|host transcription shut-off
P01310879A0000|1 17|patient suffering
P01310879A0000|39 54|thrombocytopenia
P01310879A0000|56 58|HAT
P01310879A0000|70 86|arteriothromboses
P01310879A0000|101 107|failure
P01310879A0000|113 121|treatment
P01310879A0000|134 140|heparin
P01310899A0339|12 29|receptor structure
P01310899A0339|64 69|domain
P01310899A0339|89 108|transmembrane domain
P01310899A0339|133 162|serine/threonine kinase domain
P01310935T0000|10 14|UbcD1
P01310935T0000|59 64|enzyme
P01310935T0000|84 102|protein degradation
P01312005A0600|0 7|Analysis
P01312005A0600|26 34|mt genome
P01312005A0600|49 52|MDP1
P01312005A0600|61 68|cleavage
P01312005A0600|71 81|chick mtDNA
P01312005A0600|95 95|H
P01312005A0600|128 139|target sites
P01312005A0600|158 158|A
P01312005A0600|173 177|tract
P01312005A0600|223 232|structures
P01312005A0600|250 254|bases
P01312005A0600|278 283|origin
P01312005A0600|285 286|OH
P01312005A0600|290 300|replication
P01313715A0461|3 6|goal
P01313715A0461|19 23|study
P01313715A0461|41 51|feasibility
P01313715A0461|54 63|retrovirus
P01313715A0461|72 81|expression
P01313715A0461|84 91|rp47phox
P01313715A0461|97 100|HL60
P01313715A0461|104 107|U937
P01313715A0461|126 135|cell lines
P01313715A0461|155 159|virus
P01313715A0461|171 192|B-lymphocyte cell line
P01313715A0461|192 198|EBV-BCL
P01313715A0461|229 239|CGD patient
P01313846A0850|0 9|Comparison
P01313846A0850|17 34|sequence databanks
P01313846A0850|42 48|Tactile
P01313846A0850|52 57|member
P01313846A0850|63 93|immunoglobulin gene superfamily
P01313846A0850|97 106|similarity
P01313846A0850|130 147|melanoma Ag MUC-18
P01313846A0850|147 153|members
P01313846A0850|175 183|Ag family
P01313846A0850|187 205|poliovirus receptor
P01313846A0850|218 239|cell adhesion molecule
P01313894A1179|14 20|pattern
P01313894A1179|23 29|results
P01313894A1179|45 51|respect
P01313894A1179|54 74|LMP2B mRNA expression
P01313894A1179|78 88|transcripts
P01313894A1179|111 116|subset
P01313894A1179|119 124|tumors
P01313894A1179|148 153|levels
P01313909A0526|3 12|phenotypes
P01313909A0526|18 38|ICP0 nonsense mutants
P01313909A0526|79 83|virus
P01313909A0526|115 122|sequence
P01313909A0526|140 154|nonsense mutant
P01313909A0526|181 189|phenotype
P01314457T0000|0 7|Analysis
P01314457T0000|10 28|nucleotide sequence
P01314457T0000|44 46|kbp
P01314457T0000|49 67|herpesvirus saimiri
P01314457T0000|68 70|HVS
P01314457T0000|72 76|L-DNA
P01314457T0000|85 96|conservation
P01314457T0000|106 117|organization
P01314457T0000|125 127|HVS
P01314457T0000|143 147|virus
P01314841A0724|0 8|Treatment
P01314841A0724|13 18|MK-801
P01314841A0724|27 43|burst suppression
P01314841A0724|48 50|EEG
P01314841A0724|64 67|drop
P01314841A0724|79 83|mm Hg
P01314841A0724|89 92|mean
P01314841A0724|101 108|pressure
P01314953A1266|2 9|contrast
P01314953A1266|11 40|gel mobility shift experiments
P01314953A1266|60 63|HAP2
P01314953A1266|66 69|HAP3
P01314953A1266|77 82|domain
P01314953A1266|90 103|hap3 mutations
P01314953A1266|112 120|complexes
P01315706A0000|8 22|differentiation
P01315706A0000|42 63|adenovirus E1a protein
P01315706A0000|67 89|rat L6 muscle cell line
P01316125A0176|3 12|experiment
P01316125A0176|37 39|1O2
P01316125A0176|52 59|radicals
P01316125A0176|66 67|OH
P01316125A0176|71 74|YHPD
P01316125A0176|94 96|aid
P01316125A0176|99 102|YHPD
P01316125A0176|118 124|ability
P01316125A0176|136 138|1O2
P01316125A0176|140 143|YHPD
P01316125A0176|152 155|BHPD
P01316125A0176|183 184|OH
P01316125A0176|186 189|YHPD
P01316125A0176|201 204|BHPD
P01316125A0382|3 8|points
P01316125A0382|46 51|damage
P01316125A0382|54 57|YHPD
P01316125A0382|81 83|1O2
P01316125A0382|96 103|radicals
P01316125A0382|110 111|OH
P01316125A0382|115 118|YHPD
P01316125A0382|123 128|second
P01316125A0382|156 161|damage
P01316125A0382|164 167|YHPD
P01316125A0382|188 191|BHPD
P01316125A0382|214 219|damage
P01316125A0382|247 251|yield
P01316125A0382|254 256|1O2
P01316125A0382|296 297|OH
P01316459A0311|0 3|Acad
P01316461A1083|23 32|S2 protein
P01316461A1083|44 51|peptides
P01316461A1083|67 68|S2
P01316461A1083|98 101|sera
P01316461A1083|127 132|horses
P01316461A1083|157 164|evidence
P01316461A1083|167 176|expression
P01316461A1083|183 189|protein
P01316461A1083|200 206|animals
P01316476A0842|13 26|TATA sequences
P01316476A0842|53 55|VZV
P01316476A0842|71 81|start sites
P01316476A1428|3 5|ORF
P01316476A1428|7 10|gene
P01316476A1428|40 42|ORF
P01316476A1428|45 48|gene
P01316476A1428|60 68|induction
P01316476A1428|74 78|genes
P01316476A1428|107 115|induction
P01316680A0643|17 23|IR5 ORF
P01316680A0643|25 29|EHV-1
P01316680A0643|40 47|sequence
P01316680A0643|52 62|amino acids
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|91 95|match
P01316680A0643|101 127|consensus zinc finger motif
P01316680A0643|126 141|C-X2-4-C-X2-15-C
P01316680A0643|143 150|H-X2-4-C
P01316680A0643|152 152|H
P01316900A0000|3 14|DNA sequence
P01316900A0000|19 42|sulfate activation locus
P01316900A0000|60 63|K-12
P01316903A0296|19 22|form
P01316903A0296|25 38|RNA polymerase
P01316903A0296|52 54|IIA
P01316903A0296|80 83|form
P01316903A0296|96 98|IIO
P01316903A1040|0 17|RNA polymerase IIA
P01316903A1040|53 61|complexes
P01316903A1040|64 72|reactions
P01316903A1040|83 94|input enzyme
P01316903A1040|97 114|RNA polymerase IIA
P01317376A0981|0 20|Fructokinase activity
P01317376A0981|45 54|Z. mobilis
P01317376A0981|64 71|fructose
P01317376A0981|81 87|glucose
P01317376A0981|109 116|increase
P01317376A0981|119 133|frk mRNA levels
P01318310A0000|0 15|Plasma membranes
P01318310A0000|25 29|cells
P01318310A0000|41 58|affinity receptors
P01318310A0000|65 83|density lipoprotein
P01318310A0000|84 86|HDL
P01318310A0000|107 113|removal
P01318310A0000|135 145|cholesterol
P01318739A0410|15 34|patients vincristine
P01318739A0410|47 56|teniposide
P01318739A0410|58 62|VM-26
P01318739A0410|69 81|neurotoxicity
P01320255A0795|5 11|results
P01320255A0795|39 45|element
P01320255A0795|74 84|L1 sequence
P01320255A0795|97 110|factor binding
P01320255A0795|115 121|element
P01320255A0795|134 137|role
P01320255A0795|143 155|transcription
P01320255A0795|163 164|L1
P01320640A0336|0 10|Tumor cells
P01320640A0336|53 59|enolase
P01320640A0336|61 67|insulin
P01320640A0336|69 76|glucagon
P01320640A0336|80 82|VIP
P01321277A0342|19 21|end
P01321277A0342|26 28|src
P01321277A0342|35 37|end
P01321277A0342|42 44|ros
P01321277A0342|52 54|SRC
P01321277A0342|56 58|ROS
P01321277A0342|71 96|chicken embryo fibroblasts
P01321277A0342|96 98|CEF
P01321277A0342|103 126|spindle shape morphology
P01321277A0342|141 143|UR2
P01321277A0664|0 2|ROS
P01321277A0664|4 6|SRC
P01321277A0664|8 8|R
P01321277A0664|32 39|deletion
P01321277A0664|79 84|domain
P01321277A0664|87 89|ros
P01321280A0494|11 16|number
P01321280A0494|20 25|nature
P01321280A0494|31 32|E6
P01321280A0494|36 51|E7 gene products
P01321280A0494|78 82|cells
P01321280A0494|95 125|immunoprecipitation experiments
P01321280A0494|129 136|antisera
P01321280A0494|165 172|BPV-1 E6
P01321280A0494|175 192|E7 fusion proteins
P01321332A0970|9 27|transfection assays
P01321332A0970|37 42|site A
P01321332A0970|69 71|RXR
P01321332A0970|86 100|transactivation
P01321332A0970|106 115|apoAI gene
P01321332A0970|120 127|promoter
P01321332A0970|135 154|hepatoma HepG2 cells
P01321332A0970|158 165|presence
P01321332A0970|168 169|RA
P01321332A0970|181 195|transactivation
P01321332A0970|219 225|amounts
P01321332A0970|241 245|ARP-1
P01321336A0000|3 17|enhancer region
P01321336A0000|19 21|Akv
P01321336A0000|28 41|leukemia virus
P01321336A0000|52 74|sequence motif ACAGATGG
P01321336A0731|3 17|splice variants
P01321336A0731|19 27|ALF1 cDNA
P01321336A0731|58 66|insertion
P01321336A0731|85 92|proteins
P01321336A0731|104 114|amino acids
P01321337A0318|15 23|component
P01321337A0318|43 46|mass
P01321337A0318|49 51|kDa
P01321337A0318|68 77|properties
P01321337A0318|88 94|ability
P01321337A0318|101 105|45Ca2
P01321337A0318|145 145|B
P01321337A0318|147 153|subunit
P01321337A0318|165 175|calcineurin
P01321337A0318|196 204|antiserum
P01321337A0318|224 234|calcineurin
P01321337A1161|26 39|MATa cna1 cna2
P01321337A1161|44 50|mutants
P01321337A1161|52 68|MATa cnb1 mutants
P01321337A1161|87 93|ability
P01321337A1161|127 139|growth arrest
P01324172A0880|0 9|Antibodies
P01324172A0880|29 35|protein
P01324172A0880|44 47|RIM1
P01324172A0880|50 61|mitochondria
P01324385A0329|0 6|METHODS
P01324385A0329|8 21|IgG antibodies
P01324385A0329|23 27|HHV-6
P01324385A0329|29 42|anti-HHV-6-IgG
P01324385A0329|68 85|immunofluorescence
P01324385A0329|91 94|IVDA
P01324385A0329|98 109|seronegative
P01324385A0329|130 134|HIV-1
P01324385A0329|150 154|stage
P01324385A0329|164 168|IV-C1
P01324385A0329|171 173|CDC
P01324385A0329|195 202|subjects
P01324385A0329|213 215|age
P01324385A0329|217 229|control group
P01324404A0813|21 37|activation domain
P01324404A0813|60 66|regions
P01324404A0813|93 109|carboxyl terminus
P01324404A0813|114 131|HNF-3 beta protein
P01324404A0813|131 141|amino acids
P01324404A1208|0 9|HNF-3 beta
P01324404A1208|23 31|sequences
P01324404A1208|50 55|region
P01324404A1208|75 89|transactivation
P01324404A1208|94 99|region
P01324404A1208|102 109|activity
P01324404A1208|121 133|participation
P01324404A1208|139 158|region II-III domain
P01324406A1250|8 12|roles
P01324406A1250|15 18|RAD5
P01324406A1250|27 54|ATPase/DNA helicase activity
P01324406A1250|55 64|DNA repair
P01324406A1250|72 82|maintenance
P01324406A1250|94 98|rates
P01324406A1250|101 111|instability
P01324406A1250|130 138|sequences
P01324639T0000|0 15|Susceptibilities
P01324639T0000|43 49|bacilli
P01324639T0000|52 62|amoxicillin
P01324639T0000|64 78|amoxicillin-BRL
P01324639T0000|85 107|amoxicillin-clavulanate
P01324639T0000|109 120|temafloxacin
P01324639T0000|125 135|clindamycin
P01325221A0870|10 15|arrest
P01325221A0870|18 28|DU249 cells
P01325221A0870|46 54|detection
P01325221A0870|76 85|MBP kinase
P01325221A0870|104 117|p41 MAP kinase
P01325221A0870|133 146|chromatography
P01325386A0766|3 17|hit1-1 mutation
P01325386A0766|24 29|defect
P01325386A0766|32 40|synthesis
P01325386A0766|49 66|heat shock protein
P01326329A0703|6 21|base pair region
P01326329A0703|44 51|CAP site
P01326329A0703|71 74|lack
P01326329A0703|86 93|TATA box
P01326329A0703|99 106|presence
P01326329A0703|109 117|sequences
P01326329A0703|127 134|GC boxes
P01326329A0703|135 145|CACCC boxes
P01326329A0703|146 156|CCAAT boxes
P01326329A0703|157 173|activator protein
P01326329A0703|175 178|Ap-2
P01326329A0703|180 184|sites
P01326329A0703|193 224|glucocorticoid response elements
P01326329A0703|224 227|GREs
P01326329A0703|246 266|AMP response elements
P01326329A0703|266 269|CREs
P01326557T0000|0 6|Cloning
P01326557T0000|17 25|structure
P01326557T0000|28 35|neurocan
P01326557T0000|74 105|chondroitin sulfate proteoglycan
P01326557T0000|106 110|brain
P01327280A0000|2 5|rats
P01327280A0000|25 34|chloralose
P01327280A0000|38 44|changes
P01327280A0000|60 61|pH
P01327280A0000|65 65|K
P01327280A0000|75 90|cord dorsal horn
P01327280A0000|105 106|pH
P01327280A0000|110 110|K
P01327280A0000|125 134|electrodes
P01327758A0000|0 10|Replication
P01327758A0000|19 34|papillomavirus-1
P01327758A0000|36 40|BPV-1
P01327758A0000|42 44|DNA
P01327758A0000|61 73|gene products
P01327758A0000|77 86|E1 protein
P01327758A0000|103 112|E2 protein
P01327967A0668|11 22|inactivation
P01327967A0668|25 27|sms
P01327967A0668|42 52|sensitivity
P01327967A0668|68 96|agent methylmethane sulfonate
P01327967A0668|105 115|requirement
P01327967A0668|119 124|serine
P01327967A0668|132 142|metabolites
P01328197A0985|5 12|findings
P01328197A0985|27 64|MAP kinase activator/MAP kinase system
P01328197A0985|79 88|components
P01328197A0985|91 122|ras signal transduction pathways
P01328219A1397|0 5|NSCL-1
P01328219A1397|26 31|number
P01328219A1397|39 48|cell lines
P01328681A0149|17 24|proteins
P01328681A0149|47 67|c-myc hyperexpression
P01328681A0149|89 101|transcription
P01328681A0149|108 117|activities
P01328681A0149|131 138|proteins
P01328681A0149|168 177|inhibition
P01328681A0149|180 196|protein synthesis
P01328681A0149|197 198|A.
P01328681A0348|0 6|Ruddell
P01328681A0348|8 9|M.
P01328854T0000|7 16|MEF-2 site
P01328854T0000|42 48|element
P01328854T0000|60 72|transcription
P01328854T0000|93 99|subunit
P01328854T0000|110 137|phosphoglycerate mutase gene
P01328854T0000|156 167|muscle cells
P01328884T0000|0 18|Truncation variants
P01328884T0000|20 27|peptides
P01328884T0000|40 48|MHC class
P01328884T0000|50 58|molecules
P01328884T0000|66 80|sequence motifs
P01329039A0239|11 25|E-box consensus
P01329039A0239|45 50|CANNTG
P01329039A0239|63 73|nucleotides
P01329039A0239|86 92|E-boxes
P01329039A0239|107 111|genes
P01329039A0239|130 137|proteins
P01329039A0951|0 18|Intermediate levels
P01329039A0951|20 32|gene activity
P01329039A0951|47 59|TnI enhancers
P01329039A0951|69 75|E-boxes
P01329039A0951|90 92|MCK
P01329039A0951|97 106|E-box site
P01329039A0951|115 131|Ig kappa E2 E-box
P01330077A0000|0 19|T-cell receptor beta
P01330077A0000|19 26|TCR beta
P01330077A0000|27 45|gene rearrangements
P01330077A0000|65 70|B-cell
P01330077A0000|89 97|leukemias
P01330077A0000|99 102|ALLs
P01330309A1134|3 15|CANNTG motifs
P01330309A1134|30 33|MyoD
P01330309A1134|37 60|myogenin fusion proteins
P01330309A1134|76 83|proteins
P01330309A1134|93 100|extracts
P01330309A1134|113 120|myotubes
P01330975T0000|10 23|polyneuropathy
P01330975T0000|46 52|myeloma
P01331057A0000|24 28|COX12
P01331057A0000|40 43|gene
P01331057A0000|47 57|subunit VIb
P01331057A0000|82 101|cytochrome c oxidase
P01331060A0768|3 11|structure
P01331060A0768|17 34|calcineurin A gene
P01331060A0768|48 57|comparison
P01331060A0768|73 86|cDNA sequences
P01331086T0000|8 24|promoter elements
P01331086T0000|32 59|cytochrome c oxidase subunit
P01331086T0000|59 62|gene
P01331086T0000|90 99|ets motifs
P01331086T0000|121 141|transcription factors
P01331292A1425|23 31|instances
P01331292A1425|44 58|oligonucleotide
P01331292A1425|65 71|repeats
P01331292A1425|78 83|region
P01331292A1425|100 106|variola
P01331292A1425|109 122|vaccinia virus
P01331501A0397|28 35|peptides
P01331501A0397|60 68|sequences
P01331501A0397|71 73|E1A
P01331501A0397|90 100|interaction
P01331501A0397|105 108|p107
P01331501A0397|110 117|cyclin A
P01331501A0397|121 124|p130
P01331516A0103|5 11|mutants
P01331516A0103|26 51|3T6 mouse fibroblast cells
P01331516A0103|84 88|virus
P01331516A0103|91 113|coinfection experiments
P01331516A0103|115 126|C2 myoblasts
P01332589A0666|3 6|MICs
P01332589A0666|13 20|compound
P01332589A0666|30 30|%
P01332589A0666|38 46|organisms
P01332589A0666|78 86|S. aureus
P01332589A0666|125 137|micrograms/ml
P01332964A0247|10 17|promoter
P01332964A0247|23 35|RII beta gene
P01332964A0247|68 75|elements
P01333035T0000|0 6|Mapping
P01333035T0000|10 43|cAMP receptor protein contact site
P01333035T0000|45 57|alpha subunit
P01333035T0000|74 87|RNA polymerase
P01333047A0404|23 35|growth factor
P01333047A0404|53 77|growth factor stimulation
P01333047A0404|97 101|cells
P01333047A0404|109 123|phosphorylation
P01333047A0404|126 136|Nck protein
P01333047A0404|138 145|tyrosine
P01333047A0404|147 152|serine
P01333047A0404|157 174|threonine residues
P01333053A0110|6 14|mechanism
P01333053A0110|22 59|steroid hydroxylase gene transcription
P01333053A0110|80 85|cortex
P01333053A0110|106 120|peptide hormone
P01333053A0110|121 124|ACTH
P01333053A0110|138 141|cAMP
P01333125A0000|1 11|combination
P01333125A0000|25 41|sequence analysis
P01333125A0000|57 63|methods
P01333125A0000|74 85|conservation
P01333125A0000|96 113|structure elements
P01333125A0000|132 137|region
P01333125A0000|139 141|UTR
P01333125A0000|150 162|enteroviruses
P01333125A0000|166 177|rhinoviruses
P01333317A1008|10 15|region
P01333317A1008|38 40|Sp1
P01333317A1008|58 64|protein
P01333317A1008|66 66|s
P01333317A1008|87 92|factor
P01333317A1008|94 94|s
P01333317A1008|98 102|PRF-I
P01334428A1102|0 1|Km
P01334428A1102|5 8|Vmax
P01334428A1102|15 24|substrates
P01334428A1102|37 43|peptide
P01334428A1102|47 50|poly
P01334428A1102|52 54|Glu
P01334428A1102|56 58|Tyr
P01334428A1102|73 74|mM
P01334428A1102|81 96|mumol min-1 mg-1
P01334428A1102|102 103|mM
P01334428A1102|110 125|mumol min-1 mg-1
P01334493A0289|11 14|form
P01334493A0289|20 23|HGFr
P01334493A0289|25 29|sHGFr
P01334493A0289|36 38|HGF
P01334493A0289|45 52|affinity
P01334493A0289|100 107|receptor
P01334518T0000|0 9|Strategies
P01334518T0000|13 27|blood screening
P01334518T0000|33 49|hepatitis C virus
P01334518T0000|62 83|immunodeficiency virus
P01334518T0000|89 99|risk groups
P01337142A2043|13 47|glycoprotein alpha-subunit promoter
P01337142A2043|65 67|FSK
P01337142A2043|70 76|GH4 rat
P01337142A2043|85 89|cells
P01337142A2043|92 99|ABSTRACT
P01337142A2043|114 118|WORDS
P01338867A0503|0 9|Comparison
P01338867A0503|12 15|data
P01338867A0503|31 37|results
P01338867A0503|47 55|treatment
P01338867A0503|69 78|antagonist
P01338867A0503|110 117|blockade
P01338867A0503|130 142|fatiguability
P01338867A0503|151 156|extent
P01338867A0503|168 177|activation
P01338867A0503|186 191|system
P01339125A0153|0 17|Laboratory studies
P01339125A0153|22 25|Ca45
P01339125A0153|33 37|teeth
P01339125A0153|60 64|teeth
P01339125A0153|81 90|dentifrice
P01339125A0153|106 111|enamel
P01339125A0153|114 125|bleach teeth
P01339373T0000|0 8|Structure
P01339373T0000|12 21|expression
P01339373T0000|25 28|gene
P01339373T0000|33 52|Arabidopsis thaliana
P01339373T0000|61 67|protein
P01339373T0000|77 95|SNF1 protein kinase
P01339391A0000|34 39|region
P01339391A0000|42 62|DNA surrounding HRAS1
P01339468A0272|3 14|ORF1 protein
P01339468A0272|55 79|potexvirus RNA replicases
P01339468A0272|79 82|ORF2
P01339468A0272|94 101|proteins
P01339468A0272|110 118|analogues
P01339468A0272|127 131|potex
P01339468A0272|157 164|proteins
P01339773A0000|1 5|total
P01339773A0000|11 18|patients
P01339773A0000|34 39|groups
P01339773A0000|64 72|diagnosis
P01339773A0000|93 103|capnography
P01339773A0000|105 114|spirometry
P01339773A0000|127 134|analysis
P01339773A0778|3 15|relationships
P01339773A0778|33 41|pressures
P01339773A0778|49 51|CO2
P01339773A0778|72 80|gradients
P01339773A0778|103 110|increase
P01339773A0778|116 142|ventilation-perfusion ratio
P01339815A1545|13 24|correlations
P01339815A1545|27 34|peak VO2
P01339815A1545|57 61|tests
P01340470A0000|13 24|protein gene
P01340470A0000|25 28|rbp1
P01340470A0000|67 87|RNA recognition motif
P01340470A0000|91 97|Arg-Ser
P01340470A0000|103 104|RS
P01340470A0000|106 111|domain
P01341119A0450|4 19|research studies
P01341119A0450|34 37|kind
P01341119A0450|40 45|tumors
P01341119A0450|59 67|ingestion
P01341119A0450|70 82|H2 inhibitors
P01341119A0450|85 98|others antacid
P01346262A0377|12 16|study
P01346262A0377|27 42|protein profiles
P01346262A0377|53 70|S. entomophila UC9
P01346262A0377|78 81|UC21
P01346262A0377|130 136|protein
P01346262A0377|174 180|protein
P01346534T0000|0 15|Characterization
P01346534T0000|21 27|regulon
P01346534T0000|71 77|protein
P01347476T0000|0 6|Mapping
P01347476T0000|12 26|mouse ornithine
P01347476T0000|47 61|sequence family
P01347664A1026|4 11|mutation
P01347664A1026|42 47|levels
P01347664A1026|50 57|CAD mRNA
P01347664A1026|60 66|protein
P01347664A1026|72 77|mutant
P01347908T0000|3 11|rationale
P01347908T0000|37 47|stimulation
P01347908T0000|50 57|patients
P01347908T0000|62 70|Parkinson
P01347908T0000|73 79|disease
P01347944A0964|10 16|studies
P01347944A0964|37 60|homeodomain binding site
P01347944A0964|61 68|sequence
P01347944A0964|91 100|regulation
P01348504A0757|8 32|pol alpha-primase complex
P01348504A0757|68 75|distance
P01348508A0313|17 25|positions
P01348508A0313|33 39|introns
P01348508A0313|59 68|comparison
P01348508A0313|76 80|genes
P01348508A0313|112 121|activities
P01348508A0313|136 145|literature
P01348508A0313|153 161|TGM1 gene
P01348508A0313|194 197|date
P01348508A0313|208 214|introns
P01348590A0000|16 23|analysis
P01348590A0000|26 29|data
P01348590A0000|36 40|cases
P01348590A0000|54 61|lymphoma
P01348590A0000|67 72|cohort
P01348590A0000|91 98|patients
P01348590A0000|103 107|stage
P01348590A0000|110 120|HIV-disease
P01348590A0000|125 127|CD4
P01348590A0000|139 142|time
P01348590A0000|145 153|diagnosis
P01348590A0000|161 163|use
P01348590A0000|180 185|agents
P01348590A0000|188 199|radiotherapy
P01348590A0000|218 224|outcome
P01349705T0000|0 6|Effects
P01349705T0000|9 15|dioxins
P01349705T0000|18 33|thyroid function
P01349705T0000|42 47|babies
P01349837T0000|0 10|cDNA clones
P01349837T0000|18 37|Arabidopsis thaliana
P01349837T0000|40 47|Zea mays
P01349837T0000|60 75|chaperonin HSP60
P01349837T0000|78 92|gene expression
P01349837T0000|98 113|seed germination
P01349837T0000|116 125|heat shock
P01350780A0184|0 29|Amino acid sequence comparison
P01350780A0184|46 53|homology
P01350780A0184|64 68|yeast
P01350780A0184|87 108|gamma-glutamyl kinases
P01350780A0184|123 129|lengths
P01350932A1123|9 12|site
P01350932A1123|15 27|glycosylation
P01350932A1123|44 53|C-terminus
P01350932A1123|59 80|N-glycosylation sequon
P01350932A1123|81 91|Asn-Cys-Ser
P01350932A1123|100 102|Cys
P01350932A1123|108 111|part
P01350932A1123|115 131|disulphide bridge
P01352113A0002|17 22|events
P01352113A0002|37 52|nitrogen dioxide
P01352113A0002|53 54|NO
P01352113A0002|57 64|exposure
P01352113A0002|81 83|rat
P01352113A0002|95 110|inhalation model
P01352113A0002|134 141|measures
P01352113A0231|12 18|effects
P01352113A0231|62 79|NO2 concentrations
P01352113A0231|100 102|ppm
P01352113A0231|105 111|ppm NO2
P01352113A0231|116 125|mg m-3 NO2
P01352113A0231|128 141|exposure times
P01352113A0231|153 155|min
P01353478T0000|0 10|Interaction
P01353478T0000|13 17|H-2Eb
P01353478T0000|24 42|IAP retrotransposon
P01353478T0000|47 68|A20/2J B cell lymphoma
P01354506T0000|24 31|diseases
P01354506T0000|39 46|advances
P01354506T0000|52 64|understanding
P01354506T0000|67 78|cytogenetics
P01354506T0000|80 93|histopathology
P01354506T0000|105 111|history
P01357190A0726|7 15|exception
P01357190A0726|18 24|mutants
P01357190A0726|38 59|membrane anchor domain
P01357190A0726|73 85|glycoproteins
P01357190A0726|97 103|ability
P01357190A0726|111 116|fusion
P01357190A0726|130 134|cells
P01357528A0084|3 17|subunit protein
P01357528A0084|19 23|curli
P01357528A0084|48 61|amino terminus
P01357528A0084|63 68|SEF-17
P01357528A0084|73 87|subunit protein
P01357528A0084|105 112|fimbriae
P01357528A0084|141 149|strain 3b
P01357528A0084|169 174|fibres
P01357528A0084|185 189|class
P01357528A0084|192 209|surface organelles
P01357528A0084|211 224|enterobacteria
P01358190A0654|0 11|Substitution
P01358190A0654|17 30|DR1 beta chain
P01358190A0654|33 43|H-2E beta k
P01358190A0654|56 59|loss
P01358190A0654|62 72|recognition
P01358190A0654|74 97|alpha chain substitution
P01358190A0654|110 115|effect
P01358592A0752|22 28|pathway
P01358592A0752|57 65|cell fate
P01358592A0752|89 93|state
P01358592A0752|114 119|region
P01358592A0752|125 130|embryo
P01358758A0000|9 15|portion
P01358758A0000|21 38|rat insulin I gene
P01358758A0000|47 49|DNA
P01358758A0000|61 77|sequence elements
P01358758A0000|81 83|Far
P01358758A0000|87 99|FLAT elements
P01358758A0000|117 127|combination
P01358758A0000|182 189|enhancer
P01358880A0251|10 28|amino acid sequence
P01358880A0251|38 47|% identity
P01358880A0251|65 89|transglutaminase sequence
P01359588A0375|4 14|computation
P01359588A0375|37 43|network
P01359588A0375|73 80|elements
P01360180A0513|8 14|efforts
P01360180A0513|35 47|baculoviruses
P01360180A0513|68 73|kinase
P01360180A0513|88 99|recombinants
P01360180A0513|124 129|kinase
P01360180A0513|144 149|domain
P01360180A0513|152 159|mutation
P01360180A1568|27 44|P68 amino terminus
P01360180A1568|82 86|dsRNA
P01360180A1568|122 131|properties
P01360180A1568|135 155|reporter gene product
P01360180A1568|176 178|RNA
P01360294A0000|4 9|August
P01360294A0000|16 22|October
P01360294A0000|45 49|women
P01360294A0000|57 64|subjects
P01360294A0000|80 85|levels
P01360294A0000|88 93|plasma
P01360294A0000|104 115|antithrombin
P01360294A0000|126 133|activity
P01363080A0710|6 11|acuity
P01363080A0710|37 43|changes
P01363080A0710|56 60|error
P01363080A0710|69 80|sulfonamides
P01363080A0710|95 113|agent metronidazole
P01363080A0710|122 130|diuretics
P01363080A0710|143 162|anhydrase inhibitors
P01363166T0001|0 15|Currents aspects
P01363166T0001|17 39|H2 receptor antagonists
P01363166T0001|43 51|treatment
P01363166T0001|54 59|ulcers
P01364100A0377|2 9|addition
P01364100A0377|18 36|subrepeat structure
P01364100A0377|55 58|unit
P01370281A0461|0 9|Sequencing
P01370281A0461|30 42|reading frame
P01370281A0461|57 63|protein
P01370446A0818|5 9|sites
P01370446A0818|26 57|keratan sulfate attachment sites
P01371181A0688|13 20|plasmids
P01371181A0688|26 36|pLS1 family
P01371181A0688|37 41|pE194
P01371181A0688|43 49|pADB201
P01371181A0688|54 57|pLB4
P01371181A0688|59 63|share
P01371181A0688|87 101|characteristics
P01371181A0688|108 117|regulation
P01371181A0688|125 136|copy numbers
P01371272A1167|0 11|Perturbation
P01371272A1167|14 23|dNTP pools
P01371272A1167|38 56|frameshift fidelity
P01371272A1167|72 97|yeast DNA polymerase alpha
P01371275T0000|12 21|expression
P01371275T0000|28 28|B
P01371275T0000|30 36|subunit
P01371275T0000|50 50|H
P01371275T0000|55 60|ATPase
P01371275T0000|69 75|tissues
P01371413A0742|2 9|addition
P01371413A0742|14 24|hGCSFR gene
P01371413A0742|51 72|Southern blot analysis
P01371413A0742|76 94|segregation pattern
P01371413A0742|97 101|panel
P01371413A0742|104 127|rodent-human hybrid DNAs
P01371413A0742|146 155|cDNA probe
P01371863A0000|55 65|gene family
P01371863A0000|70 98|protozoan parasite Leishmania
P01372365A1202|6 10|sites
P01372365A1202|12 13|%T
P01372365A1202|34 35|Cl
P01372365A1202|37 50|concentrations
P01372365A1202|56 56|M
P01372365A1202|70 77|sites %T
P01372365A1202|105 114|conditions
P01372456A0426|0 7|Necrosis
P01372456A0426|16 16|h
P01372456A0426|22 32|TA infusion
P01372456A0426|42 42|%
P01372456A0426|45 50|extent
P01372456A0426|58 58|h
P01372456A0426|64 64|%
P01372456A0426|72 72|h
P01372456A0426|76 82|animals
P01372456A0426|92 95|area
P01372456A0426|102 111|% necrosis
P01372802A1481|2 8|summary
P01372802A1481|13 20|segments
P01372802A1481|23 24|C3
P01372802A1481|38 56|amino acid residues
P01372802A1481|107 108|C3
P01372802A1481|110 110|D
P01372802A1481|112 119|epitopes
P01372802A1481|155 166|C3 fragments
P01372802A1481|191 210|fluid-phase fragment
P01372802A1481|221 228|segments
P01372802A1481|237 244|residues
P01372802A1481|272 273|C3
P01372802A1481|275 275|D
P01372802A1481|277 284|epitopes
P01372802A1481|321 322|C3
P01372802A1481|356 364|fragments
P01372802A1481|370 376|protein
P01372900A0448|5 9|exons
P01372900A0448|30 34|exons
P01372900A0448|65 83|amino acid residues
P01372900A0448|91 115|alpha s1-casein variant A
P01372900A0448|132 133|F.
P01372900A1017|37 48|organization
P01372900A1017|54 92|goat alpha s1-casein transcription unit
P01372900A1017|101 137|polymerase chain reaction experiments
P01373374A0735|0 9|Homodimers
P01373374A0735|20 27|proteins
P01373374A0735|52 62|G-box motif
P01373374A0735|67 70|GBF1
P01373374A0735|74 85|GBF3 binding
P01373374A0735|115 122|sequence
P01374331A0636|7 10|gene
P01374331A0636|44 53|start site
P01374331A0636|62 81|nuclease S1 analysis
P01374392A0341|3 21|hydrophobicity plot
P01374392A0341|23 27|NHE-3
P01374392A0341|49 53|NHE-1
P01374392A0341|57 61|NHE-2
P01374398A0951|10 28|translation protein
P01374398A0951|40 43|cDNA
P01374398A0951|52 54|kDa
P01374398A0951|79 100|amino acid composition
P01374398A0951|111 114|acid
P01374398A0951|127 127|%
P01374398A0951|138 156|amino acid residues
P01374688A0471|4 8|group
P01374688A0471|19 23|ml/kg
P01374688A0471|33 47|% pentafraction
P01374688A0471|49 61|% pentastarch
P01374688A0471|64 69|plasma
P01374688A0471|81 85|hours
P01374688A0471|96 110|micrograms/kg/0
P01374688A0471|113 117|hr E.
P01375224A0152|21 28|evidence
P01375224A0152|41 45|v-Crk
P01375224A0152|55 68|transformation
P01375224A0152|71 96|chicken embryo fibroblasts
P01375224A0152|111 118|activity
P01375224A0152|129 136|proteins
P01375224A0152|147 163|growth regulation
P01375913A0484|32 51|DNA oligonucleotides
P01375913A0484|53 66|U14 snRNA gene
P01375913A0484|94 124|T7 RNA polymerase promoter site
P01375913A0484|141 147|plasmid
P01376319T0000|0 3|Gene
P01376319T0000|7 16|pseudogene
P01376319T0000|22 26|mouse
P01376319T0000|43 70|mannose 6-phosphate receptor
P01377696A0000|3 7|chick
P01377696A0000|23 54|surface glycoprotein neurofascin
P01377696A0000|73 78|growth
P01377696A0000|82 94|fasciculation
P01377696A0000|107 139|antibody perturbation experiments
P01377764A0309|3 11|carcinoma
P01377764A0309|34 43|epithelium
P01377764A0309|60 64|layer
P01377764A0309|88 92|layer
P01377818A0468|2 9|addition
P01377818A0468|11 20|C/EBP beta
P01377818A0468|23 33|C/EBP gamma
P01377818A0468|79 89|C/EBP alpha
P01377962A1012|2 9|contrast
P01377962A1012|11 22|tobacco GS-2
P01377962A1012|34 41|subunits
P01377962A1012|53 56|size
P01377962A1012|62 67|organs
P01378052A0594|7 10|acoR
P01378052A0594|14 20|acoXABC
P01378052A0594|34 38|types
P01378052A0594|41 49|sequences
P01378052A0594|68 75|symmetry
P01378052A0594|77 79|CAC
P01378052A0594|82 84|N11
P01378052A0594|87 89|N18
P01378052A0594|92 94|GTG
P01378052A0594|98 100|TGT
P01378052A0594|103 105|N10
P01378052A0594|108 110|N14
P01378052A0594|113 115|ACA
P01378052A0594|132 140|sequences
P01378052A0594|153 156|NtrC
P01378052A0594|160 163|NifA
P01378052A0594|172 190|activator sequences
P01378127A0841|11 17|effects
P01378127A0841|23 40|calcium supplement
P01378127A0841|42 59|calcium antagonist
P01378127A0841|95 103|responses
P01378431A0202|0 1|C.
P01378431A0202|3 5|Sun
P01378431A0202|7 8|J.
P01378431A0202|10 12|Hsu
P01378431A0202|14 18|M.-Y.
P01378431A0202|20 34|Vallejo-Ramirez
P01378431A0202|36 37|J.
P01378431A0202|39 44|Inouye
P01378431A0202|46 47|S.
P01378431A0202|52 57|Inouye
P01378431A0202|59 60|M.
P01378506A0884|16 35|full-deletion mutant
P01378506A0884|48 52|block
P01378506A0884|55 67|virus release
P01378506A0884|82 83|NC
P01378506A0884|96 109|virus assembly
P01378526A0535|29 47|FK506 plasma levels
P01378526A0535|66 75|appearance
P01378526A0535|82 87|effect
P01379032A0495|6 12|percent
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379032A0495|62 73|steroid dose
P01379032A0495|78 82|group
P01379032A0495|94 101|steroids
P01379032A0495|108 109|mg
P01379032A0495|112 121|prednisone
P01379032A0495|125 127|day
P01379150A0996|5 15|cibenzoline
P01379150A0996|43 47|agent
P01379150A0996|78 84|profile
P01379150A0996|113 117|class
P01379150A0996|119 123|drugs
P01379150A0996|126 133|patients
P01379150A0996|143 149|therapy
P01379150A0996|157 172|risk arrhythmias
P01380062A0097|0 8|T antigen
P01380062A0097|45 56|T lymphocyte
P01380062A0097|57 59|CTL
P01380062A0097|61 80|recognition epitopes
P01380062A0097|87 93|targets
P01380062A0097|97 110|CTL clones Y-1
P01380062A0097|110 112|Y-2
P01380062A0097|114 116|Y-3
P01380062A0097|121 123|Y-5
P01380076A0165|3 8|method
P01380076A0165|32 37|column
P01380076A0165|42 61|paired-ion technique
P01380076A0165|71 85|docusate sodium
P01380076A0165|94 103|components
P01380454A0451|24 38|protein product
P01380454A0451|43 52|ref-1 gene
P01380454A0451|65 84|DNA binding activity
P01380454A0451|85 104|Fos-Jun heterodimers
P01380454A0451|105 122|Jun-Jun homodimers
P01380454A0451|125 147|Hela cell AP-1 proteins
P01380454A0451|171 191|transcription factors
P01380454A0451|200 209|NF-kappa B
P01380454A0451|210 212|Myb
P01380454A0451|216 222|members
P01380454A0451|228 242|ATF/CREB family
P01380716A0174|9 15|tissues
P01380716A0174|40 45|molars
P01380716A0174|77 91|calcium hydrate
P01380825A0622|0 21|Northern blot analyses
P01380825A0622|52 56|mRNAs
P01380825A0622|75 78|cDNA
P01380825A0622|95 101|tissues
P01380825A0622|128 134|protein
P01380825A0622|165 172|function
P01383690A1023|3 16|ARG SH2 domain
P01383690A1023|38 45|affinity
P01383690A1023|49 51|BCR
P01383690A1023|105 118|ABL SH2 domain
P01383695A0100|12 27|EBV B-cell clone
P01383695A0100|27 31|E29.1
P01383695A0100|56 61|embryo
P01383695A0100|79 87|IgM kappa
P01383695A0100|90 99|IgM lambda
P01384040A1043|18 27|activation
P01384040A1043|47 53|regions
P01384040A1043|81 91|orientation
P01384040A1043|119 123|pCF10
P01384165A0000|2 5|rats
P01384165A0000|20 25|effect
P01384165A0000|30 36|omentum
P01384165A0000|50 64|vascularization
P01384165A0000|70 76|trachea
P01384165A0000|82 93|regeneration
P01384165A0000|106 115|epithelium
P01384165A0000|130 134|stage
P01384165A0000|144 160|tracheal grafting
P01384229A0175|26 29|role
P01384229A0175|44 54|chicken ICS
P01384229A0175|57 71|oligonucleotide
P01384229A0175|91 99|sequences
P01384229A0175|105 114|BF-IV gene
P01384229A0175|152 157|copies
P01384229A0175|167 184|herpes TK promoter
P01384229A0175|197 230|chloramphenicol acetyl transferase
P01384229A0175|230 232|CAT
P01384229A0175|234 237|gene
P01384229A0175|239 245|pBLCAT2
P01385462A0151|58 61|runs
P01385462A0151|103 120|acid determination
P01385462A0151|132 144|determination
P01385462A0151|150 159|monoamines
P01386210A0293|21 23|use
P01386210A0293|43 49|therapy
P01386210A0293|53 61|treatment
P01386210A0293|70 79|depression
P01386210A0293|88 90|man
P01386210A0293|100 117|GM2 gangliosidosis
P01386897A0000|0 4|Entry
P01386897A0000|7 17|yeast cells
P01386897A0000|31 40|cell cycle
P01386897A0000|41 45|Start
P01386897A0000|56 59|form
P01386897A0000|65 76|CDC28 kinase
P01386897A0000|105 111|cyclins
P01386897A0000|121 124|CLN1
P01386897A0000|128 131|CLN2
P01386897A0000|133 135|ref
P01387105A0933|7 28|Southern blot analyses
P01387105A0933|29 31|DNA
P01387105A0933|36 44|backcross
P01387105A0933|55 58|mice
P01387105A0933|77 83|strains
P01387105A0933|95 106|cell hybrids
P01387105A0933|117 120|loci
P01387105A0933|135 140|cyclin
P01387105A0933|151 159|sequences
P01387105A0933|171 184|loci Cycb1-rs1
P01387105A0933|186 194|Cycb1-rs9
P01387105A0933|208 224|mouse chromosomes
P01387105A0933|241 241|X
P01388160A1102|5 19|residue Glu-381
P01388160A1102|21 24|beta
P01388160A1102|54 60|residue
P01388160A1102|68 82|epsilon peptide
P01388160A1102|106 121|peptide sequence
P01388160A1102|139 145|choices
P01388160A1102|148 154|Ser-106
P01388160A1102|156 162|Ser-107
P01388160A1102|166 172|Ser-108
P01389362T0000|0 8|Porcelain
P01389362T0000|17 29|bond strength
P01389362T0000|34 48|dentin adhesive
P01389573A1071|0 3|TBPf
P01389573A1071|16 23|quotient
P01389573A1071|29 38|difference
P01389573A1071|61 71|measurement
P01389573A1071|73 76|TBPf
P01389573A1071|79 80|P1
P01389573A1071|82 83|P2
P01389573A1071|87 88|A1
P01389573A1071|90 91|A2
P01389585A0825|18 27|Scotchbond
P01389585A0825|32 52|Prisma Universal Bond
P01389585A0825|73 94|dentine bonding agents
P01389585A0825|95 100|choice
P01391001A0583|26 39|yeasts species
P01391001A0583|41 45|total
P01391001A0583|50 50|%
P01391001A0583|67 76|ATB method
P01391001A0583|99 105|methods
P01392012A0228|19 29|vasopressin
P01392012A0228|33 48|oxytocin content
P01392012A0228|63 76|pressor effect
P01392012A0228|85 92|Dekanski
P01392012A0228|108 115|activity
P01392012A0228|132 141|van Dongen
P01392012A0228|144 147|Hays
P01392277A0000|0 7|Comments
P01392277A0000|28 33|status
P01392277A0000|36 46|regulations
P01392277A0000|57 61|water
P01392277A0000|64 77|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|96 105|connection
P01392277A0000|113 127|KOK regulations
P01392277A0000|154 161|standard
P01392277A0000|163 165|DIN
P01392277A0000|167 169|No.
P01392358A0389|4 8|reply
P01392358A0389|21 37|telephone contact
P01392358A0389|39 49|home visits
P01394200A0592|3 17|treatment group
P01394200A0592|33 49|T-cell activation
P01394200A0592|62 72|lymphopenia
P01394200A0592|84 104|rebound lymphocytosis
P01394200A0592|107 118|upregulation
P01394200A0592|124 142|subset markers CD25
P01394200A0592|142 152|interleukin
P01394200A0592|154 161|receptor
P01394200A0592|166 171|CD45RO
P01394200A0592|181 185|cells
P01394655A0615b|0 14|Urease activity
P01394655A0615b|26 31|amount
P01394655A0615b|34 51|ammonia production
P01394655A0615b|55 58|urea
P01394655A0615b|79 80|ng
P01394655A0615b|84 87|tube
P01394655A0615b|89 91|S/N
P01394655A0615b|101 121|Jack bean meal urease
P01395755A1023|24 34|differences
P01395755A1023|66 72|methods
P01395755A1023|84 96|oxygen uptake
P01395755A1023|105 110|ml/min
P01395755A1023|121 126|ml/min
P01395755A1023|128 128|p
P01395755A1023|137 151|oxygen delivery
P01395755A1023|161 166|ml/min
P01395755A1023|178 183|ml/min
P01395755A1023|185 185|p
P01395755A1023|204 209|output
P01395755A1023|220 224|L/min
P01395755A1023|236 240|L/min
P01395755A1023|242 242|p
P01396432A0388|13 17|range
P01396432A0388|29 37|functions
P01396432A0388|61 67|seizure
P01396432A0388|82 91|assessment
P01396432A0388|94 111|memory performance
P01396444A0934|3 13|experiments
P01396444A0934|29 39|micromilieu
P01396444A0934|45 51|alveoli
P01396444A0934|58 66|condition
P01396444A0934|72 73|AM
P01396444A0934|95 111|activation states
P01396444A0934|128 135|activity
P01396444A0934|164 169|degree
P01396444A0934|172 179|recovery
P01396572A0320|21 33|plasmid pUC19
P01396572A0320|74 86|plasmid pUC19
P01396572A0320|87 88|CG
P01396572A0320|107 111|dG-dC
P01396572A0320|114 120|segment
P01396572A0320|126 131|Z-form
P01396572A0320|146 155|competitor
P01396583A0204|1 12|cDNA library
P01396583A0204|14 25|tumour cells
P01396583A0204|42 52|interleukin
P01396583A0204|67 71|probe
P01396592A1113|3 13|experiments
P01396592A1113|28 35|SCL gene
P01396592A1113|41 46|target
P01396592A1113|62 88|transcription factor GATA-1
P01396592A1113|97 112|SCL gene product
P01396592A1113|128 136|regulator
P01396592A1113|148 162|differentiation
P01396601A0986|2 9|contrast
P01396601A0986|21 27|domains
P01396601A0986|30 35|Sec12p
P01396601A0986|37 41|Stl1p
P01396601A0986|45 49|Stl2p
P01396601A0986|68 71|size
P01396601A0986|98 105|homology
P01398068A0948|0 8|Complexes
P01398068A0948|37 42|his175
P01398068A0948|45 50|his273
P01398068A0948|57 68|p53 proteins
P01398068A0948|98 113|RGC DNA sequence
P01398071A0526|5 15|temperature
P01398071A0526|34 40|strains
P01398071A0526|58 65|extracts
P01398071A0526|77 89|BRF1 activity
P01398071A0526|120 127|activity
P01398071A0526|130 144|RNA polymerases
P01398071A0526|152 154|III
P01398073A0986|5 11|results
P01398073A0986|54 66|TFIID protein
P01398073A0986|89 99|stimulation
P01398073A0986|109 126|activation domains
P01398073A0986|143 150|promoter
P01398074A0697|3 15|gene sequence
P01398074A0697|44 46|RNA
P01398074A0697|54 62|yeast RNA
P01398074A0697|75 103|RNase MRP enzyme preparations
P01398074A1081|3 20|RNase MRP RNA gene
P01398074A1081|41 51|replacement
P01398074A1081|84 92|viability
P01398074A1081|120 123|role
P01398074A1081|127 135|RNase MRP
P01398098A0770|0 19|Clone pSRc200 hybrid
P01398098A0770|28 31|mRNA
P01398098A0770|47 57|translation
P01398098A0770|73 83|polypeptide
P01398104A0834|9 15|results
P01398104A0834|17 21|CBF-A
P01398104A0834|30 37|CArG box
P01398104A0834|39 43|ssDNA
P01398104A0834|59 65|protein
P01398104A0834|101 106|factor
P01398106A0754|0 7|Cleavage
P01398106A0754|27 32|enzyme
P01398106A0754|34 39|I-CreI
P01398106A0754|48 49|bp
P01398106A0754|54 55|bp
P01398106A0754|63 83|intron insertion site
P01398106A0754|91 94|exon
P01398106A0754|101 103|top
P01398106A0754|110 115|bottom
P01398106A0754|119 125|strands
P01398106A0754|170 178|overhangs
P01398106A0754|186 195|OH termini
P01398140A0488|16 30|Xenopus U7 gene
P01398140A0488|63 68|motifs
P01398140A0488|87 88|bp
P01398140A0488|104 106|PSE
P01398140A0488|125 132|location
P01398140A0488|146 147|bp
P01399206A0375|3 9|results
P01399206A0375|24 30|reports
P01399206A0375|35 56|collagenase inhibitors
P01399206A0375|78 94|blister formation
P01399206A0375|115 135|epidermolysis bullosa
P01400217T0000|10 17|analysis
P01400217T0000|29 66|IncP alpha plasmid transfer genes traF
P01400217T0000|65 68|traG
P01400217T0000|72 82|involvement
P01400217T0000|85 88|traF
P01400217T0000|91 107|phage sensitivity
P01400396A1265|3 10|promoter
P01400396A1265|35 48|phorbol esters
P01400396A1265|97 106|activation
P01400396A1265|109 129|protein kinase C beta
P01400401A0065|2 7|humans
P01400401A0065|13 34|AMP deaminase variants
P01400401A0065|40 40|M
P01400401A0065|42 47|muscle
P01400401A0065|50 50|L
P01400401A0065|52 56|liver
P01400401A0065|59 60|E1
P01400401A0065|65 66|E2
P01400401A0065|68 78|erythrocyte
P01400401A0065|101 107|variety
P01400401A0065|137 144|criteria
P01400401A0854|0 20|Western blot analyses
P01400401A0854|40 55|immunoreactivity
P01400401A0854|75 82|extracts
P01400401A0854|106 115|expression
P01400401A0854|128 137|AMPD3 cDNA
P01400775A0435|5 11|results
P01400775A0435|37 49|N-methylation
P01400775A0435|52 61|salsolinol
P01400775A0435|66 83|N-methylsalsolinol
P01400775A0435|95 99|brain
P01402647A0114|0 12|DR1 molecules
P01402647A0114|43 52|cell lines
P01402647A0114|80 96|peptide sequences
P01402647A0114|110 122|phage surface
P01403222A0391|4 10|article
P01403222A0391|36 39|care
P01403222A0391|45 49|woman
P01403222A0391|73 86|blood donation
P01403222A0391|101 111|transfusion
P01403391T0000|7 17|hepatitis B
P01403391T0000|34 41|children
P01404401A0740|9 22|ATPase cluster
P01404401A0740|30 43|reading frames
P01404401A0740|85 100|chloroplast gene
P01404612A0303|26 28|Ads
P01404612A0303|53 55|HIV
P01404612A0303|72 79|proteins
P01404612A0303|93 110|vaccine candidates
P01406630A0545|0 8|Alignment
P01406630A0545|22 30|sequences
P01406630A0545|50 67|consensus sequence
P01406630A0545|70 76|binding
P01406630A0545|114 121|proteins
P01406630A0545|137 152|binding analysis
P01406630A0545|165 177|DNA sequences
P01406630A0545|185 204|sequence specificity
P01406630A0545|209 216|proteins
P01406630A0965|12 14|p50
P01406630A0965|30 42|kappa B motif
P01406630A0965|68 74|binding
P01406630A0965|79 85|respect
P01406630A0965|96 102|protein
P01406630A0965|114 120|binding
P01406630A0965|152 169|NF-kappa B complex
P01406656A1075|15 19|clone
P01406656A1075|39 49|mouse alpha
P01406656A1075|53 56|gene
P01406656A1075|70 71|kb
P01406656A1075|81 82|kb
P01406656A1075|96 98|DNA
P01406656A1075|121 126|levels
P01406656A1075|129 139|fibroblasts
P01406656A1075|163 165|ras
P01406677A0000|23 38|control elements
P01406677A0000|67 76|expression
P01406677A0000|87 100|myoglobin gene
P01406677A0000|122 129|analysis
P01406677A0000|140 148|sequences
P01406677A0000|150 169|nucleotide positions
P01406677A0000|205 214|start site
P01406677A0000|231 245|luciferase gene
P01406688A0898|0 18|Sequencing analysis
P01406688A0898|34 45|rap1t allele
P01406688A0898|54 70|nonsense mutation
P01406688A0898|85 90|region
P01406688A0898|98 108|amino acids
P01406703A1435|12 31|Y1 cell cDNA library
P01406703A1435|47 52|region
P01406703A1435|58 65|H-2RIIBP
P01406703A1435|73 93|hormone receptor cDNA
P01406703A1435|104 107|cDNA
P01406703A1435|149 153|cells
P01407286A0427|0 6|Autopsy
P01407286A0427|23 30|survival
P01407286A0427|48 52|cells
P01407286A0427|61 71|integration
P01407286A0427|79 83|brain
P01407286A0427|101 106|traces
P01407286A0427|135 142|reaction
P01407286A0427|146 165|tyrosine hydroxylase
P01408090A0572|3 11|technique
P01408090A0572|17 33|TEE visualization
P01408090A0572|54 61|arteries
P01408137A0974|3 10|sequence
P01408137A0974|17 22|region
P01408137A0974|32 42|G+C content
P01408137A0974|45 45|%
P01408137A0974|85 86|bp
P01408137A0974|102 111|mRNA start
P01408137A0974|114 118|% G+C
P01408219A0670|10 17|patients
P01408219A0670|43 58|lymph-adenopathy
P01408219A0670|60 62|PGL
P01408219A0670|67 75|nontender
P01408219A0670|89 93|nodes
P01408219A0670|105 112|analysis
P01408219A0670|129 139|hyperplasia
P01408474A0531|0 13|PaO2 threshold
P01408474A0531|35 44|indwelling
P01408474A0531|47 61|sensor catheter
P01409581A0206|18 20|E26
P01409581A0206|34 38|v-ets
P01409581A0206|68 76|factor PU
P01409581A0206|99 102|site
P01409643A0618|7 28|lambda gt11 expression
P01409643A0618|38 53|oligonucleotides
P01409643A0618|77 98|immunodeficiency virus
P01409643A0618|99 110|TATA element
P01409643A0618|122 135|identification
P01409643A0618|147 153|protein
P01409643A0618|178 181|mass
P01409643A0618|187 189|kDa
P01409643A0618|205 216|TATA element
P01409643A0618|226 231|factor
P01409643A0618|233 235|TMF
P01410071T0000|0 11|Blood levels
P01410071T0000|13 21|melatonin
P01410071T0000|23 31|serotonin
P01410071T0000|33 40|cortisol
P01410071T0000|45 53|prolactin
P01410071T0000|56 63|relation
P01410071T0000|78 83|rhythm
P01410071T0000|86 110|platelet serotonin uptake
P01413984A0737|19 24|effect
P01413984A0737|30 47|FA supplementation
P01413984A0737|54 64|cholesterol
P01413984A0737|66 80|HDL cholesterol
P01413984A0737|81 95|LDL cholesterol
P01413984A0737|96 101|apo A1
P01413984A0737|102 103|Lp
P01413984A0737|108 112|HbA1C
P01413984A0737|114 120|glucose
P01413984A0737|122 131|fibrinogen
P01413984A0737|133 143|factor VIII
P01413984A0737|144 155|antithrombin
P01413984A0737|160 190|plasminogen activator inhibitor
P01413984A0737|190 217|tissue plasminogen activator
P01413984A0737|219 253|von Willebrand factor concentration
P01413984A0737|262 265|time
P01413984A0737|289 302|blood pressure
P01414219A0319|10 19|volunteers
P01414219A0319|42 52|differences
P01414219A0319|55 57|AUC
P01414219A0319|59 84|peak plasma concentrations
P01414219A0319|85 88|time
P01414219A0319|95 107|concentration
P01414219A0319|112 114|OXC
P01414219A0319|149 151|ERY
P01418272A1072|6 10|ng/mL
P01418272A1072|16 21|cutoff
P01418272A1072|26 36|sensitivity
P01418272A1072|39 41|CEA
P01418272A1072|47 47|%
P01418494T0000|8 13|spikes
P01418494T0000|26 33|function
P01418542A0000|3 8|effect
P01418542A0000|11 16|sodium
P01418542A0000|19 36|beta-glycyrrhetate
P01418542A0000|38 40|SGA
P01418542A0000|56 65|arrhythmia
P01418834A0987|12 30|hematocrit decrease
P01418834A0987|39 39|H
P01418834A0987|42 42|P
P01418834A0987|65 68|fall
P01418834A0987|71 84|blood pressure
P01418834A0987|125 129|mm Hg
P01418834A0987|143 143|P
P01418860A0797|3 9|effects
P01418860A0797|12 20|diltiazem
P01418860A0797|48 59|potentiation
P01418860A0797|74 82|diltiazem
P01418860A0797|111 115|cases
P01418860A0797|138 146|diltiazem
P01418860A0797|165 188|calcium channel blockade
P01418860A0797|193 196|role
P01418860A0797|204 215|interactions
P01419945A1386|0 11|Localization
P01419945A1386|25 30|plexus
P01419945A1386|38 53|nerve stimulator
P01419945A1386|76 87|interscalene
P01419945A1386|116 120|sites
P01420177A1065|0 11|Substitution
P01420177A1065|20 24|Val33
P01420177A1065|28 30|Gly
P01420177A1065|34 38|Gly28
P01420177A1065|42 44|Ser
P01420177A1065|68 75|residues
P01420177A1065|81 95|protein kinases
P01420177A1065|106 111|enzyme
P01420177A1065|136 143|activity
P01420223T0000|0 11|Significance
P01420223T0000|17 27|biopsy site
P01420223T0000|32 54|latissimus dorsi muscle
P01420223T0000|56 67|fiber typing
P01420363A0818|3 6|TIMP
P01420363A0818|16 23|AP1 site
P01420363A0818|37 41|motif
P01420363A0818|51 65|c-Fos/c-Jun AP1
P01420363A0818|98 107|competitor
P01420363A0818|111 117|binding
P01420363A0818|127 137|AP1 factors
P01420363A0818|142 154|consensus TRE
P01420363A0818|160 167|addition
P01420363A0818|175 181|factors
P01420363A0818|207 219|consensus TRE
P01420363T0000|0 10|Involvement
P01420363T0000|13 15|AP1
P01420363T0000|19 36|PEA3 binding sites
P01420363T0000|40 49|regulation
P01420363T0000|58 73|tissue inhibitor
P01420363T0000|75 94|metalloproteinases-1
P01420363T0000|96 101|TIMP-1
P01420363T0000|103 115|transcription
P01420579A0292|5 22|serum neutralizing
P01420579A0292|23 24|SN
P01420579A0292|26 33|antibody
P01420579A0292|42 47|calves
P01420579A0292|52 52|%
P01420579A0292|67 67|%
P01420579A0292|84 94|SN antibody
P01420579A0292|95 99|month
P01420579A0292|131 141|vaccination
P01421145A1190|0 12|Fractionation
P01421145A1190|27 34|extracts
P01421145A1190|37 66|heparin-agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|102 109|extracts
P01421145A1190|135 145|leaf tissue
P01421390T0000|11 15|trial
P01421390T0000|74 79|factor
P01421390T0000|90 105|body irradiation
P01421390T0000|115 126|chemotherapy
P01421390T0000|141 167|bone marrow transplantation
P01421390T0000|187 194|leukemia
P01421390T0000|206 213|lymphoma
P01421609A1067|5 8|data
P01421609A1067|24 27|DMVA
P01421609A1067|54 59|trauma
P01421609A1067|64 66|CPB
P01421609A1067|108 114|support
P01422265A0263|3 22|IgG subclass profile
P01422265A0263|32 46|coeliac disease
P01422265A0263|76 83|controls
P01422265A0263|85 88|IgG1
P01422265A0263|102 105|IgG2
P01422265A0263|107 110|IgG3
P01422265A0263|112 115|IgG4
P01422265A0263|129 137|magnitude
P01422265A0263|153 170|subclass responses
P01422265A0263|186 201|coeliac patients
P01423454A0309|0 10|Examination
P01423454A0309|13 16|ANCA
P01423454A0309|38 49|contribution
P01423454A0309|70 78|diagnosis
P01423454A0309|86 95|vasculitis
P01423454A0309|106 114|indicator
P01423454A0309|120 127|activity
P01423454A0309|133 139|disease
P01423454A0309|152 164|effectiveness
P01423454A0309|184 192|treatment
P01423738A0639|10 13|hand
P01423738A0639|20 31|pinealectomy
P01423738A0639|69 75|rabbits
P01423738A0639|104 115|deceleration
P01423738A0639|121 127|rhythms
P01423738A0639|129 142|mean delta tau
P01423738A0639|147 147|h
P01424674A0000|11 20|pemphigoid
P01424674A0000|43 49|disease
P01424674A0000|84 96|cicatrization
P01425653T0000|3 9|effects
P01425653T0000|15 20|levels
P01425653T0000|23 40|caffeine ingestion
P01425653T0000|60 77|oxygen consumption
P01425653T0000|88 92|women
P01425921A1286|17 24|features
P01425921A1286|38 55|amino acid changes
P01425921A1286|71 85|lysine deletion
P01425921A1286|103 120|consensus sequence
P01425921A1286|153 158|region
P01425921A1286|161 164|V1J1
P01426635A0496|9 15|profile
P01426635A0496|18 22|ZFH-2
P01426635A0496|34 36|CNS
P01426635A0496|63 65|DDC
P01426635A0496|76 84|serotonin
P01426635A0496|88 103|dopamine neurons
P01427034A0440|9 15|introns
P01427034A0440|42 54|protein genes
P01427034A0440|90 98|S13 genes
P01427034A0440|120 132|DNA sequences
P01427034A0440|141 142|bp
P01427034A0440|145 150|length
P01427034A0440|162 168|introns
P01427457A0000|33 37|trial
P01427457A0000|51 58|efficacy
P01427457A0000|76 77|SC
P01427457A0000|98 98|h
P01427457A0000|100 114|calcium heparin
P01427457A0000|131 144|sodium heparin
P01427457A0000|149 157|treatment
P01427457A0000|177 186|thrombosis
P01427457A0000|188 190|DVT
P01428490A0671|10 19|prevalence
P01428490A0671|30 40|pet allergy
P01428490A0671|48 52|cough
P01428490A0671|54 59|wheeze
P01428490A0671|61 67|attacks
P01428490A0671|70 78|shortness
P01428490A0671|81 86|breath
P01428490A0671|119 124|asthma
P01428490A0671|135 142|children
P01428490A0671|149 152|pets
P01428490A0671|158 161|past
P01428513A0440|45 51|persons
P01429596A1669|5 9|basis
P01429596A1669|23 32|properties
P01429596A1669|55 67|hemagglutinin
P01429596A1669|88 123|18K agglutination-aggregation factor
P01429596A1669|123 129|18K-LAF
P01429624A0328|3 7|shift
P01429624A0328|26 36|temperature
P01429624A0328|55 58|loss
P01429624A0328|61 66|guanyl
P01429624A0328|87 94|activity
P01429624A0328|97 111|adenylylcyclase
P01429714A0730|0 3|Clin
P01429724A0664|3 6|data
P01429724A0664|38 43|domain
P01429724A0664|46 50|Nmt1p
P01429724A0664|67 71|Ile59
P01429724A0664|75 79|Phe96
P01429724A0664|83 88|Gly451
P01429724A0664|92 97|Leu455
P01429740A1065|39 49|presequence
P01429740A1065|70 75|domain
P01429740A1065|92 96|exons
P01429740A1065|122 128|E2 gene
P01429768T0000|5 23|neutrophil response
P01429768T0000|35 42|exposure
P01429768T0000|45 48|F-75
P01429768T0000|61 65|alloy
P01429836A0457|0 9|Disruption
P01429836A0457|12 23|microtubules
P01429836A0457|39 46|fidelity
P01429836A0457|49 56|kinetics
P01429836A0457|67 81|protein sorting
P01429836A0457|96 109|Vps1p function
P01429836A0457|125 136|microtubules
P01429836A1205|7 10|form
P01429836A1205|13 17|Vps1p
P01429836A1205|45 50|domain
P01429836A1205|73 87|protein sorting
P01429836A1205|98 102|cells
P01431380A0244|14 27|field research
P01431380A0244|31 40|tick fauna
P01431380A0244|65 68|area
P01431380A0244|106 110|ticks
P01431380A0244|116 122|vectors
P01431380A0244|147 163|group rickettsiae
P01431380A0244|164 167|SFGR
P01431380A0244|169 176|antibody
P01431380A0244|179 182|mice
P01431380A0244|201 214|tick emulsions
P01431380A0244|215 222|findings
P01431380A0244|225 235|rickettsiae
P01431380A0244|246 257|patient sera
P01431380A0244|286 293|antibody
P01431380A0244|296 299|JSFR
P01431380A0244|305 319|hemolymph cells
P01431380A0244|325 329|ticks
P01431380A0244|334 341|electron
P01431380A0244|355 366|observations
P01431380A0244|369 372|SFGR
P01431380A0244|390 395|organs
P01431380A0244|416 420|gland
P01431380A0244|423 427|ticks
P01431602A0229|9 14|method
P01431602A0229|20 24|macro
P01431602A0229|26 30|assay
P01431602A0229|36 52|sensitivity range
P01431602A0229|62 82|micrograms phosphorus
P01431602A0229|93 109|microliters HClO4
P01431809T0000|0 18|Nucleotide sequence
P01431809T0000|36 43|analysis
P01431809T0000|49 63|polyhedrin gene
P01431809T0000|65 81|Spodoptera exigua
P01431809T0000|88 105|polyhedrosis virus
P01432453T0000|0 9|Validation
P01432453T0000|21 27|systems
P01432453T0000|30 46|system definition
P01433391A0594|3 13|consequence
P01433391A0594|20 26|rearing
P01433391A0594|40 46|density
P01433391A0594|57 63|neurons
P01433391A0594|66 69|area
P01433391A0594|98 102|value
P01433391A0594|127 133|kittens
P01433391A0594|165 168|area
P01433502A1163|5 11|results
P01433502A1163|32 36|class
P01433502A1163|38 54|enhancer activity
P01433502A1163|72 76|cells
P01433502A1163|90 93|part
P01433502A1163|111 116|levels
P01433502A1163|138 143|factor
P01433502A1163|162 170|repressor
P01433524A0788|7 12|domain
P01433524A0788|39 49|amino acids
P01433524A0788|51 53|IE1
P01433524A0788|92 101|activities
P01435698A0000|2 6|order
P01435698A0000|23 41|blood compatibility
P01435698A0000|53 62|vein graft
P01435698A0000|63 65|AVG
P01435698A0000|68 74|changes
P01435698A0000|77 88|prostacyclin
P01435698A0000|90 93|PGI2
P01435698A0000|95 104|production
P01435698A0000|114 123|harvesting
P01435698A0000|135 146|implantation
P01436261A0145|0 26|Subcutaneous administration
P01436261A0145|31 51|somatostatin analogue
P01436261A0145|52 61|octreotide
P01436261A0145|66 75|micrograms
P01436261A0145|108 118|improvement
P01436261A0145|121 129|diarrhoea
P01436261A0145|133 145|disappearance
P01436261A0145|154 165|incontinence
P01436261A0145|181 197|calcitonin levels
P01437562A0462|8 17|antibodies
P01437562A0462|30 36|protein
P01437562A0462|39 46|extracts
P01437562A0462|49 61|C.fasciculata
P01437562A0462|64 72|agreement
P01437562A0462|80 83|size
P01437562A0462|100 118|nucleotide sequence
P01437562A0462|129 132|gene
P01438224A0749|49 50|J.
P01438287T0000|14 28|vaccinia vector
P01438287T0000|59 63|genes
P01441120T0000|0 2|Use
P01441120T0000|16 23|minerals
P01441818T0001|0 14|Interferon type
P01441818T0001|27 40|body reactions
P01441818T0001|56 75|Klebsiella infection
P01443047A0773|7 13|changes
P01443047A0773|29 50|differentiation status
P01443047A0773|64 74|association
P01443047A0773|79 95|Id-SCL expression
P01443745T0000|11 21|interaction
P01443745T0000|33 42|anesthesia
P01443745T0000|46 53|sedation
P01443745T0000|58 66|midazolam
P01443748A1190|3 10|pressure
P01443748A1190|25 31|atm abs
P01443748A1190|43 54|excitability
P01443748A1190|60 67|tadpoles
P01443748A1190|128 136|movements
P01446132A0328|3 14|air embolism
P01446132A0328|37 42|filter
P01446132A0328|63 74|complication
P01446828A1088|5 10|region
P01446828A1088|13 16|ADH5
P01446828A1088|25 47|consensus binding sites
P01446828A1088|77 84|proteins
P01446828A1088|86 88|Sp1
P01446828A1088|90 92|AP2
P01446828A1088|94 98|LF-A1
P01446828A1088|100 103|NF-1
P01446828A1088|105 109|NF-A2
P01446828A1088|114 118|NF-E1
P01447139A0208|0 1|V.
P01447189A1546|5 8|data
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|33 47|serine protease
P01447189A1546|57 64|activity
P01447189A1546|85 92|granules
P01447189A1546|108 118|lymphocytes
P01447189T0000|0 11|Purification
P01447189T0000|15 21|cloning
P01447189T0000|30 44|serine protease
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|62 69|granules
P01447189T0000|73 75|rat
P01447189T0000|83 102|killer cell leukemia
P01448107A0361|24 37|GCN2 mutations
P01448107A0361|47 58|derepression
P01448107A0361|61 75|GCN4 expression
P01448107A0361|80 86|absence
P01448107A0361|89 109|amino acid starvation
P01448806A0135|0 13|Administration
P01448806A0135|16 29|growth hormone
P01448806A0135|42 47|growth
P01448806A0135|62 76|bone maturation
P01448917A0775|0 10|Comparisons
P01448917A0775|27 44|amino acid residue
P01448917A0775|44 45|aa
P01448917A0775|47 66|sequence information
P01448917A0775|81 88|CPMV RNA
P01448917A0775|89 96|sequence
P01448917A0775|110 117|sequence
P01448917A0775|123 145|clover mottle virus RNA
P01448917A0775|155 163|CPSMV RNA
P01448917A0775|184 186|set
P01448917A0775|199 206|proteins
P01448917A0775|211 229|proteinase cofactor
P01448917A0775|230 232|58K
P01448917A0775|241 248|helicase
P01448917A0775|250 252|VPg
P01448917A0775|262 268|protein
P01448917A0775|281 284|RNAs
P01448917A0775|286 299|24K proteinase
P01448917A0775|303 305|87K
P01448917A0775|314 323|polymerase
P01448917A0775|340 353|cleavage sites
P01448932T0000|0 46|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|2 9|addition
P01449183A0795|14 20|utility
P01449183A0795|23 26|beta
P01449183A0795|28 44|transferrin assay
P01449183A0795|49 57|diagnosis
P01449183A0795|73 86|fluid otorrhea
P01449301A0710|0 16|Cold cardioplegia
P01449301A0710|35 39|mm Hg
P01449301A0710|46 52|minutes
P01449301A0710|57 61|hours
P01450815A0337|3 10|addition
P01450815A0337|13 23|diatrizoate
P01450815A0337|29 32|IPRK
P01450815A0337|61 66|change
P01450815A0337|69 71|RPF
P01450815A0337|75 77|GFR
P01450815A0337|111 118|increase
P01450815A0337|148 155|decrease
P01451771A0619|12 19|analyses
P01451771A0619|27 42|family variables
P01451771A0619|67 70|data
P01451771A0619|95 113|components analysis
P01451771A0619|114 116|PCA
P01451771A0619|137 152|scaling analysis
P01451771A0619|153 155|MDS
P01451771A0619|174 186|health scores
P01451771A0619|189 196|husbands
P01451771A0619|203 207|wives
P01452037A0000|13 17|genes
P01452037A0000|26 65|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|66 70|GAPDH
P01452037A0000|91 96|kinase
P01452037A0000|98 100|PGK
P01452037A0000|118 121|part
P01452037A0000|124 148|triosephosphate isomerase
P01452037A0000|149 151|TIM
P01452037A0000|167 192|Bacillus megaterium DSM319
P01452037A0000|208 219|gene cluster
P01452037A0000|220 229|gap operon
P01452037A0000|232 246|complementation
P01452037A0000|266 281|gap amber mutant
P01452584T0000|21 30|exotoxin A
P01452584T0000|34 37|role
P01452584T0000|40 50|retardation
P01452584T0000|53 65|wound healing
P01452584T0000|73 86|Lindberg Award
P01452703A0782|0 17|Laboratory studies
P01452703A0782|56 59|kits
P01452703A0782|87 90|case
P01452703A0782|130 135|bodies
P01452703A0782|139 140|ml
P01452703A0782|151 160|ELISA kits
P01452703A0782|194 199|bodies
P01452703A0782|203 204|ml
P01454518A0336|10 21|significance
P01454518A0336|29 35|domains
P01454518A0336|61 72|conservation
P01454518A0336|78 81|gene
P01454518A0336|86 92|homolog
P01454518A0336|135 159|stringency hybridizations
P01454518A0336|175 180|probes
P01454518A0336|191 200|ERCC3 cDNA
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|34 45|modification
P01454819A0000|48 55|proteins
P01454819A0000|61 63|NAD
P01454819A0000|65 96|arginine ADP-ribosyltransferases
P01454819A0000|97 98|EC
P01454819A0000|130 139|hydrolases
P01454819A0000|141 142|EC
P01454819A0000|173 181|reactions
P01454819A0000|186 207|ADP-ribosylation cycle
P01456888A0074|7 12|reason
P01456888A0074|17 24|particle
P01456888A0074|32 39|capacity
P01456888A0074|42 52|derivatives
P01456888A0074|58 68|HIV-1 group
P01456888A0074|76 95|core antigen p55 gag
P01456888A0074|132 149|expression systems
P01456888A0074|161 168|bacteria
P01456888A0074|170 177|vaccinia
P01456888A0074|182 194|baculoviruses
P01456888A0074|227 242|core protein p55
P01456888A0074|261 268|sequence
P01456888A0074|281 310|myristylation consensus signal
P01457380A0000|3 11|tramtrack
P01457380A0000|13 15|ttk
P01457380A0000|17 20|gene
P01457380A0000|55 62|proteins
P01457380A0000|81 88|splicing
P01457380A0000|101 114|ttk transcript
P01457695T0000a|0 6|Removal
P01457695T0000a|9 28|beta 2-microglobulin
P01457695T0000a|30 41|hemodialysis
P01457695T0000a|45 58|hemofiltration
P01457695T0000a|65 68|year
P01457695T0000b|0 6|Removal
P01457695T0000b|9 28|beta 2-microglobulin
P01457695T0000b|30 41|hemodialysis
P01457695T0000b|45 58|hemofiltration
P01457695T0000b|65 68|year
P01458170A0155|0 9|Adapromine
P01458170A0155|32 39|decrease
P01458170A0155|45 53|amplitude
P01458170A0155|67 70|peak
P01458170A0155|82 95|theta-activity
P01458170A0155|98 110|power spectra
P01458170A0155|115 117|EEG
P01458170A0155|123 128|cortex
P01458170A0155|132 140|hippocamp
P01458170A0155|148 155|increase
P01458170A0155|163 175|wave activity
P01458170A0155|180 183|beta
P01458170A0155|185 189|range
P01458170A0155|200 205|cortex
P01458170A0155|209 217|hippocamp
P01459447A0484|5 13|sequences
P01459447A0484|28 32|clone
P01459447A0484|47 51|genes
P01459447A0484|57 61|yeast
P01459447A0484|69 75|library
P01459451A0478|18 31|antirepression
P01459451A0478|51 56|factor
P01459451A0478|68 83|co-antirepressor
P01459451A0478|124 130|embryos
P01459885A0705|7 10|days
P01459885A0705|13 33|haloperidol treatment
P01459885A0705|41 47|changes
P01459885A0705|63 67|delta
P01459885A0705|83 90|increase
P01459885A0705|93 97|alpha
P01459885A0705|104 111|decrease
P01459885A0705|118 121|beta
P01459921A0000|36 52|Hampshire wethers
P01459921A0000|77 86|experiment
P01459921A0000|105 124|linoleoyl methionine
P01459921A0000|127 143|calcium linoleate
P01459921A0000|164 167|flow
P01459921A0000|186 190|acids
P01459921A0000|192 196|C18:2
P01459921A0000|198 204|cis C18
P01460054A0478|9 13|ICSBP
P01460054A0478|45 55|amino acids
P01460054A0478|71 73|ICS
P01460054A0478|96 99|part
P01460054A0478|105 122|DNA binding domain
P01460054A0478|152 165|amino terminus
P01460054A0968|10 14|ICSBP
P01460054A0968|66 73|activity
P01460054A0968|89 93|genes
P01460054A0968|109 113|cells
P01460772T0001|1 4|case
P01460772T0001|14 24|hepatitis C
P01460772T0001|35 48|hypothyroidism
P01460772T0001|65 84|interferon treatment
P01462786T0000|0 22|Dynamic decision making
P01462786T0000|27 33|control
P01462786T0000|36 50|complex systems
P01464329T0000|19 25|protein
P01464329T0000|45 51|regions
P01464329T0000|61 80|prophase chromosomes
P01464606A0344|10 16|amounts
P01464606A0344|19 23|alpha
P01464606A0344|25 28|beta
P01464606A0344|30 37|integrin
P01464606A0344|59 63|cells
P01464606A0344|66 79|chromatography
P01464606A0344|82 99|detergent extracts
P01464606A0344|102 112|fibronectin
P01464606A0344|125 148|fragment affinity column
P01464606A0344|150 156|elution
P01464606A0344|161 164|EDTA
P01467088T0075|0 8|Abstracts
P01467828A0542|5 11|results
P01467828A0542|29 39|involvement
P01467828A0542|52 66|opioid peptides
P01467828A0542|78 84|effects
P01467828A0542|100 108|ischaemia
P01467828A0542|112 122|reperfusion
P01467828A0542|140 148|receptors
P01467828A0542|162 171|antagonism
P01468625A0282|8 14|library
P01468625A0282|16 19|LEU2
P01468625A0282|23 32|HIS3 cDNAs
P01468625A0282|48 56|frequency
P01468625A0282|86 90|cases
P01468625A0282|131 136|manner
P01468625A1080|11 14|ACT1
P01468625A1080|30 34|times
P01468625A1080|39 42|NSR1
P01468625A1080|48 52|times
P01469042A0355|5 15|CENP-B gene
P01469042A0355|37 43|species
P01469042A0355|47 58|CENP-B boxes
P01469042A0355|72 101|mouse centromere satellite DNA
P01469042A0355|105 113|satellite
P01469042A0355|148 158|interaction
P01469042A0355|180 183|kind
P01469042A0355|192 210|centromere function
P01469047A1606|15 21|portion
P01469047A1606|27 37|tail domain
P01469047A1606|38 39|aa
P01469047A1606|53 58|shares
P01469047A1606|61 90|% amino acid sequence identity
P01469047A1606|98 104|protein
P01469047A1606|109 119|mouse brain
P01469047A1606|140 157|acid decarboxylase
P01470243A0871|13 20|subgroup
P01470243A0871|31 32|Ht
P01470243A0871|39 41|l/l
P01470243A0871|43 43|n
P01470243A0871|69 77|reduction
P01470243A0871|79 79|p
P01470243A0871|91 99|mortality
P01470243A0871|106 111|months
P01470243A0871|115 115|%
P01470243A0871|121 121|%
P01470243A0871|141 148|increase
P01470243A0871|151 162|independence
P01470243A0871|165 168|home
P01470243A0871|172 172|%
P01470243A0871|178 178|%
P01470243A0871|199 207|reduction
P01470243A0871|213 221|viscosity
P01470243A0871|224 228|means
P01470243A0871|231 243|haemodilution
P01470243A0871|248 254|albumin
P01470243A0871|265 280|viscosity effect
P01470243A0871|298 302|group
P01470741T0062|0 11|Distribution
P01470741T0062|36 41|course
P01471602A0362|14 16|use
P01471602A0362|20 27|benefits
P01471602A0362|30 51|bile acid sequestrants
P01471602A0362|60 63|acid
P01471602A0362|71 75|acids
P01471602A0362|103 112|coenzyme A
P01471602A0362|113 119|HMG-CoA
P01471602A0362|121 140|reductase inhibitors
P01471602A0362|144 151|probucol
P01471602A0362|200 209|approaches
P01471602A0362|216 226|conjunction
P01471602A0362|234 238|drugs
P01473196A1016|19 30|reabsorption
P01473196A1016|51 59|clearance
P01473207A0582|20 27|findings
P01473207A0582|33 40|placenta
P01473207A0582|45 57|prematuration
P01473207A0582|61 70|hypoplasia
P01473234A1001|0 11|Green pepper
P01473234A1001|65 78|acid formation
P01473234A1001|96 99|acid
P01474990A0000|8 12|clone
P01474990A0000|14 18|pTt21
P01474990A0000|30 32|DNA
P01474990A0000|68 78|Trypanosoma
P01474990A0000|84 98|trypomastigotes
P01474990A0000|144 150|library
P01474990A0000|155 168|trypomastigote
P01474990A0000|172 188|epimastigote cDNA
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01476376T0000|7 10|urea
P01476376T0000|24 29|urease
P01476376T0000|52 59|pH-meter
P01477021A0394|0 6|RESULTS
P01477021A0394|13 21|AGA group
P01477021A0394|42 70|serum prolactin concentration
P01477021A0394|95 103|gestation
P01477021A0394|105 105|P
P01477021A0394|115 115|P
P01478672A0795|3 13|phage clone
P01478672A0795|22 29|junction
P01478672A0795|37 55|alpha satellite DNA
P01478672A0795|79 86|sequence
P01480183A0000|14 19|region
P01480183A0000|30 45|lactoferrin gene
P01480183A0000|82 88|library
P01480183A1689|22 31|mechanisms
P01480183A1689|37 51|estrogen action
P01480183A1689|64 90|lactoferrin gene expression
P01480183A1689|102 106|mouse
P01480470A0323|0 5|BiP670
P01480470A0323|21 23|Ca2
P01480470A0323|25 33|ionophore
P01480470A0323|50 59|activities
P01482912A0617|3 5|CEM
P01482912A0617|14 33|registration updates
P01482912A0617|38 48|HL7 message
P01482912A0617|60 76|data dependencies
P01482912A0617|78 82|rules
P01482912A0617|88 96|interface
P01482912A0617|102 120|relational database
P01483755A0000|8 29|resonance spectroscopy
P01483755A0000|30 32|MRS
P01483755A0000|37 43|imaging
P01483755A0000|45 47|MRI
P01483755A0000|70 79|techniques
P01483755A0000|86 90|study
P01483755A0000|101 110|metabolism
P01483755A0000|119 127|structure
P01483755A0000|130 135|muscle
P01483771A1335|22 23|NA
P01483771A1335|38 43|change
P01483771A1335|46 72|plasma epinephrine response
P01485648A0000|27 31|value
P01485648A0000|45 48|test
P01485648A0000|50 69|Pharmacia CAP System
P01485648A0000|69 92|Pharmacia Diagnostics AB
P01485648A0000|92 98|Uppsala
P01485648A0000|100 105|Sweden
P01485648A0000|126 136|measurement
P01485648A0000|156 169|IgE antibodies
P01485648A0000|171 180|comparison
P01485648A0000|185 188|RAST
P01485648A0000|192 197|groups
P01485648A0000|200 207|patients
P01486836A0774|0 7|Patients
P01486836A0774|17 19|VPA
P01486836A0774|26 36|differences
P01486836A0774|39 47|attention
P01486836A0774|49 70|visuomotor performance
P01486836A0774|77 80|span
P01486836A0774|91 110|discrimination tasks
P01486836A0774|112 113|T1
P01486836A0774|117 138|visuomotor performance
P01486836A0774|140 141|T2
P01486836A0774|154 157|span
P01486836A0774|160 161|T3
P01486836A0774|172 182|differences
P01486836A0774|197 198|T4
P01487144A0505|14 25|gene segment
P01487144A0505|38 46|mu m poly
P01487144A0505|46 46|A
P01487144A0505|48 54|signals
P01487144A0505|68 69|bp
P01487144A0505|90 97|sequence
P01487144A0505|107 130|transcription terminator
P01487144A0505|136 148|myeloma cells
P01487144A0505|151 168|L cell fibroblasts
P01490493A0416|3 6|part
P01490493A0416|15 25|examination
P01490493A0416|39 55|serum cholesterol
P01490493A0416|61 65|lipid
P01490493A0416|69 87|triglyceride levels
P01492463T0001|0 4|Alena
P01492463T0001|8 12|nurse
P01492463T0001|15 20|Prague
P01492463T0001|40 44|wages
P01492463T0001|49 52|trip
P01492463T0001|62 66|ocean
P01493864A0619|0 15|Dopamine neurons
P01493864A0619|17 24|subjects
P01493864A0619|37 42|6-OHDA
P01493864A0619|58 70|pre-treatment
P01493864A0619|75 83|GBR-12909
P01495069A0392|0 3|DIBA
P01495069A0392|51 55|value
P01495069A0392|78 87|percentage
P01495069A0392|92 95|DFAT
P01496348A0000|0 5|Caries
P01496348A0000|9 20|parodontitis
P01496348A0000|47 54|diseases
P01496348A0000|57 63|mankind
P01496784A0939|3 9|results
P01496784A0939|16 20|study
P01496784A0939|36 51|strongyloidiasis
P01496784A0939|58 62|cause
P01496784A0939|71 75|death
P01497582A0593|12 16|group
P01497582A0593|19 27|disorders
P01497582A0593|30 38|pregnancy
P01497582A0593|49 55|effects
P01497582A0593|58 67|infections
P01497582A0593|73 78|mother
P01497582A0593|86 94|pathogens
P01497582A0593|116 121|embryo
P01497582A0593|127 134|placenta
P01498607A0000|9 28|nucleotide sequences
P01498607A0000|29 33|boxes
P01498607A0000|60 73|responsiveness
P01498607A0000|79 112|parsley chalcone synthase promoter
P01499213A0185|3 6|case
P01499213A0185|36 38|man
P01499213A0185|43 52|ochronosis
P01499213A0185|65 85|hyperextension injury
P01499213A0185|90 94|spine
P01499213A0185|98 101|fall
P01499213A0185|115 122|fracture
P01499213A0185|141 156|L2-L3 disk space
P01499616A0136|7 16|blood flow
P01499616A0136|27 34|foreskin
P01499616A0136|63 63|g
P01499616A0136|87 87|%
P01499616A0136|96 104|induction
P01499616A0136|107 116|anesthesia
P01499616A0136|138 138|%
P01499616A0136|144 146|tip
P01499616A0136|169 181|foreskin flap
P01502157A0000|0 4|ME1a1
P01502157A0000|26 44|factor binding site
P01502157A0000|61 68|c-MYC P1
P01502157A0000|71 103|P2 transcription initiation sites
P01502157A0000|115 125|P2 activity
P01504178T0000|13 17|years
P01504178T0000|20 29|prevention
P01504178T0000|38 44|country
P01504178T0000|46 54|visionary
P01504178T0000|56 62|complex
P01504853A0299|9 12|LHRH
P01504853A0299|36 50|mating behavior
P01504853A0299|59 65|species
P01505488A0231|22 29|patients
P01505488A0231|41 43|EVL
P01505488A0231|53 58|period
P01505488A0231|63 68|August
P01505488A0231|76 79|July
P01505516A0928|20 23|acid
P01505516A0928|29 34|lysine
P01505516A0928|47 53|alanine
P01505516A0928|56 69|valine residue
P01505516A0928|76 84|formation
P01505516A0928|103 108|dimers
P01506705A0282|6 15|V-A bypass
P01506705A0282|16 27|hemodynamics
P01506746A0476|0 20|Greater rupture force
P01506746A0476|40 43|pigs
P01506746A0476|58 61|pigs
P01509798A0520|2 9|rest AFF
P01509798A0520|33 34|UT
P01509798A0520|38 38|%
P01509798A0520|52 53|AT
P01509798A0520|57 57|%
P01509798A0520|62 64|UEA
P01509798A0520|68 68|%
P01511231A0085|17 30|smoking habits
P01511231A0085|32 40|relapsers
P01511231A0085|42 45|year
P01511231A0085|62 84|smoking cessation trial
P01511231A0085|88 95|nicotine
P01511231A0085|98 112|placebo patches
P01511950T0000|0 7|Exposure
P01511950T0000|10 26|hepatitis B virus
P01511950T0000|37 46|population
P01511950T0000|49 56|Hisayama
P01511950T0000|58 62|Japan
P01511950T0000|64 75|significance
P01511950T0000|86 93|antibody
P01511950T0000|96 122|hepatitis B surface antigen
P01511950T0000|129 138|population
P01512259A0867|19 28|phenomenon
P01512259A0867|61 74|cysteine motif
P01512259A0867|97 101|times
P01512259A0867|104 110|Dfurin2
P01512259A0867|141 145|furin
P01512654A0503|10 13|hand
P01512654A0503|22 30|phosphate
P01512654A0503|39 54|saline injection
P01512654A0503|61 62|ES
P01512654A0503|73 86|KLH challenges
P01512654A0503|91 92|ES
P01512654A0503|118 132|threshold level
P01512654A0503|146 152|latency
P01512941A0000|45 56|levofloxacin
P01512941A0000|58 61|LVFX
P01512941A0000|63 69|DR-3355
P01512941A0000|102 111|comparison
P01512941A0000|116 128|ciprofloxacin
P01512941A0000|130 133|CPFX
P01512941A0000|136 144|ofloxacin
P01512941A0000|146 149|OFLX
P01512941A0000|154 164|norfloxacin
P01512941A0000|166 169|NFLX
P01513114A1133|7 29|serum creatinine levels
P01513114A1133|44 47|year
P01513114A1133|49 51|SPK
P01513114A1133|56 58|KTA
P01513114A1133|62 65|mg/d
P01513114A1133|69 76|ABSTRACT
P01513114A1133|91 95|WORDS
P01513213A0231|0 16|Model predictions
P01513213A0231|22 27|accord
P01513213A0231|44 62|survival experience
P01513213A0231|64 68|women
P01513213A0231|74 82|HIP trial
P01513213A0231|94 102|exception
P01513213A0231|105 109|women
P01513213A0231|115 119|years
P01513213A0231|128 135|HIP data
P01513213A0231|144 151|survival
P01516427T0000|23 32|tomography
P01516427T0000|38 46|diagnosis
P01516427T0000|56 67|tuberculosis
P01516829A0113|23 26|SNF2
P01516829A0113|28 31|SNF5
P01516829A0113|36 48|SNF6 function
P01516829A0113|81 90|activation
P01516829A0113|119 125|complex
P01516829A0460|10 18|LexA-GAL4
P01516829A0460|33 47|fusion proteins
P01516829A0460|65 68|SNF2
P01516829A0460|70 73|SNF5
P01516829A0460|78 81|SNF6
P01516829A0460|85 94|activation
P01516829A0460|97 108|target genes
P01516829A0460|131 144|lexA operators
P01518396T0000|0 8|George T.
P01518833A0397|1 24|lambda gt10 cDNA library
P01518833A0397|40 43|poly
P01518833A0397|45 45|A
P01518833A0397|48 50|RNA
P01518833A0397|63 68|leaves
P01518833A0397|71 77|spinach
P01518849A0165|0 1|NE
P01518849A0165|5 7|PR3
P01518849A0165|19 29|destruction
P01518849A0165|44 57|microorganisms
P01518849A0165|94 108|protein elastin
P01518849A0165|131 140|activities
P01518849A0165|150 187|alpha 1-proteinase inhibitor complexes
P01518849A0165|188 203|elastin peptides
P01518926T0000|8 13|topics
P01518926T0000|25 39|ultrasonography
P01522699A0092|0 6|Methods
P01522699A0092|29 34|recall
P01522699A0092|36 47|menu weights
P01522699A0092|51 65|recipe analysis
P01523111A0769|0 6|Factors
P01523111A0769|21 29|afterdrop
P01523111A0769|38 40|age
P01523111A0769|56 66|temperature
P01523111A0769|86 94|body mass
P01524549A0241|4 16|GH deficiency
P01524549A0241|33 38|growth
P01524549A0241|55 61|stature
P01524549A0241|73 82|occurrence
P01524549A0241|90 96|puberty
P01524549A0241|99 109|association
P01524549A0241|114 126|GH deficiency
P01524549A0241|136 139|time
P01524549A0241|152 161|GH therapy
P01525153A0359|2 9|contrast
P01525153A0359|11 11|d
P01525153A0359|13 18|T2AG3T
P01525153A0359|23 23|d
P01525153A0359|25 29|T2G4T
P01525153A0359|31 34|form
P01525153A0359|54 71|monomer structures
P01525153A0359|84 105|K cation concentration
P01525153A0359|125 127|Sen
P01525153A0359|129 130|D.
P01525153A0359|133 139|Gilbert
P01525153A0359|141 142|W.
P01525966T0000|25 30|stones
P01526658A0454|0 2|IFI
P01526658A0454|5 8|mRNA
P01526658A0454|54 58|cells
P01526658A0454|64 73|cell lines
P01526658A0454|82 82|T
P01526658A0454|86 95|B lineages
P01526690T0000|18 23|action
P01526690T0000|26 33|warfarin
P01526690T0000|36 46|lymphocytes
P01527020A0511|11 19|junctions
P01527020A0511|33 62|rat AdoMet decarboxylase genes
P01527020A0511|75 83|positions
P01527020A0511|94 98|exons
P01527020A0511|114 117|gene
P01527020A0511|131 134|exon
P01527020A0511|140 147|rat gene
P01529530T0000|24 38|gene expression
P01529530T0000|39 46|evidence
P01529530T0000|60 65|effect
P01529530T0000|68 74|ouabain
P01529530T0000|77 86|activation
P01529530T0000|92 118|ISGF3 transcription complex
P01531086A0127|3 6|cDNA
P01531086A0127|16 28|reading frame
P01531086A0127|33 43|amino acids
P01531086A0127|67 73|protein
P01531214A0885|9 12|LD50
P01531214A0885|15 18|mice
P01531214A0885|21 26|RP-170
P01531214A0885|31 34|g/kg
P01531214A0885|37 40|i.v.
P01531214A0885|59 62|g/kg
P01531214A0885|69 82|administration
P01531632A0000|11 18|proteins
P01531632A0000|34 42|nucleolus
P01531632A0000|73 80|proteins
P01531632A0000|82 90|nucleolin
P01531632A0000|92 102|fibrillarin
P01531632A0000|104 107|SSB1
P01531632A0000|111 114|NSR1
P01531632A0000|140 144|motif
P01531632A0000|149 158|GAR domain
P01531632A0000|172 178|glycine
P01531632A0000|182 198|arginine residues
P01532229A1264|9 13|study
P01532229A1264|22 29|evidence
P01532229A1264|51 56|factor
P01532229A1264|58 62|HF-1a
P01532229A1264|68 80|muscle factor
P01532229A1264|81 85|HF-1b
P01532229A1264|87 91|MEF-2
P01532229A1264|124 130|pathway
P01532229A1264|149 158|expression
P01532229A1264|179 190|muscle cells
P01532796A0107|0 8|Mutations
P01532796A0107|17 20|gene
P01532796A0107|41 44|step
P01532796A0107|47 54|assembly
P01532796A0107|57 58|F1
P01532796A0107|70 74|alpha
P01532796A0107|78 90|beta subunits
P01532796A0107|104 115|mitochondria
P01532796A0107|126 135|aggregates
P01532796A0107|137 144|Ackerman
P01532796A0107|146 147|S.
P01532914A0067|0 6|Expense
P01532914A0067|16 18|use
P01532914A0067|21 40|hepatitis B vaccines
P01532914A0067|62 73|immunization
P01532914A0067|104 111|strategy
P01532914A0067|122 128|studies
P01533760T0000|0 27|Estrogen replacement therapy
P01533760T0000|29 32|risk
P01533760T0000|35 47|breast cancer
P01533760T0000|48 54|results
P01533760T0000|60 72|meta-analyses
P01535242A0557|9 14|FDC-P1
P01535242A0557|16 24|MAC cells
P01535242A0557|28 33|growth
P01535242A0557|36 40|M-CSF
P01535242A0557|43 48|GM-CSF
P01535242A0557|67 77|degradation
P01535242A0557|80 89|c-fms mRNA
P01535242A0557|96 96|h
P01535242A0557|102 117|factor switching
P01536153A0574|29 38|difference
P01536153A0574|44 53|prevalence
P01536153A0574|74 81|symptoms
P01536153A0574|89 107|animal food workers
P01536153A0574|129 138|skin tests
P01536153A0574|145 148|dust
P01536153A0574|153 162|fish flour
P01536153A0574|195 197|IgE
P01536153A0574|208 214|dyspnea
P01536575A1213|12 18|finding
P01536575A1213|25 32|presence
P01536575A1213|35 42|position
P01536575A1213|64 69|dioxin
P01536575A1213|80 86|element
P01536575A1213|89 96|sequence
P01536575A1213|123 131|induction
P01536575A1213|134 146|transcription
P01536575A1213|152 174|cytochrome P450IA1 gene
P01536575A1213|174 179|CYPIA1
P01536575A1213|189 193|genes
P01536575A1213|204 228|detoxification/activation
P01536575A1213|249 260|hydrocarbons
P01537334A0507|3 6|gene
P01537334A0507|15 24|TRP-2 maps
P01537334A0507|26 41|mouse chromosome
P01537334A0507|49 54|region
P01537334A0507|60 85|coat colour mutation slaty
P01537845A0571|20 31|c-myb clones
P01537845A0571|34 39|change
P01537845A0571|45 48|rate
P01537845A0571|51 74|c-myb gene transcription
P01537845A0571|75 88|mRNA stability
P01537845A0571|108 117|cell cycle
P01538401A1244|3 27|base-pair oligonucleotide
P01538401A1244|35 45|nucleotides
P01538401A1244|60 69|S RNA gene
P01538401A1244|100 106|binding
P01538401A1244|119 124|latter
P01538401A1244|158 170|DNA fragments
P01538403A1058|12 25|reconstitution
P01538403A1058|28 31|eUSF
P01538403A1058|49 71|transcription complexes
P01538403A1058|83 99|protein fractions
P01538403A1058|121 125|TFIID
P01538403A1058|133 136|eUSF
P01538403A1058|162 178|complex formation
P01538403A1058|184 204|H5 promoter mutations
P01538403A1058|213 220|TATA-box
P01539996A0588|1 10|comparison
P01539996A0588|16 34|amino acid sequence
P01539996A0588|38 59|T. thermophilus enzyme
P01539996A0588|86 91|enzyme
P01539996A0588|104 104|%
P01539996A0588|112 121|similarity
P01539996A0588|130 141|conservation
P01539996A0588|147 157|Ser residue
P01539996A0588|199 204|enzyme
P01539996A0588|225 232|sequence
P01539996A0588|245 252|presence
P01539996A0588|263 270|residues
P01539996A0588|276 285|C terminus
P01539996A0588|290 311|T. thermophilus enzyme
P01541556A1040|13 21|palmitate
P01541556A1040|54 60|protein
P01541556A1040|73 90|lipid modification
P01541556A1040|101 114|Cys-22 residue
P01541577A0000|2 10|volunteer
P01541577A0000|15 16|Ss
P01541577A0000|35 54|volunteer hearing Ss
P01541577A0000|58 74|Stanford Hypnotic
P01541577A0000|82 86|Scale
P01541577A0000|88 91|SHCS
P01541577A0000|95 100|Morgan
P01541577A0000|104 105|J.
P01542565A0220|6 24|tobacco L12 protein
P01542565A0220|28 48|% amino acid identity
P01542565A0220|59 72|protein L7/L12
P01542565T0000|35 45|protein L12
P01542565T0000|47 63|Nicotiana tabacum
P01542565T0000|64 79|characterization
P01542565T0000|88 94|protein
P01542565T0000|98 106|isolation
P01542565T0000|110 126|sequence analysis
P01542565T0000|128 138|cDNA clones
P01542565T0000|160 168|precursor
P01542667A0125|3 6|gene
P01542667A0125|15 23|IFN-gamma
P01542667A0125|61 76|enhancer element
P01542667A0125|106 113|activity
P01542667A0125|135 144|expression
P01542667A0125|174 177|gene
P01542686A0000|9 15|cloning
P01542686A0000|21 41|polypeptide component
P01542686A0000|62 86|p75 nucleoprotein complex
P01542686A0000|99 106|identity
P01542686A0000|121 123|p65
P01542686A0000|125 131|subunit
P01542686A0000|134 144|NF-kappa B.
P01542730A1982|40 45|pacing
P01542730A1982|55 61|patient
P01542730A1982|74 77|risk
P01542730A1982|86 96|development
P01542730A1982|99 106|AV block
P01542730A1982|109 118|DDD pacing
P01542730A1982|144 150|support
P01542730A1982|185 196|dual-chamber
P01542730A1982|198 201|DDDR
P01542730A1982|203 209|devices
P01542730A1982|234 239|number
P01542730A1982|247 254|patients
P01542730A1982|257 264|ABSTRACT
P01542730A1982|279 283|WORDS
P01543909A0787|30 39|K562 cells
P01543909A0787|44 45|Lg
P01543909A0787|53 57|clone
P01543909A0787|117 131|characteristics
P01543909A0787|144 153|pseudogene
P01543909A0787|182 185|gene
P01543909A0787|201 216|ferritin subunit
P01544854A0699|5 9|drugs
P01544854A0699|29 37|WR-168643
P01544854A0699|48 56|protector
P01544854A0699|62 64|DMF
P01544918A1240|0 15|Characterization
P01544918A1240|23 32|R subunits
P01544918A1240|39 73|8-azido-cAMP photoaffinity labeling
P01544918A1240|75 90|immunoreactivity
P01544918A1240|128 141|mobility shift
P01544918A1240|143 156|sodium dodecyl
P01544918A1240|178 196|gel electrophoresis
P01544918A1240|197 204|SDS-PAGE
P01544918A1240|216 228|subunit sizes
P01544918A1240|230 237|RII beta
P01544918A1240|240 242|kDa
P01544918A1240|255 277|RII alpha dephosphoform
P01544918A1240|279 281|kDa
P01544918A1240|294 301|RI alpha
P01544918A1240|304 306|kDa
P01544928A1252|0 9|Comparison
P01544928A1252|22 33|DNA sequence
P01544928A1252|59 63|mRNAs
P01544928A1252|82 92|transcripts
P01544928A1252|117 124|splicing
P01544928A1252|136 143|pre-mRNA
P01544928A1252|156 169|cassette model
P01545523A0000|16 30|quantifications
P01545523A0000|50 57|testings
P01545523A0000|69 69|C
P01545523A0000|78 84|protein
P01545523A0000|96 101|factor
P01545523A0000|105 122|antistreptolysin O
P01545787A0345|14 21|enhancer
P01545787A0345|31 35|sites
P01545787A0345|72 76|DNase
P01545787A0345|78 87|footprints
P01545787A0345|89 94|NFAT-1
P01545787A0345|98 104|NFIL-2B
P01545792A0000|10 29|myosin light chain-2
P01545792A0000|29 33|MLC-2
P01545792A0000|35 47|gene promoter
P01545792A0000|91 99|sequences
P01545792A0000|120 129|regulation
P01545792A0000|135 144|expression
P01545792A0492|0 19|Deletion mutagenesis
P01545792A0492|43 50|elements
P01545792A0492|75 84|regulation
P01545792A0492|87 110|MLC-2 gene transcription
P01545797A0587|0 19|Disruption mutations
P01545797A0587|43 51|SLK1 gene
P01545797A0587|52 55|slk1
P01545797A0587|60 66|mutants
P01545797A0587|81 89|degrees C
P01545797A0587|97 101|cells
P01545797A0587|122 131|degrees C.
P01545806T0000|19 26|analysis
P01545806T0000|32 36|yeast
P01545806T0000|49 74|recombination genes REC102
P01545806T0000|76 86|REC107/MER2
P01545818A0696|3 6|p130
P01545818A0696|10 12|p62
P01545818A0696|36 43|proteins
P01545818A0696|57 65|v-Src SH2
P01545818A0696|90 94|v-Src
P01545818A0696|114 124|Rat-2 cells
P01545818A0696|135 141|binding
P01545818A0696|159 174|v-Src SH2 domain
P01546522A0000|0 7|Probable
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|49 51|PML
P01546522A0000|70 74|basis
P01546522A0000|85 91|picture
P01546522A0000|103 119|resonance imaging
P01546522A0000|133 135|man
P01546522A0000|149 157|remission
P01546522A0000|174 181|lymphoma
P01547775A1024|5 8|data
P01547775A1024|35 46|significance
P01547775A1024|52 61|frameshift
P01547775A1024|75 82|position
P01547775A1024|122 124|RNA
P01547775A1024|141 144|site
P01547775A1024|150 163|PLRV replicase
P01547775A1024|168 197|ORF2a/ORF2b transframe protein
P01547787A0548|0 20|Proprotein processing
P01547942A0120|12 14|LAP
P01547942A0120|29 47|dimerization domain
P01547942A0120|48 59|zipper probe
P01547942A0120|77 81|clone
P01547942A0120|113 119|protein
P01547942A0120|121 127|CHOP-10
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|67 77|aa sequence
P01547957A1083|119 124|region
P01547957A1083|134 140|portion
P01547957A1083|143 146|CYP1
P01547957A1083|150 153|CYP2
P01547957A1083|177 182|genome
P01547957A1083|198 209|DNA fragment
P01547957A1083|226 250|polymerase chain reaction
P01547957A1083|250 252|PCR
P01547957A1083|259 262|GL81
P01547957A1083|270 272|DNA
P01547957A1083|276 284|substrate
P01548756A1102|9 21|hybridization
P01548756A1102|24 28|EHS-1
P01548756A1102|49 51|DNA
P01548756A1102|72 81|EHS-1 loci
P01548756A1102|94 96|DNA
P01548756A1102|109 120|band pattern
P01548756A1102|122 135|chimpanzee DNA
P01548756A1102|146 150|locus
P01548756A1102|153 169|rhesus monkey DNA
P01548891A0635|3 7|level
P01548891A0635|38 44|hormone
P01548891A0635|50 57|patients
P01548891A0635|62 78|thyroid carcinoma
P01548891A0635|100 107|patients
P01548891A0635|115 131|thyroid carcinoma
P01548891A0635|132 132|P
P01549118A0000|3 43|Caenorhabditis elegans vitellogenin genes
P01549118A0000|53 55|sex
P01549118A0000|58 62|stage
P01549118A0000|83 92|regulation
P01549118A0000|126 148|hermaphrodite intestine
P01549123A0480|3 11|MET4 gene
P01549123A0480|27 34|sequence
P01549123A0480|56 62|protein
P01549123A0480|75 80|family
P01549123A0480|86 89|bZIP
P01549123A0480|105 114|activators
P01549125A0140|3 11|functions
P01549125A0140|22 29|portions
P01549125A0140|35 41|insulin
P01549125A0140|43 46|IAPP
P01549125A0140|51 67|beta GK promoters
P01549125A0140|93 102|expression
P01549125A0140|106 123|DNA binding assays
P01549129A0356|21 27|domains
P01549129A0356|75 86|interactions
P01549129A0356|108 118|functioning
P01549129A0356|121 123|Src
P01549346A0000|3 21|c-Ets-1 oncoprotein
P01549346A0000|24 46|transcription activator
P01549346A0000|69 71|DNA
P01549465A0122|8 34|transactivation experiments
P01549465A0122|52 62|amino acids
P01549465A0122|76 81|region
P01549465A0122|83 85|Gly
P01549465A0122|87 89|Ser
P01549465A0122|93 95|Val
P01549465A0122|129 142|discrimination
P01551176A0000|0 7|GR63178A
P01551176A0000|24 31|analogue
P01551176A0000|34 44|mitoquidone
P01551176A0000|58 71|pyrroloquinone
P01551568A1476|0 21|Marker rescue analysis
P01551568A1476|32 34|ts8
P01551568A1476|52 58|segment
P01551568A1476|61 64|rpoB
P01551568A1476|79 88|Rif domain
P01551898A1084|4 9|vector
P01551898A1084|28 32|yeast
P01551898A1084|63 72|expression
P01551898A1084|90 96|protein
P01551898A1084|99 104|levels
P01551898A1084|112 113|mg
P01551898A1084|116 125|LAPP/liter
P01551898A1084|128 141|culture medium
P01551910A0313|0 19|Competition analysis
P01551910A0313|21 54|gel mobility shift electrophoresis
P01551910A0313|80 90|interaction
P01551910A0313|117 137|transcription factors
P01551910A0978|4 12|DNA motif
P01551910A0978|43 50|sequence
P01552052A0139|0 8|OBJECTIVE
P01552052A0139|13 17|study
P01552052A0139|45 53|frequency
P01552052A0139|56 66|alterations
P01552052A0139|69 84|serum creatinine
P01552052A0139|86 93|patients
P01552052A0139|98 106|psoriasis
P01552052A0139|117 125|mg/kg/day
P01552052A0139|128 139|cyclosporine
P01552457T0000|0 23|Intrapocket chemotherapy
P01552457T0000|30 42|periodontitis
P01552457T0000|70 75|insert
P01552457T0000|86 94|ofloxacin
P01552457T0000|96 100|PT-01
P01552662A0398|15 24|blood flow
P01552662A0398|25 26|BF
P01552662A0398|28 32|probe
P01552662A0398|70 75|artery
P01552662A0398|77 79|LAD
P01552853A1377|5 15|temperature
P01552853A1377|19 22|virF
P01552853A1377|44 52|induction
P01552853A1377|58 68|yop regulon
P01553407T0000|0 7|Problems
P01553407T0000|31 34|area
P01553407T0000|49 63|risk assessment
P01554334A0000|20 35|gamma-interferon
P01554334A0000|37 45|IFN-gamma
P01554334A0000|47 58|assay system
P01554334A0000|64 72|diagnosis
P01554334A0000|81 92|tuberculosis
P01554334A0000|95 100|cattle
P01554334A0000|131 139|Committee
P01554334A0000|142 152|Agriculture
P01554334A0000|156 158|use
P01554334A0000|161 169|Australia
P01555556A0565|0 14|Control Tmuscle
P01555556A0565|27 35|degrees C
P01555556A0565|40 49|control Wi
P01555556A0565|50 52|max
P01555556A0565|63 64|SD
P01555556A0565|69 74|W.kg-1
P01556068A0000|3 32|Klebsiella aerogenes gene maoA
P01556068A0000|51 59|synthesis
P01556068A0000|62 78|monoamine oxidase
P01556068A0000|91 98|tyramine
P01556068A0000|112 120|compounds
P01556068A0000|133 142|catabolite
P01556068A0000|146 168|ammonium ion repression
P01556111A0241|13 19|regions
P01556111A0241|25 31|plasmid
P01557217A0272|33 39|lesions
P01557217A0272|73 78|h p.i.
P01557411A1282|13 20|D1A gene
P01557411A1282|32 39|category
P01557411A1282|67 71|genes
P01557411A1282|97 105|promoters
P01558942A1369|7 18|observations
P01558942A1369|49 53|genes
P01559209T0000|0 12|Preceptorship
P01559209T0000|15 26|CNS students
P01559209T0000|40 44|study
P01560021A0379|21 25|basis
P01560021A0379|32 42|differences
P01560021A0379|63 80|brain AE3 variants
P01560021A0379|109 116|rat gene
P01560774A0885|6 7|kb
P01560774A0885|14 21|fragment
P01560774A0885|60 68|fliA gene
P01562659A0676|0 10|Institution
P01562659A0676|45 58|administration
P01562659A0676|61 74|amphotericin B
P01562659A0676|107 120|administration
P01562659A0676|123 135|dexamethasone
P01562659A0676|152 161|situations
P01562659A0676|172 182|association
P01562659A0676|185 194|C. immitis
P01562659A0676|198 211|CNS vasculitis
P01562659A0676|213 224|encephalitis
P01562659A0676|263 274|confirmation
P01562659A0676|277 296|C. immitis infection
P01562659A0676|307 309|CNS
P01563343A0548|0 12|Lac operators
P01563343A0548|37 45|positions
P01563343A0548|55 66|CAB promoter
P01563343A0548|82 88|plasmid
P01563343A0548|98 104|control
P01563635T0000|0 13|Overproduction
P01563635T0000|15 26|purification
P01563635T0000|30 45|characterization
P01563635T0000|48 72|M.HinfI methyltransferase
P01563635T0000|78 92|deletion mutant
P01564653A0307|7 15|companies
P01564653A0307|27 30|type
P01564653A0307|33 36|lens
P01565093A0179|4 8|March
P01565093A0179|17 23|October
P01565093A0179|37 43|persons
P01565093A0179|69 85|blood lead levels
P01565093A0179|85 88|BLLs
P01565093A0179|98 105|hospital
P01565093A0179|136 162|disease surveillance system
P01565093A0179|176 193|Alabama Department
P01565093A0179|195 207|Public Health
P01565093A0179|208 211|ADPH
P01565882A0737|14 20|changes
P01565882A0737|23 39|perfusion defects
P01565882A0737|49 50|RD
P01565882A0737|54 63|ReI images
P01565882A0737|87 91|types
P01565882A0737|93 96|Type
P01565882A0737|99 114|perfusion defect
P01565882A0737|119 126|RD image
P01565882A0737|143 147|image
P01565882A0737|151 151|%
P01565882A0737|153 156|Type
P01565882A0737|173 181|subgroups
P01565882A0737|189 204|perfusion defect
P01565882A0737|221 222|Ia
P01565882A0737|226 226|%
P01565882A0737|239 240|Ib
P01565882A0737|244 244|%
P01565882A0737|251 258|RD image
P01566576A0605|0 3|Keck
P01566576A0605|5 8|C.J.
P01567649A0139|16 16|%
P01567649A0139|18 24|infants
P01567649A0139|47 56|hemorrhage
P01567649A0139|92 96|palsy
P01567649A0139|117 126|evaluation
P01567649A0139|134 140|infancy
P01568960A1129|9 17|mechanism
P01568960A1129|40 47|pressure
P01568960A1129|67 72|output
P01568960A1129|82 91|blood flow
P01568960A1129|95 108|corner vessels
P01568960A1129|126 137|VA/Q regions
P01569015A0120|15 19|FRAME
P01569015A0120|21 28|analysis
P01569015A0120|53 66|reading frames
P01569015A0120|67 70|ORFs
P01569015A0120|83 91|direction
P01569015A0120|111 119|direction
P01569102A0708|0 5|Domain
P01569102A0708|31 42|LDL receptor
P01569102A0708|57 63|repeats
P01569102A0708|75 86|conservation
P01569102A0708|104 112|cysteines
P01569344A0404|6 11|cities
P01569344A0404|22 31|prevalence
P01569344A0404|58 60|age
P01569344A0404|68 82|New Orleans age
P01569344A0404|97 116|HTLV-I/II prevalence
P01569344A0404|148 156|Baltimore
P01569344A0404|158 158|P
P01569581A0482|14 21|evidence
P01569581A0482|26 30|model
P01569581A0482|38 41|mRNA
P01569581A0482|64 74|nucleotides
P01569581A0482|92 102|start codon
P01569581A0482|107 110|fold
P01569581A0482|118 126|base-pair
P01569581A0482|135 163|translation initiation region
P01569581A0482|183 214|translation initiation frequency
P01569584A0672|0 17|Hybridization data
P01569584A0672|29 33|6F6.2
P01569584A0672|73 87|m6F6 cDNA clone
P01569584A0672|93 97|6F6.1
P01569584A0672|101 105|6F6.3
P01569584A0672|113 117|6F6.2
P01569584A0672|142 146|genes
P01569945A0529|3 11|SEN1 gene
P01569945A0529|37 49|reading frame
P01569945A0529|75 81|protein
P01569945A0529|92 95|mass
P01569945A0529|100 102|kDa
P01572549A0000|0 23|Protein tyrosine kinases
P01572549A0000|23 26|PTKs
P01572549A0000|46 52|control
P01572549A0000|55 65|cell growth
P01572549A0000|67 72|virtue
P01572549A0000|88 97|appearance
P01572549A0000|100 107|products
P01572549A0000|120 128|oncogenes
P01572549A0000|145 162|signal transducers
P01572549A0000|168 190|growth factor receptors
P01572549A0000|191 200|components
P01573270A0000|3 9|IA4 mAb
P01573270A0000|28 33|series
P01573270A0000|36 45|antibodies
P01573270A0000|54 64|BALB/c mice
P01573270A0000|69 80|immunization
P01573270A0000|89 97|HLA class
P01573270A0000|129 134|killer
P01573270A0000|136 138|LAK
P01573270A0000|152 172|EBV-B lymphocyte line
P01577056A0178|35 39|study
P01577056A0178|44 51|subjects
P01577056A0178|60 71|theophylline
P01577056A0178|73 79|mg.kg-1
P01577056A0178|83 85|day
P01577056A0178|90 99|omeprazole
P01577056A0178|102 103|mg
P01577056A0178|107 109|day
P01577056A0178|121 127|placebo
P01577056A0178|137 143|periods
P01577056A0178|152 155|days
P01577056A0178|169 182|washout period
P01577056A0178|185 188|days
P01577740A1111|0 15|Primer extension
P01577740A1111|18 26|mung bean
P01577740A1111|29 47|S1 nuclease mapping
P01577740A1111|63 92|transcription initiation sites
P01577740A1111|112 128|Northern analyses
P01577819A0709|10 30|PRP-precursor alleles
P01577819A0709|59 64|number
P01577819A0709|67 73|repeats
P01577819A0709|76 84|domain C.
P01579472A1018|16 31|enhancer element
P01579472A1018|36 41|region
P01579472A1018|76 81|manner
P01579537A0000|11 15|years
P01579537A0000|31 34|uses
P01579537A0000|37 51|botulinum toxin
P01579537A0000|59 68|neurotoxin
P01580738T0001|0 8|Allagille
P01580738T0001|11 18|syndrome
P01580738T0001|42 48|ascites
P01581409A0398|0 10|Sensitivity
P01581409A0398|14 24|specificity
P01581409A0398|45 64|Pharmacia CAP System
P01581409A0398|69 86|DPC AlaSTAT System
P01581409A0398|87 96|comparison
P01581409A0398|101 107|results
P01581409A0398|113 116|skin
P01581409A0398|122 125|test
P01581577A1186|0 4|PSI-G
P01581577A1186|8 12|PSI-K
P01581577A1186|37 52|gene duplication
P01581577A1186|65 68|gene
P01581965A0388|5 14|C-terminus
P01581965A0388|20 26|protein
P01581965A0388|30 35|domain
P01581965A0388|48 56|sequences
P01581965A0388|85 122|breakpoint cluster region gene product
P01581965A0388|120 129|n-chimerin
P01581965A0388|134 140|rho GAP
P01581965A0388|182 193|GAP activity
P01581965A0388|200 206|GTPases
P01582413A0192|13 23|mutagenesis
P01582413A0192|39 46|clusters
P01582413A0192|54 64|amino acids
P01582413A0192|85 90|region
P01582413A0192|108 114|helices
P01582413A0192|135 140|domain
P01582413A0192|173 183|DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|14 18|Myf-5
P01582413A0759|51 61|protein E12
P01582413A0759|80 87|affinity
P01582413A0759|91 93|DNA
P01582413A0759|111 125|transactivation
P01582413A0759|141 151|DNA binding
P01582500A0178|12 22|rhythmicity
P01582500A0178|25 29|sleep
P01583819A0377|0 2|SEA
P01583819A0377|31 37|filters
P01583819A0377|46 47|HZ
P01583819A0377|57 58|Hz
P01583819A0377|64 76|Simson method
P01584812T0000|15 24|expression
P01584812T0000|33 41|structure
P01584812T0000|57 68|localization
P01584812T0000|74 77|gene
P01584812T0000|100 126|transcription factor NGFI-C
P01585014A0000|2 11|experiment
P01585014A0000|23 29|effects
P01585014A0000|32 40|treatment
P01585014A0000|45 57|gonadotrophin
P01585014A0000|67 73|hormone
P01585014A0000|78 92|micrograms GnRH
P01585014A0000|102 102|h
P01585014A0000|108 133|progestagen sponge removal
P01585014A0000|134 139|season
P01585014A0000|142 150|treatment
P01585014A0000|152 157|autumn
P01585014A0000|160 165|spring
P01585014A0000|171 176|effect
P01585014A0000|203 213|lupin grain
P01585014A0000|216 221|autumn
P01585014A0000|233 236|days
P01585014A0000|249 252|days
P01585014A0000|258 271|sponge removal
P01585014A0000|277 280|time
P01585014A0000|283 291|ovulation
P01585014A0000|303 313|Merino ewes
P01585014A0000|331 341|combination
P01585014A0000|347 350|I.U.
P01585014A0000|359 382|mare serum gonadotrophin
P01585014A0000|382 385|PMSG
P01585014A0000|392 422|mg follicle stimulating hormone
P01585014A0000|421 425|FSH-P
P01586901A0000|9 20|interactions
P01586901A0000|43 50|patients
P01586901A0000|68 78|medications
P01586901A0000|86 90|drugs
P01586901A0000|117 122|window
P01587267A1144|3 15|sequence data
P01587267A1144|33 46|interpretation
P01587267A1144|52 56|X-ray
P01587267A1144|73 81|structure
P01587267A1144|87 92|enzyme
P01587267A1144|99 105|cloning
P01587267A1144|109 118|expression
P01587267A1144|135 138|gene
P01587267A1144|166 176|mutagenesis
P01587763A0402|5 20|body irradiation
P01587763A0402|61 66|scheme
P01587763A0402|71 79|fractions
P01587763A0402|93 95|day
P01587763A0402|97 98|hr
P01587763A0402|108 111|days
P01588270A1029|1 9|reduction
P01588270A1029|12 25|blood pressure
P01588270A1029|45 47|end
P01588270A1029|53 57|study
P01588270A1029|95 96|.9
P01588270A1029|103 106|mmHg
P01588270A1029|108 108|P
P01588270A1029|124 126|DBP
P01588315A0356|0 5|AgMNPV
P01588315A0356|9 33|Orgyia pseudotsugata MNPV
P01588315A0356|33 38|OpMNPV
P01588315A0356|52 56|terms
P01588315A0356|59 76|promoter structure
P01588315A0356|79 88|polyhedrin
P01588315A0356|96 103|sequence
P01588315A0356|111 125|polyhedrin gene
P01588315A0356|131 137|viruses
P01588315A0356|170 178|direction
P01588315A0356|181 188|relation
P01588315A0356|204 207|maps
P01588913A0000|1 4|gene
P01588913A0000|35 43|dnaA gene
P01588913A0000|81 93|transcription
P01588913A0000|127 135|P. putida
P01588961A0000|0 3|STP1
P01588961A0000|19 28|yeast gene
P01588961A0000|41 47|removal
P01588961A0000|61 69|sequences
P01588961A0000|89 96|families
P01588961A0000|129 137|pre-tRNAs
P01588963A1153|10 19|antibodies
P01588963A1153|42 51|conditions
P01588963A1153|77 89|Cdc25 protein
P01588965A0000|0 17|GCR1 gene function
P01588965A0000|49 63|gene expression
P01589576A0170|3 14|decay curves
P01589576A0170|16 39|chlorophyll fluorescence
P01589576A0170|46 58|superposition
P01589576A0170|87 96|components
P01589576A0170|101 114|time constants
P01589576A0170|116 117|T1
P01589576A0170|126 127|ps
P01589576A0170|129 130|T2
P01589576A0170|139 140|ps
P01589576A0170|144 145|T3
P01589576A0170|154 155|ns
P01592545A0726|21 34|blood pressure
P01592545A0726|40 46|average
P01592545A0726|51 51|%
P01592545A0726|54 61|patients
P01592545A0726|85 85|p
P01592545A0726|103 103|%
P01592545A0726|124 131|patients
P01594554A0845|5 11|results
P01594554A0845|32 36|roles
P01594554A0845|41 43|CCK
P01594554A0845|47 64|trypsin inhibitors
P01594554A0845|94 109|feedback control
P01594554A0845|129 136|function
P01596007A0908|10 15|events
P01596007A0908|30 35|Stages
P01596007A0908|46 48|REM
P01596007A0908|57 66|proportion
P01596007A0908|83 96|gamma OH study
P01596007A0908|106 106|%
P01596007A0908|121 135|control studies
P01596007A0908|159 159|%
P01596007A0908|187 189|SWS
P01596007A0908|194 201|gamma OH
P01596007A0908|203 210|ABSTRACT
P01596007A0908|225 229|WORDS
P01597170A0000|5 11|rabbits
P01597170A0000|34 42|mg/m3 Co2
P01597170A0000|45 49|CoCl2
P01597170A0000|62 70|mg/m3 Cr3
P01597170A0000|73 74|Cr
P01597170A0000|76 78|NO3
P01597170A0000|82 89|group Co
P01597170A0000|90 91|Cr
P01597170A0000|110 118|mg/m3 Co2
P01597170A0000|120 127|group Co
P01597170A0000|147 149|air
P01597170A0000|151 163|control group
P01597170A0000|169 174|months
P01597170A0000|177 185|days/week
P01597170A0000|191 196|hr/day
P01597272A0077|2 6|women
P01597272A0077|22 30|methadone
P01597272A0077|40 58|withdrawal symptoms
P01597462A0457|0 9|Disruption
P01597462A0457|26 30|CDC14
P01597462A0457|44 47|gene
P01600531A0483|8 11|flow
P01600531A0483|26 26|%
P01600531A0483|32 46|phosphocreatine
P01600531A0483|54 54|%
P01600531A0483|60 72|control group
P01601181A0842|3 17|60A transcripts
P01601181A0842|20 26|protein
P01601181A0842|48 52|onset
P01601181A0842|55 66|gastrulation
P01601181A0842|82 89|mesoderm
P01601181A0842|104 112|germ band
P01601869A1389|7 13|segment
P01601869A1389|30 35|region
P01601869A1389|59 63|E-box
P01601869A1389|106 111|region
P01601869A1389|150 159|activation
P01601869A1389|175 189|BC3H1 myoblasts
P01603088A1121|5 11|results
P01603088A1121|45 46|TR
P01603088A1121|70 79|activation
P01603088A1121|83 92|repression
P01603088A1121|113 118|manner
P01605038T0001|0 8|Influence
P01605038T0001|17 26|regulation
P01605038T0001|44 50|effects
P01605038T0001|53 56|GABA
P01605038T0001|59 62|rats
P01607223A0000|6 19|investigations
P01607223A0000|45 61|release technique
P01607223A0000|69 73|pulse
P01607223A0000|76 86|laser light
P01607223A0000|96 102|release
P01607223A0000|145 153|liposomes
P01607223A0000|177 187|vasculature
P01608239T0001|13 20|barriers
P01611699A0000|5 26|pyridoxine derivatives
P01611699A0000|54 62|stem bark
P01611699A0000|64 90|Albizzia julibrissin DURAZZ
P01612085A0624|3 22|serum erythropoietin
P01612085A0624|23 25|EPO
P01612085A0624|27 40|concentrations
P01612085A0624|49 59|triathletes
P01612085A0624|65 70|U.ml-1
P01612085A0624|111 126|distance runners
P01612085A0624|131 136|U.ml-1
P01612085A0624|138 138|P
P01613640A0158|3 19|coating materials
P01613640A0158|23 32|poloxamine
P01613640A0158|37 46|poloxamine
P01613640A0158|51 60|poloxamine
P01613640A0158|66 74|poloxamer
P01613640A0158|82 85|Brij
P01615049A0000|3 8|eating
P01615049A0000|12 28|drinking patterns
P01615049A0000|35 39|goats
P01615049A0000|43 48|ad lib
P01615049A0000|60 71|h light/12 h
P01615049A0000|74 78|cycle
P01615182A0206|10 14|study
P01615182A0206|28 38|improvement
P01615182A0206|41 58|sputum amoxycillin
P01615182A0206|59 63|amoxy
P01615182A0206|65 70|levels
P01615182A0206|76 93|combination tablet
P01615182A0206|94 98|amoxy
P01615182A0206|102 103|mg
P01615182A0206|108 118|bromhexeine
P01615182A0206|120 121|mg
P01615182A0206|154 158|amoxy
P01615182A0206|162 163|mg
P01615493A0408|3 4|HC
P01615493A0408|7 14|activity
P01615493A0408|18 31|antigen levels
P01615493A0408|37 37|%
P01615493A0408|43 43|%
P01615493A0408|64 71|daughter
P01615493A0408|92 97|levels
P01615493A0975|0 9|Argatroban
P01615493A0975|36 37|HC
P01615493A0975|40 49|conditions
P01615493A0975|68 77|inhibition
P01615493A0975|80 96|thrombin activity
P01615493A0975|98 102|sites
P01615493A0975|113 123|wall damage
P01616475A0756|5 11|results
P01616475A0756|32 39|validity
P01616475A0756|42 45|NFPD
P01616475A0756|48 62|CP/NCA patients
P01616475A0756|74 81|patients
P01616475A0756|86 99|family history
P01616475A0756|101 114|panic disorder
P01616475A0756|123 130|patients
P01616475A0756|149 175|panic disorder presentation
P01617242T0000|0 14|FDA regulations
P01617242T0000|17 30|growth factors
P01617242T0000|40 47|products
P01617776A0343|27 32|system
P01617776A0343|50 60|arrhythmias
P01617776A0343|74 83|infarction
P01617776A0343|112 122|innervation
P01617776A0343|128 132|heart
P01617776A0343|151 154|role
P01617776A0343|178 183|system
P01617776A0343|186 192|reentry
P01617776A0343|204 208|heart
P01617776A0343|210 213|days
P01617776A0343|219 228|infarction
P01617801A0088|0 5|DESIGN
P01617801A0088|7 23|Serum aldosterone
P01617801A0088|26 46|plasma renin activity
P01617801A0088|57 62|supine
P01617801A0088|82 88|minutes
P01617801A0088|98 106|captopril
P01617801A0088|110 111|mg
P01618027A1108|14 24|transcripts
P01618027A1108|34 37|size
P01618027A1108|67 73|profile
P01618027A1108|104 115|E10 fragment
P01618027A1108|131 136|probes
P01618027A1108|148 156|remainder
P01618027A1108|168 173|region
P01618243T0000|11 29|amine pressor tests
P01618243T0000|37 46|volunteers
P01618256A0521|3 6|mean
P01618256A0521|26 38|concentration
P01618256A0521|51 57|regimen
P01618256A0521|61 74|micrograms.l-1
P01618256A0521|81 81|%
P01618256A0521|109 114|regime
P01618256A0521|118 131|micrograms.l-1
P01619114A0383|11 15|study
P01619114A0383|19 29|performance
P01619114A0383|35 38|SMSP
P01619114A0383|67 87|Mini Speech Processor
P01619114A0383|87 89|MSP
P01619642A0131|4 10|parents
P01620118A0470|11 18|proteins
P01620118A0470|30 36|ability
P01620118A0470|59 63|kappa
P01620118A0470|89 98|activation
P01620118A0470|109 130|immunodeficiency virus
P01620118A0470|142 147|repeat
P01620118A0470|179 185|chicken
P01620118A0470|194 198|cells
P01620129A0417|20 30|interaction
P01620129A0417|40 52|factor HiNF-D
P01620129A0417|71 86|promoter element
P01620129A0417|91 103|H4-FO108 gene
P01620129A0417|105 114|cell cycle
P01620129A0417|138 142|cells
P01620129A0417|144 145|J.
P01620610A1070|2 11|conclusion
P01620610A1070|31 32|TI
P01620610A1070|45 63|expression problems
P01620610A1070|101 106|vector
P01620610A1070|127 135|mutations
P01620610A1070|159 167|sequences
P01620610A1070|172 175|rule
P01620610A1070|185 197|MTI subregion
P01620781A0611|15 22|subjects
P01620781A0611|41 49|sequences
P01620781A0611|66 72|control
P01620781A0611|78 82|words
P01620781A0611|89 90|A1
P01620781A0611|95 96|B2
P01620781A0611|101 102|A3
P01620781A0611|107 108|B4
P01620781A0611|113 114|A5
P01620781A0611|121 128|reversal
P01620781A0611|147 153|stimuli
P01620781A0611|174 181|position
P01620781A0611|188 195|sequence
P01620781A0611|200 206|members
P01620781A0611|216 220|class
P01621584A0183|0 5|UF-021
P01621584A0183|16 23|solution
P01621584A0183|35 35|%
P01621584A0183|63 66|eyes
P01621584A0183|69 75|rabbits
P01621584A0183|97 109|IOP reduction
P01621584A0183|118 121|mmHg
P01621584A0183|140 147|IOP rise
P01623900A0670|5 18|blood pressure
P01623900A0670|34 41|activity
P01623900A0670|53 59|changes
P01623900A0670|65 77|plasma levels
P01623900A0670|87 95|excretion
P01623900A0670|98 111|norepinephrine
P01623900A0670|136 143|Pl group
P01623900A0670|156 159|drop
P01623900A0670|165 170|supine
P01623900A0670|191 205|blood pressures
P01623900A0670|232 251|norepinephrine level
P01623900A0670|263 286|norepinephrine excretion
P01623900A0670|307 311|month
P01623900A0670|314 330|dF administration
P01624425A0907|9 15|protein
P01624425A0907|38 44|mutants
P01624425A0907|49 61|substitutions
P01624425A0907|67 87|consensus amino acids
P01624425A0907|102 110|azido-ATP
P01625131A0452|15 20|biopsy
P01625131A0452|28 37|stoma site
P01625131A0452|45 48|risk
P01625131A0452|63 71|rejection
P01625527A0000|5 26|blood serotonin levels
P01625527A0000|44 56|control group
P01625527A0000|57 57|n
P01625527A0000|68 72|group
P01625527A0000|87 102|failure patients
P01625527A0000|103 103|n
P01625527A0000|118 134|treatment regimen
P01625527A0000|150 158|treatment
P01625527A0000|160 160|n
P01625527A0000|166 190|maintenance haemodialysis
P01625527A0000|191 191|n
P01625527A0000|209 223|transplantation
P01625527A0000|225 225|n
P01626372T0000|0 6|Tissues
P01626372T0000|10 17|exudates
P01626372T0000|35 43|thymidine
P01626372T0000|47 52|growth
P01626372T0000|64 71|bacteria
P01626372T0000|77 84|presence
P01626372T0000|97 102|levels
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626430A1112|3 12|homologies
P01626430A1112|20 24|RAD16
P01626430A1112|26 30|RAD54
P01626430A1112|34 37|SNF2
P01626430A1112|87 91|yeast
P01626430A1112|95 110|Drosophila genes
P01626440A0449|6 26|application solutions
P01626440A0449|28 51|instrument disinfectants
P01626440A0449|79 81|day
P01626631A0557|5 17|Rett syndrome
P01626631A0557|45 56|disturbances
P01626631A0557|62 71|brain stem
P01626631A0557|123 128|system
P01626631A0557|145 153|elevation
P01626631A0557|168 172|level
P01627106A0320|10 19|experiment
P01627106A0320|33 60|nitrofurazone administration
P01627106A0320|63 86|S. enteritidis challenge
P01627106A0320|108 118|differences
P01627106A0320|121 122|S.
P01627106A0320|134 152|isolation frequency
P01627828A0475|2 10|agreement
P01627828A0475|27 34|blotting
P01627828A0475|37 45|mouse DNA
P01627828A0475|49 58|SmN probes
P01627828A0475|65 69|bands
P01627828A0475|102 111|pseudogene
P01627828A0475|156 163|SmN gene
P01627830A0000|3 7|cDNAs
P01627830A0000|16 30|casein kinase-1
P01627830A0000|51 68|yeast cDNA library
P01627830A0000|76 79|CKI1
P01627830A0000|83 86|CKI2
P01628201A0824|0 13|Incidence rate
P01628201A0824|39 42|year
P01628201A0824|58 61|year
P01628201A0824|72 78|minimum
P01628201A0824|95 102|datasets
P01628806A1347|11 28|sequence variation
P01628806A1347|44 46|ORF
P01628806A1347|53 53|Y
P01628806A1347|76 78|ORF
P01628806A1347|99 113|helicase region
P01628904A0386|8 16|screening
P01628904A0386|25 29|clone
P01628904A0386|42 49|kilobase
P01628904A0386|51 52|kb
P01628904A0386|54 59|insert
P01629768A0131|0 6|Lesions
P01629768A0131|17 34|pressure injection
P01629768A0131|42 45|acid
P01629768A0131|53 55|SOC
P01629768A0131|89 106|glass micropipette
P01630454A0635|6 9|poly
P01630454A0635|11 15|dA-dT
P01630454A0635|17 22|region
P01630454A0635|44 52|regulator
P01630454A0635|55 76|Act1 promoter activity
P01630455A0448|13 19|protein
P01630455A0448|27 39|NFIL-1 beta A
P01630455A0448|39 47|NF beta A
P01630455A0448|80 91|DNA sequence
P01630455A0448|121 134|TATA box motif
P01630455A0448|156 170|IL-1 beta genes
P01630569A0605|7 20|amphotericin B
P01630569A0605|21 23|AmB
P01630569A0605|29 37|remission
P01630569A0605|43 47|tumor
P01631229T0000|0 12|Cutis aplasia
P01633435A0743|3 7|DRF-2
P01633435A0743|15 21|protein
P01633435A0743|25 39|characteristics
P01633435A0743|84 89|factor
P01633435A0743|91 95|MEF-2
P01633435A0743|97 102|Buskin
P01633435A0743|106 113|Hauschka
P01633435A0743|119 125|Gossett
P01633816A0667|12 16|clone
P01633816A0667|22 35|EcoRI fragment
P01633816A0667|56 60|exons
P01633816A0667|67 68|kb
P01633816A0667|84 89|region
P01633816A0667|95 102|opn gene
P01633816A0667|136 145|start site
P01633816A0667|157 181|primer extension analysis
P01633816A0667|183 201|S1 nuclease mapping
P01634308A0191|0 26|Cardiovascular risk factors
P01634308A0191|51 60|techniques
P01634400A1101|0 15|Production costs
P01634400A1101|23 26|feed
P01634400A1101|36 44|operating
P01634400A1101|55 77|replacement stock costs
P01634464A0163|9 15|patient
P01634464A0163|26 45|factor VII inhibitor
P01634464A0163|55 62|reaction
P01634464A0163|65 89|penicillin administration
P01634464A0163|96 99|rise
P01634464A0163|107 117|haemorrhage
P01634861A1336|8 15|contrast
P01634861A1336|33 54|oxygen debt hypothesis
P01634861A1336|73 83|oxygen debt
P01634861A1336|86 102|lactate clearance
P01636339A0200|0 6|Account
P01636339A0200|39 46|elements
P01636339A0200|52 57|smears
P01636339A0200|71 75|mucus
P01636339A0200|91 98|crystals
P01636339A0200|100 112|pollen grains
P01636339A0200|120 128|fragments
P01636339A0200|132 136|fungi
P01636714A0845|3 9|results
P01636714A0845|40 44|areas
P01636714A0845|48 50|MBF
P01636714A0845|56 60|liver
P01636714A0845|67 72|cortex
P01636714A0845|74 79|spleen
P01636714A0845|99 104|serosa
P01636714A0845|110 112|MBF
P01636714A0845|137 137|h
P01636714A0845|143 145|CLP
P01637758A0532|2 9|addition
P01637758A0532|18 27|proportion
P01637758A0532|30 34|women
P01637758A0532|48 52|group
P01637758A0532|65 74|dilatation
P01637758A0532|78 79|cm
P01637758A0532|103 113|examination
P01637758A0532|119 129|labour ward
P01637758A0532|138 138|%
P01637758A0532|149 149|%
P01637758A0532|152 153|OR
P01637758A0532|161 164|% CI
P01637758A0532|176 176|P
P01639092A0776|0 4|Lewis
P01639092A0776|6 7|N.
P01639724A0452|1 13|control group
P01639724A0452|19 23|women
P01639724A0452|25 27|age
P01639724A0452|33 37|years
P01639724A0452|45 58|contraceptives
P01639724A0452|60 70|Nordette-28
P01639724A0452|90 94|times
P01639724A0452|102 111|pill cycle
P01640778A0485|20 25|method
P01640778A0485|34 42|MLPA test
P01640778A0485|76 84|screening
P01641628A0869|3 12|modalities
P01641628A0869|21 36|reference values
P01641628A0869|49 56|subjects
P01641628A0869|68 73|groups
P01641628A0869|100 105|points
P01641628A0869|108 115|research
P01641628A0869|156 171|reference values
P01642060A0471|11 21|application
P01642060A0471|44 57|Phthalocyanine
P01642060A0471|73 80|patients
P01642060A0471|111 119|carcinoma
P01642060A0471|121 128|FIGO III
P01643943A0300|11 29|lung cancer tissues
P01643943A0300|38 41|67Ga
P01643943A0300|55 57|TFR
P01644751A0590|8 20|reading frame
P01644751A0590|67 83|sequence analysis
P01644751A0590|100 116|msgB gene product
P01644796A0374|6 10|study
P01644796A0374|52 56|furin
P01644796A0374|75 80|medium
P01644796A0374|88 92|cells
P01644814A0068|3 7|virus
P01644814A0068|22 28|protein
P01644814A0068|30 32|tax
P01644814A0068|55 69|immortalization
P01644814A0068|72 78|T cells
P01644821A1259|8 15|butyrate
P01644821A1259|58 69|CAT activity
P01644821A1259|71 82|fusion genes
P01644821A1259|100 108|sequences
P01644821A1259|148 156|sequences
P01644821A1259|183 189|regions
P01644821A1259|195 205|PSG1-I gene
P01644821A1259|219 235|butyrate response
P01644831A0824|2 12|examination
P01644831A0824|18 21|role
P01644831A0824|27 43|carboxyl terminus
P01644831A0824|55 60|NGFI-B
P01644831A0824|76 83|activity
P01644831A0824|99 108|accordance
P01644831A0824|125 133|receptors
P01644831A0824|135 141|mutants
P01644831A0824|149 156|portions
P01644831A0824|162 178|carboxyl terminus
P01644831A0824|197 204|activity
P01645902A1462|15 21|results
P01645902A1462|37 39|Syn
P01645902A1462|41 45|locus
P01645902A1462|63 66|gene
P01645902A1462|77 78|gH
P01645902A1462|83 88|region
P01645902A1462|101 108|portions
P01645902A1462|114 115|TK
P01645902A1462|119 120|UL
P01645902A1462|123 127|genes
P01645902A1462|139 150|syn mutation
P01645902A1462|166 175|expression
P01645902A1462|178 185|activity
P01645902A1462|188 189|TK
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|14 14|N
P01645905A0341|42 55|vaccinia virus
P01645905A0341|58 61|TGEV
P01645905A0341|83 86|mass
P01645905A0341|88 89|Mr
P01645905A0341|118 128|degradation
P01645905A0341|134 143|C-terminus
P01645905A0341|160 177|breakdown products
P01646157A0414|29 54|alpha-GalNAc cDNA sequence
P01646157A0414|88 97|nucleotide
P01646157A0414|110 128|amino acid homology
P01646157A0414|139 139|%
P01646157A0414|166 186|alpha-galactosidase A
P01646157A0414|187 197|alpha-Gal A
P01646157A0414|198 201|cDNA
P01646487A0874|0 7|Patients
P01646487A0874|23 30|activity
P01646487A0874|36 36|X
P01646487A0874|51 58|decrease
P01646487A0874|64 70|content
P01646487A0874|73 75|IgA
P01646487A0874|77 79|IgG
P01646487A0874|81 83|IgM
P01646487A0874|85 85|T
P01646487A0874|89 101|B lymphocytes
P01646487A0874|117 124|activity
P01646487A0874|127 137|neutrophils
P01646487A0874|150 157|patients
P01646487A0874|182 189|activity
P01646753A0336|3 8|reason
P01646753A0336|20 24|oxide
P01646753A0336|39 55|hydroxyl radicals
P01646753A0336|88 105|reduction proceeds
P01646753A0336|114 116|N2O
P01646753A0336|167 168|EO
P01646753A0336|170 176|N2O/N2O
P01646753A0336|184 185|V.
P01647070A0232|9 22|JCV T antigens
P01647070A0232|28 30|JCV
P01647070A0232|34 45|SV40 origins
P01647070A0232|47 61|DNA replication
P01647656A0000|3 10|relation
P01647656A0000|43 50|receptor
P01647656A0000|70 71|LV
P01647656A0000|73 80|function
P01647656A0000|95 102|patients
P01647656A0000|114 118|years
P01647656A0000|135 152|LV volume overload
P01647656A0000|175 187|regurgitation
P01647813A0512|9 18|transcript
P01647813A0512|41 47|protein
P01647813A0512|53 62|complexity
P01647813A0512|76 79|need
P01647813A0512|126 132|control
P01647813A0512|135 144|expression
P01648142A1170|2 9|patients
P01648142A1170|21 27|disease
P01648142A1170|32 39|survival
P01648142A1170|56 58|arm
P01648142A1170|88 95|survival
P01648142A1170|101 107|CAV arm
P01648142A1170|108 108|P
P01648142A1170|120 127|survival
P01648142A1170|133 138|PE arm
P01648142A1170|139 139|P
P01648530A0000|14 21|M region
P01648530A0000|42 48|Xenopus
P01648530A0000|56 74|actin gene promoter
P01648530A0000|113 122|expression
P01648530A0000|133 163|actin-beta-globin reporter gene
P01648530A0000|184 187|eggs
P01649173A0160|2 9|addition
P01649173A0160|51 60|attenuator
P01649173A0160|72 82|nucleotides
P01649173A0160|109 132|transcription start site
P01649173A0160|139 148|attenuator
P01649173A0160|150 159|attenuator
P01649173A0160|172 182|nucleotides
P01649318A0734|0 5|EBNA-2
P01649318A0734|22 33|CD23 element
P01649318A0734|53 56|mRNA
P01649318A0734|74 130|herpes simplex virus TK promoter transcription start site
P01649318A1222|5 15|experiments
P01649318A1222|50 66|cell DNA fragment
P01649318A1222|79 86|evidence
P01649318A1222|91 96|EBNA-2
P01649318A1222|111 123|transcription
P01649318A1222|126 135|cell genes
P01649539T0000|0 15|Plasma vitamin E
P01649539T0000|20 25|lipids
P01649539T0000|29 50|myeloperoxidase levels
P01649539T0000|62 68|surgery
P01649835A0822|27 38|PBR/IBP cDNA
P01649835A0822|42 52|COS-7 cells
P01649835A0822|71 78|increase
P01649835A0822|84 90|density
P01649835A0822|97 104|affinity
P01649835A0822|106 107|3H
P01649835A0822|109 110|PK
P01649835A0822|116 128|binding sites
P01649835A0822|143 150|affinity
P01649835A0822|154 161|Ro5-4864
P01650524A0837|10 14|phase
P01650524A0837|34 45|permeability
P01650524A0837|61 66|cavity
P01650524A0837|70 84|LTB4 production
P01650524A0837|87 90|dose
P01650524A0837|116 140|5-LO inhibitors phenidone
P01650524A0837|140 145|BW A4C
P01650524A0837|146 151|A63162
P01650524A0837|156 158|ICI
P01650524A0837|173 185|dexamethasone
P01650524A0837|188 197|colchicine
P01650557T0000|10 16|results
P01650557T0000|22 45|latex agglutination test
P01650557T0000|49 58|assessment
P01650557T0000|61 91|cytomegalovirus antibody status
P01650557T0000|99 115|transplant donors
P01651232A0152|4 7|mRNA
P01651232A0152|34 49|uridine residues
P01651232A0152|76 82|mixture
P01651232A0152|85 87|UTP
P01651232A0152|91 98|thio-UTP
P01651918A0000|40 53|cDNA fragments
P01651918A0000|80 98|amino acid sequence
P01651918A0000|99 129|rat testis fructose-6-phosphate
P01651918A0000|131 136|kinase
P01651918A0000|138 147|fructose-2
P01651918A0000|151 164|bisphosphatase
P01652372A0153|16 19|SWI5
P01652372A0153|29 47|localization signal
P01652372A0153|48 50|NLS
P01652372A0153|74 77|cell
P01652372A0153|100 104|entry
P01652372A0153|120 126|protein
P01652515A0379|2 9|contrast
P01652515A0379|22 30|deviation
P01652515A0379|35 56|avoidance conditioning
P01652515A0379|65 75|haloperidol
P01652515A0379|89 103|microinjections
P01652515A0379|119 120|DA
P01652515A0379|129 133|level
P01652515A0379|143 153|neostriatum
P01652755A1492|18 41|transfection experiments
P01652755A1492|43 52|HeLa cells
P01652755A1492|53 66|overexpression
P01652755A1492|79 120|retinoblastoma susceptibility gene product
P01652755A1492|119 120|RB
P01652755A1492|155 158|IL-6
P01652755A1492|171 175|c-fos
P01652755A1492|191 200|beta-actin
P01652755A1492|214 222|promoters
P01652755A1492|243 246|IL-6
P01652755A1492|276 278|MHC
P01652755A1492|290 298|promoters
P01653173A0619|4 13|repression
P01653173A0619|32 38|binding
P01653173A0619|44 45|E2
P01653173A0619|57 60|site
P01653173A0619|85 106|P105 promoter TATA box
P01653173A0619|125 137|preincubation
P01653173A0619|143 171|HPV-18 P105 promoter template
P01653173A0619|183 189|extract
P01653173A0619|201 209|formation
P01653173A0619|215 235|preinitiation complex
P01653236A0895|14 16|p50
P01653236A0895|19 29|association
P01653236A0895|40 62|glucocorticoid receptor
P01653236A0895|64 70|L cells
P01653236A0895|92 114|glucocorticoid receptor
P01653236A0895|123 141|hamster ovary cells
P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|49 51|TPA
P01653238A1062|53 69|response elements
P01653238A1062|93 97|sites
P01653238A1062|104 128|transcription factor AP-1
P01653238A1062|131 148|consensus sequence
P01653238A1062|163 180|growth factor beta
P01653238A1062|181 188|TGF-beta
P01653238A1062|201 207|element
P01653238A1062|222 236|promoter region
P01653238A1715|0 2|TPA
P01653238A1715|6 13|TGF-beta
P01653238A1715|38 47|activities
P01653238A1715|59 64|enzyme
P01653918A0286|32 39|pressure
P01653918A0286|56 61|cornea
P01653918A0286|70 76|corneas
P01653918A0286|80 87|strength
P01653918A0286|105 126|corneal pain threshold
P01654349A0327|0 10|Feed intake
P01654349A0327|33 35|KCl
P01654349A0327|38 59|NaHCO3 supplementation
P01654349A0327|75 78|gain
P01654349A0327|101 101|K
P01654349A0327|131 136|NaHCO3
P01655126T0000|0 19|Extraction procedure
P01655126T0000|25 35|measurement
P01655126T0000|38 55|butyltin compounds
P01655126T0000|67 73|tissues
P01655126T0000|79 85|toluene
P01655126T0000|87 89|HBr
P01655126T0000|94 102|tropolone
P01655713A0294|6 10|study
P01655713A0294|25 30|region
P01655713A0294|69 77|phenotype
P01655713A0294|80 85|strain
P01655713A0294|89 92|exs1
P01655713A0294|95 97|Tn1
P01655713A0294|111 113|Tn1
P01655713A0294|125 132|mutation
P01656220T0000|0 2|axl
P01656220T0000|17 20|gene
P01656220T0000|52 65|leukemia cells
P01656220T0000|79 102|receptor tyrosine kinase
P01656221A1319|0 8|Alignment
P01656221A1319|14 33|amino acid sequences
P01656221A1319|43 49|Tyr-766
P01656221A1319|67 73|regions
P01656221A1319|81 85|FGFRs
P01656221A1319|103 119|tyrosine residues
P01656221A1319|129 135|members
P01656221A1319|141 151|FGFR family
P01656235A0946|22 28|element
P01656235A0946|47 54|analysis
P01656235A0946|64 69|region
P01656235A0946|83 93|CCAAT motif
P01656675A0236|0 17|Capnography curves
P01656675A0236|21 32|HVS patients
P01656675A0236|42 49|patients
P01656675A0236|68 77|complaints
P01656675A0236|90 97|controls
P01657246A0325|3 31|transcription initiation site
P01657246A0325|52 53|bp
P01657246A0325|77 79|Met
P01657249A1019|18 19|CA
P01657249A1019|38 40|VH4
P01657249A1019|46 51|chains
P01657249A1019|62 63|CA
P01657249A1019|93 95|VH4
P01657249A1019|115 132|region determinant
P01657249A1019|139 146|VH4-HV2a
P01657415A0837|0 15|Intron K1 cox1.2
P01657415A0837|58 65|location
P01657415A0837|68 76|K. lactis
P01657594A0472|23 29|mutants
P01657594A0472|39 60|complementation groups
P01657594A0472|71 74|cgs1
P01657594A0472|79 82|cgs2
P01657969A1420|8 18|alterations
P01657969A1420|48 59|interactions
P01657969A1420|77 100|amino acid substitutions
P01657969A1420|123 128|change
P01657969A1420|134 139|enzyme
P01657969A1420|157 174|calmodulin binding
P01658356A1369|3 9|results
P01658356A1369|19 30|coexpression
P01658356A1369|55 64|generation
P01658356A1369|67 83|FeLV recombinants
P01658356A1369|87 92|FeLV-C
P01658356A1369|117 131|3201B cell line
P01658356A1369|161 166|levels
P01658356A1369|192 196|mRNAs
P01658356T0000|0 12|Recombination
P01658356T0000|26 50|leukemia virus subgroup B
P01658356T0000|50 50|C
P01658356T0000|64 75|env elements
P01658356T0000|101 110|activities
P01658356T0000|116 122|viruses
P01658375A0854|3 22|nucleotide sequences
P01658375A0854|34 37|ends
P01658375A0854|45 51|introns
P01658375A0854|78 88|transcripts
P01658375A0854|119 123|genes
P01658375A0854|143 152|difference
P01658375A0854|164 166|end
P01658375A0854|172 181|LAT intron
P01658375A0854|183 184|GC
P01658375A0854|197 217|consensus sequence GT
P01658468A0123|10 15|months
P01658468A0123|28 36|isolation
P01658468A0123|39 50|C. kutscheri
P01658468A0123|61 66|cavity
P01658468A0123|68 75|hamsters
P01658468A0123|96 103|attempts
P01658468A0123|114 120|culture
P01658468A0123|148 152|sites
P01658741A1047|3 10|strategy
P01658741A1047|36 44|kilobases
P01658741A1047|47 65|nucleotide sequence
P01658741A1047|93 95|ADE
P01658741A1047|97 101|locus
P01659685T0000|14 22|promoters
P01659685T0000|45 51|regions
P01659685T0000|60 76|Dd ras expression
P01659685T0000|77 89|Dictyostelium
P01660486A1756|3 9|results
P01660486A1756|40 48|cell type
P01660486A1756|49 63|gene cotransfer
P01660486A1756|68 92|aminoglycoside resistance
P01660486A1756|105 110|marker
P01660486A1756|147 164|control mechanisms
P01660486A1756|173 183|PKC pathway
P01660486A1756|192 201|activation
P01660486A1756|204 218|gene expression
P01660925T0000|0 17|Transfer RNA genes
P01660925T0000|20 43|Dictyostelium discoideum
P01660925T0000|80 87|elements
P01660925T0000|98 112|consensus boxes
P01660925T0000|135 141|regions
P01661369A0825|13 16|strD
P01661369A0825|20 29|strE genes
P01661369A0825|50 55|probes
P01661369A0825|71 78|presence
P01661369A0825|93 100|capacity
P01661369A0825|117 124|moieties
P01662609A0398|6 10|genes
P01662609A0398|18 29|polypeptides
P01662609A0398|35 45|amino acids
P01662609A0398|46 52|M.HgiCI
P01662609A0398|60 70|amino acids
P01662609A0398|71 77|R.HgiCI
P01662794A0640|0 9|Expression
P01662794A0640|15 22|wt1 gene
P01662794A0640|34 45|transfection
P01662794A0640|48 58|COS-1 cells
P01662794A0640|69 79|kDa protein
P01662794A0640|147 154|antisera
P01662807A1182|3 8|factor
P01662807A1182|24 34|TR promoter
P01662807A1182|51 66|SV40 chromosomes
P01662807A1182|81 89|infection
P01662884A1029|0 11|Temafloxacin
P01662884A1029|15 23|mg b.i.d.
P01662884A1029|46 49|days
P01662884A1029|77 85|treatment
P01662884A1029|105 115|prostatitis
P01664192A1577|16 22|effects
P01664192A1577|42 50|ED90 dose
P01664192A1577|52 61|vecuronium
P01669611A0142|3 9|patient
P01669611A0142|24 28|fever
P01669611A0142|47 54|aneurysm
P01669611A0142|60 64|aorta
P01669611A0142|71 85|pleuropneumonia
P01669611A0142|99 106|diseases
P01671675A0483|12 22|clone pKB11
P01671675A0483|41 44|pair
P01671675A0483|46 47|bp
P01671675A0483|49 59|cDNA insert
P01671675A0483|71 77|pCAD142
P01671675A0483|83 84|bp
P01671675A0483|101 121|hybridization methods
P01671675A0483|124 140|sequence analysis
P01671675A0483|166 178|cDNA sequence
P01671675A0483|184 192|amino end
P01671675A0483|197 211|CAD polypeptide
P01671675A0905|4 13|conclusion
P01671675A0905|28 53|Northern blotting analysis
P01671675A0905|68 73|region
P01671675A0905|76 83|CAD gene
P01673220A0578|11 19|isolation
P01673220A0578|32 42|cDNA clones
P01673220A0578|64 65|Sn
P01673220A0578|67 77|bol3 allele
P01674177T0001|0 19|Histamine-2 blockade
P01674177T0001|21 29|psoriasis
P01674242A0358|3 11|clearance
P01674242A0358|57 57|%
P01674242A0358|79 90|erythromycin
P01674242A0358|92 105|troleandomycin
P01674242A0358|107 127|triacetyloleandomycin
P01674242A0358|130 142|roxithromycin
P01674242A0358|144 151|enoxacin
P01674242A0358|153 165|ciprofloxacin
P01674242A0358|167 176|pefloxacin
P01674242A0358|178 188|norfloxacin
P01674242A0358|190 198|ofloxacin
P01674242A0358|215 220|T-3262
P01674242A0358|231 234|acid
P01674242A0358|236 245|cimetidine
P01674242A0358|247 256|etintidine
P01674242A0358|258 268|propranolol
P01674242A0358|270 278|verapamil
P01674242A0358|280 288|diltiazem
P01674242A0358|290 299|nifedipine
P01674242A0358|301 310|furosemide
P01674242A0358|312 320|frusemide
P01674242A0358|343 348|agents
P01674242A0358|350 359|viloxazine
P01674242A0358|361 371|allopurinol
P01674242A0358|373 383|ticlopidine
P01674242A0358|385 396|idrocilamide
P01674242A0358|398 410|thiabendazole
P01674242A0358|412 421|disulfiram
P01674242A0358|423 431|influenza
P01674242A0358|436 450|BCG-vaccination
P01674242A0358|452 461|interferon
P01674242A0358|466 473|caffeine
P01674242A0358|475 492|half-life increase
P01674369A0417|16 22|element
P01674369A0417|53 68|restriction site
P01674369A0417|75 81|cloning
P01674662A0000|33 46|heroin addicts
P01674662A0000|64 70|disease
P01674662A0000|72 72|n
P01674662A0000|104 118|lymphadenopathy
P01674662A0000|120 120|n
P01674662A0000|140 144|study
P01674662A0000|163 173|progression
P01674662A0000|176 179|AIDS
P01674662A0000|187 193|complex
P01674662A0000|195 197|ARC
P01674662A0000|201 204|AIDS
P01674662A0000|218 224|factors
P01674662A0000|245 253|relevance
P01674817A0862|2 9|homology
P01674817A0862|25 29|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|47 51|RNA14
P01674817A0862|60 67|proteins
P01674817A0862|79 88|data banks
P01674817T0000|0 8|Mutations
P01674817T0000|14 24|yeast RNA14
P01674817T0000|27 37|RNA15 genes
P01674817T0000|55 69|mRNA decay rate
P01674817T0000|69 85|sequence analysis
P01674817T0000|105 110|domain
P01674817T0000|116 128|RNA15 protein
P01675154T0000|10 19|infarction
P01675154T0000|22 29|patients
P01675154T0000|42 55|bypass surgery
P01675424A0991|15 24|difference
P01675424A0991|35 37|NAD
P01675424A0991|39 39|P
P01675424A0991|41 53|H-NR sequence
P01675424A0991|55 64|comparison
P01675424A0991|67 83|NADH-NR sequences
P01675424A0991|104 122|pyridine nucleotide
P01675424A0991|129 132|site
P01675637T0033|7 27|amino acid difference
P01675637T0033|41 46|region
P01675637T0033|73 80|activity
P01675637T0033|84 107|receptor dimer formation
P01675763A1389|6 13|benefits
P01675763A1389|25 32|children
P01675763A1389|37 39|CD4
P01675763A1389|64 68|liter
P01675763A1389|71 75|entry
P01678287A1308|15 40|Antp TATAA binding protein
P01678287A1308|78 82|cells
P01678287A1308|101 113|homeobox gene
P01678287A1308|160 167|function
P01678287A1308|186 190|cells
P01678392A0648|5 23|% confidence values
P01678392A0648|23 25|2SD
P01678392A0648|33 38|change
P01678392A0648|41 43|Ros
P01678392A0648|68 78|variability
P01678392A0648|99 109|cmH2O l-1 s
P01679068A0000|8 14|infants
P01679068A0000|27 36|care units
P01679068A0000|46 46|%
P01679068A0000|54 58|value
P01679068A0000|60 64|range
P01679068A0000|129 135|strains
P01679068A0000|154 163|Klebsiella
P01679068A0000|166 181|Enterobacter spp
P01679124A1368|11 17|studies
P01679124A1368|37 40|loss
P01679124A1368|43 55|ChAT activity
P01679124A1368|60 65|dorsal
P01679124A1368|76 85|hippocampi
P01679124A1368|96 102|animals
P01679124A1368|120 125|levels
P01679124A1368|128 141|norepinephrine
P01679124A1368|143 144|NE
P01679124A1368|151 168|dorsal hippocampus
P01679124A1368|170 183|MS/HSI animals
P01679124A1368|185 192|ABSTRACT
P01679124A1368|207 211|WORDS
P01679749A1171|3 14|localization
P01679749A1171|21 38|proteoglycan locus
P01679749A1171|48 53|genome
P01679749A1171|60 71|availability
P01679749A1171|77 81|RFLPs
P01679749A1171|92 96|tools
P01679749A1171|106 112|studies
P01679749A1171|120 127|diseases
P01679749A1171|136 158|HSPG2 proteoglycan gene
P01681075A0429|6 8|min
P01681075A0429|11 30|dobutamine injection
P01681075A0429|40 42|min
P01681075A0429|45 64|pimobendan injection
P01681075A0429|68 77|myocardium
P01681075A0429|99 111|determination
P01681075A0429|117 129|tissue levels
P01681075A0429|131 141|metabolites
P01681075A0429|144 149|energy
P01681075A0429|153 175|carbohydrate metabolism
P01682484A0680|14 21|stenosis
P01682484A0680|28 35|contrary
P01682484A0680|50 59|procaterol
P01682484A0680|69 72|dose
P01682484A0680|116 126|dysfunction
P01682484A0680|142 149|LCX flow
P01682484A0680|156 167|hemodynamics
P01682484A0680|178 195|lactate metabolism
P01682509A0539|13 20|evidence
P01682509A0539|32 44|proteins IE86
P01682509A0539|45 48|IE72
P01682509A0539|53 56|IE55
P01682509A0539|88 94|HIV LTR
P01682509A0539|97 107|T-cell line
P01682509A0539|108 113|HUT-78
P01682542A0690|3 9|country
P01682542A0690|22 35|HIV prevalence
P01682542A0690|44 51|strategy
P01682542A0690|71 78|location
P01682542A0690|82 92|counselling
P01682542A0690|118 128|individuals
P01684791A0000|13 19|element
P01684791A0000|29 55|glucocorticoid inducibility
P01684791A0000|60 92|chicken glutamine synthetase gene
P01686909A0299|11 18|increase
P01686909A0299|28 36|excretion
P01686909A0299|66 76|elimination
P01686909A0299|79 87|bretylium
P01686909A0299|105 108|acid
P01686909A0299|115 120|kidney
P01687050T0000|10 14|value
P01687050T0000|30 51|fluid immunoglobulin G
P01687050T0000|51 53|IgG
P01687050T0000|78 85|diseases
P01688841A0430|0 9|Expression
P01688841A0430|15 19|genes
P01688841A0430|21 24|ipaB
P01688841A0430|26 29|ipaC
P01688841A0430|31 34|invE
P01688841A0430|36 39|invG
P01688841A0430|41 44|invJ
P01688841A0430|49 52|invK
P01688841A0430|89 102|regulator virF
P01688972A0803|9 10|VT
P01688972A0803|37 43|patient
P01690703A0285|0 9|Venkatesan
P01690703A0285|14 15|D.
P01690728A1166|3 10|presence
P01690728A1166|35 50|mRNA transcripts
P01690728A1166|58 71|kilobase pairs
P01690728A1166|72 73|kb
P01690728A1166|82 92|fibroblasts
P01690728A1166|103 129|Northern blot hybridization
P01690728A1166|129 156|S1 nuclease protection assay
P01690728A1166|161 185|polymerase chain reaction
P01690812A0000|15 15|%
P01690812A0000|30 32|DNA
P01690812A0000|34 37|rDNA
P01690812A0000|39 43|units
P01690812A0000|98 102|S RNA
P01690812A0000|111 125|gene insertions
P01690812A0000|126 129|type
P01690812A0000|134 137|type
P01691184A0995|0 5|Gap b3
P01691184A0995|18 35|polypeptide chains
P01691184A0995|36 37|Mr
P01691184A0995|81 97|cleavage products
P01691184A0995|108 122|disulfide bonds
P01691184A0995|127 143|precursor protein
P01692135A0783|11 39|rtFc gamma R alpha cDNA clone
P01692135A0783|77 81|mRNAs
P01692135A0783|93 105|CRNK-16 cells
P01692135A0783|126 133|Fc gamma
P01692135A0783|142 153|mRNA species
P01692135A0783|172 176|mouse
P01692135A0783|184 195|killer cells
P01692837A0390|4 8|genes
P01692837A0390|22 26|exons
P01692837A0390|31 37|introns
P01692837A0390|71 76|region
P01692837A0390|81 94|kilobase pairs
P01692837A0390|109 112|mRNA
P01692837A0390|131 139|kilobases
P01692962A0980|6 15|expression
P01692962A0980|29 33|alpha
P01692962A0980|40 52|s polypeptide
P01692962A0980|61 73|hamster ovary
P01692962A0980|74 76|CHO
P01692962A0980|78 82|cells
P01692962A0980|110 123|cAMP synthesis
P01692962A0980|140 162|protein kinase activity
P01694009A0112|4 7|exon
P01694009A0112|18 21|exon
P01694009A0112|56 61|region
P01694009A0112|78 92|signal sequence
P01694009A0112|97 107|polypeptide
P01694014A0716|0 8|Treatment
P01694014A0716|23 38|cell lines HL-60
P01694014A0716|40 43|U937
P01694014A0716|48 78|phorbol 12-myristate 13-acetate
P01694014A0716|78 80|PMA
P01694014A0716|98 98|h
P01694014A0716|107 112|levels
P01694014A0716|118 133|RNA hybridizable
P01694014A0716|135 143|LD78 cDNA
P01694280A0000|23 37|ventriculoscope
P01694280A0000|41 51|observation
P01694280A0000|57 66|ventricles
P01694280A0000|75 82|cisterns
P01694525A0000|0 24|Isopenicillin N isomerase
P01694525A0000|24 32|epimerase
P01694525A0000|84 102|amino acid sequence
P01694525A0000|106 115|N-terminus
P01695098A1116|0 8|Serum IgG
P01695098A1116|31 38|patients
P01695116A0078|3 9|patient
P01695116A0078|35 43|remission
P01695116A0078|45 47|CR1
P01695116A0078|65 76|chemotherapy
P01695116A0078|94 99|months
P01695314A0762|8 12|mg/dl
P01695314A0762|14 15|NS
P01695314A0762|18 31|glucose levels
P01695314T0000|0 19|Platelet aggregation
P01695314T0000|31 37|control
P01695314T0000|54 81|calcium antagonist treatment
P01695314T0000|82 85|type
P01695314T0000|88 104|diabetes mellitus
P01695322A0000|0 4|Wnt-1
P01695322A0000|6 10|int-1
P01695322A0000|23 30|oncogene
P01695322A0000|47 55|insertion
P01695322A0000|66 68|DNA
P01695322A0000|74 78|mouse
P01695322A0000|86 96|tumor virus
P01695378A1406|0 8|Induction
P01695378A1406|11 16|Jurkat
P01695378A1406|25 31|T cells
P01695378A1406|35 65|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|91 95|level
P01695378A1406|98 106|FKBP mRNA
P01695905A0480|0 9|GLUT5 mRNA
P01695905A0480|29 34|levels
P01695905A0480|42 50|intestine
P01695905A0480|65 70|levels
P01695905A0480|73 78|kidney
P01695905A0480|88 93|muscle
P01695905A0480|98 111|adipose tissue
P01697611A0738|20 25|tumors
P01697611A0738|61 67|growths
P01697683T0000|0 13|Identification
P01697683T0000|17 32|characterization
P01697683T0000|38 45|promoter
P01697683T0000|52 66|cytotactin gene
P01697928A1214|22 38|sequence homology
P01697928A1214|49 54|region
P01697928A1214|57 61|Ly-6E
P01697928A1214|79 87|consensus
P01697928A1214|115 130|response element
P01697928A1214|197 206|alpha/beta
P01697928A1214|227 235|promoters
P01698761A1059|15 32|DNA rearrangements
P01698761A1059|43 48|region
P01698761A1059|65 71|repeats
P01698761A1059|99 105|histone
P01698761A1059|113 121|structure
P01698761A1059|124 127|AlgP
P01698761A1059|149 155|strains
P01698761A1059|160 169|conversion
P01698761A1059|177 182|mucoid
P01698761A1059|197 205|phenotype
P01698772A0238|6 7|J.
P01699944A1538|5 11|results
P01699944A1538|59 83|CArG box binding proteins
P01699944A1538|117 132|promoter element
P01699944A1538|137 140|VLC1
P01699944A1538|149 159|alpha-actin
P01699944A1538|164 174|c-fos genes
P01700272A0838|0 14|Polyadenylation
P01700272A0838|17 22|B4 RNA
P01700272A0838|49 58|maturation
P01700272A0838|74 81|residues
P01700272A0838|94 99|number
P01700272A0838|126 136|recruitment
P01701088A1335|0 11|Co-existence
P01701088A1335|29 36|elements
P01701088A1335|46 53|elements
P01701088A1335|64 75|AP-2 element
P01701088A1335|77 85|CCAAT box
P01702361A0621|9 15|studies
P01702361A0621|18 23|agents
P01702361A0621|35 52|collagen synthesis
P01702361A0621|55 64|deposition
P01702361A0621|86 108|angiogenesis inhibitors
P01702426A0196|19 24|region
P01702426A0196|31 34|gene
P01702426A0196|61 70|regulation
P01702426A0196|76 85|expression
P01702426A0196|138 155|acid synthase gene
P01702426A1006|4 6|set
P01702426A1006|9 19|cDNA clones
P01702426A1006|43 44|kb
P01702426A1006|61 95|lambda-ZAP goose liver cDNA library
P01702426A1006|122 129|fragment
P01702426A1006|149 157|DNA clone
P01702432A1296|0 25|Northern blotting analysis
P01702432A1296|37 46|expression
P01702432A1296|52 56|genes
P01702432A1296|77 82|clones
P01702432A1296|95 107|pollen tissue
P01702972A0613|7 24|cDNA hybridization
P01702972A0613|33 41|DNA blots
P01702972A0613|56 64|subfamily
P01702972A0613|67 77|G0S19 genes
P01702972A0613|84 91|patterns
P01702972A0613|94 98|bands
P01702972A0613|116 120|cDNAs
P01702972A0613|131 140|G0S30 cDNA
P01702972A0613|166 170|genes
P01703335T0000|19 27|disorders
P01703335T0000|40 56|immunosuppression
P01703335T0000|61 62|FK
P01703335T0000|74 85|observations
P01703335T0000|94 114|transplant population
P01703632T0000|13 22|suppressor
P01703632T0000|30 33|gene
P01703632T0000|42 52|polypeptide
P01703632T0000|57 63|regions
P01703632T0000|91 98|proteins
P01707659A0458|55 58|gene
P01707659A0458|60 66|HLA-5.4
P01707659A0458|76 90|chimpanzee gene
P01707659A0458|91 94|Ch28
P01707800A0354|11 36|N13-N20 interpeak interval
P01707800A0354|61 74|parallel shift
P01707800A0354|80 84|peaks
P01707800A0354|96 110|conduction time
P01707800A0354|122 136|onset latencies
P01707800A0354|138 140|N11
P01707800A0354|144 146|N20
P01708098A0922|18 43|complex DNA binding assays
P01708098A0922|43 48|series
P01708098A0922|62 89|alpha promoter DNA sequences
P01708098A0922|102 110|basepairs
P01708098A0922|141 142|GR
P01708098A0922|152 162|control GRE
P01708098A0922|173 180|receptor
P01708771A1215|0 21|Sequence determination
P01708771A1215|31 38|peptides
P01708771A1215|52 57|Asn120
P01708771A1215|73 77|Asn65
P01708771A1215|81 86|Asn109
P01708771A1215|105 113|molecules
P01708771A1215|122 127|others
P01708771A1215|132 136|Asn72
P01708774A0203|3 14|DNA sequence
P01708774A0203|24 36|AP-1 activity
P01708774A0203|59 73|promoter region
P01709486A0000|9 16|mutation
P01709486A0000|39 39|W
P01709486A0000|48 61|proto-oncogene
P01709486A0000|63 67|c-kit
P01709933T0000|0 8|Isolation
P01709933T0000|12 27|characterization
P01709933T0000|33 35|rat
P01709933T0000|47 50|gene
P01709933T0000|55 65|polypeptide
P01709933T0000|67 69|pS1
P01709933T0000|93 98|statin
P01710766A0349|3 10|proteins
P01710766A0349|22 29|presence
P01710766A0349|32 38|absence
P01710766A0349|55 62|sequence
P01710766A0349|72 93|amino acids C terminal
P01710766A0349|109 124|initiation codon
P01710768A1172|3 9|results
P01710768A1172|25 33|existence
P01710768A1172|36 44|sequences
P01710768A1172|62 63|kb
P01710768A1172|84 90|pattern
P01710768A1172|108 117|expression
P01710768A1172|123 133|HLA-B7 gene
P01710768A1172|139 145|ability
P01710768A1172|152 155|gene
P01710768A1172|167 182|gamma interferon
P01710979T0000|3 5|SH2
P01710979T0000|9 19|SH3 domains
P01710979T0000|21 27|pp60src
P01710979T0000|40 50|association
P01710979T0000|55 62|tyrosine
P01710979T0000|77 89|proteins p130
P01710979T0000|92 95|p110
P01710985A0315|0 3|Chem
P01711041A0348|5 10|clones
P01711041A0348|46 49|gene
P01711041A0348|69 82|C5 alpha-chain
P01711041A0348|87 87|%
P01711041A0348|93 102|beta-chain
P01711041A0962|3 16|C5 alpha-chain
P01711041A0962|30 38|kilobases
P01711041A0962|51 55|exons
P01711041A0962|60 69|beta-chain
P01711041A0962|84 92|kilobases
P01711041A0962|105 109|exons
P01711048T0000|12 19|mutation
P01711048T0000|25 25|G
P01711048T0000|28 35|position
P01711048T0000|38 43|intron
P01711048T0000|51 59|pro-alpha
P01711048T0000|64 67|gene
P01711048T0000|69 74|COL1A2
P01711048T0000|94 105|RNA splicing
P01711048T0000|114 136|osteogenesis imperfecta
P01712296A0157|3 22|nucleotide sequences
P01712296A0157|29 33|genes
P01712296A0157|50 58|positions
P01712296A0157|76 97|amino acid differences
P01713213A0000|3 9|protein
P01713213A0000|24 31|sequence
P01713213A0000|42 68|pim-1 proto-oncogene shares
P01713213A0000|76 83|homology
P01713213A0000|93 124|serine/threonine protein kinases
P01713213A0000|138 149|Pim-1 enzyme
P01713213A0000|183 214|protein tyrosine kinase activity
P01713213A0488|17 26|pim-1 cDNA
P01713213A0488|54 67|vector pGEX-2T
P01713213A0488|73 85|Pim-1 protein
P01713213A0488|97 110|fusion product
P01713213A0488|123 147|glutathione S-transferase
P01713213A0488|148 150|GST
P01714322A0969|4 9|report
P01714322A0969|44 51|kDa hsps
P01714322A0969|53 57|maize
P01714322A0969|61 68|products
P01714322A0969|90 94|genes
P01714358A0990|5 19|kDa polypeptide
P01714358A0990|55 79|wheat etioplast membranes
P01714358A0990|83 91|gamma 32P
P01714358A0990|92 94|ATP
P01714452A0559|0 7|Homology
P01714452A0559|20 26|protein
P01714452A0559|35 35|%
P01714452A0559|47 59|repeat domain
P01714452A0559|73 84|conservation
P01714452A0559|87 93|serines
P01714452A0559|97 106|threonines
P01714452A0559|116 120|sites
P01714452A0559|131 153|carbohydrate attachment
P01714902A0221|2 9|addition
P01714902A0221|39 89|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|88 99|cell surface
P01714902A0221|100 107|CD3 zeta
P01714902A0221|130 153|interleukin-2 production
P01714902A0221|158 172|TCR stimulation
P01714902A0221|189 214|histocompatibility complex
P01715593A0838|4 14|desipramine
P01715593A0838|28 30|hrs
P01715593A0838|36 55|fluoxetine injection
P01715593A0838|56 67|brain levels
P01715593A0838|69 79|desipramine
P01715975A0885|8 14|effects
P01715975A0885|17 20|CYP1
P01715975A0885|57 61|cells
P01716292A0000|10 17|analysis
P01716292A0000|26 32|regions
P01716292A0000|35 41|HLA-DR1
P01716292A0000|53 74|T cell allorecognition
P01716292A0000|93 98|series
P01716292A0000|112 121|cell lines
P01716292A0000|134 141|products
P01716292A0000|155 159|DRB/H
P01716292A0000|162 169|Eb genes
P01716292A0000|186 193|DR alpha
P01716292A0000|195 204|H-2E alpha
P01716629A0000|15 25|cDNA clones
P01716629A0000|52 78|matrix glycoprotein undulin
P01717718A1255|12 26|point mutations
P01717718A1255|31 47|Gag-Pol PR domain
P01717718A1255|55 64|activation
P01717718A1255|67 68|RT
P01717718A1255|88 89|PR
P01717718A1255|115 126|conformation
P01717718A1255|132 140|PR domain
P01717718A1255|142 148|Gag-Pol
P01717718A1255|151 162|prerequisite
P01717718A1255|166 175|activation
P01717718A1255|178 179|RT
P01717833A1223|3 24|alpha inhibin promoter
P01717833A1223|41 43|CRE
P01717833A1223|61 69|forskolin
P01717833A1223|72 86|granulosa cells
P01717833A1223|102 113|CREB protein
P01717833T0000|0 9|Regulation
P01717833T0000|15 32|alpha inhibin gene
P01717833T0000|39 47|adenosine
P01717833T0000|54 66|monophosphate
P01717833T0000|72 83|transfection
P01717833T0000|88 106|rat granulosa cells
P01717925A0477|0 9|Comparison
P01717925A0477|15 34|nucleotide sequences
P01717925A0477|58 60|DNA
P01717925A0477|74 92|sequence similarity
P01717925A0477|104 105|bp
P01717925A0477|129 134|region
P01717994T0000|0 6|Cloning
P01717994T0000|15 18|cDNA
P01717994T0000|40 45|kinase
P01717994T0000|48 62|complementation
P01717994T0000|73 77|yeast
P01717994T0000|83 90|mutation
P01718043A0384|2 9|patients
P01718043A0384|14 26|osteomyelitis
P01718043A0384|35 41|empyema
P01718043A0384|43 43|n
P01718043A0384|48 59|PMN elastase
P01718043A0384|63 73|sensitivity
P01718043A0384|78 78|%
P01718043A0384|121 150|erythrocyte sedimentation rate
P01718043A0384|150 160|sensitivity
P01718043A0384|163 163|%
P01718983A1640|0 1|E.
P01718983A1640|3 9|Hession
P01718983A1640|11 12|C.
P01718983A1640|14 17|Goff
P01718983A1640|19 20|D.
P01718983A1640|22 30|Griffiths
P01718983A1640|32 33|B.
P01718983A1640|35 40|Tizard
P01718983A1640|42 43|R.
P01718983A1640|45 50|Newman
P01718983A1640|52 53|B.
P01718983A1640|55 63|Chi-Rosso
P01718983A1640|65 66|G.
P01718983A1640|71 74|Lobb
P01718983A1640|76 77|R.
P01718983A1640|85 88|Cell
P01719684A0494|8 14|results
P01719684A0494|26 33|increase
P01719684A0494|52 60|receptors
P01719684A0494|69 76|prostate
P01719684A0494|148 165|sphincter function
P01720555A1087|25 37|B2 transcript
P01720555A1087|54 67|alfalfa organs
P01720843A1506|5 11|results
P01720843A1506|27 42|sulfhydryl group
P01720843A1506|51 61|angiotensin
P01720843A1506|72 88|enzyme inhibitors
P01720843A1506|106 111|effect
P01720843A1506|127 147|nitrovasodilator EDRF
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|18 19|FK
P01721261T0000|25 43|transplant patients
P01721884A0962|26 30|match
P01721884A0962|43 48|region
P01721884A0962|72 85|ribonuclease H
P01721884A0962|86 92|RNase H
P01721884A0962|93 98|domain
P01721884A0962|126 131|region
P01721884A0962|160 172|investigators
P01721884A0962|186 192|RNase H
P01721884A0962|207 209|Pol
P01721884A0962|211 219|helices O
P01721884A0962|222 222|P
P01721884A0962|238 244|helices
P01721884A0962|249 249|D
P01721884A0962|255 279|RNase H crystal structure
P01722319A0849|0 7|Analysis
P01722319A0849|20 38|amino acid sequence
P01722319A0849|49 62|CHIP28 protein
P01722319A0849|89 95|domains
P01722319A0849|118 138|N-glycosylation sites
P01722319A0849|155 155|N
P01722319A0849|159 167|C termini
P01722479A0302|14 27|concentrations
P01722479A0302|30 32|HCG
P01722479A0302|37 47|sensitivity
P01722479A0302|54 54|%
P01722479A0302|59 69|specificity
P01722479A0302|75 75|%
P01723619A0766|10 13|rate
P01723619A0766|16 27|F absorption
P01723619A0766|36 39|rise
P01723619A0766|42 63|plasma F concentration
P01723619A0766|88 95|emptying
P01723619A0766|108 114|passage
P01723619A0766|117 117|F
P01723619A0766|130 138|intestine
P01723619A0766|149 154|factor
P01723619A0766|162 173|F absorption
P01723962A0165|3 10|activity
P01723962A0165|13 24|serum lipase
P01723962A0165|27 33|amylase
P01723962A0165|56 56|h
P01723962A0165|71 77|maximum
P01723962A0165|82 82|h
P01723962A0165|88 96|injection
P01723962A0165|99 103|Na-Tc
P01724982A0237|43 53|HCV EIA kit
P01724982A0237|53 63|Abbott Lab.
P01724982A0237|64 76|North Chicago
P01724982A0237|77 78|IL
P01725547A0354|0 8|Diltiazem
P01725547A0354|31 38|increase
P01725547A0354|51 58|diameter
P01725547A0354|63 63|%
P01725547A0354|65 65|p
P01725547A0354|86 95|blood flow
P01725547A0354|96 98|CBF
P01725547A0354|104 104|%
P01725547A0354|106 106|p
P01725622A0292|8 18|transfusion
P01725622A0292|30 47|platelet increment
P01725622A0292|51 55|Gpt/l
P01725622A0292|57 59|CCI
P01726211A0502|5 16|risk factors
P01726211A0502|33 38|groups
P01726211A0502|45 50|vessel
P01726211A0502|63 69|factors
P01726211A0502|85 90|action
P01726211A0502|100 106|factors
P01726631T0001|0 11|Epidemiology
P01726631T0001|15 24|prevention
P01726631T0001|27 45|hospital infections
P01726631T0001|50 66|Local Health Unit
P01726631T0001|67 73|Sassari
P01726631T0001|75 81|profile
P01726631T0001|93 102|resistance
P01726631T0001|119 124|agents
P01726631T0001|132 136|usage
P01727488A1146|17 21|cDNAs
P01727488A1146|36 46|stimulation
P01727488A1146|82 96|gene expression
P01727494A0000|0 13|Vaccinia virus
P01727494A0000|14 15|VV
P01727494A0000|26 34|immunogen
P01727494A0000|42 47|nature
P01727494A0000|50 60|VV proteins
P01727494A0000|73 82|activation
P01727494A0000|94 101|response
P01727494A0000|107 110|host
P01730412T0000|0 2|Max
P01730412T0000|14 20|domains
P01730412T0000|24 34|interaction
P01730412T0000|39 43|c-Myc
P01730747A0205|15 16|G1
P01730747A0205|19 25|S phase
P01730747A0205|26 31|Reilly
P01730747A0205|33 34|C.
P01731107A0928|0 12|Substitutions
P01731107A0928|25 29|bases
P01731107A0928|44 53|ICR2 motif
P01731107A0928|60 65|levels
P01731107A0928|68 83|pRNA replication
P01731107A0928|110 120|maintenance
P01731107A0928|143 151|structure
P01731107A0928|165 170|strand
P01731107A0928|181 186|genome
P01731933T0000a|0 1|Zn
P01731933T0000a|6 32|coordination domain mutants
P01731933T0000a|33 39|T4 gene
P01731933T0000a|41 47|protein
P01731933T0000b|0 1|Zn
P01731933T0000b|6 32|coordination domain mutants
P01731933T0000b|33 39|T4 gene
P01731933T0000b|41 47|protein
P01731979A1408|3 20|tissue specificity
P01731979A1408|22 36|gene expression
P01731979A1408|79 112|CaMV 35S domain B enhancer element
P01732033A0000|3 17|pathophysiology
P01732033A0000|29 38|management
P01732033A0000|46 57|brain injury
P01732033A0000|59 65|infancy
P01732033A0000|69 77|childhood
P01732033A0000|109 120|brain injury
P01732033A0000|123 127|model
P01732736A1076|0 10|Transcripts
P01732736A1076|22 36|POU-domain gene
P01732736A1076|37 42|Oct-25
P01732736A1076|60 65|levels
P01732736A1076|68 74|oocytes
P01732736A1076|83 89|embryos
P01732736A1076|131 142|gastrulation
P01732752A0156|11 17|B cells
P01732752A0156|20 26|Abelson
P01732752A0156|33 40|leukemia
P01732752A0156|58 73|pre-B-cell lines
P01732752A0156|74 80|LT mRNA
P01733105A0127|3 8|genome
P01733105A0127|11 23|Thogoto virus
P01733105A0127|35 42|segments
P01733105A0127|69 77|sense RNA
P01733358A0240|5 10|tumors
P01733358A0240|39 44|groups
P01733358A0240|48 58|cystadenoma
P01733358A0240|63 80|cystadenocarcinoma
P01733358A0240|85 87|III
P01733358A0240|89 102|adenocarcinoma
P01733358A0240|107 122|mucin production
P01733358A0240|136 139|cyst
P01734020A1318|0 13|Immunostaining
P01734020A1318|16 20|cells
P01734020A1318|41 50|constructs
P01734020A1318|102 108|mutants
P01734020A1318|124 129|nuclei
P01734020A1318|147 155|PKC alpha
P01734283A0817|27 39|RAP74 protein
P01734283A0817|51 60|HeLa cells
P01734283A0817|83 85|DNA
P01734283A0817|101 119|translation product
P01734283A0817|134 138|RAP30
P01734570T0000|0 6|Effects
P01734570T0000|9 41|thromboxane synthetase inhibition
P01734570T0000|68 77|resistance
P01734570T0000|84 87|rate
P01734570T0000|99 111|translocation
P01734570T0000|122 134|porcine model
P01735347A0482|20 25|insult
P01735347A0482|51 59|treatment
P01735347A0482|78 81|rise
P01735347A0482|84 96|plasma lipase
P01735347A0482|102 112|development
P01735347A0482|115 121|ascites
P01735347A0482|127 135|extension
P01735347A0482|151 158|necrosis
P01735447A0271|3 6|size
P01735447A0271|18 25|molecule
P01735447A0271|64 72|precursor
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|105 117|sec61 mutants
P01735447A0271|122 134|translocation
P01735447A0271|153 161|reticulum
P01735447A0833|8 27|active-site mutation
P01735447A0833|47 56|processing
P01735447A0833|82 90|precursor
P01735447A0833|93 95|PrB
P01735447A0833|105 115|kDa pro-PrB
P01735447A0833|131 139|reticulum
P01735721A0185|12 30|amino acid sequence
P01735721A0185|40 49|% identity
P01735721A0185|57 89|Bacillus stearothermophilus TyrTS
P01735721A0185|93 102|% identity
P01735721A0185|116 120|TyrTS
P01735721A0185|127 134|identity
P01735721A0185|151 172|B. subtilis TyrTS gene
P01735721A0185|181 184|tyrZ
P01735721A0185|195 195|%
P01736093A0731|14 25|CAT activity
P01736093A0731|52 60|sequences
P01736093A0731|74 81|promoter
P01736093A0731|97 107|CCAAT boxes
P01736093A0731|117 119|HSE
P01736093A0731|136 148|constructions
P01736651A0104|9 13|Women
P01736651A0104|15 21|Infants
P01736651A0104|26 41|Children clinics
P01736651A0104|43 53|Minneapolis
P01736651A0104|55 59|Minn.
P01736844T0000|0 11|Testosterone
P01736844T0000|17 28|testosterone
P01736844T0000|66 77|testosterone
P01736844T0000|86 99|androgen index
P01736844T0000|105 128|testosterone measurement
P01736844T0000|165 172|function
P01736844T0000|175 177|men
P01736844T0000|182 189|epilepsy
P01737741A0000|0 9|BACKGROUND
P01737741A0000|14 26|effectiveness
P01737741A0000|29 56|monoamine oxidase inhibitors
P01737741A0000|56 60|MAOIs
P01737741A0000|82 91|depression
P01737741A0000|131 135|study
P01737789A0800|22 31|breakpoint
P01737789A0800|52 58|repeats
P01737789A0800|64 83|acceptor splice site
P01737789A0800|93 126|down-stream alpha-delta breakpoint
P01737789A0800|147 152|intron
P01738470A0441|0 7|Patients
P01738470A0441|20 24|PDDAT
P01738470A0441|48 56|positions
P01738470A0441|71 75|order
P01738470A0441|86 103|recognition memory
P01738653T0014|0 3|Bone
P01738653T0014|7 11|bones
P01738936A0292|3 10|patients
P01738936A0292|14 29|plasma C-peptide
P01738936A0292|41 42|pM
P01738936A0292|70 77|analysis
P01739439A0257|0 6|Complex
P01739439A0257|17 26|discharges
P01739439A0257|41 47|muscles
P01739439A0257|50 57|mdx mice
P01739439A0257|62 68|complex
P01739439A0257|79 88|discharges
P01739439A0257|96 108|abnormalities
P01739439A0257|123 129|muscles
P01739439A0257|138 149|control mice
P01739956A0638|0 9|Management
P01739956A0638|23 26|beta
P01739956A0638|31 45|calcium channel
P01739956A0638|53 57|drugs
P01739956A0638|60 66|type IC
P01739956A0638|80 84|drugs
P01740121A0136|14 20|problem
P01740121A0136|41 45|Kex2p
P01740121A0136|54 94|baculovirus/insect cell expression system
P01740330A0329|0 1|J.
P01740437A0851|14 25|core protein
P01740437A0851|30 51|liver HSPG preparation
P01740437A0851|74 81|antibody
P01740437A0851|122 127|domain
P01740437A0851|130 140|fibroglycan
P01740448A1735|14 34|transmembrane regions
P01740448A1735|72 91|amino acid stretches
P01740448A1735|131 136|region
P01740448A1735|165 174|attachment
P01740448A1735|177 186|precursors
P01740448A1735|189 197|membranes
P01740682A0703|0 7|Toxicity
P01740682A0703|34 39|emesis
P01740682A0703|43 43|%
P01740682A0703|49 56|patients
P01740682A0703|60 60|%
P01740682A0703|66 72|courses
P01740682A0703|75 84|leukopenia
P01740682A0703|87 111|World Health Organization
P01740682A0703|115 119|grade
P01740682A0703|127 127|%
P01740682A0703|133 140|patients
P01740682A0703|144 144|%
P01740682A0703|150 156|courses
P01740682A0703|162 177|thrombocytopenia
P01740682A0703|181 181|%
P01740682A0703|187 194|patients
P01740682A0703|197 197|%
P01740682A0703|203 209|courses
P01741249A0177|0 3|W.G.
P01742341A0499|4 8|study
P01742341A0499|36 43|reaction
P01742341A0499|66 79|transportation
P01742341A0499|89 96|stressor
P01742341A0499|100 110|Beagle dogs
P01742606A0000|1 25|mouse brain beta-spectrin
P01742606A0000|26 29|cDNA
P01742606A0000|50 79|lambda Gt11 expression library
P01742606A0000|84 91|antibody
P01742606A0000|124 148|kDa spectrin beta-subunit
P01742879A0471|0 6|RESULTS
P01742879A0471|8 27|Plasma AVP responses
P01742879A0471|35 45|stimulation
P01742879A0471|61 70|inhibition
P01742879A0471|73 80|drinking
P01742879A0471|94 101|patients
P01742879A0471|116 129|water drinking
P01744039A0511|3 11|fragments
P01744039A0511|18 23|region
P01744039A0511|39 63|polymerase chain reaction
P01744039A0511|75 93|gel electrophoresis
P01744039A0511|114 138|conformation polymorphism
P01744042A1355|3 13|csbA fusion
P01744042A1355|55 59|phase
P01744042A1355|62 66|cells
P01744042A1355|74 84|Luria broth
P01744042A1355|95 103|% glucose
P01744042A1355|109 119|% glutamine
P01744119A0757|3 13|constraints
P01744119A0757|16 44|primase recognition sequences
P01744119A0757|44 76|nucleotide substrate requirements
P01744119A0757|82 88|effects
P01744119A0757|101 108|proteins
P01744119A0757|111 139|oligoribonucleotide synthesis
P01744119A0757|150 153|gene
P01744119A0757|155 161|protein
P01744119A0757|183 191|templates
P01744119A0757|201 208|sequence
P01747972T0000|12 18|therapy
P01747972T0000|40 56|artery dissection
P01748067A0000|12 16|trial
P01748067A0000|45 52|patients
P01748067A0000|56 58|men
P01748067A0000|64 66|age
P01748067A0000|71 75|years
P01748067A0000|80 84|women
P01748067A0000|90 92|age
P01748067A0000|97 101|years
P01748067A0000|123 125|hip
P01748067A0000|131 141|replacement
P01748067A0000|177 185|arthritis
P01748067A0000|188 195|fracture
P01748067A0000|201 204|neck
P01748067A0000|210 214|femur
P01748194A0767|8 14|lesions
P01748194A0767|34 45|hemisections
P01748194A0767|81 88|recovery
P01748194A0767|124 139|cord transection
P01748194A0767|140 140|N
P01748287T0000|16 23|proteins
P01748287T0000|36 45|properties
P01748287T0000|68 74|targets
P01748292A0000|14 18|cDNAs
P01748292A0000|23 26|gene
P01748292A0000|37 59|G protein alpha subunit
P01748292A0000|61 66|tomato
P01748292A0000|68 90|Lycopersicon esculentum
P01748292A0000|91 92|cv
P01748630A0125|0 24|Growth factor stimulation
P01748630A0125|25 29|cells
P01748630A0125|39 53|phosphorylation
P01748630A0125|59 63|c-Myc
P01748630A0125|79 95|activation domain
P01748630A0125|97 101|Ser62
P01748630A0125|121 126|region
P01748630A0125|153 159|members
P01748630A0125|165 174|Myc family
P01748630A0125|175 181|Alvarez
P01748630A0125|183 184|E.
P01748630A0125|186 194|Northwood
P01748630A0125|196 199|I.C.
P01748630A0125|201 208|Gonzalez
P01748630A0125|210 211|F.
P01751163A0000|3 9|authors
P01751163A0000|22 30|potential
P01751163A0000|44 56|complications
P01751163A0000|68 79|implantation
P01751163A0000|100 105|device
P01751163A0000|107 118|Sarns/3M-VAD
P01751163A0000|126 131|calves
P01751255A0529|7 12|output
P01751255A0529|14 15|CO
P01751255A0529|40 40|p
P01751255A0529|61 70|MBBF group
P01751970A0209|0 18|Amino acid residues
P01751970A0209|47 54|sequence
P01751970A0209|71 78|residues
P01752441A0000|15 24|activation
P01752441A0000|30 46|HIV-1 Tat protein
P01752441A0000|61 68|residues
P01752441A0000|74 92|hexanucleotide loop
P01752441A0000|95 113|trinucleotide bulge
P01752441A0000|118 144|TAR RNA stem-loop structure
P01752441A0000|167 172|leader
P01752441A0000|183 193|transcripts
P01752792A0000|22 29|evidence
P01752792A0000|35 40|coding
P01752792A0000|53 68|time differences
P01752792A0000|69 72|ITDs
P01752792A0000|81 87|stimuli
P01752792A0000|98 104|neurons
P01752792A0000|118 123|cortex
P01752792A0000|138 148|albino rats
P01753317A0879|5 11|results
P01753317A0879|46 48|TTC
P01753317A0879|51 61|combination
P01753317A0879|66 69|FDBA
P01753317A0879|81 94|bone formation
P01753317A0879|116 127|bone defects
P01754381A0000|11 14|step
P01754381A0000|25 40|characterization
P01754381A0000|54 68|DNA polymerases
P01754381A0000|70 81|trypanosomes
P01754381A0000|119 128|expression
P01754381A0000|134 144|Trypanosoma
P01754381A0000|146 156|Trypanozoon
P01754381A0000|170 173|gene
P01754381A0000|188 207|DNA polymerase alpha
P01754381A0000|215 218|core
P01754381A0000|220 228|pol alpha
P01756195A1117|2 9|addition
P01756195A1117|31 38|increase
P01756195A1117|66 79|concentrations
P01756195A1117|84 86|age
P01756195A1117|88 88|p
P01756195A1117|102 102|r
P01756539A0354|9 20|hypertension
P01756539A0354|51 59|narrowing
P01756539A0354|71 79|condition
P01756539A0354|103 112|infarction
P01757341A0591|3 17|volume fraction
P01757341A0591|18 19|Vv
P01757341A0591|24 33|number/mm2
P01757341A0591|35 36|Na
P01757341A0591|43 53|capillaries
P01757341A0591|86 89|area
P01757341A0591|92 96|brain
P01757341A0591|127 146|alkaline phosphatase
P01758750A0000|0 14|Airway pressure
P01758750A0000|17 24|air flow
P01758750A0000|53 56|tube
P01758750A0000|61 68|children
P01758750A0000|72 78|variety
P01758750A0000|81 91|ventilators
P01759052A0786|0 3|Appl
P01759282A0000|0 5|Issues
P01759282A0000|8 19|distribution
P01759282A0000|29 34|energy
P01759282A0000|49 54|object
P01759282A0000|63 81|contact interaction
P01759282A0000|85 88|head
P01759282A0000|95 100|impact
P01759282A0000|117 124|position
P01759282A0000|127 138|biomechanics
P01760166A0963|0 9|CONCLUSION
P01760166A0963|21 24|SpO2
P01760166A0963|35 45|septum site
P01760166A0963|80 90|finger site
P01760166A0963|103 110|patients
P01761736A0158|0 8|Diltiazem
P01761736A0158|26 39|body clearance
P01761736A0158|65 70|mL/min
P01761736A0158|72 72|P
P01761736A0158|101 121|elimination half-life
P01761736A0158|147 151|hours
P01761736A0158|153 153|P
P01761736A0158|168 177|antipyrine
P01761736A0158|188 194|changes
P01761736A0158|197 202|volume
P01761736A0158|205 216|distribution
P01762053A0557|3 10|granules
P01762053A0557|26 33|material
P01762053A0557|53 57|space
P01762053A0557|73 81|particles
P01762914A1218|9 20|uPA promoter
P01762914A1218|50 57|elements
P01762914A1218|76 77|kb
P01762914A1218|85 106|translation start site
P01762917A0615|13 15|Ser
P01762917A0615|19 23|Gly69
P01762917A0615|27 29|Glu
P01762917A0615|33 35|Lys
P01762917A0615|52 68|TGEK tetrapeptide
P01762917A0615|70 75|finger
P01762917A0615|80 85|TFIIIA
P01762917A0615|99 102|loss
P01762917A0615|105 115|DNA binding
P01763065A0913|0 1|P.
P01763106A0070|17 24|behavior
P01763106A0070|36 39|hole
P01763106A0070|49 58|locomotion
P01763106A0070|84 95|test session
P01764899A0399|3 7|model
P01764899A0399|32 37|effect
P01764899A0399|40 57|water fluoridation
P01764899A0399|59 75|caries prevalence
P01764899A0399|95 100|caries
P01764899A0399|114 125|cavity level
P01765095A0680|0 35|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|73 82|expression
P01765095A0680|85 89|mRNAs
P01765095A0680|110 124|regulators CMD1
P01765095A0680|127 134|myogenin
P01765266A0000|2 15|Xenopus laevis
P01765266A0000|19 22|gene
P01765266A0000|34 58|elongation factor 1-alpha
P01765266A0000|64 75|EF-1 alpha O
P01765266A0000|80 80|O
P01765266A0000|90 95|oocyte
P01765266A0000|110 116|oocytes
P01765266A0000|125 131|embryos
P01765269A0308|5 11|introns
P01765269A0308|23 27|class
P01765269A0308|37 52|pre-mRNA introns
P01765269A0308|78 96|consensus sequences
P01765269A0308|111 118|features
P01765375A0290|3 6|mRNA
P01765375A0290|31 39|rat cells
P01765375A0290|51 64|clathrin clone
P01765375A0290|72 82|transcripts
P01765375A0290|101 102|kb
P01765375A0290|140 142|kDa
P01765375A0290|152 157|weight
P01765375A0290|163 170|clathrin
P01765375A0290|176 180|chain
P01765386A0305|6 11|report
P01765386A0305|20 21|kb
P01765386A0305|24 35|DNA sequence
P01765386A0305|60 61|bp
P01765386A0305|69 72|gene
P01765386A0305|79 80|kb
P01765386A0305|83 86|exon
P01765386A0305|101 109|junctions
P01765386A0305|117 118|bp
P01765386A0305|126 129|gene
P01765407A0866|5 12|exposure
P01765407A0866|17 26|mg DMEA/m3
P01765407A0866|52 71|plasma concentration
P01765407A0866|77 88|postexposure
P01765407A0866|96 104|excretion
P01765407A0866|110 116|mumol/l
P01765407A0866|122 140|mmol/mol creatinine
P01766666A0788|0 9|Antibodies
P01766666A0788|20 23|rE12
P01766666A0788|27 33|rNFIL-6
P01766666A0788|41 63|nucleoprotein complexes
P01766666A0788|83 87|sites
P01766666A0788|102 112|interaction
P01766666A0788|127 133|factors
P01766876A0000|1 6|method
P01766876A0000|38 43|events
P01766876A0000|49 50|mu
P01766876A0000|56 65|chain gene
P01766876A0000|78 90|co-conversion
P01766876A0000|94 104|co-exchange
P01766876A0000|109 122|point mutation
P01766876A0000|137 142|marker
P01766876A0000|155 172|replacement vector
P01766999A0000|10 17|activity
P01766999A0000|20 52|allergen extract Ambrosia elatior
P01766999A0000|51 52|AE
P01766999A0000|72 81|volunteers
P01766999A0000|105 112|allergen
P01767060A0000|4 8|study
P01767060A0000|35 54|c-DDP administration
P01767060A0000|71 82|radiotherapy
P01767060A0000|96 104|frequency
P01767060A0000|108 115|duration
P01767060A0000|127 135|responses
P01767060A0000|145 152|survival
P01767060A0000|156 163|patients
P01767060A0000|191 196|stages
P01767060A0000|207 216|carcinomas
P01767060A0000|222 225|head
P01767060A0000|229 232|neck
P01767592A0682|22 30|sequences
P01767592A0682|34 53|DNA binding proteins
P01767592A0682|78 83|region
P01767592A0682|86 125|HAP2/HAP3 consensus recognition sequence
P01767592A0682|125 138|nucleotide-154
P01767592A0682|143 177|BAF1 consensus recognition sequence
P01767592A0682|177 190|nucleotide-136
P01767899A0136|6 21|thrombocytopenia
P01767899A0136|23 31|depletion
P01767899A0136|34 49|serum fibrinogen
P01767899A0136|61 71|prothrombin
P01767899A0136|91 109|thromboplastin time
P01767899A0136|138 144|minutes
P01767899A0136|161 172|envenomation
P01768648A0853|12 21|properties
P01768648A0853|24 43|LexA fusion proteins
P01768648A0853|52 63|dimerization
P01768648A0853|81 87|domains
P01768648A0853|90 93|cRel
P01769189A0000|0 11|Plasma lipid
P01769189A0000|14 33|lipoprotein profiles
P01769189A0000|60 66|runners
P01769189A0000|68 69|RU
P01769189A0000|71 71|n
P01769189A0000|86 90|years
P01769189A0000|92 95|body
P01769189A0000|105 105|%
P01769189A0000|107 123|training distance
P01769189A0000|130 138|km week-1
P01769189A0000|139 144|VO2max
P01769189A0000|151 163|ml kg-1 min-1
P01769189A0000|163 166|mean
P01769189A0000|170 171|SD
P01769189A0000|196 200|women
P01769189A0000|202 203|UT
P01769189A0000|205 205|n
P01769189A0000|216 220|years
P01769189A0000|222 225|body
P01769189A0000|235 235|%
P01769189A0000|237 242|VO2max
P01769189A0000|249 261|ml kg-1 min-1
P01769919A0393|8 23|threshold shifts
P01769919A0393|53 70|brainstem response
P01769919A0393|104 106|kHz
P01770651T0001|22 31|evaluation
P01770651T0001|34 53|equilibrium dialysis
P01770651T0001|55 77|radioimmunoassay system
P01770651T0001|80 90|measurement
P01770651T0001|93 97|serum
P01770651T0001|102 110|thyroxine
P01771593A1152|14 15|TA
P01771593A1152|31 38|decrease
P01771593A1152|41 43|AGD
P01771593A1152|46 47|GD
P01771593A1152|74 76|PCD
P01771593A1232|14 19|adults
P01771593A1232|22 26|weeks
P01771593A1232|43 51|genitalia
P01771593A1232|64 72|offspring
P01771959A0442|5 8|PTCA
P01771959A0442|10 26|ejection fraction
P01771959A0442|45 45|%
P01771959A0442|54 54|%
P01771959A0442|56 56|p
P01771959A0442|81 88|function
P01771959A0442|126 134|deviation
P01771959A0442|141 144|PTCA
P01771959A0442|161 164|PTCA
P01771959A0442|176 183|segments
P01771959A0442|205 213|deviation
P01771959A0442|220 223|PTCA
P01771959A0442|238 241|PTCA
P01772201T0001|12 18|patient
P01772201T0001|23 26|work
P01772201T0001|33 44|subjectivity
P01772201T0001|50 55|period
P01772341A0852|5 8|data
P01772341A0852|31 39|treatment
P01772341A0852|45 76|thromboxane synthetase inhibitor
P01772341A0852|79 109|thromboxane receptor antagonist
P01772341A0852|123 132|protection
P01772341A0852|140 159|digoxin intoxication
P01772341A0852|173 177|agent
P01774062A0257|7 9|YAC
P01774062A0257|11 16|A148A7
P01774062A0257|32 45|HLA-DQA1 locus
P01774062A0257|55 61|Y3/Ring
P01774062A0257|63 67|locus
P01774062A0257|89 90|kb
P01774062A0257|104 112|YAC B1D12
P01774063A0161|13 30|backcross analysis
P01774063A0161|35 41|progeny
P01774063A0161|53 59|matings
P01774063A0161|63 84|C57BL/6J x Mus spretus
P01774063A0161|83 84|F1
P01774063A0161|86 98|C57BL/6J mice
P01774063A0161|114 132|thrombospondin gene
P01774063A0161|152 155|Fshb
P01774063A0161|157 161|Actcl
P01774063A0161|163 165|Ltk
P01774063A0161|170 177|B2M loci
P01774063A0161|185 194|chromosome
P01774093T0000|13 19|outcome
P01774093T0000|30 32|IgM
P01774093T0000|41 71|Chlamydia trachomatis infection
P01774093T0000|72 80|pregnancy
P01774822A0289|23 30|computer
P01774822A0289|40 61|LV time-density curves
P01774822A0289|88 92|cycle
P01776306A0572|9 15|patient
P01776306A0572|19 20|VT
P01776715A0489|2 6|delay
P01776715A0489|25 38|centrifugation
P01776715A0489|45 55|measurement
P01776715A0489|75 78|loss
P01776715A0489|81 83|CO2
P01776715A0489|85 97|equilibration
P01776715A0489|103 108|sample
P01776715A0489|114 124|gas mixture
P01776715A0489|139 142|PCO2
P01776715A0489|147 149|kPa
P01776715A0489|160 170|measurement
P01777841A0744|11 20|mechanisms
P01777841A0744|31 41|differences
P01777841A0744|56 62|effects
P01777841A0744|67 72|muscle
P01777841A0744|85 93|afferents
P01777841A0744|96 101|adults
P01777841A0744|105 112|neonates
P01779299A0000|20 30|alterations
P01779299A0000|41 49|cockroach
P01779299A0000|51 69|Periplaneta brunnea
P01779299A0000|85 99|acanthocephalan
P01779299A0000|101 125|Moniliformis moniliformis
P01779433A0694|9 15|finding
P01779433A0694|28 44|Alu family repeat
P01779433A0694|48 55|junction
P01779433A0694|74 80|block I
P01779433A0694|83 90|homology
P01779433A0694|96 96|Y
P01779433A0694|102 106|alpha
P01779433A0694|123 126|unit
P01779433A0694|129 134|rhesus
P01779433A0694|164 180|Alu family repeat
P01779433A0694|180 182|Alu
P01779433A0694|201 208|position
P01779433A0694|230 238|insertion
P01779433A0694|251 267|Alu family repeat
P01779433A0694|275 277|end
P01779433A0694|298 314|Alu family repeat
P01779769A0000|3 10|sequence
P01779769A0000|16 30|repressor locus
P01779769A0000|31 31|c
P01779769A0000|38 49|Streptomyces
P01779769A0000|59 63|phage
P01779769A0000|65 71|phi C31
P01779769A0000|105 117|reading frame
P01779769A0000|128 138|kDa protein
P01780235A0094|3 12|EPO levels
P01780235A0094|41 51|transfusion
P01780235A0094|91 101|transfusion
P01781923A0744|16 26|sensitivity
P01781923A0744|29 30|DB
P01781923A0744|50 62|concentration
P01781923A0744|65 66|DB
P01781923A0744|78 81|loss
P01781923A0744|84 91|righting
P01781923A0744|94 95|LS
P01781923A0744|120 123|rate
P01781923A0744|139 168|barbiturate brain distribution
P01781923A0744|170 180|elimination
P01781923A0744|189 193|lines
P01782424A0278|3 11|existence
P01782424A0278|14 37|threshold concentrations
P01782424A0278|55 63|phenomena
P01782424A0278|87 90|role
P01782424A0278|93 101|sentinels
P01782669A0496|30 41|temperatures
P01782669A0496|47 54|addition
P01782669A0496|57 62|A23187
P01782982A0155|0 9|Felodipine
P01782982A0155|24 36|baseline FEV1
P01782982A0155|73 78|effect
P01782982A0155|83 91|histamine
P01782982A0155|95 97|AMP
P01782982A0155|105 123|bronchoconstriction
P01783088A1136|10 17|patients
P01783088A1136|33 39|disease
P01783088A1136|43 52|mast cells
P01783088A1136|75 75|%
P01783088A1136|77 86|hyaluronan
P01783088A1136|109 122|micrograms.l-1
P01783088A1136|126 136|fibronectin
P01783088A1136|160 173|micrograms.l-1
P01783088A1136|196 203|patients
P01783088A1136|226 232|disease
P01783088A1136|235 242|ABSTRACT
P01783088A1136|257 261|WORDS
P01783375A1066|3 9|mapping
P01783375A1066|30 40|involvement
P01783375A1066|47 50|gene
P01783375A1066|76 84|disorders
P01783375A1066|114 138|translocation breakpoints
P01784589A0000|35 38|role
P01784589A0000|41 63|5-HT2 receptor activity
P01784589A0000|68 70|rat
P01784589A0000|77 84|behavior
P01785749A0695|5 11|changes
P01785749A0695|37 41|group
P01785749A0695|49 56|children
P01785749A0695|70 75|weight
P01786094T0001|7 14|contents
P01786094T0001|23 28|copper
P01787085A0331|10 20|experiments
P01787085A0331|39 50|control rats
P01787085A0331|63 69|colloid
P01788002T0001|0 13|Magnetotherapy
P01788002T0001|16 26|hepatitis A
P01788002T0001|29 29|B
P01788002T0001|32 39|children
P01791363A0208|5 11|results
P01791363A0208|35 42|patients
P01791363A0208|69 75|sutures
P01791363A0208|86 92|testing
P01791754T0000|10 17|analysis
P01791754T0000|27 30|role
P01791754T0000|52 59|features
P01791754T0000|75 90|secretion signal
P01791754T0000|107 116|haemolysin
P01792580A0198|5 16|blood donors
P01792580A0198|21 28|Republic
P01792580A0198|31 36|Serbia
P01792580A0198|51 56|number
P01792580A0198|59 73|blood donations
P01792580A0198|77 86|percentage
P01792580A0198|95 100|donors
P01792580A0198|134 143|percentage
P01792580A0198|150 161|blood donors
P01792914T0000|14 20|relapse
P01792914T0000|23 40|childhood leukemia
P01797459A0103|0 9|Mycoplasma
P01797459A0103|45 49|fluid
P01797459A0103|56 62|patient
P01797467A0000|0 4|RU486
P01797467A0000|8 10|ONO
P01797467A0000|16 26|combination
P01797467A0000|60 70|termination
P01797467A0000|73 81|pregnancy
P01798407A1011|3 10|presence
P01798407A1011|18 30|abnormalities
P01798407A1011|37 44|patients
P01798407A1011|58 67|hypothesis
P01798407A1011|75 80|cortex
P01798407A1011|113 116|lobe
P01798407A1011|133 138|origin
P01798407A1011|144 160|laughing seizures
P01804671A1001|2 5|line
P01804671A1001|18 23|values
P01804671A1001|27 31|QS/QC
P01804671A1001|36 42|results
P01804671A1001|94 103|air spaces
P01804671A1001|108 111|lung
P01804671A1001|140 173|ventilation/perfusion distribution
P01804671A1001|190 197|gas data
P01804671A1001|201 206|CDCSF6
P01804671A1001|217 224|ml.min-1
P01804671A1001|226 231|mmHg-1
P01806314A0322|4 8|cells
P01806314A0322|40 46|markers
P01806314A0322|77 84|antibody
P01806314A0322|92 103|muscle actin
P01808049A0262|0 15|CT abnormalities
P01808049A0262|22 32|term babies
P01808049A0262|40 49|hemorrhage
P01808049A0262|66 66|%
P01808049A0262|85 85|%
P01808049A0262|88 98|hypodensity
P01808049A0262|108 108|%
P01808049A0262|122 122|%
P01808049A0262|132 132|%
P01808049A0262|135 145|hypodensity
P01808049A0262|150 159|hemorrhage
P01808049A0262|163 163|%
P01808049A0262|175 181|atrophy
P01808049A0262|185 185|%
P01808136T0000|3 9|effects
P01808136T0000|12 25|contrast media
P01808136T0000|27 48|coagulation factor XII
P01808186A0984|0 3|Pigs
P01808186A0984|44 47|diet
P01808186A0984|57 58|kg
P01808186A0984|61 63|Exp
P01808602A0000|9 16|patients
P01808602A0000|38 49|hypertension
P01808602A0000|53 59|effects
P01808602A0000|68 87|nifedipine treatment
P01808602A0000|89 93|serum
P01808602A0000|98 101|acid
P01808602A0000|110 118|excretion
P01808602A0000|125 128|acid
P01808829A0510|0 3|TPTA
P01808829A0510|12 27|brain congestion
P01808829A0510|73 83|hemorrhages
P01809854A0106|0 7|Examples
P01809854A0106|20 27|subjects
P01809854A0106|40 54|research design
P01809854A0106|65 84|consensus statements
P01809854A0106|91 103|meta-analysis
P01810108A0000|4 18|phase slug flow
P01810108A0000|24 37|heat exchanger
P01810108A0000|57 68|inactivation
P01810108A0000|71 92|Listeria monocytogenes
P01810108A0000|109 112|milk
P01810108A0000|122 125|cows
P01810154A0491|7 14|children
P01811243A0000|0 7|Regional
P01811243A0000|16 25|blood flow
P01811243A0000|26 29|rCBF
P01811243A0000|31 42|measurements
P01811243A0000|57 63|ratings
P01811243A0000|97 104|patients
P01811243A0000|110 112|age
P01811243A0000|118 122|years
P01811243A0000|144 148|years
P01811243A0000|162 166|study
P01811243A0000|193 199|ratings
P01811243A0000|214 227|rCBF technique
P01811948A0289|12 16|study
P01811948A0289|59 65|element
P01811948A0289|71 72|bp
P01811948A0289|78 79|bp
P01811948A0289|85 102|LpS1 beta promoter
P01811948A0289|108 115|sequence
P01811948A0289|117 117|G
P01811948A0289|142 152|cis-element
P01811948A0289|159 160|bp
P01811948A0289|167 168|bp
P01812102A0101|10 22|study reports
P01812102A0101|43 51|responses
P01812102A0101|54 69|pattern reversal
P01812102A0101|70 74|VEP-P
P01812102A0101|86 94|trimester
P01812102A0101|103 107|women
P01812102A0101|111 117|changes
P01812102A0101|120 126|latency
P01812102A0101|129 139|NPN complex
P01812102A0101|160 168|responses
P01812102A0101|185 189|state
P01812690A0475|2 5|case
P01812690A0475|8 10|SMF
P01812690A0475|40 45|growth
P01814182A0000|9 13|doses
P01814182A0000|16 35|15-methyl-PGF2 alpha
P01814182A0000|44 45|mg
P01814182A0000|63 72|luteolysis
P01814182A0000|76 82|oestrus
P01814182A0000|86 92|heifers
P01814182A0000|99 108|treatments
P01814182A0000|111 113|day
P01814182A0000|131 135|cycle
P01816655T0000|0 5|Review
P01816655T0000|11 20|literature
P01816655T0000|24 29|report
P01816655T0000|33 36|case
P01816655T0000|47 50|cyst
P01817497A0715|0 9|Resolution
P01817497A0715|25 33|asymmetry
P01817497A0715|40 47|decrease
P01817497A0715|50 56|Delta T
P01817497A0715|88 88|%
P01817497A0715|108 117|population
P01822581A0533|5 13|instances
P01822581A0533|25 41|alcohol responses
P01822581A0533|71 77|reading
P01822581A0533|81 95|microgram/100ml
P01822581A0533|99 112|breath samples
P01822995T0000|0 27|Maize rbcS promoter activity
P01822995T0000|34 50|sequence elements
P01822995T0000|60 79|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|35 63|haematofluorometer Buchler ZF
P01823520A0183|92 108|haematocrit value
P01823524A0238|19 24|number
P01823524A0238|27 34|examples
P01823524A0238|62 68|variety
P01823524A0238|72 81|complexity
P01823524A0238|92 99|exposure
P01823524A0238|131 137|factors
P01823524A0238|154 162|influence
P01823524A0238|180 190|differences
P01823524A0238|193 206|susceptibility
P01823524A0238|209 228|xenobiotics toxicity
P01824713A0964|3 17|12S E1A product
P01824713A0964|32 43|TRE sequence
P01824713A0964|47 60|cotransfection
P01824713A0964|65 69|c-jun
P01824713A0964|85 88|lack
P01824713A0964|91 101|stimulation
P01824944A0988|5 13|treatment
P01824944A0988|18 28|tunicamycin
P01824944A0988|33 45|transfectants
P01824944A0988|74 85|polypeptides
P01824944A0988|104 106|IgE
P01825027T0000|0 3|PAS1
P01825027T0000|6 15|yeast gene
P01825027T0000|26 46|peroxisome biogenesis
P01825027T0000|55 60|member
P01825027T0000|69 74|family
P01825027T0000|85 91|ATPases
P01826003A0694|3 6|gene
P01826003A0694|14 23|base pairs
P01826003A0694|24 25|bp
P01826003A0694|45 51|members
P01826003A0694|57 66|SIG family
P01826003A0694|70 81|beta TG gene
P01826003A0694|94 98|exons
P01826043A0431|3 33|pp90rsk-protein kinase activity
P01826043A0431|45 54|rsk-kinase
P01826043A0431|92 125|signal transducing protein kinases
P01826043A0431|151 165|protein kinases
P01826043A0431|166 172|members
P01826043A0431|178 200|protein kinase C family
P01826043A0431|206 208|Ca2
P01826043A0431|222 236|protein kinases
P01827068T0000|5 10|GATA-3
P01827068T0000|31 50|transcription factor
P01827068T0000|66 75|expression
P01827068T0000|81 106|T cell receptor alpha gene
P01827203A0136|18 38|transcription factors
P01827203A0136|44 51|proteins
P01827203A0136|58 60|DNA
P01827203A0136|63 68|dimers
P01828248A0189|15 26|UvrA protein
P01828248A0189|42 53|UvrB protein
P01828248A0189|66 75|activities
P01828248A0189|83 90|solution
P01828248A0189|96 106|association
P01828248A0189|111 113|DNA
P01828248A0189|123 135|UvrAB complex
P01828248A0189|145 161|helicase activity
P01829060A0649|3 13|ED30 values
P01829060A0649|26 30|mg/kg
P01829060A0649|56 61|values
P01829060A0649|64 73|nifedipine
P01829060A0649|75 76|ED
P01829060A0649|87 91|mg/kg
P01829460A0329|0 25|Southwestern blot analysis
P01829460A0329|44 57|phosphoprotein
P01829460A0329|68 82|kappa B element
P01830114A1587|16 21|effect
P01830114A1587|24 26|NS1
P01830114A1587|44 49|levels
P01830114A1587|52 65|P4 transcripts
P01830114A1587|77 89|amplification
P01830114A1587|92 107|gene copy number
P01830114A1587|112 120|integrity
P01830114A1587|134 140|repeats
P01830928A0361|21 38|microtubule motors
P01830928A0361|42 48|dyneins
P01830928A0361|68 78|superfamily
P01830928A0361|97 104|proteins
P01830928A0361|117 134|attachment domains
P01832019A0265|61 67|animals
P01832019A0265|81 85|weeks
P01832152A0000|3 37|incompatibility group W plasmid pSa
P01832152A0000|44 81|Agrobacterium tumefaciens oncogenicity
P01832152A0000|81 82|J.
P01832152A0902|22 34|start signals
P01832152A0902|47 50|ORF1
P01832152A0902|54 57|ORF2
P01832197T0001|0 6|Imaging
P01832197T0001|9 28|D2 dopamine receptor
P01833185A0547|3 20|Thr161Val mutation
P01833185A0547|33 41|phenotype
P01833185A0547|47 59|fission yeast
P01833185A0547|89 99|replacement
P01833185A0547|102 107|Thr161
P01833185A0547|120 123|acid
P01833185A0547|145 159|phosphorylation
P01833185A0547|167 180|uncoordination
P01833185A0547|183 189|mitosis
P01833185A0547|201 211|cytokinesis
P01833637A0531|3 11|abundance
P01833637A0531|14 24|transcripts
P01833637A0531|45 49|genes
P01833637A0531|63 69|cdc68-1
P01833637A0531|76 80|cells
P01833637A0531|86 93|transfer
P01833637A0531|110 120|temperature
P01833637A0531|137 146|transcript
P01833637A0531|155 164|HSP82 gene
P01833637A0531|185 191|fashion
P01833716A0990|0 11|Deregulation
P01833716A0990|19 28|expression
P01833716A0990|53 66|transformation
P01833716A0990|81 96|HTLV-1 infection
P01837787T0000|9 19|Mov-34 gene
P01837787T0000|31 34|cDNA
P01837787T0000|45 56|organization
P01837842A1410|0 3|CREB
P01837842A1410|27 44|protein components
P01837842A1410|58 76|gel shift complexes
P01837842A1410|95 97|CRE
P01839414T0000|3 10|spectrum
P01839414T0000|45 53|neoplasms
P01839414T0000|56 60|Sabah
P01840513A1019|29 38|SL-2 cells
P01840513A1019|39 50|pCAT plasmid
P01840513A1019|65 66|bp
P01840513A1019|80 85|region
P01840513A1019|106 113|increase
P01840513A1019|116 157|chloramphenicol acetyltransferase activity
P01840513A1019|161 169|induction
P01840513A1019|182 185|acid
P01840513A1019|192 203|8-bromo-cAMP
P01840607A0294|25 28|UTRs
P01840607A0294|40 43|type
P01840607A0294|48 51|type
P01840607A0294|66 67|bp
P01840607A0294|105 107|PFP
P01840608A0823|3 12|N-terminus
P01840608A0823|26 38|reading frame
P01840608A0823|52 55|nifA
P01840608A0823|82 85|nifB
P01840608A0823|88 117|amino acid sequence comparison
P01840711A0000|3 12|RNA genome
P01840711A0000|14 19|rabbit
P01840711A0000|31 43|disease virus
P01840711A0000|44 47|RHDV
P01840902A1089|26 31|system
P01840902A1089|57 62|plants
P01840902A1089|95 113|transport machinery
P01840902A1089|124 131|monocots
P01840902A1089|135 140|dicots
P01842498A0000|6 15|cDNA clone
P01842498A0000|21 22|R2
P01842498A0000|47 59|hybridization
P01842498A0000|63 74|cDNA library
P01842498A0000|76 93|phytohemagglutinin
P01842498A0000|95 97|PHA
P01842498A0000|100 116|phorbol myristate
P01842498A0000|134 145|Jurkat cells
P01842498A0000|162 173|cDNA library
P01842498A0000|199 215|blood lymphocytes
P01842867A0696|2 11|conclusion
P01842867A0696|29 48|regeneration ability
P01842867A0696|67 72|injury
P01842867A0696|83 88|mucosa
P01844017A0410|20 31|relationship
P01844017A0410|42 45|drop
P01844017A0410|48 91|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|95 109|vitamin E level
P01844017A0410|114 117|hand
P01844017A0410|125 132|duration
P01844017A0410|135 143|poisoning
P01844017A0410|148 161|sodium nitrite
P01844878A0000|1 6|vector
P01844878A0000|43 69|neomycin phosphotransferase
P01844878A0000|71 74|gene
P01844878A0000|90 107|promoter sequences
P01844878A0000|112 115|pool
P01844878A0000|131 143|DNA fragments
P01844982A0324|0 5|Chagas
P01844982A0324|7 13|disease
P01844982A0324|23 35|leishmaniasis
P01844982A0324|49 54|factor
P01844982A0324|56 70|schistosomiasis
P01844982A0324|82 87|factor
P01844982A0324|97 104|controls
P01845829A0158|8 15|analysis
P01845829A0158|26 33|sequence
P01845829A0158|69 75|domains
P01845829A0158|102 108|factors
P01845829A0158|123 133|brain cells
P01845885A1003|24 27|unit
P01845885A1003|39 42|UL26
P01845885A1003|65 71|protein
P01845885A1003|77 87|amino acids
P01845885A1003|98 103|family
P01845885A1003|106 113|proteins
P01845885A1003|134 137|mRNA
P01845885A1003|187 220|UL26 transcription initiation site
P01845885A1003|240 266|methionine initiation codon
P01845885A1003|274 281|position
P01845885A1003|292 295|UL26
P01845885A1003|311 314|unit
P01845899A0000|19 23|virus
P01845899A0000|25 27|AAV
P01845899A0000|29 36|rep gene
P01845899A0000|47 54|proteins
P01845899A0000|56 60|Rep78
P01845899A0000|62 66|Rep68
P01845899A0000|68 72|Rep52
P01845899A0000|77 81|Rep40
P01845899A0000|94 112|AAV DNA replication
P01845899A0000|114 132|AAV gene regulation
P01846206A0665|7 12|region
P01846206A0665|28 34|CMV dbp
P01846206A0665|46 56|replication
P01846206A0665|68 73|assays
P01846489A1119|34 48|protease domain
P01846489A1119|65 80|protease domains
P01846491A0459|19 27|positions
P01846491A0459|33 40|VV genes
P01846491A0459|41 59|genus Orthopoxvirus
P01846491A0459|99 102|ORFs
P01846491A0459|105 107|SFV
P01846491A0459|109 128|genus Leporipoxvirus
P01846491A0459|140 161|complex rearrangements
P01846491A0459|163 165|DNA
P01846491A0459|171 176|genome
P01846491A0459|195 201|viruses
P01846491A0459|219 228|divergence
P01846491A0459|240 247|ancestor
P01846803A0688|4 9|result
P01846803A0688|22 36|phosphorylation
P01846803A0688|39 41|Thr
P01846803A0688|50 52|Tyr
P01846803A0688|63 85|p34cdc2 kinase activity
P01846803A0688|87 90|line
P01846803A0688|98 105|location
P01846803A0688|113 120|residues
P01846803A0688|138 153|ATP binding site
P01846803A0688|157 162|kinase
P01847464A0856|12 26|cotransfections
P01847464A0856|29 44|pFRTK-CAT target
P01847464A0856|68 72|sites
P01847464A0856|80 89|EBV origin
P01847464A0856|91 109|plasmid replication
P01847464A0856|110 114|ori-P
P01847464A0856|152 170|EBNA-1 construction
P01847464A0856|171 181|amino acids
P01847464A0856|206 210|c-myc
P01847464A0856|218 236|localization signal
P01847665A1079|3 10|findings
P01847665A1079|31 34|idea
P01847665A1079|42 46|genes
P01847665A1079|55 68|PDGF receptors
P01847665A1079|70 81|glioma cells
P01847665A1079|95 101|concert
P01847665A1079|111 115|genes
P01847665A1079|120 129|expression
P01847665A1079|163 169|program
P01847665A1079|178 195|glia cell lineages
P01848300A0910|10 17|evidence
P01848300A0910|33 36|cstA
P01848300A0910|49 67|peptide utilization
P01848871A0392|4 8|study
P01848871A0392|18 27|hypothesis
P01848871A0392|32 45|sodium channel
P01848871A0392|53 57|drugs
P01848871A0392|83 91|potential
P01848871A0392|106 121|amplitude signal
P01848871A0392|122 128|portion
P01848871A0392|149 159|QRS complex
P01848871A0392|166 177|prolongation
P01848871A0392|187 195|potential
P01848871A0392|214 220|slowing
P01848871A0392|234 244|tachycardia
P01849509T0000|0 13|Identification
P01849509T0000|17 35|nucleotide sequence
P01849509T0000|37 79|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|77 86|similarity
P01849509T0000|105 115|transposase
P01849509T0000|125 129|ISRm3
P01849509T0000|167 171|IS256
P01849509T0000|175 204|Thiobacillus ferrooxidans IST2
P01849675A0167|14 25|relationship
P01849675A0167|33 39|viruses
P01849675A0167|52 63|DNA sequence
P01849675A0167|65 66|KV
P01849675A0167|83 84|bp
P01849734A1063|8 27|PR55 beta transcript
P01849734A1063|36 37|kb
P01849734A1063|55 60|levels
P01849734A1063|66 78|neuroblastoma
P01849734A1063|86 101|cell line LA-N-1
P01849734A1063|104 108|level
P01849734A1063|114 117|mRNA
P01849734A1063|143 152|cell lines
P01850096A0662|0 11|Heterodimers
P01850096A0662|14 21|myogenin
P01850096A0662|25 27|E12
P01850096A0662|31 34|MyoD
P01850096A0662|38 40|E12
P01850096A0662|60 79|restriction fragment
P01850096A0662|115 119|start
P01850096A0662|129 153|alpha-actin transcription
P01850105A1093|3 9|effects
P01850105A1093|12 16|c-myc
P01850105A1093|50 54|c-myc
P01850105A1093|65 79|differentiation
P01850105A1093|95 96|Id
P01850105A1093|107 115|regulator
P01850105A1093|118 139|muscle differentiation
P01850127A0000|6 16|association
P01850127A0000|19 26|U2 snRNP
P01850127A0000|33 52|branchpoint sequence
P01850127A0000|63 71|pre-mRNAs
P01850127A0000|80 86|binding
P01850127A0000|99 105|protein
P01850127A0000|111 130|polypyrimidine tract
P01850893A0286|17 26|antibodies
P01850893A0286|49 55|rabbits
P01850893A0286|72 76|farms
P01851386T0092|10 31|Lung Cancer Task Force
P01851386T0092|30 36|FONICAP
P01851527T0000|3 19|promoter activity
P01851527T0000|24 27|gene
P01851527T0000|36 75|Alzheimer beta-amyloid precursor protein
P01851527T0000|74 76|APP
P01851527T0000|94 99|blocks
P01851527T0000|110 118|sequences
P01851756A0743|0 3|Biol
P01851862A0273|0 19|Nucleotide sequences
P01851862A0273|29 36|env gene
P01851862A0273|42 44|LTR
P01851862A0273|47 51|SFV-1
P01851876A0129|4 10|element
P01851876A0129|28 38|EMBL3 mouse
P01851876A0129|45 51|library
P01852438A0928|3 11|MVV-value
P01852438A0928|31 35|level
P01852438A0928|41 44|case
P01852438A0928|52 58|percent
P01852603A0000|3 6|rad9
P01852603A0000|11 27|DNA repair mutant
P01852603A0000|33 45|fission yeast
P01852603A0000|88 89|UV
P01852603A0000|101 109|radiation
P01853796T0000|0 5|Review
P01853796T0000|7 19|deterioration
P01853796T0000|22 38|glucose tolerance
P01853796T0000|42 44|age
P01853796T0000|49 52|role
P01853796T0000|55 72|insulin resistance
P01854339A0221|5 10|region
P01854339A0221|22 40|sequence similarity
P01854339A0221|57 75|consensus promoters
P01854339A0221|94 102|sequences
P01854339A0221|116 121|levels
P01854339A0221|124 133|expression
P01855255T0000|9 18|initiation
P01855255T0000|21 27|mitosis
P01855255T0000|30 34|yeast
P01855255T0000|42 45|RCC1
P01855255T0000|61 66|GTPase
P01856021A0577|3 8|method
P01856021A0577|34 43|laboratory
P01856021A0577|48 51|year
P01856021A0577|77 85|procedure
P01856021A0577|102 108|control
P01856021A0577|123 130|exposure
P01856021A0577|133 139|toluene
P01856021A0577|146 151|xylene
P01857143A0351|3 9|patient
P01857143A0351|25 28|male
P01857143A0351|35 46|skin lesions
P01857143A0351|57 65|diagnosis
P01857143A0351|68 80|myelofibrosis
P01857326A0160|0 9|Oculus-500
P01857326A0160|13 17|group
P01857326A0160|24 48|resolution imaging boards
P01857326A0160|50 52|use
P01857326A0160|57 62|IBM-AT
P01857326A0160|76 84|computers
P01860846A0663|8 11|cDNA
P01860846A0663|36 62|tumor necrosis factor-alpha
P01860846A0663|82 106|MARCKS gene transcription
P01860846A0663|128 150|leukemia cell line HL60
P01861034A0798|5 13|resection
P01861034A0798|27 34|fragment
P01861034A0798|47 58|contact area
P01861034A0798|61 68|pressure
P01861034A0798|87 103|scaphoid fragment
P01861188A0000|0 11|Plate luting
P01861188A0000|13 21|technique
P01861188A0000|53 56|PMMA
P01861188A0000|78 82|plate
P01861188A0000|89 92|bone
P01861188A0000|112 122|screw heads
P01861188A0000|128 132|plate
P01861188A0000|146 154|stability
P01861188A0000|165 172|fixation
P01861188A0000|223 227|bones
P01861188A0000|246 256|osteotomies
P01861188A0000|280 302|ASIF compression plates
P01862027A0212|5 12|features
P01862027A0212|42 50|diagnosis
P01862027A0212|53 77|Rothmund-Thomson syndrome
P01862455T0000|0 15|Thyroid lymphoma
P01862455T0000|21 30|management
P01863768A0649|3 9|protein
P01863768A0649|19 24|ORF113
P01863768A0649|47 52|domain
P01863887A0174|0 16|Space limitations
P01863887A0174|35 40|review
P01863887A0174|54 68|pharmaceuticals
P01863887A0174|76 93|tissue plasminogen
P01863887A0174|103 111|substance
P01863887A0174|113 120|hormones
P01863887A0174|127 133|thyroid
P01863887A0174|135 141|insulin
P01863887A0174|143 156|growth hormone
P01863887A0174|157 170|erythropoietin
P01863887A0174|173 188|clotting factors
P01863887A0174|192 205|blood products
P01864510A0946|0 9|Dd PK1 RNA
P01864510A0946|23 23|h
P01864510A0946|26 35|starvation
P01864510A0946|58 62|cells
P01864821A0000|10 14|forms
P01864821A0000|23 34|cell disease
P01864821A0000|48 54|feature
P01864821A0000|67 78|globin chain
P01864821A0000|95 104|conditions
P01864821A0000|111 117|hypoxia
P01864821A0000|131 138|sickling
P01864821A0000|144 154|blood cells
P01864821A0000|157 167|obstruction
P01864821A0000|170 182|blood vessels
P01864837A1029|10 18|structure
P01864837A1029|35 42|proteins
P01864837A1029|53 62|% homology
P01864837A1029|72 87|mouse contrapsin
P01864837A1029|90 97|contrast
P01864837A1029|105 114|% homology
P01864837A1029|124 153|rat alpha 1-protease inhibitor
P01865010A0000|0 7|Patterns
P01865010A0000|10 20|connections
P01865010A0000|45 55|integration
P01865010A0000|104 110|tracers
P01865010A0000|112 122|Fluoro-Gold
P01865010A0000|126 134|diamidino
P01865010A0000|152 157|manner
P01865010A0000|178 192|representations
P01865010A0000|218 225|auditory
P01865010A0000|240 245|cortex
P01865010A0000|251 253|rat
P01867069A0000|5 13|CD-1 mice
P01867069A0000|15 18|days
P01867069A0000|35 52|% nicotine sulfate
P01867069A0000|64 67|days
P01867069A0000|97 100|pups
P01867069A0000|110 112|age
P01867069A0000|127 132|effect
P01867069A0000|138 148|development
P01867069A0000|166 171|molars
P01869565A1254|0 2|USF
P01869565A1254|25 37|transcription
P01869565A1254|41 58|translation system
P01869565A1254|72 83|ADH promoter
P01869565A1254|96 98|MLP
P01869907A2146|3 22|across-fiber pattern
P01869907A2146|27 35|responses
P01869907A2146|47 60|NaCl solutions
P01869907A2146|103 105|H2O
P01869907A2146|108 115|ABSTRACT
P01869907A2146|130 134|WORDS
P01869968A0000|8 28|radioactivity content
P01869968A0000|47 60|administration
P01869968A0000|63 67|HMPAO
P01869968A0000|80 87|subjects
P01869968A0673|6 24|regression analysis
P01869968A0673|51 56|result
P01869968A0673|69 77|clearance
P01869968A0673|79 83|HMPAO
P01869968A0673|96 99|rCBF
P01869968A0673|109 120|significance
P01869968A0673|122 122|p
P01870194A0302|5 31|immunodeficiency virus type
P01870194A0302|32 36|HIV-1
P01870194A0302|85 95|homogeneity
P01870428A0677|0 10|Thigh girth
P01870428A0677|34 36|HDL
P01870428A0677|40 45|HDL2-C
P01870428A0677|49 52|mass
P01870428A0677|61 77|LDL particle size
P01870428A0677|81 85|women
P01870500A0276|0 12|Contributions
P01870500A0276|17 21|pairs
P01870500A0276|24 29|source
P01870500A0276|33 54|target volume elements
P01870500A0276|68 75|S values
P01870500A0276|85 89|tumor
P01870500A0276|126 135|host organ
P01870500A0276|158 162|tumor
P01870500A0276|185 194|host organ
P01870500A0276|202 220|reciprocity theorem
P01871033A0434|0 4|Tests
P01871033A0434|24 33|impression
P01871033A0434|39 43|force
P01871033A0434|71 91|laboratory simulation
P01871033A0434|99 113|clearing cement
P01871033A0434|116 129|testing cement
P01871033A0434|150 155|method
P01871135A0295|3 6|cDNA
P01871135A0295|22 34|reading frame
P01871135A0295|40 41|bp
P01871135A0295|56 62|protein
P01871135A0295|68 78|amino acids
P01871135A0295|91 94|mass
P01871135A0295|99 101|kDa
P01871135A0295|107 113|protein
P01871135A0295|119 128|% identity
P01871135A0295|130 150|rat liver glucokinase
P01871971A0836|0 7|Analysis
P01871971A0836|15 21|mutants
P01871971A0836|47 55|NFIII/OCT
P01871971A0836|58 69|binding site
P01871971A0836|82 90|ATF motif
P01871971A0836|120 125|growth
P01872856A0277|0 7|Recovery
P01872856A0277|23 24|BA
P01872856A0277|32 36|urine
P01872856A0277|40 40|%
P01872856A0277|45 50|faeces
P01872856A0277|54 54|%
P01872856A0277|62 64|hrs
P01872856A0277|75 75|%
P01872856A0277|92 104|radioactivity
P01872856A0277|107 111|liver
P01872856A0277|115 120|testis
P01872856A0277|133 140|recovery
P01872856A0277|145 145|%
P01872856A0277|157 163|animals
P01873999A0000|47 58|model system
P01873999A0000|106 112|details
P01873999A0000|115 129|gene expression
P01873999A0000|135 151|secretion process
P01873999A0000|158 161|host
P01873999A0000|168 177|production
P01873999A0000|192 199|proteins
P01873999A0000|218 225|interest
P01874195A0139|25 35|GH receptor
P01874195A0139|45 49|liver
P01874195A0139|60 78|sequence similarity
P01874195A0139|80 88|receptors
P01874195A0139|98 127|signal transduction mechanisms
P01874195A0139|167 190|tyrosine kinase activity
P01874752A0948|41 59|conditions cdc2/p58
P01874752A0948|62 69|cdc2/p62
P01874752A0948|84 94|differences
P01874752A0948|111 118|activity
P01875922A0770|0 16|Mutation analysis
P01875922A0770|34 41|segments
P01875922A0770|61 66|region
P01875922A0770|96 101|effect
P01876836T0000|0 13|Identification
P01876836T0000|16 18|Ets
P01876836T0000|36 43|subunits
P01876836T0000|46 63|GA binding protein
P01878489A0959|12 19|response
P01878489A0959|22 32|neutrophils
P01878489A0959|36 44|monocytes
P01878489A0959|66 74|magnitude
P01878489A0959|80 101|NADPH oxidase activity
P01878489A0959|124 134|neutrophils
P01878489A0959|141 149|monocytes
P01878755A0496|5 9|ileum
P01878755A0496|11 21|enterotoxin
P01878755A0496|41 53|disappearance
P01878755A0496|55 55|P
P01878755A0496|82 97|blood appearance
P01878755A0496|98 98|P
P01878755A0496|115 125|chloroquine
P01881595A0476|0 7|Formalin
P01881595A0476|21 26|SNO NS
P01881595A0476|29 40|NnS neurones
P01881595A0476|63 73|NS neurones
P01881595A0476|74 74|n
P01881595A0476|96 100|phase
P01881595A0476|103 110|activity
P01881595A0476|116 127|NnS neurones
P01881595A0476|143 143|n
P01881595A0476|153 158|phases
P01881595A0476|160 160|n
P01881671T0001|0 5|Uptake
P01881671T0001|8 16|ofloxacin
P01882240A0526|17 25|attention
P01882240A0526|33 38|issues
P01882240A0526|65 71|quality
P01882240A0526|74 81|research
P01882240A0526|84 87|AIDS
P01882240A0526|95 103|behaviors
P01882240A0526|111 121|communities
P01882386A0000|3 15|effectiveness
P01882386A0000|18 36|alpha-mercapto-beta
P01882386A0000|39 45|2-furyl
P01882386A0000|54 57|acid
P01882386A0000|59 61|MFA
P01882386A0000|66 101|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|103 105|NaB
P01882386A0000|114 124|combination
P01882386A0000|131 142|mobilization
P01882386A0000|146 154|excretion
P01882386A0000|157 160|lead
P01882386A0000|178 181|rats
P01883992A0922|5 11|results
P01883992A0922|23 28|beta-1
P01883992A0922|66 74|regulator
P01883992A0922|80 89|expression
P01883992A0922|95 108|beta-zein gene
P01883992A0922|120 134|maize endosperm
P01884435A0088|4 8|study
P01884435A0088|20 26|effects
P01884435A0088|29 39|hypovolemia
P01884435A0088|58 61|ptO2
P01884435A0088|65 81|ptH distributions
P01884435A0088|91 102|tissue sites
P01884435A0088|135 148|microelectrode
P01884435A0088|174 185|measurements
P01884435A0088|188 191|ptO2
P01884435A0088|195 197|ptH
P01884998A1135|3 9|members
P01884998A1135|42 54|transcription
P01884998A1135|59 67|promoters
P01884998A1135|93 96|site
P01885006A0995|3 9|domains
P01885006A0995|20 34|superactivation
P01885006A0995|46 51|subset
P01885006A0995|88 97|activation
P01885613A1298|0 10|Information
P01885613A1298|31 39|sequences
P01885613A1298|50 56|studies
P01885613A1298|62 71|regulation
P01885613A1298|77 85|pro alpha
P01885613A1298|90 102|collagen gene
P01885752A0198|0 20|Chlamydia trachomatis
P01885752A0198|23 40|Chlamydia psittaci
P01885752A0198|57 73|methanol fixation
P01885915A0000|13 22|infections
P01885915A0000|27 37|bacteraemia
P01885915A0000|43 63|Pasteurella multocida
P01885915A0000|78 89|endocarditis
P01885915A0000|104 117|P. haemolytica
P01886043A0380|3 5|SMX
P01886043A0380|8 9|pH
P01886043A0380|18 24|complex
P01886043A0380|39 40|pH
P01886043A0380|44 47|HPCD
P01886043A0380|57 62|effect
P01886043A0380|68 77|solubility
P01886043A0380|96 98|SMX
P01886043A0380|129 137|molecules
P01886043A0380|145 163|inclusion complexes
P01886043A0380|170 173|HPCD
P01886368A0000|0 15|PO2 measurements
P01886368A0000|36 62|recess type microelectrodes
P01886368A0000|83 92|nerve head
P01886368A0000|103 106|pigs
P01886368A0000|109 116|normoxia
P01886368A0000|120 128|hyperoxia
P01886774A0000|24 30|domains
P01886774A0000|33 36|Oct3
P01886774A0000|51 65|Echerichia coli
P01886774A0000|68 83|characterization
P01886774A0000|86 96|DNA binding
P01886774A0000|101 116|octamer sequence
P01888896A0505|1 15|deletion series
P01888896A0505|30 35|region
P01888896A0505|50 57|position
P01888896A0505|96 110|initiation site
P01888896A0505|142 148|tobacco
P01889753A0441|3 12|nucleotide
P01889753A0441|14 15|nt
P01889753A0441|17 25|sequences
P01889753A0441|31 35|exons
P01889753A0441|48 57|boundaries
P01889753A0441|82 88|regions
P01890362A0305|7 14|patients
P01890362A0305|38 54|eye complications
P01890362A0305|59 65|leprosy
P01890362A0305|69 76|patients
P01890362A0305|101 105|years
P01890989A1392|31 38|elements
P01890989A1392|55 72|estrogen induction
P01890989A1392|81 85|genes
P01890989A1392|88 95|chickens
P01890989A1392|99 108|amphibians
P01892680A0907|0 7|Toxicity
P01892680A0907|27 34|regimens
P01892680A0907|44 51|sedation
P01892680A0907|76 80|arm B
P01892680A0907|81 81|p
P01893195A0000|21 27|monkeys
P01893195A0000|35 42|hamsters
P01893195A0000|51 54|mice
P01893195A0000|58 64|authors
P01893195A0000|85 94|properties
P01893195A0000|101 115|virus Issyk-Kul
P01893927A0704|22 29|pressure
P01893927A0704|32 53|phenylephrine infusion
P01893927A0704|55 60|levels
P01893927A0704|86 88|NMA
P01893927A0704|92 94|NNA
P01893927A0704|110 119|reductions
P01893927A0704|129 134|output
P01894696A0301|0 1|J.
P01895358A0000|0 5|Limits
P01895358A0000|8 22|energy turnover
P01895358A0000|24 31|relation
P01895358A0000|42 52|performance
P01895358A0000|68 72|terms
P01895358A0000|88 92|limit
P01895358A0000|94 100|changes
P01895358A0000|108 125|training programme
P01895358A0000|141 154|energy balance
P01895358A0000|165 179|energy turnover
P01895370A0199|12 21|reductions
P01895370A0199|24 27|flow
P01895370A0199|32 35|peak
P01895370A0199|37 37|S
P01895370A0199|42 47|trough
P01895370A0199|49 49|D
P01895370A0199|51 56|points
P01895370A0199|62 95|maximum shifted-frequency envelope
P01895370A0199|100 107|parallel
P01895370A0199|117 123|fashion
P01895370A0199|129 129|D
P01895384A0746|3 18|IE0 gene product
P01895384A0746|38 49|IE1 promoter
P01895384A0746|64 73|expression
P01895384A0746|84 91|promoter
P01895393A0745|9 17|promoters
P01895393A0745|29 36|TATA box
P01895393A0745|41 47|absence
P01895393A0745|50 58|Sp1 sites
P01895393A0745|60 68|Sp1 sites
P01895393A0745|73 79|absence
P01895393A0745|83 90|TATA box
P01895393A0745|125 138|RNA polymerase
P01895393A0745|141 148|promoter
P01895555T0001|0 9|Evaluation
P01895555T0001|27 34|function
P01895555T0001|61 67|imaging
P01895555T0001|72 82|Tc-99m-MIBI
P01896777T0000|0 16|Ivermectin uptake
P01896777T0000|19 30|distribution
P01896777T0000|36 41|plasma
P01896777T0000|45 50|tissue
P01896777T0000|71 78|patients
P01896777T0000|91 109|Onchocerca volvulus
P01897515A0348|0 24|Bone marrow abnormalities
P01897515A0348|25 31|Hodgkin
P01897515A0348|34 40|disease
P01897515A0348|65 77|understanding
P01897515A0348|95 104|mechanisms
P01897515A0348|122 127|anemia
P01898113A0265|10 20|uptake rate
P01898113A0265|29 42|clearance rate
P01898113A0265|60 62|BCF
P01898113A0265|66 78|SWA killifish
P01898164A0839|32 37|repair
P01898164A0839|65 69|group
P01898164A0839|72 78|infants
P01898164A0839|99 102|arch
P01898164A0839|114 134|aorta diameter ratios
P01898164A0839|134 145|arch indices
P01898928A0260|0 25|DNA hybridization analysis
P01898928A0260|64 68|cells
P01898928A0260|71 72|Y.
P01898928A0260|87 95|DNA locus
P01898928A0260|125 132|fur gene
P01899209A0883|0 8|Increases
P01899209A0883|14 27|perfusate PCO2
P01899209A0883|38 48|perfusate H
P01899209A0883|73 81|decreases
P01899209A0883|98 110|contractility
P01899209A0883|114 131|oxygen consumption
P01899209A0883|132 133|r2
P01899287A0726|0 9|Expression
P01899287A0726|13 22|cell cycle
P01899287A0726|49 58|RNA levels
P01899287A0726|117 121|cells
P01899409T0000a|0 11|Determinants
P01899409T0000a|23 31|ischaemia
P01899409T0000a|35 62|revascularisation procedures
P01899409T0000a|67 78|thrombolysis
P01899409T0000a|94 121|tissue plasminogen activator
P01899409T0000a|137 145|occlusion
P01899846A0862|13 27|rbcL-rbcS locus
P01899846A0862|65 73|condition
P01899846A0862|93 98|growth
P01900194T0000|0 11|Relationship
P01900194T0000|32 56|NADH-ubiquinone reductase
P01900194T0000|81 91|hydrogenase
P01901405A0694|0 7|Analysis
P01901405A0694|10 24|mRNA expression
P01901405A0694|33 38|AT-BP1
P01901405A0694|42 47|AT-BP2
P01901405A0694|68 74|tissues
P01901443A0297|11 18|patients
P01901443A0297|28 48|maintenance valproate
P01901443A0297|70 80|hepatitis C
P01901443A0297|112 122|hepatitis C
P01901443A0297|151 159|steatosis
P01901443A0297|181 188|O stains
P01901664T0064|1 5|cases
P01901859A0000|0 6|UDP-Gal
P01901859A0000|8 15|Gal beta
P01901859A0000|20 32|4GlcNAc alpha
P01901859A0000|37 59|3-galactosyltransferase
P01901859A0000|71 89|glycosyltransferase
P01901859A0000|114 120|variety
P01901859A0000|132 138|species
P01901859A0000|154 162|exception
P01901859A0000|165 167|man
P01901859A0000|169 172|apes
P01901859A0000|177 193|Old World monkeys
P01901946A0243|10 24|oligonucleotide
P01901946A0243|38 49|SRE sequence
P01901946A0243|56 80|mouse c-fos gene promoter
P01901946A0243|121 125|probe
P01901946A0243|132 151|mobility shift assay
P01901946A0243|153 164|Southwestern
P01901946A0243|166 176|DNA-protein
P01901946A0243|178 185|blotting
P01901946A0243|218 240|affinity chromatography
P01901950T0000|0 20|Sequence requirements
P01901950T0000|32 51|transcription arrest
P01901950T0000|65 70|intron
P01901950T0000|76 91|mouse c-fos gene
P01903404A0688|15 31|ejection fraction
P01903404A0688|51 51|%
P01903404A0688|71 77|studies
P01903404A0688|100 105|artery
P01903404A0688|109 114|patent
P01903404A0688|129 129|%
P01903404A0688|146 146|p
P01903404A0688|155 161|changes
P01903404A0688|191 207|ejection fraction
P01903404A0688|232 247|perfusion status
P01903841A0125|8 22|lysine residues
P01903841A0125|34 43|spermidine
P01903841A0125|50 57|hypusine
P01903841A0125|77 88|modification
P01903841A0125|97 102|eIF-5A
P01903841A1449|3 27|plasmid shuffle technique
P01903841A1449|54 57|gene
P01903841A1449|71 74|form
P01903841A1449|87 93|failure
P01903841A1449|99 109|yeast cells
P01904154A0164|11 14|case
P01904154A0164|16 29|identification
P01904154A0164|33 48|characterization
P01904154A0164|51 61|transcripts
P01904154A0164|69 75|Ig loci
P01904154A0164|94 106|understanding
P01904154A0164|112 137|gene rearrangement process
P01904437A0000|0 12|Transcription
P01904437A0000|18 26|metH gene
P01904437A0000|93 109|metR gene product
P01904437A0000|110 128|DNA binding protein
P01904546A0671|0 9|Disruption
P01904546A0671|26 34|AAR1 gene
P01904546A0671|36 40|alpha
P01904546A0671|44 56|a/alpha cells
P01904546A0671|77 85|phenotype
P01904546A0671|93 108|a/alpha diploids
P01905199A0210|3 8|effect
P01905199A0210|11 18|ICRF-187
P01905199A0210|24 41|antitumor response
P01905199A0210|53 63|combination
P01905199A0210|66 68|ADR
P01905199A0210|72 74|WBH
P01905199A0210|96 100|order
P01905199A0210|109 119|alterations
P01905199A0210|136 140|index
P01905199A0210|166 183|modality treatment
P01905517A1076|3 5|ORF
P01905517A1076|39 46|features
P01905517A1076|54 72|sequence data bases
P01905517A1076|86 95|homologies
P01906111A1295|4 8|study
P01906111A1295|38 44|regimen
P01906111A1295|80 82|use
P01906111A1295|91 96|marrow
P01906111A1295|114 129|toxicity profile
P01906166A0119|0 10|Mitomycin-C
P01906166A0119|25 32|necrosis
P01906166A0119|36 45|ulceration
P01906166A0119|79 82|skin
P01906166A0119|90 96|tissues
P01906166A0119|108 126|drug administration
P01906509A0072|6 10|study
P01906509A0072|38 43|region
P01906509A0072|54 65|nidogen gene
P01906692A0321|0 12|INTERVENTIONS
P01906692A0321|14 21|Patients
P01906692A0321|30 34|rt-PA
P01906692A0321|36 42|heparin
P01906692A0321|47 53|aspirin
P01907265A0670|23 28|result
P01907265A0670|48 60|endonucleases
P01907265A0670|71 82|cell extract
P01907265A0670|109 129|DNA cleavage activity
P01907941A0275|13 26|I kappa B beta
P01907941A0275|31 45|I kappa B alpha
P01907941A0275|60 66|binding
P01907941A0275|69 71|Rel
P01907941A0275|77 88|kappa B site
P01909027A0922|0 16|Sequence analysis
P01909027A0922|30 47|DNA binding domain
P01909027A0922|48 50|ILF
P01909027A0922|60 67|homology
P01909027A0922|90 117|fork head DNA binding domain
P01909027A0922|142 158|protein fork head
P01909027A0922|161 166|family
P01909027A0922|169 178|hepatocyte
P01909027A0922|186 192|factors
P01909027A0922|194 198|HNF-3
P01909621A0119|18 29|hemodialyses
P01909621A0119|49 56|lithemia
P01909621A0119|67 72|ranges
P01909960A0134|11 19|injection
P01909960A0134|36 40|mg/kg
P01909960A0134|52 64|noradrenaline
P01909960A0134|66 67|NA
P01909960A0134|69 80|biosynthesis
P01909960A0134|90 90|%
P01909960A0134|108 120|concentration
P01909960A0134|123 137|normetanephrine
P01909960A0134|139 141|NMN
P01909960A0134|146 146|%
P01909960A0134|160 168|NA levels
P01909960A0134|171 171|%
P01910505A0000|6 23|wuzi yanzong pills
P01910505A0000|42 47|effect
P01910505A0000|50 65|cyclophosphamide
P01910505A0000|73 82|leukopenia
P01910505A0000|85 88|mice
P01911767T0000|0 8|Mutations
P01911767T0000|19 25|subunit
P01911767T0000|28 59|ribulosebisphosphate carboxylase
P01911767T0000|65 79|subunit binding
P01911767T0000|82 90|catalysis
P01913955A0177|13 19|changes
P01913955A0177|34 39|artery
P01913955A0177|60 67|increase
P01913955A0177|70 75|number
P01913955A0177|86 91|artery
P01913955A0177|105 119|muscularization
P01913955A0177|122 136|precursor cells
P01913955A0177|137 145|pericytes
P01913955A0177|161 165|cells
P01913955A0177|219 222|wall
P01913955A0177|231 241|muscle cell
P01913955A0177|256 259|wall
P01913955A0177|274 284|hypertrophy
P01913955A0177|288 298|hyperplasia
P01913955A0177|307 318|muscle cells
P01913955A0177|326 337|accumulation
P01913955A0177|346 351|amount
P01913955A0177|354 361|collagen
P01913955A0177|376 379|type
P01913955A0177|381 388|collagen
P01915580A0889|5 11|results
P01915580A0889|23 28|NZ-107
P01915580A0889|41 44|drug
P01915580A0889|51 59|treatment
P01915580A0889|71 76|asthma
P01915580A0889|97 112|airway responses
P01915580A0889|115 136|airway hyperreactivity
P01916168A0969|2 6|study
P01916168A0969|12 35|correlation coefficients
P01916168A0969|45 61|ISO2 measurements
P01916168A0969|74 85|ulcer margin
P01916168A0969|107 112|mucosa
P01916168A0969|117 126|delta ISO2
P01916168A0969|150 157|observer
P01916168A0969|174 181|learners
P01916405A0242|9 24|mucosa tattooing
P01916405A0242|26 32|persons
P01916405A0242|61 68|aerosols
P01916405A0242|86 90|forms
P01916405A0242|93 94|PC
P01916405A0242|96 97|DB
P01916405A0242|104 111|diseases
P01916405A0242|113 118|stages
P01916632A0431|8 17|production
P01916632A0431|20 23|PBMC
P01916632A0431|51 54|case
P01917943A0621a|0 16|Sequence analysis
P01917943A0621a|21 25|sMtCK
P01917943A0621a|41 49|sequences
P01917943A0621a|65 73|TATAA box
P01917943A0621a|84 93|base pairs
P01917943A0621a|94 95|bp
P01917943A0621a|104 127|transfection experiments
P01917943A0621a|150 159|expression
P01917943A0621a|170 177|plasmids
P01917943A0621a|185 226|chloramphenicol acetyltransferase reporter
P01917943A0621b|0 16|Sequence analysis
P01917943A0621b|21 25|sMtCK
P01917943A0621b|41 49|sequences
P01917943A0621b|65 73|TATAA box
P01917943A0621b|84 93|base pairs
P01917943A0621b|94 95|bp
P01917943A0621b|104 127|transfection experiments
P01917943A0621b|150 159|expression
P01917943A0621b|170 177|plasmids
P01917943A0621b|185 226|chloramphenicol acetyltransferase reporter
P01917962A0152|3 14|cDNA segment
P01917962A0152|28 77|immunoglobulin gene recombination signal sequences
P01917962A0152|83 94|cDNA segment
P01917962A0152|114 126|IL-2R L chain
P01917962A0152|156 162|control
P01917962A0152|168 180|SV40 promoter
P01918010A0000|0 17|Lipoprotein lipase
P01918010A0000|18 20|LPL
P01918010A0000|27 32|enzyme
P01918010A0000|41 62|lipoprotein metabolism
P01918010A0000|74 80|pattern
P01918010A0000|83 92|regulation
P01918010A0000|111 120|expression
P01918010A1730|0 7|Deletion
P01918010A1730|21 40|octanucleotide motif
P01918010A1730|47 53|plasmid
P01918010A1730|71 78|fragment
P01918010A1730|84 95|LPL promoter
P01918010A1730|114 123|% decrease
P01918010A1730|128 132|level
P01918010A1730|135 144|expression
P01918010A1730|158 174|3T3-L1 adipocytes
P01918010A1730|177 193|HepG2 hepatocytes
P01918070A0281|13 19|binding
P01918070A0281|30 46|T3 receptor alpha
P01918070A0281|46 54|T3R alpha
P01918070A0281|110 118|mutations
P01918070A0281|124 131|rGH T3RE
P01918070A0281|163 169|potency
P01918070A0281|184 190|changes
P01918070A0281|193 203|T3R binding
P01918073A0150|0 9|Comparison
P01918073A0150|34 64|TnIcardiac amino acid sequences
P01918073A0150|71 83|TnI sequences
P01918073A0150|101 108|presence
P01918073A0150|123 140|extension sequence
P01918073A0150|153 196|protein kinase A phosphorylation target site
P01918073A0150|217 223|segment
P01918073A0150|251 257|feature
P01918073A0150|260 262|TnI
P01918073A0150|303 312|divergence
P01918073A0150|348 357|troponin C
P01918073A0150|358 360|TnC
P01918073A0150|370 382|site sequence
P01918073A0150|405 414|adaptation
P01918073A0150|417 419|TnI
P01918073A0150|423 425|TnC
P01918073A0150|444 453|TnIcardiac
P01918073A0150|462 478|actin/TnC-binding
P01918073A0150|480 500|actomyosin-inhibitory
P01918073A0150|502 507|domain
P01918073A0150|524 542|sequence divergence
P01918073A0150|555 574|TnIcardiac sequences
P01918073A0150|587 593|absence
P01918073A0150|597 624|protein kinase C target site
P01918073A0150|645 651|feature
P01918073A0150|654 656|TnI
P01918073A0150|659 665|mammals
P01919831T0000|11 29|management casebook
P01921463T0000|2 18|ASSEMBLER routine
P01921463T0000|35 41|display
P01921463T0000|45 53|averaging
P01921463T0000|56 59|data
P01921463T0000|79 91|microcomputer
P01922082A0149|0 9|Expression
P01922082A0149|15 33|mouse TSH beta gene
P01922082A0149|47 50|rise
P01922082A0149|61 65|mRNAs
P01922082A0149|97 102|region
P01922734T0000|0 10|Habituation
P01922734T0000|31 37|neurons
P01922734T0000|49 53|snail
P01922734T0000|66 76|stimulation
P01922739A0336|17 20|ROSP
P01922739A0336|31 36|number
P01922739A0336|39 50|fluctuations
P01922739A0336|75 84|directions
P01922739A0336|109 117|amplitude
P01922739A0336|123 128|course
P01922739A0336|135 138|days
P01922739A0336|151 159|operation
P01922739A0336|195 200|values
P01922739A0336|206 209|ROSP
P01922739A0336|229 235|average
P01922739A0336|238 247|electrodes
P01922739A0336|262 266|level
P01922739A0336|272 281|dura mater
P01922739A0336|293 298|values
P01922739A0336|301 310|electrodes
P01922739A0336|325 329|level
P01922739A0336|335 343|pia mater
P01923167A0000|0 28|Blood flow velocity waveforms
P01923167A0000|46 64|Doppler examination
P01923167A0000|82 88|carotid
P01923167A0000|106 113|arteries
P01923167A0000|147 151|route
P01923167A0000|176 183|approach
P01923628T0001|12 19|analysis
P01923628T0001|22 24|DNA
P01923628T0001|30 43|flow cytometry
P01923628T0001|64 71|findings
P01923628T0001|76 80|cases
P01923628T0001|90 96|myxomas
P01923766A0485|0 16|Sequence analysis
P01923766A0485|30 37|addition
P01923766A0485|54 60|variant
P01923766A0485|70 81|mRNA species
P01923766A0485|107 114|splicing
P01923766A0485|129 137|exclusion
P01923766A0485|160 170|nucleotides
P01923766A0485|172 173|nt
P01923766A0485|193 196|exon
P01923803A0609|0 7|Position
P01923803A0609|14 23|isoleucine
P01923803A0609|37 59|SsoL12 protein sequence
P01923803A0609|68 76|AUA codon
P01923985A0111|0 7|Symptoms
P01923985A0111|16 21|action
P01923985A0111|24 42|mastocyte mediators
P01924315A0158|5 9|yeast
P01924315A0158|34 46|copper levels
P01924315A0158|55 61|control
P01924315A0158|69 73|level
P01924315A0158|76 90|SOD1 expression
P01924920A0115|10 16|samples
P01924920A0115|18 30|Mobiluncus SP
P01924920A0115|50 50|%
P01924920A0115|57 69|Gram staining
P01924920A0115|81 81|%
P01924920A0115|87 99|microorganism
P01924920A0115|113 120|agar RLK
P01924920A0115|132 141|atmosphere
P01925092A0000|8 20|investigators
P01925092A0000|48 52|blood
P01925092A0000|63 68|retina
P01925092A0000|71 74|part
P01925092A0000|98 105|meshwork
P01925092A0304|11 15|hours
P01925092A0304|25 31|animals
P01925092A0304|58 66|treatment
P01925092A0304|74 83|micrograms
P01925092A0304|86 113|tissue plasminogen activator
P01925092A0304|122 127|volume
P01925092A0304|141 146|saline
P01927421A0181|16 27|examinations
P01927421A0181|55 63|nystagmus
P01927421A0181|78 86|nystagmus
P01927421A0181|97 105|nystagmus
P01927845A0107|8 17|morphology
P01927845A0107|23 29|lesions
P01927845A0107|58 66|disorders
P01927845A0107|68 72|Bowen
P01927845A0107|75 81|disease
P01928923A0000|0 12|Equine amnion
P01928923A0000|19 39|yeast cell derivative
P01928923A0000|85 100|wound medicament
P01928923A0000|118 126|treatment
P01928923A0000|140 145|wounds
P01928923A0000|157 163|portion
P01928923A0000|169 173|limbs
P01928923A0000|176 181|horses
P01930470A0337|21 29|incidence
P01930470A0337|44 46|PTH
P01930470A0337|58 77|American Association
P01930470A0337|79 89|Blood Banks
P01930470A0337|90 93|AABB
P01930470A0337|106 112|testing
P01930470A0337|146 152|markers
P01930470A0337|165 169|units
P01930470A0337|172 176|blood
P01930660T0000|12 24|growth factor
P01930660T0000|26 30|IGF-1
P01930660T0000|38 45|patients
P01931966A0490|0 5|Fusion
P01931966A0490|8 16|ubiquitin
P01931966A0490|19 24|pADPRP
P01931966A0490|37 41|yield
P01931966A0490|44 49|pADPRP
P01931966A0490|96 101|enzyme
P01932650A0435|2 6|group
P01932650A0435|11 18|patients
P01932650A0435|50 63|drainage blood
P01932650A0435|72 76|hours
P01932650A0435|82 90|operation
P01932650A0435|97 109|concentration
P01932650A0435|123 126|MBRS
P01932695A1155|3 13|suppression
P01932695A1155|45 60|expression assay
P01932695A1155|79 95|barley endosperms
P01933614A0406|3 8|effect
P01933614A0406|11 27|salmon calcitonin
P01933614A0406|32 36|spray
P01933614A0406|39 43|women
P01933614A0406|59 70|osteoporosis
P01934378A1219|8 38|muscle metaboreceptor responses
P01934378A1219|50 62|heart failure
P01934378T0000|8 47|muscle metaboreceptor exercise responses
P01934378T0000|60 72|heart failure
P01936213T0000|0 9|Evaluation
P01936213T0000|25 35|drug effect
P01936213T0000|37 53|membrane fluidity
P01936348A0155|3 14|examinations
P01936348A0155|33 38|groups
P01936348A0155|49 56|AmF/SnF2
P01936348A0155|60 63|resp
P01936997A0795|0 18|RNA gel retardation
P01936997A0795|20 39|competition analyses
P01936997A0795|51 65|TRP-185 binding
P01936997A0795|89 110|TAR RNA loop sequences
P01937790A0292|3 9|vaccine
P01937790A0292|45 52|children
P01937790A0292|56 61|adults
P01937989A0383|4 9|groups
P01937989A0383|31 39|induction
P01937989A0383|56 59|test
P01937989A0383|66 67|R2
P01938178T0000|0 11|Applications
P01938178T0000|31 38|analysis
P01938178T0000|52 55|P300
P01939131A0871|3 11|construct
P01939131A0871|29 34|BW2001
P01939131A0871|36 41|xth-11
P01939131A0871|43 47|nfo-2
P01939131A0871|49 60|strain cells
P01939199A0588|16 20|TFIID
P01939199A0588|39 51|transcription
P01939199A0588|73 80|extracts
P01939199A0588|106 119|TFIID fraction
P01939199A0588|123 132|HeLa cells
P01939199A0588|153 157|level
P01939199A0588|160 172|transcription
P01939827A0150|10 21|pretreatment
P01939827A0150|42 60|oxide surface layer
P01939827A0150|62 76|titanium powder
P01939827A0150|96 108|precipitation
P01939827A0150|113 121|solutions
P01939827A0150|133 144|mmol/L CaCl2
P01939827A0150|146 158|mmol/L KH2PO4
P01939827A0150|161 172|mmol/L Hepes
P01939827A0150|173 174|pH
P01939827A0150|190 202|precipitation
P01939827A0150|217 225|solutions
P01939827A0150|239 250|mmol/L CaCl2
P01939827A0150|254 266|mmol/L KH2PO4
P01939827A0150|269 280|mmol/L Hepes
P01939827A0150|281 282|pH
P01939827A0150|291 300|degrees C.
P01939878A0765|14 27|solidification
P01939878A0765|58 63|casein
P01939878A0765|107 114|patients
P01939878A0765|135 141|acidity
P01939899A2043|7 11|model
P01939899A2043|44 50|account
P01939899A2043|56 62|effects
P01939899A2043|72 80|variables
P01939899A2043|83 88|number
P01939899A2043|91 95|tones
P01939899A2043|99 104|amount
P01939899A2043|107 118|perturbation
P01939899A2043|121 128|ABSTRACT
P01939899A2043|143 147|WORDS
P01939906A0233|4 17|generalization
P01939906A0233|20 22|MFP
P01939906A0233|67 79|cost function
P01939906A0233|96 107|search space
P01939906A0233|112 122|environment
P01939906A0233|126 131|source
P01939906A0233|145 153|solutions
P01939906A0233|159 171|wave equation
P01939906A0233|194 212|optimization method
P01939906A0233|223 241|parameter landscape
P01939906A0233|253 259|minimum
P01939906A0233|265 277|cost function
P01942033T0000|0 12|Determination
P01942033T0000|17 29|RNA structure
P01942033T0000|39 57|splicing inhibition
P01942033T0000|75 78|exon
P01943184A1050|11 15|cells
P01943184A1050|26 35|University
P01943184A1050|38 55|Wisconsin solution
P01943184A1050|63 68|trypan
P01943184A1050|83 83|%
P01943184A1050|90 96|% cells
P01943184A1050|104 104|p
P01945430A0660|11 19|technique
P01945430A0660|60 68|ear fluid
P01945430A0660|81 89|procedure
P01945430A0660|106 119|labyrinthotomy
P01945430A0660|131 146|neuroma suspects
P01947449A0191|3 8|effect
P01947449A0191|11 30|diffusion limitation
P01947449A0191|45 49|terms
P01947449A0191|55 59|ratio
P01947449A0191|62 82|uptake/O2 requirement
P01947449A0191|84 91|fraction
P01947449A0191|109 112|area
P01947449A0191|144 154|requirement
P01947449A0191|158 168|unit volume
P01947449A0191|196 198|PO2
P01947449A0191|201 203|PO2
P01947449A1082|3 22|Diffusion limitation
P01947449A1082|40 49|model sets
P01947449A1082|61 77|requirement value
P01947449A1082|119 129|requirement
P01947449A1082|164 169|models
P01947449A1082|188 204|cylinder diameter
P01948783A0000|19 24|effect
P01948783A0000|27 33|Estulic
P01948783A0000|62 67|period
P01948783A0000|85 92|patients
P01952827A0215|5 8|time
P01952827A0215|14 20|seizure
P01952827A0215|25 31|patient
P01952827A0215|47 57|test phrase
P01954355A0997|0 18|Monitoring patients
P01954355A0997|27 34|leukemia
P01954355A0997|38 41|IL-1
P01954355A0997|45 54|TNF levels
P01954355A0997|75 80|course
P01954355A0997|83 89|disease
P01954355A0997|107 112|causes
P01954355A0997|122 129|episodes
P01954835A0000|0 22|Echinococcus granulosus
P01954835A0000|47 65|aspiration cytology
P01954835A0000|68 76|lung cyst
P01954835A0000|92 97|female
P01954835A0000|107 114|Missouri
P01956285A0000|3 10|sequence
P01956285A0000|30 40|nucleotides
P01956285A0000|56 64|bet genes
P01956285A0000|109 139|choline-glycine betaine pathway
P01956491A0095|6 14|treatment
P01956491A0095|17 30|amphotericin B
P01956491A0095|32 40|mg/kg/day
P01956491A0095|79 93|filtration rate
P01956491A0095|94 96|GFR
P01956491A0095|115 123|clearance
P01956491A0095|127 146|creatinine clearance
P01956491A0095|172 177|ml/min
P01956491A0095|194 203|comparison
P01956491A0095|221 224|rats
P01956491A0095|251 256|ml/min
P01958368A0556|0 8|Evolution
P01958368A0556|11 17|lesions
P01958368A0556|49 59|progression
P01958368A0556|75 80|stages
P01958368A0556|86 111|vitelliform classification
P01958821T0000|8 30|fluorescence microscopy
P01958821T0000|38 49|cell biology
P01960974A0000|0 6|Toluene
P01960974A0000|12 19|chemical
P01960974A0000|43 47|cases
P01960974A0000|65 72|solvents
P01961213A0150|23 32|HCB-levels
P01961213A0150|44 54|breast milk
P01961213A0150|67 71|years
P01961747A0000|1 31|herpesvirus proteinase activity
P01961747A0000|88 93|enzyme
P01961747A0000|97 111|substrate genes
P01961747A0000|122 140|transfection assays
P01961996A0522|0 6|Adult H
P01961996A0522|13 13|R
P01961996A0522|37 46|preference
P01961996A0522|65 75|opportunity
P01963419A0501|7 27|silver liquid chamber
P01963419A0501|47 57|MeV protons
P01963419A0501|59 63|water
P01963419A0501|94 96|13N
P01963419A0501|102 104|16O
P01963419A0501|106 106|p
P01963419A0501|108 112|alpha
P01963419A0501|114 125|13N reaction
P01963419A0501|128 130|18F
P01963419A0501|132 143|fluoride ion
P01963419A0501|148 150|18O
P01963419A0501|152 152|p
P01963419A0501|154 154|n
P01963419A0501|156 167|18F reaction
P01963438T0000|13 29|electron transfer
P01963438T0000|31 42|cytochrome c
P01963438T0000|55 65|polypyrrole
P01963438T0000|69 77|methylene
P01963438T0000|82 97|polypyrrole film
P01963438T0000|105 114|electrodes
P01963858T0001|9 18|activation
P01963858T0001|21 40|adrenaline secretion
P01963858T0001|45 47|rat
P01963858T0001|57 71|neuroglycopenia
P01963858T0001|83 95|microdialysis
P01964989A0145|0 14|Urine specimens
P01964989A0145|30 42|phencyclidine
P01964989A0145|44 46|PCP
P01964989A0145|97 100|acid
P01964989A0145|102 111|9-THC-COOH
P01964989A0145|132 146|sodium chloride
P01964989A0145|147 152|bleach
P01964989A0145|154 160|vinegar
P01964989A0145|162 180|potassium hydroxide
P01964989A0145|187 190|soap
P01964989A0145|192 201|2-propanol
P01964989A0145|206 212|ammonia
P01967130A0645|12 25|pair EFIA cDNA
P01967130A0645|41 52|acid protein
P01967130A0645|103 122|DNA binding proteins
P01968043A0908|20 30|cDNA clones
P01968043A0908|56 61|insert
P01968043A0908|63 68|pASB-1
P01968043A0908|88 99|orientations
P01968061A0371|0 2|Sci
P01968156T0000|0 19|Dose standardisation
P01968156T0000|21 35|botulinum toxin
P01968224A0119|3 17|coding sequence
P01968224A0119|35 53|residue polypeptide
P01968224A0119|81 86|intron
P01968224A0119|91 100|base pairs
P01968224A0119|101 102|bp
P01968224A0119|115 115|%
P01968224A0119|128 146|amino acid sequence
P01968224A0119|160 163|PCNA
P01968224A0119|181 183|rat
P01968224A0119|192 208|PCNA polypeptides
P01968224A0119|228 234|repeats
P01968224A0119|237 243|leucine
P01968224A0119|259 264|region
P01970560A1024|13 19|fusions
P01970560A1024|25 28|aroF
P01970560A1024|39 45|regions
P01970560A1024|48 51|lacZ
P01970560A1024|92 95|copy
P01970560A1024|109 118|chromosome
P01970560A1024|120 144|beta-Galactosidase assays
P01970560A1024|160 169|regulation
P01970560A1024|172 191|aroF-lacZ expression
P01970560A1024|212 225|TyrR repressor
P01970560A1024|248 256|operators
P01970560A1024|263 271|organisms
P01970560A1024|286 295|efficiency
P01970801A0925|25 29|genes
P01970801A0925|39 42|Ly-1
P01970801A0925|46 49|CD20
P01970801A0925|51 54|OSBP
P01970801A0925|83 87|group
P01970801A0925|97 99|arm
P01970801A0925|102 111|chromosome
P01970801A0925|138 140|end
P01970801A0925|143 152|chromosome
P01970801A0925|160 164|mouse
P01970926A0000|6 15|exercise K
P01970926A0000|41 46|muscle
P01970926A0000|50 57|plasma K
P01970926A0000|58 76|concentration rises
P01970984A0668|9 17|treatment
P01970984A0668|19 40|serum estradiol levels
P01970984A0668|51 58|groups E
P01970984A0668|59 59|T
P01970984A0668|63 63|E
P01970984A0668|70 77|group C.
P01971191A1271|32 38|agonist
P01971191A1271|40 52|isoproterenol
P01971191A1271|63 71|influence
P01971191A1271|82 92|capacitance
P01971191A1271|95 106|liver volume
P01971191A1271|108 111|dogs
P01971191A1271|129 146|outflow resistance
P01971191A1271|158 163|agents
P01971191A1271|170 178|histamine
P01972379T0042|0 11|DNA sequence
P01972379T0042|14 22|evolution
P01972379T0042|28 37|CPS domain
P01972379T0042|48 54|hamster
P01972379T0042|70 80|protein CAD
P01973384A0206|28 40|binding sites
P01973384A0206|70 76|ability
P01973384A0206|86 98|transcription
P01973384A0206|123 129|embryos
P01974550A0362|14 16|CBF
P01974550A0362|32 52|hexamethonium bromide
P01974550A0362|54 61|mg/kg iv
P01974550A0362|63 81|ipratropium bromide
P01974550A0362|85 99|microgram/kg iv
P01974550A0362|101 112|indomethacin
P01974550A0362|115 122|mg/kg iv
P01974550A0362|140 147|% saline
P01974876A1051|15 54|restriction fragment length polymorphism
P01974876A1051|67 69|DNA
P01974876A1051|85 95|individuals
P01974876A1051|104 115|enzyme BglII
P01975157A0836|10 23|transformation
P01975157A0836|26 27|pH
P01975157A0836|44 50|results
P01975428A0151|0 8|Telomeres
P01975428A0151|26 32|fusions
P01975428A0151|50 60|degradation
P01975428A0151|71 73|end
P01975428A0151|85 96|DNA molecule
P01975428A0151|111 118|function
P01975428A0151|121 133|cell division
P01976638A1135|39 44|region
P01976638A1135|68 76|sequences
P01977585A0222|9 14|enzyme
P01977585A0222|63 67|cells
P01977585A0222|107 114|subunits
P01977585A0222|135 148|protein kinase
P01977856A1036|4 8|study
P01977856A1036|21 25|BSPMs
P01977856A1036|40 49|assessment
P01977856A1036|52 54|AMI
P01977856A1036|57 61|terms
P01977856A1036|64 72|diagnosis
P01977856A1036|74 81|location
P01977856A1036|85 90|extent
P01977856A1036|103 109|infarct
P01978834A0076|7 39|abomasum lambda gt11 cDNA library
P01978834A0076|62 69|antibody
P01978834A0076|86 115|rabbit H,K-ATPase beta subunit
P01978857A0504|9 11|use
P01978857A0504|14 31|laboratory testing
P01978857A0504|41 50|monitoring
P01978857A0504|53 67|CD4 cell counts
P01982061A0615|9 16|TATA box
P01982061A0615|50 78|transcription initiation site
P01982061T0000|0 15|Characterization
P01982061T0000|23 25|end
P01982061T0000|53 68|hamster CAD gene
P01982190T0001|5 13|cirrhosis
P01982190T0001|22 29|modality
P01982190T0001|35 43|evolution
P01982190T0001|51 59|hepatitis
P01982997A1104|0 10|Examination
P01982997A1104|28 58|transcription factor expression
P01982997A1104|66 76|MDI regimen
P01982997A1104|88 89|RA
P01982997A1104|118 127|expression
P01982997A1104|130 139|c-Jun mRNA
P01982997A1104|162 171|expression
P01982997A1104|174 178|c-Fos
P01982997A1104|182 192|Jun-B mRNAs
P01983026A0483|8 17|heart rate
P01983026A0483|29 36|pressure
P01983026A0483|47 52|degree
P01983026A0483|54 56|min
P01983026A0483|62 71|intubation
P01983026A0483|85 101|CA concentrations
P01983026A0483|121 132|study period
P01984665T0000|0 9|Processing
P01984665T0000|11 19|secretion
P01984665T0000|24 39|immunoreactivity
P01984665T0000|42 48|carboxy
P01984665T0000|68 99|dengue-2 virus envelope proteins
P01984665T0000|114 118|cells
P01984665T0000|132 144|baculoviruses
P01985301T0000|8 14|therapy
P01985301T0000|19 24|MK-801
P01985301T0000|28 37|nimodipine
P01985301T0000|41 50|protection
P01985301T0000|61 72|brain damage
P01985920A0156|7 15|screening
P01985920A0156|19 40|rat liver cDNA library
P01985920A0156|44 64|oligonucleotide probe
P01985920A0156|78 102|rat SCP2 protein sequence
P01985920A0156|118 132|pair cDNA clone
P01985920A0156|151 171|SCP2 protein sequence
P01985920T0000|0 6|Cloning
P01985920T0000|8 17|expression
P01985920T0000|22 40|nucleotide sequence
P01985920T0000|42 73|rat liver sterol carrier protein
P01985920T0000|71 75|cDNAs
P01985924A0554|3 10|addition
P01985924A0554|24 30|complex
P01985924A0554|59 66|subunits
P01985924A0554|80 82|pol
P01985924A0554|85 94|holoenzyme
P01985924A0554|109 122|chromatography
P01985924A0554|128 135|presence
P01985924A0554|138 141|urea
P01985924A0554|168 186|initiation activity
P01985924A0554|188 190|pol
P01985924A0554|193 197|delta
P01986225A0250|15 28|identification
P01986225A0250|31 33|HSF
P01986225A0250|39 51|fission yeast
P01986241A0117|0 8|Induction
P01986241A0117|20 36|ACE1 gene product
P01986241A0117|56 60|sites
P01986241A0117|66 80|promoter region
P01986241A0117|85 93|CUP1 gene
P01986254A0452|0 24|Gel mobility shift assays
P01986254A0452|37 44|E6 motif
P01986254A0452|68 74|complex
P01986254A0452|77 84|addition
P01986254A0452|98 101|band
P01986254A0452|113 119|T cells
P01986254A0452|122 131|HeLa cells
P01986360A0000|5 10|clones
P01986360A0000|19 61|interferon response element binding factors
P01986360A0000|79 119|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|123 125|32P
P01986360A0000|143 148|trimer
P01986360A0000|154 158|mouse
P01986360A0000|166 223|oligoadenylate synthetase gene interferon response element
P01986360A0000|222 226|probe
P01988041A0281|3 10|sequence
P01988041A0281|17 22|clones
P01988041A0281|55 72|BAL cDNA structure
P01989561A0100|3 13|application
P01989561A0100|21 31|instruments
P01989561A0100|38 46|occlusion
P01989561A0100|61 65|aorta
P01989561A0100|80 96|perfusion cannula
P01989561A0100|124 127|apex
P01989561A0100|133 137|heart
P01989561A0100|173 179|venting
P01989999A0000|16 25|synthetase
P01989999A0000|27 29|IMP
P01989999A0000|31 48|L-aspartate ligase
P01989999A0000|49 51|GDP
P01989999A0000|54 55|EC
P01989999A0000|80 83|role
P01989999A0000|86 104|purine biosynthesis
P01989999A0000|130 139|conversion
P01989999A0000|142 144|IMP
P01989999A0000|147 149|AMP
P01990254A0791|0 16|Immunophenotyping
P01990254A0791|23 27|cases
P01990254A0791|52 62|cell origin
P01990254A0791|77 87|cell origin
P01990266A0678|11 34|UV cross-linking studies
P01990266A0678|46 50|UHF-1
P01990266A0678|71 78|mobility
P01990266A0678|81 94|sodium dodecyl
P01990266A0678|112 115|gels
P01990266A0678|133 135|kDa
P01990266A0678|162 169|proteins
P01990266A0678|185 192|promoter
P01990266A0678|204 207|site
P01991521A0481|3 9|results
P01991521A0481|23 32|conclusion
P01991521A0481|57 64|activity
P01991521A0481|77 86|G4 content
P01991521A0481|108 114|muscles
P01992459A0000|11 21|interaction
P01992459A0000|47 53|element
P01992459A0000|64 90|immunodeficiency virus mRNA
P01992459A0000|90 92|RRE
P01992459A0000|97 116|Rev response element
P01992459A0000|135 145|protein Rev
P01992459A0000|167 176|regulation
P01992459A0000|182 187|export
P01992459A0000|214 217|mRNA
P01992459A0000|225 231|nucleus
P01992459A0000|237 245|cytoplasm
P01992742A0000|13 19|records
P01992742A0000|25 32|patients
P01992742A0000|42 49|neuritis
P01992742A0000|74 79|period
P01992953A0247|7 12|levels
P01992953A0247|23 33|abnormality
P01992953A0247|71 81|specificity
P01992953A0247|87 90|test
P01992953A0247|110 117|patients
P01992953T0000|0 23|Alanine aminotransferase
P01992953T0000|33 40|practice
P01993181T0000|0 27|Nucleotide sequence analysis
P01993181T0000|48 79|PpG7 salicylate hydroxylase gene
P01993181T0000|78 81|nahG
P01993181T0000|100 105|region
P01993656A1860|6 14|ARF cDNAs
P01993656A1860|69 75|guanine
P01993656A1860|94 101|proteins
P01995951A0000|15 20|repeat
P01995951A0000|22 24|LTR
P01995951A0000|36 57|immunodeficiency virus
P01995951A0000|58 60|HIV
P01995951A0000|82 86|sites
P01995951A0000|108 117|factor Sp1
P01996312A0454|0 2|DNA
P01996312A0454|7 9|PCR
P01996312A0454|43 65|lambda gt11 cDNA clones
P01996312A0454|91 101|Dd kinase-2
P01997465A0276|17 23|changes
P01997465A0276|29 32|area
P01997465A0276|35 41|alveoli
P01997465A0276|45 49|septa
P01997465A0276|58 73|collagen content
P01997465A0276|83 87|weeks
P01997465A0276|93 103|irradiation
P01999035A0383|8 16|follow-up
P01999035A0383|37 44|interval
P01999035A0383|50 54|years
P01999035A0383|57 66|Caerphilly
P01999035A0383|73 77|years
P01999035A0383|80 88|Speedwell
P01999035A0383|98 107|IHD events
P01999459A0795|0 1|A.
P01999999T0001|9 16|luxation
P01999999T0001|28 33|injury
P01999999T0001|62 70|treatment
P02000093A0794|0 8|Landsberg
P02000093A0794|10 13|La-O
P02000093A0794|18 19|cv
P02001033A1907|2 8|summary
P02001033A1907|26 39|concentrations
P02001033A1907|41 50|desflurane
P02001033A1907|54 63|isoflurane
P02001033A1907|90 96|effects
P02001033A1907|111 117|absence
P02001033A1907|120 124|drugs
P02001033A1907|145 152|reflexes
P02001033A1907|154 163|desflurane
P02001033A1907|188 195|activity
P02001033A1907|211 218|decrease
P02001033A1907|229 236|pressure
P02002051A0276|15 23|isolation
P02002051A0276|38 47|cDNA clone
P02002051A0276|77 83|isoform
P02002051A0276|95 103|C-subunit
P02002051T0000|0 13|Isoform C beta
P02002051T0000|23 26|form
P02002051T0000|47 53|subunit
P02002051T0000|70 83|protein kinase
P02002511A0637|7 18|applications
P02002511A0637|21 34|PB-PK modeling
P02002511A0637|49 56|problems
P02002511A0637|75 82|examples
P02004521A0266|0 7|Patients
P02004521A0266|27 42|CT abnormalities
P02004521A0266|68 74|disease
P02004705A0686|3 15|cdr1 sequence
P02004705A0686|38 48|amino acids
P02004705A0686|63 70|fragment
P02004705A0686|82 88|product
P02004705A0686|100 101|Mr
P02005547A0121|15 27|understanding
P02005547A0121|49 56|pathways
P02005547A0121|90 100|development
P02005547A0121|115 132|hyperbilirubinemia
P02005547A0121|149 156|jaundice
P02005547A0121|161 172|practitioner
P02005547A0121|201 206|family
P02005547A0121|222 226|child
P02005547A0121|229 235|illness
P02006558A0000|0 22|Displacement thresholds
P02006558A0000|34 38|sites
P02006558A0000|55 60|vision
P02007045A0092|3 9|authors
P02007045A0092|17 20|case
P02007045A0092|40 49|irrigation
P02007045A0092|53 62|brain cyst
P02007045A0092|100 107|distress
P02008982A0463|0 4|ELISA
P02008982A0463|20 31|contribution
P02008982A0463|37 45|diagnosis
P02008982A0463|48 59|tuberculosis
P02008982A0463|75 86|sputum smear
P02010912A0366|6 10|paper
P02010912A0366|29 33|study
P02010912A0366|39 47|structure
P02010912A0366|64 67|role
P02010912A0366|73 90|MalT binding sites
P02010912A0366|121 125|pulAp
P02010912A0366|129 143|pulCp promoters
P02011924A0729|15 20|number
P02011924A0729|23 30|patients
P02011924A0729|37 41|basis
P02011924A0729|48 53|report
P02011924A0729|74 79|MU/day
P02011924A0729|82 90|alpha-IFN
P02011924A0729|103 111|treatment
P02011924A0729|115 122|patients
P02011924A0729|132 144|cell leukemia
P02012097T0000|10 21|fluctuations
P02012097T0000|32 42|parasitemia
P02012097T0000|45 73|Plasmodium falciparum malaria
P02012789A0051|10 23|family history
P02014928T0000|12 17|asthma
P02014928T0000|21 39|rhinoconjunctivitis
P02014928T0000|44 53|inhalation
P02014928T0000|73 92|serum albumin powder
P02015921A0523|8 18|subdivision
P02015921A0523|21 32|Category pN1
P02015921A0523|36 39|pN1a
P02015921A0523|41 50|metastasis
P02015921A0523|59 62|node
P02015921A0523|67 70|pN1b
P02015921A0523|81 85|nodes
P02016053A0752|0 30|Amino acid sequence comparisons
P02016053A0752|33 44|E74A protein
P02016053A0752|76 81|region
P02016053A0752|99 117|amino acid residues
P02016053A0752|165 184|DNA binding activity
P02016769A0720|22 30|strengths
P02016769A0720|36 44|promoters
P02016769A0720|67 74|contexts
P02017159A0646|0 5|Grasso
P02017159A0646|10 11|A.
P02017271A0502|6 11|months
P02017271A0502|21 31|improvement
P02017271A0502|34 41|strength
P02017271A0502|73 80|patients
P02017271A0502|86 89|none
P02017271A0502|93 100|controls
P02017414A0307|0 2|Age
P02017414A0307|5 7|POI
P02017414A0307|11 19|asymptote
P02017414A0307|40 48|Line RBC2
P02017414A0307|55 61|Line F.
P02019572A0000|13 25|DNA sequences
P02019572A0000|44 53|expression
P02019572A0000|59 83|rat liver pyruvate kinase
P02019572A0000|87 91|genes
P02019572A0000|94 99|series
P02019572A0000|102 111|constructs
P02019572A0000|122 169|chloramphenicol acetyltransferase reporter genes
P02019572A0000|191 199|fragments
P02019572A0000|209 218|base pairs
P02019572A0000|219 220|bp
P02019572A0000|239 251|gene cap site
P02019572A0000|277 286|expression
P02019572A0000|292 303|introduction
P02019572A0000|308 327|hepatoma HepG2 cells
P02019572A0000|327 341|rat hepatocytes
P02019572A0000|350 356|culture
P02019572A0000|358 371|fibroblast LTK
P02019572A0000|372 376|cells
P02019572A0000|386 396|C2C12 cells
P02019572A0000|400 408|CHO cells
P02020082A0356|3 13|disturbance
P02020082A0356|25 36|gas exchange
P02020082A0356|56 60|value
P02020082A0356|63 67|AaDO2
P02020082A0356|98 108|dysfunction
P02020082A0356|113 117|AaDO2
P02020082A0356|134 145|relationship
P02020082A0356|169 178|parameters
P02020082A0356|191 200|difference
P02020082A0356|208 221|plasma colloid
P02020082A0356|228 235|pressure
P02020082A0356|239 241|PCW
P02020314A1290|1 4|dose
P02020314A1290|12 35|micrograms/kg/day GM-CSF
P02020314A1290|45 52|severity
P02020314A1290|55 65|neutropenia
P02020314A1290|69 84|thrombocytopenia
P02020314A1290|90 130|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|158 169|chemotherapy
P02020314A1290|180 185|cancer
P02020314A1290|191 196|future
P02021630A1104|5 15|differences
P02021630A1104|47 58|interactions
P02021630A1104|69 75|protein
P02021630A1104|79 81|DNA
P02021630A1104|92 107|guanine N7 sites
P02021630A1104|116 121|groove
P02021630A1104|124 126|DNA
P02021630A1104|131 141|alterations
P02021630A1104|144 174|DNA phosphodiester conformation
P02021630A1104|182 196|protein binding
P02022188A0112|11 18|analysis
P02022188A0112|38 48|BJ1 protein
P02022188A0112|64 74|nucleosomes
P02022188A0112|92 100|chromatin
P02022188A0112|103 108|agents
P02022188A0112|129 131|DNA
P02022188A0112|160 182|mobility group proteins
P02022188A0112|182 185|HMGs
P02022188A1463|17 29|gene products
P02022188A1463|38 46|chromatin
P02022188A1463|81 95|order structure
P02022188A1463|98 109|prerequisite
P02022188A1463|123 137|gene expression
P02022920A0334|3 17|C4BP alpha gene
P02022920A0334|45 54|exon codes
P02022920A0334|68 78|nucleotides
P02022920A0334|86 88|UTR
P02023097A0000|8 34|immunodeficiency virus type
P02023097A0000|35 39|HIV-1
P02023097A0000|41 51|Rev protein
P02023097A0000|81 89|regulator
P02023097A0000|107 121|gene expression
P02023097A0000|136 152|virus replication
P02023421A0343|7 19|proliferation
P02023421A0343|22 32|fibroblasts
P02023421A0343|36 53|collagen synthesis
P02023421A0343|63 70|increase
P02023421A0343|83 90|strength
P02023421A0343|102 107|effect
P02023421A0343|110 122|wound healing
P02023421A0343|168 173|agents
P02023904A0120|3 11|CDC7 gene
P02023904A0120|25 34|AUG codons
P02023904A0120|44 66|translation start sites
P02023904A0120|95 102|proteins
P02024252A0000|9 13|years
P02024252A0000|22 26|total
P02024252A0000|32 38|persons
P02024252A0000|47 65|disability pensions
P02024252A0000|70 81|municipality
P02024252A0000|84 92|Nordreisa
P02024252A0000|103 108|Norway
P02024488A0506|0 3|HeLa
P02024488A0506|7 23|Jurkat cell lines
P02024488A0506|33 40|nef gene
P02024488A0506|51 62|CMV promoter
P02024488A0506|67 75|HIV-1 LTR
P02024488A0506|89 99|coselection
P02024488A0506|103 121|neomycin resistance
P02024625A0202|0 10|Differences
P02024625A0202|24 35|presentation
P02024625A0202|47 56|appearance
P02024625A0202|65 69|cases
P02024625A0202|86 97|similarities
P02024625A0202|114 121|features
P02024791A0582|0 11|MEASUREMENTS
P02024791A0582|15 26|MAIN RESULTS
P02024791A0582|33 38|groups
P02024791A0582|52 56|entry
P02024791A0582|64 68|study
P02024791A0582|83 99|FEV1 measurements
P02024791A0582|104 115|L atropine/0
P02024791A0582|118 133|L metaproterenol
P02024791A0582|134 134|P
P02024816A0521|7 11|ELISA
P02024816A0521|34 42|protein A
P02024816A0521|43 46|SP-A
P02024816A0521|72 89|pneumonia patients
P02025515A0979|2 5|view
P02025515A0979|16 19|t1/2
P02025515A0979|32 40|doses/day
P02026144A0741|8 14|control
P02026144A0741|17 30|GUS expression
P02026144A0741|68 76|sequences
P02026144A0741|78 81|NRS1
P02026144A0741|97 100|NRS2
P02026144A0741|133 143|domain UAS1
P02026147A0000|11 13|Ca2
P02026147A0000|16 25|calmodulin
P02026147A0000|27 29|CaM
P02026147A0000|41 54|protein kinase
P02026147A0000|55 64|CaM kinase
P02026147A0000|72 76|yeast
P02026147A0000|104 113|properties
P02026147A0000|132 135|type
P02026147A0000|138 148|CaM kinases
P02026461A0760|6 10|cases
P02026461A0760|44 54|individuals
P02026461A0760|78 82|panel
P02026461A0760|85 90|probes
P02026491A0399|3 10|patients
P02026491A0399|30 36|effects
P02026491A0399|41 43|NMF
P02026491A0399|60 66|seizure
P02026491A0399|102 105|pain
P02027839A0250|3 9|muscles
P02027839A0250|25 29|group
P02027839A0250|52 52|P
P02027839A0250|65 70|values
P02027839A0250|83 89|density
P02027839A0250|93 101|capillary
P02027839A0250|104 114|fiber ratio
P02027839A0250|150 157|distance
P02027839A0250|180 184|group
P02028125A0101|3 12|prevalence
P02028125A0101|28 36|infection
P02028125A0101|51 63|AIDS patients
P02028125A0101|69 79|probability
P02028125A0101|89 103|tumour response
P02028125A0101|112 125|cancer therapy
P02028125A0101|154 161|examples
P02028125A0101|168 176|functions
P02029468A0296|0 23|Serum TNF concentrations
P02029468A0296|36 44|diagnosis
P02029468A0296|75 90|reference limits
P02029468A0296|92 95|week
P02030910A0000|7 12|clones
P02030910A0000|33 41|ETS1 gene
P02030910A0000|84 95|organization
P02030910A1070|0 33|Polymerase chain reaction analysis
P02030910A1070|33 41|ETS1 cDNA
P02030910A1070|67 74|products
P02030910A1070|97 104|splicing
P02033038A0309|23 37|E3 polypeptides
P02033038A0309|42 46|bands
P02033038A0309|71 76|pellet
P02033038A0309|108 109|E3
P02033038A0309|130 137|fraction
P02033062A1169|6 22|promotor function
P02033062A1169|31 35|genes
P02033062A1169|58 66|fragments
P02033062A1169|69 81|chicken IGF-I
P02033062A1169|92 94|DNA
P02033062A1169|110 125|reporter plasmid
P02034655A1224|3 7|alpha
P02034655A1224|9 12|gene
P02034655A1224|23 28|region
P02034655A1224|37 44|promoter
P02034655A1224|47 65|transfection assays
P02034655T0000|0 15|Characterization
P02034655T0000|21 25|alpha
P02034655T0000|27 48|integrin gene promoter
P02034669A0293|13 22|transcript
P02034669A0293|41 47|tissues
P02034669A0293|57 66|expression
P02034669A0293|116 121|system
P02034676A0267|3 12|homologues
P02034676A0267|18 31|rhombotin gene
P02035805T0000|0 27|Angina haemorrhagica bullosa
P02035805T0000|44 54|obstruction
P02036066A0000|13 19|effects
P02036066A0000|31 39|perfusion
P02036066A0000|57 92|hemoglobin polyoxyethylene conjugate
P02036066A0000|92 94|PHP
P02036066A0000|96 103|solution
P02036066A0000|113 120|function
P02036066A0000|131 140|rat hearts
P02038293A0919|0 9|Conclusion
P02038293A0919|11 24|inlet type VSD
P02038293A0919|40 47|type TOF
P02038293A0919|59 66|features
P02038293A0919|88 93|bundle
P02038293A0919|127 137|VSD closure
P02038326A0538|3 19|gcd2-503 mutation
P02038326A0538|40 45|runoff
P02038326A0538|47 58|accumulation
P02038326A0538|69 71|80S
P02038326A0538|81 87|couples
P02038326A0538|92 103|accumulation
P02038326A0538|121 128|subunits
P02038326A0538|141 169|translation initiation factor
P02038326A0538|170 180|eIF-2 alpha
P02038326A0538|183 199|43S-48S particles
P02038326A0538|209 213|shift
P02038326A0538|230 240|temperature
P02038784A0317|5 12|patients
P02038784A0317|17 19|ARC
P02038784A0317|28 34|failure
P02041088A1053|12 28|enhancer activity
P02041088A1053|30 33|DR60
P02041088A1053|36 51|reporter plasmid
P02041088A1053|78 81|DR60
P02041088A1053|101 147|reporter chloramphenicol acetyltransferase gene
P02041088A1053|153 159|control
P02041088A1053|178 189|39K promoter
P02044785A0000|7 10|case
P02044785A0000|15 28|adenocarcinoma
P02044785A0000|40 54|retroperitoneal
P02044785A0000|67 70|cyst
P02044785A0000|100 103|cyst
P02044950A0258|8 32|polymerase chain reaction
P02044950A0258|45 56|U6 RNA genes
P02044950A0258|59 67|organisms
P02044975A0380|8 13|volume
P02044975A0380|21 24|flow
P02044975A0380|52 52|P
P02044975A0380|81 81|h
P02044975A0380|87 98|instillation
P02044975A0380|118 120|min
P02044975A0380|126 136|application
P02044975A0380|142 147|volume
P02044975A0380|152 152|%
P02044975A0380|158 161|flow
P02044975A0380|166 166|%
P02045366A1149|0 22|Hydrophobicity analysis
P02045366A1149|38 41|KlaA
P02045366A1149|45 61|KlaB polypeptides
P02045366A1149|92 107|KlaC polypeptide
P02045366A1149|155 161|domains
P02045524A0000|15 26|availability
P02045524A0000|52 57|agents
P02045524A0000|62 65|Food
P02045524A0000|69 87|Drug Administration
P02045524A0000|88 90|FDA
P02045524A0000|97 105|mid-1970s
P02045524A0000|131 137|ratings
P02045524A0000|158 162|drugs
P02045524A0000|173 184|end-of-phase
P02045524A0000|187 197|conferences
P02045524A0000|202 214|drug sponsors
P02045809A0331|2 9|contrast
P02045809A0331|18 22|rates
P02045809A0331|25 46|B. sphaericus products
P02045809A0331|46 53|ABG-6184
P02045809A0331|63 68|powder
P02045809A0331|72 76|BSP-2
P02045809A0331|85 95|concentrate
P02045809A0331|118 126|reduction
P02046202A0625|3 11|remainder
P02046202A0625|17 17|%
P02046202A0625|26 40|IgA nephropathy
P02047597A0149|23 30|vulvitis
P02047597A0149|48 62|field condition
P02047597A0149|66 73|bacteria
P02047597A0149|108 114|strains
P02052544A0641|15 28|DNA polymerase
P02052544A0641|30 36|complex
P02052544A0641|61 66|dpb2-1
P02052544A0641|73 77|cells
P02052544A0641|100 113|DNA polymerase
P02052544A0641|115 121|complex
P02052544A0641|130 133|DPB2
P02052544A0641|162 172|replication
P02052592A0000|29 32|cell
P02052592A0000|42 49|products
P02052592A0000|65 71|changes
P02052592A0000|74 86|bone turnover
P02052592A0000|105 115|development
P02052592A0000|132 143|osteoporosis
P02052592A0000|159 165|effects
P02052592A0000|168 179|oophorectomy
P02052592A0000|193 212|estrogen replacement
P02052592A0000|228 236|secretion
P02052592A0000|239 249|interleukin
P02052592A0000|252 255|IL-1
P02052592A0000|260 286|tumor necrosis factor alpha
P02052592A0000|285 293|TNF-alpha
P02052592A0000|303 320|phytohemagglutinin
P02052592A0000|330 338|secretion
P02052592A0000|381 386|factor
P02052592A0000|388 393|GM-CSF
P02052592A0000|409 413|blood
P02052592A0000|425 429|cells
P02053289A0701|15 28|nt differences
P02053289A0701|58 63|groups
P02053289A0701|83 96|nt differences
P02053289A0701|114 120|strains
P02054754A0919|11 20|principles
P02054754A0919|31 40|management
P02054754A0919|65 75|Sandostatin
P02054754A0919|83 90|patients
P02054754A0919|100 108|disorders
P02055484A0538|9 20|PCR products
P02055484A0538|29 37|mutations
P02055484A0538|40 43|ATG1
P02055484A0538|50 53|ATG2
P02056553T0000|11 15|shock
P02056553T0000|28 40|translocation
P02056553T0000|44 54|swine model
P02060052A0954|5 8|data
P02060052A0954|23 28|levels
P02060052A0954|31 36|oxygen
P02060052A0954|41 48|radicals
P02060052A0954|64 74|hepatocytes
P02060052A0954|78 89|mitochondria
P02061282A0447|3 10|sequence
P02061282A0447|16 28|pMxL1 plasmid
P02061282A0447|51 56|region
P02061282A0447|79 84|repeat
P02061282A0447|89 90|bp
P02061282A0447|96 106|orientation
P02061282A0447|120 129|pilin gene
P02061282A0447|134 139|middle
P02061282A0447|145 171|recombination junction site
P02061333A0784|2 9|evidence
P02061333A0784|16 23|presence
P02061333A0784|26 32|introns
P02061333A0784|42 50|acvA gene
P02061333A1359|5 16|observations
P02061333A1359|33 42|occurrence
P02061333A1359|56 90|phosphopantetheine-attachment sites
P02061333A1359|102 118|thioesterase site
P02061333A1359|135 143|reference
P02061333A1359|149 165|reaction sequence
P02061333A1359|174 183|production
P02061333A1359|189 202|ACV tripeptide
P02062116A0688|0 8|Pargyline
P02062116A0688|11 37|monoamine oxidase inhibitor
P02062116A0688|61 63|max
P02062933A0738|12 17|choice
P02062933A0738|34 39|female
P02062933A0738|58 61|male
P02062933A0738|67 69|AOF
P02062933A0738|71 87|flutamide females
P02062933A0738|96 103|controls
P02062933A0738|121 127|partner
P02064119A1172|18 26|responses
P02064119A1172|43 47|L/min
P02064119A1172|49 54|% SaO2
P02064119A1172|59 67|relatives
P02064119A1172|83 87|L/min
P02064119A1172|89 94|% SaO2
P02064119A1172|106 113|subjects
P02064119A1172|116 123|ABSTRACT
P02064119A1172|138 142|WORDS
P02065022A0747|9 17|deletions
P02065022A0747|36 41|region
P02065022A0747|61 81|transforming activity
P02065022A0747|83 85|dbl
P02065022A0747|101 108|deletion
P02065022A0747|122 127|region
P02065022A0747|133 138|effect
P02066246A0258|16 19|list
P02066246A0258|41 45|files
P02066246A0258|51 79|Massachusetts Cancer Registry
P02066246A0258|81 85|cases
P02068085A1273|13 20|evidence
P02068085A1273|43 49|element
P02068085A1273|65 70|region
P02068085A1273|76 78|Mlu
P02068085A1273|88 106|activation sequence
P02069738A0000|1 6|method
P02069738A0000|22 37|stimulus control
P02069738A0000|39 45|ethanol
P02069873X0000|0 8|Mechanism
P02069873X0000|11 20|activation
P02069873X0000|26 42|vav protooncogene
P02069873X0000|43 45|vav
P02069873X0000|54 58|locus
P02069873X0000|97 101|cells
P02069873X0000|117 122|origin
P02069873X0000|140 162|differentiation lineage
P02070227T0000|11 22|cell seeding
P02072238T0000|0 16|Menetrier disease
P02072238T0000|19 23|child
P02072798A0330|16 28|stabilization
P02072798A0330|33 36|goal
P02072798A0330|39 45|therapy
P02072798A0330|61 66|chance
P02072798A0330|73 77|ulcer
P02073222A0269|11 18|patients
P02073222A0269|20 34|amitriptyline n
P02073222A0269|38 50|moclobemide n
P02073222A0269|69 81|week protocol
P02073222A0269|115 124|conditions
P02075876A0408|3 20|stimulus threshold
P02075876A0408|23 25|EER
P02075876A0408|47 55|variation
P02075876A0408|60 68|amplitude
P02075876T0001|0 7|Analysis
P02075876T0001|28 35|response
P02075876T0001|37 39|EER
P02075876T0001|43 50|relation
P02075876T0001|69 75|pathway
P02075876T0001|81 83|cat
P02076620A0548|12 35|plasma fibrinogen levels
P02076620A0548|46 49|mean
P02076620A0548|56 56|%
P02076620A0548|77 82|effect
P02076620A0548|85 95|gemfibrozil
P02076620T0000|0 10|Gemfibrozil
P02076620T0000|28 35|patients
P02076620T0000|58 64|disease
P02076620T0000|82 88|actions
P02076816T0000|18 24|pathway
P02076816T0000|28 46|sporulation control
P02076816T0000|82 109|IME1 transcript accumulation
P02077560T0000|3 6|role
P02077560T0000|24 32|profiling
P02077560T0000|35 51|safety assessment
P02078080T0040|3 13|application
P02078080T0040|16 25|Madagascar
P02078080T0040|27 36|advantages
P02078080T0040|40 52|disadvantages
P02078570A0287|5 9|cases
P02078570A0287|21 30|expression
P02078570A0287|50 58|integrins
P02079811A0407|3 9|authors
P02079811A0407|29 36|efficacy
P02079811A0407|39 45|EMB AZS
P02079811A0407|56 60|ulcer
P02079811A0407|66 74|operation
P02079811A0407|80 86|stomach
P02079811A0407|100 104|level
P02079811A0407|107 121|acid production
P02079811A0407|148 155|bleeding
P02080902A0183|2 10|adulthood
P02080902A0183|16 19|rats
P02080902A0183|54 71|avoidance response
P02080902A0183|83 90|controls
P02081463A0110|16 25|regulation
P02081463A0110|28 45|Spec gene activity
P02081463A0110|48 53|region
P02081463A0110|63 67|Spec1
P02081463A0110|83 97|initiation site
P02081463A0110|111 115|sites
P02081463A0110|129 139|interaction
P02083199A1175|0 21|Phosphopeptide mapping
P02083199A1175|36 60|autophosphorylation sites
P02083199A1175|70 76|EGFR-IC
P02083199A1175|105 108|EGFR
P02083230A0938|10 17|sequence
P02083230A0938|34 47|signal peptide
P02083230A0938|76 100|amino acid residue domain
P02083230A0938|103 123|N-glycosylation sites
P02083230A0938|138 143|domain
P02083230A0938|159 164|domain
P02083230A0938|169 179|amino acids
P02083253A1512|3 26|TCF-1 alpha binding site
P02083253A1512|42 68|TCR alpha enhancer activity
P02083253A1512|91 98|extracts
P02083253A1512|103 108|Jurkat
P02083253A1512|115 124|HeLa cells
P02083253A1512|139 149|TCF-1 alpha
P02083253A1512|167 186|transcription factor
P02083546A0000|18 23|method
P02083546A0000|54 59|uptake
P02083546A0000|95 105|amine oxime
P02083546A0000|106 116|99mTc-HMPAO
P02083546A0000|139 163|photon emission tomograms
P02083546A0000|173 180|subjects
P02083546A0000|184 191|patients
P02083546A0000|196 204|Alzheimer
P02083546A0000|207 213|disease
P02083546A0000|217 224|patients
P02083546A0000|229 236|dementia
P02083546A0000|246 254|lobe type
P02083546A0000|258 265|patients
P02083546A0000|270 277|dementia
P02083546A0000|282 302|motor neurone disease
P02088781A0653|3 9|results
P02088781A0653|20 22|fog
P02088781A0653|29 33|level
P02088781A0653|36 39|base
P02088781A0653|44 46|fog
P02088781A0653|59 71|density units
P02088781A0653|77 85|influence
P02088781A0653|101 108|accuracy
P02088781A0653|114 120|absence
P02088781A0653|126 137|compensation
P02089054A0121|0 2|IdB
P02089054A0121|26 47|liquid-solid partition
P02089054A0121|53 60|extracts
P02089054A0121|103 108|column
P02089054A0121|123 132|conditions
P02089054A0121|165 175|UV detector
P02091890A0614|6 10|model
P02091890A0614|12 22|eltoprazine
P02091890A0614|63 69|profile
P02091890A0614|81 90|aggression
P02091890A0614|102 112|interaction
P02091890A0614|116 126|exploration
P02091890A0614|158 167|inactivity
P02091890A0614|170 176|measure
P02091890A0614|180 187|sedation
P02092131T0000|4 9|method
P02092131T0000|23 30|transfer
P02092131T0000|40 55|hypersensitivity
P02092131T0000|66 80|transfer factor
P02093033T0001|0 5|Effect
P02093033T0001|27 33|effects
P02093033T0001|36 48|plutonium-239
P02093033T0001|50 68|hexachlorobutadiene
P02093033T0001|72 89|tributyl phosphate
P02093033T0001|94 105|thymus gland
P02093033T0001|107 110|rats
P02093741A0211|0 14|Data collection
P02093741A0211|26 39|query language
P02093741A0211|43 55|data analysis
P02093741A0211|107 110|tool
P02093741A0211|112 118|MAXITAB
P02093741A0211|149 166|analysis technique
P02093888A0293|0 4|ARPIA
P02093888A0293|41 44|DBMS
P02093888A0293|82 90|computers
P02094221A0247|0 7|Diuresis
P02094221A0247|29 36|drinking
P02094221A0247|39 41|tea
P02094221A0247|46 49|ml/h
P02094257T0000|10 14|value
P02094257T0000|17 44|adenosine deaminase activity
P02094257T0000|56 64|effusions
P02095150T0000|7 23|strain adaptation
P02095150T0000|33 47|hip replacement
P02095150T0000|49 58|comparison
P02095150T0000|78 96|ingrowth components
P02095150T0000|98 104|canines
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|26 33|antisera
P02099622A1046|41 60|Campylobacter jejuni
P02099622A1046|82 89|staining
P02099622A1046|109 113|cells
P02099622A1046|143 151|organisms
P02099622A1046|159 167|structure
P02099622A1046|178 194|Campylobacter spp
P02102823A0492|0 18|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|57 83|neomycin phosphotransferase
P02102823A0492|85 105|reporter gene systems
P02102831A1282|5 11|regions
P02102831A1282|22 40|soybean actin genes
P02102831A1282|57 64|features
P02102831A1282|75 76|CT
P02102831A1282|78 84|repeats
P02102831A1282|92 100|stretches
P02102831A1282|118 120|DNA
P02103140A1088|8 8|%
P02103140A1088|10 17|patients
P02103140A1088|38 44|failure
P02103140A1088|56 61|grafts
P02103140A1088|108 113|grafts
P02103140A1088|149 165|retransplantation
P02103403A0149|2 8|patient
P02103403A0149|13 19|history
P02103403A0149|28 41|alcohol intake
P02103403A0149|53 58|intake
P02103403A0149|72 76|drugs
P02103403A0149|80 87|steroids
P02105497A1092|14 23|comparison
P02105497A1092|26 45|amino acid sequences
P02105497A1092|48 61|HSP70 proteins
P02105497A1092|67 73|species
P02105497A1092|86 94|BiP genes
P02105497A1092|106 113|ancestor
P02105497A1092|137 147|HSP70 genes
P02105497A1092|154 157|time
P02105497A1092|162 171|eukaryotes
P02106287A0478|0 12|Spore inocula
P02106287A0478|32 37|coupon
P02106287A0478|52 57|0.5-in
P02107073A0584|8 21|overexpression
P02107073A0584|31 34|STE4
P02107073A0584|38 51|STE18 proteins
P02107073A0584|74 91|pheromone response
P02107073A0584|95 108|overexpression
P02107073A0584|111 114|STE4
P02107073A0584|120 127|presence
P02107073A0584|139 144|levels
P02107073A0584|147 151|STE18
P02107548A0727|7 23|transcription-PCR
P02107548A0727|37 41|clone
P02107548A0727|51 54|poly
P02107548A0727|56 56|A
P02107548A0727|59 61|RNA
P02107548A0727|65 68|cDNA
P02107548A0727|96 102|homolog
P02107548A0727|105 111|psi ARF
P02107548A0727|130 132|ARF
P02109544A0000|13 16|cost
P02109544A0000|20 27|benefits
P02109544A0000|30 44|screening tests
P02109544A0000|47 67|Chlamydia trachomatis
P02109544A0000|79 83|males
P02109544A0000|97 119|decision analysis model
P02109544A0000|132 169|leukocyte esterase urine dipstick test
P02109544A0000|170 176|culture
P02109544A0000|205 212|antibody
P02109544A0000|214 216|DFA
P02109544A0000|229 234|option
P02109544A0000|239 247|screening
P02109544A0000|251 259|treatment
P02110145T0000|0 9|Sequencing
P02110145T0000|13 16|gene
P02110145T0000|52 57|enzyme
P02110145T0000|59 62|CfiA
P02110145T0000|68 78|Bacteroides
P02110145T0000|87 93|TAL2480
P02110145T0000|107 116|similarity
P02110145T0000|124 127|CfiA
P02110145T0000|131 160|Bacillus cereus beta-lactamase
P02110148A0423|9 24|HindIII fragment
P02110148A0423|40 60|DNA sequence analysis
P02110148A0423|80 83|half
P02110148A0423|89 111|B. subtilis IF2 protein
P02110148A0423|115 116|kb
P02110148A0423|135 142|sequence
P02110148A0423|168 172|probe
P02110148A0423|175 179|clone
P02110148A0423|200 203|ClaI
P02110148A0423|215 222|fragment
P02110148A0423|242 244|IF2
P02110148A0423|255 258|gene
P02111015A0574|16 26|amino acids
P02111015A0574|58 63|domain
P02111015A0574|82 100|sequence similarity
P02111015A0574|115 134|IFN response factors
P02111015A0574|134 138|IRF-1
P02111015A0574|142 146|IRF-2
P02113015A0295|8 15|seizures
P02113015A0295|33 41|pregnancy
P02113015A0295|49 52|cent
P02113174A0064|10 16|protein
P02113174A0064|26 37|zinc fingers
P02113174A0064|56 79|transcription factor Sp1
P02113174A0957|0 6|Krox-24
P02113174A0957|51 59|activator
P02113455A0207|18 28|variability
P02113455A0207|34 43|parameters
P02113455A0207|55 67|consideration
P02113455A0207|97 112|threshold levels
P02113699A0372|3 10|patients
P02113699A0372|27 35|subgroups
P02113699A0372|41 41|N
P02113699A0372|43 50|patients
P02113699A0372|66 70|spots
P02113699A0372|86 86|N
P02113699A0372|88 89|IM
P02113699A0372|96 96|N
P02113699A0372|98 105|patients
P02113699A0372|119 123|spots
P02113699A0372|145 145|N
P02113699A0372|155 155|N
P02113699A0372|157 164|patients
P02113699A0372|178 182|spots
P02113699A0372|204 204|N
P02113901A0000|8 10|CO2
P02113901A0000|18 24|changes
P02113901A0000|29 32|hypo
P02113901A0000|36 46|normocapnia
P02113901A0000|88 94|tension
P02113901A0000|96 99|PaO2
P02113901A0000|131 140|difference
P02115111T0000|0 9|Expression
P02115111T0000|11 29|nucleotide sequence
P02115111T0000|42 49|analysis
P02115111T0000|59 72|reading frames
P02115111T0000|77 91|nif gene region
P02115111T0000|92 102|Anabaena sp
P02115111T0000|103 116|strain PCC7120
P02115115A1053|32 41|suggestion
P02115115A1053|46 50|sites
P02115115A1053|66 73|CAR1 URS
P02115115A1053|102 108|regions
P02115115A1053|128 138|yeast genes
P02115116A1137|3 9|results
P02115116A1137|22 35|sequence match
P02115116A1137|42 50|enhancers
P02115116A1137|61 77|promoter elements
P02115118A0565|4 5|Mr
P02115118A0565|35 46|smg p25A GDI
P02115118A0565|56 69|sodium dodecyl
P02115118A0565|91 109|gel electrophoresis
P02115118A0565|112 155|sucrose density gradient ultracentrifugation
P02115121A0000|0 12|Yeast mutants
P02115121A0000|25 54|pet complementation group G104
P02115121A0000|86 107|dehydrogenase activity
P02115121A0000|110 115|result
P02115121A0000|118 126|mutations
P02115121A0000|132 161|dihydrolipoyl transsuccinylase
P02115121A0000|162 164|KE2
P02115121A0000|166 174|component
P02115121A0000|180 186|complex
P02115122A0562|8 15|residues
P02115122A0562|27 36|repression
P02115122A0562|68 78|amino acids
P02115122A0562|80 84|c-Fos
P02115122A0562|91 95|v-Fos
P02115122A0562|109 119|truncations
P02115122A0562|122 126|c-Fos
P02115572A1323|17 35|V lambda pseudogene
P02115572A1323|41 52|psi V lambda
P02115572A1323|54 55|kb
P02115572A1323|69 84|U266 lambda gene
P02115889A0436|6 10|paper
P02115889A0436|29 37|structure
P02115889A0436|45 48|gene
P02115889A0436|52 59|Gx alpha
P02115889A0436|80 88|kilobases
P02116071A0000|14 18|study
P02116071A0000|43 56|stage children
P02116071A0000|68 74|potency
P02116071A0000|92 121|type hypersensitivity reaction
P02116071A0000|122 129|exposure
P02116071A0000|136 142|antigen
P02116071A0000|153 157|titer
P02116071A0000|172 174|IgE
P02116071A0000|182 185|sera
P02116071A0000|214 220|attacks
P02116071A0000|233 241|reduction
P02116071A0000|247 252|amount
P02116071A0000|259 265|antigen
P02116071A0000|271 274|body
P02116071A0000|288 296|reduction
P02116071A0000|302 307|amount
P02116071A0000|322 324|IgG
P02116537A1237|5 13|influence
P02116537A1237|32 45|concentrations
P02116537A1237|53 55|MIC
P02116537A1237|58 60|AMK
P02117799T0000a|0 3|Uses
P02117799T0000a|6 20|orthoclone OKT3
P02117799T0000a|23 33|prophylaxis
P02117799T0000a|36 44|rejection
P02117799T0000a|48 56|induction
P02117799T0000a|66 76|nonfunction
P02117799T0000a|79 100|kidney transplantation
P02117799T0000b|0 3|Uses
P02117799T0000b|6 20|orthoclone OKT3
P02117799T0000b|23 33|prophylaxis
P02117799T0000b|36 44|rejection
P02117799T0000b|48 56|induction
P02117799T0000b|66 76|nonfunction
P02117799T0000b|79 100|kidney transplantation
P02118519A0516|32 47|consensus motifs
P02118519A0516|79 87|positions
P02118519A0516|93 97|genes
P02118519A0516|104 131|nerve growth factor receptor
P02118519A0516|141 161|neurofilament protein
P02118525A0737|2 9|addition
P02118525A0737|23 30|fragment
P02118525A0737|36 47|CCK promoter
P02118525A0737|71 78|enhancer
P02118525A0737|97 109|transcription
P02118525A0737|117 162|herpes simplex virus thymidine kinase promoter
P02118525A0737|161 168|position
P02118525A0737|196 201|manner
P02118612A0629|6 12|minutes
P02118612A0629|15 30|supine restraint
P02118612A0629|39 58|DOPAC concentrations
P02118612A0629|69 76|eminence
P02118612A0629|85 88|rats
P02118612A0629|123 130|exposure
P02118612A0629|133 137|ether
P02118612A0629|150 155|effect
P02119530T0000|0 8|Influence
P02119530T0000|11 30|metoprolol treatment
P02119530T0000|48 57|activation
P02119530T0000|60 71|fibrinolysis
P02119626A0471|8 12|scars
P02119626A0471|38 38|%
P02119626A0471|47 56|dimensions
P02119946T0000|8 16|dysphagia
P02119946T0000|27 38|care setting
P02119946T0000|41 52|introduction
P02120707A0594|18 23|assays
P02120707A0594|40 43|Raji
P02120707A0594|51 58|proteins
P02120707A0594|70 70|W
P02120707A0594|74 83|V elements
P02120707A0594|103 131|HLA-DRA X-box oligonucleotide
P02120833A0000|2 8|Denmark
P02120833A0000|16 20|cases
P02120833A0000|45 58|hepatitis NANB
P02120833A0000|59 66|TAH-NANB
P02120833A0000|97 100|case
P02120833A0000|111 115|units
P02121371T0000|3 11|NF1 locus
P02121371T0000|19 25|protein
P02121371T0000|56 58|GAP
P02121371T0000|62 79|yeast IRA proteins
P02122454A1042|9 19|replacement
P02122454A1042|22 27|Phe-62
P02122454A1042|32 34|Ser
P02122454A1042|55 65|determinant
P02122454A1042|71 76|lambda
P02122454A1042|83 87|chain
P02122454A1042|122 130|transport
P02122454A1042|137 144|molecule
P02123029A0478|7 13|isotype
P02123029A0478|16 34|Raja immunoglobulin
P02123029A0478|39 49|chain genes
P02123029A0478|76 94|spleen cDNA library
P02123029A0478|107 113|Raja VH
P02123029A0478|129 134|probes
P02123029A0478|161 167|regions
P02123029A0478|180 186|isotype
P02123293A0227|0 4|Petko
P02123293A0227|9 10|S.
P02123295A0645|0 9|Disruption
P02123295A0645|12 15|ARF2
P02123295A0645|34 42|phenotype
P02123300T0000|41 46|factor
P02123300T0000|48 53|factor
P02123300T0000|64 72|treatment
P02123300T0000|75 87|hemophilia A.
P02123300T0000|98 120|Factor VIII Study Group
P02123466A0272|9 15|members
P02123466A0272|22 27|family
P02123466A0272|32 35|AP-4
P02123466A0272|39 43|motif
P02123466A0272|63 68|domain
P02123466A0272|115 125|DNA binding
P02123467A0811|12 21|expression
P02123467A0811|27 34|promoter
P02123467A0811|68 72|cells
P02123467A0811|81 85|MyoD1
P02123467A0811|89 91|Sp1
P02123467A0811|121 125|sites
P02123467A0811|149 156|presence
P02123467A0811|178 180|Sp1
P02123467A0811|184 188|MyoD1
P02123820A0000|0 6|Effects
P02123820A0000|19 35|monoamine oxidase
P02123820A0000|36 38|MAO
P02123820A0000|43 51|inhibitor
P02123820A0000|53 62|clorgyline
P02123820A0000|74 88|MAO-B inhibitor
P02123820A0000|89 96|deprenyl
P02123820A0000|115 127|MAO inhibitor
P02123820A0000|128 136|nialamide
P02123820A0000|173 182|aggression
P02123820A0000|184 186|FIA
P02123820A0000|196 199|rats
P02123875A0223|20 27|features
P02123875A0223|30 37|residues
P02123875A0223|49 56|c-region
P02123875A0223|73 80|fidelity
P02123875A0223|84 93|efficiency
P02123875A0223|96 120|signal peptidase cleavage
P02123875A0223|143 155|translocation
P02123875A0223|172 195|amino acid substitutions
P02123875A0223|201 213|COOH terminus
P02123875A0223|229 232|core
P02123875A0223|241 253|substitutions
P02123875A0223|259 270|NH2 terminus
P02123875A0223|281 286|region
P02123875A0223|291 301|+1 position
P02123875A0223|305 309|model
P02123875A0223|340 348|delta pro
P02123875A0223|349 355|apoA-II
P02123877A1452|21 25|c-fos
P02123877A1452|29 39|egr-1 mRNAs
P02123877A1452|61 66|levels
P02123877A1452|79 89|liver cells
P02123877A1452|90 94|fos-B
P02123877A1452|96 100|fra-1
P02123877A1452|105 109|egr-2
P02123877A1452|134 140|factors
P02123877A1452|143 150|addition
P02123877A1452|156 176|serum response factor
P02123877A1452|191 200|regulation
P02123877A1452|218 231|gene induction
P02124433A0235|5 12|patients
P02124433A0235|17 21|cases
P02124433A0235|34 44|description
P02124433A0235|47 53|patient
P02124433A0235|56 65|background
P02124433A0235|80 86|Group A
P02124433A0235|87 93|surgery
P02124433A0235|95 97|MMC
P02124433A0235|99 102|5-FU
P02124433A0235|104 115|chemotherapy
P02124433A0235|120 124|cases
P02124433A0235|126 132|group B
P02124433A0235|133 139|surgery
P02124433A0235|141 143|MMC
P02124433A0235|145 148|5-FU
P02124433A0235|150 155|OK-432
P02124433A0235|158 160|PSK
P02124433A0235|162 179|immunochemotherapy
P02124433A0235|187 193|group C
P02124433A0235|194 200|surgery
P02124710A0193|10 17|proteins
P02124710A0193|30 34|c-fos
P02124710A0193|38 57|c-jun protooncogenes
P02124710A0193|78 97|proliferation period
P02124710A0193|99 130|osteoblast phenotype development
P02124710A1624|4 8|model
P02124710A1624|29 35|binding
P02124710A1624|41 55|Fos-Jun complex
P02124710A1624|59 67|AP-1 site
P02124710A1624|72 81|type alpha
P02124710A1624|82 98|collagen promoter
P02124710A1624|140 143|VDRE
P02125016A0145|0 3|PBSX
P02125016A0145|15 20|agents
P02125016A0145|35 46|SOS response
P02125153A0410|16 22|relapse
P02125153A0410|32 40|treatment
P02125153A0410|52 56|years
P02125153A0410|63 63|%
P02125153A0410|69 70|R3
P02125153A0410|75 75|%
P02125153A0410|80 81|R5
P02125153A0410|90 90|%
P02125153A0410|96 106|Z5 patients
P02125153A0410|110 118|organisms
P02125153A0410|130 141|streptomycin
P02125153A0410|145 153|isoniazid
P02126417A0408|5 12|controls
P02126417A0408|66 81|control subjects
P02126417A0408|93 95|VHF
P02126417A0408|106 115|hemisphere
P02126417A0408|117 125|advantage
P02126504A0602|10 22|Rh-antibodies
P02126504A0602|48 56|mechanism
P02126504A0602|78 86|Rh-system
P02129338A0568|10 28|amino acid sequence
P02129338A0568|41 48|homology
P02129338A0568|52 52|%
P02129338A0568|64 100|alga Scenedemus obliquus plastocyanin
P02131652A0883|13 39|serum gastrin concentration
P02131652A0883|63 68|ng.l-1
P02131652A0883|93 107|gastrin release
P02131652A0883|108 115|AUC0-120
P02131652A0883|143 152|ng.l-1 min
P02131652A0883|170 175|VTP-HM
P02131652A0883|185 191|VTP-Cas
P02131666A0483|15 19|group
P02131666A0483|33 52|examinees class II/2
P02131666A0483|62 70|anomalies
P02131902A0000|4 8|study
P02131902A0000|33 40|location
P02131902A0000|77 79|TEE
P02131902A0000|81 90|transducer
P02131902A0000|117 120|view
P02131902A0000|130 138|ventricle
P02131902A0000|140 143|S-LV
P02132636A0188|0 7|Subjects
P02132636A0188|25 38|schizophrenics
P02132636A0188|52 66|DST suppressors
P02132636A0188|70 83|nonsuppressors
P02133731A1572|4 5|S3
P02133731A1572|7 9|CBF
P02133731A1572|16 16|%
P02133731A1572|20 21|S5
P02133731A1572|23 25|CBF
P02133731A1572|31 31|%
P02133731A1572|34 37|%WTh
P02133731A1572|39 43|1/TPC
P02133731A1572|47 49|1/T
P02133731A1572|90 103|control levels
P02133731A1572|107 107|p
P02135343A0131|6 12|article
P02135343A0131|34 43|percentage
P02135343A0131|52 60|occlusion
P02135343A0131|67 78|distribution
P02135343A0131|81 92|maloclusions
P02135343A0131|123 134|relationship
P02135343A0131|151 155|archs
P02135343A0131|169 189|ANGLE3 classification
P02135536A0621|6 9|case
P02135536A0621|14 18|ratio
P02135536A0621|21 34|brush abrasion
P02135536A0621|67 74|strength
P02135536A0621|88 90|MPa
P02135536A0621|104 111|hardness
P02135536A0621|117 118|Hk
P02135536A0621|120 135|water absorption
P02135536A0621|139 152|micrograms/mm3
P02135536A0621|163 183|expansion coefficient
P02135536A0621|196 205|degrees C.
P02137704A0000|15 19|group
P02137704A0000|40 47|patients
P02137704A0000|66 73|strength
P02137704A0000|76 86|association
P02137704A0000|101 127|blood pressure measurements
P02137704A0000|129 129|h
P02137704A0000|156 169|blood pressure
P02137704A0000|171 171|h
P02137704A0000|191 197|morning
P02137704A0000|205 218|blood pressure
P02137704A0000|227 238|office visit
P02137704A0000|245 258|blood pressure
P02137704A0000|269 280|office visit
P02137704A0000|287 300|blood pressure
P02137704A0000|328 334|indices
P02137704A0000|356 374|target organ damage
P02137704A0000|384 391|diameter
P02137704A0000|408 410|end
P02137704A0000|420 427|diameter
P02137704A0000|438 451|wall thickness
P02137704A0000|460 473|wall thickness
P02137704A0000|482 495|wall thickness
P02137704A0000|511 514|mass
P02137704A0000|518 527|mass index
P02137704A0000|539 557|wall thickness/left
P02137704A0000|577 590|diameter ratio
P02138707A0198|39 68|lambda gt11 expression library
P02138707A0198|73 84|protein mXBP
P02138707A0198|98 105|sequence
P02138707A0198|124 126|end
P02138707A0198|138 142|class
P02138707A0198|150 194|histocompatibility complex A alpha gene X box
P02138707A0198|200 220|transcription element
P02138707A0198|238 242|class
P02138707A0198|245 249|genes
P02138915A1060|3 10|p36 gene
P02138915A1060|21 22|kb
P02138915A1060|25 30|length
P02138915A1060|44 51|sequence
P02138915A1060|68 69|kb
P02138915A1060|90 90|%
P02138915A1060|96 99|gene
P02138915A1060|102 109|ABSTRACT
P02138915A1060|124 128|WORDS
P02138992A0911|17 25|treatment
P02138992A0911|55 60|tumors
P02138992A0911|80 91|modification
P02138992A0911|105 108|work
P02138992A0911|122 129|approach
P02139473A1603|54 57|site
P02139473A1603|60 63|entC
P02139473A1603|84 101|Fur concentrations
P02139473A1603|123 128|region
P02139473A1603|161 183|Shine-Dalgarno sequence
P02139891A0532|8 15|promoter
P02139891A0532|52 65|activators EIA
P02139891A0532|68 70|EIV
P02139891A0532|86 93|elements
P02139891A0532|96 105|TAGA motif
P02139891A0532|119 126|TATA box
P02139891A0532|130 139|EIIF sites
P02139891A0532|158 168|orientation
P02139891A0532|175 187|ATF/CREB site
P02141425A0175|15 32|fingertip-to-floor
P02141425A0175|34 37|MFTF
P02141425A0175|39 44|method
P02141425A0175|46 53|patients
P02141425A0175|62 66|stool
P02141425A0175|87 98|measurements
P02141425A0175|111 118|patients
P02141425A0175|139 143|floor
P02141425A0175|160 164|level
P02141425A0175|170 174|floor
P02142240A0506|13 23|differences
P02142240A0506|37 50|response rates
P02142240A0506|64 76|concentration
P02142240A0506|79 96|estrogen receptors
P02142240A0506|98 105|presence
P02142240A0506|108 128|progesteron receptors
P02142240A0506|134 138|group
P02142240A0506|141 148|patients
P02142486A0367|0 10|Teicoplanin
P02142486A0367|47 51|fever
P02142486A0367|74 84|bacteraemia
P02142486A0367|92 100|one-third
P02142486A0367|108 112|cases
P02142921T0000|11 50|hormone-releasing hormone analog therapy
P02142921T0000|57 63|fibroid
P02142921T0000|65 72|analysis
P02142921T0000|75 81|results
P02142921T0000|94 102|buserelin
P02142921T0000|130 138|goserelin
P02142921T0000|175 179|depot
P02142955A0248|2 12|Experiments
P02142955A0248|19 25|infants
P02142955A0248|31 36|adults
P02142955A0248|63 69|objects
P02142955A0248|75 79|basis
P02142955A0248|90 99|appearance
P02142955A0248|129 137|exemplars
P02142955A0248|144 149|delays
P02142955A0248|157 160|days
P02142993A0176|11 17|picture
P02142993A0176|23 29|disease
P02142993A0176|81 93|leishmaniasis
P02142993A0176|102 111|L. tropica
P02142993A0176|132 139|patterns
P02142993A0176|148 158|L. infantum
P02142993A0176|176 182|pattern
P02142993A0176|196 201|France
P02143023A0729|18 33|octamer elements
P02143023A0729|38 54|adenovirus genome
P02143023A0729|82 94|transcription
P02143023A0729|104 119|octamer elements
P02143023A0729|137 152|repeat sequences
P02143186A0867|2 11|comparison
P02143186A0867|21 27|introns
P02143186A0867|38 41|AHA3
P02143186A0867|43 46|AHA2
P02143186A0867|59 64|intron
P02143186A0867|85 90|region
P02143186A0867|101 106|intron
P02143186A0867|122 134|coding region
P02143186A1306|0 21|Northern blot analysis
P02143186A1306|33 41|AHA2 mRNA
P02143186A1306|64 66|RNA
P02143186A1306|99 104|levels
P02143186A1306|107 117|root tissue
P02143186A1306|131 142|shoot tissue
P02143768T0000|0 8|Impaction
P02143768T0000|11 26|gastrostomy tube
P02143768T0000|40 43|wall
P02143961A0400|4 18|antidepressants
P02143961A0400|30 43|pain threshold
P02143961A0400|56 67|pretreatment
P02143961A0400|72 75|pCPA
P02143961A0400|93 101|analgesia
P02144290A1444|0 2|Sci
P02144558A1022|1 16|needs assessment
P02144558A1022|23 30|families
P02144610A1306|0 8|TCR alpha
P02144610A1306|11 30|beta gene expression
P02144610A1306|52 54|set
P02144610A1306|57 62|T-cell
P02144610A1306|70 77|proteins
P02144610A1306|87 92|T beta
P02144610A1306|93 99|element
P02144610A1306|108 110|set
P02144610A1306|119 130|AMP response
P02144610A1306|145 152|proteins
P02144610A1306|174 180|T alpha
P02144610A1306|181 187|element
P02144610A1306|198 215|TCR alpha enhancer
P02144610A1306|220 234|decamer element
P02144610A1306|249 254|number
P02144610A1306|271 288|TCR beta promoters
P02145195A0253|5 13|stem-loop
P02145195A0253|33 41|structure
P02145195A0253|47 53|species
P02145195A0253|85 96|binding site
P02145195A0253|99 109|Sm proteins
P02145268A0746|10 28|nucleotide sequence
P02145268A0746|42 50|sequences
P02145268A0746|58 64|analogy
P02145268A0746|70 81|organization
P02145268A0746|87 90|type
P02145268A0746|92 105|collagen genes
P02145268A0746|132 135|exon
P02145268A0746|143 153|COL3A1 gene
P02145268A1454|5 10|losses
P02145268A1454|24 33|resistance
P02145268A1454|36 50|EDS-IV collagen
P02145268A1454|52 67|cyanogen bromide
P02145268A1454|79 99|collagenase digestion
P02146266A0000|13 34|BamHI-HindIII fragment
P02146266A0000|51 98|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|111 115|sod-1
P02146266A0000|140 146|library
P02146266A0000|162 188|deoxyoligonucleotide probes
P02146266A0000|215 243|N. crassa amino acid sequence
P02146495A0706|8 15|peptides
P02146495A0706|56 61|region
P02146495A0706|85 105|leucine zipper domain
P02146495A0706|116 121|dimers
P02146495A0706|139 141|CRE
P02147223A1047|2 9|contrast
P02147223A1047|14 16|CRE
P02147223A1047|27 40|c-fos promoter
P02147223A1047|70 73|cAMP
P02147223A1047|77 79|E1a
P02147223A1047|86 89|HeLa
P02147223A1047|93 102|PC12 cells
P02147422A0000|29 32|gene
P02147422A0000|49 68|U1-70K snRNP protein
P02148219A0508|19 28|hypothesis
P02148219A0508|62 66|facts
P02148219A0508|78 85|rigidity
P02148219A0508|95 102|extensor
P02148219A0508|106 111|flexor
P02148219A0508|130 136|muscles
P02148291A0173|25 44|HSE oligonucleotides
P02148291A0173|50 54|types
P02148291A0173|57 62|clones
P02148291A0173|76 94|HSE binding domains
P02148291A0173|110 146|tomato lambda gt11 expression library
P02148291A0173|155 163|screening
P02148508A0374|0 4|Fluid
P02148508A0374|6 9|AVLF
P02148508A1478|3 9|results
P02148508A1478|33 41|principle
P02148508A1478|44 46|TCM
P02148508A1478|56 63|patients
P02148508A1478|98 105|patterns
P02148799A0000|3 10|nmr gene
P02148799A0000|38 41|gene
P02148799A0000|47 70|nitrogen control circuit
P02148799A0000|71 87|Neurospora crassa
P02148799A0000|124 128|genes
P02148799A0000|140 149|expression
P02148799A0000|178 182|genes
P02148799A0000|188 194|circuit
P02149487A0348|4 38|days dexamethasone suppression test
P02149487A0348|52 64|% suppression
P02149487A0348|66 96|dehydroepiandrosterone-sulphate
P02149487A0348|115 115|%
P02149487A0348|117 125|reduction
P02149487A0348|128 139|testosterone
P02149487A0348|143 164|androstenedione levels
P02149566A0478|3 7|ratio
P02149566A0478|10 19|P-31 NMR-S
P02149566A0478|35 44|phosphates
P02149566A0478|46 47|Pi
P02149566A0478|51 65|phosphocreatine
P02149566A0478|67 69|PCr
P02149566A0478|96 99|rest
P02149566A0478|102 112|LVH baboons
P02149566A0478|151 151|P
P02149570T0000|9 16|necrosis
P02149570T0000|31 50|protein S deficiency
P02150473T0067|8 12|study
P02151229A0000|0 7|Regional
P02151229A0000|16 25|blood flow
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|90 97|emission
P02151229A0000|106 115|tomography
P02151229A0000|117 118|CT
P02151229A0000|128 135|patients
P02151229A0000|160 176|diabetes mellitus
P02151229A0000|177 181|NIDDM
P02151229A0000|190 192|age
P02151229A0000|197 201|years
P02151229A0000|210 231|fasting plasma glucose
P02151229A0000|233 238|mmol/L
P02151229A0000|257 264|subjects
P02151229A0000|270 274|years
P02151229A0000|279 284|mmol/L
P02151229A0921|0 17|Mean ROI-A/B ratio
P02151229A0921|29 29|%
P02151229A0921|43 47|group
P02151229A0921|84 84|%
P02151229A0921|101 105|group
P02151229A0921|107 107|p
P02153243A0965|5 8|data
P02153243A0965|35 41|product
P02153243A0965|47 56|int-2 gene
P02153243A0965|76 106|fibroblast growth factor family
P02153243A0965|120 125|factor
P02153243A0965|149 154|tumors
P02153683A1579|4 9|result
P02153683A1579|31 39|complexes
P02153683A1579|55 61|ankyrin
P02153683A1579|65 70|fodrin
P02153683A1579|81 90|uvomorulin
P02153683A1579|93 94|Na
P02153683A1579|97 97|K
P02153683A1579|100 105|ATPase
P02153977A0364|5 9|genes
P02153977A0364|32 36|hours
P02153977A0364|42 51|initiation
P02153977A0364|54 64|development
P02153977A0364|71 75|mRNAs
P02153977A0364|89 92|peak
P02153977A0364|97 98|hr
P02153977A0364|114 124|culmination
P02154467A0709|3 13|PC2 protein
P02154467A0709|27 36|similarity
P02154467A0709|64 71|sequence
P02154467A0709|82 99|furin gene product
P02154467A0709|138 145|molecule
P02154474A1504|20 28|sequences
P02154474A1504|39 57|cAMP responsiveness
P02154474A1504|77 84|P-450scc
P02154474A1504|109 119|P-450 genes
P02154599A0382|6 10|study
P02154599A0382|18 29|footprinting
P02154599A0382|33 63|gel mobility retardation assays
P02154599A0382|95 113|Zta fusion proteins
P02154599A0382|142 147|motifs
P02154599A0382|154 156|DSL
P02154599T0000|3 20|zta transactivator
P02154599T0000|30 38|induction
P02154599T0000|46 66|cycle gene expression
P02154599T0000|93 103|lymphocytes
P02154599T0000|115 118|AP-1
P02154599T0000|122 130|ZRE sites
P02154599T0000|132 146|target promoter
P02154599T0000|149 164|enhancer regions
P02154602A0092|12 18|homolog
P02154602A0092|24 39|mouse Mx protein
P02154602A0092|48 57|resistance
P02154602A0092|60 74|influenza virus
P02154686A0185|0 8|Fragments
P02154686A0185|34 46|repeat region
P02154686A0185|50 57|enhancer
P02154686A0185|66 70|virus
P02154686A0185|97 124|beta-galactosidase synthesis
P02154686A0185|133 141|fragments
P02154686A0185|149 176|polyomavirus enhancer region
P02154686A0185|193 198|levels
P02154885A0153|3 7|sites
P02154885A0153|19 29|mutagenesis
P02154885A0153|31 38|residues
P02154885A0153|83 96|loop structure
P02154885A0153|116 136|substrate recognition
P02154885A0153|141 146|enzyme
P02155017A1106|11 18|benefits
P02155017A1106|21 31|LMW heparin
P02155017A1106|39 47|frequency
P02155017A1106|50 57|bleeding
P02155017A1106|59 69|alleviation
P02155017A1106|72 91|hypertriglyceridemia
P02155017A1106|143 160|observation period
P02155017A1106|169 177|incidence
P02155017A1106|191 203|complications
P02155017A1106|213 220|dialyses
P02156828A0164|10 28|amino acid sequence
P02156828A0164|29 35|destrin
P02156828A0164|41 48|residues
P02156828A0164|72 72|%
P02156828A0164|91 97|cofilin
P02156828A0164|146 152|protein
P02157067A0610|0 6|Summers
P02157067A0610|8 15|Virology
P02157141A0923|16 24|T antigen
P02157141A0923|29 36|presence
P02157141A0923|39 51|topoisomerase
P02157141A0923|69 71|DNA
P02157141A0923|86 94|sequences
P02157141A0923|133 135|DNA
P02157141A0923|150 156|changes
P02157141A0923|188 197|base pairs
P02157764A1115|1 16|rabbit antiserum
P02157764A1115|42 48|peptide
P02157764A1115|76 82|portion
P02157764A1115|104 116|cDNA sequence
P02157882T0000|0 11|Conservation
P02157882T0000|14 21|function
P02157882T0000|46 48|abl
P02157882T0000|63 70|proteins
P02157882T0000|73 86|transformation
P02157882T0000|98 102|cells
P02158099A0487|11 31|cotransfection assays
P02158099A0487|36 52|Chang liver cells
P02158099A0487|52 54|CCL
P02158099A0487|59 65|pM1 DNA
P02158099A0487|99 104|effect
P02158099A0487|110 119|expression
P02158099A0487|125 148|pSV2CAT reporter plasmid
P02158927A0000|19 28|nucleotide
P02158927A0000|30 31|nt
P02158927A0000|33 40|sequence
P02158927A0000|52 62|COR segment
P02158927A0000|78 84|cluster
P02158927A0000|90 94|genes
P02158927A0000|96 99|CYC1
P02158927A0000|101 104|UTR1
P02158927A0000|106 109|UTR3
P02158927A0000|111 114|OSM1
P02158927A0000|116 119|tRNA
P02158927A0000|121 123|Gly
P02158927A0000|128 131|RAD7
P02158927A0000|142 153|chromosome X
P02158927A0000|158 162|yeast
P02159470A1432|8 14|binding
P02159470A1432|20 34|protein factors
P02159470A1432|39 43|sites
P02159470A1432|63 74|Mt sequences
P02159470A1432|93 96|role
P02159470A1432|112 121|regulation
P02159470A1432|127 139|transcription
P02159470A1432|149 153|genes
P02159470A1432|162 169|subunits
P02159470A1432|206 220|phosphorylation
P02159559A0779|21 32|interference
P02159559A0779|48 64|DNA amplification
P02160502A0471|2 31|recombination signal sequences
P02160502A0471|58 76|recombination point
P02160622A0000|18 27|properties
P02160622A0000|44 53|tail-flick
P02160622A0000|57 71|hot-plate tests
P02160622A0000|78 90|motor effects
P02160622A0000|120 151|benzodiazepine agonist midazolam
P02160622A0000|162 172|combination
P02160622A0000|177 184|morphine
P02160622A0000|199 202|rats
P02160955A0899|0 9|Constructs
P02160955A0899|27 32|AATAAA
P02160955A0899|46 51|region
P02160955A0899|74 82|distances
P02160955A0899|99 100|bp
P02162049A0291|13 17|issue
P02162049A0291|22 25|gene
P02162049A0291|29 36|factor Y
P02162049A0291|66 77|DNA sequence
P02162103A0000|23 27|cDNAs
P02162103A0000|42 44|RNA
P02162103A0000|48 51|mRNA
P02162103A0000|55 68|phosphoprotein
P02162103A0000|70 70|P
P02162103A0000|79 96|parainfluenza type
P02162103A0000|97 101|virus
P02162103A0000|103 107|PIV-2
P02162103A0000|110 119|cDNA clone
P02162103A0000|130 132|RNA
P02162103A0000|140 150|nucleotides
P02162103A0000|153 158|length
P02162103A0000|168 171|poly
P02162103A0000|173 173|A
P02162103A0000|204 217|reading frames
P02162103A0000|225 232|proteins
P02162103A0000|244 254|amino acids
P02162467A0311|10 24|cytR expression
P02162467A0311|51 62|CytR protein
P02162467A0311|88 103|cAMP/CAP complex
P02162754A0339|15 19|sites
P02162754A0339|31 49|amino acid sequence
P02162754A0339|53 85|3T3-L1 adipocyte insulin receptor
P02162754A0339|88 92|mouse
P02162754A0801|0 2|PAO
P02162754A0801|9 16|turnover
P02162754A0801|22 37|phosphoryl group
P02162754A0801|39 42|pp15
P02162754A0801|54 65|accumulation
P02162754A0801|95 113|signal transmission
P02162754A0801|120 127|receptor
P02162754A0801|133 156|glucose-transport system
P02162835A0989|17 37|sequence similarities
P02162835A0989|60 71|architecture
P02162835A0989|80 97|heme binding sites
P02162835A0989|102 120|copper binding site
P02162835A0989|126 132|enzymes
P02163347A0472|3 15|cDNA sequence
P02163347A0472|30 42|reading frame
P02163347A0472|43 45|ORF
P02163347A0472|61 79|amino acid sequence
P02163347A0472|84 84|%
P02163347A0472|118 128|amino acids
P02163347A0472|138 150|ets-1 protein
P02163382A0169|17 29|O7-LPS region
P02163382A0169|44 58|cosmids pJHCV31
P02163382A0169|61 67|pJHCV32
P02163382A0169|85 106|transposon mutagenesis
P02163382A0169|110 117|Tn3HoHo1
P02163382A0169|144 153|lac operon
P02163382A0169|176 179|lacZ
P02163382A0169|195 201|fusions
P02163382A0169|206 225|target DNA sequences
P02163394T0000|3 11|sacT gene
P02163394T0000|24 35|sacPA operon
P02163394T0000|37 60|Bacillus subtilis shares
P02163394T0000|65 72|homology
P02163394T0000|92 106|antiterminators
P02164585A0416|3 14|TraD protein
P02164585A0416|21 22|Da
P02164585A0416|48 54|regions
P02164585A0416|97 102|region
P02164585A0814|3 17|protein product
P02164585A0814|19 22|orfD
P02164585A0814|43 50|tra gene
P02164585A0814|56 59|traX
P02164585A0814|72 72|%
P02164585A0814|84 94|amino acids
P02164585A0814|111 117|alanine
P02164585A0814|121 127|leucine
P02164588A0266|13 20|HN genes
P02164588A0266|47 50|role
P02164588A0266|53 60|residues
P02164588A0266|85 90|domain
P02164588A0266|115 118|tail
P02164588A0266|122 129|assembly
P02164588A0266|146 154|transport
P02164588A0266|160 174|HN glycoprotein
P02164604A0399|3 9|studies
P02164604A0399|21 28|findings
P02164604A0399|43 65|E2 transactivation gene
P02164604A0399|87 95|promoters
P02164604A1574|12 19|analysis
P02164604A1574|25 35|E2 proteins
P02164604A1574|51 60|cell lines
P02164604A1574|77 89|BPV-1 mutants
P02164604A1574|106 120|acceptor mutant
P02164604A1574|140 144|modes
P02164604A1574|147 159|E2 expression
P02164637A0515|0 9|Disruption
P02164637A0515|15 23|IRA2 gene
P02164637A0515|45 55|sensitivity
P02164637A0515|58 67|heat shock
P02164637A0515|70 88|nitrogen starvation
P02164637A0515|93 111|sporulation defects
P02164637A0515|120 130|suppression
P02164637A0515|136 144|lethality
P02164637A0515|150 161|cdc25 mutant
P02165181A0299|4 9|cohort
P02165181A0299|12 19|patients
P02165181A0299|36 40|basis
P02165181A0299|51 55|stage
P02165589A0000|1 4|gene
P02165589A0000|52 56|2C1-3
P02165589A0000|68 74|portion
P02165589A0000|80 91|X-chromosome
P02165589A0000|100 105|member
P02165589A0000|126 153|hormone receptor superfamily
P02165589A0888|1 7|portion
P02165589A0888|10 18|Region II
P02165589A0888|31 34|part
P02165589A0888|45 61|c-jun oncoprotein
P02165589A0888|63 76|leucine zipper
P02165589A0888|84 87|turn
P02165589A0888|115 137|heterodimerization site
P02165589A0888|147 149|jun
P02165589A0888|153 168|fos oncoproteins
P02166040A0385|18 25|vanadate
P02166040A0385|38 61|PEPCK gene transcription
P02166040A0385|62 67|series
P02166040A0385|78 82|genes
P02166040A0385|100 108|deletions
P02166040A0385|129 150|carboxykinase promoter
P02166040A0385|191 195|genes
P02166040A0385|221 238|phosphotransferase
P02166040A0385|240 242|neo
P02166040A0385|246 278|chloramphenicol acetyltransferase
P02166040A0385|295 308|hepatoma cells
P02166040A0385|318 324|methods
P02166040A0385|329 337|infection
P02166040A0385|343 349|Moloney
P02166040A0385|356 363|leukemia
P02166040A0385|375 384|retrovirus
P02166040A0385|389 400|transfection
P02166040A0385|410 418|selection
P02166040A0385|422 435|neo expression
P02166040A0385|450 459|expression
P02166040A0385|462 495|chloroamphenicol acetyltransferase
P02166416A0419|3 11|diagnosis
P02166416A0419|21 32|tuberculosis
P02166416A0419|67 70|ARDS
P02166416A0419|80 85|origin
P02166825A0198|2 6|order
P02166825A0198|34 41|elements
P02166825A0198|47 54|promoter
P02166825A0198|65 67|way
P02166825A0198|96 102|signals
P02166825A0198|105 110|number
P02166825A0198|113 130|promoter mutations
P02166825A0198|156 158|set
P02166825A0198|176 184|mutations
P02166825A0198|200 214|promoter region
P02167321T0000|1 9|DNA motif
P02167321T0000|36 42|element
P02167321T0000|60 78|activator protein-2
P02167321T0000|85 88|site
P02167321T0000|99 145|tissue-type plasminogen activator gene promoter
P02167321T0000|158 167|expression
P02167321T0000|177 186|activation
P02167321T0000|189 201|phorbol ester
P02167321T0000|204 207|cAMP
P02167467T0000|3 18|26S rRNA binding
P02167467T0000|26 43|protein equivalent
P02167467T0000|54 64|protein L11
P02167467T0000|94 98|genes
P02167784A0109|15 22|subjects
P02167784A0109|31 33|air
P02167784A0109|39 41|min
P02167784A0109|50 50|%
P02167784A0109|57 57|%
P02167784A0109|65 67|min
P02167784A0109|86 88|min
P02167784A0109|127 141|CO2 measurement
P02168640A0268|11 22|correlations
P02168640A0268|42 48|changes
P02168640A0268|51 54|SSEP
P02168640A0268|57 64|response
P02168640A0268|75 82|presence
P02168640A0268|108 119|disturbances
P02168640A0268|131 136|ground
P02168640A0268|151 159|disorders
P02169887A0360|3 13|transcripts
P02169887A0360|57 68|capstructure
P02169887A0360|85 92|EMCV-RNA
P02169887A0360|103 107|mRNAs
P02169887A0360|125 134|initiation
P02170687A0000|3 16|E6/E7 promoter
P02170687A0000|33 48|papillomaviruses
P02170687A0000|65 74|expression
P02170687A0000|85 102|transforming genes
P02172672T0001|1 4|case
P02172672T0001|7 17|Goodpasture
P02172672T0001|20 27|syndrome
P02173399A0333|23 30|controls
P02173399A0333|45 50|blocks
P02173399A0333|63 80|tissue radiographs
P02173399A0333|81 84|STRs
P02173399A0333|105 115|specificity
P02173399A0333|120 120|%
P02173399A0333|122 132|sensitivity
P02173399A0333|136 136|%
P02173405A0270|13 23|abnormality
P02173405A0270|49 54|period
P02173405A0270|76 89|calcifications
P02174105A1232|19 26|analysis
P02174105A1232|36 45|rat organs
P02174105A1232|55 62|staining
P02174105A1232|75 79|cells
P02174427A1574|4 10|strains
P02174427A1574|53 66|carbon sources
P02174427A1574|91 91|%
P02174427A1574|103 148|ubiquinol-cytochrome c oxidoreductase activity
P02174861A0736|0 9|Regulation
P02174861A0736|12 15|irgA
P02174861A0736|18 21|iron
P02174861A0736|24 34|V. cholerae
P02174861A0736|60 64|level
P02174861A0736|89 92|dyad
P02174861A0736|102 109|sequence
P02174861A0736|115 122|vicinity
P02174861A0736|128 135|promoter
P02174861A0736|154 156|Fur
P02174861A0736|164 168|sites
P02174974A0000|0 12|Transcription
P02174974A0000|23 28|operon
P02174974A0000|56 62|enzymes
P02174974A0000|68 78|TOL plasmid
P02174974A0000|113 129|xylR gene product
P02174974A0000|133 140|presence
P02174974A0000|143 150|m-xylene
P02175433A0575|31 48|beta A-globin gene
P02175433A0575|57 60|gene
P02175433A0575|64 83|Ylp vector sequences
P02175433A0575|95 100|copies
P02175908A0805|9 17|mutations
P02175908A0805|39 42|copy
P02175908A0805|48 62|Ulysses element
P02175908A0805|73 77|locus
P02175908A0805|115 121|element
P02175908A0805|144 151|mutation
P02176021T0000|0 12|Determination
P02176021T0000|15 20|diquat
P02176021T0000|33 41|materials
P02176021T0000|44 79|electron spin resonance spectroscopy
P02176152A0896|14 15|RA
P02176152A0896|43 50|activity
P02176152A0896|54 66|reporter gene
P02176152A0896|77 79|TPA
P02176152A0896|90 105|AP1 binding site
P02176152A0896|114 128|HSV tk promoter
P02176209A0954|21 23|EFI
P02176209A0954|25 28|NF-Y
P02176209A0954|32 39|CBF DNAs
P02176209A0954|43 46|rise
P02176209A0954|58 81|gel retardation patterns
P02176209A0954|82 89|extracts
P02176209A0954|95 101|variety
P02176209A0954|113 122|cell types
P02176232T0001|0 11|Risk factors
P02176232T0001|22 43|lymph nodes metastasis
P02176232T0001|44 54|lung cancer
P02176232T0001|58 62|stage
P02176232T0001|69 72|IIIA
P02176822A0000|15 28|protein kinase
P02176822A0000|29 32|MFPK
P02176822A0000|59 63|lyase
P02176822A0000|66 74|peptide B
P02176822A0000|79 83|sites
P02176822A0000|85 86|BT
P02176822A0000|90 91|BS
P02176822A0000|95 103|threonine
P02176822A0000|107 112|serine
P02176822A0000|127 135|inhibitor
P02176822A0000|148 154|residue
P02176822A0000|159 175|glycogen synthase
P02176822A0000|177 181|sites
P02179052A1044|16 16|Y
P02179052A1044|26 42|sequence families
P02179052A1044|63 68|system
P02179052A1044|84 104|sequence interactions
P02179052A1044|117 125|evolution
P02179188A1223|22 37|motile responses
P02179188A1223|59 66|presence
P02179188A1223|69 81|dinitrophenol
P02179188A1223|84 98|cytochalasin B.
P02179815A0582|6 13|p59v-rel
P02179815A0582|30 36|protein
P02179815A0582|39 41|CEF
P02179815A0582|51 68|immunofluorescence
P02179815A0582|79 86|p68c-rel
P02179815A0582|107 109|CEF
P02179815A0582|135 143|cytoplasm
P02179815A0582|151 155|cells
P02179815A0582|170 177|sequence
P02179815A0582|180 187|p68c-rel
P02179815A0582|226 233|sequence
P02179815A0582|273 280|p59v-rel
P02180935A0535|7 17|experiments
P02180935A0535|38 40|min
P02180935A0535|57 73|precursor protein
P02180935A0535|87 97|HL-60 cells
P02180935A0535|103 104|Mr
P02180935A0535|125 169|chondroitin sulfate proteoglycan intermediate
P02181760A0311|0 9|Blood flow
P02181760A0311|12 19|velocity
P02181760A0311|34 51|Doppler ultrasound
P02181760A0311|76 83|diastole
P02181760A0311|107 115|direction
P02181760A0311|118 137|cotyledon resistance
P02181760A0311|155 158|fold
P02182240A0355|1 5|total
P02182240A0355|11 18|patients
P02182240A0355|27 38|anistreplase
P02182240A0355|53 59|heparin
P02182240A0355|71 76|period
P02182240A0355|87 89|min
P02182240A0355|102 106|onset
P02182240A0355|109 116|symptoms
P02182323A0121|15 25|transcripts
P02182323A0121|36 39|tRNA
P02182323A0121|41 43|Val
P02182323A0121|46 48|UAC
P02182323A0121|50 53|gene
P02182323A0121|89 105|growth conditions
P02182323A0121|108 116|degrees C
P02182323A0121|149 154|region
P02182618A0168|3 19|promoter activity
P02182618A0168|42 51|expression
P02182618A0168|55 87|chloramphenicol acetyltransferase
P02182618A0168|88 90|CAT
P02182618A0168|92 95|gene
P02182618A0168|119 134|deletion mutants
P02182618A0168|150 155|region
P02183467A0668|15 18|ORFs
P02183467A0668|31 36|region
P02183467A0668|39 41|BIV
P02183467A0668|62 69|location
P02183467A0668|83 92|similarity
P02183467A0668|122 126|genes
P02183467A0668|128 130|vif
P02183467A0668|132 134|tat
P02183467A0668|139 141|rev
P02183467A0668|150 161|lentiviruses
P02183467A0668|188 191|ORFs
P02183467A0668|199 199|W
P02183467A0668|203 203|Y
P02183467A0668|220 224|exons
P02183467A0668|233 237|genes
P02185140A0000|26 34|14DM gene
P02185140A0000|43 68|cytochrome P450 lanosterol
P02185140A0000|69 85|alpha-demethylase
P02185140A0000|87 90|14DM
P02185140A0000|130 136|strains
P02185140A0000|145 151|control
P02185140A0000|177 205|yeast transcription promoters
P02185140A0000|205 209|pADC1
P02185140A0000|211 214|pGPD
P02185140A0000|216 220|pPHO5
P02185140A0000|233 239|control
P02185140A0000|248 255|promoter
P02185250A0726|0 10|Truncations
P02185250A0726|28 38|amino acids
P02185250A0726|74 91|reticulum membrane
P02185250A0726|95 107|translocation
P02187091A0721|17 26|resistance
P02187091A0721|41 57|ejection fraction
P02187091A0721|87 103|relaxation period
P02187091A0721|144 144|P
P02187871T0000|3 12|ANB1 locus
P02187871T0000|47 88|protein synthesis initiation factor eIF-4D
P02188096A0955|3 14|contribution
P02188096A0955|30 44|splicing events
P02188096A0955|46 61|c-myb expression
P02188096A0955|70 83|c-myb function
P02188168A0000|0 9|Serum beta
P02188168A0000|24 29|levels
P02188168A0000|31 38|beta-2-M
P02188168A0000|56 67|drug addicts
P02188168A0000|88 95|carriers
P02188168A0000|102 117|HIV-1 antibodies
P02188168A0000|131 138|carriers
P02188168A0000|164 178|lymphadenopathy
P02188168A0000|180 185|P.G.L.
P02188168A0000|192 196|serum
P02188168A0000|205 212|patients
P02188168A0000|238 246|community
P02188168A0000|258 262|years
P02190122A0633|4 15|emancipation
P02190122A0633|21 27|ability
P02190122A0633|50 58|influence
P02190122A0633|76 85|motivation
P02190122A0633|96 104|regulator
P02190122A0633|107 112|mating
P02190122A0633|115 122|primates
P02190134A0572|2 8|therapy
P02190134A0572|28 38|progression
P02190134A0572|44 50|disease
P02190134A0572|66 74|exception
P02190134A0572|77 108|laser photocoagulation treatment
P02190134A0572|140 148|membranes
P02190134A0572|153 159|attempt
P02190134A0572|167 179|complications
P02190134A0572|192 202|hemorrhages
P02193033A0195|0 1|R.
P02194273A0913|8 28|hyperimmune globulins
P02194273A0913|30 38|pathogens
P02194273A0913|56 65|influenzae
P02194273A0913|69 81|Streptococcus
P02194972T0000|11 17|effects
P02194972T0000|20 28|cefpirome
P02194972T0000|30 31|HR
P02194972T0000|55 64|infections
P02194972T0000|69 89|Enterococcus faecalis
P02194972T0000|109 112|mice
P02195025T0000|0 9|Regulation
P02195025T0000|12 21|yeast LEU2
P02195715A0143|10 20|individuals
P02195715A0143|35 51|purpura fulminans
P02195715A0143|53 60|newborns
P02195715A0143|74 80|protein
P02195715A0143|92 102|individuals
P02195715A0143|117 120|risk
P02195715A0143|130 139|thrombosis
P02195715A0143|152 159|embolism
P02195715T0000|8 13|stroke
P02195715T0000|19 38|protein C deficiency
P02196176A0749|0 4|TREB7
P02196176A0749|8 13|TREB36
P02196176A0749|31 37|repeats
P02196176A0749|45 46|bp
P02196176A0749|51 55|TREB5
P02196176A0749|78 83|repeat
P02196311A1034|5 11|results
P02196311A1034|24 31|KE X 3/W
P02196311A1034|45 51|regimen
P02196311A1034|64 81|antitumor immunity
P02196311A1034|83 85|RNL
P02196450A0870|0 7|Analysis
P02196450A0870|17 32|deletion mutants
P02196450A0870|48 68|sequence requirements
P02196450A0870|71 77|binding
P02196450A0870|80 82|QBP
P02196450A0870|131 140|Q activity
P02196450A0870|169 171|QBP
P02196450A0870|188 195|function
P02196450A0870|218 225|promoter
P02196565A0606|22 29|factor I
P02196565A0606|30 33|GRFI
P02196565A0606|36 75|repressor/activator site binding protein
P02196565A0606|75 78|RAP1
P02196565A0606|81 91|translation
P02196565A0606|100 105|factor
P02196565A0606|107 109|TUF
P02196565A0606|127 135|activator
P02196565A0606|138 157|MAT alpha expression
P02196565A0606|174 177|PYK1
P02196565A0606|206 218|GRFI/RAP1/TUF
P02196565A0606|239 252|gal11 mutation
P02196565T0000|0 18|Yeast Gal11 protein
P02196565T0000|43 59|activation signal
P02196565T0000|84 90|factors
P02196565T0000|92 95|Gal4
P02196565T0000|116 178|factor I/repressor/activator site binding protein 1/translation
P02196565T0000|182 187|factor
P02198259A0685|0 7|Deletion
P02198259A0685|21 21|N
P02198259A0685|35 38|ends
P02198259A0685|41 44|repA
P02198259A0685|53 58|codons
P02198259A0685|94 106|reading frame
P02198259A0685|118 126|initiator
P02198259A0685|146 153|activity
P02198289A0436|12 19|peptides
P02198289A0436|34 44|amino acids
P02198289A0436|70 80|amino acids
P02198289A0436|93 98|dimers
P02198289A0436|101 108|solution
P02198289A0436|117 119|DNA
P02198289A0436|135 139|dimer
P02199311A0620|7 28|transcription extracts
P02199311A0620|32 43|ret1-1 cells
P02199311A0620|73 105|transcription termination signals
P02199311A0620|117 126|RET1 cells
P02199311A0620|133 139|variety
P02199311A0620|142 155|tRNA templates
P02200150A1381|7 14|patients
P02200150A1381|20 27|decision
P02200150A1381|59 62|team
P02200150A1381|82 91|oncologist
P02200150A1381|93 102|geneticist
P02200150A1381|104 114|pathologist
P02200150A1381|116 130|psychotherapist
P02200150A1381|134 148|plastic surgeon
P02200315A0278|0 2|IgG
P02200315A0278|6 26|IgM antibody activity
P02200315A0278|52 59|dilution
P02200315A0278|62 66|serum
P02200315A0278|69 74|plates
P02200315A0278|85 95|A60 antigen
P02200736A1003|5 11|factors
P02200736A1003|21 23|set
P02200736A1003|45 53|molecules
P02200736A1003|64 67|AP-4
P02200736A1003|71 74|MLTF
P02200736A1003|89 102|CACCTGTC motif
P02200736A1003|111 119|sequences
P02201770A0188|10 20|flea larvae
P02201770A0188|24 42|genus Anomiopsyllus
P02201770A0188|43 57|Anomiopsyllinae
P02201770A0188|59 72|Anomiopsyllini
P02201770A0188|97 100|form
P02201770A0188|109 114|adults
P02201901A0229|23 30|antibody
P02201901A0229|59 70|SSN6 protein
P02201905A1004|11 17|results
P02201905A1004|31 42|ABFI protein
P02201905A1004|50 61|RAP1 protein
P02201905A1004|67 75|sequences
P02201905A1004|111 120|regulation
P02201905A1004|123 137|gene expression
P02202496T0000|8 16|nutrition
P02202496T0000|24 29|horses
P02203672A1542|22 35|cytocentrifuge
P02204029A0184|0 22|RNase protection assays
P02204029A0184|35 38|gene
P02204029A0184|40 42|unr
P02204029A0184|66 74|direction
P02204029A0184|77 81|N-ras
P02204029A0184|94 96|end
P02204029A0184|113 122|base pairs
P02204029A0184|133 137|point
P02204029A0184|150 162|transcription
P02204621T0000|0 8|Isolation
P02204621T0000|33 38|mutant
P02204621T0000|52 78|tRNA nucleotidyltransferase
P02204621T0000|81 87|cloning
P02204621T0000|93 96|gene
P02204621T0000|105 131|tRNA nucleotidyltransferase
P02204621T0000|136 140|yeast
P02204623A0000|3 22|juxtamembrane region
P02204623A0000|27 42|insulin receptor
P02204623A0000|43 44|IR
P02204623A0000|46 57|beta-subunit
P02204623A0000|84 98|tyrosyl residue
P02204623A0000|99 104|Tyr960
P02204623A0000|142 164|tyrosyl phosphorylation
P02204623A0000|180 189|substrates
P02204623A0000|210 218|responses
P02204623A0000|220 224|White
P02204623A0000|226 229|M.F.
P02204623A0000|231 240|Livingston
P02204623A0000|242 245|J.N.
P02204623A0000|247 252|Backer
P02204623A0000|254 257|J.M.
P02204623A0000|259 264|Lauris
P02204623A0000|266 267|V.
P02204623A0000|269 272|Dull
P02204623A0000|274 277|T.J.
P02204623A0000|279 285|Ullrich
P02204623A0000|287 288|A.
P02204623A0000|293 296|Kahn
P02204623A0000|298 301|C.R.
P02204625A1130|4 7|gene
P02204625A1130|16 20|group
P02204625A1130|23 27|genes
P02204625A1130|33 39|members
P02204625A1130|63 70|response
P02204625A1130|73 79|insulin
P02204625A1130|88 95|mitogens
P02204810A1080|5 10|region
P02204810A1080|12 14|GA2
P02204810A1080|37 46|expression
P02206430A0197|0 3|Pups
P02206430A0197|22 32|environment
P02206430A0197|42 48|mothers
P02206430A0197|72 76|level
P02206430A0197|79 89|DA turnover
P02206789A0002|3 10|efficacy
P02206789A0002|14 19|safety
P02206789A0002|40 62|anaesthetic preparation
P02206789A0002|69 79|amethocaine
P02206789A0002|122 132|environment
P02206858A0000|10 18|protein C
P02206858A0000|19 20|PC
P02206858A0000|22 31|deficiency
P02206858A0000|47 54|siblings
P02206858A0000|56 59|girl
P02206858A0000|63 65|boy
P02206858A0000|89 97|diagnoses
P02206858A0000|103 106|ages
P02206858A0000|122 126|years
P02208762A0228|3 13|grandfather
P02208762A0228|20 32|granddaughter
P02208762A0228|40 47|microtia
P02208762A0228|57 63|atresia
P02208762A0228|75 82|daughter
P02208762A0228|98 100|ear
P02208762A0228|117 122|meatus
P02208762A0228|135 144|appendages
P02209237A0239|22 29|shunting
P02209237A0239|31 33|IPS
P02209237A0239|53 57|cases
P02209237A0239|82 89|scanning
P02209237A0239|94 102|99mTc-MAA
P02209237A0239|125 129|cause
P02209237A0239|132 139|cyanosis
P02209237A0239|142 156|liver cirrhosis
P02209243A0237|10 16|protein
P02209243A0237|18 30|serum albumin
P02209243A0237|31 33|BUN
P02209243A0237|37 39|SCr
P02209243A0237|61 71|improvement
P02209540A1362|14 17|Ets1
P02209540A1362|21 24|Ets2
P02209540A1362|38 50|transcription
P02209540A1362|61 65|genes
P02209605A0510|10 17|sequence
P02209605A0510|21 29|MSAS gene
P02209605A0510|61 73|reading frame
P02209605A0510|83 89|protein
P02209605A0510|96 106|amino acids
P02209605A0510|116 117|Da
P02209605A0510|127 130|mass
P02209811T0000|11 20|peroxidase
P02209811T0000|24 42|permeability marker
P02209811T0000|51 60|rat caudal
P02209811T0000|63 76|iliac arteries
P02212540A0473|19 32|wall specimens
P02212540A0473|39 42|area
P02212540A0473|58 63|ulcers
P02212540A0473|101 116|light microscopy
P02212540A0473|121 152|transmission electron microscopy
P02213566A0000|3 9|effects
P02213566A0000|12 23|coenzyme Q10
P02213566A0000|24 26|CoQ
P02213566A0000|31 39|captopril
P02213566A0000|52 59|capacity
P02213566A0000|61 72|hemodynamics
P02213566A0000|76 83|survival
P02213566A0000|100 103|rats
P02213566A0000|144 153|infarction
P02217307T0000|0 7|Evidence
P02217307T0000|23 33|alterations
P02217307T0000|46 51|rhythm
P02217307T0000|62 78|emptying response
P02217741T0001|3 15|interrelation
P02217741T0001|21 26|levels
P02217741T0001|29 43|glucocorticoids
P02217741T0001|47 53|insulin
P02217741T0001|59 63|blood
P02217741T0001|76 82|animals
P02218094A0395|16 21|tissue
P02218094A0395|24 31|transfer
P02218094A0395|33 34|Ft
P02218094A0395|55 65|utilization
P02218094A0395|67 68|Fm
P02219751A0517|9 16|saccades
P02219751A0517|55 58|FEMs
P02219751A0517|64 68|basis
P02219751A0517|71 75|speed
P02220102A0271|0 8|Incidence
P02220102A0271|26 30|grade
P02220102A0271|37 47|hygiene und
P02220102A0271|58 64|disease
P02220304A0501|3 7|study
P02220304A0501|20 23|area
P02220304A0501|26 30|Alcoy
P02220304A0501|34 54|medium MS risk region
P02220304A0501|66 71|thesis
P02220304A0501|74 79|Kurzke
P02220304A0501|93 100|MS areas
P02220304A0501|129 143|MS distribution
P02220304A0501|153 158|Europe
P02223652A0939|4 26|antithrombin unit basis
P02223652A0939|26 27|CY
P02223652A0939|34 35|CY
P02223652A0939|70 71|UH
P02223773A0000|0 38|Chick brain actin depolymerizing factor
P02223773A0000|36 38|ADF
P02223773A0000|49 55|protein
P02223773A0000|66 80|actin filaments
P02223773A0000|88 101|actin monomers
P02223928T0069|7 16|experience
P02223928T0069|22 38|serotonin agonist
P02225687A0546|0 17|Comprehensive care
P02225687A0546|22 28|patient
P02225687A0546|44 52|teratogen
P02225687A0546|67 76|discussion
P02225687A0546|97 106|procedures
P02225687A0546|115 142|pregnancy management options
P02227438A0492|0 24|Primer extension analysis
P02227438A0492|26 39|RNA sequencing
P02227438A0492|58 82|transcription start point
P02227438A0492|83 94|rat ODC mRNA
P02227438A0492|105 106|nt
P02227438A0492|122 130|A residue
P02227438A0492|135 145|start codon
P02228615A0974|3 6|85Sr
P02228615A0974|28 52|distribution coefficients
P02228615A0974|69 90|desorption experiments
P02228615A0974|93 102|indication
P02228615A0974|120 128|formation
P02228615A0974|131 149|metal-oxyhydroxides
P02228615A0974|161 168|reaction
P02229068A0156|0 14|Gene constructs
P02229068A0156|35 37|tat
P02229068A0156|39 41|rev
P02229068A0156|43 45|tat
P02229068A0156|47 49|rev
P02229068A0156|55 63|env genes
P02229068A0156|89 99|COS-1 cells
P02229068A0156|101 115|precursor SU-TM
P02229068A0156|116 120|gp160
P02229068A0156|123 124|SU
P02229068A0156|126 127|TM
P02229068A0156|129 135|gp120 x
P02229068A0156|151 161|rev protein
P02229072A1012|4 16|growth arrest
P02229072A1012|43 48|medium
P02229072A1012|56 65|conditions
P02229072A1012|76 80|cells
P02229072A1012|112 121|metabolism
P02229282A0454|0 7|Patients
P02229282A0454|22 37|serum TNF levels
P02229282A0454|57 79|serum T3 concentrations
P02229282A0454|109 114|levels
P02229541T0000|0 4|Giant
P02229541T0000|15 23|carcinoma
P02229541T0000|25 30|report
P02229541T0000|34 39|review
P02229541T0000|45 54|literature
P02231162T0000|7 13|studies
P02231162T0000|26 33|movement
P02231162T0000|43 55|tooth contact
P02231479A0585|4 9|parent
P02231479A0585|43 45|son
P02231479A0585|48 55|daughter
P02231479A0585|67 79|conversations
P02231479A0585|101 112|conversation
P02231479A0585|128 140|task activity
P02233626T0000|32 39|symptoms
P02233626T0000|63 80|strabismus surgery
P02233680A1115|5 11|results
P02233680A1115|41 48|elements
P02233680A1115|73 79|control
P02233680A1115|85 108|HaG3-A helianthinin gene
P02233680A1115|123 124|kb
P02233680A1115|133 138|region
P02233680A1115|145 148|gene
P02233715A0914|3 11|induction
P02233715A0914|14 31|pseudorabies virus
P02233715A0914|35 48|IL-6 construct
P02233715A0914|61 73|IL-6 TATA box
P02233715A0914|78 91|RNA start site
P02233715A0914|92 100|initiator
P02233715A0914|107 113|element
P02233715A0914|124 133|MRE region
P02233715A0914|151 153|Dex
P02233715A0914|159 166|presence
P02233715A0914|178 179|GR
P02233729A1065|4 12|mutations
P02233729A1065|21 24|Dhfr
P02233729A1065|39 44|manner
P02233729A1065|65 74|startpoint
P02233729A1065|90 105|Dhfr transcripts
P02233729A1065|126 134|abundance
P02233729A1065|148 163|Dhfr transcripts
P02234345A0215|8 16|cyst wall
P02234345A0215|26 29|part
P02234345A0215|51 60|epithelium
P02234731A0503|14 18|class
P02234731A0503|29 34|smears
P02234731A0503|55 66|inflammation
P02234731A0503|86 93|findings
P02234731A0503|96 106|condylomata
P02234731A0503|118 126|dysplasia
P02236002A0958|4 10|mammals
P02236002A0958|24 43|nucleotide diversity
P02236002A0958|59 67|junctions
P02236002A0958|82 90|diversity
P02236002A0958|102 109|elements
P02236002A0958|112 133|chicken TCR beta cDNAs
P02236022A0000|3 21|protooncogene c-myb
P02236022A0000|36 55|transcription factor
P02236022A0000|66 68|DNA
P02236022A0000|89 94|manner
P02236022A0000|112 124|transcription
P02236022A0000|150 154|genes
P02236060A1671|0 11|Modification
P02236060A1671|24 31|compound
P02236060A1671|53 58|amount
P02236060A1671|95 101|protein
P02236064A1178|0 19|S6 kinase activation
P02236064A1178|26 37|displacement
P02236064A1178|54 60|segment
P02236064A1178|107 121|phosphorylation
P02236276T0000|0 3|Rats
P02236276T0000|20 23|bulb
P02236276T0000|50 54|naris
P02236276T0000|70 74|odors
P02237431A0000|0 9|Expression
P02237431A0000|20 34|T cell receptor
P02237431A0000|34 36|TCR
P02237431A0000|38 47|alpha gene
P02237431A0000|61 61|T
P02237431A0000|90 97|enhancer
P02237431A0000|114 122|kilobases
P02237431A0000|124 125|kb
P02237431A0000|134 153|C alpha gene segment
P02237431A0833|3 20|Ets-1 binding site
P02237431A0833|41 44|pair
P02237431A0833|46 47|bp
P02237431A0833|49 54|region
P02237431A0833|64 66|end
P02237431A0833|69 75|T alpha
P02241742A0766|8 11|flow
P02241742A0766|15 24|resistance
P02241742A0766|36 45|reductions
P02241742A0766|50 51|HD
P02241892A0681|0 10|Utilization
P02241892A0681|24 46|polyadenylation signals
P02241892A0681|88 92|mRNAs
P02241892A0681|104 105|kb
P02241892A0681|123 128|length
P02241892A0681|150 156|regions
P02242222T0000|12 18|address
P02242222T0000|40 43|cold
P02243093A0000|5 30|T-cell leukemia virus type
P02243093A0000|30 35|HTLV-I
P02243093A0000|58 64|protein
P02243093A0000|66 68|Tax
P02243093A0000|85 97|transcription
P02243093A0000|114 117|pair
P02243093A0000|119 120|bp
P02243093A0000|122 128|repeats
P02243093A0000|134 142|U3 region
P02243386A0113|27 32|serial
P02243386A0113|42 49|passages
P02243386A0113|52 54|MHV
P02243386A0113|62 67|DI RNA
P02243386A0113|68 72|DIssF
P02243386A0113|104 110|virions
P02246362T0000|3 25|Jenkins Activity Survey
P02246362T0000|49 56|evidence
P02246362T0000|81 84|type
P02246362T0000|86 91|traits
P02246447A0460|8 15|evidence
P02246447A0460|28 44|regression slopes
P02246447A0460|70 82|portion sizes
P02246447A0460|93 103|food groups
P02246447A0460|112 120|r2 values
P02246447A0460|134 146|portion sizes
P02246803A0692|3 8|result
P02246803A0692|37 46|TTD method
P02246803A0692|108 113|output
P02247069A0261|3 11|TUP1 gene
P02247069A0261|25 30|screen
P02247069A0261|34 38|genes
P02247069A0261|51 61|mating type
P02247069A0261|62 65|V.L.
P02247072A0794|3 27|SUP44 suppressor mutation
P02247072A0794|37 42|region
P02247072A0794|48 54|protein
P02247072A0794|80 88|positions
P02247072A0794|91 101|alterations
P02247072A0794|112 124|ram mutations
P02247081A0223|14 23|disruption
P02247081A0223|29 39|VPS34 locus
P02247081A0223|71 83|growth defect
P02247081A0223|101 110|VPS34 gene
P02247081A0223|134 139|growth
P02247081A0223|154 172|growth temperatures
P02247924A0078|11 14|case
P02247924A0078|29 35|abscess
P02247924A0078|47 60|amphotericin B
P02247924A0078|63 73|nephrectomy
P02248732A1113|20 23|data
P02248732A1113|36 46|haloperidol
P02248732A1113|68 75|increase
P02248732A1113|81 91|firing rate
P02248732A1113|93 100|LC cells
P02248732A1113|105 105|%
P02248732A1113|142 149|turnover
P02248732A1113|152 153|NA
P02248732A1113|167 179|DOPAC changes
P02249872A1051|4 14|interaction
P02249872A1051|30 34|range
P02249872A1051|41 50|parameters
P02249872A1051|55 68|charge density
P02249872A1051|86 95|microC/cm2
P02249872A1051|103 108|charge
P02249872A1051|112 116|phase
P02249872A1051|138 143|microC
P02249872A1051|147 151|phase
P02250919A0404|0 10|Perceptions
P02250919A0404|13 33|illness intrusiveness
P02250919A0404|64 75|muscle cramp
P02250919A0404|78 94|headache symptoms
P02250919A0404|117 136|assessment intervals
P02250919A0404|152 164|muscle cramps
P02250919A0404|166 174|headaches
P02251119A0319|0 6|Results
P02251119A0319|34 41|presence
P02251119A0319|49 51|U14
P02251119A0319|68 74|regions
P02251119A0319|91 97|introns
P02251119A0319|111 115|mouse
P02251119A0319|123 143|hsc70 heat shock gene
P02252891T0000|13 19|protein
P02252891T0000|36 46|interleukin
P02252891T0000|48 58|stimulation
P02252891T0000|88 92|sites
P02252891T0000|114 118|sites
P02252953A0300|19 23|girls
P02252953A0300|47 55|EAT score
P02252953A0300|76 80|girls
P02252953A0300|100 106|mothers
P02252953A0300|108 121|susceptibility
P02252953A0300|140 146|effects
P02252953A0300|157 167|mood states
P02252953A0300|174 189|eating behaviour
P02253274A0000|3 14|Mauriceville
P02253274A0000|18 23|Varkud
P02253274A0000|37 44|plasmids
P02253274A0000|78 81|DNAs
P02253274A0000|92 93|kb
P02253274A0000|116 130|characteristics
P02253274A0000|133 145|mtDNA introns
P02253274A0000|155 162|elements
P02253663A0687|12 17|rhythm
P02253663A0687|47 56|difference
P02253663A0687|64 70|minimum
P02253663A0687|77 77|h
P02253663A0687|82 88|maximum
P02253663A0687|95 95|h
P02253663A0687|97 116|serum concentrations
P02253663A0687|123 123|%
P02254282T0000|0 7|Sequence
P02254282T0000|18 29|organization
P02254282T0000|33 62|Zymomonas mobilis gene cluster
P02254282T0000|78 84|enzymes
P02254282T0000|87 104|glucose metabolism
P02254418A0641|4 10|strains
P02254418A0641|14 14|%
P02254418A0641|18 31|S. lugdunensis
P02254418A0641|40 54|delta hemolysin
P02254418A0641|79 85|species
P02254418A0641|88 90|CNS
P02254749A0133|8 12|cDNAs
P02254749A0133|26 28|60K
P02254749A0133|30 32|87K
P02254749A0133|34 37|110K
P02254749A0133|41 52|170K protein
P02254749A0133|58 66|sequences
P02254749A0133|89 103|ATG start codon
P02254749A0133|108 111|cDNA
P02254749A0133|125 127|60K
P02254749A0133|134 141|sequence
P02254749A0133|147 149|TAA
P02254749A0133|154 158|codon
P02254749A0133|191 198|sequence
P02256678A1224|22 42|footprinting analysis
P02256678A1224|55 60|region
P02256678A1224|89 98|HSC82 gene
P02256678A1224|108 115|presence
P02256678A1224|131 147|protein complexes
P02257251T0000|0 14|Pathophysiology
P02257251T0000|17 25|bone loss
P02257251T0000|36 42|animals
P02257899T0000|15 25|interaction
P02257899T0000|31 40|generation
P02257899T0000|43 50|saccades
P02257899T0000|53 55|man
P02258918A0242|10 13|lung
P02258918A0242|24 29|slices
P02258918A0242|47 55|disectors
P02258918A0242|91 107|sampling fraction
P02259334A0205|11 18|promoter
P02259334A0205|43 50|sequence
P02259334A0205|63 66|gene
P02259334A0205|78 84|protein
P02259334A0205|87 88|Mr
P02259334A0205|91 93|kDa
P02259334A0205|103 110|function
P02259795A0570|10 20|consumption
P02259795A0570|34 37|skin
P02259795A0570|55 66|calculations
P02259795A0570|81 89|water PO2
P02259795A0570|100 104|mm Hg
P02259795A0570|113 113|%
P02259795A0570|132 137|uptake
P02259795A0570|154 157|skin
P02261254A0168|0 10|Experiments
P02261254A0168|30 35|arrest
P02261254A0168|47 57|circulation
P02261254A0168|63 72|conditions
P02261254A0168|89 99|circulation
P02261254A0168|115 125|development
P02261254A0168|128 135|ischemia
P02261254A0168|161 166|tissue
P02262439A0508|0 11|MCh infusion
P02262439A0508|41 48|increase
P02262439A0508|51 67|airway resistance
P02262439A0508|77 79|QBA
P02264601A0000|0 21|Taste reactivity tests
P02264601A0000|49 57|responses
P02264601A0000|60 66|alcohol
P02264601A0000|78 78|P
P02264601A0000|80 83|rats
P02264601A0000|87 107|alcohol nonpreferring
P02264601A0000|108 109|NP
P02264601A0000|111 114|rats
P02264601A0000|120 124|taste
P02264601A0000|127 133|alcohol
P02265055A0417|0 20|Plasma concentrations
P02265055A0417|22 31|atracurium
P02265055A0417|35 45|laudanosine
P02265055A0417|59 73|micrograms ml-1
P02265055A0417|85 99|micrograms ml-1
P02265055A0417|113 129|CSF concentration
P02265055A0417|131 141|laudanosine
P02265055A0417|151 157|ng ml-1
P02266679A0740|0 8|Plasma Al
P02266679A0740|29 36|baseline
P02266679A0740|40 50|drug course
P02268461A0224|3 10|survival
P02268461A0224|16 19|case
P02268461A0224|27 34|patients
P02268461A0224|49 53|years
P02269281A1276|3 12|occurrence
P02269281A1276|14 24|maintenance
P02269281A1276|36 46|involvement
P02269281A1276|62 70|sequences
P02269281A1276|103 112|structures
P02269281A1276|128 135|relation
P02269281A1276|143 150|location
P02269281A1276|156 161|region
P02269281A1276|164 178|control signals
P02269426A0428|0 2|IST
P02269426A0428|11 20|RNA target
P02269426A0428|21 23|TAR
P02269426A0428|28 47|Tat trans-activation
P02269426A0428|89 95|factors
P02269426A0428|99 106|activity
P02269426A0428|108 110|IST
P02269426A0428|136 146|RNA targets
P02269426A0428|149 168|Tat trans-activation
P02269426A0428|176 186|requirement
P02269426A0428|206 220|mRNA expression
P02270096T0000|9 16|activity
P02270096T0000|36 46|nitrosamine
P02270587A0000|13 26|treatment need
P02270587A0000|49 53|order
P02270587A0000|56 64|magnitude
P02270834A0123|7 12|method
P02270834A0123|21 30|HML method
P02272095A0832|5 11|results
P02272095A0832|22 32|involvement
P02272095A0832|45 55|enkephalins
P02272095A0832|58 72|pain modulation
P02272095A0832|74 81|patients
P02272095A0832|94 109|cluster headache
P02273690T0001|0 6|Effects
P02273690T0001|9 17|cisapride
P02273690T0001|42 49|motility
P02273690T0001|62 69|hormones
P02274343A0064|6 21|foot pathologies
P02274343A0064|24 32|heel pain
P02274343A0064|33 45|metatarsalgia
P02274343A0064|47 56|hammertoes
P02274343A0064|60 67|clawtoes
P02274343A0064|69 75|bunions
P02274343A0064|77 90|hallux rigidus
P02274343A0064|91 95|corns
P02274343A0064|99 106|calluses
P02274343A0064|108 123|nail pathologies
P02274343A0064|124 132|arthritis
P02274343A0064|137 148|neuropathies
P02274509A0623|0 16|Liver dysfunction
P02274509A0623|21 28|presence
P02274509A0623|47 55|reactions
P02274509A0623|76 83|activity
P02274509A0623|89 99|blood serum
P02274509A0623|101 123|indicator liver enzymes
P02274509A0623|151 158|function
P02276891T0000|0 11|Coenzyme Q10
P02276891T0000|12 23|blood levels
P02276891T0000|35 40|demand
P02277005A0227|3 20|CT characteristics
P02277005A0227|44 53|literature
P02277319A0211|19 31|preservatives
P02277319A0211|67 72|assays
P02277319A0211|88 104|product sterility
P02277319A0211|106 121|bioburden levels
P02277452A0116|4 11|patients
P02277452A0116|16 30|angina pectoris
P02277452A0116|34 40|changes
P02277452A0116|43 46|LVEF
P02277452A0116|48 52|LVESV
P02277452A0116|56 64|PSP/LVESV
P02277452A0116|88 96|detection
P02277452A0116|115 122|ischemia
P02277452A0116|130 139|appearance
P02277452A0116|142 151|chest pain
P02277452A0116|157 163|changes
P02277452A0116|166 168|ECG
P02278217A0372|6 11|groups
P02278217A0372|22 39|management failure
P02278217A0372|41 47|therapy
P02278217A0372|66 75|medication
P02278217A0372|87 98|section lead
P02278217A0372|100 107|delivery
P02278474A0000|0 32|Serum Fibrin Degradation Products
P02278474A0000|31 33|FDP
P02278474A0000|57 71|cancer patients
P02278474A0000|82 92|individuals
P02278474A0000|103 106|kind
P02278474A0000|109 117|treatment
P02280777T0000|3 22|uteroglobin promoter
P02280777T0000|43 50|estrogen
P02280777T0000|61 67|element
P02281118A1191|0 33|Prostaglandin synthesis inhibitors
P02281118A1191|52 58|healing
P02281118A1191|61 64|bone
P02281118A1191|80 90|limitations
P02281118A1191|98 100|use
P02281118A1191|117 126|situations
P02281330A0556|14 33|oxygen concentration
P02281330A0556|40 43|FiO2
P02281330A0556|51 67|Horowitz quotient
P02281330A0556|95 100|manner
P02281330A0556|118 120|day
P02281330A0556|126 131|trauma
P02281948A0245|3 6|corn
P02281948A0245|10 30|mineral oil emulsions
P02281948A0245|52 55|milk
P02281948A0245|76 82|sucrose
P02281948A0245|87 87|M
P02281948A0245|102 110|ingestion
P02282815T0000|0 11|Significance
P02282815T0000|28 45|basement membranes
P02282815T0000|56 63|children
P02283148T0000|0 11|Significance
P02283148T0000|14 32|cytokine production
P02283148T0000|35 52|adhesion molecules
P02283148T0000|62 76|immunopathology
P02283378A0385|9 17|procedure
P02283378A0385|97 116|ultrafiltration tube
P02283378T0000|6 11|method
P02283378T0000|15 27|determination
P02283378T0000|33 53|cephalosporin DQ-2556
P02283378T0000|65 70|fluids
P02283378T0000|95 108|chromatography
P02283873A0308|8 12|group
P02283873A0308|15 25|adolescents
P02283873A0308|63 75|parents smoke
P02283873A0308|84 94|involvement
P02283873A0308|97 114|smoking prevention
P02283873A0308|128 135|enhancer
P02284393A0751|7 14|research
P02284393A0751|41 53|coping styles
P02284393A0751|74 106|EE/low EE research classification
P02284573A0943|14 17|MoAB
P02284573A0943|25 33|BAL fluid
P02284573A0943|74 93|methenamine staining
P02284573A0943|95 97|BAL
P02284573A0943|99 101|TBB
P02284573A0943|105 121|brushing material
P02287860T0001|30 34|study
P02287860T0001|47 62|parenchyma cells
P02287860T0001|64 67|mice
P02287860T0001|81 94|X-ray exposure
P02289102A0114|7 24|audiotape cassette
P02289102A0114|27 36|headphones
P02289102A0114|40 47|duration
P02289102A0114|53 66|hallucinations
P02289639A0989|7 12|change
P02289639A0989|15 18|HbA1
P02289639A0989|41 45|value
P02289639A0989|54 54|%
P02289639A0989|79 79|%
P02289639A0989|85 97|control group
P02289639A0989|98 98|p
P02290216T0001|0 5|Effect
P02290216T0001|15 25|obstruction
P02290216T0001|29 39|cholangitis
P02290216T0001|42 59|serum SPan-1 level
P02291144A0493|8 15|accuracy
P02291144A0493|17 17|r
P02291144A0493|60 60|H
P02291144A0493|75 81|machine
P02291144A0493|88 104|reference methods
P02291144A0493|114 118|MCHCH
P02291144A0493|122 135|basophil count
P02291628A0264|9 12|part
P02291628A0264|19 23|paper
P02291628A0264|40 51|applications
P02291628A0264|62 68|aspects
P02291628A0264|71 73|NMR
P02291628A0264|79 82|help
P02291628A0264|89 96|examples
P02291628A0264|110 119|literature
P02291628A0264|151 163|endocrinology
P02292272T0000|0 21|Interlimb coordination
P02292272T0000|34 43|locomotion
P02292272T0000|57 59|cat
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|20 22|ALP
P02293019A0000|30 32|mol
P02293019A0000|51 57|protein
P02293019A0000|71 77|tissues
P02293019A0000|90 99|activities
P02293019A0000|112 117|serine
P02293019A0000|127 146|proteinases elastase
P02293019A0000|149 159|cathepsin-G
P02293664A0946|14 19|series
P02293664A0946|22 30|deletions
P02293664A0946|36 52|vimentin promoter
P02293664A0946|75 83|sequences
P02293664A0946|88 97|base pairs
P02293664A0946|121 130|base pairs
P02293664A0946|143 155|mRNA cap site
P02294048A0881|20 53|% amino acid sequence similarities
P02294048A0881|68 72|hsp70
P02294048A0881|93 111|Bacillus megaterium
P02295521A0922|8 16|relations
P02295521A0922|37 47|correlation
P02295521A0922|58 62|level
P02295521A0922|65 82|trapezius activity
P02295521A0922|85 94|complaints
P02295521A0922|117 126|individual
P02295521A0922|139 162|muscle activity patterns
P02295521A0922|185 195|risk factor
P02295521A0922|198 208|development
P02295521A0922|227 236|complaints
P02296509A0997|18 34|household members
P02296509A0997|46 57|seronegative
P02296509A0997|81 97|serum p24 antigen
P02298741A0809|0 7|Analysis
P02298741A0809|34 43|antibodies
P02298741A0809|55 59|alpha
P02298741A0809|61 64|beta
P02298741A0809|68 76|gamma PKC
P02298741A0809|97 101|types
P02298741A0809|104 106|PKC
P02298741A0809|121 128|JK cells
P02298741A0809|137 146|JKPE cells
P02298741A0809|171 173|kDa
P02298741A0809|197 203|protein
P02298741A0809|226 239|alpha antibody
P02299543A0317|43 49|outlook
P02300541A0000|14 20|effects
P02300541A0000|35 41|barrier
P02300541A0000|51 57|surface
P02300541A0000|64 69|agents
P02300541A0000|72 77|series
P02300541A0000|87 99|dose inhalers
P02300541A0000|100 103|MDIs
P02300541A0000|125 128|dose
P02300541A0000|140 149|surfactant
P02300541A0000|155 161|airways
P02300541A0000|180 188|rat lungs
P02300577A0852|3 12|beta chain
P02300577A0852|41 59|glycosylation sites
P02300577A0852|63 87|endoglycosidase digestion
P02300577A0852|103 112|beta chain
P02300577A0852|129 135|complex
P02300577A0852|148 158|side chains
P02300759A0000|14 22|protocole
P02300759A0000|32 55|Gustave Roussy Institute
P02300759A0000|65 75|epithelioma
P02300759A0000|88 93|cervix
P02300759A0000|110 114|forms
P02300759A0000|116 121|T1B-T2
P02300759A0000|142 150|radiology
P02300759A0000|154 160|surgery
P02303158T0000|19 28|expression
P02303158T0000|32 35|gene
P02303158T0000|49 55|protein
P02303158T0000|68 79|trk oncogene
P02303470A0242|3 9|introns
P02303470A0242|20 22|kbp
P02303874A1643|14 29|titration period
P02303874A1643|32 41|adjustment
P02303874A1643|58 61|dose
P02303874A1643|76 80|doses
P02303874A1643|96 112|micrograms/24 hrs
P02303874A1643|113 116|mean
P02303874A1643|120 136|micrograms/24 hrs
P02305014A0226|10 15|series
P02305014A0226|18 28|experiments
P02305014A0226|48 51|rats
P02305014A0226|81 94|guide cannulas
P02305014A0226|111 119|ventricle
P02306539T0000|0 2|Use
P02306539T0000|5 29|Selenastrum capricornutum
P02306539T0000|32 41|Microfeast
P02306539T0000|44 47|food
P02306539T0000|51 63|Daphnia pulex
P02307067A1348|3 13|persistence
P02307067A1348|16 22|members
P02307067A1348|40 56|families Tydeidae
P02307067A1348|57 70|Nanorchestidae
P02307067A1348|74 85|Tarsonemidae
P02307067A1348|111 111|%
P02307067A1348|113 136|concentration treatments
P02307067A1348|152 159|evidence
P02307067A1348|162 172|adaptations
P02307067A1348|192 199|habitats
P02307371A0263|11 19|mechanism
P02307371A0263|37 40|loss
P02307371A0263|43 75|transcription elongation blockage
P02307371A0263|86 103|c-myc deregulation
P02307371A0263|105 111|Burkitt
P02307371A0263|114 121|lymphoma
P02307371A0263|133 154|transcription patterns
P02307371A0263|159 166|transfer
P02307371A0263|178 184|Burkitt
P02307371A0263|187 208|lymphoma c-myc alleles
P02307371A0263|217 221|cells
P02307371A0263|225 238|Xenopus oocyte
P02307371A0263|246 253|vesicles
P02307613A0783|0 39|Erythrocyte protoporphyrin concentration
P02307613A0783|61 61|P
P02307613A0783|79 82|days
P02307613A0783|85 88|dogs
P02307613A0783|100 103|diet
P02307613A0783|149 152|dogs
P02307613A0783|170 175|groups
P02307613A0783|182 190|remainder
P02307613A0783|196 200|study
P02307848A0347|9 17|sequences
P02307848A0347|23 31|Crry gene
P02307848A0347|46 47|kb
P02307848A0347|50 52|DNA
P02307848A0347|71 79|sequences
P02307848A0347|110 124|Eco-R1 fragment
P02307848T0042|28 37|complexity
P02307848T0042|43 46|Crry
P02307848T0042|57 61|genes
P02307850A0000|6 31|RNK-16 lambda-gt11 library
P02307850A0000|63 87|cDNA rat NK cell protease
P02307850A0000|86 91|RNKP-1
P02307850A0000|100 114|characteristics
P02307850A0000|123 138|serine proteases
P02307850A1197|3 11|induction
P02307850A1197|14 30|RNKP-1 expression
P02307850A1197|35 37|Con
P02307850A1197|48 59|spleen cells
P02307850A1197|74 82|increases
P02307850A1197|89 90|NK
P02307850A1197|114 141|killer lymphocyte activities
P02308496A0000|3 7|paper
P02308496A0000|26 29|data
P02308496A0000|32 37|change
P02308496A0000|43 53|blood level
P02308496A0000|55 58|ACTH
P02308496A0000|60 62|STH
P02308496A0000|64 66|TSH
P02308496A0000|68 75|cortisol
P02308496A0000|77 78|T3
P02308496A0000|80 86|insulin
P02308496A0000|88 96|C-peptide
P02308496A0000|113 119|session
P02308496A0000|122 132|respiration
P02308496A0000|153 159|mixture
P02308496A0000|166 173|% oxygen
P02308496A0000|174 179|GHM-10
P02310261A0115|3 9|abscess
P02310261A0115|27 32|septum
P02310261A0115|54 58|layer
P02310261A0115|71 81|pericardium
P02310300A0298|4 17|% lymphography
P02310300A0298|38 39|CT
P02310350A0221|10 14|study
P02310350A0221|26 31|effect
P02310350A0221|34 42|intensity
P02310350A0221|44 47|rate
P02310350A0221|52 59|polarity
P02310350A0221|73 79|content
P02310350A0221|82 85|ABRs
P02310350A0221|104 111|subjects
P02310496X0000|7 24|memory impairments
P02310496X0000|60 63|band
P02310496X0000|66 70|Broca
P02310496X0000|74 88|nucleus basalis
P02310496X0000|96 99|rats
P02310496X0000|104 117|memory defects
P02310496X0000|126 148|nucleus basalis lesions
P02310496X0000|159 164|degree
P02310496X0000|190 198|cell loss
P02310496X0000|202 209|function
P02310496X0000|212 226|nucleus basalis
P02310496X0000|227 228|NB
P02310496X0000|262 265|band
P02310496X0000|268 272|Broca
P02310496X0000|274 280|MS-VDBB
P02310496X0000|285 305|place navigation task
P02310496X0000|313 328|reference memory
P02311544A0086|0 6|Studies
P02311544A0086|25 36|relationship
P02311544A0086|47 55|MSMR cyst
P02311544A0086|65 69|signs
P02311544A0086|72 79|symptoms
P02311544A0086|82 88|disease
P02312470A0774|3 15|BAL-to-plasma
P02312470A0774|24 31|activity
P02312470A0774|34 37|urea
P02312470A0774|57 58|Na
P02312470A0774|75 78|urea
P02312470A0774|94 96|ELF
P02312470A0774|112 113|Na
P02312470A0774|126 126|s
P02312470A0774|148 151|time
P02312470A0774|166 169|urea
P02312470A0774|173 174|Na
P02312470A0774|195 205|circulation
P02312470A0774|212 215|time
P02312470A0774|220 225|lavage
P02312689A0360|3 19|kappa coefficient
P02312689A0360|21 29|agreement
P02312689A0360|40 51|Patho Dx Kit
P02312689A0360|56 70|standard method
P02315151T0020|6 12|systems
P02315151T0020|24 29|health
P02315151T0020|33 39|illness
P02315151T0020|45 47|age
P02315472A0583|17 28|imaging time
P02315472A0583|32 41|parameters
P02315472A0583|68 71|RASE
P02315472A0583|78 80|C/A
P02315472A0583|84 92|unit time
P02315472A0583|102 102|%
P02317413A0364|0 7|Patients
P02317413A0364|27 36|infarction
P02317413A0364|46 66|plasma concentrations
P02317413A0364|68 86|neutrophil elastase
P02317413A0364|104 108|diene
P02317413A0364|119 124|isomer
P02317413A0364|135 138|acid
P02317413A0364|149 158|volunteers
P02317413A0364|161 168|patients
P02317413A0364|188 200|heart disease
P02317554T0000|0 12|Determination
P02317554T0000|32 49|imaging properties
P02317554T0000|57 73|microscope system
P02318208A0817|13 19|element
P02318208A0817|33 43|CACGTGACCCG
P02318208A0817|56 57|bp
P02318208A0817|73 101|transcription initiation site
P02318208A0817|115 127|core sequence
P02318208A0817|140 156|promoter sequence
P02318208A0817|158 163|Ad2MLP
P02319610A1527|11 19|relevance
P02319610A1527|27 34|findings
P02319610A1527|54 64|observation
P02319610A1527|76 82|results
P02319610A1527|99 103|P.HCl
P02319610A1527|128 132|route
P02320008A0651|0 5|TMBr-1
P02320008A0651|27 50|muscle alpha-tropomyosin
P02320008A0651|54 64|amino acids
P02320008A0651|105 110|region
P02320008A0651|115 125|amino acids
P02320999A0606|3 11|procedure
P02320999A0606|33 41|materials
P02320999A0606|43 56|particle board
P02320999A0606|60 65|carpet
P02320999A0606|67 78|gypsum board
P02320999A0606|82 90|wallpaper
P02320999A0606|95 101|plywood
P02320999A0606|106 125|polyurethane lacquer
P02320999A0606|149 164|emission factors
P02320999A0606|165 174|mg m-2 h-1
P02320999A0606|183 191|compounds
P02322535A0658|0 5|Intron
P02322535A0658|12 13|kb
P02322535A0658|32 36|sizes
P02322535A0658|39 45|introns
P02322535A0658|69 70|kb
P02323517A0557|6 6|h
P02323517A0557|8 14|lesions
P02323517A0557|29 32|part
P02323517A0557|38 44|stomach
P02323517A0557|65 90|prostaglandin E2 synthesis
P02323517A0557|113 146|prostaglandin generation technique
P02324102A1157|0 9|Comparison
P02324102A1157|12 24|transmembrane
P02324102A1157|39 45|domains
P02324102A1157|66 77|proteoglycan
P02324102A1157|79 82|48K5
P02324102A1157|92 107|lung fibroblasts
P02324102A1157|108 114|Marynen
P02324102A1157|116 117|P.
P02324102A1157|119 123|Zhang
P02324102A1157|125 126|J.
P02324102A1157|128 135|Cassiman
P02324102A1157|137 138|J.
P02324102A1157|140 152|Vanden Berghe
P02324102A1157|153 154|H.
P02324102A1157|159 163|David
P02324102A1157|165 166|C.
P02324104A0151|15 15|%
P02324104A0151|40 66|phosphotransferase activity
P02324104A0151|90 98|fractions
P02324104A0151|101 111|homogenates
P02324104A0151|136 146|populations
P02324104A0151|149 158|C. elegans
P02324104A0516|4 9|levels
P02324104A0516|12 21|C subunits
P02324104A0516|65 70|stages
P02324104A0516|73 83|development
P02324104A0929|13 21|C subunit
P02324104A0929|22 32|CeCAT alpha
P02324104A0929|37 44|residues
P02324104A0929|83 88|region
P02324104A0929|120 127|splicing
P02324104A0929|133 142|C pre-mRNA
P02324104A1195|14 17|exon
P02324104A1195|36 52|carboxyl terminus
P02324104A1195|59 81|translation stop signal
P02324104A1195|119 126|sequence
P02324104A1195|149 156|residues
P02324104A1195|159 169|CeCAT alpha
P02324104A1195|188 198|nucleotides
P02325208A0209|0 5|French
P02325208A0209|7 8|M.
P02325895T0000b|14 17|type
P02325895T0000b|19 43|mechanoreceptor discharge
P02325895T0000b|46 53|function
P02325895T0000b|63 67|force
P02325895T0000b|81 92|displacement
P02325895T0000b|103 106|skin
P02325895T0000b|109 115|raccoon
P02325895T0000b|119 138|squirrel monkey hand
P02326716A0139|0 6|Methods
P02326716A0139|18 27|Cobb angle
P02326716A0139|40 49|evaluation
P02326716A0139|51 56|T7-T12
P02326716A0139|66 71|convex
P02326716A0139|75 101|concave rib-vertebra angles
P02326716A0139|101 104|RVAs
P02326716A0139|119 135|angle differences
P02326716A0139|136 140|RVADs
P02326716A0139|152 159|rotation
P02326716A0139|161 164|tilt
P02326716A0139|168 179|displacement
P02326946T0000|0 42|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|42 45|LCAT
P02326946T0000|47 54|activity
P02326946T0000|71 76|donors
P02326946T0000|79 87|predictor
P02326946T0000|90 108|allograft viability
P02326946T0000|118 138|liver transplantation
P02327159T0001|0 3|Lars
P02327159T0001|7 10|AIDS
P02327159T0001|27 30|life
P02327159T0001|35 38|care
P02327159T0001|41 44|home
P02328328A0419|13 18|status
P02328328A0419|20 54|tumour progesterone receptor status
P02328328A0419|56 61|season
P02328328A0419|64 79|tumour detection
P02328328A0419|102 109|survival
P02328328A0419|135 137|yrs
P02328328A0419|160 162|yrs
P02328328A0419|164 171|patients
P02329840A0383|3 13|application
P02329840A0383|21 35|microelectrodes
P02329840A0383|41 51|measurement
P02329840A0383|69 75|changes
P02329840A0383|86 86|K
P02329840A0383|89 89|o
P02330041A0335|0 9|Expression
P02330041A0335|19 30|localization
P02330041A0335|41 61|transcription studies
P02330041A0335|80 83|hUBF
P02330041A0335|101 106|factor
P02330041A0335|141 155|control element
P02330041A0335|158 161|core
P02330041A0335|167 184|rRNA gene promoter
P02330041A0335|193 205|transcription
P02330041A0335|209 215|binding
P02330041A0335|230 235|manner
P02330110A1085|17 34|laboratory studies
P02330110A1085|41 45|value
P02330110A1085|73 79|outcome
P02330333A0325|0 12|Accumulations
P02330333A0325|15 18|Tl+1
P02330333A0325|20 30|202Tl label
P02330333A0325|36 40|times
P02330333A0325|49 50|Ga
P02330333A0325|60 64|brain
P02330333A0325|68 74|muscles
P02330333A0325|81 85|times
P02330333A0325|88 93|plasma
P02331361A0268|16 23|increase
P02331361A0268|29 44|myocyte diameter
P02331361A0268|55 57|age
P02331361A0268|63 68|biopsy
P02331361A0268|72 88|autopsy specimens
P02332018A0538|10 16|absence
P02332018A0538|35 40|asthma
P02332018A0538|42 44|EIA
P02332018A0538|60 65|WH air
P02332018A0538|75 82|patients
P02332018A0538|110 127|mean GH increments
P02332018A0538|136 143|subjects
P02332018A0538|153 157|ng/ml
P02332018A0538|159 159|P
P02332798A0725|3 11|afferents
P02332798A0725|13 17|phase
P02332798A0725|20 27|response
P02332798A0725|53 67|EVS stimulation
P02333239T0000|9 11|age
P02333239T0000|15 21|problem
P02333545A0313|3 14|distribution
P02333545A0313|22 38|fibrinogen levels
P02333545A0313|74 85|distribution
P02333545A0313|97 104|controls
P02333749A0411|19 37|regression analysis
P02333749A0411|39 41|SPT
P02333749A0411|45 53|RAST data
P02333749A0411|57 66|occurrence
P02333749A0411|69 88|serum IgE antibodies
P02333749A0411|89 101|P. orbiculare
P02333749A0411|125 129|value
P02333749A0411|140 145|eczema
P02334972A0145|3 13|examination
P02334972A0145|26 35|assessment
P02334972A0145|47 51|types
P02334972A0145|54 59|drusen
P02334972A0145|63 72|evaluation
P02334972A0145|78 88|development
P02334972A0145|92 100|incidence
P02334972A0145|103 114|risk factors
P02334972A0145|123 135|complications
P02334972A0145|139 142|loss
P02334972A0145|152 157|vision
P02335034A0584|33 43|heat stress
P02335034A0584|58 62|suits
P02335034A0584|72 78|minutes
P02335034A0584|81 84|LBNP
P02335521T0000|13 42|vitellogenin activator element
P02335521T0000|49 61|transcription
P02335521T0000|87 122|Xenopus laevis vitellogenin promoter
P02335713A0905|5 15|correlation
P02335713A0905|38 40|PbB
P02335713A0905|44 56|ALAD activity
P02335713A0905|61 76|stearate workers
P02335815A0530|5 21|carboxyl terminus
P02335815A0530|22 29|deletion
P02335815A0530|37 43|residue
P02335815A0530|66 68|TRF
P02335815A0530|70 79|C assembly
P02335815A0530|104 111|activity
P02336338A0931|3 9|effects
P02336338A0931|12 25|mean luminance
P02336338A0931|52 61|expression
P02336338A0931|83 89|account
P02339005T0000|0 5|Effect
P02339005T0000|8 20|hyperglycemia
P02339005T0000|23 36|pain threshold
P02339005T0000|54 57|rats
P02339447A0162|18 24|7,7-2H2
P02339447A0162|30 32|OHA
P02339447A0162|41 57|deuterium content
P02339447A0162|74 80|7,7-2H2
P02339447A0162|82 82|A
P02339447A0162|87 94|9,11-2H2
P02339447A0162|96 102|estrone
P02339447A0162|104 105|E1
P02339447A0162|134 138|assay
P02339447A0162|141 158|serum level 19-OHA
P02339447A0162|158 158|A
P02339447A0162|163 164|E1
P02339447A0162|173 236|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|252 259|subjects
P02339447A0162|270 278|pregnancy
P02340595A0124|0 16|Sequence analysis
P02340595A0124|23 27|genes
P02340595A0124|47 55|sequences
P02340595A0124|93 102|tRNA genes
P02340595A0124|106 123|plant mitochondria
P02341669A0000|0 10|Experiments
P02341669A0000|31 40|brain-stem
P02341669A0000|56 64|responses
P02341669A0000|66 70|BAERs
P02341669A0000|89 93|types
P02341669A0000|96 120|pseudorandom pulse trains
P02341669A0000|120 143|maximum length sequences
P02341669A0000|143 145|MLS
P02341669A0000|150 167|Legendre sequences
P02341669A0000|168 170|LGS
P02342477A1292|8 11|UfAP
P02342477A1292|15 18|UTMP
P02342477A1292|53 60|features
P02342477A1292|72 75|site
P02342477A1292|78 89|biosynthesis
P02342477A1292|95 105|endometrium
P02342477A1292|107 123|P4-responsiveness
P02342477A1292|128 135|presence
P02342477A1292|141 147|mannose
P02342477A1292|168 185|recognition marker
P02342477A1292|201 219|sequence similarity
P02342477A1292|223 226|UfAP
P02342477A1292|233 236|UTMP
P02342477A1292|254 261|function
P02343033A0000|7 11|light
P02343033A0000|15 27|dates infants
P02343033A0000|35 43|placentae
P02343033A0000|70 76|infants
P02343033A0000|85 93|placentae
P02344529T0000|13 19|anaemia
P02344529T0000|40 53|erythropoietin
P02347102A0000|3 25|pseudolymphoma syndrome
P02347102A0000|46 54|condition
P02347102A0000|67 71|fever
P02347102A0000|73 87|lymphadenopathy
P02347102A0000|102 105|rash
P02347407A0217|21 25|field
P02347407A0217|30 36|animals
P02347407A0217|49 57|SE-sector
P02347655A0193|15 18|lung
P02347655A0193|36 39|lung
P02347655A0193|53 59|tissues
P02347655A0193|61 73|gas exchanges
P02347655A0193|88 97|parameters
P02347655A0193|99 120|blood inlet conditions
P02347655A0193|120 134|blood flow rate
P02347655A0193|134 144|temperature
P02347655A0193|146 156|composition
P02347655A0193|162 172|gas mixture
P02347655A0193|179 189|ventilation
P02347655A0193|191 212|blood tissue perfusion
P02347655A0193|214 224|consumption
P02348225A0192|0 3|Mean
P02348225A0192|8 9|SE
P02348225A0192|11 22|measurements
P02348225A0192|25 33|clearance
P02348225A0192|58 66|mL/min/m2
P02348225A0192|69 77|half-life
P02348225A0192|98 102|hours
P02348225A0192|108 113|volume
P02348225A0192|116 127|distribution
P02348225A0192|150 153|L/m2
P02348225A0192|186 193|patients
P02348225A0192|198 205|jaundice
P02348225A0192|222 229|controls
P02348408A0126|0 8|Attitudes
P02348408A0126|50 59|dimensions
P02348408A0126|81 87|samples
P02348728A1153|14 23|DNA ploidy
P02348728A1153|50 55|factor
P02348728A1153|70 80|determinant
P02348728A1153|95 103|carcinoma
P02349827A0193|21 26|system
P02349827A0193|28 36|Videoplan
P02349942A0287|13 19|factors
P02349942A0287|47 53|cohorts
P02349942A0287|83 88|recall
P02349998A0297|0 20|Dopamine SERS spectra
P02349998A0297|28 37|electrodes
P02349998A0297|73 82|electrodes
P02351239A0693|5 12|findings
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|58 64|removal
P02351239A0693|81 86|mucosa
P02351239A0693|92 94|rat
P02351239A0693|105 111|effects
P02351239A0693|130 141|HDC activity
P02351239A0693|142 164|histamine concentration
P02351239A0693|167 182|ECL cell density
P02351239A0693|183 198|hypergastrinemia
P02351239A0693|218 233|gastrin infusion
P02351239A0693|246 254|treatment
P02351239A0693|268 284|antisecretagogues
P02351297A0000|20 36|toxicity research
P02351297A0000|64 100|atmosphere metal corrosion inhibitors
P02351297A0000|108 111|cent
P02351297A0000|145 148|cent
P02351297A0000|157 161|level
P02351297A0000|174 180|percent
P02351297A0000|201 204|cent
P02353453A1249|3 7|order
P02353453A1249|13 26|helicase motif
P02353453A1249|32 51|nsP3 homology region
P02353453A1249|55 64|RUB genome
P02353453A1249|78 84|respect
P02353453A1249|90 106|alphavirus genome
P02353453A1249|128 140|rearrangement
P02353453A1249|161 169|evolution
P02353453A1249|177 183|viruses
P02353875A0800|3 9|results
P02353875A0800|17 26|followings
P02353875A0800|35 45|eosinophils
P02353875A0800|49 59|neutrophils
P02353875A0800|73 86|hypersecretion
P02353875A0800|89 95|type Ib
P02353875A0800|103 107|cases
P02353875A0800|116 126|eosinophils
P02353875A0800|139 143|cases
P02354381A0207|10 19|treatments
P02354381A0207|21 27|control
P02354381A0207|29 29|C
P02354381A0207|56 61|corner
P02354381A0207|67 70|cage
P02354381A0207|72 72|S
P02354381A0207|76 94|fiberglass rollaway
P02354381A0207|109 114|corner
P02354381A0207|120 123|cage
P02354381A0207|125 125|H
P02354381A0207|148 150|H/S
P02354381A0207|154 161|nest box
P02354381A0207|174 177|back
P02354381A0207|183 186|cage
P02354381A0207|206 206|N
P02355293A0749|18 28|differences
P02355293A0749|41 49|responses
P02355293A0749|52 74|failure characteristics
P02355293A0749|112 117|grafts
P02355293A0749|123 126|drip
P02355293A0749|133 148|bath environment
P02355293A0749|164 170|tissues
P02355293A0749|181 188|strength
P02355293A0749|192 198|modulus
P02355765A0220|3 9|patient
P02355765A0220|24 44|benzathine penicillin
P02355765A0220|54 61|U weekly
P02355765A0220|69 73|weeks
P02355920A0681|1 22|consensus binding site
P02355920A0681|27 50|transcription factor SP1
P02355920A0681|64 69|intron
P02355920A0681|87 125|proenkephalin germ cell cap site region
P02356823A0063|12 17|method
P02356823A0063|29 37|principle
P02356823A0063|43 56|sets technique
P02356823A0063|90 93|time
P02356823A0063|96 111|alarm properties
P02357537A0451|3 9|effects
P02357537A0451|18 26|latencies
P02357537A0451|35 39|paCO2
P02357537A0451|42 44|pHa
P02357537A0451|58 65|naloxone
P02357537A0451|68 72|mg/kg
P02357537A0451|111 117|animals
P02358975A0709|59 66|symptoms
P02358975A0709|92 104|gluten intake
P02358975A0709|120 133|IgA deficiency
P02360336A0574|0 3|Drug
P02360336A0574|7 21|personnel costs
P02360336A0574|36 54|batch manufacturing
P02360336A0574|63 77|multidose vials
P02360336A0574|130 134|vials
P02361008T0000|0 6|Changes
P02361008T0000|9 17|prognosis
P02361008T0000|24 29|births
P02361008T0000|36 40|years
P02361575T0000|6 13|toxicity
P02361575T0000|17 31|carcinogenicity
P02361575T0000|55 63|diepoxide
P02361575T0000|66 77|Fischer rats
P02361575T0000|80 90|B6C3F1 mice
P02361812A1110|3 12|kg FFM SMR
P02361812A1110|30 44|baseline values
P02361812A1110|50 57|EX group
P02361812A1110|82 89|subjects
P02361812A1110|110 115|values
P02361812A1110|117 118|EX
P02361812A1110|125 128|cent
P02361812A1110|132 132|D
P02361812A1110|134 135|DE
P02361812A1110|143 146|cent
P02361812A1110|162 170|treatment
P02361812A1110|172 172|P
P02362161T0000|0 5|MK-927
P02362161T0000|48 66|anhydrase inhibitor
P02362803A0608|11 19|fragments
P02362803A0608|30 35|probes
P02362803A0608|42 50|isolation
P02362803A0608|56 69|U3 snRNA genes
P02362803A0608|80 86|library
P02362803A0608|89 99|Arabidopsis
P02368931A0587|2 34|addition serum IgE concentrations
P02370571A0663|3 10|findings
P02370571A0663|31 47|iodine deficiency
P02370571A0663|64 68|cause
P02370571A0663|71 76|goiter
P02370571A0663|82 91|immigrants
P02370571A0663|101 106|cohort
P02370571A0663|122 131|population
P02370571A0663|148 150|men
P02370571A0663|154 158|women
P02370571A0663|181 186|factor
P02370571A0663|188 188|s
P02371273A0144|18 21|unit
P02371273A0144|39 44|region
P02371273A0144|54 67|kilobase pairs
P02371273A0144|68 70|kbp
P02371517A0747|8 15|patients
P02372496A0782|0 16|Co-administration
P02372496A0782|19 21|5FU
P02372496A0782|23 33|angiotensin
P02372496A0782|39 50|microspheres
P02372496A0782|64 69|artery
P02372496A0782|79 91|drug exposure
P02372496A0782|104 114|compartment
P02372496A0782|152 156|ratio
P02372496A0782|159 176|5FU administration
P02372496A0782|189 194|artery
P02372712A0002|3 9|effects
P02372712A0002|12 14|tap
P02372712A0002|16 17|TW
P02372712A0002|32 33|CW
P02372712A0002|35 39|water
P02372712A0002|50 51|pH
P02372712A0002|60 67|pressure
P02372712A0002|70 83|carbon dioxide
P02372712A0002|84 87|PCO2
P02372712A0002|92 105|plasma lactate
P02372712A0002|134 141|broilers
P02373686T0000|9 18|expression
P02373686T0000|29 58|chicken progesterone receptors
P02373686T0000|95 104|initiation
P02373686T0000|116 119|mRNA
P02373686T0000|125 133|mechanism
P02373686T0000|147 163|receptor isoforms
P02373810A1118|2 9|contrast
P02373810A1118|19 19|%
P02373810A1118|33 44|risk factors
P02373810A1118|51 54|risk
P02373810A1118|68 68|%
P02373810A1118|76 80|weeks
P02373810A1118|82 82|p
P02374886A0305|3 28|Community Adjustment Scale
P02374886A0305|35 46|outcome data
P02374886A0305|58 65|subjects
P02374886A0305|67 72|degree
P02374886A0305|75 86|productivity
P02374886A0305|88 94|ability
P02374886A0305|110 122|relationships
P02374886A0305|127 142|presence/absence
P02374886A0305|145 158|symptomatology
P02374886A0305|161 167|average
P02374886A0305|172 176|years
P02374886A0305|189 197|admission
P02376023A0307|12 17|months
P02376023A0307|20 22|age
P02376023A0307|43 48|levels
P02376023A0307|51 54|IgG1
P02376023A0307|56 56|P
P02376023A0307|75 78|IgG4
P02376023A0307|80 80|P
P02376023A0307|105 111|infants
P02376023A0307|126 128|IgE
P02376023A0307|153 156|kU/l
P02376023A0307|179 183|level
P02378615A0807|3 18|protein sequence
P02378615A0807|48 66|glycosylation sites
P02378615A0807|91 96|region
P02378615A0807|114 117|site
P02378615A0807|121 130|attachment
P02378615A0807|141 152|carbohydrate
P02378945A0487|4 13|adaptation
P02378945A0487|30 35|stress
P02378945A0487|60 65|effect
P02378945A0487|94 103|vagal tone
P02383693A0301|16 21|column
P02383693A0301|53 60|solution
P02383693A0301|71 79|lucigenin
P02383693A0301|83 94|Triton X-100
P02383693A0301|102 115|M KOH solution
P02383693A0301|116 120|pumps
P02383693A0301|136 161|chemiluminescence detector
P02383771A0544|12 22|examination
P02383771A0544|34 43|epithelium
P02383771A0544|55 62|membrane
P02383771A0544|94 103|epithelium
P02383771A0544|115 126|distribution
P02383771A0544|137 142|nuclei
P02383771A0544|158 166|cytoplasm
P02384265A0947|5 11|results
P02384265A0947|30 33|risk
P02384265A0947|46 51|cancer
P02384265A0947|57 70|polyp patients
P02384265A0947|76 86|possibility
P02384265A0947|89 107|prophylactic effect
P02384265A0947|109 119|polypectomy
P02384265A0947|137 142|cancer
P02384389A0854|7 11|trend
P02384389A0854|27 28|YG
P02384389A0854|32 38|heifers
P02384389A0854|42 43|YG
P02384389A0854|76 85|deposition
P02384389A0854|88 95|seam fat
P02384389A0854|97 106|fed cattle
P02386485A0554|3 21|nucleotide sequence
P02386485A0554|33 34|bp
P02386485A0554|53 58|region
P02386485A0554|64 65|bp
P02386485A0554|74 79|region
P02386485A0554|86 87|bp
P02386485A0554|106 111|region
P02386485A0554|124 130|bp poly
P02386485A0554|131 131|A
P02386485A0554|133 136|tail
P02386895A0496|0 9|Toxicities
P02386895A0496|19 33|nausea/vomiting
P02386895A0496|37 37|%
P02386895A0496|40 47|headache
P02386895A0496|51 51|%
P02386895A0496|54 59|chills
P02386895A0496|63 63|%
P02386895A0496|66 69|pain
P02386895A0496|72 82|tumor sites
P02386895A0496|85 85|%
P02386895A0496|88 98|hypotension
P02386895A0496|102 102|%
P02386895A0496|108 119|hypertension
P02386895A0496|123 123|%
P02388685A0577|3 9|results
P02388685A0577|32 59|oyster shell supplementation
P02388685A0577|76 104|alkaline phosphatase activity
P02388685A0577|104 122|bone mineralization
P02388685A0577|163 174|coefficients
P02388685A0577|177 185|variation
P02388685A0577|187 188|CV
P02388685A0577|201 201|%
P02388685A0577|214 214|%
P02388685A0577|218 224|calcium
P02388685A0577|228 245|phosphorus content
P02388685A0577|250 254|femur
P02388685A0577|258 262|tibia
P02390538A0000|7 13|infants
P02390538A0000|31 35|weeks
P02390538A0000|38 46|gestation
P02390538A0000|80 88|anomalies
P02390538A0000|94 100|airways
P02390538A0000|136 145|fiberscope
P02390538A0000|147 160|Olympus PF18 S
P02390538A0000|163 164|mm
P02390633T0000|5 16|encephalitis
P02390633T0000|20 26|patient
P02390633T0000|55 61|disease
P02390989A0745|13 23|counterpart
P02390989A0745|29 36|GPB gene
P02390989A0745|37 40|exon
P02390989A0745|47 54|GPE gene
P02390989A0745|69 83|point mutations
P02390989A0745|86 94|insertion
P02390989A0745|99 100|bp
P02390989A0745|106 115|stop codon
P02390989A0745|131 143|reading frame
P02391344T0000|9 15|cloning
P02391344T0000|19 22|cDNA
P02391344T0000|31 62|rat NADH-cytochrome b5 reductase
P02391344T0000|79 82|gene
P02392032A0657|3 9|results
P02392032A0657|24 27|idea
P02392032A0657|35 43|structure
P02392032A0657|46 62|relaxation curves
P02392032A0657|70 80|information
P02392032A0657|86 99|distance scale
P02392032A0657|107 118|architecture
P02392032A0657|124 133|pore space
P02392032A0657|171 181|ambiguities
P02392511T0000|0 31|Serotonin 5-HT2 receptor binding
P02392511T0000|31 45|blood platelets
P02392511T0000|48 52|state
P02392511T0000|62 67|marker
P02392511T0000|84 91|disorder
P02393001A0324|8 10|%BF
P02393001A0324|34 37|BMIs
P02393001A0324|39 39|r
P02393001A0324|69 79|definitions
P02393001A0324|82 88|obesity
P02393001A0324|96 99|BMIs
P02393001A0324|102 104|%BF
P02393001A0324|107 118|densitometry
P02393001A0324|143 149|results
P02393895A0918|3 11|RF values
P02393895A0918|60 64|scale
P02393895A0918|67 74|severity
P02393895A0918|83 95|insufficiency
P02393895A0918|97 97|r
P02393895A0918|105 105|p
P02393895A0918|143 149|authors
P02393895A0918|168 182|differentiation
P02393895A0918|207 220|regurgitations
P02393895A0918|243 246|ones
P02394707A0789|0 16|Promoter elements
P02394707A0789|33 40|TATA box
P02394707A0789|41 44|GTTA
P02394707A0789|50 58|CCAAT box
P02394707A0789|76 90|initiation site
P02394707A0789|103 113|compliments
P02394707A0789|116 120|CCAAT
P02394707A0789|122 126|ATTGG
P02394707A0789|150 169|nucleotide stretches
P02394718A0130|9 13|genes
P02394718A0130|37 45|libraries
P02394718A0130|48 70|hybridization screening
P02394718A0130|79 105|deoxyoligonucleotide probes
P02394718A0130|134 152|amino acid sequence
P02394718A0130|164 169|enzyme
P02395868A0322|3 9|pattern
P02395868A0322|22 31|zinc sites
P02395868A0322|42 48|ligands
P02395868A0322|56 63|sequence
P02395868A0322|82 87|ligand
P02395868A0322|103 115|hydrogen bond
P02395868A0322|125 131|ligands
P02396415T0001|0 6|Results
P02396415T0001|21 31|observation
P02396415T0001|35 43|treatment
P02396415T0001|46 53|patients
P02396415T0001|66 77|hypertension
P02398897A0000|10 30|transcription factors
P02398897A0000|43 56|RNA polymerase
P02398897A0000|73 82|efficiency
P02398897A0000|85 94|elongation
P02398897A0000|128 137|RNA chains
P02399053A0153|21 24|rats
P02399053A0153|26 26|n
P02399053A0153|42 49|% oxygen
P02399053A0153|55 62|room air
P02399053A0153|63 64|RA
P02399053A0153|81 84|days
P02399053A0153|87 90|life
P02399053A0153|99 100|RA
P02399053A1032|3 4|Lm
P02399053A1032|20 30|alveoli/mm2
P02399053A1032|41 55|recoil pressure
P02400070T0000|0 9|Comparison
P02400070T0000|12 19|propofol
P02400070T0000|23 33|thiopentone
P02400070T0000|47 52|agents
P02400070T0000|73 79|therapy
P02400457A0469|2 11|Experiment
P02400457A0469|35 48|supine cycling
P02400457A0469|51 59|% VO2 max
P02400457A0469|64 70|minutes
P02400457A0469|83 97|LBNP conditions
P02400457A0469|109 113|women
P02400457A0469|154 160|manners
P02400457A0469|180 190|adjustments
P02400457A0469|202 207|phases
P02400457A0469|215 227|Experiment I.
P02402678A0463|21 32|formulations
P02402678A0463|38 38|%
P02402678A0463|43 61|% lambdacyhalothrin
P02402678A0463|83 87|water
P02402678A0463|91 93|ULV
P02402678A0463|98 119|aerosol space-spraying
P02402678A0463|125 139|diesel/kerosene
P02402678A0463|150 156|fogging
P02402678A0463|170 186|application rates
P02402678A0463|193 199|g ai/ha
P02402678A0463|202 217|mosquito control
P02402678A0463|221 227|g ai/ha
P02402678A0463|230 245|housefly control
P02403035A0621|9 21|reading frame
P02403035A0621|44 52|precursor
P02403035A0621|68 75|fumarase
P02403634A0788|0 16|Sequence analysis
P02403634A0788|31 38|addition
P02403634A0788|43 45|ATA
P02403634A0788|49 54|GC box
P02403634A0788|59 64|region
P02403634A0788|73 79|domains
P02403634A0788|107 116|regulation
P02403634A0788|139 143|genes
P02403634A0788|146 153|CArG box
P02403634A0788|158 159|bp
P02403634A0788|200 205|factor
P02403634A0788|207 229|binding site homologies
P02403634A0788|246 247|bp
P02403634A0788|253 282|muscle-CAAT consensus sequence
P02403634A0788|287 288|bp
P02403634A0788|302 309|cap site
P02403926A0000|3 17|trk-2h oncogene
P02403926A0000|38 70|breast carcinoma cell line MDA-MB
P02403926A0000|79 94|DNA-transfection
P02403926A0000|99 110|NIH3T3 cells
P02403926A0000|124 164|trk proto-oncogene receptor kinase domain
P02403926A0000|181 190|amino acid
P02403926A0000|200 207|sequence
P02403926A0000|209 213|Kozma
P02403926A0000|215 218|S.C.
P02403926A0000|220 226|Redmond
P02403926A0000|228 233|S.M.S.
P02403926A0000|235 244|Xiao-Chang
P02403926A0000|246 247|F.
P02403926A0000|249 254|Saurer
P02403926A0000|256 259|S.M.
P02403926A0000|261 266|Groner
P02403926A0000|268 269|B.
P02403926A0000|273 277|Hynes
P02403926A0000|279 282|N.E.
P02403926A0307|0 9|Antibodies
P02403926A0307|43 85|beta gal-trk receptor kinase fusion protein
P02403926A0307|94 110|kd phosphoprotein
P02403926A0307|126 131|serine
P02403926A0307|133 141|threonine
P02403926A0307|145 152|tyrosine
P02403926A0307|155 162|extracts
P02403926A0307|182 193|NIH3T3 cells
P02404451A1532|15 40|scanning-deletion analysis
P02404451A1532|69 74|region
P02404451A1532|78 85|activity
P02404451A1532|90 96|Cys-118
P02404451A1532|104 110|Cys-118
P02404451A1532|132 139|activity
P02404451A1532|158 172|Cys-118 residue
P02404451A1532|192 204|glycosylation
P02404451A1532|223 230|activity
P02404451A1532|233 238|GM-CSF
P02405393T0000|22 37|characterization
P02405393T0000|43 50|promoter
P02405393T0000|53 56|ETS2
P02405393T0000|66 77|c-ets-2 gene
P02405589A0000|0 10|Information
P02405589A0000|27 43|drug interactions
P02405589A0000|53 63|pharmacists
P02405589A0000|78 95|drug-use decisions
P02405818A0550|0 15|Branch occlusion
P02405818A0550|17 23|Heubner
P02405818A0550|26 31|artery
P02405818A0550|35 45|perforators
P02405818A0550|85 92|arteries
P02405818A0550|107 115|mechanism
P02405818A0550|118 127|infarction
P02406570A0466|15 19|sites
P02406570A0466|33 38|origin
P02406570A0466|52 54|UAS
P02406570A0466|83 95|test plasmids
P02406570A0898|2 12|examination
P02406570A0898|18 27|properties
P02406570A0898|30 38|sequences
P02406570A0898|50 53|ARS1
P02406570A0898|65 75|possibility
P02406570A0898|80 83|ABFI
P02406570A0898|95 104|initiation
P02406570A0898|107 121|DNA replication
P02406570A0898|123 126|ARS1
P02406570A0898|144 153|activation
P02406992A0192|34 42|disorders
P02406992A0192|64 78|amaurosis fugax
P02406992A0192|93 101|algorithm
P02406992A0192|105 114|evaluation
P02406992A0192|139 149|examination
P02406992A0192|151 168|laboratory studies
P02406992A0192|183 204|carotid artery studies
P02408248A0414|35 40|action
P02408248A0414|53 69|enzyme inhibitors
P02409297A0984|10 18|antiserum
P02409297A0984|33 46|fusion protein
P02409297A0984|86 97|polypeptides
P02409297A0984|102 116|virus particles
P02409297A0984|121 132|polypeptides
P02409297A0984|155 172|HBsAg determinants
P02411513A0667|5 19|characteristics
P02411513A0667|22 28|N22/P22
P02411513A0667|76 80|event
P02411513A0667|104 109|dipole
P02411513A0667|114 130|dorsal negativity
P02411513A0667|154 163|positivity
P02417023T0001|0 3|Role
P02417023T0001|6 25|superoxide dismutase
P02417023T0001|44 52|processes
P02417023T0001|56 61|method
P02417023T0001|67 79|determination
P02417023T0001|92 100|materials
P02417669A0218|2 25|maximum photosensitivity
P02417669A0218|38 48|amino acids
P02417669A0218|66 69|acid
P02417669A0218|73 79|taurine
P02417669A0218|100 109|asparagine
P02417669A0218|111 120|metabolite
P02417669A0218|136 155|amino acid aspartate
P02417669A0218|177 183|animals
P02418701A0000|14 23|likelihood
P02418701A0000|26 32|tissues
P02418701A0000|64 70|antigen
P02418701A0000|77 85|intensity
P02418701A0000|104 119|antigen staining
P02418701A0000|121 129|specimens
P02418701A0000|139 146|adenomas
P02418701A0000|153 160|polypoid
P02418701A0000|168 175|adenomas
P02418701A0000|185 192|adenomas
P02418701A0000|197 210|diverticulitis
P02418701A0000|244 252|technique
P02419327A0998|3 18|priming activity
P02419327A0998|20 22|DNA
P02419327A0998|53 59|enzymes
P02419327A0998|96 105|incubation
P02419327A0998|162 164|DNA
P02419327A0998|173 176|side
P02419327A0998|189 192|site
P02419588A0284|0 1|A.
P02420432A1060|12 22|conjunction
P02420432A1060|36 49|pregnancy test
P02420432A1060|55 61|patient
P02420432A1060|72 78|history
P02420432A1060|106 123|serum PAPP-A level
P02420432A1060|133 141|diagnosis
P02420432A1060|156 164|pregnancy
P02423533A1314|3 8|levels
P02423533A1314|44 48|mRNAs
P02423533A1314|80 84|brain
P02423533A1314|89 93|level
P02423533A1314|109 112|mRNA
P02423533A1314|136 149|rat PC12 cells
P02423533A1314|152 159|exposure
P02423533A1314|162 180|nerve growth factor
P02423533A1790|3 7|cDNAs
P02423533A1790|34 42|sequences
P02423533A1790|45 47|rat
P02423533A1790|58 68|chicken DNA
P02423533A1790|79 81|DNA
P02423533A1790|86 89|frog
P02423533A1790|104 113|sea urchin
P02423773T0001|12 17|method
P02423773T0001|31 38|glycerin
P02423773T0001|44 48|blood
P02423850A0292|0 16|Deletion analysis
P02423850A0292|36 39|part
P02423850A0292|56 61|region
P02423850A0292|69 76|homology
P02423850A0292|90 95|region
P02423850A0292|101 115|yeast CYC1 gene
P02424743A0280|3 4|N1
P02424743A0280|8 9|P2
P02424743A0280|26 34|amplitude
P02424743A0280|64 70|periods
P02427024X0000|0 8|Tolerance
P02427024X0000|11 31|fenfluramine anorexia
P02427024X0000|32 35|fact
P02427024X0000|38 44|fiction
P02427024X0000|52 59|findings
P02427024X0000|66 75|laboratory
P02427024X0000|80 85|regard
P02427024X0000|88 96|tolerance
P02427024X0000|99 119|fenfluramine anorexia
P02427024X0000|134 140|respect
P02427024X0000|143 152|generality
P02427024X0000|169 178|phenomenon
P02427797A0199|4 7|dogs
P02427797A0199|15 18|limb
P02427797A0199|20 23|tail
P02427797A0199|30 37|pancreas
P02427797A0199|69 74|cavity
P02427797A0199|80 88|cessation
P02427797A0199|91 100|blood flow
P02427797A0199|113 120|ischemia
P02427797A0199|136 138|min
P02427797A0199|142 145|dogs
P02427797A0199|152 161|time point
P02427797A0199|188 194|Ringers
P02427797A0199|196 202|lactate
P02427797A0199|228 234|vessels
P02427812A0865|5 11|results
P02427812A0865|22 25|view
P02427812A0865|30 38|clonidine
P02427812A0865|42 47|6-OHDA
P02427812A0865|55 62|alpha-MD
P02427812A0865|75 89|pressor actions
P02427812A0865|94 96|rat
P02427812A0865|128 133|action
P02427869A0939|12 15|beta
P02427869A0939|30 40|sensitivity
P02427869A0939|63 65|BHT
P02431314A0834|14 19|Hansel
P02431314A0834|51 61|recognition
P02431314A0834|64 77|eosinophiluria
P02431314A0834|92 97|Wright
P02436005A0707|5 11|results
P02436005A0707|43 48|action
P02436005A0707|51 60|nicorandil
P02436005A0707|71 80|inhibition
P02436005A0707|83 91|Ca influx
P02436005A0707|107 118|mobilization
P02436005A0707|121 122|Ca
P02437625A0197|3 7|study
P02437625A0197|19 22|eyes
P02437625A0197|41 63|histoplasmosis syndrome
P02437625A0197|64 67|POHS
P02437625A0197|90 101|degeneration
P02437625A0197|103 105|AMD
P02437792T0000|0 9|Comparison
P02437792T0000|12 21|elastase-1
P02437792T0000|26 32|amylase
P02437792T0000|34 39|lipase
P02437792T0000|56 71|immunoreactivity
P02437792T0000|77 85|diagnosis
P02437792T0000|93 104|pancreatitis
P02437895A0000|1 5|probe
P02437895A0000|12 31|potentials procedure
P02437895A0000|57 66|engagement
P02437895A0000|81 91|hemispheres
P02437895A0000|99 111|language task
P02437895A0000|129 134|groups
P02437895A0000|144 149|adults
P02437895A0000|155 164|hemisphere
P02437895A0000|166 167|LH
P02437895A0000|177 184|aphasics
P02437895A0000|199 204|stroke
P02437895A0000|206 216|dysarthrics
P02437895A0000|223 232|hemisphere
P02437895A0000|234 235|RH
P02437895A0000|255 262|patients
P02437895A0000|280 287|subjects
P02438637T0000|0 17|Mucolipidosis type
P02438637T0000|28 35|spectrum
P02438637T0000|46 52|history
P02442837A0060|13 18|groups
P02442837A0060|35 43|dauricine
P02442837A0060|51 73|calcium channel blocker
P02442837A0060|76 84|verapamil
P02442837A0060|108 130|calcium channel blocker
P02442837A0060|149 155|minutes
P02442837A0060|171 173|end
P02442837A0060|179 194|bypass procedure
P02442837A0060|196 201|period
P02442837A0060|206 212|minutes
P02443028A0695|2 7|reflow
P02443028A0695|33 39|percent
P02443028A0695|45 67|muscle microvasculature
P02443028A0695|71 81|reperfusion
P02443924A0083|7 14|patients
P02443924A0083|73 78|cancer
P02443924A0083|93 100|survival
P02444507A0240|0 16|Lysozyme activity
P02444507A0240|65 68|sera
P02444507A0240|83 90|patients
P02445751A0925|16 27|measurements
P02445751A0925|39 50|state levels
P02445751A0925|52 56|mRNAs
P02445751A0925|60 66|subunit
P02445751A0925|70 87|cytochrome oxidase
P02445751A0925|93 104|beta subunit
P02445751A0925|106 114|F1 ATPase
P02445751A0925|120 123|type
P02445751A0925|130 140|hem2 mutant
P02446871A1021|10 18|structure
P02446871A1021|48 53|region
P02446871A1021|83 91|LSU rRNAs
P02446871A1021|94 101|contrast
P02446871A1021|114 122|structure
P02446871A1021|139 141|end
P02446871A1021|149 157|molecules
P02449431A1121|0 21|ATP gamma S inhibition
P02449431A1121|38 51|concentrations
P02449431A1121|54 56|ATP
P02449431A1121|58 61|dATP
P02449431A1121|63 68|araATP
P02449431A1121|72 76|ddATP
P02451872A0391|3 10|recovery
P02451872A0391|21 35|methoxydextrane
P02451872A0391|44 44|%
P02452313A0114|0 7|ASL-8123
P02452313A0114|54 70|blocking activity
P02452313A0114|80 101|guinea pig right atria
P02452313A0114|104 106|pA2
P02452313A0114|135 142|activity
P02452313A0114|160 165|tissue
P02452313A0114|168 181|concentrations
P02452313A0114|184 191|ASL-8123
P02452313A0114|197 197|X
P02452313A0114|207 207|X
P02452313A0114|214 215|M.
P02454390T0000|0 7|Enhancer
P02454390T0000|11 27|promoter elements
P02454390T0000|36 45|activation
P02454390T0000|49 73|glucocorticoid repression
P02454390T0000|78 101|alpha 1-fetoprotein gene
P02454390T0000|102 112|hepatocytes
P02454976A0944|12 18|results
P02454976A0944|21 28|relation
P02454976A0944|39 45|systems
P02454976A0944|84 88|gyrus
P02454976A0944|94 96|cat
P02454976A0944|111 121|possibility
P02454976A0944|126 134|divisions
P02454976A0944|166 170|gyrus
P02454976A0944|191 195|areas
P02454976A0944|223 227|gyrus
P02454976A0944|230 237|primates
P02455821A0099|3 6|gene
P02455821A0099|37 75|AccI-EcoRI restriction fragment mapping
P02455821A0099|75 77|map
P02455821A0099|106 114|UL region
P02455821A0099|119 130|EHV-1 genome
P02455821A0099|150 154|right
P02456827A0899|3 6|4-AP
P02456827A0899|12 13|mM
P02456827A0899|15 20|effect
P02456827A0899|32 39|decrease
P02456827A0899|52 59|activity
P02456827A0899|84 86|TEA
P02456827A0899|89 91|Ba2
P02457922A0991|0 12|Hybridization
P02457922A0991|16 20|probe
P02457922A0991|29 34|region
P02457922A0991|52 56|blots
P02457922A0991|59 62|RNAs
P02457922A0991|81 87|tissues
P02457922A0991|106 117|2.8-kilobase
P02457922A0991|119 120|kb
P02457922A0991|122 128|message
P02457922A0991|148 152|bands
P02457922A0991|162 163|kb
P02457922A0991|166 169|size
P02458080T0000|0 8|Prognosis
P02458080T0000|31 37|myeloma
P02458234T0000|4 9|method
P02458234T0000|28 35|analysis
P02458234T0000|38 51|sleep spindles
P02458234T0000|76 89|EEG recordings
P02458699A0650|0 7|Svensson
P02459309T0000|10 16|release
P02459309T0000|27 35|serotonin
P02459309T0000|60 63|acid
P02459309T0000|69 83|caudate-putamen
P02459309T0000|89 91|rat
P02459309T0000|117 124|dialysis
P02459309T0000|156 169|chromatography
P02459309T0000|186 194|detection
P02461368A0162|6 11|report
P02461368A0162|33 36|time
P02461368A0162|55 63|structure
P02461368A0162|66 80|type X collagen
P02461368A0162|87 93|cloning
P02461368A0162|97 106|sequencing
P02461368A0162|109 112|cDNA
P02461368A0162|123 125|DNA
P02462047A0208|6 15|flap areas
P02462047A0208|47 62|pedicle ligation
P02462047A0208|67 73|vessels
P02462047A0208|80 85|artery
P02462047A0208|88 91|vein
P02462047A0208|104 106|day
P02462047A0208|112 128|flap replantation
P02462047A0208|134 139|island
P02462047A0208|147 151|flaps
P02462305A1071|3 18|size discrepancy
P02462305A1071|28 40|glycosylation
P02462305A1071|43 57|phosphorylation
P02462305A1071|60 63|Ag35
P02462305A1071|93 100|sequence
P02462305A1071|118 128|polypeptide
P02462523A0394|7 24|KpnI-SalI fragment
P02462523A0394|36 46|DNA changes
P02462523A0394|60 61|su
P02462523A0394|63 64|Hw
P02462523A0394|66 74|mutations
P02462523A0394|104 105|su
P02462523A0394|107 108|Hw
P02462523A0394|116 124|phenotype
P02462523A0394|148 171|germ-line transformation
P02463050A0514|3 47|corticosterone synthesis inhibitor metyrapone
P02463050A0514|48 52|mg/kg
P02463050A0514|80 83|rise
P02463050A0514|86 99|corticosterone
P02463050A0514|103 107|level
P02463050A0514|125 129|males
P02464097T0000|3 9|effects
P02464097T0000|12 15|L655
P02464097T0000|31 41|thromboxane
P02464097T0000|45 81|prostaglandin endoperoxide antagonist
P02464097T0000|83 90|ischemia
P02464097T0000|121 131|arrhythmias
P02466414A0000|21 24|dogs
P02466414A0000|26 41|plasma viscosity
P02466414A0000|42 43|Ep
P02466414A0000|75 89|blood viscosity
P02466414A0000|90 91|Ea
P02466414A0000|119 123|steps
P02466414A0000|126 145|exchange transfusion
P02466414A0000|150 151|ml
P02466414A0000|154 159|plasma
P02466414A0000|164 169|plasma
P02466414A0000|193 206|weight dextran
P02466414A0000|207 209|mol
P02466414A0000|222 229|% wt/vol
P02466665A0202|19 25|protein
P02466665A0202|51 55|fluid
P02468795A1086|0 4|Serum
P02468795A1086|14 36|acid phosphatase levels
P02468795A1086|61 71|correlation
P02468795A1086|76 88|cancer volume
P02468795A1086|89 89|r
P02468795A1086|126 134|parameter
P02469451A0239|3 15|investigation
P02469451A0239|46 52|fashion
P02469451A0239|77 83|mg dose
P02469451A0239|88 111|MAO-B inhibitor deprenyl
P02469451A0239|119 126|subjects
P02470955A0101|5 11|studies
P02470955A0101|37 44|increase
P02470955A0101|47 61|CSF AP activity
P02470955A0101|70 81|meningitides
P02470955A0101|97 108|meningitides
P02473156A0000|1 4|cDNA
P02473156A0000|22 53|lymphocyte cell surface molecule
P02473156A0000|91 96|member
P02473156A0000|118 123|family
P02473156A0000|126 142|adhesion proteins
P02473198A0613|0 7|Dopamine
P02473198A0613|24 39|potassium efflux
P02473198A0613|49 52|86Rb
P02473198A0613|54 59|efflux
P02473198A0613|71 76|glands
P02473198A0613|91 96|effect
P02473198A0613|109 114|glands
P02473619A0202|11 23|sensitization
P02473619A0202|40 48|chemicals
P02473619A0202|52 61|proportion
P02473619A0202|64 78|control animals
P02473619A0202|123 135|sensitization
P02473619A0202|138 145|patients
P02473619A0202|163 171|reactions
P02473619A0202|187 194|blockers
P02473619A0202|202 209|exposure
P02473619A0202|220 233|IgE antibodies
P02473693A0174|4 11|approach
P02473693A0174|40 46|protein
P02473693A0174|48 53|HGB F.
P02473718A0000|3 15|investigation
P02473718A0000|35 46|relationship
P02473718A0000|61 71|metabolites
P02473718A0000|74 82|serotonin
P02473718A0000|86 98|catecholamine
P02473718A0000|100 105|5-HIAA
P02473718A0000|109 111|VMA
P02473718A0000|114 120|T-cells
P02473718A0000|122 125|OKT3
P02473718A0000|129 136|T-helper
P02473718A0000|138 141|OKT4
P02473718A0000|145 156|T-suppressor
P02473718A0000|158 161|OKT8
P02473718A0000|167 173|B-cells
P02473718A0000|193 197|cells
P02473718A0000|210 217|subjects
P02473718A0000|220 225|female
P02473718A0000|228 231|male
P02473718A0000|233 235|age
P02473718A0000|242 246|years
P02473718A0000|251 256|stress
P02473718A0000|269 276|subjects
P02473718A0000|280 287|subjects
P02473718A0000|290 295|female
P02473718A0000|299 302|male
P02473718A0000|304 306|age
P02473718A0000|313 317|years
P02473907A1338|7 11|C mAb
P02473907A1338|22 25|site
P02473907A1338|28 30|IgE
P02473907A1338|63 74|Fc epsilon R
P02473907A1338|80 83|site
P02473907A1338|103 106|site
P02473907A1338|109 111|IgE
P02473907A1338|147 158|Fc epsilon R
P02473907A1338|164 167|site
P02473942A1207|16 20|plots
P02473942A1207|65 72|segments
P02473942A1207|99 120|transmembrane segments
P02474093T0000|0 10|Angiotensin
P02474093T0000|21 37|enzyme inhibitors
P02474093T0000|63 70|efficacy
P02474093T0000|73 81|diuretics
P02474093T0000|115 121|effects
P02474110A1039|2 9|addition
P02474110A1039|26 34|reduction
P02474110A1039|37 50|blood pressure
P02474110A1039|54 64|angiotensin
P02474110A1039|75 80|enzyme
P02474110A1039|82 84|ACE
P02474110A1039|86 103|inhibitor ramipril
P02474110A1039|121 130|regression
P02474110A1039|158 168|hypertrophy
P02474110A1039|191 207|resonance imaging
P02474110A1039|210 225|echocardiography
P02474204A0105|9 13|cells
P02474204A0105|27 31|means
P02474204A0105|34 42|Grimelius
P02474204A0105|50 57|staining
P02474204A0105|61 74|immunostaining
P02474204A0105|78 89|chromogranin
P02474204A0105|99 104|marker
P02474204A0105|116 120|cells
P02474356A0559|3 7|ratio
P02474356A0559|10 22|radioactivity
P02474356A0559|25 30|tumour
P02474356A0559|49 54|tissue
P02474356A0559|56 56|T
P02474356A0559|58 64|N ratio
P02474356A0559|106 117|microspheres
P02474356A0559|125 130|portal
P02474356A0559|142 152|circulation
P02474356A0559|159 164|animal
P02475506A0878|3 6|mRNA
P02475506A0878|21 24|cDNA
P02475506A0878|42 76|polymerase chain reaction technique
P02475717A0565|0 14|Tissue necrosis
P02475717A0565|31 59|triphenyltetrazolium staining
P02475717A0565|82 100|baseline predictors
P02475717A0565|102 113|infarct size
P02475717A0565|122 135|risk zone size
P02475717A0565|145 159|collateral flow
P02476030A0000|17 23|surface
P02476030A0000|34 36|eye
P02476030A0000|56 61|states
P02476030A0000|68 92|laser scanning tomography
P02476664A0563|24 31|sequence
P02476664A0563|37 40|gene
P02476664A0563|54 56|K14
P02476664A0563|58 59|D.
P02477373A0930|10 17|TATA box
P02477373A0930|28 37|base pairs
P02477373A0930|55 83|transcription initiation site
P02479635A0659|0 13|Cotransfection
P02479635A0659|22 30|construct
P02479635A0659|35 42|plasmids
P02479635A0659|51 53|PKI
P02479635A0659|97 103|phorbol
P02479635A0659|120 129|expression
P02479823A0727|0 16|Sequence analysis
P02479823A0727|31 36|region
P02479823A0727|52 59|GC boxes
P02479823A0727|76 83|TATA box
P02480419A0735|13 21|cirrhosis
P02480419A0735|43 43|%
P02480419A0735|65 65|%
P02480419A0735|71 81|hepatitis B
P02480419A0735|88 96|infection
P02480419A0735|112 112|%
P02480959A0470|4 16|P-450scc mRNA
P02480959A0470|28 38|consequence
P02480959A0470|50 54|surge
P02480959A0470|95 99|cells
P02480959A0470|110 113|days
P02480959A0470|129 132|days
P02480959A0470|139 145|absence
P02480959A0470|148 160|gonadotropins
P02480959A0470|177 186|modulation
P02480959A0470|189 197|prolactin
P02480959A0470|222 225|cAMP
P02481230A1258|23 44|bovine alpha transgene
P02481230A1258|57 64|placenta
P02481230A1258|77 80|mice
P02481429T0000|6 23|staining technique
P02481429T0000|26 45|Leishmania parasites
P02481429T0000|62 67|smears
P02481779A0213|0 6|NIK-244
P02481779A0213|25 32|ligation
P02481779A0213|54 64|arrhythmias
P02481779A0213|88 108|plasma concentrations
P02481779A0213|111 121|arrhythmias
P02481779A0213|150 157|ligation
P02481779A0213|161 169|digitalis
P02481779A0213|189 198|mg/kg i.v.
P02481779A0213|215 224|mg/kg i.v.
P02481779A0213|246 255|mg/kg i.v.
P02481779A0213|256 267|microgram/ml
P02481779A0213|282 285|mean
P02481779A0213|289 290|SD
P02481779A0213|296 299|mean
P02481779A0213|301 301|n
P02482293A1518|15 41|T24 bladder carcinoma cells
P02482293A1518|40 42|TNF
P02482293A1518|56 93|EGF-R tyrosine protein kinase activity
P02482293A1518|102 104|EGF
P02482293A1518|108 120|phorbol ester
P02482293A1518|151 158|activity
P02482293A1518|164 171|receptor
P02482293A1518|179 183|cells
P02482511A0860|5 32|phosphodiesterase inhibitors
P02482511A0860|67 74|syndrome
P02482511A0860|98 104|stimuli
P02482511A0860|108 118|weight loss
P02482511A0860|135 153|withdrawal syndrome
P02482511A0860|167 176|naltrexone
P02482511A0860|197 200|rats
P02483210A0000|13 17|value
P02483210A0000|20 30|blood serum
P02483210A0000|40 46|amylase
P02483210A0000|48 53|lipase
P02483210A0000|58 64|trypsin
P02483210A0000|67 79|exacerbations
P02483210A0000|89 110|relapsing pancreatitis
P02483438A0498|5 9|basis
P02483438A0498|15 23|mechanism
P02483438A0498|26 31|action
P02483438A0498|36 41|groups
P02483438A0498|44 54|inodilators
P02483438A0498|75 102|phosphodiesterase inhibitors
P02483438A0498|120 125|agents
P02484714T0000|10 21|organization
P02484714T0000|25 34|expression
P02484714T0000|40 62|mouse estrogen receptor
P02484994T0001|11 25|gamma globulins
P02485188A0415|9 25|chondroitinase AC
P02485188A0415|28 40|ABC digestion
P02485188A0415|49 57|reactions
P02485188A0415|81 86|levels
P02485188A0415|89 104|dermatan sulfate
P02485188A0415|113 120|diabetes
P02485188A0415|130 134|group
P02485188A0415|136 136|p
P02485188A0415|169 169|p
P02485188A0415|193 200|diabetes
P02485188A0415|220 225|levels
P02485188A0415|228 247|chondroitin sulfates
P02485188A0415|256 263|diabetes
P02485188A0415|269 273|group
P02485188A0415|275 275|p
P02486634A0632|10 18|perfusion
P02486634A0632|51 55|level
P02486634A0632|61 78|contrast injection
P02486634A0632|85 89|level
P02486634A0632|108 117|morphology
P02486634A0632|121 126|degree
P02486634A0632|129 150|collateral development
P02487898A0315|4 21|NGF administration
P02487898A0315|74 77|ways
P02487898A0315|80 97|NGF administration
P02488148A1156|9 15|program
P02488148A1156|18 20|use
P02488148A1156|26 37|RSNA meeting
P02488148A1156|41 47|program
P02488148A1156|66 74|diagnosis
P02488148A1156|89 89|%
P02488148A1156|95 98|time
P02489032A0000|0 13|Immunoglobulin
P02489032A0000|19 23|chain
P02489032A0000|25 27|IgL
P02489032A0000|29 37|diversity
P02489032A0000|54 60|chicken
P02489032A0000|63 75|recombination
P02489032A0000|102 109|variable
P02489032A0000|111 112|VL
P02489032A0000|125 126|JL
P02489032A0000|128 140|gene segments
P02489032A0000|160 174|diversification
P02489032A0000|190 198|VL region
P02489753A0581|3 9|results
P02489753A0581|41 52|EMG activity
P02489753A0581|54 61|FB group
P02489753A0581|95 102|position
P02489753A0581|117 118|CG
P02489753A0581|122 129|GF group
P02489753A0581|139 146|position
P02489753A0581|149 156|position
P02489895T0001|0 12|Muscle action
P02489895T0001|35 40|rhythm
P02489895T0001|70 76|muscles
P02489895T0001|79 86|children
P02489895T0001|90 95|adults
P02492111A0670|4 4|%
P02492111A0670|19 26|children
P02492111A0670|28 43|bone lead values
P02492111A0670|52 55|LXRF
P02492111A0670|123 128|adults
P02492111A0868|36 42|effects
P02492111A0868|45 52|children
P02492111A0868|59 64|levels
P02492111A0868|68 75|exposure
P02492111A0868|88 94|results
P02492111A0868|135 140|margin
P02492111A0868|143 148|safety
P02492111A0868|163 168|safety
P02492111A0868|188 202|U.S. guidelines
P02492111A0868|226 249|blood lead concentration
P02492111A0868|252 264|micrograms/dl
P02493644A0588|9 17|3T3 cells
P02493644A0588|18 22|jun-D
P02493644A0588|43 47|level
P02493644A0588|58 62|c-jun
P02493644A0588|66 70|jun-B
P02493644A0588|78 90|transcription
P02493644A0588|117 136|serum growth factors
P02495745T0000|15 21|effects
P02495745T0000|30 62|tissue-type plasminogen activator
P02495745T0000|62 67|AK-124
P02495745T0000|97 106|thrombosis
P02496090A0252|5 7|CO2
P02496090A0252|13 29|tracheostomy tube
P02496090A0252|56 72|mass spectrometry
P02496090A0252|108 125|sampling technique
P02496100T0000|26 30|assay
P02496100T0000|43 54|aflatoxin B1
P02496100T0000|56 74|cottonseed products
P02496100T0000|82 85|feed
P02496100T0000|100 104|study
P02496109A0754|8 18|experiments
P02496109A0754|23 32|S1 mapping
P02496109A0754|40 50|transcripts
P02496109A0754|52 67|gene disruptions
P02496109A0754|72 83|alpha region
P02496109A0754|114 126|fusion vector
P02496109A0754|155 163|promoters
P02496109A0754|200 205|growth
P02496109A0754|219 226|promoter
P02496109A0754|233 244|alpha operon
P02496109A0754|262 267|region
P02496109A0754|285 289|genes
P02496109A0754|295 297|IF1
P02496109A0754|300 311|L17 interval
P02497340A0989|20 33|antibody genes
P02497340A0989|49 50|JH
P02497340A0989|54 55|VH
P02497340A0989|61 72|chain probes
P02497340A0989|79 80|Jk
P02497340A0989|84 85|Vk
P02497340A0989|91 102|chain probes
P02498322A0226|22 30|complexes
P02498322A0226|47 68|gel retardation assays
P02498322A0226|72 80|HeLa cell
P02498322A0226|87 94|extracts
P02498322A0226|100 120|oligonucleotide probe
P02498322A0226|142 147|region
P02498652A0460|5 16|transfection
P02498652A0460|26 51|TSH beta promoter activity
P02498652A0460|96 98|GH3
P02498652A0460|118 130|cell cultures
P02500432A1416|32 45|CAT expression
P02500432A1416|74 81|kilobase
P02500432A1416|84 86|DNA
P02500432A1416|96 98|end
P02500432A1416|116 122|segment
P02500432A1416|145 155|orientation
P02500432A1416|158 162|front
P02500432A1416|168 175|CAT gene
P02502096A0462|18 27|blood flow
P02502096A0462|56 74|excretion processes
P02502602A0323|0 8|Tonometry
P02502602A0323|11 23|blood samples
P02502602A0323|27 34|patients
P02502602A0323|53 65|determination
P02502602A0323|68 87|acid-base quantities
P02502602A0323|107 114|affinity
P02502602A0323|119 121|p50
P02502960A0762|8 9|p.
P02504603T0000|0 8|Isolation
P02504603T0000|11 26|Weeksella virosa
P02504603T0000|35 47|CDC group IIf
P02504603T0000|59 64|sample
P02505087A1037|15 38|dimerization specificity
P02505087A1037|40 42|Fos
P02505087A1037|66 79|leucine zipper
P02505087A1037|91 94|GCN4
P02506390T0001|0 5|Growth
P02506390T0001|16 26|anastomoses
P02506390T0001|36 42|animals
P02506740A0742|28 32|hours
P02506740A0742|35 42|recovery
P02506740A0742|66 71|effect
P02506740A0742|81 87|hypoxia
P02506740A0742|98 107|blood flow
P02507523A0791|3 14|ORF1 product
P02507523A0791|28 37|competence
P02507523A0791|44 47|ORF2
P02507523A0791|74 77|ORF1
P02507523A0791|98 104|protein
P02507523A0791|110 120|amino acids
P02507815A0000|0 7|Kindling
P02507815A0000|26 31|cortex
P02507815A0000|33 34|VC
P02507815A0000|60 67|amygdala
P02507815A0000|70 73|cats
P02508306A0528|8 19|infiltration
P02508306A0528|22 32|lymphocytes
P02508306A0528|36 47|plasma cells
P02508306A0528|75 83|carcinoma
P02508306A0528|114 122|follicles
P02508726A0498|5 16|case reports
P02508726A0498|30 37|evidence
P02508726A0498|42 46|LiCO3
P02508726A0498|59 68|medication
P02508726A0498|74 82|treatment
P02508726A0498|95 102|behavior
P02508726A0498|115 125|instability
P02508726A0498|131 142|brain injury
P02508726A0498|166 174|potential
P02508726A0498|178 190|neurotoxicity
P02508726A0498|197 206|population
P02508726A0498|230 240|conjunction
P02508726A0498|256 261|agents
P02509123A0371|5 12|sessions
P02509123A0371|18 20|IFN
P02509123A0371|25 31|latency
P02509123A0371|37 50|P100 component
P02509123A0371|55 57|VEP
P02509123A0371|82 100|baseline conditions
P02510242A0313|8 12|cases
P02510242A0313|31 39|hepatitis
P02510242A0313|54 70|hepatitis B virus
P02510242A0313|87 92|search
P02510242A0313|96 101|HBs Ag
P02510242A0313|131 137|viruses
P02510242A0313|173 177|tests
P02510242A0313|192 198|viruses
P02510242A0313|209 211|CMV
P02511069A0532|15 23|mutations
P02511069A0532|45 51|failure
P02511069A0532|76 84|lethality
P02511069A0532|87 88|Df
P02511069A0532|90 91|3L
P02511069A0532|93 95|RR2
P02511069A0532|98 105|deletion
P02511069A0532|111 120|DRE region
P02511069A0532|136 160|polytene chromosome bands
P02511150T0025|7 12|status
P02511150T0025|22 33|perspectives
P02511207A0282|0 1|K.
P02511430A0000|15 16|bp
P02511430A0000|18 23|region
P02511430A0000|29 38|mouse MOPC
P02511430A0000|40 44|kappa
P02511430A0000|56 83|immunoglobulin gene enhancer
P02511430A0000|108 114|binding
P02511430A0000|146 152|factors
P02511898A0000|4 8|paper
P02511898A0000|20 26|reasons
P02511898A0000|30 38|countries
P02511898A0000|46 59|Chagas disease
P02511898A0000|93 100|research
P02512010A0801|3 20|PETCO2 measurement
P02512010A0801|36 46|compression
P02512010A0801|59 65|success
P02512010A0801|68 81|defibrillation
P02512010A0801|86 91|return
P02512010A0801|105 115|circulation
P02514498A0000|7 14|CO2/HCO3
P02514498A0000|30 36|absence
P02514498A0000|51 60|inhibition
P02514498A0000|63 76|acid secretion
P02514498A0000|78 82|intra
P02514498A0000|99 118|pCO2/pH measurements
P02514498A0000|122 128|persons
P02514498A0000|150 157|equation
P02514498A0000|160 180|Henderson-Hasselbalch
P02514498A0000|182 185|pCO2
P02514498A0000|201 203|use
P02514498A0000|210 218|electrode
P02515953A0459|9 13|study
P02515953A0459|22 22|%
P02515953A0459|30 37|patients
P02515953A0459|42 54|effectiveness
P02517008A0481|8 15|patients
P02517008A0481|28 32|trial
P02517008A0481|48 52|doses
P02517008A0481|55 65|monotherapy
P02518645T0001|8 21|Chagas disease
P02518645T0001|22 41|laboratory diagnosis
P02518645T0001|55 58|year
P02518645T0001|61 64|life
P02518691A0251|12 41|IL2R alpha promoter constructs
P02518691A0251|50 61|transfection
P02518691A0251|65 82|DNA binding assays
P02518691A0251|102 110|sequences
P02518691A0251|155 170|kappa B enhancer
P02518691A0251|188 197|regulation
P02518691A0251|200 225|IL2R alpha gene expression
P02519327T0001|11 20|rheumatism
P02519679T0000|0 9|Inefficacy
P02519679T0000|12 31|phosphine fumigation
P02519679T0000|38 42|ticks
P02520622A0200|5 12|patients
P02520622A0200|65 77|transit times
P02520622A0200|90 97|symptoms
P02520622A0200|114 132|cimetropium bromide
P02520622A0200|134 142|mg t.d.s.
P02520622A0200|144 150|placebo
P02520622A0200|155 159|month
P02520622A0200|193 204|group design
P02521217A1035|24 30|protein
P02521217A1035|44 51|ribosome
P02521217A1035|55 72|membrane fractions
P02521217A1035|74 85|mitochondria
P02521674T0000|0 6|Mapping
P02521674T0000|9 11|RNA
P02521674T0000|34 40|mutants
P02521674T0000|50 54|virus
P02521674T0000|56 86|complementation group F mutants
P02521674T0000|88 94|lesions
P02521674T0000|97 100|nsP4
P02522297A0000|3 8|effect
P02522297A0000|14 27|thromboxane A2
P02522297A0000|28 31|TXA2
P02522297A0000|34 79|prostaglandin endoperoxide receptor antagonist
P02522297A0000|78 79|SQ
P02522297A0000|102 109|ischemia
P02522297A0000|147 150|dogs
P02523800A1178|23 30|sequence
P02523800A1178|36 44|CHS1 gene
P02523800A1178|49 56|fragment
P02523800A1178|69 75|repeats
P02523800A1178|79 104|TGAAACA consensus sequence
P02523800A1178|150 162|BAR1 promoter
P02523800A1178|163 170|Kronstad
P02523800A1178|172 173|J.
P02525044A1026|3 16|recovery index
P02525044A1026|17 23|T25-T75
P02525044A1026|33 40|infusion
P02525044A1026|60 67|patients
P02525044A1026|79 88|mivacurium
P02525044A1026|108 120|suxamethonium
P02526165X0000|3 6|sign
P02526165X0000|9 20|Leser-Trelat
P02526165X0000|37 40|sign
P02526165X0000|43 54|Leser-Trelat
P02526165X0000|92 97|marker
P02526165X0000|108 117|malignancy
P02527365T0000|0 14|Xenopus homolog
P02527365T0000|19 35|mos protooncogene
P02527365T0000|54 64|fibroblasts
P02527365T0000|75 84|maturation
P02527365T0000|87 101|Xenopus oocytes
P02527745A0865|0 21|Southern blot analyses
P02527745A0865|49 59|copy number
P02527745A0865|66 69|gene
P02527745A0865|73 84|conservation
P02527745A0865|91 96|domain
P02527745A0865|104 114|vertebrates
P02528329A0000|5 20|missense mutants
P02528329A0000|22 28|subunit
P02528329A0000|50 60|F1F0-ATPase
P02528329A0000|94 118|hydroxylamine mutagenesis
P02528329A0000|121 127|plasmid
P02528329A0000|139 142|uncB
P02528329A0000|144 150|subunit
P02528329A0000|153 156|gene
P02528730A1073|9 16|exons 2a
P02528730A1073|21 25|share
P02528730A1073|35 42|sequence
P02528730A1073|70 72|use
P02528730A1073|86 103|donor splice sites
P02528730A1073|105 106|bp
P02528730A1073|117 120|gene
P02529378A0536|0 19|S1 nuclease analysis
P02529378A0536|20 22|RNA
P02529378A0536|36 47|transfection
P02529378A0536|55 68|HIV constructs
P02529378A0536|72 81|HeLa cells
P02529378A0536|102 111|adenovirus
P02529378A0536|128 135|enhancer
P02529378A0536|137 139|SP1
P02529378A0536|141 144|TATA
P02529378A0536|150 156|portion
P02529378A0536|188 194|element
P02529378A0536|238 247|activation
P02529378A0536|253 259|HIV LTR
P02530413A0195|2 16|supine position
P02530413A0195|17 33|plasma ANP levels
P02530413A0195|44 48|pg/ml
P02530413A0195|55 59|pg/ml
P02530413A0195|74 78|level
P02530413A0195|92 96|pg/ml
P02530470A0604|10 19|prevalence
P02530470A0604|22 32|HBV markers
P02530470A0604|46 58|staff members
P02530470A0604|67 78|blood donors
P02530470A0604|83 86|area
P02531203A0241|12 22|predictions
P02531203A0241|49 57|responses
P02531203A0241|71 79|negatives
P02531203A0241|98 107|SSTS model
P02532032A0385|0 20|Plasma concentrations
P02532032A0385|22 24|ANF
P02532032A0385|26 29|pANF
P02532032A0385|32 42|aldosterone
P02532032A0385|44 46|PAC
P02532032A0385|51 55|renin
P02532032A0385|57 59|PRC
P02532032A0385|96 105|parameters
P02532210A0000|3 21|adenovirus E1A gene
P02532210A0000|28 34|protein
P02532210A0000|75 79|genes
P02534067A0316|0 13|Administration
P02534067A0316|16 28|dexamethasone
P02534067A0316|57 61|rises
P02534067A0316|64 69|plasma
P02534067A0316|72 92|alpha OH progesterone
P02534067A0316|94 112|beta-desoxycortisol
P02534067A0316|114 126|DHEA sulphate
P02534067A0316|127 141|androstenedione
P02534067A0316|145 156|testosterone
P02534067A0316|186 194|excretion
P02534067A0316|197 208|androsterone
P02534067A0316|212 231|beta OH androsterone
P02534067A0316|231 245|etiocholanolone
P02534067A0316|247 250|DHEA
P02534067A0316|257 269|alpha OH DHEA
P02535460A1443|0 14|RNA transcripts
P02535460A1443|49 52|gene
P02536096A0327|2 11|HeLa cells
P02536096A0327|23 35|transcription
P02536096A0327|43 67|herpes simplex virus type
P02536096A0327|66 90|thymidine kinase promoter
P02536096A0327|100 137|chloramphenicol acetyltransferase gene
P02536096A0327|157 167|orientation
P02536096A0327|181 205|thymidine kinase promoter
P02536096A0327|221 258|chloramphenicol acetyltransferase gene
P02536096A0327|263 270|sequence
P02536160A0518|22 30|condition
P02536160A0518|32 36|Ren1d
P02536160A0518|47 54|sequence
P02536160A0518|60 76|sense orientation
P02536160A0518|90 103|CAT expression
P02536160A0518|110 120|TK promoter
P02536160A0518|122 128|pUTKAT1
P02536160A0518|144 151|sequence
P02536160A0518|166 176|orientation
P02537441A0231|0 3|None
P02537441A0231|30 35|duties
P02537441A0231|46 61|varicella-zoster
P02537441A0231|68 75|globulin
P02537441A0231|88 94|disease
P02537485A0841|5 17|formalin test
P02537485A0841|26 33|naloxone
P02537485A0841|44 61|morphine analgesia
P02537485A0841|71 75|doses
P02537485A0841|86 90|mg/kg
P02537485A0841|106 123|morphine analgesia
P02537485A0841|135 138|dose
P02537485A0841|142 146|mg/kg
P02538450A0000|14 24|cDNA clones
P02538450A0000|28 36|rat brain
P02538450A0000|44 48|liver
P02538450A0000|66 72|isoform
P02538450A0000|78 101|Na,K-ATPase beta subunit
P02538656A0172|27 36|E1 mutants
P02538656A0172|52 52|M
P02538656A0172|56 64|R regions
P02538656A0172|74 79|mutant
P02538656A0172|103 108|region
P02538656A0172|120 140|transforming activity
P02538656A0172|142 157|mouse C127 cells
P02538656A0172|172 177|genome
P02538720A0582|0 3|UbiA
P02538720A0582|26 44|polyubiquitin genes
P02538720A0582|71 77|introns
P02538720A0582|93 100|sequence
P02541251A1327|9 15|T2 gene
P02541251A1327|40 44|sites
P02541251A1327|67 90|transcription factor SP1
P02541251A1327|95 98|TATA
P02541251A1327|101 115|CCAAT sequences
P02541251A1327|136 138|end
P02541251A1327|159 166|features
P02541251A1327|192 198|T1 gene
P02541882A0251|0 16|Radiation therapy
P02541882A0251|52 61|metastasis
P02541882A0251|72 79|patients
P02542194A1496|5 11|results
P02542194A1496|24 31|patients
P02542194A1496|55 65|irradiation
P02542194A1496|72 76|grade
P02542194A1496|83 94|astrocytomas
P02542194A1496|113 123|ependymomas
P02542194A1496|140 147|survival
P02542270A0000|3 13|methylation
P02542270A0000|26 41|chloroplast DNAs
P02542270A0000|58 65|relation
P02542270A0000|88 97|expression
P02542270A0000|100 122|C4 photosynthesis genes
P02542270A0000|126 138|bundle sheath
P02542270A0000|141 155|mesophyll cells
P02542270A0000|167 174|greening
P02542270A0000|189 193|maize
P02542612A0530|0 19|S1 nuclease analysis
P02542612A0530|20 22|RNA
P02542612A0530|44 54|B95-8 cells
P02542612A0530|61 70|Vero cells
P02542612A0530|87 110|NotI repeat promoter-CAT
P02542612A0530|112 112|Z
P02542612A0530|123 139|Z transactivation
P02542612A0530|151 155|level
P02542612A0530|183 197|RNA transcripts
P02543226A1559|20 29|likelihood
P02543226A1559|41 49|carcinoma
P02543226A1559|60 70|hyperplasia
P02543226A1559|87 110|adipose tissue component
P02543226A1559|124 138|breast biopsies
P02543226A1559|182 187|method
P02543226A1559|190 197|sampling
P02543226A1559|211 225|breast biopsies
P02543226A1559|255 261|maximum
P02543226A1559|266 271|blocks
P02543226A1559|281 290|parenchyma
P02543226A1559|298 301|case
P02543226A1559|328 333|tissue
P02543226A1559|354 362|carcinoma
P02543226A1559|373 383|hyperplasia
P02543226A1559|401 406|blocks
P02543621A0788|0 7|Analysis
P02543621A0788|13 15|DNA
P02543621A0788|22 26|cases
P02543621A0788|48 52|Wilms
P02543621A0788|54 58|tumor
P02543621A0788|74 80|changes
P02543621A0788|99 122|translocation breakpoint
P02543621A0788|141 144|gene
P02543679A1291|13 20|evidence
P02543679A1291|35 42|lambda O
P02543679A1291|45 56|P initiators
P02543679A1291|68 71|DnaJ
P02543679A1291|75 98|DnaK heat shock proteins
P02543679A1291|107 110|role
P02543679A1291|116 126|propagation
P02543679A1291|129 146|lambda replication
P02543734A0414|9 24|oligonucleotides
P02543734A0414|42 55|bp repeat unit
P02543734A0414|72 79|activity
P02543734A0414|85 107|IE1/2 enhancer/promoter
P02543734A0414|109 129|cotransfection assays
P02543734A0414|143 152|expression
P02544059A0377|0 6|Effects
P02544059A0377|9 16|nitrogen
P02544059A0377|18 20|PN2
P02544059A0377|28 30|MPa
P02544059A0377|35 40|helium
P02544059A0377|42 44|PHe
P02544059A0377|53 55|MPa
P02545357A0000|3 32|mustard chloroplast gene rps16
P02545357A0000|44 51|bp group
P02545357A0000|60 65|intron
P02545903A0639|0 9|Antibodies
P02545903A0639|30 32|NS3
P02545903A0639|35 46|immunization
P02545903A0639|49 52|mice
P02545903A0639|65 67|NS3
P02545903A0639|71 74|NS3A
P02545903A0639|92 100|BHK cells
P02545903A0639|116 137|BTV-10 virus particles
P02546234A1382|26 36|tachycaydia
P02546234A1382|59 65|efforts
P02546234A1382|101 107|outcome
P02547079A0910|11 25|calcium balance
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|76 89|administration
P02547079A0910|92 93|Cd
P02547079A0910|125 133|excretion
P02547079A0910|136 142|calcium
P02547611A0318|0 7|Clone 4c
P02547611A0318|12 13|bp
P02547611A0318|25 30|region
P02547611A0318|48 56|clone 22c
P02547611A0318|78 83|intron
P02547611A0318|89 90|bp
P02547706A0928|3 13|application
P02547706A0928|16 18|ISH
P02547706A0928|22 24|IHC
P02547706A0928|70 83|classification
P02547706A0928|86 95|pneumonias
P02547706A0928|100 105|CMV-IP
P02547706A0928|109 111|IIP
P02547706T0001|0 7|Validity
P02547706T0001|10 24|immunohistology
P02547706T0001|34 46|hybridization
P02547706T0001|64 72|diagnosis
P02547706T0001|75 99|cytomegalovirus pneumonia
P02547706T0001|124 132|pneumonia
P02547706T0001|147 173|bone marrow transplantation
P02547778A0786|9 14|nature
P02547778A0786|18 28|arrangement
P02547778A0786|34 37|ANT1
P02547778A0786|53 68|control elements
P02547778A0786|97 106|expression
P02548683T0001|6 12|account
P02548683T0001|22 28|seminar
P02548683T0001|31 38|Shanghai
P02548683T0001|46 56|hepatitis A
P02549036A0000|3 29|Bacillus subtilis phage phi
P02549036A0000|30 38|repressor
P02549036A0000|41 46|lambda
P02549036A0000|86 92|protein
P02549036A0000|143 153|homogeneity
P02549036A0000|156 160|order
P02549036A0000|191 200|properties
P02549343A1008|2 12|consequence
P02549343A1008|17 19|gpI
P02549343A1008|31 35|cells
P02549343A1008|48 51|mO74
P02549343A1008|67 81|characteristics
P02549343A1008|98 100|gpI
P02549343A1008|117 121|cells
P02549343A1008|141 167|immunoprecipitation pattern
P02549343A1008|188 193|weight
P02549343A1008|200 210|polypeptide
P02549343A1008|227 234|antibody
P02549343A1008|245 251|rabbits
P02549343A1008|275 279|virus
P02549343A1008|288 308|neutralizing activity
P02549343A1008|316 323|reaction
P02549343A1008|340 349|complement
P02549417A0000|12 17|stages
P02549417A0000|37 45|parasites
P02549417A0000|53 74|acristate mitochondria
P02549417A0000|79 87|functions
P02550118A0610|33 45|infiltrations
P02550118A0610|57 60|days
P02550682A0411|11 19|incidence
P02550682A0411|23 40|type IIc carcinoma
P02550682A0411|46 46|%
P02550682A0411|57 59|IIc
P02550682A0411|64 67|type
P02550682A0411|75 75|%
P02551886A0332|0 15|Restriction maps
P02551886A0332|26 33|plasmids
P02551886A0332|62 68|inserts
P02551886A0332|91 99|fragments
P02552143A0748|0 2|VP5
P02552143A0748|24 37|capsid protein
P02552143A0748|52 89|chloramphenicol acetyltransferase gene
P02552316A0526|26 35|caretakers
P02552316A0526|50 56|average
P02552316A0526|62 65|days
P02552316A0526|69 73|woman
P02552316A0526|103 121|seroconversion rate
P02552316A0526|125 131|percent
P02554310A0419|2 9|contrast
P02554310A0419|19 26|fragment
P02554310A0419|49 54|region
P02554310A0419|75 80|effect
P02555177A0488|7 11|pet54
P02555177A0488|14 17|LEU2
P02555177A0488|59 64|genome
P02555177A0488|78 99|COX1 introns aI5 alpha
P02555177A0488|100 107|aI5 beta
P02555177A0488|124 143|COX3 gene expression
P02555177A0488|150 167|COX1 mRNA splicing
P02555177A0488|168 183|mRNA translation
P02555418A0973|0 6|Insert2
P02555418A0973|39 47|sequences
P02555418A0973|67 74|sequence
P02555519A0798|17 26|variations
P02555519A0798|29 34|length
P02555519A0798|45 52|sequence
P02555519A0798|58 61|CDR3
P02555519A0798|63 96|complementarity determining region
P02555519A0798|96 103|peptides
P02555519A0798|112 119|H-chains
P02555519A0798|131 142|conservation
P02555519A0798|148 165|D-region structure
P02555519A0798|203 216|hapten binding
P02555703T0000|0 24|Tyrosine kinase oncogenes
P02555703T0000|31 54|interleukin-3 dependence
P02555703T0000|69 73|cells
P02555703T0000|81 98|signaling pathways
P02555703T0000|107 111|c-myc
P02555703T0000|124 133|regulation
P02555703T0000|136 154|c-myc transcription
P02555703T0000|177 181|v-abl
P02556264A0278|4 17|TC-II enhanson
P02556264A0278|39 51|kappa B motif
P02556264A0278|57 76|kappa chain enhancer
P02556264A0278|114 118|cells
P02556264A0278|167 182|cell specificity
P02556264A0278|187 199|kappa B motif
P02556269A0187|3 11|DNA helix
P02556269A0187|33 46|13mer sequence
P02556269A0187|87 102|hypersensitivity
P02556269A0187|127 134|nuclease
P02556269A0187|159 165|plasmid
P02556269A0187|190 192|DNA
P02556269A0187|226 244|gel electrophoresis
P02556269A0187|246 256|topoisomers
P02556603A0606|19 29|improvement
P02556603A0606|65 70|cancer
P02556603A0606|72 89|gallbladder cancer
P02556603A0606|104 119|bile duct cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|15 18|ACTH
P02557217A0000|22 39|cortisol secretion
P02557217A0000|71 75|males
P02557217A0000|86 105|spray administration
P02557217A0000|108 127|IU salmon calcitonin
P02557217A0398|3 6|data
P02557217A0398|19 28|calcitonin
P02557217A0398|51 58|increase
P02557217A0398|80 110|corticotrophin-cortisol release
P02557350A0632|3 15|DNA sequences
P02557350A0632|22 29|proteins
P02557350A0632|33 39|SRP54sc
P02557350A0632|43 49|SRP54sp
P02557350A0632|59 59|%
P02557350A0632|65 65|%
P02557350A0632|77 84|SRP54mam
P02559630A0270|15 20|values
P02559630A0270|50 69|thromboplastin times
P02559630A0270|70 86|prothrombin times
P02559630A0270|87 100|thrombin times
P02559630A0270|101 110|fibrinogen
P02559630A0270|112 126|platelet counts
P02559630A0270|130 167|fibrin/fibrinogen degradation products
P02560415T0012|14 18|tumor
P02560415T0012|23 32|metastasis
P02560415T0012|35 39|mouth
P02560415T0012|41 43|jaw
P02560415T0012|47 58|face regions
P02562787A0637|19 25|protein
P02562787A0637|35 37|NBP
P02562787A0637|40 43|CNBP
P02562825A0413|0 13|Responsiveness
P02562825A0413|16 37|beta-2 agonist therapy
P02562825A0413|55 60|agents
P02562825A0413|62 62|p
P02565405T0000|0 7|Drug use
P02565405T0000|9 22|trauma victims
P02565683A0841|9 18|heart rate
P02565683A0841|46 50|state
P02565683A0841|71 79|instances
P02565683A0841|82 90|reentrant
P02565683A0841|108 118|tachycardia
P02565683A0841|140 150|tachycardia
P02565807A1198|2 9|contrast
P02565807A1198|14 31|neu proto-oncogene
P02565807A1198|41 55|kinase activity
P02565807A1198|69 78|properties
P02565807A1198|101 106|levels
P02565807A1198|109 121|NIH 3T3 cells
P02565807A1198|122 129|ABSTRACT
P02565807A1198|144 148|WORDS
P02566613A0831|8 15|sequence
P02566613A0831|51 58|enhancer
P02566613A0831|60 62|CRE
P02566613A0831|64 71|TGACGTCA
P02566613A0831|73 83|nucleotides
P02566613T0000|0 27|Somatostatin gene expression
P02566613T0000|38 48|islet cells
P02566613T0000|73 92|DNA control elements
P02566613T0000|105 112|proteins
P02566680A0820|2 9|contrast
P02566680A0820|27 43|agonists fentanyl
P02566680A0820|44 51|morphine
P02566680A0820|53 63|I-methadone
P02566680A0820|67 77|levorphanol
P02566680A0820|88 88|%
P02566680A0820|121 125|doses
P02566680A0820|139 143|times
P02566680A0820|178 191|response rates
P02566680A0820|195 195|%
P02567030A0482|30 43|discrimination
P02567030A0482|48 55|controls
P02567030A0482|71 80|difficulty
P02567030A0482|99 106|reversal
P02568930T0000|0 8|Isolation
P02568930T0000|12 27|characterization
P02568930T0000|31 34|cDNA
P02568930T0000|52 59|cytokine
P02568930T0000|76 86|stimulation
P02568930T0000|93 105|CD2 structure
P02568930T0000|112 124|T lymphocytes
P02569411A0151|5 15|termination
P02569411A0151|18 27|medication
P02569411A0151|31 37|animals
P02569411A0151|66 81|nucleus amygdala
P02571924A0000|7 11|cells
P02571924A0000|14 26|mating type A
P02571924A0000|45 75|yeast Rhodosporidium toruloides
P02571924A0000|82 97|mating pheromone
P02571924A0000|98 112|rhodotorucine A
P02571924A0000|122 134|undecapeptide
P02571924A0000|145 163|S-farnesyl cysteine
P02571924A0000|168 183|carboxy terminus
P02572777T0000|0 21|Tumour necrosis factor
P02572777T0000|39 55|distress syndrome
P02572928T0000|0 9|Monitoring
P02572928T0000|22 30|arthritis
P02573303A0000|3 10|decrease
P02573303A0000|29 30|LV
P02573303A0000|32 44|stroke volume
P02573303A0000|72 79|pressure
P02573303A0000|81 84|PEEP
P02573303A0000|112 113|LV
P02573303A0000|134 150|contractile state
P02573336A0000|2 11|experiment
P02573336A0000|32 34|ROF
P02573336A0000|53 57|snake
P02573336A0000|74 81|subjects
P02573336A0000|84 88|order
P02573336A0000|117 121|event
P02573336A0000|145 150|retest
P02573336A0000|164 172|magnitude
P02573336A0000|178 180|ROF
P02573829T0000|12 23|conservation
P02573829T0000|45 49|sites
P02573829T0000|58 66|sequences
P02573829T0000|92 109|transcription unit
P02573829T0000|124 140|segmentation gene
P02573836A0244|21 30|importance
P02573836A0244|38 40|NBS
P02573836A0244|53 77|drug resistance phenotype
P02573836A0244|87 90|mdr1
P02573836A0244|104 127|amino acid substitutions
P02573836A0244|131 153|core consensus sequence
P02573836A0244|155 172|nucleotide binding
P02573836A0244|173 178|GXGKST
P02574016A0428|20 22|TOF
P02574016A0428|49 49|%
P02574016A0428|52 64|control value
P02574016A0428|65 75|neostigmine
P02574016A0428|90 102|micrograms/kg
P02574016A0428|105 110|adults
P02574016A0428|114 126|micrograms/kg
P02574016A0428|129 135|infants
P02574016A0428|139 146|children
P02574052A0910|13 23|differences
P02574052A0910|35 42|relation
P02574052A0910|45 60|Type A behaviour
P02574052A0910|62 87|beta-adrenoceptor blockade
P02574193A0663|0 8|Selection
P02574193A0663|16 20|items
P02574193A0663|34 80|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|80 85|CIWA-B
P02574193A0663|121 131|differences
P02574193A0663|139 146|baseline
P02574193A0663|158 175|withdrawal periods
P02574193A0663|186 193|subjects
P02574193A0663|204 211|symptoms
P02574193A0663|226 232|placebo
P02574193A0663|236 243|diazepam
P02574193A0663|254 261|subjects
P02574193A0663|268 285|contingency tables
P02574193A0663|296 314|regression analysis
P02574551T0000|0 13|Antihistamines
P02574551T0000|16 21|asthma
P02575174A0229|27 34|efficacy
P02575174A0229|38 43|safety
P02575174A0229|46 54|doxazosin
P02575174A0229|81 85|alpha
P02575174A0229|87 93|blocker
P02575174A0229|97 104|patients
P02575174A0229|117 128|hypertension
P02575174A0229|144 161|airflow limitation
P02575490A1021|0 21|Northern blot analysis
P02575490A1021|36 53|oIGF-I transcripts
P02575490A1021|61 64|band
P02575490A1021|76 86|nucleotides
P02575490A1021|95 105|transcripts
P02575490A1021|123 128|weight
P02575490A1021|131 135|liver
P02575567T0001|0 24|Materials science studies
P02575567T0001|59 63|wires
P02575959A0643|3 14|latency time
P02575959A0643|20 40|lactate concentration
P02575959A0643|53 58|values
P02575959A0643|78 85|training
P02575959A0643|87 88|T2
P02576405A0223|2 9|patients
P02576405A0223|21 23|VAD
P02576405A0223|34 42|therapies
P02576405A0223|58 66|melphalan
P02576405A0223|69 83|CBV combination
P02576405A0223|84 110|cyclophosphamide-BCNU-VP-16
P02576405A0223|116 127|EDAP regimen
P02576405A0223|128 132|VP-16
P02576405A0223|134 141|platinum
P02576405A0223|151 159|responses
P02576405A0223|169 169|%
P02576405A0223|172 179|patients
P02577458A0412|3 12|discussion
P02577458A0412|39 43|drugs
P02577458A0412|48 58|angiotensin
P02577458A0412|69 85|enzyme inhibitors
P02577458A0412|102 118|receptor blockers
P02577458A0412|122 140|calcium antagonists
P02577867T0000|16 22|homolog
P02577867T0000|28 40|oncogene jun.
P02580830A1131|7 14|sequence
P02580830A1131|30 35|region
P02580830A1131|49 56|cap site
P02580830A1131|66 73|AFP gene
P02580830A1131|81 92|% similarity
P02580830A1131|112 117|region
P02580830A1131|123 136|mouse AFP gene
P02582240A1009|4 17|ATP/GTP ratios
P02582240A1009|25 34|initiation
P02582240A1009|37 56|RNA primer synthesis
P02582240A1009|60 70|dCTTT sites
P02582240A1009|81 94|ATP/GTP ratios
P02582240A1009|102 111|initiation
P02582240A1009|117 126|dCCC sites
P02582918A0000|5 36|hepatitis B vaccine immunization
P02582918A0000|35 57|serum antibody response
P02582918A0000|68 71|type
P02582918A0000|76 80|cases
P02582918A0000|85 92|anti-HBs
P02582918A0000|104 106|S/N
P02582918A0000|108 121|S/N Ratio Unit
P02582918A0000|123 124|T0
P02582918A0000|145 148|rate
P02582918A0000|156 156|%
P02582918A0000|162 162|%
P02582918A0000|168 168|%
P02582918A0000|176 176|%
P02582918A0000|179 180|T1
P02582918A0000|182 183|T2
P02582918A0000|185 186|T0
P02582918A0000|190 192|T12
P02584969A0119|15 20|design
P02584969A0119|42 57|regression model
P02584969A0119|68 77|treatments
P02584969A0119|94 102|end point
P02584969A0119|105 105|%
P02584969A0119|110 124|protection time
P02585492A1005|13 33|complementation tests
P02585492A1005|46 56|P7 proteins
P02585492A1005|77 83|P1 parA
P02585492A1005|85 96|parB mutants
P02585492A1005|103 113|P1 proteins
P02585492A1005|132 143|P7 mutations
P02586485A0511|0 4|GN101
P02586485A0511|6 12|YC819-9
P02586485A0511|17 19|SB3
P02586513A0622|0 7|Analysis
P02586513A0622|34 46|ama-1 product
P02586513A0622|64 71|identity
P02586513A0622|86 92|subunit
P02586513A0622|95 98|RNAP
P02586513A0622|110 118|organisms
P02586513A0622|132 139|presence
P02586513A0622|143 159|zinc finger motif
P02586513A0622|165 178|amino terminus
P02586513A0622|200 205|domain
P02586513A0622|228 236|heptamers
P02586513A0622|244 260|consensus Tyr Ser
P02586513A0622|262 268|Thr Ser
P02586513A0622|271 273|Ser
P02590097A0093|7 17|involvement
P02590097A0093|27 30|lung
P02590097A0093|34 45|infiltration
P02590097A0093|51 56|mucosa
P02590097A0093|71 83|lobe bronchus
P02590097A0093|118 127|gammopathy
P02590097A0093|129 131|IgA
P02590097A0093|134 143|Type Kappa
P02590391A0442|0 3|None
P02590391A0442|17 26|parameters
P02590391A0442|28 41|heart contents
P02590391A0442|50 55|lipids
P02590391A0442|62 74|phospholipids
P02590391A0442|76 94|phosphatidylcholine
P02590391A0442|96 119|phosphatidylethanolamine
P02590391A0442|121 142|diphosphatidylglycerol
P02590391A0442|144 156|sphingomyelin
P02590391A0442|165 180|acid composition
P02590391A0442|186 203|phospholipid class
P02590391A0442|230 236|grading
P02590391A0442|242 248|lesions
P02590540A0741|5 9|women
P02590540A0741|27 35|diagnoses
P02590540A0741|41 41|%
P02590540A0741|46 47|CA
P02590540A0741|51 56|levels
P02590540A0741|59 64|excess
P02590540A0741|69 72|U/ml
P02590540A0741|79 79|%
P02590540A0741|94 97|U/ml
P02590615A0636|22 26|state
P02590615A0636|30 35|timing
P02590615A0636|44 47|meal
P02590615A0636|89 94|manner
P02590615A0636|98 113|pharmacokinetics
P02590615A0636|116 125|nifedipine
P02590615A0636|148 154|tablets
P02590869A0743|14 19|calves
P02590869A0743|32 40|serum IgG
P02590869A0743|41 50|lavage IgG
P02590869A0743|53 55|IgA
P02590869A0743|68 77|LNA titers
P02590869A0743|83 95|lavage fluids
P02590869A0743|98 102|serum
P02590869A0743|115 121|SC dose
P02590869A0743|129 136|bacteria
P02591078A0000|6 19|investigations
P02591078A0000|33 42|Grenz rays
P02591078A0000|64 90|contact dermatitis reaction
P02591078A0000|106 121|Langerhans cells
P02591078A0000|134 148|OKT6 antibodies
P02591078A0000|151 169|electron microscopy
P02591078A0000|186 194|epidermis
P02591078A0000|204 207|time
P02591969A0961|3 10|elements
P02591969A0961|25 50|glucocorticoid stimulation
P02591969A0961|52 73|ADH gene transcription
P02591969A0961|99 104|region
P02592543A0106|10 16|studies
P02592543A0106|38 52|characteristics
P02592543A0106|54 81|Kanagawa hemolysin reactions
P02592543A0106|84 99|plasmid profiles
P02592543A0106|103 109|patient
P02592543A0106|129 136|isolates
P02592543A0106|142 149|organism
P02592640A0466|4 9|values
P02592640A0466|16 22|retinol
P02592640A0466|26 38|beta-carotene
P02592640A0466|57 63|cheeses
P02592640A0466|75 79|cream
P02592640A0466|91 96|cheese
P02592640A0466|129 129|g
P02592640A0466|139 143|cream
P02592640A0466|157 162|cheese
P02592640A0466|195 195|g
P02592640A0466|205 209|cream
P02592640A0466|223 229|retinol
P02592640A0466|238 250|beta-carotene
P02592961A0327|0 5|COGLAB
P02592961A0327|14 21|measures
P02592961A0327|65 87|psychomotor performance
P02595451A1136|5 8|data
P02595451A1136|18 30|aniridia gene
P02595451A1136|31 33|AN2
P02595451A1136|48 73|T-cell leukemia breakpoint
P02595451A1136|73 76|TCL2
P02595451A1136|83 97|marker sequence
P02595451A1136|108 112|sides
P02595451A1136|115 118|MIC1
P02595451T0000|15 26|deletion map
P02595451T0000|33 46|chromosome 11p
P02595451T0000|47 54|analysis
P02595451T0000|57 73|J1 series hybrids
P02597484A0624|4 10|respect
P02597484A0624|22 32|diffusivity
P02597484A0624|35 43|platelets
P02597484A0624|45 46|De
P02597484A0624|54 71|surface reactivity
P02597484A0624|80 80|K
P02597484A0624|98 108|differences
P02597484A0624|133 141|materials
P02597549A0964|16 23|patients
P02597549A0964|33 36|days
P02597549A0964|54 65|dipyridamole
P02597549A0964|69 78|mg X 3/day
P02597549A0964|81 87|aspirin
P02597549A0964|91 96|mg/day
P02597549A0964|111 125|recovery period
P02597549A0964|134 137|days
P02597549A0964|157 167|prothrombin
P02597549A0964|178 197|thromboplastin times
P02598034A0000|0 22|Middle-latency auditory
P02598034A0000|28 37|potentials
P02598034A0000|39 43|MAEPs
P02598034A0000|59 66|controls
P02598034A0000|70 77|patients
P02598034A0000|87 93|lesions
P02598034A0000|118 123|cortex
P02598745A0251|24 38|Sylvius fissure
P02598745A0251|41 45|cases
P02599995A1031|13 28|activity studies
P02599995A1031|47 55|times MBC
P02599995A1031|60 69|penicillin
P02599995A1031|87 94|activity
P02599995A1031|115 127|staphylococci
P02599995A1031|137 144|survival
P02599995A1031|149 149|%
P02600306A0140|48 56|detection
P02600306A0140|59 82|envelope phase disparity
P02600306A0140|98 107|processing
P02600306A0140|121 127|channel
P02600306A0140|138 145|AM tones
P02601707A0986|0 21|Gel retardation assays
P02601707A0986|32 36|DNase
P02601707A0986|38 49|footprinting
P02601707A0986|53 86|diethyl pyrocarbonate interference
P02601707A0986|103 108|factor
P02601707A0986|127 137|C2 myotubes
P02601707A0986|140 153|BC3H1 myocytes
P02601707A0986|173 173|A
P02601707A0986|181 188|sequence
P02601707A0986|218 223|region
P02602150A0993|14 19|plants
P02602150A0993|52 59|analysis
P02602150A0993|62 78|sequence elements
P02602150A0993|87 111|replication origin region
P02602150A0993|121 132|construction
P02602150A0993|139 148|generation
P02602150A0993|151 157|vectors
P02602150A0993|161 178|gene amplification
P02602150A0993|180 185|plants
P02602150A0993|202 215|virus replicon
P02603374A0383|7 15|rhinotomy
P02603374A0383|37 52|dorsal rhinotomy
P02603374A0383|60 76|patient morbidity
P02603374A0383|97 109|complications
P02603923A0220|18 31|skin incisions
P02603923A0220|44 47|back
P02603923A0220|58 61|pigs
P02603923A0220|79 81|day
P02603923A0220|87 90|days
P02603923A0220|96 97|ml
P02603923A0220|109 121|growth factor
P02603923A0220|125 129|ng/ml
P02603923A0220|134 135|ml
P02603923A0220|138 143|Ringer
P02603923A0220|146 161|lactate solution
P02603923A0220|187 193|fashion
P02604420A0234|6 14|challenge
P02604420A0234|16 23|rebiopsy
P02604420A0234|35 54|reticulin antibodies
P02604420A0234|76 80|years
P02604420A0234|82 86|range
P02604420A0234|92 93|.0
P02604420A0234|102 104|end
P02604420A0234|113 122|year study
P02605160A0000|3 8|effect
P02605160A0000|11 21|iron intake
P02605160A0000|23 37|59Fe absorption
P02605160A0000|47 55|pregnancy
P02605160A0000|78 86|Fe status
P02605160A0000|96 98|end
P02605160A0000|101 109|pregnancy
P02605160A0000|128 131|rats
P02605182A0936|10 25|protein sequence
P02605182A0936|75 88|signal peptide
P02605182A0936|125 135|polypeptide
P02605679A0306|0 7|Analysis
P02605679A0306|13 26|rate constants
P02605679A0306|42 63|isomerization rate k12
P02605679A0306|96 111|degradation rate
P02605679A0306|116 120|delta
P02605679A0306|122 131|ester kdeg
P02605679A0306|148 162|hydrolysis rate
P02605679A0306|167 171|delta
P02605679A0306|173 181|ester k24
P02607766A0000|1 8|protocol
P02607766A0000|27 37|preparation
P02607766A0000|41 56|characterization
P02607766A0000|60 83|quality control material
P02607766A0000|83 85|QCM
P02607766A0000|106 118|concentration
P02607766A0000|121 127|cadmium
P02607766A0000|129 130|Cd
P02607766A0000|136 146|microgram/L
P02607766A0000|151 154|lead
P02607766A0000|156 157|Pb
P02607766A0000|164 176|micrograms/dL
P02607766A0000|188 192|blood
P02607766A0000|206 208|QCM
P02607766A0000|219 220|Cd
P02607766A0000|225 236|micrograms/L
P02607766A0000|239 245|mercury
P02607766A0000|247 248|Hg
P02607766A0000|255 266|micrograms/L
P02607766A0000|272 273|Pb
P02607766A0000|279 291|micrograms/dL
P02607766A0000|303 307|blood
P02607766A0000|325 341|spiking-solutions
P02607766A0000|354 358|salts
P02607766A0000|361 362|Cd
P02607766A0000|364 365|Hg
P02607766A0000|370 371|Pb
P02609112A0000|0 13|Reagent strips
P02609112A0000|35 42|practice
P02609112A0000|45 63|laboratory medicine
P02609112A0000|93 104|laboratories
P02614668A0971|19 31|concentration
P02614668A0971|38 42|ng/ml
P02614668A0971|48 52|serum
P02615078A0283|13 22|antibodies
P02615078A0283|38 50|actinomycetes
P02615078A0283|54 57|M.f.
P02617623A0740|0 5|LON-72
P02617623A0740|9 16|isolates
P02617623A0740|19 24|LON-73
P02617623A0740|29 34|LON-71
P02617623A0740|41 46|LON-10
P02617623A0740|61 69|altitudes
P02617623A0740|80 80|m
P02617623A0740|98 104|village
P02620085A0656|0 5|Animal
P02620085A0656|29 40|applications
P02620085A0656|43 48|plates
P02620085A0656|50 55|screws
P02620085A0656|74 93|replacement implants
P02620085A0656|112 119|material
P02620085A0656|133 139|results
P02621983T0001|0 11|Significance
P02621983T0001|34 46|acid analysis
P02621983T0001|56 60|tests
P02623038A0632|2 8|changes
P02623038A0632|32 42|performance
P02623038A0632|45 52|controls
P02623038A0632|70 86|saline injections
P02627159A0899|19 31|IgG4 antibody
P02627159A0899|42 46|index
P02627159A0899|59 71|immunotherapy
P02629109A0000|11 27|fertility decline
P02629109A0000|37 46|population
P02629109A0000|52 68|Mississippi Delta
P02629109A0000|141 150|population
P02629109A0000|206 216|1880 levels
P02630543A0210|16 32|staining affinity
P02630543A0210|41 50|antibodies
P02630543A0210|64 75|tissue cells
P02630543A0210|91 91|T
P02630543A0210|94 94|T
P02630543A0210|97 97|T
P02630543A0210|104 104|T
P02630543A0210|117 123|changes
P02630543A0210|129 135|numbers
P02630543A0210|143 158|cell populations
P02630543A0210|172 177|volume
P02630543A0210|200 205|tissue
P02631505A0382|0 9|Ampicillin
P02631505A0382|11 13|AMP
P02631505A0382|28 41|aminoglycoside
P02631505A0382|43 45|AMI
P02631505A0382|53 61|treatment
P02631505A0382|70 74|cases
P02631566A0151|0 13|Alkoxymetgyl-3
P02631566A0151|17 44|dimethylpyridinium chlorides
P02631566A0151|69 88|3,4-dimethylpyridine
P02631566A0151|93 117|chloromethyl alkyl ethers
P02631566A0151|167 175|chlorides
P02631566A0151|190 198|reactions
P02631566A0151|201 224|1-ethyloxymethylimidazol
P02631566A0151|229 255|chloromethyl alkyl sulfides
P02631743A0275|17 25|incidence
P02631743A0275|38 53|color deficiency
P02631743A0275|58 64|Koreans
P02631743A0275|70 72|use
P02631743A0275|75 79|H-R-R
P02631743A0275|98 103|plates
P02631887A0000|6 13|patients
P02631887A0000|26 29|HGGM
P02631887A0000|47 55|lymphomas
P02632904A0619|3 10|relation
P02632904A0619|18 23|VE/VO2
P02632904A0619|27 31|Q/VO2
P02632904A0619|58 68|correlation
P02632904A0619|70 70|r
P02632904A0619|78 78|p
P02634490A0186|15 23|diagnosis
P02634490A0186|30 39|affections
P02634490A0186|60 65|course
P02634490A0186|67 77|sialography
P02634490A0186|81 94|CT examination
P02634490A0186|114 126|ATB treatment
P02634490A0186|165 171|therapy
P02634872A0000|0 9|Retrograde
P02634872A0000|34 51|endodontics system
P02634872A0000|70 73|zone
P02634872A0000|87 94|approach
P02636920T0001|13 17|study
P02636920T0001|28 74|Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|11 17|studies
P02637597A0362|28 40|relapse stage
P02637597A0362|46 52|disease
P02637597A0362|68 76|serum ANA
P02637597A0362|77 79|IgA
P02637597A0362|83 91|IgM level
P02637597A0362|101 103|IgG
P02637597A0362|107 114|decrease
P02637597A0362|117 118|C3
P02637597A0362|122 123|C4
P02638964A0372|3 16|maximum stress
P02638964A0372|35 45|examination
P02638964A0372|51 59|composite
P02638964A0372|67 72|kg/mm2
P02638964A0372|75 85|equilibrium
P02638964A0372|91 95|water
P02638964A0372|109 117|composite
P02641762T0001|8 20|heart disease
P02641762T0001|31 58|exercise stress thallium-201
P02641762T0001|67 78|scintigraphy
P02641762T0001|81 90|comparison
P02641762T0001|93 97|SPECT
P02641762T0001|101 104|bull
P02641762T0001|107 117|eye display
P02642466T0000|0 16|Sequence analysis
P02642466T0000|47 64|membrane immunogen
P02642976A1474|9 27|consensus sequences
P02642976A1474|52 59|elements
P02644735A0427|2 10|FP mutant
P02644735A0427|11 19|AcFP875-2
P02644735A0427|32 40|insertion
P02644735A0427|43 59|S. frugiperda DNA
P02644735A0427|67 69|end
P02644735A0427|77 87|transcripts
P02644735A0427|95 105|S1 analysis
P02644735A0427|133 150|host cell sequence
P02645276T0088|0 11|Construction
P02645276T0088|15 34|RIP1 deletion strain
P02645276T0088|36 44|isolation
P02645276T0088|68 74|mutants
P02645431A1562|5 8|data
P02645431A1562|20 33|hypocitraturia
P02645431A1562|36 39|type
P02645431A1562|53 60|acidosis
P02645431A1562|72 77|defect
P02645431A1562|94 101|function
P02646007T0000|29 36|leukemia
P02646007T0000|50 57|leukemia
P02646007T0000|62 71|thrombosis
P02646007T0000|76 95|protein C deficiency
P02647403A0000|11 24|hallucinations
P02647403A0000|37 51|psychopathology
P02647403A0000|85 89|years
P02647918A0423|10 14|group
P02647918A0423|21 22|GH
P02647918A0423|26 45|somatomedin-C levels
P02647918A0423|59 62|mean
P02647918A0423|75 79|error
P02647918A0423|85 88|mean
P02647918A0423|115 119|ng/ml
P02647918A0423|147 150|U/ml
P02647918A0588|0 10|Application
P02647918A0588|22 29|criteria
P02647918A0588|32 35|cure
P02647918A0588|50 57|patients
P02647918A0588|61 61|%
P02647918A0588|71 79|GH levels
P02647918A0588|85 89|ng/ml
P02647918A0588|93 100|patients
P02647918A0588|104 104|%
P02647918A0588|115 134|somatomedin-C values
P02647918A0588|137 144|patients
P02647918A0588|148 148|%
P02647918A0588|161 174|GH suppression
P02647918A0588|184 188|ng/ml
P02647918A0588|196 199|OGTT
P02647918A0588|206 213|patients
P02647918A0588|217 217|%
P02647918A0588|240 247|criteria
P02647918A0588|252 264|disappearance
P02647918A0588|281 291|GH response
P02647918A0588|293 305|TRH/GnRH test
P02647937A0191|11 18|sequence
P02647937A0191|29 36|planning
P02647937A0191|68 71|ways
P02647937A0191|88 95|problems
P02648396A0565|2 13|Rat-1a cells
P02648396A0565|16 25|expression
P02648396A0565|33 42|c-jun mRNA
P02648396A0565|62 68|ability
P02648396A0565|71 75|clone
P02648396A0565|82 88|agarose
P02648396A0565|92 102|form tumors
P02648396A0565|108 111|mice
P02648396A1033|12 20|formation
P02648396A1033|23 26|foci
P02648396A1033|40 43|RECs
P02648396A1033|58 68|combination
P02648396A1033|92 142|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 25|Platelet activating factor
P02648646A0216|37 41|doses
P02648646A0216|46 61|minute intervals
P02648646A0216|64 78|airway response
P02648646A0216|88 93|change
P02648646A0216|103 117|expiratory flow
P02648646A0216|121 121|%
P02648646A0216|129 136|capacity
P02648646A0216|138 141|Vp30
P02648646A0932|21 31|correlation
P02648646A0932|39 64|baseline PC40 methacholine
P02648646A0932|76 79|fall
P02648646A0932|82 85|Vp30
P02648646A0932|108 117|micrograms
P02648646A0932|130 133|dose
P02648646A0932|137 146|micrograms
P02648646A0932|150 175|platelet activating factor
P02649445A0412|4 5|BG
P02649445A0412|9 26|IRI concentrations
P02649445A0412|35 38|OGTT
P02649445A0412|54 66|body builders
P02649445A0412|67 72|medium
P02649445A0412|75 82|controls
P02649445A0412|104 106|men
P02649811T0000|10 22|contraception
P02649811T0000|25 45|family planning study
P02650663A0178|4 9|rating
P02650663A0178|35 42|subjects
P02650663A0178|62 71|impairment
P02650663A0178|83 90|dementia
P02650663A0178|96 109|Alzheimer type
P02650663A0178|141 146|degree
P02650663A0178|157 165|diagnosis
P02650663A0178|176 183|dementia
P02651448A0000|20 23|drug
P02651448A0000|32 40|diffusion
P02651448A0000|55 65|dissolution
P02651448A0000|87 94|material
P02651448A0000|102 117|depolymerization
P02651448A0000|119 124|Type A
P02651448A0000|129 138|bioerosion
P02651448A0000|148 163|depolymerization
P02651448A0000|165 170|Type B
P02651487A0000|25 48|calcium channel blockers
P02651487A0000|59 69|contraction
P02651487A0000|86 91|muscle
P02651487A0000|104 112|knowledge
P02651487A0000|118 123|effect
P02651487A0000|126 156|excitation contraction coupling
P02651487A0000|169 174|glands
P02651487A0000|196 202|insulin
P02651487A0000|206 221|glucagon release
P02655381A0000|4 10|studies
P02655381A0000|28 38|possibility
P02655381A0000|56 62|factors
P02655381A0000|73 81|impotence
P02655381A0000|99 103|means
P02655381A0000|106 130|laboratory investigations
P02655381A0000|135 146|hypogonadism
P02655381A0000|148 165|hyperprolactinemia
P02655381A0000|167 176|occlusions
P02655381A0000|200 203|site
P02655381A0000|215 222|arteries
P02655381A0000|230 241|incompetence
P02655381A0000|254 265|neuropathies
P02656257A0000|16 39|DNA inversion system Cin
P02656257A0000|49 64|bacteriophage P1
P02656257A0000|75 85|recombinase
P02656257A0000|98 116|crossing-over sites
P02656257A0000|135 142|enhancer
P02657388A1011|3 19|terminator region
P02657388A1011|28 38|termination
P02657388A1011|41 51|transcripts
P02657388A1011|63 78|RNA polymerase I
P02657883A0000|0 9|US-Doppler
P02657883A0000|27 35|attention
P02657883A0000|50 55|method
P02657883A0000|72 81|evaluation
P02657883A0000|97 104|fistulas
P02657883A0000|106 108|FAV
P02657883T0001|0 6|Doppler
P02657883T0001|36 43|fistulae
P02657883T0001|47 54|dialysis
P02664229A0138|8 15|cosmesis
P02664229A0138|17 25|extension
P02664229A0138|31 35|scope
P02664229A0138|41 48|problems
P02664229A0138|75 80|repair
P02664229A0138|91 99|treatment
P02664229A0138|125 131|fistula
P02664229A0138|139 142|ease
P02664229A0138|155 168|Arap procedure
P02664229A0138|188 197|advantages
P02664229A0138|206 214|operation
P02664229A0138|240 258|hypospadias repairs
P02666034A1520|12 19|patients
P02666034A1520|27 32|course
P02666034A1520|35 41|therapy
P02666034A1520|56 85|vasodilator calcium antagonist
P02666034A1520|109 120|vasodilation
P02666034A1520|172 185|placebo course
P02666034A1520|187 193|therapy
P02666404A0220|3 23|galactose transporter
P02666404A0220|32 39|sequence
P02666404A0220|53 60|homology
P02666404A0220|66 76|superfamily
P02666404A0220|79 96|sugar transporters
P02666404A0220|117 133|HepG2-erythrocyte
P02666404A0220|142 168|muscle glucose transporters
P02666404A0220|171 179|rat brain
P02666404A0220|182 207|liver glucose transporters
P02666404A0220|225 230|xylose
P02666404A0220|234 252|arabinose permeases
P02666404A0220|271 277|glucose
P02666404A0220|279 285|maltose
P02666404A0220|290 311|galactose transporters
P02666568A0000|24 31|patients
P02666568A0000|48 52|study
P02666568A0000|55 69|protocol TCL821
P02667259A0331|20 23|cent
P02667259A0331|32 40|reactions
P02667259A0331|42 45|ADRs
P02667259A0331|54 57|case
P02667259A0331|64 69|nausea
P02667259A0331|71 79|dizziness
P02667259A0331|101 104|flow
P02668691A0570|4 7|mRNA
P02668691A0570|23 26|nagB
P02668691A0570|30 33|nagA
P02668691A0570|76 80|genes
P02668691A0570|82 85|nagC
P02668691A0570|89 92|nagD
P02669199A0000|0 20|Tumor necrosis factor
P02669199A0000|20 22|TNF
P02669199A0000|42 55|shock syndrome
P02669199A0000|78 86|endotoxin
P02669199A0000|88 90|LPS
P02670457T0000|3 21|calcium requirement
P02670457T0000|35 41|storage
P02670457T0000|54 60|explant
P02674141A1202|10 25|cysteine residue
P02674141A1202|27 30|CTSE
P02674141A1202|49 73|activation peptide region
P02674141A1202|77 85|proenzyme
P02674327A0493|3 5|p34
P02674327A0493|8 11|gene
P02674327A0493|22 37|codon usage bias
P02674327A0493|75 89|polyhedrin gene
P02674671A0601|20 36|DNA transformants
P02674671A0601|39 39|%
P02674671A0601|52 62|replacement
P02674671A0601|76 88|met2 mutation
P02674671A0601|111 116|allele
P02674674A1308|3 9|results
P02674674A1308|28 33|notion
P02674674A1308|53 57|sites
P02674674A1308|64 75|OBF1 protein
P02674674A1308|96 107|ARS function
P02674674A1308|111 116|origin
P02674674A1308|119 129|replication
P02674679A1237|5 9|basis
P02674679A1237|12 42|S1 nuclease protection analysis
P02674679A1237|42 57|RNA preparations
P02674679A1237|68 80|mouse tissues
P02674679A1237|85 88|dhfr
P02674679A1237|101 105|genes
P02674679A1237|119 124|levels
P02674679A1237|127 136|expression
P02674679A1237|151 161|specificity
P02674679A1237|164 185|start site utilization
P02675492A0806|11 18|patients
P02675492A0806|33 43|improvement
P02675492A0806|55 67|Ritchie-Index
P02675492A0806|69 78|pain score
P02675492A0806|79 81|ESR
P02675492A0806|85 87|CRP
P02677002A0205|29 35|enzymes
P02677002A0205|37 39|ATP
P02677002A0205|54 56|14C
P02677002A0205|58 60|Asp
P02677002A0205|63 96|equilibrium N-carbamyl-L-aspartate
P02677002A0205|97 101|C-Asp
P02677002A0205|110 112|32P
P02677002A0205|114 131|carbamyl phosphate
P02677002A0205|132 134|C-P
P02677002A0205|138 161|equilibrium Pi exchanges
P02677429A0366|0 13|Survival rates
P02677429A0366|27 41|treatment group
P02677429A0366|49 49|%
P02677429A0366|57 57|%
P02677429A0366|67 72|months
P02677429A0366|100 114|treatment group
P02677429A0366|119 119|%
P02677429A0366|127 127|%
P02677429A0366|137 142|months
P02677429A0366|164 164|%
P02677429A0366|172 172|%
P02677429A0366|182 187|months
P02677429A0366|207 214|subjects
P02677429A0366|219 222|AIDS
P02677429A0366|230 230|%
P02677429A0366|238 238|%
P02677429A0366|258 265|subjects
P02677429A0366|282 288|complex
P02677429A0366|302 316|treatment group
P02677666A0356|0 6|Mapping
P02677666A0356|30 50|complementation group
P02677666A0356|67 73|mutants
P02677666A0356|88 95|ag alpha
P02677666A0356|96 103|mutation
P02679804A2000|3 10|products
P02679804A2000|13 23|genes ura10
P02679804A2000|26 29|ura3
P02679804A2000|59 68|channeling
P02679804A2000|71 93|orotidine monophosphate
P02680843A0724|8 18|application
P02680843A0724|21 22|RS
P02680843A0724|26 36|REM latency
P02680843A0724|53 58|groups
P02680843A0724|64 76|investigation
P02684159A0870|0 21|Hybridization analysis
P02684159A0870|34 37|size
P02684159A0870|43 46|mRNA
P02684159A0870|57 65|kilobases
P02684585T0001|0 24|Agranulocytosis treatment
P02684585T0001|28 35|rhGM-CSF
P02685331A0523|3 27|R. meliloti nifH promoter
P02685331A0523|34 35|K.
P02685331A0523|46 58|nifH promoter
P02685331A0523|64 68|sigma
P02685331A0523|81 102|methylation protection
P02685331A0523|104 119|guanine residues
P02685331A0523|151 161|nucleotides
P02685331A0523|178 182|sigma
P02685331A0523|195 203|promoters
P02685461A0380|13 20|symptoms
P02685461A0380|26 32|disease
P02685461A0380|50 54|group
P02685461A0380|57 64|patients
P02685565A0165|31 34|form
P02685565A0165|50 53|mRNA
P02685565A0165|79 83|cells
P02685565A0165|118 128|c-myb genes
P02686588A0592|15 22|analysis
P02686588A0592|36 45|hematocrit
P02686588A0592|49 58|hemoglobin
P02686588A0592|71 73|BUN
P02686588A0592|77 96|alkaline phosphatase
P02686588A0592|108 112|group
P02686749A0000|11 29|health significance
P02686749A0000|44 50|changes
P02686749A0000|63 70|exposure
P02686749A0000|73 79|cadmium
P02686749A0000|83 89|workers
P02686749A0000|101 108|exposure
P02686749A0000|121 129|discovery
P02686749A0000|150 158|excretion
P02686749A0000|161 180|beta 2-microglobulin
P02686749A0000|182 204|retinol binding protein
P02686749A0000|232 235|year
P02686749A0000|243 247|years
P02686980A0000|2 6|order
P02686980A0000|40 51|organization
P02686980A0000|67 75|nucleolus
P02686980A0000|123 132|components
P02686980A0000|138 142|yeast
P02686985A0811|1 36|transcription factor exclusion assay
P02686985A0811|54 66|PCF1 mutation
P02686985A0811|84 89|stages
P02686985A0811|92 104|transcription
P02686985A0811|133 149|complex formation
P02686985A0811|162 168|effects
P02686985A0811|183 191|component
P02686985A0811|203 209|complex
P02688772T0000|0 9|Psychiatry
P02688772T0000|16 19|skin
P02689136A1851|12 18|effects
P02689136A1851|35 38|time
P02689439A0000|12 37|glutathione S-transferases
P02689439A0000|38 41|GSTs
P02689439A0000|43 44|EC
P02689439A0000|58 68|superfamily
P02689439A0000|78 87|isoenzymes
P02689439A0000|104 114|conjugation
P02689439A0000|130 139|substrates
P02689439A0000|144 154|glutathione
P02689439A0402|30 36|regions
P02689439A0402|39 44|pmGT10
P02689439A0402|59 64|degree
P02689439A0402|67 74|homology
P02689439A0402|82 87|region
P02689439A0402|93 104|rat Yb1 gene
P02689439A0402|113 118|region
P02689439A0402|121 125|pmGT2
P02689439A0402|140 147|homology
P02689439A0402|166 171|region
P02689439A0402|177 188|rat Yb2 gene
P02689544A0456|0 4|Model
P02689544A0456|15 23|abutments
P02689544A0456|38 44|incisor
P02689544A0456|73 81|abutments
P02691557A0273|3 11|incidence
P02691557A0273|19 37|breathing movements
P02691557A0273|49 49|h
P02691557A0273|85 87|age
P02691557A0273|106 119|concentrations
P02691557A0273|122 131|plasma PGE
P02691557A0273|164 169|period
P02691557A0273|172 180|gestation
P02691811A0355|15 17|min
P02691811A0355|20 27|recovery
P02691811A0355|29 44|plasma potassium
P02691811A0355|57 61|spite
P02691811A0355|79 92|blood acidosis
P02691811A0355|129 141|concentration
P02691998A0672|10 13|data
P02691998A0672|62 64|bed
P02691998A0672|86 88|bed
P02691998A0672|107 126|bolus administration
P02691998A0672|128 131|ET-1
P02692881A0354|2 11|comparison
P02692881A0354|30 34|women
P02692881A0354|56 60|women
P02692881A0354|62 66|women
P02692881A0354|71 73|PIH
P02692881A0354|82 89|increase
P02692881A0354|92 101|heart rate
P02692881A0354|144 147|tone
P02692881A0354|161 171|derangement
P02692881A0354|179 186|function
P02692881A0354|199 206|increase
P02692881A0354|209 213|serum
P02692881A0354|218 221|acid
P02692881A0354|225 233|reduction
P02692881A0354|236 251|sodium excretion
P02692881A0354|254 258|total
P02692881A0354|272 288|calcium excretion
P02692881A0354|298 302|level
P02692881A0354|305 320|sodium excretion
P02693208A0166|17 20|role
P02693208A0166|26 38|recombination
P02693208A0166|59 67|mutations
P02693208A0166|69 72|rad1
P02693208A0166|76 80|rad52
P02693208A0166|90 109|repeat recombination
P02693208A0166|145 153|sequences
P02693593A0866|10 16|protein
P02693593A0866|21 35|leader sequence
P02693593A0866|39 49|amino acids
P02694731A0241|10 13|hand
P02694731A0241|15 23|knowledge
P02694731A0241|29 40|epidemiology
P02694731A0241|43 51|Parkinson
P02694731A0241|54 60|disease
P02694731A0241|93 102|hypotheses
P02694731A0241|113 122|hypotheses
P02694731A0241|155 161|profile
P02694731A0241|176 182|testing
P02695914T0000|3 19|stereoselectivity
P02695914T0000|22 32|drug action
P02700977A0444|0 9|Scotchbond
P02700977A0444|28 38|penetration
P02700977A0444|69 81|XR bond/Silus
P02700977A0444|85 95|combination
P02702566A0000|1 11|combination
P02702566A0000|14 22|cisplatin
P02702566A0000|26 39|5-fluorouracil
P02702566A0000|58 61|days
P02702566A0000|76 83|infusion
P02702566A0000|106 109|head
P02702566A0000|113 123|neck cancer
P02702849A0418|0 30|Metformin plasma concentrations
P02702849A0418|55 62|patients
P02702849A0418|86 86|g
P02702849A0418|97 98|mg
P02702849A0418|117 146|patients plasma concentrations
P02702849A0418|182 193|micrograms/l
P02702849A0418|195 195|p
P02703121T0000|0 8|Diagnosis
P02703121T0000|18 39|sclerosing cholangitis
P02703121T0000|42 52|blood donor
P02703121T0000|64 93|serum alanine aminotransferase
P02703925A0359|34 45|subgroupings
P02703925A0359|65 90|sedimentation coefficients
P02703925A0359|93 115|polydispersity profiles
P02703925A0359|136 146|conclusions
P02703925A0359|151 154|loss
P02703925A0359|157 180|proteoglycan aggregation
P02703925A0359|183 197|sedimentability
P02703925A0359|221 224|sign
P02703925A0359|227 254|cartilage matrix degradation
P02703925A0359|263 270|S values
P02703925A0359|273 285|proteoglycans
P02703925A0359|295 300|weight
P02703925A0359|302 303|HW
P02703925A0359|313 317|areas
P02703925A0359|326 331|values
P02703925A0359|348 353|weight
P02703925A0359|355 356|LW
P02703925A0359|366 370|areas
P02703925A0359|383 389|finding
P02703925A0359|398 414|cartilage samples
P02703925A0359|418 426|inversion
P02703925A0359|433 439|pattern
P02703925A0359|455 472|matrix degradation
P02703925A0359|490 499|HW regions
P02703925A0359|531 535|areas
P02703925A0359|550 569|S value distribution
P02703925A0359|574 592|cartilage thickness
P02703925A0359|624 643|proteoglycan content
P02703925A0359|649 656|distance
P02703925A0359|670 676|surface
P02703925A0359|694 708|cartilage layer
P02703925A0359|718 722|cases
P02703925A0359|735 740|amount
P02703925A0359|743 752|aggregates
P02703925A0359|775 789|sedimentability
P02703925A0359|812 815|zone
P02703925A0359|827 833|samples
P02704579A1078|12 23|relationship
P02704579A1078|40 48|evolution
P02704579A1078|54 60|disease
P02704579A1078|68 73|CRS/BW
P02704579A1078|77 99|gas exchange parameters
P02704579A1078|99 102|FIO2
P02704579A1078|106 116|a/AO2 ratio
P02704579A1078|118 118|P
P02704579A1078|136 147|gas exchange
P02704579A1078|166 179|lung mechanics
P02705072A0464|0 9|End points
P02705072A0464|52 61|infarction
P02705072A0464|63 64|MI
P02705072A0464|66 69|rate
P02705072A0464|73 77|death
P02705296A0231|21 26|weight
P02705296A0231|32 42|polyprotein
P02705296A0231|52 55|ORF1
P02705296A0231|60 70|kilodaltons
P02705296A0231|72 74|kDa
P02705556A1049|4 5|RV
P02705556A1049|8 13|demand
P02705556A1049|22 23|RC
P02705556A1049|26 31|supply
P02705556A1049|52 63|flow reserve
P02707909A0209|2 19|alternative method
P02707909A0209|21 23|UKM
P02707909A0209|57 64|fraction
P02707909A0209|72 85|dialysate flow
P02707909A0209|100 107|dialyses
P02708288A0139|0 20|Liquid chromatography
P02708288A0139|36 44|detection
P02708288A0139|46 50|LC/AD
P02708288A0139|78 81|acid
P02708288A0139|97 106|metabolism
P02708288A0139|109 123|base hydrolysis
P02708288A0139|125 139|fluazifop-butyl
P02708288A0139|142 149|soybeans
P02708288A0139|153 163|soybean oil
P02708288A0621|3 17|dichloromethane
P02708288A0621|34 38|phase
P02708288A0621|57 64|aliquots
P02708288A0621|81 92|PRP-1 liquid
P02708288A0621|107 112|column
P02708288A0621|123 126|acid
P02708288A0621|153 161|compounds
P02708288A0621|184 192|potential
P02708288A0621|200 200|V
P02708288A0621|236 243|detector
P02708288A0621|249 262|oxidation mode
P02708353A1080|0 27|Primer extension experiments
P02708353A1080|42 70|transcription initiation site
P02708353A1080|78 85|position
P02708353A1080|88 91|gene
P02708353A1080|149 159|P-450e gene
P02708353A1452|17 41|polymerase chain reaction
P02708353A1452|63 66|gene
P02708353A1452|69 79|transcripts
P02708353A1452|105 122|polysome fractions
P02708353A1452|144 154|utilization
P02708353A1452|161 166|tissue
P02709081T0000|0 9|Validation
P02709081T0000|15 20|survey
P02709081T0000|23 33|work styles
P02709081T0000|35 49|profile measure
P02709081T0000|54 77|type A behaviour pattern
P02709819A0495|7 9|ADR
P02709819A0495|32 52|ciprofloxacin therapy
P02711145T0000|0 17|HIV infectiousness
P02711145T0000|23 26|AIDS
P02711167A0818|4 6|day
P02711167A0818|14 20|turnout
P02711167A0818|25 33|PFB-group
P02711167A0818|55 77|serum pepsinogen levels
P02711167A0818|96 101|degree
P02711167A0818|112 117|damage
P02711167A0818|125 131|animals
P02711601A0601|16 25|inhibition
P02711601A0601|28 52|acid phosphatase activity
P02711601A0601|53 59|control
P02711601A0601|73 83|guinea pigs
P02711601A0601|91 91|%
P02711601A0601|100 100|%
P02712246T0042|29 43|characteristics
P02712450A0989|12 16|PACO2
P02712450A0989|20 24|mm Hg
P02712450A0989|36 40|drive
P02712450A0989|64 64|p
P02712450A0989|83 90|subjects
P02712450A0989|92 95|Type
P02712450A0989|97 104|response
P02712450A0989|136 141|others
P02712450A0989|143 146|Type
P02712450A0989|148 155|response
P02712450A0989|162 172|hypercapnia
P02712450A0989|177 183|changes
P02712450A0989|186 190|drive
P02712450A0989|211 216|groups
P02713310T0000|0 13|Fundus changes
P02713310T0000|16 19|type
P02713310T0000|40 57|glomerulonephritis
P02713310T0000|68 73|drusen
P02713310T0000|93 98|report
P02713520T0000|7 18|dose effects
P02713520T0000|20 35|methyl parathion
P02713520T0000|37 46|nuthatches
P02713520T0000|48 61|cholinesterase
P02713520T0000|65 79|ptilochronology
P02713994A0482|3 7|titer
P02713994A0482|14 21|HSV type
P02713994A0482|29 36|HSV type
P02713994A0482|37 46|antibodies
P02713994A0482|52 58|mothers
P02713994A0482|63 72|cord blood
P02714525A0529|0 12|Kidney weight
P02714525A0529|29 40|weight ratio
P02714525A0529|77 86|dose level
P02714525A0529|93 97|weeks
P02714525A0529|115 125|dose levels
P02714525A0529|132 136|weeks
P02714525A0529|139 146|exposure
P02714852T0000|7 15|variation
P02714852T0000|18 22|HLA-B
P02714852T0000|26 40|HLA-C sequences
P02714852T0000|46 54|evolution
P02714852T0000|60 72|HLA-B alleles
P02717133T0001|1 6|method
P02717133T0001|28 49|development conditions
P02717133T0001|51 76|summary oxygen consumption
P02717349A0311|0 2|Men
P02717349A0311|37 43|fitness
P02717349A0311|48 52|women
P02718683A0142|0 19|Handgrip dynamometry
P02718683A0142|46 53|patients
P02720966A0455|15 19|fluid
P02720966A0455|23 25|ADA
P02720966A0455|35 47|concentration
P02720966A0455|57 64|mu kat/L
P02720966A0455|91 100|meningitis
P02720966A0455|103 110|patients
P02720966A0455|121 125|years
P02720966A0455|127 137|sensitivity
P02720966A0455|143 153|specificity
P02720966A0455|161 170|efficiency
P02721169A0171|0 8|NERVTRACK
P02721169A0171|31 40|data items
P02721169A0171|60 65|manner
P02721169A0171|99 111|relationships
P02723503T0000|0 8|Swim-over
P02723503T0000|12 29|alternative method
P02723503T0000|48 58|spermatozoa
P02724227T0000|0 16|Perfusion washout
P02724227T0000|45 58|flap tolerance
P02724227T0000|60 67|ischemia
P02725495A0929|13 20|sequence
P02725495A0929|26 38|U2 RNA region
P02725495A0929|56 87|pre-mRNA branchpoint recognition
P02725495A0929|88 92|yeast
P02725495A0929|115 130|metazoan U2 RNAs
P02725495A0929|151 162|trypanosomes
P02725513A0617|25 43|CHO spacer promoter
P02725513A0617|71 74|rule
P02725513A0617|79 101|metazoan RNA polymerase
P02725513A0617|101 109|promoters
P02725513A0617|118 126|G residue
P02725513A0617|128 135|position
P02727909A0383|7 15|amplitude
P02727909A0383|21 31|aggregation
P02727909A0383|34 39|plates
P02727909A0383|44 51|decrease
P02727909A0383|57 65|threshold
P02727909A0383|73 83|sensitivity
P02727909A0383|86 88|ADP
P02727909A0383|109 115|persons
P02727909A0383|120 128|types IIa
P02727909A0383|131 137|IIb HLP
P02727909A0383|142 144|CHD
P02727909A0383|152 154|HLP
P02729666A0267|11 32|intergroup differences
P02729666A0267|61 73|dentoskeletal
P02729666A0267|81 104|tissue profile variables
P02731611A0134|3 8|author
P02731611A0134|18 26|rationale
P02731611A0134|45 48|view
P02731611A0134|61 64|case
P02731611A0134|85 91|hiccups
P02731611A0134|121 130|principles
P02731611A0134|145 169|Mental Research Institute
P02731671A0000|11 18|toxicity
P02731671A0000|21 32|nickel oxide
P02731671A0000|33 35|NiO
P02731671A0000|38 63|nickel sulfate hexahydrate
P02731671A0000|63 67|NiSO4
P02731671A0000|70 72|H2O
P02731671A0000|78 94|nickel subsulfide
P02731671A0000|95 99|Ni3S2
P02731671A0000|113 123|F344/N rats
P02731671A0000|126 136|B6C3F1 mice
P02731671A0000|141 159|inhalation exposure
P02731671A0000|163 168|hr/day
P02731671A0000|171 179|days/week
P02731671A0000|186 190|weeks
P02732341A0000|47 53|studies
P02732341A0000|65 72|neoplasm
P02732341A0000|78 81|year
P02732341A0000|85 89|woman
P02732341A0000|120 127|lymphoma
P02732341A0000|145 152|staining
P02732341A0000|156 177|chloroacetate esterase
P02732341A0000|198 206|diagnosis
P02733116T0000|7 25|National Institutes
P02733116T0000|27 32|Health
P02733690T0000|9 15|cloning
P02733690T0000|19 34|characterisation
P02733690T0000|53 57|genes
P02733690T0000|74 82|reductase
P02733690T0000|85 91|tobacco
P02735364A1330|10 14|model
P02735364A1330|16 20|grade
P02735364A1330|22 22|p
P02735364A1330|51 57|results
P02735364A1330|59 59|p
P02735364A1330|69 96|progesterone receptor status
P02735364A1330|96 96|p
P02735364A1330|108 110|age
P02735364A1330|124 131|variable
P02735364A1330|133 133|p
P02735364A1330|182 189|survival
P02736482A0550|2 9|contrast
P02736482A0550|26 42|radiation therapy
P02736482A0550|43 58|brain metastases
P02739739T0000|0 24|COUP transcription factor
P02739739T0000|26 31|member
P02739739T0000|37 64|steroid receptor superfamily
P02740196A0704|2 11|Experiment
P02740196A0704|25 38|classification
P02740196A0704|51 58|standard
P02740196A0704|72 77|center
P02740196A0704|83 87|range
P02740196A0704|90 103|target numbers
P02740347A0644|0 12|Cosmid clones
P02740347A0644|26 39|VNTR sequences
P02740347A0644|57 75|restriction mapping
P02740347A0644|99 100|kb
P02740627A0137|3 15|oxygen uptake
P02740627A0137|16 18|VO2
P02740627A0137|21 41|carbon dioxide output
P02740627A0137|41 44|VCO2
P02740627A0137|58 61|rate
P02740627A0137|63 64|fR
P02740627A0137|67 84|minute ventilation
P02740627A0137|85 86|VE
P02740627A0137|97 107|ventilation
P02740627A0137|109 110|VA
P02740627A0137|121 135|oxygen pressure
P02740627A0137|136 139|PAO2
P02740627A0137|145 156|VE/VO2 ratio
P02740627A0137|171 174|cows
P02740627A0137|189 194|volume
P02740627A0137|196 197|VT
P02740627A0137|219 223|space
P02740627A0137|225 226|VD
P02740627A0137|243 248|horses
P02740874A0957|10 15|damage
P02740874A0957|35 42|controls
P02740874A0957|54 60|tissues
P02740874A0957|70 72|SO2
P02740955A0333|11 18|patients
P02740955A0333|30 43|mortality rate
P02740955A0333|66 73|patients
P02740955A0333|86 95|deliveries
P02743842A0000|10 14|study
P02743842A0000|34 47|prostaglandins
P02743842A0000|49 59|cytoprotect
P02743842A0000|71 76|mucosa
P02743842A0000|102 118|stress ulceration
P02743842A0000|132 140|influence
P02743842A0000|157 172|prostaglandin E2
P02743842A0000|181 184|PGE2
P02743842A0000|207 222|lesion formation
P02743842A0000|235 243|tissue pH
P02743842A0000|244 244|H
P02743842A0000|246 259|back-diffusion
P02743842A0000|271 280|blood flow
P02743842A0000|282 284|rat
P02743842A0000|292 297|mucosa
P02743842A0000|314 317|acid
P02743842A0000|322 327|mM HCl
P02743842A0000|345 349|shock
P02743842A0000|353 357|ml/kg
P02743842A0000|363 365|min
P02743981A0347|0 10|Transcripts
P02743981A0347|55 58|L11e
P02743981A0347|74 98|L1e-L10e-L12e transcripts
P02743981A0347|126 133|NAB-L11e
P02743981A0347|150 164|NAB transcripts
P02743981A0347|181 183|ORF
P02743981A0347|197 206|transcript
P02744123A0237|17 23|results
P02744123A0237|43 49|species
P02744123A0237|55 67|rhesus monkey
P02744123A0237|70 72|man
P02744123A0237|96 103|branches
P02744123A0237|137 140|time
P02744123A0237|175 194|background luminance
P02744490A0894|0 7|Evidence
P02744490A0894|15 23|structure
P02744490A0894|27 32|number
P02744490A0894|35 45|cDNA clones
P02744490A0894|54 64|S1 nuclease
P02744490A0894|67 90|primer extension studies
P02744490A0894|100 109|hypothesis
P02744490A0894|117 126|PTHrP gene
P02744490A0894|144 174|mRNA transcription start points
P02744490A0894|203 209|domains
P02745280A0276|6 10|level
P02745280A0276|13 16|PaO2
P02745280A0276|39 46|measures
P02745280A0276|66 76|blood gases
P02745280A0276|83 103|lactate concentration
P02745280A0276|107 113|changes
P02745280A0276|127 140|concentrations
P02745280A0276|152 160|phosphate
P02745280A0276|162 176|phosphocreatine
P02745280A0276|181 183|ATP
P02745280A0276|196 198|31P
P02745280A0276|207 228|resonance spectroscopy
P02745444A0391|3 31|transcription initiation site
P02745444A0391|45 63|S1 nuclease mapping
P02745666A0000|11 18|biopsies
P02745666A0000|22 38|plasma oestradiol
P02745666A0000|39 40|E2
P02745666A0000|45 56|progesterone
P02745666A0000|58 59|P4
P02745666A0000|61 66|levels
P02745666A0000|71 78|patients
P02745666A0000|100 125|replacement therapy cycles
P02745666A0000|143 149|failure
P02746099A0000|3 10|mobility
P02746099A0000|29 37|premolars
P02746099A0000|43 46|load
P02746099A0000|64 71|relation
P02746099A0000|90 96|contact
P02746099A0000|108 113|facets
P02747653A0910|19 25|protein
P02747653A0910|50 57|staining
P02747653A0910|60 64|serum
P02747653A0910|67 74|tadpoles
P02747653A0910|84 92|beginning
P02747653A0910|95 107|metamorphosis
P02747653A0910|110 114|stage
P02748188A0091|27 31|group
P02748188A0091|33 34|PT
P02748188A0091|38 39|Ss
P02748188A0091|64 67|test
P02748188A0091|69 73|means
P02748188A0091|82 84|sec
P02748188A0091|107 111|group
P02748188A0091|113 114|PS
P02748188A0091|118 119|Ss
P02748188A0091|146 148|sec
P02748188A0091|166 169|test
P02748188A0091|171 171|t
P02748188A0091|179 179|P
P02748188A0091|217 223|studies
P02748595A0492|17 34|baboon liver class
P02748595A0492|34 36|ADH
P02748595A0492|57 63|lineage
P02748595A0492|74 81|ADH-beta
P02749215A0000|8 18|proteinuria
P02749215A0000|31 39|hematuria
P02749215A0000|46 51|pyuria
P02749215A0000|64 70|finding
P02751080A0176|14 17|shot
P02751080A0176|20 26|bullets
P02751080A0176|35 41|minutes
P02751080A0176|47 61|intensity level
P02751080A0176|76 77|dB
P02752303A0000|0 13|Lithium delays
P02752303A0000|25 30|rhythm
P02752303A0000|54 61|hamsters
P02752303A0000|64 84|plasma concentrations
P02752303A0000|94 95|mM
P02752303A0000|115 125|weight loss
P02752629A0163|0 6|Dynamic
P02752629A0163|16 26|scintigrams
P02752629A0163|46 68|methylene diphosphonate
P02752629A0163|97 101|weeks
P02752629A0163|107 114|fracture
P02752651A0480|2 10|admission
P02752651A0480|16 25|department
P02752651A0480|28 36|September
P02752651A0480|46 52|patient
P02752651A0480|74 84|paraparesis
P02752651A0480|89 98|impairment
P02752651A0480|111 120|modalities
P02752651A0480|129 133|level
P02752651A0480|136 137|Th
P02752651A0480|150 160|disturbance
P02756731T0001|0 13|Prostaglandins
P02756731T0001|17 26|gallstones
P02756878A0075|3 8|nature
P02756878A0075|14 20|process
P02756878A0075|42 52|occurrences
P02756878A0075|59 68|arrhythmia
P02756878A0075|82 89|patients
P02756878A0075|95 101|history
P02756878A0075|125 126|AF
P02757033A0905|19 24|effect
P02757033A0905|41 45|genes
P02757033A0905|64 66|arm
P02757033A0905|91 105|heterochromatin
P02757033A0905|127 141|position effect
P02757033A0905|144 156|transcription
P02757033A0905|164 168|genes
P02757862T0000|7 16|experience
P02757862T0000|22 35|microprocessor
P02757862T0000|58 70|defibrillator
P02758382A0478|0 6|Obesity
P02758382A0478|35 45|proportions
P02758382A0478|80 88|estradiol
P02758382A0478|116 143|sex hormone binding globulin
P02758382A0478|142 145|SHBG
P02758382A0478|147 152|levels
P02758382A0478|159 168|proportion
P02758382A0478|181 189|estradiol
P02760922A0000|20 36|ribonucleoprotein
P02760922A0000|38 42|hnRNP
P02760922A0000|44 58|core protein A1
P02760922A0000|65 73|component
P02760922A0000|85 89|hnRNP
P02760922A0000|92 102|S particles
P02761008X0000|0 28|Brain cholinesterase activity
P02761008X0000|42 47|egrets
P02761008X0000|54 59|egrets
P02761008X0000|76 87|night-herons
P02761008X0000|89 98|inhibition
P02761008X0000|101 120|brain cholinesterase
P02761008X0000|121 123|ChE
P02761008X0000|125 132|activity
P02761008X0000|135 139|birds
P02761008X0000|161 168|exposure
P02761008X0000|171 175|death
P02761008X0000|180 195|organophosphorus
P02761008X0000|198 217|carbamate pesticides
P02761150A0000|3 8|effect
P02761150A0000|11 25|zinc deficiency
P02761150A0000|27 38|trace metals
P02761150A0000|43 47|liver
P02761150A0000|49 54|spleen
P02761150A0000|56 61|kidney
P02761150A0000|63 70|pancreas
P02761150A0000|74 81|duodenum
P02761150A0000|102 108|control
P02761150A0000|126 129|rats
P02761150A0000|134 137|days
P02761150A0000|143 146|days
P02761150A0000|149 157|pregnancy
P02761492A0124|3 10|findings
P02761492A0124|21 24|view
P02761492A0124|42 48|genesis
P02761492A0124|61 71|involvement
P02761492A0124|80 87|patients
P02761537A0168|0 12|Heating cells
P02761537A0168|16 24|degrees C
P02761537A0168|36 41|amount
P02761537A0168|60 63|rRNA
P02761537A0168|75 75|%
P02761537A0168|81 93|control level
P02761537A0168|114 125|% inhibition
P02761537A0168|127 151|transcription termination
P02761537A0168|154 159|region
P02761537A0168|168 178|nucleotides
P02761537A0168|196 198|end
P02761537A0168|201 208|28S rRNA
P02761537A0168|213 223|readthrough
P02761537A0168|245 262|transcription unit
P02761540A0873|0 16|Deletion analysis
P02761540A0873|29 34|NF-4FA
P02761540A0873|36 41|NF-4FB
P02761540A0873|46 59|AP-1 sequences
P02761540A0873|82 98|enhancer activity
P02762006A0071|0 3|Cord
P02762006A0071|26 33|patients
P02762006A0071|54 60|lesions
P02762198T0001|0 3|Reye
P02762198T0001|6 13|syndrome
P02762198T0001|15 21|reports
P02762198T0001|25 29|cases
P02762198T0001|35 40|period
P02763467A0903|19 36|polyacrylamide gel
P02763467A0903|51 58|patterns
P02763467A0903|62 64|35S
P02763467A0903|84 91|proteins
P02763467A0903|104 108|cells
P02763467A0903|143 149|viruses
P02763467A0903|164 167|spot
P02763467A0903|230 234|point
P02763467A0903|259 265|N1L ORF
P02764797A0182|0 4|PULSE
P02764797A0182|20 22|NMR
P02764797A0182|36 45|parameters
P02764797A0182|51 55|delay
P02764797A0182|59 66|duration
P02764797A0182|69 70|rf
P02764797A0182|89 93|gates
P02764797A0182|95 102|rf phase
P02764797A0182|103 116|sampling times
P02764797A0182|124 141|imaging parameters
P02764797A0182|143 156|rf pulse shape
P02764797A0182|158 175|gradient waveforms
P02765001A0105|8 11|JPsA
P02765001A0105|15 22|patients
P02765001A0105|36 44|arthritis
P02765001A0105|105 108|rash
P02765001A0105|112 120|arthritis
P02765001A0105|141 148|criteria
P02765001A0105|150 159|dactylitis
P02765001A0105|161 164|nail
P02765001A0105|187 190|rash
P02765001A0105|194 207|family history
P02765001A0105|209 217|psoriasis
P02765214A0486|12 16|Kurti
P02765214A0486|19 24|demand
P02765214A0486|45 54|importance
P02765214A0486|60 68|arguments
P02766330A0779|3 8|author
P02766330A0779|16 22|account
P02766330A0779|77 83|effects
P02766330A0779|90 108|calcium antagonists
P02766330A0779|125 135|application
P02766508A0421|1 23|correlation coefficient
P02766508A0421|45 54|similarity
P02766508A0421|61 71|map pattern
P02766508A0421|84 97|mean IQRST map
P02766745T0000|15 19|study
P02766745T0000|25 36|relationship
P02766745T0000|52 59|placenta
P02766745T0000|63 70|mastitis
P02766745T0000|73 82|dairy cows
P02767166A0368|17 34|lipid peroxidation
P02767166A0368|52 62|development
P02767166A0368|71 78|cataract
P02767166A0368|92 102|consequence
P02767166A0368|112 117|damage
P02767166A0368|128 139|pathogenesis
P02767166A0368|142 149|cataract
P02767166A0368|152 159|diabetes
P02767166A0368|171 176|myopia
P02767733A0690|15 21|grading
P02767733A0690|38 42|cases
P02767733A0690|46 47|G1
P02767733A0690|51 52|G2
P02767733A0690|56 57|G3
P02767733A0690|72 77|spread
P02767733A0690|93 97|cases
P02767733A0690|101 101|%
P02772495A0641|0 5|Asthma
P02772495A0641|45 53|ASA group
P02772495A0641|56 56|%
P02772495A0641|62 62|%
P02772495A0641|65 66|AT
P02772495A0641|78 78|%
P02772495A0641|81 90|INTR group
P02773507A0750|1 5|value
P02773507A0750|11 14|l/kg
P02773507A0750|25 25|V
P02773507A0750|48 63|sample estimates
P02773507A0750|65 73|clearance
P02773507A0750|75 76|CL
P02773507A0750|83 87|value
P02773507A0750|93 96|l/kg
P02773507A0750|121 136|sample estimates
P02773507A0750|138 146|clearance
P02773507A0750|149 154|plasma
P02773507A0750|162 165|drug
P02773507A0750|167 171|CLunb
P02773930T0000|11 16|kidney
P02773930T0000|19 23|model
P02773930T0000|33 47|hyperfiltration
P02773930T0000|50 55|humans
P02774271A0000|0 8|Halothane
P02774271A0000|35 41|pathway
P02774271A0000|62 73|end products
P02774271A0000|89 92|acid
P02774271A0000|94 97|TFAA
P02774271A0000|102 108|bromide
P02774271A0000|110 111|Br
P02774271A0000|129 136|pathways
P02774271A0000|154 161|fluoride
P02774271A0000|163 163|F
P02774808A0194|3 8|values
P02774808A0194|31 31|P
P02774808A0194|51 56|summer
P02774808A0194|69 85|micrograms/100 ml
P02774808A0194|99 104|winter
P02775136A1151|5 11|results
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|59 76|breathing patterns
P02775136A1151|82 89|altitude
P02775136A1151|115 125|development
P02775136A1151|128 130|AMS
P02775136A1151|182 199|breathing patterns
P02775136A1151|203 207|cause
P02775136A1151|212 217|effect
P02775136A1151|220 222|AMS
P02775333A1137|0 9|Buflomedil
P02775333A1137|11 14|i.v.
P02775333A1137|38 45|increase
P02775333A1137|55 60|output
P02775333A1137|72 76|mg/kg
P02775333A1137|86 92|changes
P02775333A1137|106 110|mg/kg
P02775333A1137|121 128|decrease
P02775333A1137|148 155|increase
P02775333A1137|164 167|dose
P02775333A1137|174 178|mg/kg
P02776471A0235|26 32|animals
P02776471A0235|47 56|responders
P02776471A0235|71 77|pattern
P02776471A0235|93 100|response
P02776742A0000|0 9|Heart rate
P02776742A0000|10 11|HR
P02776742A0000|20 30|temperature
P02776742A0000|32 34|Tre
P02776742A0000|37 50|blood pressure
P02776742A0000|51 61|temperature
P02776742A0000|73 88|humidity changes
P02776742A0000|94 101|clothing
P02776742A0000|130 136|firemen
P02776742A0000|142 144|age
P02776742A0000|155 156|yr
P02776742A0000|158 164|VO2 max
P02776742A0000|172 184|ml kg-1 min-1
P02776742A0000|191 202|fire fighter
P02776742A0000|204 211|uniforms
P02776742A0000|213 214|SU
P02776742A0000|229 232|fire
P02776742A0000|254 261|clothing
P02776742A0000|266 269|self
P02776742A0000|279 297|breathing apparatus
P02776742A0000|298 299|FE
P02776823A0000|11 19|tolerance
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|41 43|FCE
P02776823A0000|50 55|sodium
P02776823A0000|57 58|5R
P02776823A0000|60 61|6S
P02776823A0000|68 69|1R
P02776823A0000|72 83|hydroxyethyl
P02776823A0000|88 127|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|134 138|penem
P02776823A0000|183 191|i.v. dose
P02776823A0000|194 200|mg.kg-1
P02776823A0000|217 226|volunteers
P02777797A0720|0 21|DNA blot hybridization
P02777797A0720|35 44|rat genome
P02777797A0720|65 68|gene
P02777797A0720|77 99|PtdIns transfer protein
P02778237A0585|8 11|term
P02778237A0585|36 37|IA
P02778237A0585|57 63|problem
P02778237A0585|73 74|IA
P02778237A0585|84 113|maintenance prednisone therapy
P02778873A0761|7 13|segment
P02778873A0761|16 19|CRL3
P02778873A0761|47 63|enhancer function
P02778873A0761|87 95|sequences
P02778873A0761|97 101|DR-A1
P02778873A0761|105 109|DR-A2
P02779752A0000|3 12|1-Naphthyl
P02779752A0000|14 23|piperazine
P02779752A0000|25 28|1-NP
P02779752A0000|51 81|serotonin antagonist properties
P02779752A0000|85 97|5-HT2 subtype
P02779752A0000|99 106|receptor
P02779752A0000|142 156|agonist actions
P02779752A0000|161 170|5-HT1 site
P02779752A0776|3 16|m-Chlorophenyl
P02779752A0776|18 27|piperazine
P02779752A0776|29 32|mCPP
P02779752A0776|41 45|mg/kg
P02779752A0776|53 75|m-trifluoromethylphenyl
P02779752A0776|77 86|piperazine
P02779752A0776|88 92|TFMPP
P02779752A0776|101 105|mg/kg
P02779752A0776|135 145|5-HT1 sites
P02779752A0776|176 181|effect
P02779752A0776|194 205|methysergide
P02779752A0776|211 214|1-NP
P02779752A0776|224 233|ketanserin
P02780157A0576|17 23|feature
P02780157A0576|26 30|liver
P02780157A0576|34 51|spleen MP function
P02780157A0576|52 59|patients
P02780157A0576|64 66|VHA
P02780157A0576|81 97|HBsAg carriership
P02780157A0576|111 114|lack
P02780157A0576|132 139|reaction
P02780157A0576|145 148|part
P02780157A0576|151 159|spleen MP
P02780157A0576|191 200|overstrain
P02780157A0576|207 214|standing
P02780157A0576|218 226|depletion
P02780157A0576|232 240|MP system
P02780157A0576|263 273|stimulation
P02780157A0576|276 280|HBsAg
P02781495T0001|0 6|Changes
P02781495T0001|9 33|xanthine oxidase activity
P02781495T0001|34 41|patients
P02781495T0001|57 63|failure
P02781567A0544|1 4|soap
P02781567A0544|8 12|water
P02781567A0544|18 20|v/v
P02781567A0544|22 29|solution
P02781567A0544|63 77|stratum corneum
P02783181A0000|29 38|activities
P02783181A0000|44 61|antacid magaldrate
P02783181A0000|62 70|ES Riopan
P02783181A0000|82 88|effects
P02783181A0000|105 114|blood flow
P02783181A0000|117 132|mucus secretions
P02783181A0000|152 154|rat
P02784507A0000|8 34|immunodeficiency virus type
P02784507A0000|35 39|HIV-1
P02784507A0000|62 64|CD4
P02784507A0000|66 78|T lymphocytes
P02784507A0000|98 105|provirus
P02784507A0000|117 121|cells
P02784507A0000|133 139|periods
P02787430A0124|11 22|panniculitis
P02787430A0124|36 51|biopsy specimens
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|22 24|4F2
P02789062A0000|30 34|chain
P02789062A0000|36 40|4F2HC
P02789062A0000|42 45|gene
P02789062A0000|49 60|model system
P02789062A0000|62 68|studies
P02789062A0000|100 105|events
P02789062A0000|135 149|gene expression
P02789062A0000|166 182|T-cell activation
P02789062A1420|1 4|cDNA
P02789062A1420|16 46|NF-4FB enhancer binding protein
P02789062A1420|69 92|lambda gt11 cDNA library
P02789062A1420|108 122|oligonucleotide
P02789062A1420|141 167|NF-4FB recognition sequence
P02789180A0407|36 46|hypertrophy
P02789180A0407|74 84|hypertrophy
P02789180A0407|88 95|patients
P02789217A1323|6 21|IL6 mRNA species
P02789217A1323|45 59|polyadenylation
P02789217A1323|62 66|sites
P02789217A1323|79 86|distance
P02789217A1323|92 100|kilobases
P02790009A0375|0 18|Sequencing analysis
P02790009A0375|47 55|fragments
P02790009A0375|80 90|nucleotides
P02790009A0375|105 110|region
P02790009A0375|122 129|fragment
P02790009A1052|9 15|protein
P02790009A1052|60 65|region
P02790009A1052|90 115|serine protease inhibitors
P02790009A1052|115 122|residues
P02792270A1220|13 27|EPSP components
P02792270A1220|80 88|responses
P02792270A1220|91 108|flexor motoneurons
P02792270A1220|131 139|amplitude
P02792270A1220|149 161|flexion phase
P02792430A0000|0 10|Experiments
P02792430A0000|20 23|rats
P02792430A0000|29 39|guinea pigs
P02792430A0000|85 94|inhibition
P02792430A0000|97 120|prostaglandins synthesis
P02792430A0000|129 139|development
P02792430A0000|151 156|oedema
P02792430A0000|178 182|serum
P02792430A0000|185 188|rats
P02792430A0000|194 201|vagotomy
P02792430A0000|204 214|guinea pigs
P02793216A0876|10 13|hand
P02793216A0876|15 18|lack
P02793216A0876|21 32|conservation
P02793216A0876|38 65|membrane attachment sequence
P02793216A0876|89 92|acid
P02793216A0876|119 128|importance
P02793216A0876|131 133|CgA
P02793620A0214|21 24|cows
P02793620A0214|54 64|parturition
P02793620A0214|67 75|Charolais
P02793620A0214|79 92|Red Poll bulls
P02793620A0214|106 113|pastures
P02793753A0354|10 13|lobe
P02793753A0354|18 30|PA dispersion
P02793753A0354|39 43|cmH2O
P02793753A0354|46 48|CFV
P02793753A0354|53 57|l/min
P02793753A0354|63 66|flow
P02793753A0354|77 78|PA
P02793753A0354|84 88|sites
P02793753A0354|117 126|dispersion
P02794828A0214|3 8|system
P02794828A0214|35 39|heart
P02794828A0214|52 64|microcomputer
P02794828A0214|103 111|pacemaker
P02795923A0000|2 6|order
P02795923A0000|36 49|CT appearances
P02795923A0000|63 71|pneumonia
P02795923A0000|105 109|study
P02795923A0000|143 147|lungs
P02795923A0000|152 158|autopsy
P02795923A0000|162 168|surgery
P02796216A0063|3 9|disease
P02796216A0063|23 28|course
P02796216A0063|39 55|jaundice syndrome
P02796216A0063|62 74|enterorrhagia
P02796216A0063|82 91|appearance
P02796216A0063|94 100|roseola
P02796988A0735|3 26|transcription factor Sp1
P02796988A0735|37 41|sites
P02796988A0735|59 77|footprinting assays
P02796988A0735|80 97|gel shift analysis
P02796988A0735|108 110|Sp1
P02797877A0475|3 17|combination PIP
P02797877A0475|19 28|micrograms
P02797877A0475|30 32|PEF
P02797877A0475|34 43|micrograms
P02797877A0475|72 79|regrowth
P02797877A0475|90 94|hours
P02797877A0475|102 112|antibiotics
P02798953A0307|5 10|sample
P02798953A0307|13 19|mothers
P02798953A0307|29 35|infants
P02798953A0307|45 53|subscales
P02798953A0307|66 75|instrument
P02798953A0307|77 81|WPL-R
P02798953A0307|96 101|levels
P02798953A0307|112 122|consistency
P02798953A0307|135 149|days postpartum
P02798953A0307|153 161|stability
P02798953A0307|168 182|administrations
P02799892A0154|13 15|use
P02799892A0154|34 38|cells
P02799892A0154|40 44|WRBCs
P02799892A0154|72 80|hemolysis
P02799892A0154|86 96|transfusion
P02799892A0154|99 106|patients
P02799892A0154|111 113|PNH
P02800417A0332|5 9|group
P02800417A0332|12 21|asthmatics
P02800417A0332|46 56|correlation
P02800417A0332|72 86|PC20 PGF2 alpha
P02800417A0332|88 103|histamine values
P02800417A0332|104 104|r
P02800417A0332|112 112|p
P02800435A0000|5 15|experiments
P02800435A0000|39 42|cats
P02800435A0000|46 50|mg/kg
P02800435A0000|80 85|effect
P02800435A0000|89 89|T
P02800435A0000|107 111|field
P02800435A0000|113 115|PMF
P02800435A0000|132 137|system
P02800435A0000|143 145|leg
P02802280A0495|13 23|differences
P02802280A0495|43 44|TS
P02802280A0495|51 53|PTS
P02805945A0000|3 13|percentages
P02805945A0000|22 26|cysts
P02805945A0000|30 41|growth rates
P02805945A0000|91 97|cosinor
P02805945A0000|108 115|cultures
P02805945A0000|118 145|Scripsiella trochoidea Stein
P02805945A0000|153 157|years
P02805945A0000|163 183|laboratory conditions
P02805945A0000|217 226|view point
P02805945A0000|241 251|temperature
P02805945A0000|259 266|degree C
P02805945A0000|268 275|lighting
P02805945A0000|279 294|microEin m-2 s-1
P02805945A0000|308 315|seawater
P02806916A0000|8 16|DNA clone
P02806916A0000|24 36|oryzacystatin
P02806916A0000|38 39|Oc
P02806916A0000|43 71|cysteine proteinase inhibitor
P02806916A0000|71 78|cystatin
P02806916A0000|82 85|rice
P02806916A0000|103 128|lambda EMBL3 phage library
P02806916A0000|141 146|Sau3AI
P02806916A0000|154 160|digests
P02806916A0000|163 166|rice
P02806916A0000|178 180|DNA
P02806916A0000|199 205|oc cDNA
P02806916A0000|208 212|probe
P02807780A0143|3 5|use
P02807780A0143|21 28|solution
P02807780A0143|31 44|methylene blue
P02807780A0143|48 48|%
P02807780A0143|54 59|M NaCl
P02807780A0143|64 66|min
P02807780A0143|78 85|staining
P02807780A0143|100 104|areas
P02807780A0143|108 110|CIS
P02807780A0143|125 133|diagnosis
P02808232A0681|5 10|limits
P02808232A0681|16 28|micrograms/kg
P02808232A0681|57 67|reliability
P02808232A0681|71 71|%
P02809116A0237|25 31|effects
P02809116A0237|65 71|effects
P02809116A0237|74 81|husbands
P02809116A0237|83 92|retirement
P02809116A0237|105 116|satisfaction
P02809116A0237|127 131|wives
P02809651A0492|6 9|turn
P02809651A0492|31 34|role
P02809651A0492|37 49|meta-analysis
P02809651A0492|59 68|clinicians
P02809651A0492|72 84|policy makers
P02809651A0492|98 106|questions
P02809722A0926|16 22|patient
P02809722A0926|29 39|improvement
P02809722A0926|67 78|GH secretion
P02809831A0799|2 9|contrast
P02809831A0799|14 17|PPSF
P02809831A0799|19 26|DBP side
P02809831A0799|37 43|amounts
P02809831A0799|46 59|bone formation
P02809831A0799|63 66|bone
P02810911A0372|3 12|accuracies
P02810911A0372|15 22|presence
P02810911A0372|25 31|absence
P02810911A0372|34 46|neuroblastoma
P02810911A0372|66 82|131I-MIBG imaging
P02810911A0372|92 104|tumor markers
P02811378A0250|13 17|forms
P02811378A0250|20 24|cases
P02811378A0250|45 51|infants
P02811378A0250|66 71|mucosa
P02811378A0250|98 102|ridge
P02811378A0250|108 114|maxilla
P02811378A0250|120 127|mandible
P02811378A0379|19 25|studies
P02811378A0379|42 49|staining
P02811378A0379|53 64|S100 protein
P02811378A0379|80 90|cell tumors
P02811378A0379|105 108|none
P02811378A0379|132 144|cell epulides
P02813369A0390|22 26|males
P02813369A0390|47 51|years
P02813369A0390|61 71|territories
P02813369A0390|95 100|harems
P02813369A0390|106 110|years
P02813369A0390|126 134|neighbors
P02813404T0000|13 24|antigen gene
P02813404T0000|69 74|stages
P02813404T0000|77 91|spermatogenesis
P02814182A1211|2 5|rats
P02814182A1211|38 42|4-EPI
P02814182A1211|57 64|ABSTRACT
P02814182A1211|79 83|WORDS
P02814820A0967|9 17|Roux limb
P02814820A0967|36 45|pacemakers
P02814820A0967|62 69|emptying
P02814820A0967|72 78|liquids
P02814820A0967|93 96|rate
P02814820A0967|107 119|Billroth dogs
P02814820A0967|120 123|t1/2
P02814820A0967|130 133|Roux
P02814820A0967|142 148|minutes
P02814820A0967|150 157|Billroth
P02814820A0967|165 171|minutes
P02814820A0967|173 173|p
P02814820A0967|215 220|solids
P02815229A0139|3 12|treatments
P02815229A0139|19 27|mg t.i.d.
P02815229A0139|33 41|mg t.i.d.
P02815229A0139|49 52|days
P02815229A0139|54 62|treatment
P02815229A0139|75 78|dose
P02815229A0139|93 95|MBq
P02815229A0139|97 99|14C
P02815229A0139|101 109|diltiazem
P02816251A0397|25 35|capillaries
P02816251A0397|97 103|network
P02816251A0397|130 136|surface
P02816251A0397|143 152|ventricles
P02817724A0075|3 13|examination
P02817724A0075|25 26|T1
P02817724A0075|30 41|T2 sequences
P02817724A0075|44 48|scans
P02817724A0075|56 61|planes
P02818122A0000|6 9|deal
P02818122A0000|12 22|information
P02818122A0000|39 48|morphology
P02818122A0000|54 62|claustrum
P02818122A0000|72 85|animal species
P02818122A0000|107 118|distribution
P02818122A0000|122 134|relationships
P02818122A0000|150 155|cortex
P02818122A0000|164 169|nuclei
P02818260T0000|9 14|glioma
P02820128A1333|2 6|terms
P02820128A1333|9 28|sequence repetitions
P02820128A1333|50 55|copies
P02820128A1333|61 81|hexanucleotide ATTGTT
P02820128A1333|97 103|regions
P02820128A1333|106 118|dyad symmetry
P02820128A1333|136 142|ORF T3C
P02820128A1670|3 14|significance
P02820128A1670|33 39|domains
P02820128A1670|46 48|ORF
P02820128A1670|64 74|coincidence
P02820128A1670|80 82|end
P02820128A1670|94 103|palindrome
P02820128A1670|111 113|end
P02820128A1670|129 144|protein sequence
P02820128A1670|151 158|homology
P02820128A1670|166 172|B chain
P02820128A1670|174 180|insulin
P02820128A1670|196 206|palindromes
P02820128A1670|219 228|T2 protein
P02820128A1670|249 253|units
P02821340A0434|17 24|exercise
P02821340A0434|26 28|DCR
P02821340A0434|34 40|UT dogs
P02821340A0434|61 65|value
P02821340A0434|79 98|mm Hg X ml-1 X min-1
P02821340A0434|107 126|mm Hg X ml-1 X min-1
P02821340A0434|125 132|workload
P02821340A0434|138 140|kph
P02821340A0434|142 146|speed
P02821340A0434|151 151|%
P02821340A0434|153 157|grade
P02824334A0972|5 8|data
P02824334A0972|23 43|G-protein gene family
P02824334A0972|77 87|chromosomes
P02825139A0661|16 18|DNA
P02825139A0661|35 42|homology
P02825139A0661|66 79|acid sequences
P02825750A0260|13 20|patients
P02825750A0260|24 36|response rate
P02825750A0260|41 41|%
P02825750A0260|58 65|response
P02826127A0709|29 39|interaction
P02826127A0709|50 67|SV40 octamer motif
P02826127A0709|93 106|protein oct-B2
P02826127A0709|131 139|component
P02826127A0709|159 166|extracts
P02826127A0709|186 195|cell lines
P02826717A0179|0 5|Anoxia
P02826717A0179|33 36|gill
P02826717A0179|41 45|water
P02826717A0179|56 61|oxygen
P02826717A0179|76 85|water flow
P02826717A0179|90 93|gill
P02826729A0790|0 5|Growth
P02826729A0790|7 10|4-PA
P02826729A0790|14 30|14C turnover data
P02826729A0790|42 43|WB
P02826729A0790|57 66|B-6 intake
P02826729A0790|73 76|rats
P02828926A1870|21 27|factors
P02828926A1870|117 124|programs
P02828926A1870|127 147|actin gene expression
P02828926A1870|166 187|muscle differentiation
P02829183A0117|0 20|DNA sequence analysis
P02829183A0117|36 41|clones
P02829183A0117|59 63|forms
P02829183A0117|66 76|translocase
P02830214A0000|3 8|effect
P02830214A0000|11 23|acetazolamide
P02830214A0000|25 27|ACZ
P02830214A0000|31 34|HCO3
P02830214A0000|39 40|Cl
P02830214A0000|42 51|activities
P02830214A0000|59 67|ear fluid
P02830214A0000|97 118|microelectrode methods
P02830265A0341|0 5|RPA190
P02830265A0341|14 30|polypeptide chain
P02830265A0341|39 45|daltons
P02830265A0341|67 79|reading frame
P02830282A0155|13 22|A1 protein
P02830282A0155|39 46|fragment
P02830282A0155|51 61|UP1 protein
P02830282A0155|96 107|V-8 protease
P02830282A0155|119 130|polypeptides
P02830282A0155|135 145|amino acids
P02831398A0346|0 6|Irmiere
P02831398A0346|11 12|W.
P02831556A0173|5 13|offspring
P02831556A0173|19 27|alpha-MSH
P02831556A0173|35 41|mothers
P02831556A0173|61 64|pain
P02831556A0173|70 75|adults
P02831556A0173|99 106|response
P02831556A0173|109 116|morphine
P02831796A0000|6 27|immunodeficiency virus
P02831796A0000|28 30|SIV
P02831796A0000|35 44|lentivirus
P02831796A0000|74 85|similarities
P02831796A0000|93 114|immunodeficiency virus
P02831796A0000|127 131|agent
P02831796A0000|142 166|immunodeficiency syndrome
P02831796A0000|167 170|AIDS
P02831796A0000|174 179|humans
P02832149A1009|3 6|lack
P02832149A1009|9 14|change
P02832149A1009|20 24|ratio
P02832149A1009|40 47|products
P02832149A1009|94 96|myb
P02832149A1009|120 128|insertion
P02832149A1009|143 153|amino acids
P02832149A1009|164 178|myb transcripts
P02832149A1009|184 194|consequence
P02832149A1009|211 220|activation
P02832149A1009|226 243|mouse myb oncogene
P02832293T0000|3 5|use
P02832293T0000|8 13|CRF-41
P02832293T0000|31 39|diagnosis
P02832293T0000|42 48|Cushing
P02832293T0000|51 58|syndrome
P02832293T0000|62 68|obesity
P02832744A0403|10 24|mos transcripts
P02832744A0403|26 33|Northern
P02832744A0403|35 37|RNA
P02832744A0403|39 46|analyses
P02832744A0403|49 51|RNA
P02832744A0403|64 70|chicken
P02832744A0403|74 86|quail ovaries
P02832744A0403|89 94|testes
P02833012A0428|12 17|L mRNA
P02833012A0428|24 34|nucleotides
P02833012A0428|62 74|reading frame
P02833012A0428|91 99|L protein
P02833012A0428|115 125|amino acids
P02833012A0428|130 131|MW
P02833021A1185|3 9|results
P02833021A1185|24 35|organization
P02833021A1185|48 52|units
P02833021A1185|63 68|repeat
P02833021A1185|95 105|enhancement
P02833021A1185|116 123|promoter
P02833021A1185|158 174|promoter function
P02833049A0630|0 9|Variations
P02833049A0630|23 24|U3
P02833049A0630|43 52|insertions
P02833049A0630|56 64|deletions
P02833049A1041|2 9|analysis
P02833049A1041|21 36|state RNA levels
P02833049A1041|47 56|cell lines
P02833049A1041|105 115|transcripts
P02833049A1041|131 138|products
P02833049A1041|148 155|majority
P02833049A1041|167 177|RD-114 mRNA
P02833049A1041|228 231|loci
P02833049A1041|292 301|cell types
P02833101T0000|8 13|crisis
P02833101T0000|22 35|cell disorders
P02833101T0000|36 55|bone marrow necrosis
P02833101T0000|62 81|parvovirus infection
P02833517A0467|24 32|sequences
P02833517A0467|43 50|cleavage
P02833517A0467|61 67|element
P02834478A0000|12 26|weight heparins
P02834478A0000|44 51|interest
P02834478A0000|89 94|action
P02834478A0000|97 105|Xa factor
P02834843A0000|15 22|activity
P02834843A0000|31 51|rifamycin derivatives
P02834843A0000|53 61|rifabutin
P02834843A0000|63 65|RBU
P02834843A0000|68 70|FCE
P02834843A0000|77 79|F22
P02834843A0000|82 92|rifapentine
P02834843A0000|94 96|RPE
P02834843A0000|99 101|CGP
P02834843A0000|108 110|C29
P02834843A0000|113 115|CGP
P02834843A0000|121 123|C70
P02834843A0000|128 130|CGP
P02834843A0000|137 139|C27
P02834843A0000|144 153|rifampicin
P02834843A0000|155 157|RMP
P02834843A0000|184 192|log phase
P02834843A0000|205 208|test
P02834843A0000|222 229|activity
P02834843A0000|248 261|phase cultures
P02834843A0000|263 288|Mycobacterium tuberculosis
P02834843A0000|289 293|H37Rv
P02836623A1094|0 1|Mo
P02836623A1094|3 4|SV
P02836623A1094|22 28|animals
P02836623A1094|50 71|months postinoculation
P02836623A1094|79 86|delta Mo
P02836623A1094|87 88|SV
P02836623A1094|106 112|animals
P02836623A1094|134 155|months postinoculation
P02837575A0979|0 13|Sodium dodecyl
P02837575A0979|29 36|cleavage
P02837575A0979|49 61|topoisomerase
P02837575A0979|77 82|enzyme
P02837575A0979|111 113|end
P02837575A0979|119 121|DNA
P02837763A0259|0 18|Amino acid sequence
P02837763A0259|27 37|liver clone
P02837763A0259|38 42|HL-14
P02837763A0259|61 66|rabbit
P02837763A0259|75 100|muscle phosphatase 2A cDNA
P02837763A0259|105 125|% nucleotide identity
P02838246A0225|0 21|Herpes virus infection
P02838246A0225|38 46|inversion
P02838246A0225|52 62|T4/T8 ratio
P02838246A0225|71 81|sensitivity
P02838246A0225|84 84|%
P02838246A0225|86 96|specificity
P02838246A0225|99 99|%
P02838246A0225|110 122|proliferation
P02838246A0225|128 143|T8 subpopulation
P02838246A0225|166 173|findings
P02838246A0225|176 183|patients
P02838246A0225|188 203|rejection crises
P02838246A0225|228 228|P
P02838319A0527|0 3|RVEF
P02838319A0527|7 10|LVEF
P02838319A0527|33 33|%
P02838319A0527|35 35|p
P02838319A0527|51 51|p
P02838710A0299|3 8|levels
P02838710A0299|11 16|NPY-ir
P02838710A0299|22 24|rat
P02838710A0299|84 92|treatment
P02839488A1314|12 17|assays
P02839488A1314|28 35|activity
P02839488A1314|50 58|alpha s-1
P02839488A1314|96 116|erythrocyte type-1 Gs
P02839488A1314|135 142|products
P02839488A1314|169 174|margin
P02839488A1314|177 181|error
P02839716A0673|7 11|cells
P02839716A0673|13 23|E2 proteins
P02839716A0673|47 52|effect
P02839716A0673|73 80|activity
P02839716A0673|86 114|HPV-11 enhancer-SV40 promoter
P02839716A1907|3 11|mechanism
P02839716A1907|19 22|E2-C
P02839716A1907|44 60|enhancer activity
P02839716A1907|78 88|competition
P02839716A1907|93 94|E2
P02839716A1907|139 142|site
P02839716A1907|145 152|ABSTRACT
P02839716A1907|167 171|WORDS
P02840034A1266|8 17|evaluation
P02840034A1266|23 31|treatment
P02840034A1266|53 72|lung cancer patients
P02840034A1266|98 104|factors
P02840034A1266|109 115|account
P02840376A0461|1 8|anti-IIa
P02840376A0461|13 18|Holmer
P02843495A0544|0 11|Introduction
P02843495A0544|14 18|v-fms
P02843495A0544|24 28|CSF-1
P02843495A0544|44 63|macrophage cell line
P02843495A0544|69 87|factor independence
P02843495A0544|90 103|tumorigenicity
P02843495A0544|119 127|mechanism
P02843694T0001|7 25|E-B virus infection
P02843694T0001|45 52|lymphoma
P02843694T0001|55 65|case report
P02844767A0191|10 18|structure
P02844767A0191|22 36|cotranscription
P02844767A0191|42 52|petCA genes
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|90 95|plants
P02844767A0191|100 112|apocytochrome
P02844767A0191|114 121|proteins
P02844767A0191|149 154|Kallas
P02844767A0191|156 157|T.
P02844767A0191|159 165|Spiller
P02844767A0191|167 168|S.
P02844767A0191|173 178|Malkin
P02844767A0191|180 181|R.
P02844767A0596|3 20|Nostoc petBD genes
P02844767A0596|43 51|psbB gene
P02844767A0596|69 79|photosystem
P02844767A0596|82 92|polypeptide
P02844767A0596|109 115|introns
P02844767A0596|137 153|chloroplast genes
P02844767A1022|0 22|RNA blot hybridizations
P02844767A1022|39 42|mRNA
P02844767A1022|51 63|cytochrome b6
P02844767A1022|66 72|subunit
P02844767A1022|107 110|mRNA
P02844767A1022|124 130|subunit
P02844767A1022|133 142|gene probe
P02844797A1225|10 23|muscle isoform
P02844797A1225|36 46|amino acids
P02844797A1225|66 89|sequence Ala-Ile-Leu-Glu
P02844797A1225|99 105|isoform
P02844797A1225|112 122|amino acids
P02844797A1225|124 129|length
P02844797A1225|138 148|replacement
P02844797A1225|161 171|amino acids
P02844797A1225|184 196|acid sequence
P02844797A1225|218 237|transmembrane domain
P02844797A1225|248 265|consensus sequence
P02844797A1225|278 295|glycosylation site
P02845654A0510|0 11|Substitution
P02845654A0510|15 31|threonine residue
P02845654A0510|35 49|alanine residue
P02845654A0510|51 58|position
P02845654A0510|62 63|P2
P02845654A0510|71 83|cleavage site
P02845654A0510|92 99|cleavage
P02845654A0510|108 119|substitution
P02845654A0510|123 138|tyrosine residue
P02845654A0510|141 161|phenylalanine residue
P02845654A0510|163 181|amino acid position
P02845654A0510|183 184|P1
P02845654A0510|191 203|cleavage site
P02845654A0510|218 227|processing
P02846640A0643|24 31|bacteria
P02846640A0643|37 55|indoxyl phosphatase
P02846640A0643|60 61|pI
P02846852A1459|3 8|number
P02846852A1459|11 21|polymerases
P02846852A1459|40 56|E strand promoter
P02846852A1459|70 75|number
P02846852A1459|78 88|polymerases
P02846852A1459|94 110|L strand promoter
P02848842A0643|1 6|family
P02848842A0643|9 21|RNA molecules
P02848842A0643|31 32|.2
P02848842A0643|34 47|kilobase range
P02848842A0643|62 66|probe
P02848842A0643|75 78|gene
P02848842A0643|109 113|cells
P02849100A0441|18 25|sequence
P02849100A0441|57 65|extremity
P02849100A0441|71 78|molecule
P02849100A0441|103 108|anchor
P02849100A0441|114 128|plasma membrane
P02849759A0865|3 15|SV40 enhancer
P02849759A0865|24 34|replication
P02849759A0865|41 44|fold
P02850472A0112|14 24|origin core
P02850472A0112|42 56|DNA replication
P02850967T0000|0 8|Induction
P02850967T0000|11 42|proto-oncogene fos transcription
P02850967T0000|51 75|adenylate cyclase pathway
P02850967T0000|75 90|characterization
P02850967T0000|109 115|element
P02850971A0180|7 26|oligodeoxynucleotide
P02850971A0180|44 49|region
P02850971A0180|55 78|VtHb amino acid sequence
P02850971A0180|86 104|hybridization probe
P02850971A0180|113 124|Vitreoscilla
P02850971A0180|132 138|library
P02850971A0180|168 187|cosmid vector pVK102
P02852805A0216|13 18|solids
P02852805A0216|35 49|characteristics
P02852805A0216|58 66|influence
P02852805A0216|78 87|treatments
P02852894T0000|0 5|Causes
P02852894T0000|8 12|death
P02852894T0000|37 41|study
P02852894T0000|50 57|chickens
P02852894T0000|60 72|Thai villages
P02853799T0001|3 13|progression
P02853799T0001|16 20|non-A
P02853799T0001|27 35|hepatitis
P02853799T0001|45 52|diseases
P02853799T0001|60 73|transformation
P02853799T0001|90 98|carcinoma
P02853922A0596|8 10|IOP
P02853922A0596|24 31|patients
P02853922A0596|35 38|eyes
P02853922A0596|49 53|study
P02856622T0001|0 2|Use
P02856622T0001|5 37|serum thyroglobulin determination
P02856622T0001|41 49|follow-up
P02856622T0001|66 75|carcinomas
P02856622T0001|81 87|thyroid
P02859434T0000|0 12|Poor response
P02859434T0000|16 25|laboratory
P02859434T0000|37 41|range
P02859434T0000|45 57|serum lithium
P02861067A0000|3 5|aim
P02861067A0000|12 16|study
P02861067A0000|36 42|effects
P02861067A0000|54 64|ipratropium
P02861067A0000|67 74|patients
P02861067A0000|84 89|asthma
P02861067A0000|92 96|order
P02861067A0000|128 148|bronchodilator effect
P02861067A0000|151 167|beta agonist drug
P02861144A0242|7 14|analysis
P02861144A0242|21 32|DNA fragment
P02861144A0242|46 50|genes
P02861144A0242|61 77|encoding proteins
P02861144A0242|94 97|kDal
P02861238T0000|7 11|virus
P02862656T0000|0 6|Changes
P02862656T0000|9 37|dopamine receptor sensitivity
P02862656T0000|38 43|humans
P02862656T0000|54 67|alcohol intake
P02863492A0544|13 23|differences
P02863492A0544|37 52|treatment groups
P02863492A0544|70 79|responders
P02863492A0544|91 94|mean
P02863492A0544|121 129|IgG index
P02863492A0544|193 202|responders
P02863747T0000|0 10|Replacement
P02863747T0000|18 30|histone genes
P02863747T0000|48 56|sequences
P02865502T0000|22 26|trial
P02865502T0000|40 72|tissue-type plasminogen activator
P02865502T0000|77 83|placebo
P02865502T0000|101 110|infarction
P02868446A0184|13 19|domains
P02868446A0184|21 24|CTDs
P02868446A0184|31 48|RPase beta subunit
P02868446A0184|50 60|DNA primase
P02868446A0184|61 72|dnaG protein
P02868446A0184|147 157|RPase alpha
P02868446A0184|174 178|alpha
P02868446A0184|191 196|enzyme
P02868446A0184|228 247|core enzyme subunits
P02868446A0184|249 255|primase
P02868848A0167|8 17|vancomycin
P02868848A0167|21 30|fosfomycin
P02868848A0167|74 81|activity
P02868848A0167|104 115|penicillin G
P02868848A0167|118 125|imipenem
P02868848A0167|142 145|mode
P02868848A0167|154 165|gas gangrene
P02869125A0120|0 7|Fentanyl
P02869125A0120|29 44|receptor agonist
P02869125A0120|77 84|syndrome
P02869125A0120|106 114|analgesia
P02869125A0120|118 138|locomotor stimulation
P02869125A0120|146 156|tachycardia
P02869125A0120|158 167|tachypnoea
P02869125A0120|182 188|arousal
P02870249T0000|12 23|chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870720A0188|33 60|beta-adrenoceptor antagonist
P02870720A0188|64 73|pA2 values
P02870720A0188|90 101|isoprenaline
P02870720A0188|104 119|guinea pig atria
P02870720A0188|121 135|tracheal muscle
P02870851A0349|0 5|Output
P02870851A0349|8 15|99mTcO-4
P02870851A0349|21 33|parotid gland
P02870851A0349|48 59|fluctuations
P02870851A0349|62 85|parotid saliva flow rate
P02872786A0147|19 26|equation
P02872786A0147|44 50|effects
P02872786A0147|61 69|parasites
P02872786A0147|75 81|foregut
P02872786A0147|103 111|sandflies
P02872786A0147|114 123|blood flow
P02873593A0581|11 14|rats
P02873593A0581|85 90|reward
P02873593A0581|92 94|BZP
P02873593A0581|120 128|frequency
P02873593A0581|148 153|reward
P02873593A0581|168 187|5-HT uptake blockers
P02873593A0581|203 209|effects
P02874078A0252|13 35|luteal phase deficiency
P02874078A0252|52 52|%
P02874078A0252|64 71|patients
P02874635T0000|8 15|exposure
P02874635T0000|21 37|fungicide dinocap
P02874635T0000|53 63|torticollis
P02874635T0000|65 74|ballooning
P02874635T0000|78 89|cleft palate
P02874635T0000|91 94|mice
P02874635T0000|102 105|rats
P02874635T0000|108 115|hamsters
P02875224A1059|0 10|Reperfusion
P02875224A1059|21 25|blood
P02875224A1059|31 37|beating
P02875224A1059|46 51|hearts
P02875224A1059|77 82|damage
P02875224A1059|91 96|reflow
P02875224A1059|116 128|contractility
P02875224A1059|134 141|instance
P02875224A1059|146 146|%
P02875224A1059|166 166|p
P02875967A0377|3 13|sensitivity
P02875967A0377|32 41|adrenaline
P02875967A0377|67 77|guinea pigs
P02875967A0377|97 110|fertility rate
P02876820A0841|11 18|acidosis
P02876820A0841|34 44|stimulation
P02876820A0841|67 68|mV
P02876899A0568|2 5|Days
P02876899A0568|32 39|subjects
P02876899A0568|64 70|decline
P02876899A0568|73 104|bevantolol plasma concentrations
P02876899A0568|108 123|absorption phase
P02877124A0000|12 16|B6AF1
P02877124A0000|20 30|B6D2F1 mice
P02877124A0000|48 56|tap water
P02877124A0000|58 73|promethazine HCl
P02877124A0000|75 87|phenothiazine
P02877124A0000|92 120|H1 receptor blocking activity
P02877124A0000|120 135|chlorpheniramine
P02877124A0000|139 148|H1 blocker
P02877124A0000|151 165|trifluoperazine
P02877124A0000|168 180|phenothiazine
P02877124A0000|187 206|H1 blocking activity
P02877124A0000|213 226|drinking water
P02877124A0000|233 239|effects
P02877124A0000|247 252|agents
P02877124A0000|255 274|bone mineral content
P02877124A0000|322 335|body retention
P02877124A0000|337 338|Tc
P02877124A0000|342 364|methylene diphosphonate
P02877124A0000|365 366|Tc
P02877124A0000|370 372|MDP
P02877124A0000|376 384|indicator
P02877124A0000|387 401|bone metabolism
P02877124A0000|410 412|end
P02877124A0000|418 424|studies
P02877124A0000|441 447|weights
P02877124A0000|450 454|femur
P02877124A0000|456 460|ilium
P02877124A0000|464 469|sacrum
P02878100A0674|7 13|results
P02878100A0674|40 49|inhibition
P02878100A0674|62 73|transmission
P02878100A0674|76 84|diltiazem
P02878100A0674|100 108|diltiazem
P02878100A0674|139 146|activity
P02878100A0674|179 190|transmission
P02879906A0000|0 6|Studies
P02879906A0000|40 44|veins
P02879906A0000|52 62|rabbit face
P02879906A0000|74 85|relationship
P02879906A0000|93 130|beta adrenoceptor subtype distribution
P02879906A0000|146 149|tone
P02879906A0000|164 180|nerve innervation
P02879951T0000|0 6|Effects
P02879951T0000|29 33|agent
P02879951T0000|35 42|SGB-1534
P02879951T0000|46 69|rat platelet aggregation
P02880841A0313|8 16|stability
P02880841A0313|19 21|TF1
P02880841A0313|41 49|structure
P02880841A0313|60 63|gene
P02880841A0313|73 75|TF1
P02880841A0313|90 98|structure
P02880841A0313|104 115|beta subunit
P02880841A0313|132 150|nucleotide sequence
P02880841A0313|155 158|gene
P02880841A0313|171 178|sequence
P02880841A0313|190 193|beta
P02880841A0313|208 217|categories
P02880841A0313|220 221|F1
P02880841A0313|236 244|membranes
P02880841A0313|246 257|chloroplasts
P02880841A0313|262 273|mitochondria
P02882893A0301|0 15|Body temperature
P02882893A0301|25 35|conductance
P02882893A0301|69 83|P. s. campbelli
P02882893A0301|98 99|sp
P02883327A0413|3 23|polyadenylation sites
P02883327A0413|40 42|end
P02883327A0413|54 54|E
P02883327A0413|56 61|region
P02883327A0413|72 74|DNA
P02883327A0413|89 91|end
P02883327A0413|102 102|L
P02883327A0413|104 109|region
P02883871A1075|1 4|drug
P02883871A1075|9 11|ISA
P02883871A1075|27 40|beta receptors
P02883871A1075|53 56|drug
P02883871A1075|95 115|drug hypersensitivity
P02883871A1075|117 124|contrast
P02883871A1075|127 132|agents
P02883871A1075|140 142|ISA
P02883963A0000|3 10|patients
P02883963A0000|20 25|T-cell
P02883963A0000|38 47|virus type
P02883963A0000|49 54|HTLV-I
P02883963A0000|67 76|myelopathy
P02883963A0000|78 80|HAM
P02883963A0000|113 119|methods
P02884860A0329|0 8|Terazosin
P02884860A0329|21 26|analog
P02884860A0329|29 36|prazosin
P02884860A0329|50 54|alpha
P02884860A0329|56 68|adrenoceptors
P02884860A0329|104 110|therapy
P02885517T0000|7 18|blood donors
P02885517T0000|21 25|non-A
P02885517T0000|32 40|hepatitis
P02889352A0000|4 11|patients
P02889352A0000|20 33|blood pressure
P02889352A0000|34 35|BP
P02889352A0000|62 68|classes
P02889352A0000|71 79|compounds
P02889352A0000|91 102|beta blocker
P02889352A0000|113 128|enzyme inhibitor
P02889352A0000|130 147|calcium antagonist
P02889495A0000|25 29|study
P02889495A0000|38 59|episode schizophrenics
P02889495A0000|68 75|pimozide
P02889495A0000|78 89|flupenthixol
P02889495A0000|98 102|weeks
P02889495A0000|116 119|dose
P02889495A0000|125 127|end
P02889495A0000|135 145|mg pimozide
P02889495A0000|150 164|mg flupenthixol
P02890200T0001|41 45|tumor
P02890200T0001|48 61|Recklinghausen
P02890200T0001|64 80|neurofibromatosis
P02892762A0296|17 31|repeat elements
P02892762A0296|50 60|nucleotides
P02892762A0296|62 63|nt
P02892762A0296|73 85|promoter site
P02894689A0000|27 39|DNA fragments
P02894689A0000|44 48|bases
P02894689A0000|51 65|chromatin loops
P02894689A0000|72 75|help
P02894689A0000|84 103|extraction procedure
P02894689A0000|110 118|lithium-3
P02894689A0000|124 139|diiodosalicylate
P02894741A0000|24 28|doses
P02894741A0000|31 40|vecuronium
P02894741A0000|52 68|muscle relaxation
P02894741A0000|84 101|NLA II anaesthesia
P02894789A0954|11 26|recovery indexes
P02894789A0954|42 46|times
P02894789A0954|58 62|T1/T0
P02894789A0954|66 70|T4/T1
P02894789A0954|83 83|%
P02894789A0954|88 88|%
P02895472A0178|20 27|colonies
P02895472A0178|54 61|plasmids
P02895472A0178|72 75|cDNA
P02895472A0178|85 87|BiP
P02895472A0178|105 120|mRNA translation
P02895566A0187|0 2|DPA
P02895566A0187|16 23|increase
P02895566A0187|29 37|intensity
P02895566A0187|54 77|pressure pain components
P02895566A0187|90 106|ischemia duration
P02895566A0187|117 122|effect
P02895566A0187|128 150|pressure pain component
P02895754A0000|8 28|percent isoproterenol
P02895754A0000|33 40|presence
P02895754A0000|46 85|phosphodiesterase inhibitor theophylline
P02895754A0000|99 105|ability
P02895754A0000|120 123|rate
P02895754A0000|133 142|humor flow
P02895754A0000|160 166|chamber
P02895754A0000|222 224|eye
P02895754A0000|226 231|Horner
P02895754A0000|234 241|syndrome
P02897651A0000|0 14|Hyperthyroidism
P02897651A0000|33 38|causes
P02897651A0000|41 51|infertility
P02897651A0000|64 71|abortion
P02898752A0683|7 17|correlation
P02898752A0683|34 40|numbers
P02898752A0683|43 48|CFU-GM
P02898752A0683|65 68|rate
P02898752A0683|71 82|granulocytes
P02898752A0683|86 103|platelets recovery
P02899177A0605|16 24|technique
P02899177A0605|27 48|low-frequency kindling
P02899177A0605|69 73|model
P02899177A0605|88 94|effects
P02899177A0605|125 129|drugs
P02899177A0605|135 146|excitability
P02899177A0605|158 164|regions
P02899792T0000|0 8|Oestrogen
P02899792T0000|16 23|overdose
P02900760A0073|5 21|sequence elements
P02900760A0073|64 88|transcription termination
P02900760A0073|90 105|RNA polymerase I
P02900760A0073|105 109|pol I
P02900760A0073|133 152|transcription system
P02900760A0073|166 177|transfection
P02900760A0073|180 203|rDNA minigene constructs
P02900760A0073|206 214|3T6 cells
P02901498A0354|3 14|biosynthesis
P02901498A0354|18 26|stability
P02901498A0354|43 50|proteins
P02901498A0354|83 94|erbB protein
P02901498A0354|117 123|ability
P02901498A0354|135 160|chicken embryo fibroblasts
P02901763A0977|0 10|Codon usage
P02901763A0977|12 38|C. reinhardtii mitochondria
P02901763A0977|61 66|codons
P02901763A0977|102 106|genes
P02901763A0977|126 136|codon usage
P02901763A0977|162 181|C. reinhardtii mtDNA
P02901763A0977|202 207|number
P02901763A0977|210 214|tRNAs
P02901763A0977|243 259|protein synthesis
P02902615A0000|22 30|treatment
P02902615A0000|44 56|polyarteritis
P02902615A0000|67 74|advances
P02902615A0000|80 88|treatment
P02902615A0000|104 114|hepatitis B
P02902615A0000|126 133|patients
P02902656A0481|11 16|testes
P02902656A0481|29 34|testes
P02902656A0481|39 49|hypointense
P02902656A0481|52 54|fat
P02902656A0481|57 65|sequences
P02902656A0481|76 90|repetition time
P02902656A0481|91 92|TR
P02902656A0481|101 104|time
P02902656A0481|106 107|TE
P02902656A0481|114 118|cases
P02902656A0481|123 134|hyperintense
P02902656A0481|137 146|isointense
P02902656A0481|149 151|fat
P02902656A0481|158 172|TR/TE sequences
P02902656A0481|183 187|cases
P02902844A1219|12 15|gene
P02902844A1219|29 32|gene
P02902844A1219|59 65|protein
P02902844A1219|99 109|atp operons
P02902844A1219|118 130|bacterium PS3
P02902844A1219|133 145|cyanobacteria
P02902927A0145|18 26|isolation
P02902927A0145|38 58|rat GHF-1 cDNA clones
P02903500A0278|22 31|properties
P02903500A0278|37 43|protein
P02903500A0278|53 55|neu
P02903500A0278|67 77|fusion gene
P02903500A0278|100 105|domain
P02903500A0278|108 110|neu
P02903500A0278|129 135|portion
P02903500A0278|140 153|immunoglobulin
P02903500A0278|159 163|chain
P02904322A0002|21 28|antelope
P02904322A0002|49 62|model ruminant
P02904322A0002|76 82|studies
P02906027A0553|2 20|sequence comparison
P02906027A0553|23 28|blocks
P02906027A0553|31 38|homology
P02906027A0553|65 70|region
P02906027A0553|92 101|CpG island
P02906027A0553|128 144|CpG dinucleotides
P02906027A1156|12 19|features
P02906027A1156|42 42|G
P02906027A1156|59 67|sequences
P02906027A1156|85 90|intron
P02906249A1195|10 14|group
P02906249A1195|20 29|% Prazosin
P02906249A1195|33 37|mg/kg
P02906249A1195|73 77|hours
P02906249A1195|87 97|application
P02906249A1195|100 105|Oxy-Hb
P02906249A1195|108 117|PGF2 alpha
P02906673T0000|0 7|Efficacy
P02906673T0000|11 26|field evaluation
P02906673T0000|28 49|Bacillus thuringiensis
P02906673T0000|50 53|H-14
P02906673T0000|58 70|B. sphaericus
P02906673T0000|77 97|floodwater mosquitoes
P02906673T0000|99 108|California
P02907308T0001|1 5|cases
P02907308T0001|8 11|type
P02907308T0001|14 24|tyrosinosis
P02907308T0001|26 49|Richner-Hanhart syndrome
P02907533A0362|4 7|loss
P02907533A0362|24 41|drug concentration
P02907533A0362|45 61|correction factor
P02907533A0362|94 115|diazepam concentration
P02907533T0000|0 6|Effects
P02907533T0000|27 42|blood substitute
P02907533T0000|44 59|diazepam binding
P02907533T0000|66 72|albumin
P02909528A1081|7 23|promoter activity
P02909528A1081|41 46|region
P02909528A1081|80 90|start sites
P02910496A0583|1 16|decamer sequence
P02910496A0583|20 32|CGA-CCCCUCC-3
P02910496A0583|60 67|sequence
P02910496A0583|90 102|cleavage site
P02910496A0583|120 132|RNA substrate
P02910496A0583|147 160|RNAase MRP RNA
P02910989T0000|0 6|Effects
P02910989T0000|9 13|aging
P02910989T0000|17 40|beta-adrenergic-blockade
P02910989T0000|59 72|QT/QS2 changes
P02911540A0478|1 7|patient
P02911540A0478|22 26|wound
P02911540A0478|42 45|area
P02911540A0478|47 51|hands
P02911540A0478|53 56|feet
P02911540A0478|58 61|face
P02911540A0478|65 72|perineum
P02911540A0478|111 114|care
P02913368A1037|0 19|Pharmacology studies
P02913368A1037|23 40|potassium chloride
P02913368A1037|43 55|acetylcholine
P02913368A1037|67 73|raveron
P02913368A1037|81 98|calcium antagonist
P02913368A1037|111 116|influx
P02913368A1037|132 138|calcium
P02914422A0409|0 16|Computer analysis
P02914422A0409|31 39|averaging
P02914422A0409|78 92|frequency bands
P02914422A0409|94 98|order
P02914422A0409|113 127|frequency range
P02914422A0409|142 148|notches
P02914422A0409|152 156|slurs
P02914492A0183|2 10|admission
P02914492A0183|16 18|ICU
P02914492A0183|23 30|patients
P02914492A0183|34 40|percent
P02914492A0183|45 58|hypomagnesemia
P02914492A0183|60 67|serum Mg
P02914492A0183|78 83|mEq/dl
P02914492A0183|88 95|patients
P02914492A0183|99 105|percent
P02914492A0183|110 124|normomagnesemia
P02914492A0183|134 139|mEq/dl
P02914492A0183|148 155|patients
P02914492A0183|158 164|percent
P02914492A0183|169 183|hypermagnesemia
P02914492A0183|199 204|mEq/dl
P02916764A0253|3 14|risk factors
P02916764A0253|29 31|sex
P02916764A0253|33 44|hypertension
P02916764A0253|46 62|diabetes mellitus
P02916764A0253|63 82|hypercholesterolemia
P02916764A0253|84 100|cigarette smoking
P02916764A0253|110 119|life-style
P02916764A0253|124 137|family history
P02918474A0817|7 15|verapamil
P02918474A0817|19 28|nifedipine
P02918474A0817|36 45|collateral
P02918474A0817|56 65|blood flow
P02918474A0817|85 98|subendocardium
P02918474A0817|113 120|ml/min/g
P02918474A0817|126 138|subepicardium
P02919483A0091|11 14|boys
P02919483A0091|20 24|girls
P02919483A0091|35 37|age
P02919483A0091|48 57|half years
P02919530A0000|28 38|reperfusion
P02919530A0000|49 58|myocardium
P02919530A0000|84 99|artery occlusion
P02919530A0000|123 128|effect
P02919530A0000|150 160|wall motion
P02919530A0000|184 194|alterations
P02919832A0144|7 13|disease
P02919832A0144|32 37|M-mode
P02919832A0144|74 97|Doppler echocardiography
P02920591A0251|11 20|assessment
P02920591A0251|50 63|administration
P02920591A0251|66 72|digoxin
P02920591A0251|75 87|micrograms/kg
P02920591A0251|92 99|dopamine
P02920591A0251|106 122|micrograms/kg/min
P02923687A0218|17 28|relationship
P02923687A0218|39 42|side
P02923687A0218|45 53|sinusitis
P02923687A0218|60 69|cleft side
P02923687A0218|71 78|patients
P02923687A0218|93 104|cleft palate
P02925013A1112|24 29|levels
P02925013A1112|38 45|aluminum
P02925013A1112|69 74|tissue
P02925013A1112|87 98|accumulation
P02925013A1112|111 124|citrate ligand
P02925568A0460|8 14|effects
P02925568A0460|17 30|father absence
P02925568A0460|42 51|conditions
P02925568A0460|71 77|samples
P02925568A0460|99 105|effects
P02925568A0460|130 145|family stressors
P02925568A0460|155 169|psychopathology
P02926499A0340|32 43|analog model
P02926499A0340|45 53|heat flow
P02926499A0340|62 66|brain
P02926499A0340|94 103|expression
P02926499A0340|107 109|CBF
P02926499A0340|125 127|CBF
P02926499A0340|129 130|Cb
P02926499A0340|139 139|c
P02926499A0340|146 148|tau
P02926499A0340|161 165|decay
P02926499A0340|175 177|rho
P02926499A0340|183 189|density
P02926499A0340|192 196|blood
P02926499A0340|201 201|c
P02926499A0340|215 218|heat
P02927391A0238|21 30|proviruses
P02927391A0238|49 71|founder SWR/J-RF/J mice
P02927391A0238|102 110|germ line
P02927391A0238|134 140|tissues
P02927391A0238|164 174|integration
P02927391A0238|192 200|germ line
P02927391A0238|225 232|lineages
P02928112T0000|9 15|cloning
P02928112T0000|21 24|cDNA
P02928112T0000|36 37|U2
P02928112T0000|52 52|A
P02928112T0000|54 60|protein
P02928376A0312|13 16|work
P02928376A0312|23 27|water
P02928376A0312|47 53|mixture
P02928376A0312|56 57|H2
P02928376A0312|63 67|gases
P02928376A0312|80 90|heat defect
P02928376A0312|110 110|%
P02929056T0000|10 12|use
P02929056T0000|15 38|transureteroureterostomy
P02929056T0000|48 67|ureterosigmoidostomy
P02929056T0000|84 90|failure
P02930623A0404|6 21|flexion whiplash
P02930623A0404|25 30|torque
P02930623A0404|45 51|condyle
P02930623A0404|63 71|direction
P02930623A0404|81 82|ms
P02930623A0404|88 93|impact
P02934778A0702|3 6|data
P02934778A0702|19 26|presence
P02934778A0702|29 33|5-HT2
P02934778A0702|46 54|receptors
P02934778A0702|69 74|artery
P02934778A0702|82 88|species
P02934889A0558|0 10|Oxfendazole
P02934889A0558|40 43|time
P02934889A0558|52 55|days
P02934889A0558|64 68|start
P02934889A0558|71 77|grazing
P02934889A0558|79 81|May
P02934889A0558|101 114|cent reduction
P02934889A0558|116 133|Ostertagia species
P02934889A0558|145 158|cent reduction
P02934889A0558|160 170|D viviparus
P02934891A0845|11 16|method
P02934891A0845|47 54|extracts
P02934891A0845|57 59|ner
P02934891A0845|73 77|cells
P02934891A0845|118 122|sites
P02934891A0845|140 150|nucleotides
P02934891A0845|169 170|Mu
P02934891A0845|175 177|end
P02935638A0000|35 43|structure
P02935638A0000|49 58|Spec1 gene
P02935638A0000|63 102|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 16|Platelet function
P02936163T0000|56 66|interaction
P02936163T0000|69 76|patients
P02936163T0000|90 119|platelet lipoxygenase activity
P02936284A0357|11 21|degradation
P02936284A0357|24 33|atracurium
P02936284A0357|36 41|plasma
P02936284A0357|52 56|route
P02936284A0357|59 69|elimination
P02936284A0357|72 74|man
P02936284A0357|97 117|elimination half-life
P02936284A0357|135 137|min
P02938185A0223|11 20|cell lines
P02938185A0223|36 38|E1a
P02938185A0223|41 43|E1a
P02938185A0223|47 63|E1b gene products
P02938185A0223|78 84|viruses
P02938185A0223|121 126|growth
P02938185A0223|131 139|degrees C
P02938185A0223|147 155|degrees C
P02938185A0223|178 189|architecture
P02938185A0223|225 234|CREF cells
P02939260A1553|17 44|amino acid sequence analysis
P02939260A1553|55 57|43K
P02939260A1553|61 74|42K T antigens
P02939260A1553|80 89|methionine
P02939260A1553|92 99|residues
P02939260A1553|124 135|DNA sequence
P02939260A1553|145 154|methionine
P02939260A1553|173 185|39K T antigen
P02939260A1553|201 206|cycles
P02939260A1553|209 225|Edman degradation
P02940334A0141|0 6|Group A
P02940334A0141|31 35|doses
P02940334A0141|38 48|hepatitis B
P02940334A0141|54 61|globulin
P02940334A0141|63 66|HBIG
P02940334A0141|89 97|schedules
P02941237A0160|11 18|instance
P02941237A0160|22 29|addition
P02941237A0160|32 44|serum calcium
P02941237A0160|47 76|phosphorous ion concentrations
P02941237A0160|76 84|tissue pH
P02941237A0160|85 96|blood supply
P02941237A0160|97 104|hormones
P02941237A0160|111 119|vitamin D
P02941237A0160|120 128|vitamin A
P02941237A0160|139 145|enzymes
P02941237A0160|152 171|alkaline phosphatase
P02941237A0160|174 188|pyrophosphatase
P02941237A0160|257 261|roles
P02943562T0000|0 23|Penicillinase production
P02943562T0000|45 51|strains
P02943562T0000|62 71|importance
P02947866A1416|17 24|analysis
P02947866A1416|27 45|thallium-201 uptake
P02947866A1416|48 54|washout
P02947866A1416|72 79|evidence
P02947866A1416|101 109|perfusion
P02947866A1416|123 133|angioplasty
P02949170A0184|4 8|study
P02949170A0184|19 25|effects
P02949170A0184|29 39|preparation
P02949170A0184|46 73|micrograms ethinyl estradiol
P02949170A0184|76 97|mg cyproterone acetate
P02949170A0184|98 110|gonadotropins
P02949170A0184|112 120|prolactin
P02949170A0184|122 133|testosterone
P02949170A0184|135 162|sex hormone binding globulin
P02949170A0184|161 164|SHBG
P02949170A0184|167 181|androstenedione
P02949170A0184|200 217|testosterone index
P02949170A0184|234 239|months
P02949170A0184|242 250|treatment
P02950216A0084|10 13|flow
P02950216A0084|31 53|laser Doppler flowmetry
P02950216A0084|53 55|LDF
P02950216A0084|69 81|output signal
P02950216A0084|82 96|blood cell flux
P02950216A0084|96 98|BCF
P02950216A0084|114 118|terms
P02950216A0084|121 125|volts
P02957125A0601|6 13|patients
P02957125A0601|23 29|failure
P02957125A0601|37 49|haemodialysis
P02957125A0601|72 85|cent reduction
P02957125A0601|87 110|plasma ANP concentration
P02958204A0175|16 22|effects
P02958204A0175|25 36|isotretinoin
P02958204A0175|39 41|HDL
P02958204A0175|53 57|HDL-C
P02958204A0175|59 75|HDL phospholipids
P02958204A0175|76 81|HDL-PL
P02958204A0175|84 96|apoprotein A1
P02958204A0175|97 103|apo A-1
P02958204A0175|108 125|HDL-C subfractions
P02958204A0175|126 131|HDL2-C
P02958204A0175|135 140|HDL3-C
P02958204A0175|158 165|patients
P02958204A0175|183 188|course
P02958204A0175|191 202|isotretinoin
P02958204A0175|207 215|mg/kg/day
P02958204A0175|220 228|treatment
P02958204A0175|237 249|acne vulgaris
P02958233A0123|11 17|picture
P02958233A0123|21 41|laboratory parameters
P02958233A0123|60 82|serum sickness reaction
P02958660A1094|3 6|data
P02958660A1094|32 40|existence
P02958660A1094|44 60|conversion factor
P02958660A1094|63 72|LDF signal
P02958660A1094|82 92|flow values
P02958660A1094|96 105|experiment
P02958660A1094|108 117|experiment
P02959089T0000|10 15|effect
P02959089T0000|18 25|ONO-3708
P02959089T0000|28 37|thrombosis
P02959089T0000|41 50|vasospasms
P02960012A0838|3 11|frequency
P02960012A0838|14 25|PPNG strains
P02960012A0838|41 41|%
P02960012A0838|53 53|%
P02962859A0276|12 21|antibodies
P02962859A0276|36 68|beta-galactosidase fusion protein
P02962859A0276|75 79|clone
P02962859A0276|94 95|U1
P02962859A0276|110 118|A antigen
P02963517A0453|12 19|analysis
P02963517A0453|33 40|stenosis
P02963517A0453|66 69|PTCA
P02963517A0453|77 86|dilatation
P02963517A0453|99 106|increase
P02963517A0453|138 141|area
P02963517A0453|166 168|mm2
P02964329A0000|3 14|pathogenesis
P02964329A0000|24 37|Joint Mobility
P02964329A0000|38 40|LJM
P02964329A0000|44 51|diabetes
P02964329A0000|68 78|abnormality
P02964329A0000|114 122|incidence
P02964329A0000|125 139|microangiopathy
P02965149A0727|11 15|study
P02965149A0727|17 22|Brandl
P02965149A0727|24 25|C.
P02966671A0151|15 24|end points
P02966671A0151|31 34|time
P02966671A0151|53 58|tumors
P02966671A0151|67 71|times
P02966671A0151|77 90|treatment size
P02966671A0151|94 101|survival
P02966671A0151|104 113|stem cells
P02966671A0151|126 131|crypts
P02966671A0151|139 152|breathing rate
P02966671A0151|171 175|weeks
P02966671A0151|190 194|weeks
P02966671A0151|201 209|treatment
P02966671A0551|0 7|Schedule
P02966671A0551|20 30|mg/kg c-DDP
P02966671A0551|62 66|X-ray
P02966671A0551|81 84|days
P02966671A0551|103 108|degree
P02966671A0551|111 121|enhancement
P02966671A0551|124 139|radiation effect
P02966671A0551|162 167|factor
P02966671A0551|188 198|enhancement
P02966671A0551|214 224|mg/kg c-DDP
P02966671A0551|238 238|h
P02966671A0551|248 252|start
P02966671A0551|272 283|radiotherapy
P02967496A0182|16 25|transcript
P02967496A0182|43 56|reading frames
P02967496A0182|96 109|leader segment
P02967496A0182|121 125|cpc-1
P02967496A0182|132 137|region
P02967915A0000|15 46|hormone 1,25-dihydroxyvitamin D3
P02967915A0000|63 72|expression
P02967915A0000|76 98|calcium binding protein
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|120 126|variety
P02967915A0000|129 142|target tissues
P02967915A0968|2 9|addition
P02967915A0968|14 36|calbindin-D28K promoter
P02967915A0968|49 55|variety
P02967915A0968|72 80|sequences
P02967915A0968|96 105|components
P02967915A0968|126 132|signals
P02968055A0984|3 5|HOI
P02968055A0984|28 35|increase
P02968055A0984|38 40|ANF
P02969316A0002|11 17|ability
P02969316A0002|23 27|atria
P02969316A0002|46 66|plasma concentrations
P02969316A0002|85 91|peptide
P02969316A0002|93 95|ANP
P02969316A0002|109 115|changes
P02969316A0002|118 142|plasma ANP concentrations
P02969316A0002|183 186|dogs
P02969316A0002|194 194|h
P02969316A0002|218 223|pacing
P02969819A0814|0 21|Ig D-JH recombinations
P02969819A0814|30 51|TcR gene recombination
P02969819A0814|62 73|T cell lines
P02969819A0814|103 117|Cmu transcripts
P02970061A0271|3 12|RAD18 gene
P02970061A0271|16 28|reading frame
P02970061A0271|36 42|protein
P02970061A0271|48 58|amino acids
P02970061A0271|83 88|weight
P02970640A0341|6 33|absorption spectrophotometry
P02970640A0341|62 73|E1A proteins
P02970640A0341|97 108|acid protein
P02970640A0341|116 123|zinc ion
P02970640A0341|143 154|acid protein
P02970640A0341|161 164|zinc
P02971603A0883|4 11|patients
P02971603A0883|21 27|tablets
P02971603A0883|30 38|injection
P02971603A0883|45 47|day
P02971710A0734|0 4|Plots
P02971710A0734|7 8|RV
P02971710A0734|10 11|LV
P02971710A0734|13 13|S
P02971710A0734|17 25|2A weight
P02971710A0734|31 40|hematocrit
P02971710A0734|58 68|inflections
P02971710A0734|75 84|hematocrit
P02971710A0734|87 87|%
P02971710A0734|108 111|role
P02971710A0734|123 131|viscosity
P02971710A0734|134 135|CO
P02971710A0734|159 168|hematocrit
P02971957A0287|24 27|mesh
P02971957A0287|41 51|improvement
P02971957A0287|62 66|cases
P02971957A0287|84 93|techniques
P02971957A0287|113 120|bleeding
P02973304A0000|12 17|course
P02973304A0000|20 39|Budd-Chiari syndrome
P02973304A0000|53 62|thrombosis
P02973304A0000|74 77|vein
P02973304A0000|107 123|patient suffering
P02973304A0000|142 156|cardiosclerosis
P02975680A0000|8 26|accommodation night
P02975680A0000|27 46|sleep EEG recordings
P02975680A0000|80 85|nights
P02975680A0000|100 109|inpatients
P02975680A0000|131 146|anxiety disorder
P02975680A0000|147 149|GAD
P02975680A0000|166 175|depression
P02975680A0000|190 192|age
P02975680A0000|208 212|group
P02975680A0000|215 222|patients
P02975680A0000|227 229|GAD
P02975680A0000|234 238|group
P02975680A0000|263 270|disorder
P02975680A0000|272 274|MDD
P02975680A0000|276 283|patients
P02975753A1333|0 26|Oligonucleotide mutagenesis
P02975753A1333|33 47|binding domains
P02975753A1333|61 70|importance
P02975753A1333|91 100|regulation
P02975753A1333|106 116|E3 promoter
P02975753A1333|118 128|yeast cells
P02976332A1277|3 15|concentration
P02976332A1277|18 21|PGI2
P02976332A1277|46 52|surface
P02979426T0000|0 20|Organ transplantation
P02979426T0000|22 28|Denmark
P02979834T0000|0 6|Effects
P02979834T0000|26 61|maltose tetrapalmitate immunotherapy
P02979834T0000|61 89|cyclophosphamide chemotherapy
P02979834T0000|92 103|radiotherapy
P02979834T0000|106 120|ethyl carbamate
P02979834T0000|138 148|lung cancer
P02979834T0000|150 157|A/J mice
P02981457A0368|0 1|D.
P02981840A0907|9 21|pair sequence
P02981840A0907|62 72|nucleotides
P02981840A0907|90 90|d
P02981840A0907|92 93|AC
P02981840A0907|95 101|repeats
P02982332T0001|0 4|Phase
P02982332T0001|7 11|study
P02982332T0001|14 18|VP-16
P02982332T0001|20 26|capsule
P02982332T0001|35 40|tumors
P02983316A0310|13 20|segments
P02983316A0310|35 43|framework
P02983316A0310|47 81|complementarity-determining regions
P02983316A0310|89 93|genes
P02983316A0310|106 120|probe sequences
P02983316A0310|139 146|analysis
P02983316A0310|167 178|caiman genes
P02983316A0310|233 240|sequence
P02983316A0310|267 278|preservation
P02983316A0310|281 299|nucleotide sequence
P02983316A0310|313 318|period
P02983316A0310|333 336|time
P02983331T0000|0 7|Evidence
P02983331T0000|12 15|role
P02983331T0000|51 56|factor
P02983331T0000|64 68|ether
P02983331T0000|70 83|immobilization
P02983331T0000|97 102|stress
P02985812A0984|9 15|feature
P02985812A0984|34 38|genes
P02985812A0984|55 58|mRNA
P02985812A0984|80 92|reading frame
P02985812A0984|103 106|mRNA
P02985820A1287|9 25|sequence elements
P02985820A1287|44 50|vectors
P02985820A1287|57 66|c-myc gene
P02985820A1287|82 88|genesis
P02985820A1287|106 122|retroviruses CMII
P02985820A1287|123 126|MC29
P02985820A1287|130 132|MH2
P02986279A0000|2 13|milk samples
P02986279A0000|28 33|donors
P02986279A0000|35 38|days
P02986279A0000|42 47|months
P02986279A0000|53 60|delivery
P02986279A0000|79 88|occurrence
P02986279A0000|91 105|cytomegalovirus
P02986279A0000|107 109|CMV
P02987220A0472|0 9|Subcloning
P02987220A0472|12 24|DNA fragments
P02987220A0472|44 45|kb
P02987220A0472|47 52|insert
P02987220A0472|55 59|pAVO4
P02987220A0472|72 83|DNA fragment
P02987220A0472|110 112|FBP
P02987220A0472|114 117|gene
P02987220A0472|134 139|region
P02987777A0000|5 9|cases
P02987777A0000|30 43|cell carcinoma
P02987777A0000|48 53|rectum
P02988457A0650|3 6|data
P02988457A0650|42 53|potentiality
P02988457A0650|56 73|Bestatin treatment
P02988457A0650|81 85|types
P02988457A0650|88 97|malignancy
P02989637A0671|5 8|data
P02989637A0671|32 41|regulation
P02989637A0671|51 81|zona glomerulosa corticosteroid
P02989637A0671|88 102|renin secretion
P02989637A0671|112 119|patients
P02989637A0671|134 150|cord transections
P02989637A0671|177 184|pathways
P02989637A0671|206 211|system
P02989637A0671|227 252|metoclopramide stimulation
P02989637A0671|254 264|aldosterone
P02989637A0671|268 282|renin secretion
P02989637A0671|284 286|men
P02989786A0328|5 11|absence
P02989786A0328|14 31|enhancer sequences
P02989786A0328|35 53|adenovirus E1A gene
P02989786A0328|67 82|CATase synthesis
P02991060A0465|5 18|IgG antibodies
P02991060A0465|23 28|babies
P02991060A0465|51 58|delivery
P02991060A0465|84 88|cases
P02991060A0465|99 104|months
P02991060A0465|107 110|ages
P02991060A0465|118 123|babies
P02991060A0465|130 135|months
P02993630A1190|4 11|analysis
P02993630A1190|17 32|nucleotide level
P02993630A1190|42 47|events
P02993630A1190|53 61|digestion
P02993630A1190|66 76|nuclease S1
P02993630A1190|88 101|enzyme attacks
P02993630A1190|118 125|sequence
P02993630A1190|127 129|G-A
P02993630A1190|138 144|message
P02993630A1190|158 163|strand
P02994253A0482|5 11|dosages
P02994253A0482|25 41|mean NTE activity
P02994253A0482|48 51|cord
P02994253A0482|74 74|%
P02994253A0482|78 82|brain
P02994253A0482|105 105|%
P02994253A0482|108 121|control values
P02994253A0482|129 143|hr postexposure
P02994253A0482|163 176|cord pathology
P02994253A0482|178 194|days postexposure
P02994253A0482|218 218|%
P02994253A0482|235 241|animals
P02994336A0864|0 1|FK
P02994336A0864|31 38|analogue
P02994336A0864|50 60|plasma ACTH
P02994336A0864|64 64|%
P02994336A0864|72 76|level
P02994336A0864|83 95|bromocriptine
P02994336A0864|97 102|CB-154
P02994336A0864|123 128|change
P02995967T0000|15 27|protooncogene
P02995967T0000|29 36|c-erbB-2
P02995967T0000|55 62|c-erbB-1
P02995967T0000|73 99|growth factor-receptor gene
P02995967T0000|128 147|gland adenocarcinoma
P02995999A0000|3 19|sequence analysis
P02995999A0000|25 32|products
P02995999A0000|45 47|phi
P02995999A0000|63 82|recombination events
P02995999A0000|97 109|recombination
P02995999A0000|124 133|attachment
P02995999A0000|135 137|att
P02995999A0000|139 142|site
P02995999A0000|173 178|joints
P02995999A0000|194 201|position
P02995999A0000|206 224|recombination event
P02995999A0000|241 258|base-pair deletion
P02995999A0000|269 288|recombination events
P02995999A0000|316 338|base-pair substitutions
P02997622A0916|9 16|sequence
P02997622A0916|44 62|SCLC cell line DNAs
P02997622A0916|68 87|SCLC tumour specimen
P02997622A0916|104 110|patient
P02997777A0609|17 27|experiments
P02997777A0609|51 55|cells
P02997777A0609|59 73|delta top1 top2
P02997777A0609|94 95|ts
P02997777A0609|123 136|top2 ts strain
P02997777A0609|158 163|blocks
P02997777A0609|174 180|killing
P02997777A0609|186 192|top2 ts
P02997777A0609|214 224|temperature
P02997777A0609|233 242|treatments
P02997777A0609|269 278|cell death
P02997777A0609|283 300|delta top1 top2 ts
P02998016A0527|3 10|homology
P02998016A0527|13 17|v-mil
P02998016A0527|39 46|sequence
P02998016A0527|49 52|exon
P02998016A0527|84 89|region
P02998016A0527|92 95|exon
P02998016A0527|101 111|nucleotides
P02998016A0527|129 142|nonsense codon
P02998016A0527|165 177|reading frame
P02998016A0527|190 194|c-mil
P02998016A0527|198 202|v-mil
P02998043A1199|0 10|Examination
P02998043A1199|16 23|sequence
P02998043A1199|29 53|Punta Toro M gene product
P02998043A1199|60 67|presence
P02998043A1199|89 97|sequences
P02998043A1199|116 119|acid
P02998043A1199|121 136|carboxy-proximal
P02998043A1199|149 154|region
P02998043A1199|156 157|G2
P02999267A0606|8 10|FAP
P02999267A0606|22 32|amyloidosis
P02999267A0606|68 74|uptakes
P02999267A0606|82 90|intensity
P02999267A0606|111 117|sternum
P02999267A0885|3 11|intensity
P02999267A0885|24 29|uptake
P02999267A0885|32 41|Tc-99m-PYP
P02999267A0885|44 51|patients
P02999267A0885|88 98|hypertrophy
P02999267A0885|131 136|echoes
P02999267A0885|164 173|appearance
P02999267A0885|175 176|GS
P02999267A0885|206 213|patients
P02999267A0885|235 245|hypertrophy
P02999267A0885|249 250|GS
P03000457A1554|6 18|kDa precursor
P03000457A1554|36 36|t
P03000457A1554|42 42|h
P03000457A1554|57 66|processing
P03000457A1554|75 77|kDa
P03000457A1554|79 83|alpha
P03000457A1554|91 93|kDa
P03000457A1554|95 98|beta
P03000457A1554|101 107|species
P03000489A0822|8 18|lymphocytes
P03000489A0822|50 57|patients
P03000489A0822|62 65|AIDS
P03000489A0822|67 70|mean
P03000489A0822|82 82|%
P03000489A0822|84 88|range
P03000489A0822|93 93|%
P03000489A0822|98 100|CGL
P03000489A0822|102 105|mean
P03000489A0822|117 117|%
P03000489A0822|119 123|range
P03000489A0822|128 128|%
P03000489A0822|134 141|criteria
P03000489A0822|144 153|activation
P03000489A0822|172 188|blood lymphopenia
P03001054A0703|25 29|nicks
P03001054A0703|65 69|sites
P03001084A0406|3 10|sequence
P03001084A0406|37 40|pair
P03001084A0406|42 43|bp
P03001084A0406|45 51|segment
P03001084A0406|70 71|bp
P03001084A0406|79 86|cap site
P03001084A0406|88 92|alpha
P03001084A0406|99 100|bp
P03001084A0406|105 113|psi alpha
P03001086A0587|12 30|amino acid sequence
P03001086A0587|43 50|homology
P03001086A0587|70 74|hsp70
P03001086A0587|76 86|trout hsp70
P03001086A0587|87 99|Xenopus hsp70
P03001086A0587|100 110|yeast hsp70
P03001086A0587|118 125|homology
P03001086A0587|145 161|dnaK gene product
P03001110A0546|4 18|phosphorylation
P03001110A0546|30 47|peptide substrates
P03001110A0546|61 68|function
P03001110A0546|71 99|receptor self-phosphorylation
P03001110A0546|100 123|tyrosine kinase activity
P03001110A0546|161 163|mol
P03001110A0546|166 174|phosphate
P03001110A0546|178 180|mol
P03001110A0546|183 190|receptor
P03001353A0146|2 13|temperatures
P03001353A0146|27 40|transformation
P03001353A0146|42 50|6m2 cells
P03001353A0146|57 62|P58gag
P03001353A0146|91 92|kb
P03001353A0146|99 108|RNA genome
P03001353A0146|111 120|P85gag-mos
P03001353A0146|149 152|mRNA
P03001645A0785|3 7|pet56
P03001645A0785|11 20|his3 genes
P03001645A0785|49 64|initiation sites
P03001645A0785|89 90|bp
P03001705T0000|9 22|transformation
P03001705T0000|32 40|fragments
P03001705T0000|43 67|herpes simplex virus type
P03001705T0000|66 68|DNA
P03001705T0000|79 84|region
P03001705T0000|91 102|gene product
P03001952A0958|19 26|patients
P03001952A0958|50 55|herpes
P03001952A0958|60 63|type
P03001952A0958|66 68|HSV
P03001952A0958|87 97|determinant
P03001952A0958|110 120|recurrences
P03001952A0958|139 147|acyclovir
P03001952A0958|157 162|effect
P03001952A0958|175 185|recurrences
P03002501A1327|0 9|Comparison
P03002501A1327|12 20|sequences
P03002501A1327|38 40|rat
P03002501A1327|44 75|guinea-pig alpha s1-casein mRNAs
P03002501A1327|92 99|homology
P03002501A1327|131 137|regions
P03002786A0143|3 7|group
P03002786A0143|9 9|n
P03002786A0143|32 40|midazolam
P03002786A0143|45 51|mg kg-1
P03002786A0143|55 62|atropine
P03002786A0143|70 76|mg i.m.
P03003695A0395|0 9|Comparison
P03003695A0395|32 47|c-sis cDNA clone
P03003695A0395|47 53|Collins
P03003695A0395|60 65|Nature
P03003695A0395|102 115|kbp DNA region
P03003695A0395|131 140|c-sis exon
P03003695A0395|153 154|bp
P03004364A0775|35 44|activities
P03004364A0775|47 50|5-FU
P03004364A0775|52 54|ADM
P03004364A0775|58 60|MMC
P03004364A0775|63 68|FAMLIP
P03004364A0775|81 85|FULIP
P03004364A0775|87 92|ADRLIP
P03004364A0775|96 101|MMCLIP
P03004739A0753|14 14|C
P03004739A0753|17 30|G transversion
P03004739A0753|40 46|residue
P03004739A0753|52 70|CAT pentanucleotide
P03004739A0753|94 101|activity
P03004739A0753|108 116|promoters
P03004739A0753|135 142|affinity
P03004739A0753|148 166|CAT binding protein
P03004982A0199|3 21|nucleotide sequence
P03004982A0199|27 28|bp
P03004982A0199|37 50|R. sphaeroides
P03004982A0199|61 63|DNA
P03004982A0199|92 101|genes fbcF
P03004982A0199|102 105|fbcB
P03004982A0199|109 112|fbcC
P03004982A1094|13 20|sequence
P03004982A1094|37 43|peptide
P03004982A1094|49 59|FeS protein
P03004982A1094|91 108|fbcF reading frame
P03005231A0649|22 30|sequences
P03005231A0649|52 60|sequences
P03005231A0649|81 90|initiation
P03005231A0649|94 104|termination
P03005231A0649|107 119|transcription
P03005231A0649|141 149|promoters
P03005231A0649|188 196|sequences
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|27 28|Mr
P03006066A0653|35 53|translation product
P03006066A0653|55 59|c-myb
P03006066A0653|61 68|P75c-myb
P03006066A0653|86 93|proteins
P03006066A0653|95 102|P54c-ets
P03007281A0905|3 14|Dox-A2 locus
P03007281A0905|30 31|kb
P03007281A0905|37 38|Df
P03007281A0905|40 41|2L
P03007281A0905|43 57|OD15 breakpoint
P03007281A0905|79 82|loci
P03007281A0905|90 96|maximum
P03007281A0905|103 104|kb
P03008094A0697|13 15|end
P03008094A0697|22 32|polypeptide
P03008094A0697|45 49|types
P03008094A0697|60 68|sequences
P03008405A0532|7 15|outbreaks
P03008405A0532|24 30|disease
P03008405A0532|42 52|deer calves
P03008405A0532|60 64|HVC-1
P03009366A0438|36 42|studies
P03009366A0438|59 62|Type
P03009366A0438|65 75|pneumocytes
P03009366A0438|86 91|target
P03009366A0438|94 102|radiation
P03009366A0438|109 115|release
P03009366A0438|118 127|surfactant
P03009366A0438|155 162|exposure
P03009366A0438|174 177|days
P03009366A0438|181 185|weeks
P03009826A0201|11 16|clones
P03009826A0201|38 57|base-pair dimer unit
P03009826A0201|61 66|repeat
P03010281A0220|3 8|copies
P03010281A0220|19 24|repeat
P03010281A0220|42 51|activation
P03010281A0220|54 68|gene expression
P03011793A0582|7 20|reading frames
P03011793A0582|22 25|rbsD
P03011793A0582|27 30|rbsA
P03011793A0582|35 38|rbsC
P03011793A0582|45 52|proteins
P03011793A0582|69 87|amino acid residues
P03013477A0000|2 6|order
P03013477A0000|17 25|influence
P03013477A0000|28 40|iron overload
P03013477A0000|62 70|leucocyte
P03013477A0000|72 74|PMN
P03013477A0000|76 85|metabolism
P03013477A0000|88 95|patients
P03013477A0000|105 116|hemodialysis
P03013477A0000|118 127|generation
P03013477A0000|130 145|superoxide anion
P03013477A0000|152 154|PMN
P03013477A0000|162 166|blood
P03013477A0000|183 188|groups
P03013477A0000|203 210|patients
P03013477A0000|212 216|group
P03013477A0000|239 249|individuals
P03013477A0000|254 274|serum ferritin levels
P03013477A0000|282 286|ng/ml
P03013477A0000|290 296|group B
P03013477A0000|306 316|individuals
P03013477A0000|321 341|serum ferritin levels
P03013477A0000|349 353|ng/ml
P03013841A0207|0 7|Cattaneo
P03013841A0207|12 13|J.
P03014515T0000|5 25|alpha-galactosidase A
P03014515T0000|26 44|nucleotide sequence
P03014515T0000|47 56|cDNA clone
P03014515T0000|73 78|enzyme
P03014593A0681|0 7|Diazepam
P03014593A0681|10 14|mg/kg
P03014593A0681|29 30|Ro
P03014593A0681|67 75|Ro 5-4864
P03014593A0681|77 81|mg/kg
P03014593A0681|87 91|mg/kg
P03015611A0331|3 21|amino acid sequence
P03015611A0331|37 44|residues
P03015611A0331|60 73|lysine residue
P03015611A0331|105 108|site
P03015628A1078|0 10|Osteocalcin
P03015628A1078|22 35|hydroxyproline
P03015628A1078|62 81|hyperphosphatasaemia
P03015628A1078|97 106|mechanisms
P03015628A1078|125 137|bone turnover
P03015628A1078|169 203|serum alkaline phosphatase activity
P03015628A1078|208 215|subjects
P03015953T0000|0 7|Analysis
P03015953T0000|10 23|glucocorticoid
P03015953T0000|36 48|cell variants
P03015953T0000|54 82|mouse glucocorticoid receptor
P03015953T0000|94 102|DNA clone
P03016301A0605|8 19|v-myc codons
P03016301A0605|57 64|terminus
P03016301A0605|76 85|c-myc exon
P03016301A0605|92 97|codons
P03016301A0605|113 117|c-myc
P03016301A0605|124 129|region
P03016506A0611|12 17|vector
P03016506A0611|19 22|p410
P03016506A0611|61 68|fragment
P03016506A0611|70 80|nucleotides
P03016506A0611|100 111|B95-8 strain
P03016506A0611|144 157|antigen EBNA-1
P03016506A0611|172 179|sequence
P03016506A0611|187 202|BamHI-C fragment
P03016506A0611|225 235|marker gene
P03016506A0611|243 258|G-418 resistance
P03016506A0611|260 271|animal cells
P03016883A0000|2 4|men
P03016883A0000|10 16|history
P03016883A0000|35 59|herpes simplex virus type
P03016883A0000|59 63|HSV-2
P03016883A0000|65 73|infection
P03016883A0000|95 99|weeks
P03016883A0000|104 110|samples
P03016883A0000|123 129|urethra
P03016883A0000|133 147|virus isolation
P03017225A0706|9 17|carcinoma
P03017225A0706|29 42|leather bottle
P03017225A0706|43 63|linitis plastica type
P03017225A0706|68 74|stomach
P03017225A0706|85 96|II c portion
P03017225A0706|100 106|stomach
P03017225A0706|124 129|glands
P03017225A0706|147 155|carcinoma
P03017225A0706|178 182|focus
P03017225A0706|193 200|Nakamura
P03017225A0706|203 208|theory
P03017996A0731|9 20|biosynthesis
P03017996A0731|37 48|polypeptides
P03017996A0731|53 66|signal peptide
P03017996A0731|113 119|protein
P03017996A0731|133 142|mutants X2
P03017996A0731|145 146|X3
P03017996A0731|150 162|cleavage site
P03018491A0840|3 16|hexanucleotide
P03018491A0840|20 27|TGTCCT-3
P03018491A0840|53 64|GRE activity
P03018491A0840|86 93|sequence
P03018491A0840|113 118|region
P03018491A0840|149 151|end
P03018491A0840|157 160|gene
P03018491A0840|183 198|receptor binding
P03019505A0390|4 11|patients
P03019505A0390|31 36|spread
P03019505A0390|56 60|tumor
P03020001A0781|16 31|mini-Mu elements
P03020001A0781|40 53|kilobase pairs
P03020001A0781|69 75|cloning
P03020001A0781|78 90|DNA fragments
P03020001A0781|100 113|kilobase pairs
P03020001A0781|139 152|kilobase pairs
P03020001A0781|166 171|clones
P03020001A0781|177 186|insertions
P03020001A0781|201 214|kilobase pairs
P03020513T0000|13 19|subunit
P03020513T0000|22 41|T4 DNA topoisomerase
P03020513T0000|57 68|gyrA-protein
P03020513T0000|71 76|gyrase
P03021050A0501|22 26|peaks
P03021050A0501|32 43|quantitation
P03021050A0501|46 54|sulbactam
P03021088A0135|9 15|periods
P03021088A0135|29 37|exclusion
P03021088A0135|43 52|occurrence
P03021088A0135|66 71|ulcers
P03021088A0135|86 96|gastrectomy
P03021088A0135|101 108|Billroth
P03021088A0135|111 114|type
P03021088A0135|117 130|reconstruction
P03021088A0135|145 148|days
P03021088A0135|153 157|years
P03021088A0135|165 171|average
P03021088A0135|177 181|years
P03022129A0842|14 19|arrays
P03022129A0842|30 37|MPE X Fe
P03022129A0842|37 38|II
P03022129A0842|72 75|loss
P03022129A0842|78 83|detail
P03022129A0842|108 120|accessibility
P03022129A0842|125 130|extent
P03022129A0842|166 183|transcription rate
P03022129A0842|189 192|gene
P03023067A0779|0 10|Translation
P03023067A0779|29 33|genes
P03023067A0779|63 73|transcripts
P03023679A0624|12 17|weight
P03023679A0624|34 41|proteins
P03023679A0624|88 95|proteins
P03023679A0624|129 140|modification
P03023682A0271|0 8|Insertion
P03023682A0271|12 13|bp
P03023682A0271|21 24|SV40
P03023682A0271|48 80|chloramphenicol acetyltransferase
P03023682A0271|81 83|CAT
P03023682A0271|85 94|expression
P03023859A0000|5 8|DNAs
P03023859A0000|43 59|leukemia patients
P03023859A0000|68 71|date
P03023859A0000|74 83|breakpoint
P03023859A0000|86 95|chromosome
P03023859A0000|102 115|Ph1 chromosome
P03023859A0000|138 142|probe
P03023859A0000|150 152|bcr
P03023859A0000|154 178|breakpoint cluster region
P03023887A0470|0 20|Nuclease footprinting
P03023887A0470|40 62|glucocorticoid receptor
P03023887A0470|85 89|sites
P03023887A0470|104 110|borders
P03023887A0470|132 145|sequence motif
P03023887A0470|156 157|Sa
P03023970A0922|8 13|insert
P03023970A0922|24 41|termination signal
P03023970A0922|64 74|termination
P03023970A0922|80 86|protein
P03023970A0922|100 109|generation
P03023970A0922|113 123|p53 product
P03023970A0922|124 134|amino acids
P03024343A0372|3 8|tumors
P03024343A0372|33 46|neuroendocrine
P03024343A0372|49 54|origin
P03024703A1036|9 14|region
P03024703A1036|21 31|nucleotides
P03024703A1036|46 62|polypeptide chain
P03024703A1036|67 77|amino acids
P03024703A1036|94 99|weight
P03024703A1036|114 127|hsp108 protein
P03025606T0000|15 29|control signals
P03025606T0000|32 56|herpes simplex virus type
P03025606T0000|60 64|gamma
P03025606T0000|67 74|gene lie
P03025606T0000|80 84|bases
P03025606T0000|109 116|terminus
P03025606T0000|122 125|mRNA
P03025655T0000|13 18|domain
P03025655T0000|60 66|kinases
P03025655T0000|78 92|kinase function
P03025655T0000|95 115|transforming activity
P03025655T0000|117 150|Fujinami sarcoma virus P130gag-fps
P03025661A0260|0 6|Gluzman
P03025661A0260|8 14|EMBO J.
P03025862A0860|7 10|exon
P03025862A0860|40 50|amino acids
P03025862A0860|55 63|ssd chain
P03025862A0860|83 88|region
P03025862A0860|94 97|mRNA
P03025862A0860|110 113|poly
P03025862A0860|115 115|A
P03025862A0860|118 130|addition site
P03026915A1024|19 27|sequences
P03026915A1024|31 35|parts
P03026915A1024|47 55|sequences
P03026915A1024|65 75|yeast genes
P03026915A1024|107 125|lacZ fusion vectors
P03027661A0000|3 12|activities
P03027661A0000|18 26|D protein
P03027661A0000|31 43|miniF plasmid
P03027779A0000|0 16|SPECT examination
P03027779A0000|21 23|TMJ
P03027779A0000|32 37|Tc-MDP
P03027779A0000|54 61|patients
P03027779A0000|97 107|dislocation
P03027779A0000|113 116|disc
P03027779A0000|124 130|normals
P03027905A0632|0 20|Plasma renin activity
P03027905A0632|29 52|plasma aldosterone level
P03027905A0632|66 75|lisinopril
P03029111A0155|3 9|mutants
P03029111A0155|15 28|representative
P03029111A0155|40 64|pet complementation group
P03031602A1001|9 13|group
P03031602A1001|26 33|elements
P03031602A1001|56 61|region
P03031602A1001|68 72|genes
P03032143A0218|1 10|centromere
P03032143A0218|36 41|region
P03032143A0218|44 46|DNA
P03032143A0218|64 65|bp
P03032143A0218|68 73|length
P03032143A0218|99 115|sequence elements
P03032143A0218|134 141|proteins
P03032143A0218|155 166|conformation
P03032143A0218|172 180|chromatin
P03032143A0218|185 201|yeast kinetochore
P03032964T0000|12 19|function
P03032964T0000|42 49|promoter
P03032964T0000|60 68|sequences
P03032964T0000|81 88|activity
P03033283A0837|22 25|loci
P03033283A0837|54 62|IE68 gene
P03033283A0837|64 67|HCMV
P03033283A0837|69 73|Towne
P03033283A0837|75 77|DNA
P03033283A0837|88 91|case
P03033283A0837|95 106|DNA sequence
P03033283A0837|109 146|competition filter binding experiments
P03033283A0837|154 160|maximum
P03033283A0837|177 199|consensus binding sites
P03033283A0837|230 235|region
P03033283A1415|26 29|sets
P03033283A1415|61 75|repeat elements
P03033283A1415|132 139|strength
P03033283A1415|151 161|arrangement
P03033283A1415|206 210|sites
P03033283A1415|260 269|host range
P03033283A1415|272 281|expression
P03033283A1415|284 292|SCMV IE94
P03033283A1415|304 312|HCMV IE68
P03034570A0943|10 14|genes
P03034570A0943|17 29|gene segments
P03034570A0943|34 37|code
P03034570A0943|53 85|chloramphenicol acetyltransferase
P03034570A0943|98 101|gene
P03034570A0943|112 121|resistance
P03034570A0943|129 138|hygromycin
P03034570A0943|146 151|ORF E7
P03034570A0943|161 179|papillomavirus type
P03034570A0943|190 196|vectors
P03034956A0666|2 9|contrast
P03034956A0666|28 42|androgen levels
P03034956A0666|91 98|subjects
P03034956A0666|108 110|day
P03034956A0666|119 121|day
P03034956A0666|125 134|prednisone
P03034956A0666|136 136|P
P03035056T0000|6 11|lambda
P03035056T0000|15 47|kappa antibody gene rearrangement
P03035056T0000|47 53|Abelson
P03035056T0000|60 67|leukemia
P03035056T0000|90 99|cell lines
P03035218T0000|0 13|Identification
P03035218T0000|41 49|sequences
P03035218T0000|64 89|T-cell leukemia virus type
P03035218T0000|100 105|repeat
P03035658A0355|19 28|anesthesia
P03035658A0355|38 40|VO2
P03035658A0355|48 56|ml/kg/min
P03035658A0355|74 84|epinephrine
P03035658A0355|88 91|dose
P03035658A0355|101 106|manner
P03035658A0355|109 129|plasma concentrations
P03035658A0355|139 143|ng/ml
P03035658A0355|145 147|VO2
P03035658A0355|153 161|ml/kg/min
P03035658A0355|170 174|ng/ml
P03035658A0355|176 178|VO2
P03035658A0355|184 192|ml/kg/min
P03036415T0000|0 8|Influence
P03036415T0000|11 36|cyclo-oxygenase inhibition
P03036415T0000|41 69|leukotriene receptor blockade
P03036415T0000|87 122|pressure/cardiac index relationships
P03036415T0000|144 147|dogs
P03036817A0213|24 34|mutagenesis
P03036817A0213|52 72|NdeI restriction site
P03036817A0213|83 85|ATG
P03036817A0213|91 98|yeast R.
P03036933A0774|0 11|ACTH release
P03036933A0774|40 47|children
P03036933A0774|62 75|ACTH treatment
P03037334A0932|33 48|promoter element
P03037334A0932|53 68|yeast RP39A gene
P03037334A0932|91 105|sequence motifs
P03038643A1374|5 8|data
P03038643A1374|38 51|alpha-spectrin
P03038643A1374|61 71|duplication
P03038643A1374|80 89|divergence
P03038643A1374|122 125|gene
P03038891A0935|0 16|Northern analyses
P03038891A0935|18 21|RNAs
P03038891A0935|26 38|mouse tissues
P03038891A0935|41 50|cell lines
P03038891A0935|63 77|p11 mRNA levels
P03039177A0503|3 7|group
P03039177A0503|13 23|cDNA clones
P03039177A0503|55 64|transcript
P03039177A0503|77 94|IR2 repeat element
P03039177A0503|102 130|restriction site polymorphism
P03039177A0503|135 145|enzyme SmaI
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|50 52|BCG
P03039387A0920|64 74|enhancement
P03039387A0920|89 94|effect
P03039387A0920|123 133|combination
P03039387A0920|136 147|methotrexate
P03039387A0920|152 154|BCG
P03039387A0920|158 173|cyclophosphamide
P03039387A0920|178 187|levamisole
P03040023A0113|0 7|Morphine
P03040023A0113|31 41|bradycardia
P03040023A0113|52 62|tachycardia
P03040403A0155|3 10|PSS gene
P03040403A0155|33 40|fragment
P03040403A0155|46 54|yeast DNA
P03040403A0155|59 70|YEp13 vector
P03041046A0127|7 12|A-MuLV
P03041046A0127|32 38|viruses
P03041046A0127|49 60|Moloney MuLV
P03041046A0127|102 107|A-MuLV
P03041046A0127|128 134|viruses
P03041046A0127|145 150|BALB/c
P03041046A0127|169 172|MuLV
P03041046A0127|209 217|potential
P03041046A0127|219 220|N.
P03041802A0975|3 10|presence
P03041802A0975|24 42|platelet aggregates
P03041802A0975|53 58|levels
P03041802A0975|61 76|fibrinopeptide A
P03041802A0975|78 93|cleavage product
P03041802A0975|114 132|platelet activation
P03041802A0975|141 150|deposition
P03041802A0975|159 162|role
P03041802A0975|168 179|pathogenesis
P03041802A0975|186 193|disorder
P03042778A0643|3 6|gene
P03042778A0643|21 25|yeast
P03042778A0643|36 41|growth
P03045117A0936|13 18|values
P03045117A0936|35 41|methods
P03045117A0936|48 56|agreement
P03045117A0936|64 70|species
P03045117A0936|82 94|growth factor
P03045117A0936|108 112|order
P03045117A0936|118 121|type
P03045117A0936|133 137|Glu24
P03045117A0936|156 160|Asp27
P03045117A0936|191 193|Thr
P03045117A0936|205 209|Tyr29
P03045117A0936|228 232|Leu47
P03045725A0872|17 27|suppression
P03045725A0872|38 53|prolactin levels
P03045725A0872|76 97|breast cancer patients
P03045725A0872|121 137|tumor sensitivity
P03045725A0872|139 150|chemotherapy
P03046655A0000|9 24|prevalence study
P03046655A0000|39 44|acuity
P03046655A0000|58 60|eye
P03046655A0000|74 81|patients
P03046655A0000|94 102|keratitis
P03046655A0000|122 127|period
P03046931A0247|13 18|eIF-4A
P03046931A0247|29 38|retroposon
P03046931A0247|62 65|cDNA
P03046931A0247|82 102|nucleotide difference
P03048024A0418|13 19|culture
P03048024A0418|32 37|tissue
P03048024A0418|54 55|IB
P03048024A0418|63 70|NIB rats
P03048024A0418|71 71|p
P03049570A1242|5 16|similarities
P03049570A1242|33 43|E2 proteins
P03050147A0896|5 13|infection
P03050147A0896|19 23|cells
P03050147A0896|50 66|E1a-E1b functions
P03050147A0896|72 78|viruses
P03050147A0896|92 98|amounts
P03050147A0896|113 130|mRNA transcription
P03050147A1520|4 14|observation
P03050147A1520|37 50|scanning model
P03050147A1520|62 71|initiation
P03050147A1520|87 95|ribosomes
P03050147A1520|128 136|mRNA site
P03050147A1520|147 165|initiator AUG codon
P03050147A1520|170 178|C protein
P03052327A1474|2 5|view
P03052327A1474|13 19|results
P03052327A1474|33 63|pancreas-kidney transplantation
P03052327A1474|77 85|treatment
P03052327A1474|88 93|choice
P03052327A1474|97 100|Type
P03052327A1474|110 117|patients
P03052641A0204|14 22|compounds
P03052641A0204|35 42|vehicles
P03052641A0204|59 63|gases
P03053713A0752|0 13|DNA sequencing
P03053713A0752|18 26|DPM1 gene
P03053713A0752|40 52|reading frame
P03053713A0752|57 61|bases
P03057259A0514|3 14|relationship
P03057259A0514|38 45|lymphoma
P03057259A0514|51 57|thyroid
P03057259A0514|68 78|thyroiditis
P03059171A1232|0 13|Administration
P03059171A1232|16 29|anticoagulants
P03059171A1232|36 42|heparin
P03059171A1232|44 59|prostaglandin E1
P03059171A1232|62 72|ticlopidine
P03059171A1232|104 111|symptoms
P03059171A1232|134 146|deterioration
P03060846T0000|10 17|analysis
P03060846T0000|23 37|L1 binding site
P03060846T0000|38 45|23S rRNA
P03060953A0481|0 6|Animals
P03060953A0481|27 37|vaccination
P03060953A0481|49 58|mechanisms
P03060953A0481|79 87|outbreaks
P03061301A0624|0 21|Prostacyclin formation
P03061301A0624|36 49|excretion rate
P03061301A0624|60 99|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|111 115|means
P03061301A0624|118 133|radioimmunoassay
P03061301A0624|142 156|urine specimens
P03061301A0624|183 188|period
P03061301A0624|197 208|participants
P03061301A0624|219 223|smoke
P03061301A0624|245 254|cigarettes
P03061301A1409|8 16|excretion
P03061301A1409|39 46|F1 alpha
P03061301A1409|68 74|smokers
P03061301A1409|86 99|contraceptives
P03061301A1409|117 121|ng/gm
P03061301A1409|124 133|creatinine
P03061301A1409|135 135|p
P03061383A0000|10 17|activity
P03061383A0000|20 29|mecillinam
P03061383A0000|55 58|acid
P03061383A0000|81 87|strains
P03061383A0000|97 111|beta-lactamases
P03061383A0000|117 121|TEM-1
P03061383A0000|123 127|Oxa-1
P03061383A0000|142 145|type
P03061383A0000|165 169|broth
P03061383A0000|173 195|agar dilution technique
P03062370A0000|0 3|GCN4
P03062370A0000|27 35|activator
P03062370A0000|38 47|amino acid
P03062370A0000|59 63|genes
P03062370A0384|5 11|results
P03062370A0384|24 35|GCN3 product
P03062370A0384|51 60|repression
P03062370A0384|63 72|activation
P03062370A0384|75 89|GCN4 expression
P03062370A0384|100 122|amino acid availability
P03064524A0160|3 10|efficacy
P03064524A0160|35 39|drugs
P03064811A0485|3 21|amino acid sequence
P03064811A0485|25 41|S. aureus peptide
P03064811A0485|51 66|phosphoryl group
P03064811A0485|150 152|Asp
P03065140A0273|5 13|mutations
P03065140A0273|22 28|regions
P03065140A0273|31 42|GAL4 protein
P03065140A0273|46 63|DNA binding domain
P03065140A0273|69 99|transcription activation domain
P03065141A0448|3 9|results
P03065141A0448|26 30|genes
P03065141A0448|32 35|citA
P03065141A0448|39 42|citB
P03065141A0448|56 64|promoters
P03065141A0448|72 79|location
P03065141A0448|85 92|promoter
P03065141A0448|99 107|citB gene
P03065141A0448|112 137|Tn3411 nucleotide sequence
P03065141A0448|158 163|pMS185
P03065610A0375|3 10|rci gene
P03065610A0375|22 25|lacZ
P03065610A0375|32 43|gene product
P03065610A0375|58 78|Western blot analysis
P03065621T0000|0 8|Structure
P03065621T0000|12 21|regulation
P03065621T0000|32 35|gene
P03065621T0000|74 78|MRP13
P03065621T0000|81 87|protein
P03065621T0000|98 104|subunit
P03065621T0000|123 130|ribosome
P03066131A0000|6 11|survey
P03066131A0000|43 47|basis
P03066131A0000|59 67|treatment
P03066131A0000|70 88|behaviour disorders
P03066131A0000|102 108|lesions
P03066131A0000|114 121|amygdala
P03066131A0000|143 154|hypothalamus
P03066131A0000|158 163|author
P03066131A0000|179 189|experiences
P03066131A0000|197 206|operations
P03066131A0000|210 216|control
P03066131A0000|244 257|aggressiveness
P03066208A0310|12 22|examination
P03066208A0310|48 51|cyst
P03066208A0310|71 84|cell carcinoma
P03066625A0756|26 32|studies
P03066625A0756|65 77|contributions
P03066625A0756|88 99|risk factors
P03066625A0756|123 134|risk factors
P03066625A0756|138 144|studies
P03066625A0756|177 185|questions
P03067505A0688|5 16|prostacyclin
P03067505A0688|42 49|property
P03067505A0688|60 70|ear vessels
P03069046A0126|3 8|method
P03069046A0126|28 36|precision
P03069046A0126|48 58|sensitivity
P03069980T0000|0 6|Factors
P03069980T0000|21 33|bond strength
P03069980T0000|40 58|glass polyalkenoate
P03069980T0000|59 65|ionomer
P03069980T0000|67 73|cements
P03069980T0000|77 83|dentine
P03072021A0696|3 22|amino acid sequences
P03072021A0696|26 30|yeast
P03072021A0696|56 74|targeting sequences
P03072021A0696|111 122|polypeptides
P03072580A0455|0 11|Van der Ende
P03072580A0455|11 12|R.
P03073091A0338|6 21|insulin infusion
P03073091A0338|25 43|% dextrose solution
P03073091A0338|55 63|Biostator
P03073091A0338|66 70|order
P03073091A0338|84 90|patient
P03073091A0338|93 100|glycemia
P03073091A0338|105 109|mg/dl
P03073091A0449|0 6|Amounts
P03073091A0449|9 15|glucose
P03073091A0449|38 40|min
P03073091A0449|48 68|hour insulin infusion
P03073091A0449|108 116|treatment
P03073091A0449|118 118|K
P03073091A0449|124 129|mmol/l
P03073091A0449|141 149|mg/kg/min
P03073091A0449|156 169|spironolactone
P03073091A0449|171 171|K
P03073091A0449|177 182|mmol/l
P03073091A0449|195 203|mg/kg/min
P03073091A0449|210 222|indomethacine
P03073091A0449|224 224|K
P03073091A0449|230 235|mmol/l
P03073091A0449|244 252|mg/kg/min
P03073091A0449|266 270|drugs
P03073091A0449|272 272|K
P03073091A0449|278 283|mmol/l
P03073091A0449|295 303|mg/kg/min
P03073192T0000|0 52|Mycobacterium avium-intracellulare complex infections
P03073192T0000|63 87|immunodeficiency syndrome
P03075154T0000|0 9|Recurrence
P03075154T0000|12 29|oxalate deposition
P03075154T0000|37 46|transplant
P03075154T0000|53 73|ciclosporin A therapy
P03076124A0496|3 24|bile acid sequestrants
P03076124A0496|24 37|cholestyramine
P03076124A0496|41 50|colestipol
P03076124A0496|62 65|acid
P03076124A0496|67 77|fenofibrate
P03076124A0496|81 90|inhibitors
P03076124A0496|93 124|hydroxymethylglutaryl coenzyme A
P03076124A0496|124 130|HMG CoA
P03076124A0496|131 139|reductase
P03076124A0496|145 154|lovastatin
P03076124A0496|157 167|simvastatin
P03076124A0496|188 192|drugs
P03076124A0496|196 198|use
P03076124A0496|201 208|patients
P03076124A0496|220 240|hypercholesterolaemia
P03076124A0496|247 252|agents
P03076124A0496|259 279|plasma concentrations
P03076124A0496|281 285|total
P03076124A0496|289 303|LDL-cholesterol
P03076124A0496|312 312|%
P03078268A0529|29 35|aspects
P03078268A0529|45 57|acidification
P03078268A0529|93 107|acidosis models
P03078268A0529|117 123|maleate
P03078268A0529|127 150|amphotericin B treatment
P03078268A0529|166 175|mechanisms
P03078268A0529|188 191|role
P03078268A0529|201 208|steroids
P03078268A0529|218 230|acidification
P03079276T0029|0 7|Analysis
P03079276T0029|11 16|groups
P03079276T0029|19 26|patients
P03079276T0029|72 80|flare-ups
P03080793T0000|0 8|Statement
P03080793T0000|14 24|development
P03080793T0000|27 36|guidelines
P03080793T0000|43 52|prevention
P03080793T0000|55 71|AIDS transmission
P03080793T0000|76 84|workplace
P03083441T0000|0 12|Modifications
P03083441T0000|29 43|postcontraction
P03083441T0000|54 59|people
P03088643A0000|15 18|rats
P03088643A0000|28 37|preference
P03088643A0000|69 75|stimuli
P03088643A0000|77 78|CS
P03088643A0000|105 116|control rats
P03090237A0202|10 18|schedules
P03090237A0202|31 42|response run
P03090237A0202|80 84|times
P03090237A0202|90 101|response key
P03090237A0202|102 109|work key
P03090237A0202|140 151|response key
P03090237A0202|162 164|key
P03090372A0607|11 33|glucose tolerance tests
P03090372A0607|51 59|operation
P03090372A0607|75 77|CyA
P03090372A0607|87 91|weeks
P03091849A0000|3 9|effects
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|28 37|dimensions
P03091849A0000|41 54|ultrastructure
P03091849A0000|70 73|beds
P03091849A0000|76 88|rat mesentery
P03091849A0000|104 108|kinds
P03091849A0000|111 120|experiment
P03091849A0000|138 145|fixative
P03091849A0000|162 170|perfusion
P03091849A0000|174 181|pressure
P03091849A0000|186 190|mm Hg
P03091849A0000|195 205|superfusion
P03091849A0000|233 240|membrane
P03097509A0654|8 11|rise
P03097509A0654|14 26|RNA molecules
P03097509A0654|45 51|regions
P03097509A0654|75 84|base pairs
P03097643A1357|8 18|BALB/c gene
P03097643A1357|33 44|substitution
P03097643A1357|57 72|octamer sequence
P03097643A1357|95 105|nucleotides
P03097643A1357|125 130|region
P03097643A1357|151 160|expression
P03098018A0139|8 15|findings
P03098018A0139|21 26|height
P03098018A0139|30 31|cm
P03098018A0139|33 38|weight
P03098018A0139|41 42|kg
P03098018A0139|53 58|length
P03098018A0139|66 70|limbs
P03098018A0139|72 85|P2-A2 pilosity
P03098018A0139|88 97|micropenis
P03102289A0786|3 6|data
P03102289A0786|48 65|hCG administration
P03102289A0786|67 74|midcycle
P03102289A0786|91 96|number
P03102289A0786|99 107|follicles
P03102289A0786|120 121|cm
P03102289A0786|124 133|ultrasound
P03102289A0786|136 144|cycle day
P03102289A0786|159 161|hCG
P03102289A0786|166 180|serum E2 levels
P03102289A0786|194 199|pmol/l
P03102289A0786|203 210|follicle
P03104245A0402|4 11|patients
P03104245A0402|21 25|Ir192
P03104245A0402|35 42|addition
P03104245A0402|53 61|radiation
P03104245A0402|77 77|p
P03104245A0402|84 91|survival
P03104245A0402|136 141|months
P03104245A0402|143 147|range
P03104245A0402|155 160|months
P03104245A0402|169 174|months
P03104245A0402|176 180|range
P03104245A0402|187 192|months
P03104248A0322|6 13|Stage IA
P03104248A0322|17 24|patients
P03104248A0322|46 50|tumor
P03104248A0322|52 53|G1
P03104248A0322|89 93|tumor
P03104248A0322|95 96|G2
P03104248A0322|104 111|patients
P03104248A0322|136 137|G3
P03104914T0000|0 8|Mechanism
P03104914T0000|14 14|t
P03104914T0000|33 45|translocation
P03104914T0000|57 64|analysis
P03104914T0000|98 105|partners
P03104982A0690|5 7|age
P03104982A0690|15 31|hemoglobin levels
P03104982A0690|34 36|men
P03104982A0690|67 71|women
P03104982A0690|86 99|sex difference
P03104982A0690|116 120|years
P03104982A0690|123 125|age
P03108171A0088|0 9|Ritanserin
P03108171A0088|16 24|substance
P03108171A0088|44 60|blocking activity
P03108171A0088|62 73|S2 receptors
P03108171A0088|76 79|5-HT
P03108171A0088|99 104|system
P03109147A0000|0 14|Ethylene glycol
P03109147A0000|17 33|diethylene glycol
P03109147A0000|79 84|groups
P03109147A0000|96 104|NMRI mice
P03109147A0000|107 113|dosages
P03109147A0000|120 122|und
P03109147A0000|124 125|mg
P03109147A0000|132 135|dose
P03109147A0000|139 143|mouse
P03109147T0127|0 7|Research
P03109147T0127|10 24|ethylene glycol
P03109147T0127|27 43|diethylene glycol
P03109147T0127|58 64|effects
P03109954A0945|3 9|results
P03109954A0945|41 49|influence
P03109954A0945|67 73|ethinyl
P03109954A0945|94 95|OC
P03109954A0945|106 115|inhibition
P03109954A0945|126 147|artery atherosclerosis
P03109954A0945|182 189|lowering
P03109954A0945|192 227|plasma HDL cholesterol concentration
P03109954A0945|249 255|balance
P03109954A0945|270 278|influence
P03109954A0945|284 295|relationship
P03109954A0945|303 315|plasma lipids
P03109954A0945|318 330|atherogenesis
P03110119A0267|6 7|BH
P03110119A0267|11 20|ventilator
P03110119A0267|40 48|bias flow
P03110119A0267|52 52|%
P03110119A0267|60 64|l/min
P03110119A0267|87 96|side ports
P03110119A0267|104 111|catheter
P03110119A0267|117 119|tip
P03110119A0267|134 144|cm cephalad
P03110119A0267|149 154|carina
P03110678A0702|0 9|Comparison
P03110678A0702|12 15|beta
P03110678A0702|31 37|removal
P03110678A0702|50 70|polysulphone membrane
P03110678A0702|73 85|haemodialysis
P03110678A0702|89 103|haemofiltration
P03110678A0702|113 132|beta 2-microglobulin
P03110678A0702|158 167|convection
P03110678A0702|174 182|diffusion
P03110678A0702|191 205|treatment modes
P03110678A0702|218 227|blood flow
P03110678A0702|230 243|urea clearance
P03110692A0156|11 14|mg/l
P03110692A0156|16 17|SD
P03110692A0156|32 32|P
P03110692A0156|47 53|beta 2m
P03110692A0156|80 87|patients
P03110692A0156|92 101|bone cysts
P03110692A0156|113 116|mg/l
P03110692A0156|141 148|duration
P03110692A0156|151 158|dialysis
P03110692A0156|176 176|P
P03110692A0156|198 205|patients
P03110692A0156|210 219|bone cysts
P03110692A0156|226 231|months
P03110692A0156|234 240|beta 2m
P03110692A0156|250 257|patients
P03110692A0156|270 277|dialysis
P03110692A0156|290 293|year
P03110692A0156|310 321|urine volume
P03110692A0156|338 342|litre
P03110692A0156|346 348|day
P03110746A0146|7 16|percentage
P03110746A0146|27 30|acid
P03110746A0146|36 48|triglycerides
P03110746A0146|66 79|adipose tissue
P03110746A0146|80 85|PLASAT
P03110746A0146|94 101|subjects
P03110746A0146|142 146|group
P03110794A0991|2 10|overdoses
P03110794A0991|16 28|g fluvoxamine
P03110794A0991|42 48|effects
P03110801A0532|20 44|plasma prolactin response
P03110801A0532|49 58|micrograms
P03111946A0309|2 7|effect
P03111946A0309|26 33|behavior
P03112028A0404|15 22|patients
P03112028A0404|44 44|n
P03112028A0404|57 57|n
P03112028A0404|68 77|parameters
P03112412A0985|2 9|addition
P03112412A0985|21 26|strain
P03112412A0985|72 90|synthetase mutation
P03112412A0985|105 125|thr operon expression
P03112412A0985|143 153|temperature
P03112412A0985|162 165|none
P03112412A0985|171 177|mutants
P03112412A0985|187 192|change
P03114188A0907|28 35|problems
P03114188A0907|59 64|decade
P03114188A0907|68 75|patients
P03114188A0907|89 106|chest wall sarcoma
P03114188A0907|116 123|patients
P03114188A0907|144 145|Gy
P03114188A0907|148 153|breast
P03114188A0907|170 174|areas
P03114829T0000|21 30|correlates
P03114829T0000|33 44|panic states
P03114995T0000|0 6|Effects
P03114995T0000|28 36|nutrition
P03114995T0000|39 53|gastrin release
P03114995T0000|55 58|dogs
P03115087A0515|7 12|weight
P03115087A0515|16 32|height velocities
P03115087A0515|39 39|%
P03115087A0515|46 46|%
P03115087A0515|52 59|standard
P03115787A0633|3 10|patients
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|39 56|hexamethylmelamine
P03115787A0633|58 67|adriamycin
P03115787A0633|71 79|cisplatin
P03115787A0633|81 86|CHAP-5
P03115787A0633|103 109|disease
P03115787A0633|126 133|response
P03115787A0633|144 152|responses
P03115787A0633|164 169|months
P03115787A0633|181 189|responses
P03115787A0633|200 205|months
P03117046T0000|0 8|Isolation
P03117046T0000|12 27|characterization
P03117046T0000|31 43|vinculin cDNA
P03117046T0000|59 69|fibroblasts
P03117147A1059|14 18|study
P03117147A1059|32 40|agreement
P03117147A1059|48 54|surface
P03117147A1059|58 73|oesophageal EMGd
P03117147A1059|91 102|surface EMGd
P03117147A1059|123 126|tool
P03117147A1059|138 150|investigation
P03118631A0140|2 12|differences
P03118631A0140|15 30|fixation quality
P03118631A0140|49 56|cochleas
P03118631A0140|77 85|perfusion
P03118631A0140|89 96|cochleas
P03118631A0140|121 129|perfusion
P03119227A0079|3 14|DNA sequence
P03119227A0079|22 28|protein
P03119227A0079|35 45|amino acids
P03119227A0079|49 65|sequence homology
P03119227A0079|75 102|c-abl proto-oncogene product
P03119227A0079|116 129|amino terminus
P03119227A0079|144 154|amino acids
P03119227A0079|164 169|region
P03119227A0079|182 205|tyrosine kinase activity
P03119485A0476|3 13|requirement
P03119485A0476|39 43|acids
P03119485A0476|46 53|patients
P03119485A0476|73 81|nutrition
P03119485A0476|92 97|injury
P03119485A0476|109 116|interest
P03119485A0476|121 127|respect
P03119485A0476|133 143|development
P03119485A0476|147 155|prognosis
P03119485A0476|158 162|shock
P03119485A0476|164 169|sepsis
P03119485A0476|188 204|distress syndrome
P03120334A0893|4 4|%
P03120334A0893|18 21|vein
P03120334A0893|41 46|origin
P03120334A0893|64 67|vein
P03120334A0893|77 82|system
P03120334A0893|100 104|veins
P03123310A0000|25 33|Gart gene
P03123310A0000|54 63|activities
P03123310A0000|69 75|pathway
P03123310A0000|79 84|purine
P03123310A0000|91 99|synthesis
P03123983T0000|3 6|role
P03123983T0000|9 23|neuroplasticity
P03123983T0000|29 36|response
P03123983T0000|39 43|drugs
P03125420A0421|0 3|Biol
P03125422A0202|3 9|results
P03125422A0202|17 27|experiments
P03125422A0202|58 76|activator sequences
P03125422A0202|77 79|UAS
P03125422A0202|95 103|induction
P03125422A0202|106 114|galactose
P03126531T0000|0 7|Reversal
P03126531T0000|13 20|increase
P03126531T0000|42 51|stereotypy
P03126531T0000|55 64|aggression
P03126531T0000|67 75|REM sleep
P03126531T0000|83 86|rats
P03126531T0000|89 118|dopamine agonist pretreatments
P03127034A0591|3 12|heart rate
P03127034A0591|24 27|rate
P03127034A0591|58 67|resistance
P03127463A1017|5 9|rIL-3
P03127463A1017|21 30|COS7 cells
P03127463A1017|47 58|CSF activity
P03127463A1017|69 76|cultures
P03127463A1017|79 95|bone marrow cells
P03127463A1017|119 131|proliferation
P03127463A1017|134 138|My-10
P03127463A1017|140 145|marrow
P03127463A1017|148 163|cord blood cells
P03127463A1017|170 177|cultures
P03132498A0730|4 11|patients
P03132498A0730|17 21|PaCO2
P03132498A0730|47 50|torr
P03132498A0730|52 56|range
P03132498A0730|63 66|torr
P03132498A0730|79 90|asthma score
P03132498A0730|104 108|PaCO2
P03132498A0730|119 122|mean
P03132498A0730|129 132|torr
P03132498A0730|140 143|mean
P03132498A0730|149 153|hours
P03133250A0000|23 27|study
P03133250A0000|56 66|stimulation
P03133250A0000|86 97|gonadotropin
P03133250A0000|99 101|hMG
P03133250A0000|131 137|hormone
P03133250A0000|139 142|hFSH
P03133250A0000|155 167|fertilization
P03133250A0000|171 185|embryo transfer
P03133250A0000|186 191|IVF-ET
P03133250A0000|193 199|program
P03133360A1215|3 10|findings
P03133360A1215|25 35|mtr product
P03133360A1215|45 69|transcription attenuation
P03133360A1215|72 81|inhibition
P03133360A1215|84 94|translation
P03133360A1215|97 105|trpE mRNA
P03134872T0029|0 6|Apropos
P03134872T0029|10 13|case
P03137105A0146|1 22|prostaglandin analogue
P03137105A0146|34 42|pregnancy
P03137105A0146|60 71|gonadotropin
P03137105A0146|84 86|end
P03137105A0146|109 113|phase
P03137105A0146|151 155|cycle
P03137105A0146|163 179|oocyte collection
P03137105A0146|199 204|cycles
P03137105A0146|207 219|oocyte donors
P03137105A0146|222 238|embryo recipients
P03137346A0319|3 16|nucleolin gene
P03137346A0319|31 40|base-pairs
P03137346A0319|57 61|exons
P03137346A0319|78 96|amino acid residues
P03137346A0319|100 106|protein
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|38 41|DOPS
P03137601A0212|56 69|norepinephrine
P03137601A0212|71 72|NE
P03137601A0212|74 82|precursor
P03137601A0212|96 105|immobility
P03137601A0212|114 117|mice
P03137601A0212|119 122|DOPS
P03137601A0212|143 152|immobility
P03137601A0212|155 158|mice
P03137601A0212|185 202|NE neurotoxin DSP4
P03138190A0347|11 17|amounts
P03138190A0347|29 38|ampicillin
P03138190A0347|64 76|Kupffer cells
P03138190A0347|80 91|target cells
P03138190A0347|124 134|inoculation
P03138449A0759|17 21|delta
P03138449A0759|26 30|delta
P03138449A0759|32 54|desaturation activities
P03138449A0759|70 79|conditions
P03138449A0759|88 90|C18
P03138449A0759|93 101|w6 supply
P03139750A0000|10 14|basis
P03139750A0000|21 30|expression
P03139750A0000|40 50|VH allotype
P03139750A0000|55 60|rabbit
P03142875A0366|23 46|6-kilobase cDNA sequence
P03142875A0366|55 59|chain
P03142875A0366|66 76|amino acids
P03142875A0366|95 103|structure
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|18 18|%
P03143048A1091|20 20|P
P03143048A1091|36 53|apolipoprotein A-I
P03143048A1091|56 56|%
P03143048A1091|58 58|P
P03143048A1091|71 84|concentrations
P03143485A0366|3 9|Euglena
P03143485A0366|19 38|protein gene cluster
P03143485A0366|62 75|protein operon
P03143485A0366|94 110|gene organization
P03143485A0366|134 138|order
P03143485A0366|153 157|genes
P03143485A0366|163 169|tobacco
P03143485A0366|173 201|liverwort chloroplast genomes
P03144705A0859|3 14|distribution
P03144705A0859|20 24|sites
P03144705A0859|42 51|resolution
P03144705A0859|86 93|gradient
P03144705A0859|96 114|sequence divergence
P03144705A0859|137 137|%
P03144705A0859|143 143|X
P03144705A0859|185 185|X
P03144705A0859|208 225|Alu family repeats
P03146017A0983|3 21|nucleotide sequence
P03146017A0983|26 31|region
P03146017A0983|44 45|M.
P03146017A0983|52 58|ORFtrpA
P03146017A0983|86 93|presence
P03146017A0983|98 100|ORF
P03146017A0983|107 117|nucleotides
P03146017A0983|119 125|ORFtrpB
P03146017A0983|139 160|amino acid polypeptide
P03146017A0983|161 163|mol
P03146150T0000|0 11|Potentiation
P03146150T0000|29 36|efficacy
P03146150T0000|51 59|urokinase
P03146150T0000|61 73|Pro-urokinase
P03146150T0000|77 83|heparin
P03146784A0158|4 12|receptors
P03146784A0158|25 29|phase
P03146784A0158|34 44|ventilation
P03146784A0158|92 108|stretch receptors
P03146784A0158|147 163|stretch receptors
P03146784A0158|164 166|PSR
P03146784A0158|210 223|chemoreceptors
P03146784A0158|225 227|IPC
P03147912A0422|11 26|hyperventilators
P03147912A0422|37 42|number
P03147912A0422|45 49|sighs
P03147912A0422|67 78|fluctuations
P03147912A0422|81 88|baseline
P03147912A0422|103 106|time
P03147912A0422|118 121|time
P03147912A0422|126 131|PETCO2
P03149774A0173|5 11|IA task
P03149774A0173|40 49|injections
P03149774A0173|52 61|picrotoxin
P03149774A0173|65 75|bicuculline
P03149774A0173|98 108|enhancement
P03149774A0173|111 119|retention
P03149774A0173|130 130|h
P03149774A0173|139 146|training
P03149774A0173|153 161|retention
P03149774A0173|178 199|bicuculline methiodide
P03149774A0173|201 224|GABA receptor antagonist
P03149774A0173|260 266|barrier
P03150015T0001|8 15|research
P03150015T0001|18 22|non-A
P03150015T0001|45 53|hepatitis
P03150296A0594|20 22|use
P03150296A0594|35 54|creatinine clearance
P03150296A0594|77 91|filtration rate
P03150296A0594|92 94|GFR
P03150296A0594|104 110|caution
P03150296A0594|117 127|recognition
P03150296A0594|133 143|limitations
P03150296A0594|149 154|method
P03150296A0594|170 179|techniques
P03150296A0594|181 196|serum creatinine
P03150296A0594|217 236|creatinine clearance
P03150296A0594|259 266|practice
P03154072A0862|3 18|protein mixtures
P03154072A0862|20 31|sesame flour
P03154072A0862|34 46|soybean flour
P03159903A0352|5 7|end
P03159903A0352|19 24|region
P03159903A0352|65 83|amino acid sequence
P03159903A0352|103 121|amino acid sequence
P03159903A0352|122 124|IHF
P03166458A1356|1 17|protein footprint
P03166458A1356|38 51|GC box element
P03166458A1356|52 62|nucleotides
P03167060A0000|12 24|growth factor
P03167060A0000|27 31|IGFII
P03167060A0000|45 55|polypeptide
P03167060A0000|60 64|mRNAs
P03167060A0000|92 96|forms
P03167060A0000|105 114|derivation
P03167060A0000|126 129|gene
P03168709A0000|16 21|fields
P03168709A0000|40 52|glaucoma eyes
P03168709A0000|70 78|threshold
P03168709A0000|86 108|suprathreshold strategy
P03171221A0531|3 13|variability
P03171221A0531|27 32|result
P03171221A0531|46 53|splicing
P03171221A0531|56 60|exons
P03171221A0531|75 93|elastin transcripts
P03171279A0158|12 21|conclusion
P03171279A0158|39 44|artery
P03171279A0158|60 65|toe MP
P03171279A0158|70 75|grafts
P03171279A0158|108 113|artery
P03171279A0158|127 133|toe PIP
P03171279A0158|138 143|grafts
P03171279A0158|170 175|dorsal
P03171279A0158|185 188|vein
P03172863T0000|0 5|Effect
P03172863T0000|15 28|undernutrition
P03172863T0000|31 44|susceptibility
P03172863T0000|51 56|stress
P03172863T0000|76 79|rats
P03175942A0706|4 9|effect
P03175942A0706|16 19|fact
P03175942A0706|32 36|doses
P03175942A0706|51 54|dams
P03175942A0706|74 83|experiment
P03175942A0706|103 107|doses
P03178097A0000|3 20|CHARGE association
P03178097A0000|23 32|collection
P03178097A0000|35 45|multisystem
P03178097A0000|56 64|anomalies
P03178097A0000|81 87|atresia
P03178161A0000|10 14|brush
P03178161A0000|26 34|screening
P03178161A0000|51 70|blood concentrations
P03178161A0000|72 85|micronutrients
P03178161A0000|87 95|vitamin A
P03178161A0000|96 96|E
P03178161A0000|98 100|B12
P03178161A0000|107 110|acid
P03178161A0000|114 123|methionine
P03178161A0000|139 144|adults
P03178161A0000|147 150|risk
P03178161A0000|164 172|carcinoma
P03178161A0000|174 175|EC
P03178161A0000|179 186|Transkei
P03178161A0000|190 195|Ciskei
P03178161A0000|197 211|Southern Africa
P03178626A0137|0 7|Aviators
P03178626A0137|20 30|Attack Wing
P03178626A0137|31 37|Pacific
P03178626A0137|56 62|results
P03178626A0137|80 92|aircraft type
P03179496T0000|0 9|Evaluation
P03179496T0000|26 53|modified-hemoglobin solution
P03179496T0000|70 74|fluid
P03179496T0000|78 101|blood volume replacement
P03180595A1040|7 31|gallbladder visualization
P03180595A1040|34 42|reduction
P03180595A1040|45 61|ejection fraction
P03180595A1040|88 97|indicators
P03180595A1040|107 113|disease
P03181276A0422|2 15|micrograms PAF
P03181276A0422|17 23|placebo
P03181276A0422|47 52|cavity
P03181276A0422|54 54|h
P03181276A0422|59 59|h
P03181276A0422|72 89|allergen challenge
P03182802A0278|0 2|Sci
P03182872A1122|0 3|Chem
P03183103A0000|10 24|MR examinations
P03183103A0000|34 39|cavity
P03183103A0000|52 58|sinuses
P03183103A0000|82 89|h period
P03183103A0000|101 110|volunteers
P03183127A0068|0 9|Comparison
P03183127A0068|43 60|imaging modalities
P03183127A0068|69 70|CT
P03183127A0068|72 82|myelography
P03183127A0068|84 102|CT ventriculography
P03183127A0068|106 127|CT myelocisternography
P03184267A0000|3 6|feed
P03184267A0000|19 34|broiler chickens
P03184267A0000|85 92|serotype
P03184267A0000|122 131|infections
P03184267A0000|152 159|chickens
P03184267A0000|163 176|food poisoning
P03184267A0000|178 183|humans
P03185322A1305|5 15|correlation
P03185322A1305|72 77|result
P03185322A1305|79 83|class
P03185322A1305|108 116|diagnosis
P03185322A1305|120 120|%
P03185322A1305|123 136|class-2 smears
P03185322A1305|165 173|dysplasia
P03185540T0000|0 6|Factors
P03185540T0000|25 37|transcription
P03185540T0000|49 62|RNA polymerase
P03185540T0000|65 76|purification
P03185540T0000|85 95|specificity
P03185540T0000|100 129|TATA box-promoter interactions
P03185540T0000|130 134|TFIID
P03186091T0000|0 5|Change
P03186091T0000|8 35|plasma cystyl aminopeptidase
P03186091T0000|35 45|oxytocinase
P03186091T0000|59 63|weeks
P03186091T0000|65 73|gestation
P03186091T0000|77 85|predictor
P03186091T0000|105 116|hypertension
P03186270T0001|10 18|diagnosis
P03190481A0292|3 6|test
P03190481A0292|24 31|esterase
P03190481A0292|35 46|quantitation
P03190481A0292|49 59|macrophages
P03190481A0292|69 74|number
P03190481A0292|79 100|infiltration area unit
P03190481A0292|112 118|abscess
P03190481A0292|133 143|correlation
P03190481A0292|162 167|number
P03190481A0292|170 180|macrophages
P03190481A0292|187 191|width
P03190481A0292|197 203|capsule
P03190914A0149|12 34|migration differentials
P03190914A0149|61 74|responsiveness
P03190914A0149|107 111|group
P03192537A0370|20 29|amino acid
P03192537A0370|35 42|sequence
P03192537A0370|54 58|HMG-I
P03192537A0370|60 60|Y
P03192537A0370|62 65|cDNA
P03192537A0370|92 110|amino acid sequence
P03192537A0370|116 120|HMG-I
P03192537A0370|149 159|amino acids
P03192537A0370|177 183|protein
P03192724A0000|13 29|style differences
P03192724A0000|34 45|drug abusers
P03192724A0000|62 65|Ryan
P03192724A0000|85 90|system
P03192724A0000|93 113|FIRO-B interpretation
P03192799T0000|0 8|Statement
P03192799T0000|14 29|American Academy
P03192799T0000|31 47|Implant Dentistry
P03192950A0566|0 3|Sera
P03192950A0566|42 46|women
P03192950A0566|54 63|TSH levels
P03192950A0566|78 82|range
P03194410A0771|2 12|UOxase mRNA
P03194410A0771|37 43|tissues
P03194410A0771|46 48|rat
P03194410A0771|60 77|tissue specificity
P03194410A0771|79 88|expression
P03194410A0771|95 105|UOxase gene
P03195167A0104|3 24|platelet adhesion rate
P03195167A0104|30 35|layers
P03195167A0104|59 67|valuation
P03195167A0104|73 90|haemocompatibility
P03195167A0104|96 122|basic-polymers polyurethane
P03195167A0104|123 125|PUR
P03195167A0104|128 144|polyvinylchloride
P03195167A0104|146 148|PVC
P03195167A0104|154 164|polystyrene
P03195167A0104|166 167|PS
P03195167A0104|189 201|test chambers
P03198436T0000|12 20|treatment
P03198436T0000|23 39|bladder carcinoma
P03198436T0000|48 57|cystectomy
P03198436T0000|73 79|iridium
P03198525A0164|8 20|feedlot trial
P03198525A0164|24 30|heifers
P03198525A0164|45 49|light
P03198525A0164|51 56|medium
P03198525A0164|65 70|weight
P03198525A0164|83 92|treatments
P03198525A0164|101 103|MGA
P03198525A0164|107 113|mg.hd-1
P03198525A0164|115 117|d-1
P03198525A0164|120 126|control
P03198525A0164|130 132|MGA
P03198525A0164|136 143|DEPO-MGA
P03198525A0164|146 146|d
P03198525A0164|161 165|ml/hd
P03198525A0164|176 184|mg MGA/hd
P03199043A0248|0 8|Existence
P03199043A0248|12 21|uniqueness
P03199043A0248|24 32|solutions
P03199043A0248|49 71|boundary value problems
P03199043A0248|90 93|case
P03199043A0248|101 125|permeability coefficients
P03199043A0248|128 142|transport rates
P03199043A0248|150 171|diffusion coefficients
P03199043A0248|179 188|resistance
P03199043A0248|195 203|constants
P03199436A1060|9 21|gene clusters
P03199436A1060|29 53|photosynthesis components
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|87 104|psbE-psbF clusters
P03200488A0439|3 9|results
P03200488A0439|30 32|TIQ
P03200488A0439|43 55|turnover rate
P03200488A0439|73 88|dopamine neurons
P03200488A0439|101 114|administration
P03200488A0439|123 128|period
P03200488A0439|131 134|mice
P03200844A1211|10 17|sequence
P03200844A1211|36 52|pore glycoprotein
P03200844A1211|63 72|similarity
P03200844A1211|93 100|proteins
P03200844A1211|124 131|features
P03200844A1211|135 140|member
P03200844A1211|146 151|family
P03200844A1211|161 178|pore glycoproteins
P03207975A0709|11 15|hours
P03207975A0709|21 34|administration
P03207975A0709|37 46|vitamin K1
P03207975A0709|47 67|plasma concentrations
P03207975A0709|72 78|vitamin
P03208493A0849|13 27|filtration rate
P03208493A0849|42 58|lithium clearance
P03208493A0849|66 66|%
P03209019A0662|14 31|promotion bioassay
P03209019A0662|32 37|groups
P03209019A0662|46 54|CD-1 mice
P03209019A0662|75 84|microliter
P03209019A0662|93 96|DMBA
P03209019A0662|101 105|mg/ml
P03209019A0662|109 115|acetone
P03209019A0662|127 131|weeks
P03209019A0662|155 158|week
P03209019A0662|163 175|test material
P03209019A0662|192 196|weeks
P03212551T0001|3 14|pathogenesis
P03212551T0001|17 25|Dupuytren
P03212551T0001|28 38|contracture
P03212929A0000|2 16|ELISA procedure
P03212929A0000|52 63|IgE response
P03212929A0000|65 68|dogs
P03212929A0000|71 99|Dirofilaria immitis infection
P03214709A0559|5 7|min
P03214709A0559|13 19|release
P03214709A0559|24 29|stress
P03214709A0559|42 69|plasma corticosterone levels
P03214709A0559|77 82|stress
P03214709A0559|103 107|group
P03214709A0559|138 142|group
P03216131A0559|7 13|isolate
P03216131A0559|16 35|Aeromonas hydrophila
P03216131A0559|52 62|enterotoxin
P03218714A0000|14 17|girl
P03218714A0000|31 55|Dandy-Walker malformation
P03218714A0000|56 58|DWM
P03218714A0000|74 82|tetralogy
P03218714A0000|85 90|Fallot
P03218714A0000|92 94|TOF
P03219107A0212|3 11|incidence
P03219107A0212|27 37|convulsions
P03219107A0212|47 52|babies
P03219107A0212|68 73|births
P03220077A0274|9 16|survival
P03220077A0274|49 52|time
P03220077A0274|58 62|years
P03223123T0001|8 17|evaluation
P03223123T0001|27 33|methods
P03223123T0001|47 53|markers
P03223123T0001|61 68|maturity
P03223123T0001|79 83|fluid
P03227288A0542|7 13|infants
P03227288A0542|29 32|loss
P03227288A0542|55 60|months
P03227288A0542|70 72|age
P03227568T0001|0 6|Variety
P03227568T0001|9 12|cows
P03227568T0001|16 20|sires
P03227568T0001|32 36|types
P03227568T0001|39 53|dermatoglyphics
P03227568T0001|55 62|patterns
P03227568T0001|80 85|mirror
P03227568T0001|88 93|cattle
P03228518A0339|38 44|samples
P03228518A0339|55 62|Academic
P03228518A0339|64 86|Personal Responsibility
P03228518A0339|110 119|dimensions
P03228785A1047|0 7|Recovery
P03228785A1047|31 41|improvement
P03228785A1047|61 70|parameters
P03228785A1047|84 87|week
P03228785A1047|120 123|area
P03228785A1047|149 153|weeks
P03228785A1047|161 163|cm2
P03228785A1047|165 165|p
P03228785A1047|184 190|control
P03228785A1047|194 201|ABSTRACT
P03228785A1047|216 220|WORDS
P03229917A0099|26 34|resection
P03229917A0099|57 73|remnant infection
P03232410A1467|33 37|cases
P03232410A1467|40 50|lung cancer
P03232410A1467|69 72|year
P03232410A1467|89 95|smoking
P03233862T0000|0 19|Neuromyelitis optica
P03233862T0000|27 34|syndrome
P03233862T0000|54 62|sclerosis
P03234790T0001|0 5|Effect
P03234790T0001|11 17|methods
P03234790T0001|29 42|administration
P03234790T0001|45 66|methyl isobutyl ketone
P03234790T0001|70 77|toxicity
P03235487A0404|0 12|Incorporation
P03235487A0404|23 51|M sodium dihydrogen phosphate
P03235487A0404|54 68|sugar solutions
P03235487A0404|79 86|decrease
P03235487A0404|92 101|shelf-life
P03235487A0404|104 112|diltiazem
P03237446A0377|0 3|None
P03237446A0377|12 18|history
P03237446A0377|34 43|infections
P03237446A0377|62 72|lymphopenia
P03239106A0856|13 30|phosphorus content
P03239106A0856|35 38|diet
P03239106A0856|50 61|reabsorption
P03239106A0856|64 70|calcium
P03239106A0856|74 82|magnesium
P03243027T0000|20 29|regulation
P03243027T0000|41 63|protein gene expression
P03243027T0000|68 78|development
P03243027T0000|81 104|Dictyostelium discoideum
P03243920A0591|20 60|plasma concentration-effect relationships
P03243920A0591|89 96|modeling
P03243920A0591|106 115|regression
P03246999A0483|3 10|increase
P03246999A0483|13 22|amplitudes
P03246999A0483|28 33|b-wave
P03246999A0483|43 59|adaptation period
P03246999A0483|89 96|subjects
P03246999A0483|103 110|controls
P03249792A0241|8 14|factors
P03249792A0241|21 31|development
P03249792A0241|43 56|symptomatology
P03249792A0241|63 78|group activities
P03249792A0241|84 87|role
P03249792A0241|90 103|group dynamics
P03249792A0241|111 124|stress factors
P03249792A0241|147 155|psychoses
P03249792A0241|174 187|manifestations
P03249840A0411|0 20|Baseline measurements
P03249840A0411|38 43|volume
P03249840A0411|47 47|s
P03249840A0411|49 52|FEV1
P03249840A0411|63 80|airway conductance
P03249840A0411|81 84|SGaw
P03249840A0411|103 106|dose
P03249840A0411|109 117|carbachol
P03249840A0411|128 138|% reduction
P03249840A0411|140 143|SGaw
P03249840A0411|145 148|PD35
P03249840A0411|157 167|% reduction
P03249840A0411|169 172|FEV1
P03249840A0411|174 177|PD20
P03249840A0411|196 200|entry
P03249840A0411|210 216|subject
P03249840A0411|225 231|smoking
P03251210A0981|4 11|children
P03251210A0981|16 18|BGC
P03251210A0981|36 46|development
P03251210A0981|51 64|calcifications
P03251210A0981|96 100|forms
P03251210A0981|113 123|dysfunction
P03253219T0000|6 12|voltage
P03253219T0000|33 37|leads
P03253219T0000|40 67|anthracycline cardiomyopathy
P03253219T0000|77 81|study
P03256150A1866|3 9|results
P03256150A1866|32 43|requirements
P03256150A1866|47 50|task
P03257146A1037|5 11|results
P03257146A1037|24 28|CSFHU
P03257146A1037|40 56|neutrophil counts
P03257146A1037|71 76|number
P03257146A1037|80 87|maturity
P03257146A1037|93 120|marrow neutrophil precursors
P03257146A1037|125 129|types
P03257146A1037|132 140|childhood
P03257146A1037|148 158|neutropenia
P03258069A0000|3 10|purposes
P03258069A0000|17 21|study
P03258069A0000|40 45|effect
P03258069A0000|52 60|intensity
P03258069A0000|65 73|frequency
P03258069A0000|98 114|nerve stimulation
P03258069A0000|125 142|acupuncture points
P03258069A0000|156 169|pain threshold
P03258069A0000|182 186|wrist
P03258069A0000|206 212|changes
P03258069A0000|215 220|effect
P03258069A0000|225 228|time
P03259437A0140|13 46|neonates serum alpha-amylase value
P03259437A0140|66 78|starch method
P03259437A0140|88 88|%
P03259437A0140|102 109|controls
P03259437A0140|118 122|value
P03259437A0140|137 140|IU/l
P03259437A0140|151 158|neonates
P03259437A0140|182 182|p
P03259437A0140|205 209|value
P03259437A0140|223 226|IU/l
P03259437A0140|241 248|neonates
P03261005A0216|0 6|Records
P03261005A0216|11 18|children
P03261005A0216|23 26|AIDS
P03261005A0216|41 47|complex
P03261005A0216|79 87|care unit
P03261005A0216|106 112|failure
P03261005A0216|132 137|period
P03261223A0644|8 15|patients
P03261223A0644|35 47|disease group
P03261223A0644|64 68|SPECT
P03261223A0644|76 78|TCT
P03261331A0563|0 4|SPECT
P03261331A0563|18 20|aid
P03261331A0563|26 34|diagnosis
P03261331A0563|37 57|AIDS dementia complex
P03261331A0563|75 87|understanding
P03261331A0563|111 120|mechanisms
P03261331A0563|127 134|disorder
P03263357A0112|29 40|relationship
P03263357A0112|60 65|rhythm
P03263357A0112|68 83|body temperature
P03263357A0112|90 99|variations
P03263357A0112|102 122|plasma concentrations
P03263357A0112|124 127|iron
P03263357A0112|129 132|zinc
P03263357A0112|145 160|leukocyte counts
P03263357A0112|164 181|plasma interleukin
P03263357A0112|183 186|IL-1
P03263357A0112|188 195|activity
P03263465T0000|9 17|MHC class
P03263465T0000|18 22|genes
P03263465T0000|24 28|H-2Dq
P03263465T0000|32 36|H-2Lq
P03263465T0000|73 77|H-2Ld
P03263465T0000|85 89|genes
P03263465T0000|120 127|antigens
P03264073A0224|9 19|derivatives
P03264073A0224|32 37|series
P03264073A0224|69 76|activity
P03264073A0224|111 121|albino mice
P03264073A0224|135 142|activity
P03264073A0224|145 155|albino rats
P03264299A0679|11 14|mice
P03264299A0679|28 35|activity
P03264299A0679|48 58|macrophages
P03264299A0679|75 77|day
P03264299A0679|81 84|days
P03264299A0679|90 101|ip injection
P03264886A0000|6 15|population
P03264886A0000|24 31|children
P03264886A0000|38 42|years
P03264886A0000|45 47|age
P03264886A0000|50 55|medium
P03264886A0000|61 65|towns
P03264886A0000|74 78|areas
P03264886A0000|94 100|Germany
P03264886A0000|109 109|%
P03264886A0000|111 115|cases
P03264886A0000|118 122|croup
P03264886A0000|146 158|months period
P03264886A0000|174 183|physicians
P03267732A0788|15 33|Ga-fbg scintigraphy
P03267732A0788|46 51|method
P03267732A0788|106 112|thrombi
P03267732A0788|132 137|effect
P03267732A0788|153 159|therapy
P03268555T0000|7 16|assessment
P03268555T0000|22 37|biocompatibility
P03268555T0000|46 54|materials
P03268555T0000|60 82|millipore filter method
P03270085A0382|0 13|Hypomagnesemia
P03270085A0382|22 38|magnesium wasting
P03270085A0382|43 48|kidney
P03274204A0642|0 11|Dentalplaque
P03274204A0642|42 46|index
P03274204A0642|57 65|dentition
P03274204A0642|93 111|cent alkaline fuxin
P03275867A0187|0 3|GRFI
P03275867A0187|11 19|sequences
P03275867A0187|43 50|elements
P03275867A0187|52 60|silencers
P03275867A0187|73 94|mating type loci HML E
P03275867A0187|94 98|HMR E
P03275867A0187|124 131|sequence
P03275867A0187|133 135|UAS
P03275867A0187|148 160|transcription
P03275867A0187|166 180|MAT alpha genes
P03275873A0379|3 9|effects
P03275873A0379|17 25|mutations
P03275873A0379|28 41|RNA polymerase
P03275873A0379|43 50|activity
P03275873A0379|76 82|ability
P03275873A0379|91 95|genes
P03275873A0379|118 127|resistance
P03275873A0379|133 144|transfection
P03275873A0379|164 168|cells
P03276246A0037|11 13|use
P03276246A0037|42 48|colloid
P03276246A0037|54 63|blood cell
P03276246A0037|64 70|TAC-WBC
P03276246A0037|81 90|evaluation
P03276246A0037|93 104|appendicitis
P03276924A0090|12 17|tumors
P03276924A0090|29 41|rearrangement
P03276924A0090|56 64|insertion
P03276924A0090|75 89|MoMuLV provirus
P03278829A0082|3 13|indications
P03278829A0082|20 22|use
P03278829A0082|65 73|candidate
P03278829A0082|80 89|tip grafts
P03278829A0082|106 112|tension
P03278829A0082|120 128|deformity
P03280021A1615|12 13|dT
P03280021A1615|15 22|affinity
P03280021A1615|43 49|buffers
P03280021A1615|65 70|M NaCl
P03280021A1615|88 93|M NaBr
P03280021A1615|96 128|measure alpha log Kobsd/alpha log
P03280021A1615|126 129|NaBr
P03280021A1615|153 157|value
P03280021A1615|165 167|T/O
P03280807A0000|0 8|Mutations
P03280807A0000|14 24|suf12 locus
P03280807A0000|73 83|suppressors
P03280807A0000|88 107|frameshift mutations
P03280807A0000|109 115|glycine
P03280807A0000|117 119|GGX
P03280807A0000|124 130|proline
P03280807A0000|132 134|CCX
P03280807A0000|136 141|codons
P03280807A0000|151 153|UGA
P03280807A0000|157 178|UAG nonsense mutations
P03280807A1447|3 10|behavior
P03280807A1447|13 28|suf12-null/SUF12
P03280807A1447|30 42|heterozygotes
P03280807A1447|56 60|suf12
P03280807A1447|100 104|suf12
P03280807A1447|120 130|suppression
P03280807A1447|170 177|proteins
P03280807A1447|188 196|variation
P03280807A1447|216 220|SUF12
P03280807A1447|222 229|activity
P03280912T0000|0 22|Antituberculosis agents
P03280946A0375|11 26|immunity protein
P03280946A0375|46 48|35S
P03280946A0375|69 76|proteins
P03280946A0375|87 95|minicells
P03280946A0375|104 106|cni
P03280946A0375|118 137|lac promoter control
P03280946A0375|147 150|gene
P03280946A0375|167 184|expression vectors
P03280946A0375|192 198|control
P03280946A0375|202 226|bacteriophage T7 promoter
P03282232A0743|0 9|Antibodies
P03282232A0743|21 34|fusion protein
P03282232A0743|47 56|DP1A clone
P03282232A0743|79 82|DP-I
P03282232A0743|91 101|immunoblots
P03282813A0794|20 24|range
P03282813A0794|27 29|QO2
P03282813A0794|31 47|oxygen extraction
P03282813A0794|59 66|patients
P03282813A0794|71 74|ARDS
P03282813A0794|85 92|patients
P03282813A0794|116 122|failure
P03282813A0794|124 124|r
P03282813A0794|134 138|slope
P03282813A0794|147 147|r
P03282813A0794|157 161|slope
P03282813A0794|169 169|p
P03283881A0216|6 13|patients
P03283881A0216|24 37|hypersecretion
P03283881A0216|47 54|evidence
P03283881A0216|62 73|inflammation
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|28 39|hypogonadism
P03285764A0675|54 65|neuropathies
P03285764A0675|75 82|stenoses
P03285764A0675|100 107|leakages
P03285764A0675|126 129|role
P03285764A0675|148 155|cofactor
P03285764A0675|166 177|consequences
P03285764A0675|212 218|factors
P03285764A0675|253 260|failures
P03286611A1198|0 3|Yang
P03286611A1198|7 8|H.
P03287597T0000|9 16|function
P03287597T0000|22 35|prostate gland
P03292076A0820|7 17|endotoxemia
P03292076A0820|75 86|permeability
P03292076A0820|91 98|tendency
P03292076A0820|118 128|circulation
P03292076A0820|149 154|degree
P03292076A0820|157 170|refractoriness
P03292076A0820|193 204|hemodynamics
P03292076A0820|208 230|eicosanoid biosynthesis
P03292082A0486|2 9|contrast
P03292082A0486|25 38|concentrations
P03292082A0486|47 54|patients
P03292082A0486|59 64|tumors
P03292082A0486|84 89|system
P03292082A0486|103 112|meningioma
P03292082A0486|119 130|glioblastoma
P03292082A0486|141 149|neurinoma
P03293844T0000|0 3|Diet
P03293844T0000|13 18|eczema
P03296019T0000|0 17|Time delay effects
P03296019T0000|28 40|bond strength
P03296019T0000|54 63|Silicoater
P03296212A0603|3 8|future
P03296212A0603|11 18|research
P03296212A0603|23 32|interferon
P03296212A0603|54 58|areas
P03296212A0603|60 66|Efforts
P03296212A0603|116 122|synergy
P03296212A0603|147 151|terms
P03296212A0603|155 159|order
P03296212A0603|179 187|potential
P03296212A0603|190 192|IFN
P03296212A0603|194 201|research
P03296212A0603|225 229|agent
P03296212A0603|239 245|disease
P03296212A0603|269 283|tumor debulking
P03296212A0603|297 305|diagnosis
P03296212A0603|317 325|community
P03296212A0603|347 353|history
P03296212A0603|360 367|diseases
P03296212A0603|386 394|potential
P03296212A0603|408 413|agents
P03296212A0603|451 456|agents
P03296254A0556|5 15|differences
P03296254A0556|29 37|latamoxef
P03296254A0556|61 69|elevation
P03296254A0556|72 87|prothrombin time
P03296254A0556|112 121|depression
P03296254A0556|124 129|factor
P03296254A0556|135 144|factor VII
P03297181A0127|14 21|subjects
P03297181A0127|40 44|doses
P03297181A0127|54 60|release
P03297181A0127|62 63|RR
P03297181A0127|65 81|quinidine sulfate
P03297181A0127|91 97|release
P03297181A0127|99 100|SR
P03297181A0127|102 120|quinidine bisulfate
P03297181A0127|130 133|dose
P03297181A0127|141 147|product
P03297181A0127|152 155|food
P03297181A0127|157 160|SR-F
P03298134A0000|4 9|report
P03298134A0000|27 30|work
P03298134A0000|35 52|interferon alfa-2b
P03298134A0000|53 60|Intron A
P03298134A0000|61 75|Schering-Plough
P03298134A0000|82 90|treatment
P03298134A0000|98 110|cell leukemia
P03298134A0000|111 113|HCL
P03300118A0392|0 14|Oxygen delivery
P03300118A0392|17 27|base excess
P03300118A0392|56 59|pigs
P03304015T0000|8 16|chemistry
P03304866T0001|0 16|Revascularization
P03304866T0001|52 60|osteotomy
P03305875T0000|6 13|orthoses
P03305875T0000|20 29|management
P03305875T0000|32 42|microstomia
P03306340A0537|18 23|spread
P03306340A0537|29 37|carcinoma
P03306340A0537|58 65|invasion
P03306340A0537|68 76|carcinoma
P03306340A0537|78 85|hardness
P03306340A0537|91 94|body
P03306340A0537|98 101|tail
P03306340A0537|103 113|obstruction
P03306340A0537|130 133|duct
P03306340A0537|146 160|pancreaticogram
P03308909A0485|9 15|enzymes
P03308909A0485|27 35|cartilage
P03309892A0637|13 23|observation
P03309892A0637|37 38|S.
P03309892A0637|44 48|genes
P03309892A0637|72 76|yeast
P03309892A0637|93 113|actin gene transcript
P03309892A0637|125 135|nucleotides
P03309892A0637|149 169|initiation start site
P03309892A0637|187 191|yeast
P03311954A0000|12 16|study
P03311954A0000|34 45|institutions
P03311954A0000|71 78|efficacy
P03311954A0000|82 87|safety
P03311954A0000|90 99|ranitidine
P03311954A0000|103 111|mg b.i.d.
P03311954A0000|114 123|ranitidine
P03311954A0000|127 134|mg nocte
P03311954A0000|139 147|treatment
P03311954A0000|150 168|reflux oesophagitis
P03312033A0501|0 10|Monotherapy
P03312033A0501|15 25|ceftazidime
P03312033A0501|73 91|combination therapy
P03312033A0501|95 103|cefazolin
P03312033A0501|107 116|tobramycin
P03312514A0756|3 9|N3 wave
P03312514A0756|14 17|SSEP
P03312514A0756|69 76|recovery
P03312514A0756|90 90|%
P03312514A0756|96 96|%
P03312514A0756|102 122|preischemia amplitude
P03312514A0756|142 148|animals
P03312514A0756|162 162|%
P03312514A0756|168 168|%
P03312514A0756|180 184|group
P03312514A0756|190 190|%
P03312514A0756|196 196|%
P03312514A0756|202 216|control animals
P03315359A0732|0 10|Proctoscopy
P03315359A0732|30 36|studies
P03315359A0732|53 56|part
P03315359A0732|59 68|evaluation
P03315359A0732|82 89|patients
P03315359A0732|112 122|suppuration
P03315359A0732|124 129|masses
P03315359A0732|137 144|fissures
P03317796A0853|5 17|control group
P03317796A0853|32 38|picture
P03317796A0853|48 61|osteoarthritis
P03319621A0707|2 9|contrast
P03319621A0707|16 19|mRNA
P03319621A0707|23 23|%
P03319621A0707|26 30|alpha
P03319621A0707|34 49|beta actin mRNAs
P03319621A0707|68 76|myoblasts
P03319621A0707|80 87|myotubes
P03319646T0000|0 20|Plasma renin activity
P03319646T0000|52 59|efficacy
P03319646T0000|62 75|chlorthalidone
P03319912A0000|0 9|Cephradine
P03319912A0000|13 14|mg
P03319912A0000|17 21|night
P03319912A0000|27 32|months
P03319912A0000|44 63|prophylactic measure
P03319912A0000|73 80|patients
P03319912A0000|83 90|mean age
P03319912A0000|94 98|years
P03319912A0000|107 113|history
P03319912A0000|130 135|months
P03319912A0000|156 161|median
P03319912A0000|165 172|episodes
P03319912A0000|175 183|frequency
P03319912A0000|190 196|dysuria
P03320875A2090|24 31|Supramid
P03320875A2090|42 47|record
P03320875A2090|55 74|tissue compatibility
P03320875A2090|77 86|resistance
P03320875A2090|89 97|infection
P03322829A0952|3 6|size
P03322829A0952|12 16|group
P03322829A0952|35 53|compliance category
P03322829A0952|58 60|use
P03322829A0952|66 79|digoxin marker
P03322829A0952|94 97|size
P03322829A0952|101 105|group
P03322829A0952|108 115|patients
P03322829A0952|140 140|%
P03322829A0952|158 161|dose
P03322829A0952|173 181|deviation
P03322829A0952|193 193|%
P03322829A0952|203 214|prescription
P03325081A0524|7 17|keratopathy
P03325081A0524|37 42|origin
P03325081A0524|81 91|keratopathy
P03325081A0524|93 95|PBK
P03325081A0524|113 117|cause
P03325081A0524|127 137|keratopathy
P03326381A0423|18 25|findings
P03326381A0423|45 63|C-peptide excretion
P03326381A0423|88 94|effects
P03326381A0423|129 134|action
P03326381A0423|140 144|drugs
P03326381A0423|163 170|pancreas
P03329716A0187|3 10|activity
P03329716A0187|16 36|EGF receptor promoter
P03329716A0187|51 61|E1A protein
P03329716A0187|64 82|receptor RNA levels
P03329716A0187|92 102|stimulation
P03329716A0187|107 119|phorbol ester
P03329716A0187|126 135|calf serum
P03330711T0000|19 26|activity
P03330711T0000|29 32|neem
P03330711T0000|34 54|Azadirachta indica A.
P03331525T0001|9 13|study
P03331525T0001|16 30|dentin adhesion
P03331525T0001|32 40|adhesives
P03331525T0001|49 66|urethane molecules
P03331525T0001|74 79|groups
P03331525T0001|82 91|isocyanate
P03331933T0048|2 15|Felix Lagrange
P03332022A1094|8 33|cysteine clustering region
P03332022A1094|46 51|region
P03332022A1094|57 61|c-raf
P03332022A1094|66 72|product
P03332022A1094|87 105|nucleotide sequence
P03332022A1094|113 138|cysteine clustering region
P03332022A1094|192 197|region
P03332022A1094|200 215|protein kinase C
P03332022A1094|235 251|cysteine clusters
P03332848A0000|25 38|Doppler probes
P03332848A0000|63 70|analysis
P03332848A0000|94 116|carotid artery stenosis
P03334950A0000|3 16|German Society
P03334950A0000|18 35|Pediatric Oncology
P03334950A0000|53 69|Cooperative Ewing
P03334950A0000|71 83|Sarcoma Study
P03334950A0000|84 87|CESS
P03334950A0000|106 116|combination
P03334950A0000|119 130|chemotherapy
P03334950A0000|153 159|control
P03334950A0000|164 170|surgery
P03334950A0000|177 185|radiation
P03335127A0176|3 9|program
P03335127A0176|34 38|BASIC
P03335127A0176|41 45|order
P03335127A0176|55 63|procedure
P03335398A0568|9 14|levels
P03335398A0568|17 32|immunoglobulin G
P03335398A0568|58 64|surface
P03335398A0568|70 72|NVS
P03335398A0568|78 89|immunization
P03335398A0568|91 118|passive transfer experiments
P03335444A0000|1 5|study
P03335444A0000|26 29|male
P03335444A0000|44 50|mixture
P03335444A0000|53 57|241Am
P03335444A0000|61 62|Pu
P03335651A0000|10 15|method
P03335651A0000|30 48|parameter weighting
P03335651A0000|58 66|resonance
P03335651A0000|68 69|MR
P03335651A0000|71 77|imaging
P03335651A0000|102 108|concept
P03335651A0000|122 132|sensitivity
P03335651A0000|142 149|approach
P03335651A0000|175 181|indexes
P03335651A0000|185 186|T1
P03335651A0000|188 189|T2
P03335651A0000|194 211|hydrogen weighting
P03335923A0257|10 17|patients
P03335923A0257|33 38|groups
P03335923A0257|63 74|presentation
P03335923A0257|93 102|volunteers
P03335923A0257|106 113|patients
P03335923A0257|134 151|reflux gastropathy
P03335923A0257|152 154|DRG
P03335923A0257|159 166|patients
P03335923A0257|180 185|ulcers
P03335923A0257|199 202|bulb
P03335923A0257|204 206|RUD
P03335923A0257|214 221|patients
P03335923A0257|226 233|Moynihan
P03335923A0257|236 242|disease
P03337024A0000|10 16|studies
P03337024A0000|34 50|pharmaco-dynamics
P03337024A0000|64 75|procainamide
P03337024A0000|95 98|dose
P03337024A0000|103 107|mg/kg
P03337024A0000|114 117|rate
P03337024A0000|122 127|mg/min
P03337024A0000|139 146|practice
P03337024A0000|173 179|testing
P03338154T0000|4 17|concentrations
P03338154T0000|36 52|trypsin inhibitor
P03338154T0000|66 73|patients
P03340548A1018|5 17|chicken liver
P03340548A1018|18 23|levels
P03340548A1018|26 40|chicken MT mRNA
P03340548A1018|59 64|metals
P03340548A1018|66 68|Cd2
P03340548A1018|71 73|Zn2
P03340548A1018|76 78|Cu2
P03340548A1018|82 96|glucocorticoids
P03340548A1018|100 117|lipopolysaccharide
P03340726A1103|4 12|histology
P03340726A1103|16 20|Evans
P03340726A1103|25 34|injections
P03340726A1103|47 65|barrier alterations
P03340726A1103|83 86|days
P03340726A1103|93 96|dose
P03340726A1103|101 102|Gy
P03340774A0328|10 18|estimates
P03340774A0328|27 32|organs
P03340774A0328|58 60|rad
P03340774A0328|71 72|Gy
P03340774A0328|103 110|estimate
P03340774A0328|117 119|rad
P03340774A0328|125 126|Gy
P03343730A0486|12 22|association
P03343730A0486|31 44|family history
P03343730A0486|61 62|pH
P03343730A0486|88 109|calcium stone patients
P03344586T0000|0 15|New technologies
P03344586T0000|17 25|diagnosis
P03344586T0000|29 42|classification
P03344586T0000|45 54|malignancy
P03344812A0924|14 17|data
P03344812A0924|33 34|BP
P03344812A0924|38 52|HR measurements
P03344812A0924|89 95|factors
P03344812A0924|126 132|factors
P03344812A0924|160 164|state
P03344812A0924|176 177|BP
P03344812A0924|181 189|HR values
P03344812A0924|211 215|cycle
P03344812A0924|219 224|animal
P03344812A0924|243 251|influence
P03344812A0924|269 275|ranking
P03344812A0924|281 290|individual
P03344812A0924|293 294|BP
P03344812A0924|298 306|HR levels
P03344812A0924|315 324|population
P03345706A0561|3 13|correlation
P03345706A0561|21 25|PaCO2
P03345706A0561|29 33|PtcO2
P03345706A0561|36 38|RDS
P03345706A0561|68 76|judgement
P03346157A0000|14 18|times
P03346157A0000|34 42|ABCC/RERF
P03346157A0000|55 66|examinations
P03346157A0000|71 88|Adult Health Study
P03346157A0000|88 90|AHS
P03346157A0000|92 99|subjects
P03346157A0000|133 141|exposures
P03346157A0000|151 156|x-rays
P03346157A0000|174 185|institutions
P03346157A0000|195 198|RERF
P03346157A0000|201 205|order
P03346157A0000|219 225|numbers
P03346157A0000|228 239|examinations
P03346157A0000|256 260|doses
P03346210A0000|12 24|growth factor
P03346210A0000|25 27|EGF
P03346210A0000|29 36|receptor
P03346210A0000|60 91|protein tyrosine kinase activity
P03346210A0000|120 148|self-phosphorylation reaction
P03346210A0000|157 170|EGF activation
P03348382A0785|13 19|ouabain
P03348382A0785|42 45|HCO3
P03348382A0785|47 55|secretion
P03351478A0371|8 14|regions
P03351478A0371|23 26|runs
P03351478A0371|35 37|% C
P03351478A0371|41 52|% G residues
P03352254A0203|15 23|structure
P03352254A0203|32 41|prediction
P03352254A0203|64 69|vowels
P03352254A0203|80 88|syllables
P03352439T0000|5 33|cord abduction rehabilitation
P03352439T0000|50 60|anastomosis
P03352727T0000|0 1|UK
P03352727T0000|4 16|biotechnology
P03352727T0000|24 34|specialists
P03352947T0001|1 4|case
P03352947T0001|19 25|complex
P03352947T0001|27 33|ARC/LAS
P03352947T0001|38 50|health worker
P03354295A0157|7 12|spread
P03354295A0157|25 32|patients
P03354295A0157|36 36|%
P03354295A0157|50 57|serum Tg
P03354295A0157|70 81|micrograms/l
P03354341A0177|13 27|filtration rate
P03354341A0177|44 54|plasma flow
P03354341A0177|79 94|clearance method
P03354341A0177|114 121|infusion
P03354341A0177|124 129|inulin
P03354341A0177|151 154|acid
P03355122A0238|8 11|meal
P03355122A0238|22 27|potato
P03355122A0238|29 49|plasma glucose levels
P03355122A0238|73 75|min
P03355122A0238|95 100|levels
P03355122A0238|105 105|h
P03359860A0000|3 11|relations
P03359860A0000|54 68|characteristics
P03359860A0000|75 84|aggression
P03359860A0000|86 92|anxiety
P03359860A0000|94 108|undercompliance
P03359860A0000|120 123|mood
P03359860A0000|128 137|adjustment
P03359860A0000|157 159|use
P03359860A0000|162 165|data
P03359860A0000|184 210|New York Longitudinal Study
P03360667A0000|13 18|effect
P03360667A0000|21 28|altitude
P03360667A0000|41 46|growth
P03360667A0000|50 60|development
P03360667A0000|67 72|groups
P03360667A0000|97 101|youth
P03360667A0000|124 129|status
P03360667A0000|139 146|grouping
P03360667A0000|159 167|sea level
P03360667A0000|168 168|n
P03360667A0000|174 181|subjects
P03360667A0000|184 195|mid-altitude
P03360667A0000|197 197|n
P03360667A0000|203 210|subjects
P03360667A0000|220 227|altitude
P03360667A0000|229 229|n
P03360667A0000|235 242|subjects
P03360948A0477|10 12|CAP
P03360948A0477|21 29|variables
P03360948A0477|49 56|behavior
P03360948A0477|70 81|relationship
P03360948A0477|103 105|CAP
P03360948A0477|112 119|MHI Loss
P03360948A0477|121 154|Behavioral/Emotional Control scale
P03361653A0459|17 22|system
P03361653A0459|33 52|contour digitization
P03361653A0459|79 89|limitations
P03361653A0459|114 120|objects
P03366720A1335|5 10|change
P03366720A1335|37 47|utilization
P03366720A1335|75 78|acid
P03366720A1335|91 100|metabolism
P03366720A1335|103 109|glucose
P03366720A1335|113 122|glycolysis
P03366864A0099|3 11|skin site
P03366864A0099|47 54|segments
P03366864A0099|60 67|catheter
P03366864A0099|81 85|blood
P03368701A0113|17 27|reliability
P03368701A0113|41 53|arteriography
P03368701A0113|63 67|place
P03368701A0113|70 75|choice
P03368701A0113|91 108|imaging techniques
P03370815T0000|5 13|detection
P03370815T0000|45 54|test serum
P03370815T0000|60 69|radioassay
P03370815T0000|72 82|vitamin B12
P03371139A0829|9 13|group
P03371139A0829|36 43|material
P03371139A0829|63 68|groups
P03371806A0000|10 24|data processing
P03371806A0000|25 27|EDP
P03371806A0000|29 45|latex immunoassay
P03371806A0000|67 82|acid phosphatase
P03371806A0000|99 103|serum
P03371806A0000|120 126|species
P03371806A0000|130 149|organ identification
P03371806A0000|163 168|stains
P03371894A0355|0 18|Vimentin positivity
P03371894A0355|62 71|components
P03372422A0558|3 21|maximum deflections
P03372422A0558|23 27|phase
P03372422A0558|33 34|Ar
P03372422A0558|38 39|N2
P03372422A0558|56 60|phase
P03372422A0558|64 69|slopes
P03372422A0558|91 98|position
P03372422A0558|121 145|tracer gas concentrations
P03372422A0558|153 157|lungs
P03373755T0001|6 17|developments
P03373755T0001|20 24|drugs
P03373755T0001|39 45|factors
P03373755T0001|59 63|ulcer
P03373755T0001|74 81|efficacy
P03373755T0001|85 92|problems
P03373755T0001|94 120|gastrin receptor blockaders
P03375184A0000|3 24|spermicide nonoxynol-9
P03375184A0000|27 32|member
P03375184A0000|46 51|series
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|78 95|polyethoxyethanols
P03375184A0000|106 125|formula C9H19-C6H6-O
P03375184A0000|127 133|CH2CH2O
P03375184A0000|135 146|n-1 CH2CH2OH
P03377864A0000|14 19|fields
P03377864A0000|29 37|diffusion
P03377864A0000|50 58|particles
P03377864A0000|61 69|solutions
P03377864A0000|80 92|Lorentz force
P03377864A0000|95 108|Maxwell stress
P03377891A0652|13 23|disturbance
P03377891A0652|43 59|life stress group
P03377891A0652|82 91|elevations
P03377891A0652|103 116|severity index
P03377891A0652|121 140|Symptom Checklist-90
P03377891A0652|143 152|elevations
P03377891A0652|155 166|somatization
P03377891A0652|201 211|sensitivity
P03377891A0652|213 222|depression
P03377891A0652|224 230|anxiety
P03377891A0652|234 255|psychoticism subscales
P03378994T0000|7 20|administration
P03378994T0000|23 36|sodium cyanate
P03378994T0000|47 62|extraction ratio
P03378994T0000|64 67|dogs
P03379058A0188|0 20|Nucleotide sequencing
P03379058A0188|37 55|E1 alpha cDNA clone
P03379058A0188|59 68|base pairs
P03379058A0188|69 70|bp
P03379058A0188|74 79|length
P03379058A0188|90 102|reading frame
P03379058A0188|108 109|bp
P03379058A0188|129 134|region
P03379058A0188|140 141|bp
P03380547A0169|0 2|SPA
P03380547A0169|7 15|PAG sites
P03380547A0169|32 39|aversion
P03381039A0364|2 9|contrast
P03381039A0364|14 16|MAN
P03381039A0364|39 50|distribution
P03381039A0364|57 61|range
P03381039A0364|84 89|micron
P03381039A0364|94 100|maximum
P03381039A0364|106 111|micron
P03382310A0903|8 20|technetium Tc
P03382310A0903|32 36|scans
P03382310A0903|39 46|patients
P03382310A0903|72 86|polyarthralgias
P03382310A0903|108 118|arthropathy
P03382310A0903|132 151|management decisions
P03382310A0903|175 182|outcomes
P03382772A0319|0 17|Practical interest
P03382772A0319|23 29|studies
P03382772A0319|62 71|parameters
P03382772A0319|100 102|man
P03382772A0319|109 113|phase
P03382772A0319|115 120|trials
P03382855A0368|3 13|artery cuff
P03382855A0368|40 43|wrap
P03382855A0368|70 78|adhesions
P03382855A0368|101 107|picture
P03383897A0189|17 22|action
P03383897A0189|29 45|radiation therapy
P03383897A0189|78 83|effect
P03383897A0189|86 97|leukopoiesis
P03383897A0189|128 137|conditions
P03383897A0189|143 150|patients
P03383897A0189|153 158|course
P03383897A0189|161 169|treatment
P03384033A0155|7 11|units
P03384033A0155|34 39|motion
P03384033A0155|46 47|Hz
P03384033A0155|52 55|cm/s
P03384033A0155|63 63|%
P03384033A0155|83 95|otolith input
P03384033A0155|107 107|%
P03384033A0155|134 138|input
P03384033A0155|153 153|%
P03384033A0155|170 179|modalities
P03384272A0145|14 21|location
P03384272A0145|25 28|size
P03384272A0145|34 37|mass
P03384272A0145|44 48|range
P03384272A0145|59 71|presentations
P03384272A0145|91 96|lesion
P03387665A0000|3 13|development
P03387665A0000|17 28|distribution
P03387665A0000|31 41|Trypanosoma
P03387665A0000|53 59|T vivax
P03387665A0000|62 69|T brucei
P03387665A0000|74 77|skin
P03387665A0000|80 84|goats
P03387665A0000|104 110|animals
P03387665A0000|131 158|Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03390074A0000|41 49|technique
P03390074A0000|68 77|assessment
P03390074A0000|89 99|dysfunction
P03395009A1750|11 18|analysis
P03395009A1750|24 30|degrees
P03395009A1750|48 63|cord compression
P03395009A1750|77 88|group-1 dogs
P03395009A1750|111 116|ratios
P03395009A1750|145 153|diameters
P03395009A1750|175 187|cord sections
P03395009A1750|191 199|locations
P03395009A1750|207 209|T12
P03395009A1750|212 213|L1
P03395009A1750|224 226|T11
P03395009A1750|228 233|T11-12
P03395009A1750|235 238|L1-2
P03395009A1750|243 244|L2
P03395009A1750|249 254|region
P03395009A1750|265 276|intervention
P03395164A0000|18 24|effects
P03395164A0000|35 46|compound WEB
P03395164A0000|50 51|FU
P03395249A1044|17 27|examination
P03395249A1044|48 60|proliferation
P03395249A1044|63 66|type
P03395249A1044|69 79|pneumocytes
P03395249A1044|82 85|dams
P03395249A1044|89 101|proliferation
P03395249A1044|116 120|cells
P03395249A1044|147 157|development
P03395249A1044|160 167|neonates
P03395249A1044|170 177|ABSTRACT
P03395249A1044|192 196|WORDS
P03396437A0321|7 14|problems
P03396437A0321|36 42|strains
P03396628A0207|9 26|observation period
P03396628A0207|34 38|weeks
P03396628A0207|52 56|spots
P03396628A0207|67 75|ventricle
P03396628A0207|78 88|BALB/c mice
P03396628A0207|112 116|weeks
P03396628A0207|123 126|mice
P03396628A0207|130 130|%
P03396628A0207|146 154|incidence
P03396628A0207|169 173|spots
P03396628A0207|191 195|weeks
P03396628A0207|203 206|mice
P03396628A0207|210 210|%
P03398433T0001|3 7|state
P03398433T0001|13 17|liver
P03398433T0001|31 35|forms
P03398433T0001|51 59|infection
P03398714A0594|13 14|RH
P03398714A0594|23 23|%
P03398714A0594|34 42|solvation
P03398714A0594|48 61|peroxy radical
P03398714A0594|84 90|radical
P03398714A0594|106 133|propagation transition state
P03398823A0459|3 9|effects
P03398823A0459|24 37|administration
P03398823A0459|43 56|mg/kg p-xylene
P03398823A0459|58 64|toluene
P03398823A0459|79 80|hr
P03398823A0459|90 95|effect
P03398823A0459|105 112|p-xylene
P03398823A0459|131 133|min
P03398823A0459|136 142|removal
P03398823A0459|150 157|exposure
P03400694A0245|0 7|PATIENTS
P03400694A0245|11 17|METHODS
P03400694A0245|19 30|Thallium-201
P03400694A0245|41 52|scintigraphy
P03400694A0245|67 70|rest
P03400694A0245|83 87|mg/kg
P03400694A0245|99 110|dipyridamole
P03400694A0245|121 127|minutes
P03400694A0245|132 139|patients
P03400694A0245|144 154|sarcoidosis
P03401060A0000|4 12|melanomas
P03402183A0171|3 11|TA muscle
P03402183A0171|28 32|forms
P03402183A0171|52 63|contractions
P03402183A0171|84 95|contractions
P03402183A0171|97 99|MVC
P03402183A0171|105 107|MVC
P03402183A0171|112 122|circulation
P03402183A0171|153 164|contractions
P03402183A0171|171 172|Hz
P03402183A0171|185 203|voltage stimulation
P03402183A0171|227 238|contractions
P03402183A0171|243 253|circulation
P03403313A0298|17 29|control rates
P03403313A0298|33 37|years
P03403313A0298|49 64|treatment groups
P03403313A0298|86 93|excision
P03403313A0298|102 102|%
P03403313A0298|112 119|excision
P03403313A0298|137 153|radiation therapy
P03403313A0298|156 156|%
P03403313A0298|166 173|excision
P03403313A0298|182 182|%
P03403412A0000|3 9|effects
P03403412A0000|20 27|implants
P03403412A0000|30 33|rate
P03403412A0000|35 45|composition
P03403412A0000|58 67|efficiency
P03403412A0000|70 75|growth
P03403412A0000|98 106|fed diets
P03403412A0000|115 120|forage
P03403412A0000|124 136|grain content
P03403480A0299|9 18|suspension
P03403480A0299|38 43|change
P03403480A0299|58 70|configuration
P03403480A0299|76 93|femur middiaphysis
P03403480A0299|115 122|diameter
P03403480A0299|126 126|%
P03403480A0299|149 159|alterations
P03403480A0299|170 173|area
P03403480A0299|175 181|density
P03403480A0299|183 189|mineral
P03403480A0299|194 216|collagen concentrations
P03403826T0000|77 88|measurements
P03403826T0000|91 107|stenosis severity
P03403826T0000|109 118|comparison
P03403826T0000|133 140|analysis
P03403826T0000|154 166|cineangiogram
P03403826T0000|187 198|flow reserve
P03403826T0000|201 249|exercise/redistribution thallium-201 scintigraphy
P03404334T0000|0 12|Water content
P03404334T0000|15 41|equilibrium water partition
P03404334T0000|50 58|cartilage
P03404495A0172|0 21|Thyroid function tests
P03404495A0172|38 47|admissions
P03406054A0351|0 3|Data
P03406054A0351|9 28|line spread function
P03406054A0351|28 30|LSF
P03406054A0351|51 55|image
P03406054A0351|62 63|mm
P03406054A0351|68 71|slit
P03406054A0351|79 86|tungsten
P03406054A0351|116 124|isocentre
P03406054A0351|127 131|front
P03406054A0351|135 145|polystyrene
P03407676A0585|7 15|infection
P03407843T0000|0 5|Papers
P03407843T0000|11 17|Society
P03407843T0000|37 43|Surgery
P03413681A0659|8 20|heart disease
P03413681A0659|21 23|age
P03413681A0659|36 40|years
P03413681A0659|48 51|fact
P03413681A0659|59 65|patient
P03413681A0659|70 74|woman
P03413681A0659|90 99|predictors
P03413681A0659|113 120|function
P03413890T0001|0 8|Prognosis
P03413890T0001|11 15|Bowen
P03413890T0001|18 24|disease
P03413890T0001|50 55|region
P03417104A0536|17 23|results
P03417104A0536|35 50|chlorphentermine
P03417104A0536|78 93|stimulus effects
P03417104A0536|95 101|animals
P03417588T0000|0 5|Liquid
P03417588T0000|21 26|method
P03417588T0000|30 42|determination
P03417588T0000|45 57|citreoviridin
P03417588T0000|60 63|corn
P03417588T0000|67 70|rice
P03417668A1233|5 12|findings
P03417668A1233|25 43|autophosphorylation
P03417668A1233|46 51|Thr286
P03417668A1233|53 65|alpha subunit
P03417668A1233|69 74|Thr287
P03417668A1233|76 87|beta subunit
P03417668A1233|104 113|transition
P03417668A1233|116 128|CaM-kinase II
P03417668A1233|133 135|Ca2
P03417668A1233|149 152|form
P03418727A0992|21 31|penetration
P03418727A0992|59 70|chemotherapy
P03418727A0992|79 85|insight
P03418727A0992|93 102|myelopathy
P03418727A0992|120 129|treatments
P03420266A0000|3 13|interaction
P03420266A0000|16 24|radiation
P03420266A0000|28 39|hyperthermia
P03420266A0000|69 82|Dunning R3327G
P03420266A0000|91 104|adenocarcinoma
P03420266A0000|119 130|animal model
P03420266A0000|147 152|cancer
P03420324A0178|8 11|rats
P03420324A0178|33 41|following
P03420324A0178|48 48|%
P03420324A0178|53 54|N2
P03420324A0178|60 60|%
P03420324A0178|67 70|days
P03420324A0178|82 84|day
P03420324A0178|99 107|pregnancy
P03420324A0178|114 114|%
P03420324A0178|119 120|N2
P03420324A0178|126 126|%
P03420324A0178|134 148|h/day beginning
P03420324A0178|150 152|day
P03420324A0178|165 165|%
P03420324A0178|170 171|N2
P03420324A0178|195 197|day
P03420324A0178|204 206|day
P03420466A0000|3 11|incidence
P03420466A0000|14 30|cryptosporidiosis
P03420466A0000|38 45|children
P03420466A0000|61 68|staining
P03420466A0000|77 85|specimens
P03420466A0000|99 105|Kinyoun
P03421425A0878|5 12|patients
P03421425A0878|17 23|percent
P03421425A0878|34 47|hypothyroidism
P03421425A0878|72 85|determinations
P03423732A0341|0 7|Addition
P03423732A0341|10 19|sucralfate
P03423732A0341|22 27|De-Nol
P03423732A0341|38 47|increments
P03423732A0341|57 70|HCO3 secretion
P03423732A0341|86 86|%
P03423732A0341|92 92|%
P03423732A0341|119 131|HCO3 response
P03423732A0341|147 150|PGE2
P03423732A0341|152 157|dmPGE2
P03427474A0853|15 26|control rats
P03427474A0853|34 40|animals
P03427474A0853|51 58|aversion
P03427474A0853|71 84|concentrations
P03427474A0853|87 105|saccharin solutions
P03427613A0659|30 35|system
P03427613A0659|44 50|vessels
P03427613A0659|75 86|pineal organ
P03427613A0659|94 101|portions
P03427613A0659|107 111|brain
P03428084A0430|4 18|degrees stimuli
P03428084A0430|35 53|scalp distributions
P03428084A0430|59 79|pattern reversal P100
P03428084A0430|84 99|pattern onset C1
P03428084A0430|112 118|striate
P03428084A0430|148 154|origins
P03428274A0000|7 12|factor
P03428274A0000|17 21|NFIII
P03428274A0000|26 32|protein
P03428274A0000|37 46|HeLa cells
P03428274A0000|63 72|initiation
P03428274A0000|75 89|adenovirus type
P03428274A0000|91 93|Ad2
P03428274A0000|95 109|DNA replication
P03428274A0000|129 147|nucleotide sequence
P03428274A0000|152 157|origin
P03428274A0000|179 184|factor
P03428274A0000|186 201|recognition site
P03429306T0000|1 11|Golgi study
P03429306T0000|21 25|layer
P03429306T0000|39 44|cortex
P03429371A1051|14 34|cephalothin clearance
P03429371A1051|49 52|site
P03429371A1051|65 74|phagocytes
P03429371A1051|122 125|site
P03430221A1236|3 10|findings
P03430221A1236|28 34|context
P03430221A1236|42 51|properties
P03430221A1236|66 74|detectors
P03434347A0358|0 8|Mean rCBF
P03434347A0358|23 30|patients
P03434347A0358|34 38|weeks
P03434347A0358|44 50|surgery
P03434347A0358|67 70|side
P03436119A0000|20 29|tomography
P03436119A0000|51 70|bone mineral content
P03436119A0000|79 89|sensitivity
P03436119A0000|93 107|reproducibility
P03436529A1066|3 11|structure
P03436529A1066|17 24|enhancer
P03436529A1066|50 53|pair
P03436529A1066|78 98|oligodeoxynucleotides
P03436529A1066|118 123|region
P03436529A1066|131 142|nt positions
P03436529A1066|167 174|template
P03436529A1066|189 196|enhancer
P03436877A0950|0 1|Kf
P03436877A0950|3 3|c
P03436877A0950|7 8|CT
P03436877A0950|32 40|lung mass
P03436877A0950|62 71|reductions
P03436877A0950|74 93|lung mass % delta Kf
P03436877A0950|91 91|c
P03436877A0950|102 107|% mass
P03436877A0950|115 115|r
P03436877A0950|122 122|P
P03436877A0950|139 148|% delta CT
P03436877A0950|158 163|% mass
P03436877A0950|171 171|r
P03436877A0950|178 178|P
P03436877A0950|192 204|relationships
P03436877A0950|225 244|blocker pretreatment
P03436877A0950|246 253|ABSTRACT
P03436877A0950|268 272|WORDS
P03439248A0000|16 22|methods
P03439248A0000|31 42|dipyridamole
P03439248A0000|46 66|exercise thallium-201
P03439248A0000|76 92|perfusion imaging
P03439248A0000|120 134|artery stenosis
P03439248A0000|150 157|patients
P03439248A0000|179 192|artery disease
P03440780A0779|9 15|results
P03440780A0779|34 37|EDLF
P03440780A0779|46 71|vasoconstrictor properties
P03440780A0779|99 122|calcium entry mechanisms
P03440780A0779|136 146|differences
P03440780A0779|152 174|vasoconstrictor effects
P03440780A0779|176 180|EDLFs
P03440780A0779|185 191|respect
P03440780A0779|211 214|beds
P03441587A0000|0 7|Research
P03441587A0000|36 42|factors
P03441587A0000|48 52|serum
P03441587A0000|58 65|patients
P03441587A0000|68 72|means
P03441587A0000|78 82|tests
P03441587A0000|92 102|polystyrene
P03441587A0000|113 124|erythrocytes
P03441587A0000|132 138|results
P03441587A0000|165 170|method
P03441587A0000|173 181|reference
P03443144A0409|4 28|aspirin esterase activity
P03443144A0409|45 50|factor
P03443144A0409|71 77|aspirin
P03443144A0409|87 95|reactions
P03443566A0675|6 16|experiments
P03443566A0675|30 33|gain
P03443566A0675|37 54|gain-to-feed ratio
P03443566A0675|68 69|TR
P03443566A0675|73 74|CR
P03443573A0329|7 19|least-squares
P03443573A0329|45 62|longissimus muscle
P03443573A0329|77 79|fat
P03443573A0329|103 104|mg
P03443573A0329|122 122|g
P03443573A0329|125 130|tissue
P03443609A0000|3 6|role
P03443609A0000|22 41|fluid chromatography
P03443609A0000|42 44|SFC
P03443609A0000|55 63|technique
P03443609A0000|88 95|products
P03443609A0000|138 155|column methodology
P03446332A0831|0 12|Nitrofurazone
P03446332A0831|36 39|rise
P03446332A0831|42 43|LH
P03446332A0831|53 56|LHRH
P03448035T0000|7 12|tumors
P03448035T0000|15 23|pregnancy
P03449358T0001|15 19|study
P03449358T0001|22 34|polyarteritis
P03450438A0446|0 6|X2 test
P03450438A0446|11 26|Yates correction
P03450438A0446|28 31|need
P03450438A0446|54 59|method
P03451761A0215|6 19|baseline study
P03451761A0215|20 31|WPW syndrome
P03451761A0215|45 55|stimulation
P03451761A0215|72 76|sites
P03451761A0215|86 89|base
P03451761A0215|95 104|ventricles
P03451761A0215|109 111|RNV
P03452920T0001|0 2|Man
P03452920T0001|6 11|insect
P03452920T0001|13 16|past
P03457330A0271|3 10|patients
P03457330A0271|17 18|CA
P03457330A0271|22 26|assay
P03457330A0271|45 48|week
P03457330A0271|71 79|operation
P03459385T0000|0 6|Allergy
P03459385T0000|10 17|Tourette
P03459385T0000|20 27|syndrome
P03459736A0184|3 11|criterion
P03459736A0184|30 37|sessions
P03459736A0184|41 54|generalization
P03459736A0184|58 64|variety
P03459736A0184|67 71|pills
P03459736A0184|75 82|capsules
P03463537T0001|8 13|method
P03463537T0001|20 28|treatment
P03463537T0001|31 35|Class
P03463537T0001|46 54|anomalies
P03463537T0001|63 66|bite
P03463543A1613|0 7|Enoxacin
P03463543A1613|35 43|treatment
P03463543A1613|57 59|UTI
P03465957A1008|0 20|Mean fluorosis scores
P03466730A0210|9 20|dysfunctions
P03466730A0210|42 47|pupils
P03473253A0000|28 49|cohort mortality study
P03473253A0000|67 82|chemical workers
P03473253A0000|123 152|chloromethyl ether manufacture
P03473253A0000|159 172|U.S. companies
P03473379A0183|3 11|diagnosis
P03473379A0183|14 24|amyloidosis
P03473379A0183|57 68|gland biopsy
P03476002A0148|0 3|Hair
P03476002A0148|7 19|blood samples
P03476002A0148|34 42|vitamin C
P03476002A0148|44 66|placebo supplementation
P03476002A0148|88 96|intervals
P03476002A0148|115 120|months
P03478354A0436|9 13|herds
P03478354A0436|15 18|cows
P03478354A0436|29 40|d postpartum
P03478354A0436|45 57|corpus luteum
P03478354A0436|65 86|prostaglandin F2 alpha
P03479897A0961|10 13|hand
P03479897A0961|28 36|angle ANB
P03479897A0961|62 66|angle
P03479897A0961|79 86|relation
P03479897A0961|89 97|Class III
P03484075T0001|0 18|Emergency treatment
P03484075T0001|49 56|injuries
P03484894A0782|4 8|cases
P03484894A0782|10 17|isolates
P03484894A0782|47 53|biotype
P03484894A0782|65 71|biotype
P03484894A0782|90 97|biotypes
P03484894A0782|103 104|V.
P03485064A0135|1 5|total
P03485064A0135|11 24|EVS treatments
P03485064A0135|41 48|patients
P03486405A0341|19 25|portion
P03486405A0341|31 51|precursor polypeptide
P03486405A0341|74 78|exons
P03486405A0341|92 95|form
P03486405A0341|98 107|IL-1 alpha
P03486405A0341|135 139|exons
P03487348A0000|11 17|version
P03487348A0000|20 26|Kernell
P03487348A0000|40 44|model
P03487348A0000|59 80|afterhyperpolarization
P03487348A0000|82 84|AHP
P03488532A0235|18 23|report
P03488532A0235|41 50|resolution
P03488532A0235|53 68|dermatomal signs
P03488532A0235|71 78|symptoms
P03488532A0235|83 101|acyclovir treatment
P03491190A0233|3 15|detectability
P03491190A0233|21 27|defects
P03491190A0233|30 32|RCA
P03491190A0233|35 44|LAD region
P03491190A0233|49 49|%
P03491190A0233|67 71|scans
P03491190A0233|74 87|stress studies
P03493240T0000|13 22|properties
P03493240T0000|37 42|agents
P03493240T0000|60 64|drugs
P03494649A0472|20 28|challenge
P03494649A0472|42 49|increase
P03494649A0472|52 54|CBF
P03494649A0472|60 66|absence
P03494649A0472|72 77|change
P03494649A0472|80 83|MABP
P03499608A1054|5 8|data
P03499608A1054|35 42|reagents
P03499608A1054|46 67|heterozygote detection
P03499608A1054|78 86|diagnosis
P03499608A1054|91 117|beta-hydroxylase deficiency
P03499608A1054|139 143|cause
P03499608A1054|163 173|hyperplasia
P03499657A0000|0 10|Osteocalcin
P03499657A0000|12 33|serum bone-Gla protein
P03499657A0000|33 36|sBGP
P03499657A0000|39 64|serum alkaline phosphatase
P03499657A0000|64 66|sAP
P03499657A0000|78 108|hydroxyproline/creatinine ratio
P03499657A0000|109 127|uOH-Prol/creatinine
P03499657A0000|149 156|patients
P03499657A0000|168 186|hyperparathyroidism
P03499657A0000|188 191|PHPT
P03499657A0000|202 209|patients
P03499657A0000|214 227|hypercalcaemia
P03499657A0000|230 239|malignancy
P03499657A0000|241 242|HM
P03499822A0182|20 38|regression analysis
P03499822A0182|51 64|seropositivity
P03499822A0182|93 102|prevalence
P03499822A0182|105 115|hepatitis B
P03499822A0182|119 126|employee
P03499822A0182|129 135|country
P03499822A0182|138 142|birth
P03499822A0182|150 152|age
P03504971A0000|0 5|Hexsyn
P03504971A0000|11 23|Goodyear Tire
P03504971A0000|26 49|Rubber Company tradename
P03504971A0000|52 68|polyolefin rubber
P03504971A0000|98 114|% methylhexadiene
P03504971A0000|119 124|source
P03504971A0000|141 145|bonds
P03504971A0000|149 161|vulcanization
P03507689A0000|8 39|phage-plasmid expression vectors
P03507689A0000|57 73|pUC18/19 plasmids
P03507689A0000|98 100|DNA
P03507689A0000|102 106|ssDNA
P03507689A0000|108 113|origin
P03507689A0000|116 126|replication
P03507689A0000|131 146|bacteriophage f1
P03507689A0000|159 183|bacteriophage T7 promoter
P03507689A0000|191 213|beta-galactosidase gene
P03508698A0535|2 6|order
P03508698A0535|19 22|rate
P03508698A0535|24 37|finger flexors
P03508698A0535|38 40|jaw
P03508698A0535|49 57|adductors
P03508698A0535|62 77|triceps reflexes
P03508698A0535|109 114|groups
P03510185A0187|0 4|Natl.
P03513989A0580|7 13|ethanol
P03513989A0580|17 24|estrogen
P03513989A0580|44 58|UROD-deficiency
P03513989A0580|61 67|animals
P03513989A1149|21 28|disorder
P03513989A1149|57 67|disturbance
P03513989A1149|70 89|porphyrin metabolism
P03513989A1149|95 103|countries
P03513989A1149|115 121|insight
P03513989A1149|136 147|pathogenesis
P03513989A1149|172 178|effects
P03513989A1149|194 199|agents
P03515840A0000|25 29|cases
P03515840A0000|41 48|symptoms
P03515840A0000|60 68|granuloma
P03515840A0000|95 107|histiocytosis
P03515840A0000|120 126|sarcoma
P03515840A0000|140 145|months
P03515840A0000|149 153|years
P03515840A0000|159 172|generalization
P03515840A0000|176 180|death
P03516189A0406|3 10|patients
P03516189A0406|23 35|suxamethonium
P03516189A0406|39 50|mg kg-1 i.v.
P03517388A0763|23 33|CK-MB level
P03517388A0763|45 46|BC
P03517388A0763|48 49|BC
P03517388A0763|58 60|U/L
P03517388A0763|62 63|CC
P03517388A0763|72 74|U/L
P03517388A0763|76 76|p
P03520729A0381|10 16|changes
P03520729A0381|19 28|heart rate
P03520729A0381|29 39|body weight
P03520729A0381|43 55|plasma levels
P03520729A0381|57 70|renin activity
P03520729A0381|73 97|aldosterone concentration
P03522105A1011|4 34|trough serum TOB concentrations
P03522105A1011|50 54|death
P03522105A1011|65 70|levels
P03522105A1011|75 82|recovery
P03526279T0000|14 20|schools
P03526279T0000|23 34|nursing R.N.
P03528748A0414|3 17|maxicell system
P03528748A0414|18 24|protein
P03528748A0414|51 56|weight
P03531317A0930|16 19|loss
P03531317A0930|22 31|recessives
P03531317A0930|56 69|hypergeometric
P03531317A0930|85 89|model
P03531317A0930|92 97|Fisher
P03534581A0976|3 11|incidence
P03534581A0976|29 37|neoplasms
P03534581A0976|50 50|%
P03534581A0976|57 61|group
P03534581A0976|73 86|5-fluorouracil
P03534581A0976|88 98|doxorubicin
P03534581A0976|103 118|cyclophosphamide
P03534581A0976|138 150|control group
P03534581A0976|154 154|%
P03536682A0572|0 8|Ovulation
P03536682A0572|27 27|%
P03536682A0572|29 36|patients
P03536864A0000|10 13|work
P03537686A0099|8 11|size
P03537686A0099|15 23|placement
P03537686A0099|29 46|mutagenesis marker
P03537686A0099|50 74|supF suppressor tRNA gene
P03537686A0099|101 106|vector
P03537686A0099|130 138|frequency
P03537686A0099|152 160|mutations
P03537686A0099|182 193|transfection
P03537686A0099|205 209|cells
P03537686A0099|214 224|plasmid DNA
P03537686A0099|241 249|mutations
P03537686A0099|289 298|background
P03537711A0181|0 1|W.
P03537721A0491|6 13|analysis
P03537721A0491|24 48|recombination experiments
P03537721A0491|60 68|PEP4 gene
P03537721A0491|78 81|GAL4
P03537721A0491|84 97|chromosome XVI
P03537721A0876|10 21|observations
P03537721A0876|33 37|model
P03537721A0876|53 71|precursor molecules
P03537721A0876|86 108|PEP4 gene self-activate
P03537721A0876|116 128|yeast vacuole
P03537721A0876|164 173|hydrolases
P03537727A0243|3 6|poly
P03537727A0243|8 8|A
P03537727A0243|10 16|segment
P03537727A0243|22 24|RNA
P03537727A0243|79 85|protein
P03537727A0243|90 96|protein
P03540591A0330|7 17|translation
P03540591A0330|20 22|RNA
P03540591A0330|47 51|cDNAs
P03540591A0330|64 77|P0 transcripts
P03540591A0330|115 121|protein
P03540591A0330|149 161|reading frame
P03540853A0652|13 31|amino acid sequence
P03540853A0652|32 34|Mop
P03540853A0652|38 54|sequence homology
P03540853A0652|58 77|DNA binding proteins
P03541263A0368|10 19|techniques
P03541263A0368|45 51|control
P03541263A0368|54 61|diabetes
P03542945T0000|0 12|Ciprofloxacin
P03542945T0000|16 23|overview
P03542945T0000|33 43|experiences
P03543485A0069|20 29|mechanisms
P03543485A0069|43 49|changes
P03543485A0069|52 59|response
P03543485A0069|62 81|space flight effects
P03543936A0000|3 11|rho genes
P03543936A0000|44 49|family
P03543936A0000|65 72|homology
P03543936A0000|78 96|ras oncogene family
P03544858A0374|5 13|component
P03544858A0374|49 55|insulin
P03544858A0374|59 65|VO2 max
P03544858A0374|72 76|sexes
P03544858A0374|89 98|metabolism
P03544858A0374|102 116|HDL-cholesterol
P03544858A0374|120 126|females
P03544858A0374|130 134|males
P03545955A0751|3 15|glucose areas
P03545955A0751|27 35|ingestion
P03545955A0751|41 45|foods
P03545955A0751|51 55|Study
P03545955A0751|58 64|glucose
P03545955A0751|76 80|juice
P03545955A0751|85 91|sucrose
P03545955A0751|96 102|glucose
P03545955A0751|104 111|fructose
P03545955A0751|119 126|fructose
P03545955A0751|130 139|mmol X h/l
P03545955A0751|139 143|Study
P03545955A0751|146 152|glucose
P03545955A0751|164 168|juice
P03545955A0751|173 178|apples
P03545955A0751|186 196|apple juice
P03545955A0751|199 208|mmol X h/l
P03545955A0751|208 212|Study
P03545955A0751|215 221|glucose
P03545955A0751|227 235|ice cream
P03545955A0751|239 242|milk
P03545955A0751|250 256|lactose
P03545955A0751|260 269|mmol X h/l
P03545955A1378|3 24|serum insulin response
P03549045A0878|0 2|SCL
P03549045A0878|25 33|verapamil
P03549045A0878|38 49|sinus arrest
P03549045A0878|67 71|group
P03549045A0878|85 89|group
P03549045A0878|91 97|animals
P03550444T0000|0 10|Development
P03550444T0000|14 25|yeast system
P03550444T0000|27 31|assay
P03550444T0000|42 52|specificity
P03552363A0568|11 30|serum insulin levels
P03552363A0568|48 59|correlations
P03552363A0568|83 103|blood pressure levels
P03552363A0568|104 106|men
P03552363A0568|142 149|subjects
P03552363A0568|161 172|correlations
P03552363A0568|206 225|blood pressure level
P03553149A0299|30 40|mutagenesis
P03553149A0299|49 52|site
P03553149A0299|55 58|MucA
P03553149A0299|81 93|cleavage site
P03553149A0299|95 98|LexA
P03553439A0404|3 8|latter
P03553439A0404|32 35|Type
P03553439A0404|43 54|tumor tissue
P03553439A0404|90 100|tumor cells
P03553439A0404|101 104|Type
P03553439A0404|113 124|tumor tissue
P03553439A0404|156 166|tumor cells
P03553439A0404|167 170|Type
P03553439A0404|183 193|tumor cells
P03555318T0000|3 14|pharmacology
P03555318T0000|17 25|carnitine
P03556834T0000|5 23|inhalation toxicity
P03556834T0000|25 37|T-2 mycotoxin
P03556834T0000|39 42|mice
P03559193A0000|10 22|investigation
P03559193A0000|51 60|dimensions
P03559193A0000|66 80|Framingham Type
P03559193A0000|81 85|scale
P03559193A0000|87 90|FTAS
P03559193A0000|142 151|correlates
P03559232T0000|12 16|study
P03559232T0000|27 35|arthritis
P03559287T0000|0 9|Legionella
P03559287T0000|20 26|ecology
P03559287T0000|44 54|consumption
P03561036T0000|0 9|Lymphatics
P03561036T0000|15 19|aorta
P03561036T0000|22 25|rats
P03561036T0000|46 56|oil extract
P03561036T0000|57 66|lipofundin
P03561622A0659|7 12|resort
P03561622A0659|40 46|patient
P03561622A0659|49 56|dialysis
P03561622A0659|69 74|health
P03561622A0659|80 106|DiaTAP button graft complex
P03561622A0659|164 177|blood cultures
P03561622A0659|186 208|term vancomycin therapy
P03563399A0534|3 18|signal durations
P03563399A0534|28 29|ms
P03563399A0534|42 45|SoNo
P03563399A0534|49 65|S pi No threshold
P03563399A0534|100 109|difference
P03563604A1075|3 13|spleen rate
P03563604A1075|23 31|villagers
P03563604A1075|34 35|RK
P03563604A1075|52 52|%
P03563604A1075|59 71|parasite rate
P03563604A1075|75 75|%
P03563604A1075|85 101|drug intervention
P03567017A0000|8 13|dosing
P03567017A0000|18 22|times
P03567017A0000|32 35|days
P03567017A0000|38 47|indoprofen
P03567017A0000|51 52|mg
P03567017A0000|85 88|drug
P03567017A0000|99 107|half-life
P03567017A0000|109 112|t1/2
P03567017A0000|123 139|drug accumulation
P03567017A0000|153 160|subjects
P03568311A0273|4 11|patients
P03568311A0273|31 39|tamponade
P03568311A0273|50 63|wedge pressure
P03568311A0273|64 66|PWP
P03568311A0273|69 71|RAP
P03568311A0273|76 78|IPP
P03568311A0273|100 106|indexes
P03568311A0273|117 124|function
P03568311A1361|12 20|tamponade
P03568311A1361|24 46|pericardiocentesis data
P03568311A1361|62 78|stroke work index
P03568311A1361|91 101|correlation
P03568311A1361|106 110|TMFP1
P03568311A1361|112 112|r
P03568311A1361|121 125|TMFP2
P03568311A1361|127 127|r
P03568311A1361|143 147|TMFP3
P03570455A0433|0 6|Rabbits
P03570455A0433|24 35|hypocalcemia
P03570455A0433|41 46|levels
P03570455A0433|79 83|mg/dl
P03570455A0433|92 100|influence
P03570455A0433|103 108|TSST-1
P03571135T0000|6 10|value
P03571135T0000|21 28|features
P03571135T0000|31 38|language
P03571135T0000|77 84|children
P03572706A0329|19 33|interpretations
P03572706A0329|46 54|protocols
P03572706A0329|86 95|therapists
P03572706A0329|120 138|treatment condition
P03572706A0329|141 149|elevation
P03572706A0329|155 155|F
P03572706A0329|159 169|F-K indices
P03572706A0329|179 190|MMPI profile
P03575656A0120|25 37|chemical form
P03575656A0120|38 41|90Sr
P03575656A0120|68 71|lung
P03575656A0120|74 77|bone
P03575656A0120|95 101|portion
P03575656A0120|121 126|period
P03575656A0120|129 132|time
P03577670A0102|3 7|study
P03577670A0102|28 34|atrophy
P03577670A0102|59 78|matter hypodensities
P03577670A0236|3 11|diagnosis
P03577670A0236|27 40|leukodystrophy
P03577670A0236|42 44|MLD
P03577670A0236|63 69|finding
P03577670A0236|75 89|arylsulfatase A
P03577670A0236|90 92|ASA
P03577670A0236|94 99|levels
P03577670A0236|110 120|fibroblasts
P03577670A0236|127 133|sisters
P03578948A0448|10 20|ventilation
P03578948A0448|44 49|volume
P03578948A0448|54 62|ml X kg-1
P03578948A0448|65 68|rate
P03578948A0448|77 85|c X min-1
P03581160A0583|18 38|heart rate reactivity
P03581160A0583|79 110|artery pulse amplitude responses
P03581160A0583|132 142|TH subjects
P03581160A0583|148 155|controls
P03582149T0001|17 22|survey
P03582149T0001|34 46|valve disease
P03582149T0001|58 62|fever
P03582149T0001|84 98|school students
P03582149T0001|100 115|Jiangxi Province
P03582184A0448|0 4|Drugs
P03582184A0448|26 30|phase
P03582184A0448|33 41|reactions
P03582184A0448|61 77|dosage adjustment
P03582982A0000|1 5|study
P03582982A0000|13 17|genes
P03582982A0000|27 28|U4
P03582982A0000|41 43|RNA
P03583001A0111|19 27|procedure
P03583001A0111|39 51|gas injection
P03583001A0111|53 58|bubble
P03583001A0111|121 128|drainage
P03583001A0111|141 145|fluid
P03583001A0111|148 157|vitrectomy
P03584426A0706|16 26|enterotoxin
P03584426A0706|28 29|LT
P03584426A0706|50 63|stool isolates
P03584426A0706|66 66|%
P03584426A0706|86 93|isolates
P03584426A0706|96 96|%
P03584426A0706|121 128|activity
P03584426A0706|131 143|suckling mice
P03584426A0706|146 146|%
P03584426A0706|171 177|strains
P03584426A0706|199 206|material
P03586925T0001|0 10|Development
P03586925T0001|46 64|descriptor language
P03586925T0001|68 102|Roentgenology and Medical Radiology
P03586925T0001|104 106|use
P03586925T0001|112 127|Medinform system
P03590911T0001|22 31|dermatosis
P03590911T0001|45 61|light sensitivity
P03591464A0840a|14 17|test
P03591464A0840a|37 52|disease activity
P03591464A0840a|58 65|efficacy
P03591464A0840a|68 95|calcium antagonist treatment
P03591464A0840b|14 17|test
P03591464A0840b|37 52|disease activity
P03591464A0840b|58 65|efficacy
P03591464A0840b|68 95|calcium antagonist treatment
P03592297A0138|0 16|Dorsal foot TcpO2
P03592297A0138|47 56|electrodes
P03592297A0138|61 80|surface temperatures
P03592297A0138|84 92|degrees C
P03592297A0138|97 105|degrees C
P03592297A0138|108 113|theory
P03592297A0138|115 121|changes
P03592297A0138|135 142|activity
P03592297A0138|155 168|vasomotor tone
P03592297A0138|171 175|TcpO2
P03592297A0138|178 181|skin
P03592297A0138|191 199|electrode
P03592297A0138|204 212|degrees C
P03592297A0138|223 234|vasodilation
P03592297A0138|247 255|degrees C
P03592297A0138|263 274|vasodilation
P03592297A0679|2 9|subjects
P03592297A0679|11 11|n
P03592297A0679|19 30|quadriplegia
P03592297A0679|52 55|tone
P03592297A0679|75 85|cord trauma
P03592297A0679|86 90|TcpO2
P03592297A0679|95 103|degrees C
P03592297A0679|106 123|vasodilation index
P03592297A0679|141 144|mmHg
P03592297A0679|154 158|TcpO2
P03592297A0679|163 171|degrees C
P03595418A0688|3 22|nucleotide sequences
P03595418A0688|41 69|ornithine decarboxylase mRNAs
P03595418A0688|77 86|% homology
P03595418A0688|110 116|regions
P03597218A0901|11 24|concentrations
P03597218A0901|27 31|alpha
P03597218A0901|41 49|inhibitor
P03597218A0901|51 71|alpha 2-macroglobulin
P03597218A0901|75 86|antithrombin
P03597218A0901|103 110|exercise
P03597218A0901|115 115|P
P03597218A0901|138 151|concentrations
P03597218A0901|173 178|shifts
P03597218A0901|181 192|plasma water
P03597218A0901|198 205|exercise
P03597218A0901|210 217|quantity
P03597218A0901|225 234|inhibitors
P03597218A0901|256 256|P
P03597269A0409|8 12|model
P03597269A0409|27 37|exponential
P03597269A0409|42 49|constant
P03597269A0409|55 61|form La
P03597269A0409|65 65|b
P03597269A0409|67 69|exp
P03597269A0409|71 74|cVO2
P03600633A1069|0 3|Cell
P03600705T0000|0 5|Timing
P03600705T0000|8 15|symptoms
P03600705T0000|19 34|oocyst excretion
P03600705T0000|41 57|cryptosporidiosis
P03601275A0601|5 21|dopamine infusion
P03601275A0601|23 27|women
P03601275A0601|47 54|syndrome
P03601275A0601|67 74|controls
P03601275A0601|82 93|state levels
P03601275A0601|95 109|plasma dopamine
P03601275A0601|110 123|norepinephrine
P03601275A0601|131 135|ratio
P03601275A0601|138 160|dopamine/norepinephrine
P03601275A0601|180 185|groups
P03601533T0001|10 19|importance
P03601533T0001|36 58|complement constituents
P03601533T0001|60 67|children
P03601533T0001|82 92|thyroiditis
P03602261A0238|31 39|condition
P03602261A0238|62 73|correlations
P03602261A0238|75 75|p
P03602261A0238|110 123|blood pressure
P03602261A0238|126 133|dopamine
P03602261A0238|135 135|r
P03602261A0238|143 156|norepinephrine
P03602261A0238|158 158|r
P03602261A0238|168 178|epinephrine
P03602261A0238|180 180|r
P03602261A0238|211 222|correlations
P03602261A0238|230 238|melatonin
P03602261A0238|242 249|dopamine
P03602261A0238|251 251|r
P03602261A0238|260 273|norepinephrine
P03602261A0238|275 275|r
P03602261A0238|286 299|growth hormone
P03602261A0238|300 300|r
P03605895A0888|4 11|patients
P03605895A0888|16 39|carboxyhemoglobin levels
P03605895A0888|41 46|excess
P03605895A0888|51 51|%
P03605895A0888|70 94|carbon monoxide poisoning
P03605895A0888|99 108|population
P03607109A0370|8 16|processes
P03607109A0370|48 52|month
P03607109A0370|55 63|pregnancy
P03607109A0370|80 86|picture
P03607109A0370|92 99|controls
P03607961T0001|12 17|action
P03607961T0001|28 41|zhuang qi gong
P03607961T0001|47 55|mechanism
P03607961T0001|58 74|diabetes mellitus
P03608916A0790|2 6|cases
P03608916A0790|10 20|degrees HPT
P03608916A0790|24 29|plasma
P03608916A0790|36 37|OH
P03608916A0790|39 46|2D level
P03608916A0790|68 72|cases
P03608916A0790|74 74|P
P03608916A0790|100 106|pattern
P03608916A0790|112 119|increase
P03608989A0668|4 9|region
P03608989A0668|14 24|amino acids
P03608989A0668|50 61|interactions
P03608989A0668|93 110|filament formation
P03608989A0668|115 124|rod region
P03610663A0201|4 11|approach
P03610663A0201|22 28|sources
P03610663A0201|31 35|error
P03610663A0201|41 51|calculation
P03610663A0201|54 73|nutrient utilization
P03610663A0201|103 108|effect
P03610663A0201|111 119|precision
P03610663A0201|166 171|states
P03610674T0000|3 8|effect
P03610674T0000|18 32|zinc deficiency
P03610674T0000|42 59|fiber zinc content
P03610674T0000|63 77|rat hippocampus
P03612316A0102|6 9|rats
P03612316A0102|24 27|diet
P03612316A0102|31 41|low-protein
P03612316A0102|53 56|diet
P03612316A0102|73 78|saline
P03612316A0102|81 89|thyroxine
P03612316A0102|106 109|g BW
P03612316A0102|115 118|days
P03612648A0085|22 40|lupus anticoagulant
P03612648A0085|68 86|thromboplastin time
P03612648A0085|93 100|antibody
P03612648A0085|103 113|cardiolipin
P03615550A0000|3 9|effects
P03615550A0000|25 32|agonists
P03615550A0000|45 63|antagonist naloxone
P03615550A0000|77 80|rats
P03615550A0000|97 120|fixed-consecutive-number
P03615550A0000|122 124|FCN
P03615550A0000|126 133|schedule
P03615550A1094|18 24|effects
P03615550A1094|27 34|morphine
P03615550A1094|38 43|U50488
P03615550A1094|79 88|mg/kg dose
P03615550A1094|90 97|naloxone
P03615763A0170|0 3|Data
P03615763A0170|11 13|men
P03615763A0170|19 23|women
P03615763A0170|42 52|angiography
P03615763A0170|62 72|opportunity
P03615763A0170|87 98|associations
P03615763A0170|101 108|relation
P03615763A0170|131 137|measure
P03615763A0170|140 154|atherosclerosis
P03615763A0170|174 176|age
P03615763A0170|178 180|sex
P03615763A0170|182 187|income
P03615763A0170|189 200|hypertension
P03615763A0170|202 218|serum cholesterol
P03615763A0170|219 225|smoking
P03615763A0170|227 232|angina
P03615763A0170|234 241|diabetes
P03615763A0170|243 256|family history
P03615763A0170|258 270|heart disease
P03615763A0170|271 293|Type A behavior pattern
P03615763A0170|295 303|hostility
P03616174A1069|12 17|change
P03616174A1069|20 30|temperature
P03616174A1069|45 53|degrees C
P03616174A1069|83 92|blood flow
P03616174A1069|111 120|blood flow
P03616174A1069|133 139|tissues
P03616174A1069|180 190|circulation
P03616237T0001|10 27|status epilepticus
P03616237T0001|32 39|infusion
P03616237T0001|42 50|cisplatin
P03618039A0126|3 10|presence
P03618039A0126|17 24|patients
P03618039A0126|27 36|antibodies
P03618039A0126|39 48|adrenaline
P03618039A0126|52 64|noradrenaline
P03618039A0126|91 100|disruption
P03618039A0126|103 133|catecholamine biotransformation
P03619249A0428|12 18|markers
P03619249A0428|37 41|serum
P03619249A0428|43 46|skin
P03619249A0428|50 54|liver
P03619249A0428|60 67|patients
P03619249A0428|79 87|hepatitis
P03619249A0428|89 91|HBV
P03619249A0428|93 98|HBs Ag
P03619249A0428|101 106|HBe Ag
P03619249A0428|107 114|anti-HBs
P03619249A0428|140 144|serum
P03619249A0428|146 148|HBs
P03619249A0428|152 157|HBc Ag
P03619249A0428|162 166|liver
P03619249A0428|191 192|Ag
P03619249A0428|196 203|antibody
P03619249A0428|214 219|non-Bc
P03619249A0428|225 229|serum
P03619249A0428|231 235|non-A
P03619249A0428|243 244|Ag
P03619249A0428|250 254|liver
P03622423A0000|0 5|Groups
P03622423A0000|8 11|male
P03622423A0000|21 27|Fischer
P03622423A0000|31 34|rats
P03622423A0000|36 46|B6C3F1 mice
P03622423A0000|50 68|Hartley guinea pigs
P03622423A0000|86 87|hr
P03622423A0000|94 107|concentrations
P03622423A0000|131 137|control
P03622423A0000|139 141|ppm
P03622423A0000|144 160|methyl isocyanate
P03622423A0000|161 163|MIC
P03622423A0000|165 169|vapor
P03622571A0208|0 17|Radionuclide study
P03622571A0208|34 39|biopsy
P03622571A0208|58 69|degeneration
P03622571A0208|72 81|myocardium
P03625688A0372|0 13|Immobilization
P03625688A0372|19 26|fracture
P03625688A0372|30 35|collar
P03625688A0372|39 48|cuff sling
P03625688A0372|77 83|methods
P03625762A0308|0 9|Comparison
P03625762A0308|12 19|patients
P03625762A0308|29 37|phenytoin
P03625762A0308|80 84|serum
P03625762A0308|114 122|phenytoin
P03625762A0308|148 157|difference
P03625762A0308|168 177|sub-groups
P03625762A0308|182 188|respect
P03625762A0308|191 201|vitamin B12
P03625762A0308|203 226|behaviour problem rating
P03626129T0001|0 6|Effects
P03626129T0001|20 29|laser beam
P03626129T0001|34 38|cells
P03626129T0001|48 53|embryo
P03627720A0196|26 33|features
P03627720A0196|48 55|sac cyst
P03628532A0000|3 6|role
P03628532A0000|9 14|saliva
P03628532A0000|21 36|taste perception
P03628532A0000|54 59|series
P03628532A0000|63 73|experiments
P03628596A0000|0 6|Samples
P03628596A0000|27 34|patients
P03628596A0000|63 67|value
P03628596A0000|70 94|acid alpha 1-glycoprotein
P03628596A0000|117 121|fluid
P03628713A0961|8 18|experiments
P03628713A0961|27 29|AIB
P03628713A0961|33 45|86RbCl uptake
P03628713A0961|47 58|36B-10 cells
P03628713A0961|70 73|days
P03628713A0961|85 98|Gy irradiation
P03628713A0961|117 130|radiation dose
P03628713A0961|140 147|capacity
P03628713A0961|150 160|tumor cells
P03628713A0961|162 169|trap AIB
P03628713A0961|171 172|Rb
P03628794A0648|3 10|patients
P03628794A0648|36 42|disease
P03628794A0648|47 50|data
P03628794A0648|62 84|I-131 MIBG scintigraphy
P03628794A0648|88 98|examination
P03628794A0648|101 106|choice
P03629973A0240|0 1|W.
P03629974A1468|0 9|Comparison
P03629974A1468|15 33|amino acid sequence
P03629974A1468|37 49|M RNA product
P03629974A1468|50 64|Uukuniemi virus
P03629974A1468|74 83|Punta Toro
P03629974A1468|86 110|Rift Valley fever viruses
P03629974A1468|120 124|cases
P03629974A1468|130 137|homology
P03629974A1468|165 172|proteins
P03629974A1468|198 200|end
P03629974A1468|206 214|precursor
